<SEC-DOCUMENT>0001376339-22-000127.txt : 20221102
<SEC-HEADER>0001376339-22-000127.hdr.sgml : 20221102
<ACCEPTANCE-DATETIME>20221102161547
ACCESSION NUMBER:		0001376339-22-000127
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221102
DATE AS OF CHANGE:		20221102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MIMEDX GROUP, INC.
		CENTRAL INDEX KEY:			0001376339
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				262792552
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35887
		FILM NUMBER:		221354289

	BUSINESS ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062
		BUSINESS PHONE:		(770) 651-9100

	MAIL ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alynx, Co.
		DATE OF NAME CHANGE:	20060922
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mdxg-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:75aec70c-8992-4432-a811-2ecd9b0ef10b,g:2668ca8b-9129-4930-9d6a-e03d3677c28b,d:de1fe17276234d55bab608462fe4131b--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:mdxg="http://mimedx.com/20220930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mdxg-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV8zLTEtMS0xLTkwMTk0_eedafa71-94f3-44f1-aa02-dd490e68b0f1">0001376339</ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV80LTEtMS0xLTkwMTk0_ca53414f-12bb-4e48-8a32-2a2540348aec">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV81LTEtMS0xLTkwMTk0_1f332f5f-e7b4-485d-940e-dfa2510811f2">Large accelerated filer</ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV83LTEtMS0xLTkwMTk0_f157020c-d2ec-464d-afc3-9dd7d6b00b6f">2022</ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV84LTEtMS0xLTkwMTk0_4779e553-d7cf-4bb0-bd5b-6419afb99c8c">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV8xMC0xLTEtMS05MDE5NA_96810ea4-9e8e-4510-b5da-59f7b9f56697">false</ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV8xMS0xLTEtMS05MDE5NA_3a785232-53fb-483f-8656-6940d8d4b10b">&#9744;</ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV8xMi0xLTEtMS05MDE5NA_3408746a-dd43-458f-8739-0f11c1f40940">&#9744;</ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV8xMy0xLTEtMS05MDE5NA_241deca2-03c7-4bf7-84ea-2649490a8d34">September 30, 2022</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="i67a12c73e9034b38960c751d13ea184e_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzMzL2ZyYWc6NDIxODRiNGEwZWNmNDdlM2I3NGRjM2Q0MGIyMDQxMTgvdGV4dHJlZ2lvbjo0MjE4NGI0YTBlY2Y0N2UzYjc0ZGMzZDQwYjIwNDExOF8yNzQ4Nzc5MDY5NTYw_34ac89ca-1c03-4a00-a7cb-fda59eaa95ca">1</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="i67a12c73e9034b38960c751d13ea184e_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzMzL2ZyYWc6NDIxODRiNGEwZWNmNDdlM2I3NGRjM2Q0MGIyMDQxMTgvdGV4dHJlZ2lvbjo0MjE4NGI0YTBlY2Y0N2UzYjc0ZGMzZDQwYjIwNDExOF8yNzQ4Nzc5MDY5NTYz_41af2b11-f377-4f01-a30e-b778387bc281">1</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mdxg-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i650ac95e3e044da397aabd67d763d4a6_I20221026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4bd517c3847841b09c02473de630860c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9c87d212d19e46b4a198d7406d22de6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba863cfdd014259beb502f94590fb92_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05b234f7a63247d18255f80516b6b090_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i010a2081c1d248cfb4d5387b5bbf34cb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2c1ec8ce8b4a1a914dc56aec2bfe32_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed50021a0c24811907cc1f60c6d2cdf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie562cf214f3146d48637101b5f2efb7e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4adfca19515f406a8294d42cfdc70386_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i426adda60bd7408fa92b3d909af64f9d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2e885d3bd7477eba0a6949abfbc7e9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6439b5cd06945f59b73261db40e5502_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21cf100acb94a0d9ea1bba0d5056893_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0422e54ed7ae463d9a2bd382de7c4376_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54ac1c07b4df44d9a33e5760e89f8c92_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i960535ac6f674eb3841e739b8d82ee9f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36cbd2d2be4247e1bf671be0206a929a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37e08c0b3a7447538e513cbcf68f082c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d4e1cc067d40bf8351fad15af71351_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc5ba08b772c48e2a5927ce471578129_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cdd5e7db696459ba5ef33f6dca38591_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia13d4f326df848e2877be82415791199_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48d07b19e6c84b74baa49dc3385595a9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i633727b5068940b985f2cd3490575ca0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6eb0110a1d742c1b1bdca7f8dcb37e1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if938b4beab4546c9b2569f821725e575_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91fe605c0c2e4cfb8945c919830b2ab5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5210ebd6b19497b800bc4f988408437_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if74b4382e4f4415ca684233d6d54025e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7c70317011347c28bda53c1ba6ef71c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib877a57ab1704b83960f1ec88ba5f101_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5122095cb1394cab9cd9024590777b14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f8827f716654e7f849b34c082fd49e6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5b940257a7a48998d89e37643d2bea8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b433355fba44f8902c37168d015ce7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i442c898781d04f8abe327191b2190538_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c3b930d9e8c47b89eeb9e3f88386a6a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8859ee77eae6426780f3132bfcc5b59c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia87984b643cc43d69c2042ee0608e0bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib60f056199c240ba8e0dc19accdb2766_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide40f0ea6322436d87854e83f0309547_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794708492f6546f0a4986be2d9546a2d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mdxg:segment</xbrli:measure></xbrli:unit><xbrli:context id="i64c6f2694f674696aab0be0e9ea8fdcf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:InternationalSection351Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3da0f7b3f74c86bf4b94446691f8cf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:InternationalSection351Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie527d102dd6e4325ad714fa0d48400c5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:InternationalSection351Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i131cd49a86304288b8b62abaeab421af_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:InternationalSection351Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df0f9cc41a6412e917f9a0100673e83_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d42aa93cf554f31bdf7957ad6cc2c35_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacbeb9a9186744ee819f52f94ba86e20_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ef134bfecc49ddb64f099bb97426e5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if48f5f99a2a84b0bbb4b58930500f84e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b90d323d6c9405688c45fcb1f025c0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9ef31f44ca74b6cb34d09779c82912b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc5b133a447a448cbfbd88970beedf99_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74c78ba1965249998d6dc020ae794009_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2e0a68a303f40bba14b646d9df1b2ef_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i907909b20b2e448c9e0b5b78f71df456_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5850839a03ec478ab31c891fe1d1573b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68aef08154104f7a9e1912924d2a94bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e71c1046d64413295469b7be58e7419_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4ace787428240a4aca18f56aebd13d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89b2e3aad6cd4af1b759a3681f47bf28_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdxg:AssetRetirementCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida2ac468ebe44af2a56555cff32b5007_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdxg:AssetRetirementCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0104112777e4d14bd77bb3e2902b0a5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mdxg:WoundSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ffd915aa45d4727b23956af58280014_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mdxg:RegenerativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6136baa90f844b998d36da85b2453db_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i659a8e16e9c94e5a93efa999dc1cca89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb08258960c42db90551aecd2db413d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec6c48c7387b4e87940f4064398a14df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddd1d1c82ab24631a37cd041c9a9dbe2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mdxg:PatentsinProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4963e235cc9f495d91c3496c848f2cdb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mdxg:PatentsinProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a12c73e9034b38960c751d13ea184e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida0d445363084e00b087a41a67afce57_D20220228-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i78a81d5053e240d4b3ca17890dd5c28f_D20220228-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19941ad137e24c988a6625220a34fbe7_D20220228-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied1ef014d51f4e56b7b022759ec9dc30_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca2668ba8fb4aa5a0b452209fcbf752_D20220228-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:CreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2747f527fb9748c58c87520ae15d6b71_D20220228-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:CreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i113d9f8cbf62488ba9b7295966501570_D20220228-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:CreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if13a467d34074320a376b1a5273913b3_D20220228-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:CreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddda1184b02a44928b0c26d038f76bca_I20200702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01dffba8325446a929870e45228e37c_I20200702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:CreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea70269e38be47efb68e17ebedd54b55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06158252259a4bb1be9943fc4f9b8256_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32894e2f8cb4b40bf661b269dd42436_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db0a9efc4324b35ab710da5c792ca3e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ae78b34019f45208b00a4a3385ba0bf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ed176b1136d4fa38e04ca50f5c1469a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa56b9335b624293aeb4786b43d54f20_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8e4da241644f84bd4f549f2c4d5255_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:TermLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7039d72af5a465f8d691ffc8453f767_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a6dd65cf2d47b89031b83212416a42_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10cd3b0255d2440e86f4416f3ed9495c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f700fb64114418187f075f2e5eed841_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i146f3a7b53384556923cbc98e604b7dd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ec389008cfe43948414a92568159be9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaf79e5f3ce64e96aa536b235a512ffc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a4925e322ff4faba0e3ed48e1b84008_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i355ee9dd6fe8464cb242d9207054f6bf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70d9b122152d409a9b10de3cb3c9ae48_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f5ff9fed4948129ee9e875deb95c7b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i258db741a42246298eb7aaa18e77a486_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c7a54774bb43fdba585d030dec991b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0df82c48fe04e96b6b5e4d0a4612c4f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b8df31d2af641618c113c2cbd9b7b1a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide1a4fd077334136967497c6a2232e0d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6b3e0608d9f482b868123001407b5ec_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f6805f07fe4bdcb90650b3893165d9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39ab2e69b02a42ddb73366a8e9c08937_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i212a4290c2bd47fca04f586a83a7f287_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271d80de58474816b4025b9aebb971f8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9bb93242bb443ba66fd70a01eef477_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i692c59774d81444084dea717ebd32069_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i784df8506ab9410ea02678d62f33b782_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie017b823195c4cd28a0e2f85512d9175_D20200702-20200702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DividendsAxis">mdxg:DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-02</xbrli:startDate><xbrli:endDate>2020-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2c96a645d0e4a2f9342b55b1148c6a5_D20200702-20200702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DividendsAxis">mdxg:PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-02</xbrli:startDate><xbrli:endDate>2020-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f3a41d5bd2a49d5b12ac3a2ed050c26_I20200702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-02</xbrli:startDate><xbrli:endDate>2020-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>mdxg:day</xbrli:measure></xbrli:unit><xbrli:unit id="director"><xbrli:measure>mdxg:director</xbrli:measure></xbrli:unit><xbrli:context id="iea291f2f9ce54206890c533e3a98eb90_D20200702-20200702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-02</xbrli:startDate><xbrli:endDate>2020-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2897a774ae4848988d5570070d7984aa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebe0c3fba405441db5355c5f6db48438_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie539807062614f8bb0131c5c6847be0d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i753d059860334ec081dc4d69d43cf1c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf3436aa84a4190833ba27b0b9cde6c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15a5bbe694014b15a1e01cde9e802a57_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic02bab3165234f9eb46d4f4c01c5fc77_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5bc17a4ac384d59a3a5c5e10da5eb81_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdxg:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib50e54e252d5492ca1c749cc11fabfe4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdxg:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3049036812934641abae9137fa8bdf2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f95c7c08b84d32a4a79f8a8db06aa4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa7c606187fb4813a87a34ec4af106b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04da0588d95741f9bde5e0e130fa9c99_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6572eec66ddc4973bfa1f4addf16e03f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b6f7cb18684bc78a9c1ac2d353eadf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2b50c892e824477a3935a03b5a37bc1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31fe266b4c6443febd173cafdd41434d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic48fb527e30240a4917a52a042ced3d9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03bb1d037d4e4920880de2544e838583_D20220607-20220607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-07</xbrli:startDate><xbrli:endDate>2022-06-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a6f0c76a58f4f19bb54eedc889f9037_I20220607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ece39c082f4511b28e1e8f2974b42a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib46a2b85eab64b269ab8d468f2d3b464_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib26f2b9f669f4ee6ac92ff0803d5fe9c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3172438f25f94d9b8023b961aedcb60f_I20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mdxg:SeparationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if25b98ea5f0947a9a6a36132f5efc122_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mdxg:SeparationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fd877d9ecb24d80b443c4b5961d54c0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mdxg:SeparationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d6590c804a4af396fb91f11d61ca98_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mdxg:SeparationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e04c486503f40a1843903fe17980c71_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mdxg:NordicBioscienceClinicalDevelopmentASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070672d37c8e47f4a3a16fbd57ba5691_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mdxg:NordicBioscienceClinicalDevelopmentASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i320fdbb729ab4be69c2a59f489c97765_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mdxg:NordicBioscienceClinicalDevelopmentASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2d728dc47344bca02856d03ee8d0b4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mdxg:NordicBioscienceClinicalDevelopmentASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbc4ddf32d59495c88aa620c69ed64cb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdxg:InsuranceProvidersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6fd656cd99342d2afc041b6ba933413_D20190116-20190116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-16</xbrli:startDate><xbrli:endDate>2019-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="class_action"><xbrli:measure>mdxg:class_action</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>mdxg:product</xbrli:measure></xbrli:unit><xbrli:context id="i04190c43aa5d47839d90cf05de41f75a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareTissueAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eec3159aafd457684861f891a8f27b9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareTissueAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5fd9ecb73bd40f28e4562a1cd66d365_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareTissueAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9866ce2797684d89afbfd9e13fe710b6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareTissueAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1eade6c04c44338ba36a2a117e94a53_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2702a8fab749619f28b833e531c5d1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea05bcc2c0134bd5964b7bc8be495e5d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eba5ab3ff8b4cecb6daaf14306ea281_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63d182d5355d40909bfcd1ecad0c38f9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:Section351ProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie699609ee0a24b2795a89d47dab42904_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:Section351ProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ce6151aa0c4089a54a9ba0539e2058_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:Section351ProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib83b2b7d758f4908890825b2a2b0d822_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:Section351ProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8fcb780f1414fd8b5dfecc6d1682d35_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6449c9a80962496d82d4f44a69334d4a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b7935978392476a8eb950a2156ec688_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c14d491f3ed491ea1459de970ab3387_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="distribution_channel"><xbrli:measure>mdxg:distribution_channel</xbrli:measure></xbrli:unit><xbrli:context id="ic08501ad9a844ed4bfcec556b74f305f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c8e45a1b351403d8b7085dbe2706856_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0af08c412f7f4e7f82c54239d39b7b11_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1dffc619904a4d9e56ade452761dd4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f77e1063b8c4fa59391a91c4b07687c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad1c7de372124c51b75ab2ddc755118f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8de990b776a540a18972151167955eaf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8be7f2d7a9034919910bd938ce9e1003_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:WoundSurgicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:RegenerativeMedicineSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:WoundSurgicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:RegenerativeMedicineSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d33b69702834f838661561304e8f6bd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:WoundSurgicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:RegenerativeMedicineSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:WoundSurgicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:RegenerativeMedicineSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ide1fe17276234d55bab608462fe4131b_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzg3_d1cb78ee-a6b7-49d8-b32c-6c353758defa">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:481.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6ODczNDA5MzYzOWM3NDNmNDg0NzFiOTM2NWIxNjcxNzEvdGFibGVyYW5nZTo4NzM0MDkzNjM5Yzc0M2Y0ODQ3MWI5MzY1YjE2NzE3MV8wLTAtMS0xLTkwMTk0_267ebed8-f643-40ae-b4ac-a78d496458b0">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly Period Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xMjM_241deca2-03c7-4bf7-84ea-2649490a8d34">September&#160;30, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:25.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:483.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6YTYyYmUxOGE2N2FmNDkzNjkxNDgxNTI5NzRkM2M3MTMvdGFibGVyYW5nZTphNjJiZTE4YTY3YWY0OTM2OTE0ODE1Mjk3NGQzYzcxM18wLTAtMS0xLTkwMTk0_d3945fd4-0266-4e0b-9b53-b572efd7ca56">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from _____________________to______________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzg0_6a90178d-90c5-42ac-9475-4c239e12881f">001-35887</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzg4_23d8bb68-b6e0-4b1b-8d29-48e963b294b4">MIMEDX GROUP, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6ODlhMDIzMmExNWY1NDgyMGExNjcyYmQxYjhlZjA0NTgvdGFibGVyYW5nZTo4OWEwMjMyYTE1ZjU0ODIwYTE2NzJiZDFiOGVmMDQ1OF8wLTAtMS0xLTkwMTk0_102b3d00-a94a-4f22-8702-f07394b69f1a">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6ODlhMDIzMmExNWY1NDgyMGExNjcyYmQxYjhlZjA0NTgvdGFibGVyYW5nZTo4OWEwMjMyYTE1ZjU0ODIwYTE2NzJiZDFiOGVmMDQ1OF8wLTItMS0xLTkwMTk0_05d108e4-e48f-46a8-ab87-5684c5e8e031">26-2792552</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTlkNzVmMTcxNGM3NDE5Zjk5ZmVlNGU4NjZkZThiYzMvdGFibGVyYW5nZTo1OWQ3NWYxNzE0Yzc0MTlmOTlmZWU0ZTg2NmRlOGJjM18wLTAtMS0xLTkwMTk0L3RleHRyZWdpb246ZTEwZjQ2NGEwNzE2NGQ5MDk4MjgzMjIzMzhhYTgzNTVfNA_4dec4393-244a-435c-ba08-1365b56afab9">1775 West Oak Commons Ct NE</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTlkNzVmMTcxNGM3NDE5Zjk5ZmVlNGU4NjZkZThiYzMvdGFibGVyYW5nZTo1OWQ3NWYxNzE0Yzc0MTlmOTlmZWU0ZTg2NmRlOGJjM18wLTAtMS0xLTkwMTk0L3RleHRyZWdpb246ZTEwZjQ2NGEwNzE2NGQ5MDk4MjgzMjIzMzhhYTgzNTVfNw_c682f7d1-c5f0-4ea5-a728-1b374e69fb16">Marietta</ix:nonNumeric>, <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTlkNzVmMTcxNGM3NDE5Zjk5ZmVlNGU4NjZkZThiYzMvdGFibGVyYW5nZTo1OWQ3NWYxNzE0Yzc0MTlmOTlmZWU0ZTg2NmRlOGJjM18wLTAtMS0xLTkwMTk0L3RleHRyZWdpb246ZTEwZjQ2NGEwNzE2NGQ5MDk4MjgzMjIzMzhhYTgzNTVfMTE_f3e26488-8f70-4bdd-ab29-3322d97e7298">GA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTlkNzVmMTcxNGM3NDE5Zjk5ZmVlNGU4NjZkZThiYzMvdGFibGVyYW5nZTo1OWQ3NWYxNzE0Yzc0MTlmOTlmZWU0ZTg2NmRlOGJjM18wLTItMS0xLTkwMTk0_3d03003a-414f-463e-bdb3-1c7af2ea34a9">30062</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzg1_4691e973-1842-4c49-bf14-57b227ec8b60">770</ix:nonNumeric>) <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzgx_b596d1d6-009e-41a6-a28d-12216f6cfd02">651-9100</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTZkZmI4YmJjOWY2NDBiNTkwNDliZWRiMmIxYjI5OWMvdGFibGVyYW5nZTo1NmRmYjhiYmM5ZjY0MGI1OTA0OWJlZGIyYjFiMjk5Y18xLTAtMS0xLTkwMTk0_cf678b41-4550-41ae-9875-da4740c02729">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTZkZmI4YmJjOWY2NDBiNTkwNDliZWRiMmIxYjI5OWMvdGFibGVyYW5nZTo1NmRmYjhiYmM5ZjY0MGI1OTA0OWJlZGIyYjFiMjk5Y18xLTEtMS0xLTkwMTk0_e52eb002-e79b-438f-9beb-7c5f8b9b5e7b">MDXG</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTZkZmI4YmJjOWY2NDBiNTkwNDliZWRiMmIxYjI5OWMvdGFibGVyYW5nZTo1NmRmYjhiYmM5ZjY0MGI1OTA0OWJlZGIyYjFiMjk5Y18xLTItMS0xLTkwMTk0_26a36f2e-2ff7-41ff-a5aa-62bc70c9529b">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzgy_79fad0f8-7227-4776-805c-ec56084dfecc">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> x </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzgz_9bc4d436-7375-4221-842a-62adc6d5121d">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> x </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:18.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6OWU3NjNlNDAyMTE1NGIzYThjYTRlMzMzYTM5NGI2MzkvdGFibGVyYW5nZTo5ZTc2M2U0MDIxMTU0YjNhOGNhNGUzMzNhMzk0YjYzOV8wLTAtMS0xLTkwMTk0L3RleHRyZWdpb246NDJhZGU3MWJmMTNiNDYyNjgyZmM2YzJiMTBlZGEyMDNfNA_1f332f5f-e7b4-485d-940e-dfa2510811f2">Large accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Do not check if a smaller reporting company)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6OWU3NjNlNDAyMTE1NGIzYThjYTRlMzMzYTM5NGI2MzkvdGFibGVyYW5nZTo5ZTc2M2U0MDIxMTU0YjNhOGNhNGUzMzNhMzk0YjYzOV8wLTMtMS0xLTkwMTk0L3RleHRyZWdpb246NWNkODM0ZmI5YWZlNDE4ZGI2YWY4NmExOGViMjBjMGZfMzA_3408746a-dd43-458f-8739-0f11c1f40940">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6OWU3NjNlNDAyMTE1NGIzYThjYTRlMzMzYTM5NGI2MzkvdGFibGVyYW5nZTo5ZTc2M2U0MDIxMTU0YjNhOGNhNGUzMzNhMzk0YjYzOV8wLTQtMS0xLTkwMTk0L3RleHRyZWdpb246ZjRjZDQzODVjYzlmNGRkNDk5NTUwZjc3MjU2MjljY2JfMjg_3a785232-53fb-483f-8656-6940d8d4b10b">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes &#9744; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN180OTQ3ODAyMzI2Nzgy_e35453a0-a7cc-4640-9256-8b9048bd71d2">x</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="i650ac95e3e044da397aabd67d763d4a6_I20221026" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNjg4_907bd376-15dd-4707-9747-1f5f7acb7581">113,668,179</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.001 per share, outstanding as of October&#160;26, 2022.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.259%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part I&#160;&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements (Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_22">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Stockholders&#8217; (Deficit) Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_25">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_34">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to the Condensed Consolidated Financial Statements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_37">11</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_91">28</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_139">39</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_142">39</a></span></div></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part II&#160;&#160;&#160;OTHER INFORMATION</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_148">40</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_151">40</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unregistered Sales of Equity Securities and Use of Proceeds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_154">40</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults&#160;upon Senior Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_157">40</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_160">40</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_163">40</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_166">41</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_169">41</a></span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used herein, the terms &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MIMEDX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">us</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Important Cautionary Statement Regarding Forward-Looking Statements </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (this &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quarterly Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) contains forward-looking statements. All statements relating to events or results that may occur in the future are forward-looking statements, including, without limitation, statements regarding the following: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategic focus and current business priorities, and our ability to implement these priorities, including as a result of our no longer being able to market our micronized products and certain other products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to fund our ongoing operations and future operating costs and the sufficiency of our liquidity and existing capital resources to implement our current business priorities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding future income tax liability;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the advantages of our products and development of new products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding the size of potential markets for our products and any growth in such markets;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding the regulatory pathway for our products, including our existing and planned investigative new drug application and pre-market approval requirements; current plans, designs, expected timelines, and expectations for success of our clinical trials; and our expectations regarding timing and receipt of necessary regulatory approvals for certain of our products, including Biological License Applications (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">BLAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;); </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding ongoing regulatory obligations and oversight and the changing nature thereof impacting our products, research and clinical programs, and business, including those relating to patient privacy;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding our ability to manufacture certain of our products in compliance with current Good Manufacturing Practices (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">CGMP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) in sufficient quantities to meet current and potential demand;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding costs relating to compliance with regulatory requirements, including those arising from our clinical trials, pursuit of Investigational New Drug applications and BLAs, and CGMP compliance;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the likelihood, timing, and scope of possible regulatory approval and commercial launch of our late-stage product candidates and new indications for our products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding government and other third-party coverage and reimbursement for our existing and new products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding future revenue growth;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief in the sufficiency of our intellectual property rights in our technology;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to procure sufficient supplies of human tissue to manufacture and process our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the outcome of pending litigation and investigations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the ongoing and future effects arising from the investigation conducted by the Audit Committee (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of our Board of Directors (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) that concluded in May 2019 relating to allegations regarding certain sales and distribution practices at the Company and certain other matters (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the restatement of our consolidated financial statements previously filed in our Annual Report for the year ended December 31, 2016, as well as selected unaudited condensed consolidated financial data as of and for the years ended December 31, 2015 (Restated) and 2014 (Restated), which reflected adjustments to our previously filed consolidated financial statements as of and for the years ended December 31, 2015 and 2014 (collectively, the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restatement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and related litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ongoing and future effects arising from the COVID-19 pandemic (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Covid-19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) on our business, employees, suppliers and other third parties with whom we do business, and our responses intended to mitigate such effects;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demographic and market trends; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete effectively.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements generally can be identified by words such as &#8220;expect,&#8221; &#8220;will,&#8221; &#8220;change,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;future,&#8221; &#8220;plan,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;to be&#8221; and similar expressions. These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could significantly affect the Company&#8217;s operations and may cause the Company&#8217;s actual actions, results, financial condition, performance or achievements to differ materially from any future actions, results, financial condition, performance or achievements expressed or implied by any such forward-looking statements. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may cause such a difference include, without limitation, those discussed under the heading &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021 (our &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), filed with the Securities and Exchange Commission (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on February 28, 2022. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless required by law, the Company does not intend, and undertakes no obligation, to update or publicly release any revision to any forward-looking statements, whether as a result of the receipt of new information, the occurrence of subsequent events, a change in circumstances or otherwise. Each forward-looking statement contained in this Quarterly Report is specifically qualified in its entirety by the aforementioned factors. Readers are advised to carefully read this Quarterly Report in conjunction with the important disclaimers set forth above prior to reaching any conclusions or making any investment decisions and not to place undue reliance on forward-looking statements, which speak only as of the date of the filing of this Quarterly Report with the SEC.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimates and Projections</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Quarterly Report includes certain estimates, projections and other statistical data. These estimates and projections reflect management&#8217;s best estimates based upon currently available information and certain assumptions we believe to be reasonable as of the date of this Quarterly Report. These estimates are inherently uncertain, subject to risks and uncertainties, many of which are not within our control, have not been reviewed by our independent auditors and may be revised as a result of management&#8217;s further review. In addition, these estimates and projections are not a comprehensive statement of our financial results, and our actual results may differ materially from these estimates and projections due to developments that may arise between now and the time the results are final. There can be no assurance that the estimates will be realized, and our results may vary significantly from the estimates, including as a result of unexpected issues in our business and operations. Accordingly, you should not place undue reliance on such information. Projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="ide1fe17276234d55bab608462fe4131b_16"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="ide1fe17276234d55bab608462fe4131b_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX GROUP, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMy0xLTEtMS05MDE5NA_12f9999c-0372-471b-aa92-cf335cde8eef">73,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMy0zLTEtMS05MDE5NA_0b2855b2-28a2-4e20-819b-d895e7c5d913">87,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNC0xLTEtMS05MDE5NA_375f69d4-4d14-4685-bf3f-070a79cb7dd0">40,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNC0zLTEtMS05MDE5NA_e66b5138-a04c-4407-990c-cd34aff26104">40,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNS0xLTEtMS05MDE5NA_b0b003b4-2b4d-4c1b-abd5-06106f4dda14">13,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNS0zLTEtMS05MDE5NA_d8b2f630-1374-4c33-ad04-c3e7164531d4">11,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNi0xLTEtMS05MDE5NA_bb3446c0-52c1-4069-8046-ac1c1ecdbc87">4,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNi0zLTEtMS05MDE5NA_7013defa-d1ea-4bcf-90d2-e07aa937c677">6,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNy0xLTEtMS05MDE5NA_ee7fb04c-2e41-4759-9c82-5a667f3168fe">756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNy0zLTEtMS05MDE5NA_28fb6e39-cda7-465c-882a-7dbf946f58af">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfOC0xLTEtMS05MDE5NA_cde854f6-be2a-4e62-b2a3-c51e830795ea">2,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfOC0zLTEtMS05MDE5NA_959e9cb6-c823-4d48-b95c-633ff6e3ea92">2,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfOS0xLTEtMS05MDE5NA_70c619d6-2f9e-413d-94ae-b3a8240e2381">136,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfOS0zLTEtMS05MDE5NA_29d0aab6-59e9-48b9-bfc4-eafb228f040b">148,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTEtMS0xLTEtOTAxOTQ_2fde3b7a-a964-4e09-acfd-207ac2ad37a6">7,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTEtMy0xLTEtOTAxOTQ_1e865462-d57a-4d19-bd0d-6df9a9fd1449">9,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTItMS0xLTEtOTAxOTQ_8e1594d8-7cb8-4925-94c0-dfcb8c2f9ab9">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTItMy0xLTEtOTAxOTQ_6f63dca3-7460-4b21-a613-b46f3bb003da">4,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTMtMS0xLTEtOTAxOTQ_9e29d382-fe03-403c-aef4-bac3ad0d42cf">19,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTMtMy0xLTEtOTAxOTQ_3d5eaa8a-434b-4bd1-b7b9-df8e261dd3ed">19,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTQtMS0xLTEtOTAxOTQ_7962b092-2c32-4a5d-b95c-6473265070d7">4,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTQtMy0xLTEtOTAxOTQ_1173dc1d-38d7-48aa-ba4f-7df6ec17b41f">5,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTYtMS0xLTEtOTAxOTQ_63c2603b-1fb0-44f5-9892-4dfc875643ef">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTYtMy0xLTEtOTAxOTQ_0e6e0b1b-c0e1-4888-9e41-a1313dbab55c">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTctMS0xLTEtOTAxOTQ_766b602c-405b-4bfc-8ce0-5fc3d2c7d362">172,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTctMy0xLTEtOTAxOTQ_e4f922d1-419a-4f95-8387-c2ba321ad49f">187,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjAtMS0xLTEtOTAxOTQ_4fd468d5-16c4-4fa2-b638-44a11f191d68">8,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjAtMy0xLTEtOTAxOTQ_3065d841-57aa-46a5-9188-b717bb902f3c">7,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjEtMS0xLTEtOTAxOTQ_5d063a28-e00b-4bc0-84e1-51e7ba4118c3">24,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjEtMy0xLTEtOTAxOTQ_961ae9bf-e55c-424c-987d-0903fc729b06">23,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjItMS0xLTEtOTAxOTQ_092680ae-bd64-4b87-899b-6e4121b21a3a">10,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjItMy0xLTEtOTAxOTQ_7a256399-697b-426d-8a6d-6b7c67dde8cd">9,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjctMS0xLTEtOTAxOTQ_f0fde1d5-26a9-413e-9249-2b173338f258">1,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjctMy0xLTEtOTAxOTQ_c2c7f87b-e836-4854-b43c-78d14b4d78d4">1,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjgtMS0xLTEtOTAxOTQ_dae3552c-3907-4811-abf6-de832e9e589b">45,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjgtMy0xLTEtOTAxOTQ_ef183e15-e752-4ee9-9c17-3592168af6e0">42,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjktMS0xLTEtOTAxOTQ_05d0d5b2-4124-469f-bcd3-2c5a8e832ba3">48,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjktMy0xLTEtOTAxOTQ_a2ac952a-6c2e-444a-9968-04f2baa90530">48,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzAtMS0xLTEtOTAxOTQ_65dd7283-3ca4-4fe0-9727-e4b2574dd4fb">5,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzAtMy0xLTEtOTAxOTQ_321bec83-2254-475c-b540-574f69398036">4,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzEtMS0xLTEtOTAxOTQ_774ae092-184b-4427-b8aa-9eb8a9cfa810">99,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzEtMy0xLTEtOTAxOTQ_929810fc-ebe6-452a-baf9-d1a72cedb07e">95,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 13)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzItMS0xLTEtOTAxOTQ_d37d3253-8e4f-49d7-bf41-6dc3c5220476"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzItMy0xLTEtOTAxOTQ_27f23da7-801e-4b8c-962d-0827a0bccb4c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock Series B; $<ix:nonFraction unitRef="usdPerShare" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF80Mg_26288bc2-aafc-4dc8-b828-8df1920975ee"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF80Mg_e29828cc-5cf4-4f19-ab78-58a0630b237f">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_1ecd6db1-0f36-4b73-8e15-21dd80a0237a"><ix:nonFraction unitRef="shares" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_2157cec0-0f01-4c69-835c-67bdf989dcaa"><ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_464d09af-0840-44e5-8d66-bc742b50a390"><ix:nonFraction unitRef="shares" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_5d892bdf-e510-41a5-8e3e-0e54b3f063c0"><ix:nonFraction unitRef="shares" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_664c56a0-e83c-4fe4-82ad-2b62d2b700d0"><ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_8e0146f7-77cd-4988-ad8c-3c5aa1fdc92e">100,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMS0xLTEtOTAxOTQ_8a3d55e2-797e-40e2-832c-48c31c072453">92,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMy0xLTEtOTAxOTQ_a05fbb38-af6d-4c58-abe3-fade4420c958">92,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' (deficit) equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock Series A; $<ix:nonFraction unitRef="usdPerShare" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV8zMA_56647d72-e0bb-4e8e-b35f-13048ca07505"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV8zMA_70212ba0-fc19-4334-9f65-feb7bb57ccf7">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV80NA_623cd614-6fc1-42a5-9d83-f90cec3a2259"><ix:nonFraction unitRef="shares" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV80NA_d1bd0863-d90f-444e-bd5f-99d74d1fdbca">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV82Ng_1504bef4-973f-4345-9aff-8183dbafabaf"><ix:nonFraction unitRef="shares" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV82Ng_1ac19ad3-5855-44d5-9654-5c5e686ed2c3"><ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV82Ng_1d9143bb-4bc0-40d9-b5f7-f32d75ce8eb1"><ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV82Ng_f8b6ecb0-adf3-4252-8485-0adb7a8bb39e">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMS0xLTEtOTAxOTQ_38491c2c-d9ef-4d47-be0a-849b2b6fef97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMy0xLTEtOTAxOTQ_67a1fcf1-e731-46ec-af4d-dcba076f8bfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV8xOA_02ca41ba-a564-4e99-a758-6fbb44ef38cf"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV8xOA_8267f66f-5867-4ae9-976e-308a9c4385c4">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV8zMg_66974e12-74e6-4781-b8d4-cc3ae0918209"><ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV8zMg_b6ea7ae5-c683-4fe3-8978-d969b6857204">187,500,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV81NA_e5d1937f-554c-4ea9-83b7-783ac2a34bf9">113,670,017</ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV82OA_860188d2-c6d5-4bd1-92a4-879c7ab838c1">113,668,179</ix:nonFraction> outstanding at September&#160;30, 2022 and <ix:nonFraction unitRef="shares" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV85Mw_3a6e94be-5c36-4815-91cf-0b2b0aee40da">112,703,926</ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV8xMDc_afc3e15c-d6bb-47ce-bab1-15ad3c32837f">111,925,216</ix:nonFraction> outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMS0xLTEtOTAxOTQ_d3e585fd-04d1-433f-ae9a-5b164723c5b1">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMy0xLTEtOTAxOTQ_8fab6f4a-755b-4555-a91a-ec813f6cf0b3">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzctMS0xLTEtOTAxOTQ_6516c0d0-fa1f-4ac6-b554-32bfcd788558">171,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzctMy0xLTEtOTAxOTQ_72fa076c-e4ed-4868-8a28-029a2aaa3da5">165,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock at cost; <ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzgtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjphYzU4NzUzZTBhNTE0YzgzYWFhZDE3MzdkOTBhYTM0NV8yOA_90e39a81-cfa5-4067-b89d-9a91522136d9">1,838</ix:nonFraction> shares at September&#160;30, 2022 and <ix:nonFraction unitRef="shares" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzgtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjphYzU4NzUzZTBhNTE0YzgzYWFhZDE3MzdkOTBhYTM0NV80OA_66a8391b-98e1-4dd1-a231-a14949458552">778,710</ix:nonFraction> shares at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzgtMS0xLTEtOTAxOTQ_1e8194f0-da23-48c3-9fa7-5ea664100269">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzgtMy0xLTEtOTAxOTQ_0d95405c-7d3c-49fc-9a8d-75913ef7eb11">4,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzktMS0xLTEtOTAxOTQ_61d1e25d-14f2-41dc-9375-b9a697d2d332">191,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzktMy0xLTEtOTAxOTQ_7f74392f-788f-42b4-9e51-fd9a89b46e29">161,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' (deficit) equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNDAtMS0xLTEtOTAxOTQ_5c2c0747-b7aa-448c-aac7-8671d772415c">19,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNDAtMy0xLTEtOTAxOTQ_9ece2aec-7ca2-4a03-bdd7-03fa3bd96c21">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, convertible preferred stock, and stockholders&#8217; (deficit) equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNDEtMS0xLTEtOTAxOTQ_7ba2bd0a-60ef-470d-997a-ef583c09854d">172,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNDEtMy0xLTEtOTAxOTQ_bf4ad484-292c-49cf-b181-cebe686a9fe3">187,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX GROUP, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMy0xLTEtMS05MDE5NA_70458ce1-45cb-4d24-95b9-f3917af3cae5">67,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMy0zLTEtMS05MDE5NA_dc456ab6-8073-4702-a75f-7aa5418a3380">63,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMy01LTEtMS05MDE5NA_0f0d8aca-03d7-4cc1-aa3d-ff8ea4ab28d5">193,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMy03LTEtMS05MDE5NA_3fd7e7bb-ee0e-4166-b838-780aac74fdca">191,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNC0xLTEtMS05MDE5NA_d52e2412-f254-4849-bdf7-be7073dd4a8f">12,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNC0zLTEtMS05MDE5NA_2dead21f-edc4-42e3-8dcc-d8987871e676">10,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNC01LTEtMS05MDE5NA_7e067564-8774-4be7-a652-ea223a38a077">33,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNC03LTEtMS05MDE5NA_41d809c7-c1f0-443b-8d07-b4dcf4771967">32,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNS0xLTEtMS05MDE5NA_65caca90-5dab-43b1-b206-1c6c5ede9a23">55,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNS0zLTEtMS05MDE5NA_dfae5498-63ae-4b0f-8f64-9c3715f773fc">52,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNS01LTEtMS05MDE5NA_d7190298-7963-4989-ac1c-a935b7fb74c7">159,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNS03LTEtMS05MDE5NA_166ce8a9-ae8e-40ff-bdc2-ea583ecdee75">158,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOC0xLTEtMS05MDE5NA_334ef8c4-303c-4e0e-a2f6-23fc3a228175">53,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOC0zLTEtMS05MDE5NA_4e6f90ab-60d4-4e18-9307-c220aec7e6d0">46,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOC01LTEtMS05MDE5NA_40007806-314d-4f53-8c8b-5d089f70af92">158,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOC03LTEtMS05MDE5NA_c8eaebaf-f662-46a7-bb28-39879fcdca6b">145,291</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOS0xLTEtMS05MDE5NA_53ca9d48-eb7e-46f5-9300-d9942649efac">5,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOS0zLTEtMS05MDE5NA_3babddb1-ac57-4289-983b-e3af652fb633">4,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOS01LTEtMS05MDE5NA_a904f3b2-88ac-492f-b3c9-dddcc8c00189">17,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOS03LTEtMS05MDE5NA_a95a6282-f0ee-4bb3-bea8-e7ac4c0173f3">12,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="mdxg:InvestigationRestatementAndRelated" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTAtMS0xLTEtOTAxOTQ_3814843b-45ba-4b9d-b786-f0dd1baba88d">3,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="mdxg:InvestigationRestatementAndRelated" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTAtMy0xLTEtOTAxOTQ_82484051-697b-43e8-83ea-0b47c25378a1">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="mdxg:InvestigationRestatementAndRelated" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTAtNS0xLTEtOTAxOTQ_dad1b718-41fa-46f0-95e8-81d112bd2a39">8,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="mdxg:InvestigationRestatementAndRelated" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTAtNy0xLTEtOTAxOTQ_5243efe8-f261-4b4d-b7fc-69ff4b97f7fb">8,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTEtMS0xLTEtOTAxOTQ_ecb678e2-85e0-494b-8aac-686515841fc8">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTEtMy0xLTEtOTAxOTQ_072ce126-4765-45ee-b170-6680df750884">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTEtNS0xLTEtOTAxOTQ_9aa894c3-f52d-418a-990f-aafe1a864caf">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTEtNy0xLTEtOTAxOTQ_815a0aef-17d3-4c74-a64e-ac06e32039cc">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTMtMS0xLTEtOTAxOTQ_5e490f43-f6d1-464d-a00c-0e2b63262d13">7,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTMtMy0xLTEtOTAxOTQ_4948a8ba-536f-4d39-ae9c-806973f2219a">1,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTMtNS0xLTEtOTAxOTQ_83ebf85a-d0ac-483b-8372-7417d12bd933">26,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTMtNy0xLTEtOTAxOTQ_15439f75-4535-4013-813c-ca3cc9788177">8,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTctMS0xLTEtOTAxOTQ_996288a3-c5a9-4c35-8ac1-794ba60bd48b">1,270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTctMy0xLTEtOTAxOTQ_480dd87c-8e4b-4b8c-b9ff-841a4757cfd7">963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTctNS0xLTEtOTAxOTQ_abfd0890-8676-46dc-a721-1fd03f4f9949">3,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTctNy0xLTEtOTAxOTQ_b54943c6-a05b-4563-950f-95d73427278d">3,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTgtMS0xLTEtOTAxOTQ_c10b2dd5-cd48-4596-adf3-5f5af82f99d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTgtMy0xLTEtOTAxOTQ_2729d223-de1f-4369-a792-4b35f71a0326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTgtNS0xLTEtOTAxOTQ_aaf84531-ae21-4844-9b04-b9b04b4c2f66">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTgtNy0xLTEtOTAxOTQ_d9d841a5-c9c3-4288-a097-e64aecce83cf">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTktMS0xLTEtOTAxOTQ_00632026-7341-4a37-9cf2-8fc80b400400">8,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTktMy0xLTEtOTAxOTQ_1c83f109-a47e-4082-ac1a-6def11ce696e">2,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTktNS0xLTEtOTAxOTQ_b1f6a275-0087-4e96-a346-8345526a1380">29,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTktNy0xLTEtOTAxOTQ_50dfeec7-0073-496e-a57b-4dea64a0eb17">12,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjAtMS0xLTEtOTAxOTQ_884dde60-f160-46e1-be9f-6c803449672c">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjAtMy0xLTEtOTAxOTQ_6f75ee6a-2fae-4267-b657-7a550a59aea4">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjAtNS0xLTEtOTAxOTQ_419faf9f-5e0d-417e-93af-86cac5b875b4">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjAtNy0xLTEtOTAxOTQ_0149ece2-0379-4f59-bb6c-284118316dfe">355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjEtMS0xLTEtOTAxOTQ_714db2dd-ad2a-4363-b532-5bb15142259b">8,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjEtMy0xLTEtOTAxOTQ_6a59818d-5fd7-4094-8fe8-38e55bab1dab">2,339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjEtNS0xLTEtOTAxOTQ_a263527b-3007-4898-bb47-24aa9e7106f2">29,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjEtNy0xLTEtOTAxOTQ_e8883b67-b096-4312-95fd-a30f15033258">12,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common stockholders (Note 9)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtMS0xLTEtOTAxOTQ_157c151c-762c-456f-943a-ff7552247c10"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtMS0xLTEtOTAxOTQ_9893e43e-4f71-4b48-bd68-bf7abcbfda21">10,096</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtMy0xLTEtOTAxOTQ_3f7070a0-32f3-476d-be79-f5c7866f98fc"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtMy0xLTEtOTAxOTQ_8d720cc4-e40c-4cc9-b0f6-a84e3699ed29">3,913</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtNS0xLTEtOTAxOTQ_24b23f3c-68b9-49fd-95c6-b0c43e3643d0">34,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtNy0xLTEtOTAxOTQ_cf34b72c-8241-4215-8776-0db9d3b1bf29">17,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjYtMS0xLTEtOTAxOTQ_d0c1f6de-121f-41d9-8115-673a366455c3">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjYtMy0xLTEtOTAxOTQ_f743c046-e1f3-49bc-b509-c62a98716cae">0.04</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjYtNS0xLTEtOTAxOTQ_416d0c97-fbab-4098-b246-b83f5ee421b1">0.31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjYtNy0xLTEtOTAxOTQ_830fef12-96cc-44c6-bdf3-747601bdee50">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjctMS0xLTEtOTAxOTQ_e79751ba-5c68-41ed-b311-87192fe99915">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjctMy0xLTEtOTAxOTQ_c75c9b7c-7137-48de-8a7c-2def7e671478">0.04</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjctNS0xLTEtOTAxOTQ_456e8651-5103-4786-b4a5-55a00acc3265">0.31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjctNy0xLTEtOTAxOTQ_6f7c8c87-e4e8-47a1-a43c-21983f637c68">0.15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjktMS0xLTEtOTAxOTQ_83ed1151-2540-42c9-89de-027e9edc17b2">113,448,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjktMy0xLTEtOTAxOTQ_8b7ecceb-f863-45a8-8f8b-759e224f80e6">110,717,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjktNS0xLTEtOTAxOTQ_aa5d1507-f3f4-49c4-ba92-e34c5c33bd68">112,650,713</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjktNy0xLTEtOTAxOTQ_820814e9-4777-45de-b846-b4badb1e26c3">110,136,517</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMzAtMS0xLTEtOTAxOTQ_0f90b0dd-d17d-4793-b174-11f9d8d77488">113,448,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMzAtMy0xLTEtOTAxOTQ_76e46b7f-0cd8-44d1-a0f5-1950cea463f5">110,717,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMzAtNS0xLTEtOTAxOTQ_aeb181e6-4faf-4f50-9f0e-b379c1c16ca8">112,650,713</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMzAtNy0xLTEtOTAxOTQ_f308a1ea-60c4-4ff3-bcc9-8dfb7007d7ad">110,136,517</ix:nonFraction></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div id="ide1fe17276234d55bab608462fe4131b_25"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX GROUP, INC. AND SUBSIDIARIES<br/>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; (DEFICIT) EQUITY<br/>(in thousands, except share data)<br/>(unaudited)</span></div><div id="ide1fe17276234d55bab608462fe4131b_28"></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional Paid - in</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Deficit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifba863cfdd014259beb502f94590fb92_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi0xLTEtMS05MDE5NA_91585c07-da24-4afc-b06e-2e0070e7bc62">113,609,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba863cfdd014259beb502f94590fb92_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi0yLTEtMS05MDE5NA_bc7342a3-1b64-4d65-aad3-10958911f40c">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b234f7a63247d18255f80516b6b090_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi0zLTEtMS05MDE5NA_62e7ee6a-37d3-40fe-a6c1-512e7532e430">169,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i010a2081c1d248cfb4d5387b5bbf34cb_I20220630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi00LTEtMS05MDE5NA_edd36b42-8fbd-4ce1-8b1e-7400204ed9a3">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i010a2081c1d248cfb4d5387b5bbf34cb_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi01LTEtMS05MDE5NA_65ffbe5b-366c-459d-8dc0-a66f875d093c">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f2c1ec8ce8b4a1a914dc56aec2bfe32_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi02LTEtMS05MDE5NA_c4f9e39b-dbf5-4e08-9c3c-27cc885d5bae">183,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ed50021a0c24811907cc1f60c6d2cdf_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi03LTEtMS05MDE5NA_b2a03df1-68d5-4cb2-8bdd-2e7ef39c5900">13,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation&#160;expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie562cf214f3146d48637101b5f2efb7e_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNS0zLTEtMS05MDE5NA_020e25b4-117d-4b95-a0f5-2ad7f76bf3d2">2,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNS03LTEtMS05MDE5NA_13c2a776-f189-4a7e-9d17-c9baf7069bc1">2,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4adfca19515f406a8294d42cfdc70386_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNy0xLTEtMS05MDE5NA_849e1b71-387b-4725-84ab-d91034928eae">49,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie562cf214f3146d48637101b5f2efb7e_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNy0zLTEtMS05MDE5NA_5a0c0a8b-6f79-4153-aac4-e8d71a486f2e">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i426adda60bd7408fa92b3d909af64f9d_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNy00LTEtMS05MDE5NA_f330378d-3450-4483-bc77-8040377a3b95">1,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i426adda60bd7408fa92b3d909af64f9d_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNy01LTEtMS05MDE5NA_5e6ddc5e-fdf6-4a83-8f04-e2cf7aca89af">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNy03LTEtMS05MDE5NA_0deb9cbe-b3b9-4d4b-86f5-d31f68ffdfa0">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4adfca19515f406a8294d42cfdc70386_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfOS0xLTEtMS05MDE5NA_dd3b8084-51b9-4f84-aed0-c45630302958">11,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfOS03LTEtMS05MDE5NA_3d51aea6-9b09-4762-97fd-69b1a868ea75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock canceled/forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie562cf214f3146d48637101b5f2efb7e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTAtMy0xLTEtOTAxOTQ_def7fa7b-73be-43fb-ad98-c2b2c1e758c1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i426adda60bd7408fa92b3d909af64f9d_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTAtNC0xLTEtOTAxOTQ_180f5afe-2eb2-4fc3-a6ce-e06734e01fa7">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i426adda60bd7408fa92b3d909af64f9d_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTAtNS0xLTEtOTAxOTQ_8d9c0b34-287f-412c-a47c-155b1df65361">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTAtNy0xLTEtOTAxOTQ_3e48f1e4-b447-458d-adaa-32426565c2fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a2e885d3bd7477eba0a6949abfbc7e9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTQtNi0xLTEtOTAxOTQ_ff8539de-fa23-4d31-922f-68d3fc3461c7">8,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTQtNy0xLTEtOTAxOTQ_1320cc3e-c46f-4504-86f4-01bbac97bedf">8,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6439b5cd06945f59b73261db40e5502_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtMS0xLTEtOTAxOTQ_68d42d1e-2609-4288-8ab5-57a198f093d2">113,670,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6439b5cd06945f59b73261db40e5502_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtMi0xLTEtOTAxOTQ_d7d6430f-71e9-4bd5-83da-bd0c532b1204">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21cf100acb94a0d9ea1bba0d5056893_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtMy0xLTEtOTAxOTQ_7c431a3c-7804-47e9-a38e-e9cc5399d28f">171,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0422e54ed7ae463d9a2bd382de7c4376_I20220930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtNC0xLTEtOTAxOTQ_103c2b1f-a2e5-49b2-8529-5fc32da112c0">1,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0422e54ed7ae463d9a2bd382de7c4376_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtNS0xLTEtOTAxOTQ_6c925565-0413-49a5-8d59-fa2275f340c1">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54ac1c07b4df44d9a33e5760e89f8c92_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtNi0xLTEtOTAxOTQ_f87037db-686f-456a-a8ca-ddbc228d0fe7">191,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtNy0xLTEtOTAxOTQ_ba978041-0d4e-4fc2-a255-419ad169af78">19,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional Paid - in</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Deficit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i960535ac6f674eb3841e739b8d82ee9f_I20210630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi0xLTEtMS05MDE5NA_b5805fbc-7e1c-4dce-8fcb-b85e76970714">112,703,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i960535ac6f674eb3841e739b8d82ee9f_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi0yLTEtMS05MDE5NA_f2d548ad-9211-4ae6-8620-d9dbe91a6896">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36cbd2d2be4247e1bf671be0206a929a_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi0zLTEtMS05MDE5NA_3901679c-7940-4acc-86fb-cf178921146c">158,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37e08c0b3a7447538e513cbcf68f082c_I20210630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi00LTEtMS05MDE5NA_0ed81c6f-baf2-4d8d-b31f-e27c9ec09939">821,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37e08c0b3a7447538e513cbcf68f082c_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi01LTEtMS05MDE5NA_9c007287-0288-4851-abdb-4f58a22ce48e">4,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40d4e1cc067d40bf8351fad15af71351_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi02LTEtMS05MDE5NA_6b3809a4-ddc4-40f7-a403-f06bbaab5a29">161,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc5ba08b772c48e2a5927ce471578129_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi03LTEtMS05MDE5NA_e04db16e-a69f-415e-8a07-75f74b06f244">7,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdd5e7db696459ba5ef33f6dca38591_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNC0zLTEtMS05MDE5NA_bf1e4073-4206-4bdb-80eb-86199942eaa1">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNC03LTEtMS05MDE5NA_17726fca-f6f6-4589-9735-d5cc26e7313b">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdd5e7db696459ba5ef33f6dca38591_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNS0zLTEtMS05MDE5NA_bcb93de6-0f68-47df-9d9a-db0dab2b3cb7">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNS00LTEtMS05MDE5NA_90067c2e-378e-4ecf-a92b-629c0ab52775">30,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNS01LTEtMS05MDE5NA_fb8fd851-66cb-4bb7-a684-67b0c063125b">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNS03LTEtMS05MDE5NA_0f855aa9-5a13-4004-bee1-b8a9266d29c5">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdd5e7db696459ba5ef33f6dca38591_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNi0zLTEtMS05MDE5NA_2036ab0b-5326-4942-ae59-85fc63a4fe58">477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNi00LTEtMS05MDE5NA_c6f40547-996b-49db-88ff-027198e2d667">48,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNi01LTEtMS05MDE5NA_c8621a51-cf9f-4661-901a-aabb88cc5aa6">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNi03LTEtMS05MDE5NA_090c3c8e-4461-4b2c-aec3-66eb556c0e2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock shares canceled/forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdd5e7db696459ba5ef33f6dca38591_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNy0zLTEtMS05MDE5NA_23e8354d-7a1b-49c6-8d17-88663e52afe6">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNy00LTEtMS05MDE5NA_c5220717-163d-40ba-a218-330c67514e9c">18,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNy01LTEtMS05MDE5NA_36da734d-ab6a-4e3f-9c0a-a20e213b63e3">199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNy03LTEtMS05MDE5NA_0ee223d8-0727-438d-b5c9-a0e7e0482761">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased for tax withholding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfOC00LTEtMS05MDE5NA_8caa32f0-8f14-4597-8248-a8388873af4a">15,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfOC01LTEtMS05MDE5NA_ddd6d575-c70e-417c-9122-2843c88c4e42">188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfOC03LTEtMS05MDE5NA_6fbfdfde-c08f-4939-98ef-bb26e91f30a2">188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48d07b19e6c84b74baa49dc3385595a9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfOS02LTEtMS05MDE5NA_bedf0dd3-1b0c-4a50-b5b1-aa1b1727f981">2,339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfOS03LTEtMS05MDE5NA_3ff8b4a2-3883-438c-b06a-352d28d56e82">2,339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i633727b5068940b985f2cd3490575ca0_I20210930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtMS0xLTEtOTAxOTQ_f1dedfa5-666b-43de-81c0-7032a18a75e7">112,703,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633727b5068940b985f2cd3490575ca0_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtMi0xLTEtOTAxOTQ_4a6847e0-283b-4bea-84e0-c487f5da7121">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6eb0110a1d742c1b1bdca7f8dcb37e1_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtMy0xLTEtOTAxOTQ_dbb9ca14-e860-4660-b4f8-3a2b16c6a10a">162,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if938b4beab4546c9b2569f821725e575_I20210930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtNC0xLTEtOTAxOTQ_684b47f5-7123-498f-81e1-92f314ce8f91">777,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if938b4beab4546c9b2569f821725e575_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtNS0xLTEtOTAxOTQ_861acb1e-e566-4c13-abff-e8ba4163d49b">4,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91fe605c0c2e4cfb8945c919830b2ab5_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtNi0xLTEtOTAxOTQ_e63333b9-9390-4b29-a1fd-a22733a46813">163,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5210ebd6b19497b800bc4f988408437_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtNy0xLTEtOTAxOTQ_ca8ca762-da54-4b95-a2f2-05d1a8bf6924">5,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div id="ide1fe17276234d55bab608462fe4131b_31"></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional Paid - in</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Deficit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if74b4382e4f4415ca684233d6d54025e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi0xLTEtMS05MDE5NA_ffd409c9-2395-4fc8-bc00-5b04ac9f64ca">112,703,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74b4382e4f4415ca684233d6d54025e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi0yLTEtMS05MDE5NA_999af9d8-0fbf-4cc7-97b1-a5131764c8f5">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c70317011347c28bda53c1ba6ef71c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi0zLTEtMS05MDE5NA_2b12ed6a-fe09-46e6-8d7c-ac604e919ad9">165,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib877a57ab1704b83960f1ec88ba5f101_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi00LTEtMS05MDE5NA_9bd05367-0a07-499e-a84b-0c2af8085d8a">778,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib877a57ab1704b83960f1ec88ba5f101_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi01LTEtMS05MDE5NA_0e6ad4ed-0e7a-43b1-963d-991fa70dec8f">4,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5122095cb1394cab9cd9024590777b14_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi02LTEtMS05MDE5NA_8677b913-caee-4552-826c-90e02ee9e5de">161,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi03LTEtMS05MDE5NA_d38c9161-730a-4a15-927b-481bf65581ea">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation&#160;expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8827f716654e7f849b34c082fd49e6_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNS0zLTEtMS05MDE5NA_29172c41-b4e5-404f-8886-16a137ed80ac">10,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNS03LTEtMS05MDE5NA_771271a1-3abf-4c31-bb2f-bbb841033009">10,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5b940257a7a48998d89e37643d2bea8_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNi0xLTEtMS05MDE5NA_4b883477-16ef-4a31-94cb-3e24b25849b5">133,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8827f716654e7f849b34c082fd49e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNi0zLTEtMS05MDE5NA_6a46ccce-e773-4ebb-818c-bcbde20098d3">697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNi00LTEtMS05MDE5NA_8fbc7cbd-15a7-4997-8f59-daad1276085f">151,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNi01LTEtMS05MDE5NA_8edee74d-873e-425a-b813-d5adae770504">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNi03LTEtMS05MDE5NA_c5355cd7-cc9e-4936-b651-7f8235016920">574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5b940257a7a48998d89e37643d2bea8_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy0xLTEtMS05MDE5NA_d5f7bd73-f844-4aba-a423-ab8254cbec68">832,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5b940257a7a48998d89e37643d2bea8_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy0yLTEtMS05MDE5NA_11d764d4-445f-4a7d-9543-db02e0c23749">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8827f716654e7f849b34c082fd49e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy0zLTEtMS05MDE5NA_bf2e5e4d-3e31-407c-8e85-f7352cb4a8e6">3,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy00LTEtMS05MDE5NA_30f88cfc-aba4-4d15-8631-8daac690cd61">880,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy01LTEtMS05MDE5NA_b9481293-9a9a-4f42-9eb7-1adb967e4132">3,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy03LTEtMS05MDE5NA_3bab4c9b-d346-4b56-87df-2c3b3cc470b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock canceled/forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8827f716654e7f849b34c082fd49e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOC0zLTEtMS05MDE5NA_b9591c00-1c63-4711-9776-5dfd90bc756b">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOC00LTEtMS05MDE5NA_7d80429f-7585-497c-8c6c-6d8e5fa2412e">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOC01LTEtMS05MDE5NA_e45b5cf0-7069-4899-8e8f-5c0377f6cc9d">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOC03LTEtMS05MDE5NA_35f1edaa-881f-47ec-a252-c684f29fad26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased for tax withholding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOS00LTEtMS05MDE5NA_4849fcb8-c017-47ce-a4a4-77d1763ca11d">249,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOS01LTEtMS05MDE5NA_128892ff-9d05-4415-9eea-1091c3edccff">1,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOS03LTEtMS05MDE5NA_5130c707-ace5-430d-8e41-8a997614a822">1,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b433355fba44f8902c37168d015ce7_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTAtNi0xLTEtOTAxOTQ_83fdd220-7a7b-4777-831c-3f89ee78af0a">29,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTAtNy0xLTEtOTAxOTQ_5043ee53-3af4-4f73-91d0-9364db1040df">29,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6439b5cd06945f59b73261db40e5502_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtMS0xLTEtOTAxOTQ_4259bb80-2344-4272-8818-5dfd5ad5e18f">113,670,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6439b5cd06945f59b73261db40e5502_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtMi0xLTEtOTAxOTQ_a2be4190-ff51-4336-84b1-b9af304c2fcd">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21cf100acb94a0d9ea1bba0d5056893_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtMy0xLTEtOTAxOTQ_7dfef7c6-5efc-4701-9017-e66bdd319d55">171,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0422e54ed7ae463d9a2bd382de7c4376_I20220930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtNC0xLTEtOTAxOTQ_1fcbcba3-7134-4830-bb6b-cb3256173cd7">1,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0422e54ed7ae463d9a2bd382de7c4376_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtNS0xLTEtOTAxOTQ_4985a46c-3512-4740-86fa-3c7a5c178e39">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54ac1c07b4df44d9a33e5760e89f8c92_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtNi0xLTEtOTAxOTQ_2ec241be-476a-46b0-a775-e3e44fb421de">191,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtNy0xLTEtOTAxOTQ_2ad5577e-d7cd-466c-9d54-5b879990c231">19,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional Paid - in</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Deficit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i442c898781d04f8abe327191b2190538_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi0xLTEtMS05MDE5NA_482e26e2-87bf-417a-a5dc-40033eddf44c">112,703,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i442c898781d04f8abe327191b2190538_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi0yLTEtMS05MDE5NA_1ac48086-ea4f-4e44-a63f-bf01b7a9e79a">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c3b930d9e8c47b89eeb9e3f88386a6a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi0zLTEtMS05MDE5NA_27e6b783-1d2d-4a6f-ad42-b713ff40f009">158,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8859ee77eae6426780f3132bfcc5b59c_I20201231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi00LTEtMS05MDE5NA_dab73fa1-77ca-41ba-851c-606b71c23cb7">1,773,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8859ee77eae6426780f3132bfcc5b59c_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi01LTEtMS05MDE5NA_30678e4b-041d-42eb-b332-9a7b993405ee">7,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia87984b643cc43d69c2042ee0608e0bf_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi02LTEtMS05MDE5NA_1f43a0b3-4e7d-4563-93a7-29171df326aa">151,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib60f056199c240ba8e0dc19accdb2766_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi03LTEtMS05MDE5NA_4b9e4cc6-7328-4483-9881-58dd70cbb832">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMy0zLTEtMS05MDE5NA_adaf80d5-f9c7-4b89-bc15-9f933295f1c9">926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMy03LTEtMS05MDE5NA_de54cfb2-190c-4e6b-bdcb-c2664e82037e">926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation&#160;expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNC0zLTEtMS05MDE5NA_cb4c30f3-93c7-4d54-886d-e103b77d2232">11,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNC03LTEtMS05MDE5NA_670e9c2b-6b2c-45a5-9612-8f6d61b8ae17">11,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNS0zLTEtMS05MDE5NA_2ee43318-5552-4899-9375-118f3367aa0e"><ix:nonFraction unitRef="usd" contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNS0zLTEtMS05MDE5NA_b84302f3-37cb-4d5c-82ba-eb4566fa133c">1,184</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNS00LTEtMS05MDE5NA_234fc477-4c23-40e2-9633-3a77aaa26643">482,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNS01LTEtMS05MDE5NA_3b683a00-67ab-492a-94f5-aedd2c5a04af">2,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNS03LTEtMS05MDE5NA_f366ff74-6bb5-4dd3-a08e-4f468c004e60">1,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNi0zLTEtMS05MDE5NA_1400c978-c0c3-45c2-87ea-5eb69dccec53"><ix:nonFraction unitRef="usd" contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNi0zLTEtMS05MDE5NA_1826a4a5-9d8a-4aca-851c-3e0784213f1e">4,053</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNi00LTEtMS05MDE5NA_5bb59f2f-887e-4763-8a0c-af5e2a6dff54">810,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNi01LTEtMS05MDE5NA_8b4ab8e9-f87b-43c4-9905-880af332b7a1">4,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNi03LTEtMS05MDE5NA_9f2dd0d6-03c3-4adb-9ede-be59754c0177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock canceled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNy0zLTEtMS05MDE5NA_6f9c2059-c70f-4068-9f95-a90c9f20c3cb"><ix:nonFraction unitRef="usd" contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNy0zLTEtMS05MDE5NA_d226deb5-87de-4757-ac09-09d2c9731f7f">450</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNy00LTEtMS05MDE5NA_8e986447-02eb-41aa-94d0-b60bd094e8e6">66,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNy01LTEtMS05MDE5NA_f19055b2-818a-4d99-8e68-63563bf4abd3">450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNy03LTEtMS05MDE5NA_d0b4554c-a206-4928-9124-d3011f9e0ffa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased for tax withholding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfOC00LTEtMS05MDE5NA_02bedd3b-4b76-46cf-85df-648f218de6cb">469,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfOC01LTEtMS05MDE5NA_4c2095df-b981-4273-9703-82d5a56211ba">4,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfOC03LTEtMS05MDE5NA_43854307-5397-4d53-8e90-3ed8fe2f779e">4,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i794708492f6546f0a4986be2d9546a2d_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfOS02LTEtMS05MDE5NA_1afe3ca8-b085-47c5-ac86-3ae3c34f1c00">12,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfOS03LTEtMS05MDE5NA_8a082ffb-ec1c-42c4-9a97-fa0bc5135f47">12,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTAtMy0xLTEtOTQ1MDM_3ef47413-2252-4ce9-b82d-f4253f729617">2,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930" decimals="INF" name="mdxg:TreasuryStockSharesAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTAtNC0xLTEtOTQ1MDM_7ddcb896-561f-4329-bf52-8508b3e3cdab">239,502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTAtNS0xLTEtOTQ1MDM_3836fe17-29ac-450e-b1c2-d4323b31d4d7">2,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTAtNy0xLTEtOTQ1MDY_ef0e5e3b-f4e3-4e45-b2b8-e9c929e0a6eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i633727b5068940b985f2cd3490575ca0_I20210930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtMS0xLTEtOTAxOTQ_f2b1ab16-b4b7-48d2-97e1-8fb8055fd96b">112,703,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633727b5068940b985f2cd3490575ca0_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtMi0xLTEtOTAxOTQ_86746cd2-4ce3-4bf0-94de-106868bcfb26">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6eb0110a1d742c1b1bdca7f8dcb37e1_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtMy0xLTEtOTAxOTQ_c7e96c76-d386-4a8b-a490-01d72bf6495f">162,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if938b4beab4546c9b2569f821725e575_I20210930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtNC0xLTEtOTAxOTQ_751ceb8f-5d38-4b72-aab5-84d38e7ff191">777,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if938b4beab4546c9b2569f821725e575_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtNS0xLTEtOTAxOTQ_eb767fd0-39f6-4fac-adf4-96e437dba413">4,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91fe605c0c2e4cfb8945c919830b2ab5_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtNi0xLTEtOTAxOTQ_546f2dd0-6ede-4528-a22a-65823d961300">163,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5210ebd6b19497b800bc4f988408437_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtNy0xLTEtOTAxOTQ_0f15a905-690b-41e0-a8a3-6c6a11b1d59e">5,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX GROUP, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.247%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMy0xLTEtMS05MDE5NA_ab3e893f-5693-4a30-9bf7-7b0cd6a1cfa0">29,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMy0zLTEtMS05MDE5NA_c783e8cc-9fce-4d8d-9d15-0c6b35200137">12,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash flows (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNS0xLTEtMS05MDE5NA_916ff3c3-eadf-4f61-8134-f34d8a8eb8a1">10,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNS0zLTEtMS05MDE5NA_f7aa874a-d9be-4c72-9f4f-0e7e93f0deb3">11,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNi0xLTEtMS05MDE5NA_934cccb7-e908-404b-a622-9ebe21370bfd">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNi0zLTEtMS05MDE5NA_9a130457-280b-47c9-b63d-c1f6cab7028c">3,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNy0xLTEtMS05MDE5NA_c77b6d99-a581-471f-8898-81201239a3cb">2,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNy0zLTEtMS05MDE5NA_5dc1f46b-29e9-4189-8afb-922b8deb7127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfOC0xLTEtMS05MDE5NA_81f6b5ac-a1a0-4007-91bf-3e81208b89a4">519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfOC0zLTEtMS05MDE5NA_244e42a3-482e-4746-8b09-bab07643a38f">647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfOS0xLTEtMS05MDE5NA_604ad515-4942-4c59-93b0-a05e67dddcf2">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfOS0zLTEtMS05MDE5NA_21a63862-4244-49e4-9966-8223c84cefec">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTAtMS0xLTEtOTAxOTQ_13845862-2e7a-46ab-bf33-232559e12a44">931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTAtMy0xLTEtOTAxOTQ_b9750a1f-9536-49d5-bd63-03119c9c3dc8">724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of asset retirement obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:AssetRetirementObligationAccretionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTEtMS0xLTEtOTAxOTQ_83ce2b00-f401-4625-b328-0342fa337cb5">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:AssetRetirementObligationAccretionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTEtMy0xLTEtOTAxOTQ_cfead552-a779-417f-8b4c-816529182298">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on fixed asset disposal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTItMS0xLTEtOTAxOTQ_c9a0e0ad-74d8-429c-a9e8-56b5c9a9d978">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTItMy0xLTEtOTAxOTQ_573e65cf-44ec-4b8a-ad39-5e8df9fc7f3c">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash resulting from changes in:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTYtMS0xLTEtOTAxOTQ_b30bfcb3-4182-4823-8983-3132ad9b56a8">3,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTYtMy0xLTEtOTAxOTQ_44d3d896-2360-450b-b52e-536217585f2b">1,113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTctMS0xLTEtOTAxOTQ_7040900e-ff23-4224-ab95-79625a3f4e4b">2,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTctMy0xLTEtOTAxOTQ_ba64db23-2170-43b5-9817-0206b8b04be0">835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTgtMS0xLTEtOTAxOTQ_0081eb16-f019-480f-9e22-b342fdedb837">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTgtMy0xLTEtOTAxOTQ_a7bb1b5c-89f0-4815-8c51-732cce6a9e14">3,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTktMS0xLTEtOTAxOTQ_8ff476f4-80b5-4f83-a1a2-24539c5c3666">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTktMy0xLTEtOTAxOTQ_48bd1106-ea23-448e-b0f3-8a924dc02e37">9,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjAtMS0xLTEtOTAxOTQ_8997fc21-ca0c-449c-8989-6ae176f578a5">287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjAtMy0xLTEtOTAxOTQ_98a1d089-e8c6-4efa-94cd-729b7bf97b36">1,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjEtMS0xLTEtOTAxOTQ_6fafb9cf-cfb0-47c9-b254-e8da7baa22d4">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjEtMy0xLTEtOTAxOTQ_5f437c59-f09a-404b-9568-140a37ff6d6f">828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjItMS0xLTEtOTAxOTQ_ab68fde2-4c7e-4221-8b8a-f111e087778f">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjItMy0xLTEtOTAxOTQ_4439b0ba-19ca-449a-84da-627ab42f57be">2,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjMtMS0xLTEtOTAxOTQ_dc0199a1-410e-41a8-8825-de4fd8bf017e">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjMtMy0xLTEtOTAxOTQ_c04f4a8b-66a6-4ea4-a144-f43f60786ad6">16,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjQtMS0xLTEtOTAxOTQ_c5417857-fd43-483b-94f0-273c8fb4653f">905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjQtMy0xLTEtOTAxOTQ_4b6f5151-cf40-4275-9f6c-54c545bf00aa">840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash flows (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjUtMS0xLTEtOTAxOTQ_09af2d8d-df88-456e-a5e3-6a64d846fbbf">12,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjUtMy0xLTEtOTAxOTQ_32a2d919-5553-4a13-9941-5b4f6d8f980d">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash&#160;flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjgtMS0xLTEtOTAxOTQ_55985f64-0fd5-4c59-b53d-33ae1669b9ab">847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjgtMy0xLTEtOTAxOTQ_60aa0094-d0f1-4dfe-962a-2581b9eb742f">2,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent application costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="mdxg:PaymentsForApplicationCostsPatent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjktMS0xLTEtOTAxOTQ_40b2584b-a814-49c7-83b4-c7fa0971056a">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="mdxg:PaymentsForApplicationCostsPatent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjktMy0xLTEtOTAxOTQ_81c370cb-9881-40f4-9d30-41bf7b5e4244">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments from note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzAtMS0xLTEtOTAxOTQ_c49d12a0-2b12-4421-ad23-418fc708fcba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzAtMy0xLTEtOTAxOTQ_5d5455bb-5f12-4183-9e46-90b82f84b26d">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzEtMS0xLTEtOTAxOTQ_aab01171-576d-464b-b740-71a3ee2da86c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzEtMy0xLTEtOTAxOTQ_da4ec9da-6599-49e1-a1e6-f137972c1437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzItMS0xLTEtOTAxOTQ_342d1386-5c6a-43f8-bb71-6afcee1e8522">951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzItMy0xLTEtOTAxOTQ_3b7229b9-30bf-4b2f-bfbb-2e18a3537c3b">3,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock repurchased for tax withholdings on vesting of restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzUtMS0xLTEtOTAxOTQ_4f314b25-df12-4560-8edc-251a38a60d3b">1,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzUtMy0xLTEtOTAxOTQ_da48c2ba-3a97-408d-bf06-cf5f16ae9af8">4,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzYtMS0xLTEtOTAxOTQ_b66e447c-0a6a-4b56-bfa0-f83d2fdde4b0">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzYtMy0xLTEtOTAxOTQ_b662661d-c89f-41fb-853e-2898f3f9bd55">1,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on finance lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzctMS0xLTEtOTAxOTQ_3c087d18-f8a3-4a94-a7d3-d01f2971fd18">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzctMy0xLTEtOTAxOTQ_8f264bf9-3981-4008-8d2f-5bb39b4cca19">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash flows used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzgtMS0xLTEtOTAxOTQ_c1a45c8d-1d8f-4cbc-9963-078afc8ee997">646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzgtMy0xLTEtOTAxOTQ_f01a6b61-3863-407d-9d11-5d06a8c2e53d">3,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDAtMS0xLTEtOTAxOTQ_69f5e0c7-e6aa-4e7f-9704-59d416b6a9c3">13,866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDAtMy0xLTEtOTAxOTQ_08b85f93-2f20-4f1a-a661-5051248ca3c2">5,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDItMS0xLTEtOTAxOTQ_67ff3159-9185-4cd4-aa58-25357cf1ba4f">87,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib60f056199c240ba8e0dc19accdb2766_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDItMy0xLTEtOTAxOTQ_472ec8f4-3d3e-4e75-9c4e-a5cae78b0696">95,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDMtMS0xLTEtOTAxOTQ_07461691-ef7d-44d8-a70f-cc14926c2b7c">73,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5210ebd6b19497b800bc4f988408437_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDMtMy0xLTEtOTAxOTQ_277fd20d-0408-4bb4-a7a4-527a3f6043eb">90,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MIMEDX GROUP, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER&#160;30, 2022 AND 2021</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div id="ide1fe17276234d55bab608462fe4131b_40"></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjc0ODc3OTA3MzkxNg_9e1a4c0c-6dc1-4861-9bf6-80c438196f51" continuedAt="i6cc041fd6ad94fb5807e5071af9b803d" escape="true">Nature of Business</ix:nonNumeric></span></div><ix:continuation id="i6cc041fd6ad94fb5807e5071af9b803d"><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MiMedx Group, Inc. (together with its subsidiaries, except where the context otherwise requires, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MIMEDX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; or the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, the Company is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company derives its products from human placental tissues and processes these tissues using its proprietary methods, including the PURION&#174; process. The Company applies Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce its allografts. MIMEDX provides products primarily in the wound care, burn, and surgical recovery sectors of healthcare. All of its products are regulated by the U.S. Food &amp; Drug Administration (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company manages itself as <ix:nonFraction unitRef="segment" contextRef="i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjc0ODc3OTA3MzY0OQ_12172f67-b2ca-47fe-b9a6-7cb7221ffded">two</ix:nonFraction> reportable segments: Wound &amp; Surgical and Regenerative Medicine. Information regarding the principal operations and results of these segments can be found in Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business is currently focused primarily in the United States. The Company is pursuing opportunities for international expansion, with specific focus on the launch of its placental tissue products in Japan.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enforcement Discretion</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the FDA published a series of guidances that established an updated framework for the regulation of cellular and tissue-based products. These guidances clarified the FDA&#8217;s views about the criteria that differentiate those products subject to regulation solely under Section 361 of the Public Health Service Act (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) from those considered to be drugs, devices, and/or biological products subject to licensure under Section 351 of the Public Health Service Act and related regulations. The Company identified its micronized and certain other products (collectively, the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 351 products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) as being subject to regulation under Section 351, requiring pre-market approval from the FDA for a specified indication with demonstrated clinical efficacy.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA exercised enforcement discretion with respect to Investigational New Drug applications and pre-market approval requirements through May 31, 2021. As of May 31, 2021, the Company stopped marketing its Section 351 products in the United States and is precluded from marketing such products until a Biologics License Application (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is granted. If and when the FDA approves a BLA, the Company expects to be allowed to market its Section 351 products in the United States again, but only for specific indications as permitted by the FDA. Sales of the Company&#8217;s Section 351 products were $<ix:nonFraction unitRef="usd" contextRef="i64c6f2694f674696aab0be0e9ea8fdcf_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjU1Nw_0874cc39-ff17-4ec1-b5f1-19a53884cd97">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7d3da0f7b3f74c86bf4b94446691f8cf_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjU2NA_9b87ba3e-7614-4364-8e40-bf0cd5b4006d">0.5</ix:nonFraction>&#160;million for the three months ended September&#160;30, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ie527d102dd6e4325ad714fa0d48400c5_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjYyMw_6c0d5517-ccbd-41f7-8737-ac1226897c28">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i131cd49a86304288b8b62abaeab421af_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjYzMA_758ff576-ea79-42d3-8aa9-b63be4610dc0">17.2</ix:nonFraction>&#160;million for the nine months ended September 30, 2022 and 2021, respectively. Sales of Section 351 products during the three and nine months ended September&#160;30, 2022 were derived from sales outside the United States.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently markets EPICORD&#174; and AMNIOCOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D&#174; tissue products derived from human umbilical cord as providing a protective environment or as a barrier. If the FDA were to determine that EPICORD and AMNIOCORD do not meet the requirements for regulation solely under Section 361, then pre-market clearance or approval would be required for these products. The loss of the Company&#8217;s ability to market and sell its umbilical cord-derived products could have an adverse effect on the Company&#8217;s revenue, business, financial condition, and results of operations. Net sales of the Company&#8217;s umbilical cord-derived products were $<ix:nonFraction unitRef="usd" contextRef="i4df0f9cc41a6412e917f9a0100673e83_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMzQyNg_5c8b7478-4376-47e8-b287-130be4e95b30">5.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5d42aa93cf554f31bdf7957ad6cc2c35_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjc0ODc3OTA3MzkwMw_37b9e84d-378f-4437-b8d9-72f80e87530f">6.2</ix:nonFraction>&#160;million for the three months ended September&#160;30, 2022 and 2021 and $<ix:nonFraction unitRef="usd" contextRef="iacbeb9a9186744ee819f52f94ba86e20_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMzQ3OA_6155f6bc-22f7-4fd7-a399-1ce2141b4183">17.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i81ef134bfecc49ddb64f099bb97426e5_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMzQ4NQ_0bda4f03-7067-4a7a-9320-a62b1736e81e">17.1</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively. The Company&#8217;s cord inventory, which would be at risk for write-down in the case of such a determination by the FDA, was $<ix:nonFraction unitRef="usd" contextRef="if48f5f99a2a84b0bbb4b58930500f84e_I20220930" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMzY1OA_4b0af92e-2927-4871-be83-299218b92449">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1b90d323d6c9405688c45fcb1f025c0f_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMzY2NQ_453627ed-bd64-498c-be25-292600afe4d4">1.9</ix:nonFraction> million as of September&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div></ix:continuation><div id="ide1fe17276234d55bab608462fe4131b_43"></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMzk0MA_2afb8e87-843e-466d-90d8-d192352e419d" continuedAt="i10a38ca3ae2943e2a1bd00f67e798fd5" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><ix:continuation id="i10a38ca3ae2943e2a1bd00f67e798fd5" continuedAt="idf6743c70b97429aaec12081407e154f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 2 to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), filed with the Securities and Exchange Commission (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on February 28, 2022 for a description of all significant accounting policies.</span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="idf6743c70b97429aaec12081407e154f" continuedAt="i6379933f624d499b9042e39cd86f3df6"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMzk0MQ_d51497dd-8557-4f20-bcc6-5a14f8080dd0" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GAAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;The operating results for the three and nine months ended September&#160;30, 2022 and 2021 are not necessarily indicative of the results that may be expected for the full fiscal year.&#160;The balance sheet as of December&#160;31, 2021 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2021 Form 10-K.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMzkyNw_5bac6acf-3a14-45e9-8387-b1be34d9dd71" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported unaudited condensed consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates regarding asset retirement obligations, estimates for contingent liabilities, estimates related to the Company&#8217;s assessment of goodwill impairment, the measurement of right of use assets and lease liabilities, management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern, estimates of fair value of share-based payments, estimate for allowance for doubtful accounts, estimates of sales returns and allowances, and valuation of deferred tax assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMzkzOQ_0cdff72e-6dbc-425d-8df8-72a3ea05f65a" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk1NA_983b67f4-6a52-4e3f-96bd-88829f8351c8" continuedAt="i6b546d45af284a0da765245df3fc570a" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of GAAP requires the use of the &#8220;management approach&#8221; model for segment reporting. The management approach model is based on the way a company&#8217;s chief operating decision maker (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CODM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) organizes segments within the Company for which separate, discrete financial information is available regarding resource allocation and assessing performance. The Company has concluded that its Chief Executive Officer (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CEO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is its CODM. Prior to June 30, 2022, the Company assessed that it operated as <ix:nonFraction unitRef="segment" contextRef="ia9ef31f44ca74b6cb34d09779c82912b_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk5Mg_ab2da8ce-4a1e-4b95-af72-39dd8582f563"><ix:nonFraction unitRef="segment" contextRef="ia9ef31f44ca74b6cb34d09779c82912b_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk5Mg_bb5672d4-e3e3-4aed-8e8f-4f9ad56b84b8">one</ix:nonFraction></ix:nonFraction> operating and reportable segment. The Company reassesses the existence of operating segments when facts and circumstances suggest that there may have been a change in the way that the Company was managed.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b546d45af284a0da765245df3fc570a">On September&#160;30, 2022, the Company reassessed its operating segments, concluding that the CODM assesses performance and allocates resources between <ix:nonFraction unitRef="segment" contextRef="i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk5Mw_a3c17ed2-d691-4332-86b4-bcc933782f9c">two</ix:nonFraction>, distinct reportable segments: Wound &amp; Surgical and Regenerative Medicine.</ix:continuation> Information regarding the principal operations and results of these segments can be found in Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk1NQ_ca3d3800-a192-4168-ae0f-79ff9be20c67" continuedAt="i9e7e4781373b4915b0576ba4a344a86d" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment at least annually on October 1 and more frequently whenever events or substantive changes in circumstances indicate that it is more likely than not that goodwill is impaired. In performing the goodwill impairment test, the Company first assesses qualitative factors to determine the existence of impairment. If the qualitative factors indicate that the carrying value of a reporting unit exceeds its fair value, the Company proceeds to a quantitative test to measure the existence and amount, if any, of goodwill impairment. The Company may also choose to bypass the qualitative assessment and proceed directly to the quantitative test.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the quantitative test, impairment loss is recorded to the extent that the carrying value of the reporting unit exceeds its assessed fair value. The Company determines the fair value using the income and market approaches. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the income approach, the fair value of a reporting unit is the present value of its future cash flows as viewed from the lens of a hypothetical market participant in an orderly transaction. These future cash flows are derived from expectations of revenue, expenses, tax deductions and credits, working capital flows, capital expenditures, and other projected sources and uses of cash, as applicable. Value indications are developed by discounting expected cash flows to their present value using a discount rate commensurate with the risks associated with the reporting unit subject to testing.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i6379933f624d499b9042e39cd86f3df6"><ix:continuation id="i9e7e4781373b4915b0576ba4a344a86d" continuedAt="i1b9e63f630f641eb9aa76ec5c5f25f39"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the market approach, the Company uses market multiples derived from the various comparable companies based on measures salient to investors in those companies. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company concludes that a reporting unit is being managed on the basis of multiple reporting units, the goodwill assigned to the original reporting unit is allocated to the new reporting units based on the relative fair value of the new reporting units.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1b9e63f630f641eb9aa76ec5c5f25f39">As indicated above, on September 30, 2022, the Company changed its operating segments, determining that it operates as <ix:nonFraction unitRef="segment" contextRef="i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjE5OTAyMzI2OTc5Mw_6b179c54-c1fe-4af5-b318-260379f876ab">three</ix:nonFraction> operating segments. In concert with this re-evaluation, the Company concluded that it has <ix:nonFraction unitRef="segment" contextRef="i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk5MQ_24155079-fdd7-432e-98bd-3141184dbc67">three</ix:nonFraction> reporting units. Management performed a goodwill impairment test as of that date on its previous reporting unit, concluding that goodwill was not impaired as of that date. Management subsequently allocated the goodwill assigned to its previous reporting unit to its new reporting units.</ix:continuation> Refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding the reallocation of goodwill to the new reporting units.</span></div><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMzkzMw_d99722b8-6063-4564-b52e-32a54d18d054" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FASB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) issued Accounting Standards Update (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) 2021-10, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832)&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides disclosure requirements regarding government grants and contributions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ASU requires disclosure of the nature of transactions and related accounting policies used to account for transactions, the effect, including amounts, of government assistance on individual line items on the financial statements, and significant terms and conditions of the transactions, including commitments and contingencies. This ASU is effective for fiscal years beginning after December 15, 2021. The Company adopted the provisions of this ASU effective January 1, 2022. There was no impact upon adoption.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All ASUs issued and not yet effective for the three and nine months ended September&#160;30, 2022, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company&#8217;s financial position and results of operations.</span></div></ix:nonNumeric></ix:continuation><div id="ide1fe17276234d55bab608462fe4131b_49"></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.    <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:AccountsAndNontradeReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfMzc2_ea9d2feb-d5bb-4c9f-929f-5c7f1afb73d7" continuedAt="i86e7d89e1785420885b529c4c45ea459" escape="true">Accounts Receivable, Net</ix:nonNumeric></span></div><ix:continuation id="i86e7d89e1785420885b529c4c45ea459"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfMzc3_56093fbc-24e5-47bb-925d-a543dd4bb037" escape="true"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMS0xLTEtMS05MDE5NA_69164580-c09d-4453-8835-9640b50fa7a8">44,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMS0zLTEtMS05MDE5NA_2a4f309a-f2d4-4abf-83b8-06bc43b30d7f">41,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMi0xLTEtMS05MDE5NA_ad4b419d-8983-4217-8e54-1aee86dfac86">3,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMi0zLTEtMS05MDE5NA_1b6a80f5-99d3-4672-b254-05913f564974">1,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMy0xLTEtMS05MDE5NA_1adec637-4f58-4786-8eda-e770521f9330">40,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMy0zLTEtMS05MDE5NA_2f25ab12-f2f5-4d92-9e27-f4e1841d07f7">40,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bad debt expense, included in selling, general and administrative expense on the condensed consolidated statements of operations, for the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-5" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfMjY5_199e7144-92d6-4e37-a3cf-e2adee3f73d3">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-5" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfMjc2_5df9bb6a-b5c4-4bb9-b6ca-6af169010181">2.8</ix:nonFraction> million, respectively. Bad debt expense for the three and nine months ended September&#160;30, 2021 was <ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-5" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfNDk0NzgwMjMyNTM3MA_a22854a0-2bc7-4767-ba42-e0867026cd85"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-5" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfNDk0NzgwMjMyNTM3MA_e6ab3fa5-9f6b-49ea-a2f4-1c2ae36631cd">no</ix:nonFraction></ix:nonFraction>t significant in either period.</span></div></ix:continuation><div id="ide1fe17276234d55bab608462fe4131b_52"></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfNDE1_c319c315-dd26-47b6-8eec-39bec4b3c24f" continuedAt="i1c1e2a812a1e4b36951d50613e6db5a4" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i1c1e2a812a1e4b36951d50613e6db5a4" continuedAt="ie7a3f0e766cd489ca06052af2581b041"><div style="margin-bottom:9pt;margin-top:6pt"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfNDI1_cbd27220-3cb7-46aa-bc19-0ec222ef5e68" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMS0xLTEtMS05MDE5NA_acc82e90-a436-4751-8498-689d2dbfe074">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMS0zLTEtMS05MDE5NA_3847f9de-37b4-4a5a-928f-782fc4680178">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMi0xLTEtMS05MDE5NA_1ed80eb0-344e-4de9-903d-64ff15d36c1b">7,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMi0zLTEtMS05MDE5NA_cc36fac6-a559-41aa-a194-96c61dc0fac7">6,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMy0xLTEtMS05MDE5NA_009fdaa8-7146-4349-b108-fc9b89aa0f62">5,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMy0zLTEtMS05MDE5NA_a71c2c9b-a7e1-4822-9e6e-23f0a8e8fddf">4,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfNi0xLTEtMS05MDE5NA_b2efe1d8-243c-4e12-9165-a4701cac8be5">13,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfNi0zLTEtMS05MDE5NA_3c6f3345-4028-473c-b5e8-459bb0345dc9">11,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the conclusion of the FDA&#8217;s period of Enforcement Discretion on May 31, 2021, the Company wrote-off $<ix:nonFraction unitRef="usd" contextRef="i131cd49a86304288b8b62abaeab421af_D20210101-20210930" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfMTg5_d19acc49-c5f6-4e8d-a4e9-99d8b2fc7140">1.0</ix:nonFraction> million of its Section 351 product inventory during the nine months ended September 30, 2021. In addition, during the three and nine months ended September 30, 2021, the Company wrote-down $<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfMTY0OTI2NzQ0MjYxNw_4f014d67-5f66-4c85-99be-a9e58ffa19e4">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfMTY0OTI2NzQ0MjYyOQ_8305bec5-c9d1-44d1-8d85-59b952682a26">0.7</ix:nonFraction> million, respectively, for inventory related to product lines which had been discontinued. These amounts are included as part of cost of sales on the unaudited condensed consolidated statements of operations for those periods.</span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie7a3f0e766cd489ca06052af2581b041">There were <ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfNDk0NzgwMjMyNjMwNA_75d4d1fb-3218-48d2-961a-b1e0948c0cf1"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfNDk0NzgwMjMyNjMwNA_af6ea045-aa53-4460-a9ba-ad918c255030">no</ix:nonFraction></ix:nonFraction> significant, unusual write-downs of inventory during the three or nine months ended September&#160;30, 2022</ix:continuation>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RleHRyZWdpb246ZTI2MjI4YjYwOTQzNDJiNzk1N2E5NzUxMzM1ZDEwNTBfNDIy_27fdea60-f37b-434e-a646-e94b69d120c8" continuedAt="i85ea4b3bd8f14986900c24f99fa31162" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="i85ea4b3bd8f14986900c24f99fa31162"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RleHRyZWdpb246ZTI2MjI4YjYwOTQzNDJiNzk1N2E5NzUxMzM1ZDEwNTBfNDMz_9c8b9c67-d349-43ce-a2a4-f3acfae9d4f7" escape="true"><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5b133a447a448cbfbd88970beedf99_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMS0xLTEtMS05MDE5NA_0a55387a-5366-48a2-8a8c-9434379828cd">9,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c78ba1965249998d6dc020ae794009_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMS0zLTEtMS05MDE5NA_5e672848-adc9-4963-aa88-efa48f078686">9,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and clean room equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2e0a68a303f40bba14b646d9df1b2ef_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMi0xLTEtMS05MDE5NA_54a3f76b-21b3-4e5a-b1df-ee5645384cfa">16,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i907909b20b2e448c9e0b5b78f71df456_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMi0zLTEtMS05MDE5NA_91785763-bc63-4da3-bab2-bf6e65d8d7e4">16,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5850839a03ec478ab31c891fe1d1573b_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMy0xLTEtMS05MDE5NA_c7661937-f874-45a0-aa55-a03e0dc76d27">14,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68aef08154104f7a9e1912924d2a94bf_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMy0zLTEtMS05MDE5NA_789fcff7-9b32-4683-acaa-6366496b3dcc">14,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e71c1046d64413295469b7be58e7419_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNC0xLTEtMS05MDE5NA_658158f8-f918-4c31-975a-71bb0b964031">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ace787428240a4aca18f56aebd13d4_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNC0zLTEtMS05MDE5NA_23ee7649-279c-4bd5-bf13-d11d480b2736">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b2e3aad6cd4af1b759a3681f47bf28_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNS0xLTEtMS05MDE5NA_73d216a2-b82f-4986-a368-b4fc853dbcec">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida2ac468ebe44af2a56555cff32b5007_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNS0zLTEtMS05MDE5NA_8440dc61-b735-45af-96e5-e8aa4cf25cf8">863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNi0xLTEtMS05MDE5NA_9f6d7f05-cc9c-49e3-9f19-0c1bc0050abc">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNi0zLTEtMS05MDE5NA_358e059c-d8f6-4804-b397-1ad66e20d279">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNy0xLTEtMS05MDE5NA_7fe275f0-d0bc-4be0-83b2-1debd2c58755">43,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNy0zLTEtMS05MDE5NA_555535be-3f81-4809-8557-f924f540d12b">42,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfOC0xLTEtMS05MDE5NA_2035603d-e7f9-452e-a72f-3cb15d111114">35,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfOC0zLTEtMS05MDE5NA_e973e8f7-d1e7-44ea-9894-fd6f0731044f">32,878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfOS0xLTEtMS05MDE5NA_36864f6e-f2e2-4a74-84c2-9f5d16bdaa44">7,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfOS0zLTEtMS05MDE5NA_eeefd5ec-90c4-4a25-aa78-732cce53808a">9,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="mdxg:ScheduleOfDepreciationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RleHRyZWdpb246ZTI2MjI4YjYwOTQzNDJiNzk1N2E5NzUxMzM1ZDEwNTBfNDM0_137606e8-535c-45c3-84f2-b8e2ab58634b" escape="true"><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three and nine months ended September&#160;30, 2022 and 2021 is summarized in the table below (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjhiODI3NjlkZWYyNzQzODE4NmE5MDU4MDQ4MzIzNmZjL3RhYmxlcmFuZ2U6OGI4Mjc2OWRlZjI3NDM4MTg2YTkwNTgwNDgzMjM2ZmNfMi0xLTEtMS05MDE5NA_ca60018b-e933-4ede-ad20-cfd9ab9bf1e1">831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjhiODI3NjlkZWYyNzQzODE4NmE5MDU4MDQ4MzIzNmZjL3RhYmxlcmFuZ2U6OGI4Mjc2OWRlZjI3NDM4MTg2YTkwNTgwNDgzMjM2ZmNfMi0zLTEtMS05MDE5NA_766548c4-d978-4994-a5dc-56953551c8f2">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjhiODI3NjlkZWYyNzQzODE4NmE5MDU4MDQ4MzIzNmZjL3RhYmxlcmFuZ2U6OGI4Mjc2OWRlZjI3NDM4MTg2YTkwNTgwNDgzMjM2ZmNfMi01LTEtMS05MDE5NA_f28cbb48-c497-4bdf-b6e0-cd95bf22c0c2">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjhiODI3NjlkZWYyNzQzODE4NmE5MDU4MDQ4MzIzNmZjL3RhYmxlcmFuZ2U6OGI4Mjc2OWRlZjI3NDM4MTg2YTkwNTgwNDgzMjM2ZmNfMi03LTEtMS05MDE5NA_9347929b-21ff-42c7-9d4b-b562e76d15f4">3,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense is allocated amongst cost of sales, research and development expense, and selling, general, and administrative expense on the unaudited condensed consolidated statements of operations.</span></div></ix:continuation><div id="ide1fe17276234d55bab608462fe4131b_61"></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjk3_03812d5f-e54e-478e-8ece-a4d1d404b343" continuedAt="i222432554bc541a2a1b962402713615e" escape="true">Goodwill and Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="i222432554bc541a2a1b962402713615e" continuedAt="ia69e6212aa334cb6b272f826087e2f74"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Company had concluded that it operated as a single operating segment and single reporting unit. During the three and nine months ended September 30, 2022, as a result of changes in the management of the Company&#8217;s business, management concluded that the Company operates as <ix:nonFraction unitRef="segment" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI2MTUwMQ_443d8121-fd3d-4c9f-b0e3-055714c80d02"><ix:nonFraction unitRef="segment" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI2MTUwMQ_a113c65c-5a93-48b4-861d-c65921131191">three</ix:nonFraction></ix:nonFraction> operating segments, including <ix:nonFraction unitRef="segment" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI1OTc2OA_292f9d38-6d9c-40cb-8bd2-41e1ddc34d37"><ix:nonFraction unitRef="segment" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI1OTc2OA_966903ef-6a75-4214-a183-d05eb1c81b87">two</ix:nonFraction></ix:nonFraction> distinct reportable segments: Wound &amp; Surgical and Regenerative Medicine. See Note 15 for a description of the Company&#8217;s operating segments. Management further concluded that it had <ix:nonFraction unitRef="segment" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI2MDU2Mw_4a2b205c-a68f-45ba-a84e-b2d93a9cf758"><ix:nonFraction unitRef="segment" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI2MDU2Mw_75be6a99-918e-4753-a89a-0b2208c0e865">three</ix:nonFraction></ix:nonFraction> reporting units. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the $<ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI2MzAyNw_5fd48bd6-c47d-4789-9723-e10b923cb5d9">20.0</ix:nonFraction>&#160;million of consolidated goodwill, which was entirely allocated to its previous reporting unit, to each of Wound &amp; Surgical and Regenerative Medicine based on their relative fair values from a market participant standpoint. The result was $<ix:nonFraction unitRef="usd" contextRef="ia0104112777e4d14bd77bb3e2902b0a5_I20220930" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMTI2NDQzODM3MjY0MjY_f26ae2fb-4d07-440d-922c-77da6a25ce7b">19.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0ffd915aa45d4727b23956af58280014_I20220930" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMTI2NDQzODM3MjY0ODY_09dae41c-90c5-414a-8f60-98ba9cc8891c">0.5</ix:nonFraction> million allocated to Wound &amp; Surgical and Regenerative Medicine, respectively. A third reporting unit associated with the Company&#8217;s third operating segment was deemed immaterial and no goodwill was assigned to it. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed goodwill impairment tests using the Company&#8217;s single reporting unit and the new reporting units. In all cases, the Company concluded that the estimated fair values of each reporting unit exceeded their respective carrying values. Therefore, the Company did not record impairment for goodwill during the three or nine months ended September 30, 2022. There was no other activity related to goodwill during the three or nine months ended September&#160;30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ia69e6212aa334cb6b272f826087e2f74"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjky_734bebad-670d-4d50-85fa-acd9614f3589" escape="true"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjc5_b70f7d7b-fd73-4892-875b-e064cfe807f5" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, are summarized as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:38.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and know-how</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6136baa90f844b998d36da85b2453db_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy0xLTEtMS05MDE5NA_e717ad6c-8c80-4c37-a3c2-23f496c718b7">9,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6136baa90f844b998d36da85b2453db_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy0yLTEtMS05MDE5NA_d133a86d-249a-43e6-a0d8-6e586e7bbbbf">6,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6136baa90f844b998d36da85b2453db_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy0zLTEtMS05MDE5NA_2a164aa1-dea8-42e5-848c-c2c5a96b397c">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i659a8e16e9c94e5a93efa999dc1cca89_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy01LTEtMS05MDE5NA_cbebcf21-7832-4478-b9c9-0f6b270dc3e6">9,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i659a8e16e9c94e5a93efa999dc1cca89_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy02LTEtMS05MDE5NA_b6667252-9118-4525-9628-6dd5a1b5615d">6,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i659a8e16e9c94e5a93efa999dc1cca89_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy03LTEtMS05MDE5NA_21117fed-d8f1-4608-8898-a7de1bdf960a">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tradenames and trademarks</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb08258960c42db90551aecd2db413d_I20220930" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTAtMS0xLTEtOTAxOTQ_10562fbf-fdce-41b2-a570-18b8f7008ae4">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb08258960c42db90551aecd2db413d_I20220930" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTAtMy0xLTEtOTAxOTQ_6ed25df1-38f9-4ddd-a0f5-0dd9fa0f56b4">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6c48c7387b4e87940f4064398a14df_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTAtNS0xLTEtOTAxOTQ_128d2803-49e4-44c0-be52-36bcf8f97eb7">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6c48c7387b4e87940f4064398a14df_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTAtNy0xLTEtOTAxOTQ_88e4d483-b43c-485a-b509-1c4679da6602">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd1d1c82ab24631a37cd041c9a9dbe2_I20220930" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTEtMS0xLTEtOTAxOTQ_3b018d2a-96e4-41dd-902b-01d80dab67e3">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd1d1c82ab24631a37cd041c9a9dbe2_I20220930" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTEtMy0xLTEtOTAxOTQ_e4e24344-e4bc-4406-b3b2-de454865a9b3">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4963e235cc9f495d91c3496c848f2cdb_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTEtNS0xLTEtOTAxOTQ_acdea93a-0956-403a-93a4-d911cad0cd3e">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4963e235cc9f495d91c3496c848f2cdb_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTEtNy0xLTEtOTAxOTQ_60759c4a-cccf-4f97-94fc-01e8bacc5531">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTItMS0xLTEtOTAxOTQ_381599d9-a283-4903-8d1e-a8c153df5c3e">11,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTItMy0xLTEtOTAxOTQ_34da7b5b-9af1-45c7-9f7c-c9c5e8a1610c">4,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTItNS0xLTEtOTAxOTQ_ea12fcd9-eaf1-454d-abca-02cdbf2185a2">11,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTItNy0xLTEtOTAxOTQ_d4f11fc2-5a51-439d-920e-aa36448636c5">5,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three and nine months ended September 30, 2022 and 2021 is summarized in the table below (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:28.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.963%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjAyYTBlZTZhODBmYTQ0MmI4Y2YxZGU2ZWE1NjZlOTkwL3RhYmxlcmFuZ2U6MDJhMGVlNmE4MGZhNDQyYjhjZjFkZTZlYTU2NmU5OTBfMi0xLTEtMS05MDE5NA_ecb678e2-85e0-494b-8aac-686515841fc8">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjAyYTBlZTZhODBmYTQ0MmI4Y2YxZGU2ZWE1NjZlOTkwL3RhYmxlcmFuZ2U6MDJhMGVlNmE4MGZhNDQyYjhjZjFkZTZlYTU2NmU5OTBfMi0zLTEtMS05MDE5NA_072ce126-4765-45ee-b170-6680df750884">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjAyYTBlZTZhODBmYTQ0MmI4Y2YxZGU2ZWE1NjZlOTkwL3RhYmxlcmFuZ2U6MDJhMGVlNmE4MGZhNDQyYjhjZjFkZTZlYTU2NmU5OTBfMi01LTEtMS05MDE5NA_9aa894c3-f52d-418a-990f-aafe1a864caf">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjAyYTBlZTZhODBmYTQ0MmI4Y2YxZGU2ZWE1NjZlOTkwL3RhYmxlcmFuZ2U6MDJhMGVlNmE4MGZhNDQyYjhjZjFkZTZlYTU2NmU5OTBfMi03LTEtMS05MDE5NA_815a0aef-17d3-4c74-a64e-ac06e32039cc">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjk1_8b1809c7-904b-4807-ad24-138b08a22459" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization of intangible assets as of September&#160;30, 2022, is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated<br/>Amortization <br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the nine months ended September 30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfMS0xLTEtMS05MDE5NA_93c82161-33b6-4e7f-ad89-0ac744f698c3">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfMi0xLTEtMS05MDE5NA_bda20683-c9c9-4d51-9924-e67f02255ab4">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfMy0xLTEtMS05MDE5NA_9a20f31a-0cbe-43b4-83cf-0a18b481be4d">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfNC0xLTEtMS05MDE5NA_e5898bb4-fe46-43d1-910e-95ebca527704">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfNS0xLTEtMS05MDE5NA_abe434ed-3e3e-48ae-840d-cbcf1a01f8c4">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="mdxg:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfNi0xLTEtMS05MDE5NA_2623a19d-1124-4526-91fc-1cfd20ded703">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortized intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfNy0xLTEtMS05MDE5NA_5eb02a74-9dec-40d7-9ab3-d2730699a2c0">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ide1fe17276234d55bab608462fe4131b_64"></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.     <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RleHRyZWdpb246NzQ4NDgxZjRjODNjNGIwMjg5NTljYjAwY2I0MTM5MTRfOTA_d8aac797-201d-4206-9f72-8638f328017d" continuedAt="if88392b841a24016b14b15f9664e781d" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="if88392b841a24016b14b15f9664e781d"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RleHRyZWdpb246NzQ4NDgxZjRjODNjNGIwMjg5NTljYjAwY2I0MTM5MTRfOTE_fbdd7350-d9bc-441c-b0f0-e285b9ce7709" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses&#160;consisted of the following&#160;(in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"></td><td style="width:53.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and settlement costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMS0xLTEtMS05MDE5NA_c3499187-b375-45c3-a413-3c391b28468a">4,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMS0zLTEtMS05MDE5NA_526161ad-bf47-4bda-94bb-0a3d31c51093">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commissions to sales agents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMy0xLTEtMS05MDE5NA_0b1d5982-eb0e-4cc0-9414-0c085150b22f">2,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMy0zLTEtMS05MDE5NA_706043ed-9305-487c-abc9-b9ddd26c5661">2,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="mdxg:AccruedRebates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNC0xLTEtMS05NDY0Mw_d63fa2b6-c6f3-4179-a152-68cacba01e50">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="mdxg:AccruedRebates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNC0zLTEtMS05NDY0Mw_58e18f50-71a9-4dde-8c52-9343d2d73e88">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued group purchasing organization fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="mdxg:AccruedAdministrativeFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNC0xLTEtMS05MDE5NA_64c7770c-e1e2-43a9-bfee-5a5b076b6874">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="mdxg:AccruedAdministrativeFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNC0zLTEtMS05MDE5NA_2e0fe34f-d727-4b59-806e-f72ce6fe778b">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated sales returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNS0xLTEtMS05MDE5NA_7acce63b-5504-46b7-9d5b-9c2b539bf831">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNS0zLTEtMS05MDE5NA_4b09ceac-e8a9-48c2-b370-cba0a0db99ea">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued travel</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="mdxg:AccruedTravel" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNi0xLTEtMS05MDE5NA_d25efe01-01f2-4a60-bf04-5742aa6d6dd2">402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="mdxg:AccruedTravel" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNi0zLTEtMS05MDE5NA_93f62dde-0056-462f-a733-16e87c83128e">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="mdxg:AccruedClinicalTrialsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNy0xLTEtMS05MDE5NA_dd5249ea-06c4-4f71-99fc-b5a3110e643f">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="mdxg:AccruedClinicalTrialsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNy0zLTEtMS05MDE5NA_d068731d-e455-4075-a622-99e5e9eab25e">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfOS0xLTEtMS05MDE5NA_b8ea42d5-9f86-40cc-abe1-5e73bf8a8b0d">1,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfOS0zLTEtMS05MDE5NA_c1428516-0e3e-4ca9-b14f-707379027632">607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMTAtMS0xLTEtOTAxOTQ_ec51b82c-52bb-408b-b299-9506e535bd71">10,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMTAtMy0xLTEtOTAxOTQ_f9ea00c1-e262-430a-8dcf-6e4403f65bbe">9,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">        8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjc2MQ_5fa692ea-bc6d-4217-a30c-3837cd490b24" continuedAt="i7bcc49744935424fa94a1f9c7f8d39de" escape="true">Long Term Debt, Net</ix:nonNumeric></span></div><ix:continuation id="i7bcc49744935424fa94a1f9c7f8d39de" continuedAt="i3ecefbc25ef3412c85bca1c667219d36"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hayfin Loan Agreement</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2020, the Company entered into a Loan Agreement with, among others, Hayfin Services, LLP (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hayfin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), an affiliate of Hayfin Capital Management LLP (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hayfin Loan Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which Hayfin funded on July 2, 2020 (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Closing Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), providing the Company with a senior secured term loan in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMzg2_0b259269-84a4-484c-b0d5-5abbf92f4934">50</ix:nonFraction>&#160;million (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Term Loan matures on June 30, 2025 (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maturity Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Interest is payable on the Term Loan for the principal balance outstanding quarterly through the Maturity Date. No principal payments on the Term Loan are due and payable until the Maturity Date.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hayfin Loan Agreement also provided the Company an option to draw on an additional delayed draw term loan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DD TL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; collectively with the Term Loan, the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in the form of a committed but undrawn facility until June 30, 2021. The Company did not exercise the option.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022 (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Company executed an Amendment to the Hayfin Loan Agreement (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Amendment was accounted for as a modification. No gain or loss was recognized nor was there a change to the carrying amount of the debt as a result of the Amendment.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on any borrowings under the Hayfin Loan Agreement, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Hayfin Loan Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), is equal to the London Interbank Offered Rate (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LIBOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (subject to a floor of <ix:nonFraction unitRef="number" contextRef="ida0d445363084e00b087a41a67afce57_D20220228-20220228" decimals="INF" name="mdxg:DebtInstrumentInterestRateFloorPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTQ0MQ_1ab51810-95d5-43fe-9bc2-c833d411913c">1.5</ix:nonFraction>%), plus a margin of <ix:nonFraction unitRef="number" contextRef="ida0d445363084e00b087a41a67afce57_D20220228-20220228" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTQ2Mg_f25f1251-d78f-44f9-bea4-a793f155b56e">6.75</ix:nonFraction>% per annum. If LIBOR is unavailable, the Term Loan will carry interest at the <ix:nonFraction unitRef="number" contextRef="ida0d445363084e00b087a41a67afce57_D20220228-20220228" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTU0Mg_f25f1251-d78f-44f9-bea4-a793f155b56e">6.75</ix:nonFraction>% margin plus the greatest of the Prime Rate, the Federal Funds Rate plus <ix:nonFraction unitRef="number" contextRef="i78a81d5053e240d4b3ca17890dd5c28f_D20220228-20220228" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTYxNw_29b4dda6-3f6d-42ab-bf10-ef58cdd851fc">0.5</ix:nonFraction>% per annum, and <ix:nonFraction unitRef="number" contextRef="i19941ad137e24c988a6625220a34fbe7_D20220228-20220228" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTYzNQ_7d882433-d2b1-4eb1-a7eb-872397943dbd">2.5</ix:nonFraction>%.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional <ix:nonFraction unitRef="number" contextRef="ida0d445363084e00b087a41a67afce57_D20220228-20220228" decimals="INF" name="mdxg:DebtInstrumentDefaultInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTY1Mw_d692de87-a7ab-4b52-91f4-94e730d7d5b0">3.0</ix:nonFraction>% margin is applied to the interest rate in the event of a default as defined in the Amended Hayfin Loan Agreement. The Term Loan carried an interest rate of <ix:nonFraction unitRef="number" contextRef="i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTgxMg_c2402cb5-8b87-4006-9dd0-2fa93b703cb8">8.3</ix:nonFraction>% at issuance and <ix:nonFraction unitRef="number" contextRef="ied1ef014d51f4e56b7b022759ec9dc30_I20220930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTgzMg_9262ebc9-daa0-443d-9ab9-aaa9dbcc6210">10.4</ix:nonFraction>% as of September&#160;30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Hayfin Loan Agreement, contains financial covenants requiring the Company, on a consolidated basis, to maintain the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum Consolidated Total Net Sales (as defined in the Amended Hayfin Loan Agreement) of varying amounts, required to be calculated on a quarterly basis, and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum Liquidity (as defined in the Amended Hayfin Loan Agreement) of $<ix:nonFraction unitRef="usd" contextRef="i5ca2668ba8fb4aa5a0b452209fcbf752_D20220228-20220228" decimals="INF" name="mdxg:DebtCovenantMinimumLiquidity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMjIxNg_5dbeef5b-ad97-49fc-93e1-315af3fd69ab">20</ix:nonFraction> million, an at-all-times financial covenant tested monthly.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company is in compliance with all applicable financial covenants under the Amended Hayfin Loan Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Hayfin Loan Agreement also includes certain negative covenants and events of default customary for facilities of this type, and upon the occurrence of such events of default, subject to customary cure rights, the Term Loan may be accelerated or the lenders&#8217; commitments terminated. Mandatory prepayments are also required in the event of a change in control, incurring other indebtedness, certain proceeds from disposal of assets and insured casualty event (as defined in the Amended Hayfin Loan Agreement). Annually, beginning with the fiscal year ended December 31, 2021, the Company is required to prepay the outstanding loans based on a percentage of Excess Cash Flow (as defined in the Amended Hayfin Loan Agreement), if such is generated. No such prepayments have been required as of September&#160;30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A breach of a financial covenant in the Amended Hayfin Loan Agreement, if uncured or unable to be cured, would likely result in an event of default that could trigger the lender&#8217;s remedies, including acceleration of the entire principal balance of the loan as well as any applicable prepayment premiums.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Hayfin Loan Agreement also specifies that any prepayment of the Term Loan, voluntary or mandatory, will subject the Company to a prepayment premium applicable as of the date of the prepayment as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On or before July 2, 2023: <ix:nonFraction unitRef="number" contextRef="i2747f527fb9748c58c87520ae15d6b71_D20220228-20220228" decimals="INF" name="mdxg:DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMzcxMg_994b69e6-abed-4f1c-a0bd-e8f4f8424d2a">2</ix:nonFraction>% of the principal balance repaid.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">After July 2, 2023 and on or before July 2, 2024: <ix:nonFraction unitRef="number" contextRef="i113d9f8cbf62488ba9b7295966501570_D20220228-20220228" decimals="INF" name="mdxg:DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMzc5OA_b2c8f930-e799-4ddb-b1b3-bfa7430440c9">1</ix:nonFraction>% of the principal balance repaid.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">After July 2, 2024: <ix:nonFraction unitRef="number" contextRef="if13a467d34074320a376b1a5273913b3_D20220228-20220228" decimals="INF" name="mdxg:DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMzg1NA_3e575920-5f6f-42f7-ac2a-14e4ee385871">no</ix:nonFraction> premium.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hayfin maintains a first-priority security interest in substantially all of the Company&#8217;s assets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i3ecefbc25ef3412c85bca1c667219d36" continuedAt="id9ceeb3476f045269f477977079e1861"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Original issue discount and deferred financing costs were allocated between the sale of the Series B Preferred Stock (which occurred on the same day as the funding of the Hayfin Loan Agreement as described in Note 10) and the Hayfin Loan Agreement on the basis of the relative fair values of the transactions. The costs allocated to the Hayfin Loan Agreement were further allocated between the Term Loan and the DD TL on the basis of the maximum potential principal outstanding between the Credit Facilities. <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="mdxg:ScheduleOfDebtIssuanceCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjc2Nw_0fa92771-6de8-4b33-85e8-d3ce71829747" continuedAt="i07d0063e62f045f2818dd3b1df103c23" escape="true">The allocation of the deferred financing costs and original issue discount between the Term Loan and the DD TL on July 2, 2020 was as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><ix:continuation id="i07d0063e62f045f2818dd3b1df103c23"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.263%"><tr><td style="width:1.0%"></td><td style="width:24.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DD TL</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue discount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfMy0xLTEtMS05MDE5NA_8eb6e66c-927c-4dd9-847a-60300c6fcbef">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddda1184b02a44928b0c26d038f76bca_I20200702" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfMy0zLTEtMS05MDE5NA_cf9df8e7-1162-470a-bb6e-fd63c58acfe7">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01dffba8325446a929870e45228e37c_I20200702" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfMy01LTEtMS05MDE5NA_4869010c-96d9-45b9-b597-7684e531c6b0">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfNC0xLTEtMS05MDE5NA_576ca5ac-d47c-4543-9796-854b50abb1d6">2,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddda1184b02a44928b0c26d038f76bca_I20200702" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfNC0zLTEtMS05MDE5NA_2dffd4b3-37ec-421a-a23a-12ebcbe450c8">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01dffba8325446a929870e45228e37c_I20200702" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfNC01LTEtMS05MDE5NA_171dfed9-7a60-4b2f-bfed-9deae918aa50">3,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs and original issue discount associated with the Term Loan are amortized using the effective interest method through the Maturity Date. The amortization of such amounts is presented as part of interest expense, net on the unaudited condensed consolidated statement of operations. Unamortized deferred financing costs and original issue discount associated with the Term Loan are presented as a reduction to the principal balance on the Term Loan as part of long term debt, net on the unaudited condensed consolidated balance sheets as of September&#160;30, 2022 and December&#160;31, 2021.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs and original issue discount associated with the DD TL were amortized using the straight-line method through the expiration of the DD TL commitment term on June 30, 2021. Amortization of these amounts is presented as part of interest expense, net on the unaudited condensed consolidated statement of operations for the nine months ended September 30, 2021. The DD TL was subject to a commitment fee of <ix:nonFraction unitRef="number" contextRef="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930" decimals="INF" name="mdxg:DebtInstrumentUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNTYyNQ_cfd0956f-1007-447c-b347-f93f47e38b33">1</ix:nonFraction>% per annum of the amount undrawn, which was recognized as interest expense.</span></div><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjc2NA_9c85174a-615e-47d1-870a-8cdc81f09e32" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balances of the Term Loan as of September&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.941%"><tr><td style="width:1.0%"></td><td style="width:33.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1ef014d51f4e56b7b022759ec9dc30_I20220930" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMS0xLTEtMS05MDE5NA_0c27408a-d05b-488e-9ab6-532f449ab6fe">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea70269e38be47efb68e17ebedd54b55_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMS0zLTEtMS05MDE5NA_aadce124-63dd-4c78-ba18-b27bd1a107aa">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied1ef014d51f4e56b7b022759ec9dc30_I20220930" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMi0xLTEtMS05MDE5NA_862775b4-525f-463b-9d8e-bc8659fe03f5">1,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea70269e38be47efb68e17ebedd54b55_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMi0zLTEtMS05MDE5NA_f85ddb24-243f-4251-90c8-089a210e10a0">1,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied1ef014d51f4e56b7b022759ec9dc30_I20220930" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMy0xLTEtMS05MDE5NA_2e645275-3ec0-4fee-bd75-ba610684afaf">203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea70269e38be47efb68e17ebedd54b55_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMy0zLTEtMS05MDE5NA_81387de9-594f-428e-b1c0-75343bbd85a2">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1ef014d51f4e56b7b022759ec9dc30_I20220930" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfNC0xLTEtMS05MDE5NA_74b5485e-7515-4aa1-8712-6722532ea983">48,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea70269e38be47efb68e17ebedd54b55_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfNC0zLTEtMS05MDE5NA_7160f34e-c7dd-449e-b7fc-172acd9e7675">48,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="mdxg:ScheduleOfInterestExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjc2OA_19a66f5b-3f25-405e-bd36-f57b6d439ab3" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the Term Loan, included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:33.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.774%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stated interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMi0xLTEtMS05MDE5NA_16a2cb8e-0836-4e6e-84fd-f765d59df7ac">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06158252259a4bb1be9943fc4f9b8256_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMi0zLTEtMS05MDE5NA_225c5c87-f8fe-4213-ae34-13bac9997267">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie32894e2f8cb4b40bf661b269dd42436_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMi01LTEtMS05MDE5NA_a886e3f7-055a-4888-88f4-c508ca44af07">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db0a9efc4324b35ab710da5c792ca3e_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMi03LTEtMS05MDE5NA_02f62d58-c00c-4fcd-af82-6be9ee87f4fb">3,116</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMy0xLTEtMS05MDE5NA_f9f052d0-f902-46f8-bc9f-2b38d30287d1">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06158252259a4bb1be9943fc4f9b8256_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMy0zLTEtMS05MDE5NA_afb7e5d0-a65d-44ce-8ef2-e3d7f49e86fc">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie32894e2f8cb4b40bf661b269dd42436_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMy01LTEtMS05MDE5NA_9ecb9fe7-721f-45be-83df-315cd08bff5e">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db0a9efc4324b35ab710da5c792ca3e_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMy03LTEtMS05MDE5NA_1eb9c85f-d97e-43ff-b88e-093229097bca">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNC0xLTEtMS05MDE5NA_5b9240e1-4278-4228-afac-5b0394c7c8bf">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06158252259a4bb1be9943fc4f9b8256_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNC0zLTEtMS05MDE5NA_01fb905d-121c-423e-8d59-bb76a51b418c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie32894e2f8cb4b40bf661b269dd42436_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNC01LTEtMS05MDE5NA_74dd4d13-90af-4d32-ae0b-6dc753d530fa">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db0a9efc4324b35ab710da5c792ca3e_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNC03LTEtMS05MDE5NA_55a167b1-c684-4232-a5b3-825bc0445477">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNS0xLTEtMS05MDE5NA_d2a836a8-d089-4925-a3fe-79ccf90bbb27">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06158252259a4bb1be9943fc4f9b8256_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNS0zLTEtMS05MDE5NA_60f89a52-b091-492e-8120-20f4ce873a3f">1,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie32894e2f8cb4b40bf661b269dd42436_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNS01LTEtMS05MDE5NA_17ff5415-c9f9-4c04-aac0-926ed4741600">3,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db0a9efc4324b35ab710da5c792ca3e_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNS03LTEtMS05MDE5NA_c144bdc9-64f1-41e4-b01c-f4939865c777">3,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the DD TL, included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:34.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.467%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitment fee</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae78b34019f45208b00a4a3385ba0bf_D20220701-20220930" decimals="-3" name="mdxg:DebtInstrumentCommitmentFees" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMi0xLTEtMS05MDE5NA_68185efa-9941-4788-a891-3e6cfb399c1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed176b1136d4fa38e04ca50f5c1469a_D20210701-20210930" decimals="-3" name="mdxg:DebtInstrumentCommitmentFees" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMi0zLTEtMS05MDE5NA_dd7978e8-8f94-4ad3-91ab-b36ce5d5ec28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa56b9335b624293aeb4786b43d54f20_D20220101-20220930" decimals="-3" name="mdxg:DebtInstrumentCommitmentFees" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMi01LTEtMS05MDE5NA_06ec32cd-4c9b-4d30-8398-52e8433671b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930" decimals="-3" name="mdxg:DebtInstrumentCommitmentFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMi03LTEtMS05MDE5NA_fd1fa013-010f-41aa-a458-ddda231e1245">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae78b34019f45208b00a4a3385ba0bf_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMy0xLTEtMS05MDE5NA_cf5c70e7-9eff-4f2a-865a-0ed3e8899166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed176b1136d4fa38e04ca50f5c1469a_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMy0zLTEtMS05MDE5NA_6f380b88-710b-4959-9baf-19bc849581a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa56b9335b624293aeb4786b43d54f20_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMy01LTEtMS05MDE5NA_e434433e-8155-492f-8455-35f3af0d4502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMy03LTEtMS05MDE5NA_daa26dce-9ebd-47d3-8702-5e1f19983d03">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae78b34019f45208b00a4a3385ba0bf_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNC0xLTEtMS05MDE5NA_24ebf47d-b1ae-4b0f-8ded-63a3101c3294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed176b1136d4fa38e04ca50f5c1469a_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNC0zLTEtMS05MDE5NA_139130a2-f02e-46a5-a095-87125be7bb81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa56b9335b624293aeb4786b43d54f20_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNC01LTEtMS05MDE5NA_69036717-a79c-4179-9acd-b980bcc519e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNC03LTEtMS05MDE5NA_9f0afe7f-a946-4398-bed0-2675e79742ab">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae78b34019f45208b00a4a3385ba0bf_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNS0xLTEtMS05MDE5NA_1c1d2f6a-2dec-400f-8cd3-1db43960e1b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed176b1136d4fa38e04ca50f5c1469a_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNS0zLTEtMS05MDE5NA_0d8cf607-42ab-43f9-8003-dfa506c79197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa56b9335b624293aeb4786b43d54f20_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNS01LTEtMS05MDE5NA_283aea11-c5ee-4143-aa8b-09359dbb7660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNS03LTEtMS05MDE5NA_518f725a-7cee-4749-a363-d7ed436cc14b">751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="id9ceeb3476f045269f477977079e1861"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjc2OQ_fa5a10fd-0224-41dc-9cf3-c72cd1617f6f" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of principal payments due on the Term Loan, by year, from September&#160;30, 2022 through maturity are as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the nine months ended September&#160;30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfMS0xLTEtMS05MDE5NA_f7dccd7d-fc0b-4e5d-a4a4-e5df678ba0f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfMi0xLTEtMS05MDE5NA_1eece9f3-cfdf-41c2-a63e-24331337793b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfMy0xLTEtMS05MDE5NA_e12464e0-5a62-4cdc-8fae-971e91297884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfNC0xLTEtMS05MDE5NA_8e8370ae-e3ca-4be9-9783-75a63fd6e18a">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfNS0xLTEtMS05MDE5NA_8525376a-b5d9-48e8-bb53-e17bc2d20049">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="mdxg:LongTermDebtMaturityAfterYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfNi0xLTEtMS05MDE5NA_86692126-954c-4961-960a-c538831e4a46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfNy0xLTEtMS05MDE5NA_5c86d873-68b0-4ccf-a8f9-b60607b88107">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the fair value of the Term Loan was $<ix:nonFraction unitRef="usd" contextRef="i4c8e4da241644f84bd4f549f2c4d5255_I20220930" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjMwNg_e963e6ef-f137-4d51-afaa-514ff0769c2a">44.7</ix:nonFraction>&#160;million. This valuation was calculated based on a series of Level 2 and Level 3 inputs, including a discount rate based on the credit risk spread of debt instruments of similar risk character in reference to U.S. Treasury instruments with similar maturities, with an incremental risk premium for risk factors specific to the Company. The remaining cash flows associated with the Term Loan were discounted to September&#160;30, 2022 using this discount rate to determine fair value.</span></div></ix:continuation><div id="ide1fe17276234d55bab608462fe4131b_70"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.   <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RleHRyZWdpb246ZWE2YzIyMGNjY2E4NGExMDlkZmJhNzAzY2E1NGFiZjRfMjQzNw_c039632a-3459-42c3-b5a3-266fbcb0fce0" continuedAt="i6a8a1191cf784cbfbfb3b8e3c216a7c6" escape="true">Net Loss Per Common Share</ix:nonNumeric></span></div><ix:continuation id="i6a8a1191cf784cbfbfb3b8e3c216a7c6" continuedAt="i2301d17087334c3ca12a4759e9518e95"><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share is calculated using two methods: basic and diluted.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic Net Loss Per Common Share</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated as net loss available to common stockholders divided by weighted average common shares outstanding. Net loss available to common stockholders is calculated as net loss less (i) dividends accumulated on the Company&#8217;s Series B Convertible Preferred Stock during the period, and (ii) periodic accretion of the increasing-rate dividend feature.</span></div><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RleHRyZWdpb246ZWE2YzIyMGNjY2E4NGExMDlkZmJhNzAzY2E1NGFiZjRfMjQzNA_ac131eb0-fcae-4d40-95ee-2e3690c89d66" escape="true"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of net loss to net loss available to common stockholders and calculation of basic net loss per common share for each of the three and nine months ended September&#160;30, 2022 and 2021 (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:38.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfMi0xLTEtMS05MDE5NA_fa3601b2-199a-46be-a446-fe6e6755f314">8,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfMi0zLTEtMS05MDE5NA_f99d2cca-4dd3-4749-b59d-3ae08f559ee4">2,339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfMi01LTEtMS05MDE5NA_a64fc793-22d0-4382-9433-7fd17aa22c49">29,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfMi03LTEtMS05MDE5NA_b93fb229-62e5-4609-84be-84f077ebd74f">12,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile to net loss available to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated dividend on Series B Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNC0xLTEtMS05MDE5NA_d7cd34d2-c93c-41f6-833c-6ef2cc3032f2">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNC0zLTEtMS05MDE5NA_27942509-de31-4b31-98c3-8a012cb73ebc">1,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNC01LTEtMS05MDE5NA_f6b27d25-6000-4a87-abbe-afe9faac6368">4,884</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNC03LTEtMS05MDE5NA_05bf4efb-3e73-4b41-8932-e84b71e7e3fd">3,613</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of increasing-rate dividend feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNS0xLTEtMS05MDE5NA_6dc280c8-a0c0-419e-979b-996e7ab7d83b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNS0zLTEtMS05MDE5NA_f2ba41db-cd47-479a-a6f5-b774f4d2e532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNS01LTEtMS05MDE5NA_e7ea6316-6b37-4c77-b8ba-5cb53fbb84bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNS03LTEtMS05MDE5NA_cf35fd41-f023-45cd-8649-15bd01e7c54e">926</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNi0xLTEtMS05MDE5NA_a93a34d0-9a66-4eca-9384-0c76de1f6ca3">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNi0zLTEtMS05MDE5NA_06c4b57a-fa3b-420a-9445-9b124e3b6710">1,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNi01LTEtMS05MDE5NA_88b15fee-1be8-463c-8bc7-8727ba4133f6">4,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNi03LTEtMS05MDE5NA_b4ddc6c5-b941-4a00-92b2-bb2d8962e8fc">4,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNy0xLTEtMS05MDE5NA_6a21da31-ce9e-4799-8cc5-6aae1b32bca4">10,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNy0zLTEtMS05MDE5NA_5ff0c814-61aa-4bab-99d6-cd54dcc6e0aa">3,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNy01LTEtMS05MDE5NA_470a15b7-e236-4689-943b-5116b4d42d0a">34,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNy03LTEtMS05MDE5NA_540b0d44-f147-47a2-9e8f-89090b71190e">17,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOC0xLTEtMS05MDE5NA_8a36f4af-c8b2-4346-8a1d-7558317c4f93">113,448,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOC0zLTEtMS05MDE5NA_8b7ecceb-f863-45a8-8f8b-759e224f80e6">110,717,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOC01LTEtMS05MDE5NA_aa5d1507-f3f4-49c4-ba92-e34c5c33bd68">112,650,713</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOC03LTEtMS05MDE5NA_be74db14-6190-47bc-ba50-024b22df1bff">110,136,517</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOS0xLTEtMS05MDE5NA_2544a5a7-c514-4639-84d0-891bc4bfa5f8">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOS0zLTEtMS05MDE5NA_f0a96186-c7cf-4229-9c32-128baa9d0f11">0.04</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOS01LTEtMS05MDE5NA_f184ed3b-226d-4ac7-bc18-b143a653061c">0.31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOS03LTEtMS05MDE5NA_352f5b8a-a550-4211-a350-322ee2418755">0.15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diluted Net Loss Per Common Share</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per common share is calculated as net loss available to common stockholders, adjusted for dividends on convertible preferred stock (to the extent conversion would be dilutive), divided by weighted average common shares outstanding plus potential common shares. The calculation of potential common shares considers incremental shares resulting from certain transactions, including the exercise of stock options and the issuance of restricted stock, using the treasury stock method, as well as the hypothetical conversion of the Company&#8217;s Series B Convertible Preferred Stock using the if-converted method. The treasury stock method assumes that proceeds from the transaction are used to purchase common stock at the average market price throughout the period. The if-converted method adds back periodic accrued or deemed dividends on the Company&#8217;s Series B Convertible Preferred Stock, and assumes conversion as of the beginning of the period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i2301d17087334c3ca12a4759e9518e95"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each individual transaction is assessed for its dilutive effect on net loss per common share. To the extent that the transaction is antidilutive or does not reduce net loss per common share, the effect is excluded from the calculation.</span></div><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RleHRyZWdpb246ZWE2YzIyMGNjY2E4NGExMDlkZmJhNzAzY2E1NGFiZjRfMjQzNg_645b8efb-a3a1-4c54-94bc-262d5fe1d8b7" escape="true"><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of diluted net loss per common share (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:38.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.507%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMi0xLTEtMS05MDE5NA_1d3dce21-d941-4462-8a7c-608706b01075">10,096</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMi0zLTEtMS05MDE5NA_c5a10547-9fd1-4456-b46c-f48d4887e545">3,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMi01LTEtMS05MDE5NA_b53b724e-584e-4043-911d-eca64dd96311">34,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMi03LTEtMS05MDE5NA_8ed7a881-6bcc-4acd-9e77-c5c081d14b33">17,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends on Series B Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNC0xLTEtMS05MDE5NA_283408ca-eec3-4c5b-a37b-d5f7472c56a0">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNC0zLTEtMS05MDE5NA_06c4b57a-fa3b-420a-9445-9b124e3b6710">1,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNC01LTEtMS05MDE5NA_1a9b4824-131d-4a99-9df9-5deeff6f5501">4,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNC03LTEtMS05MDE5NA_e2fd4472-9690-4f92-8533-e5da96d2daf8">4,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: antidilutive adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherPreferredStockDividendsAndAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNS0xLTEtMS05MDE5NA_62cbf76a-6d9c-4554-80b5-9251121d704c">1,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherPreferredStockDividendsAndAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNS0zLTEtMS05MDE5NA_476516f4-eb32-4d7a-aee8-ece88836a691">1,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherPreferredStockDividendsAndAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNS01LTEtMS05MDE5NA_d3401128-3f75-4ae7-9c90-053611f749bb">4,884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherPreferredStockDividendsAndAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNS03LTEtMS05MDE5NA_b2d3ddcd-36e6-45c6-bf64-69a5e1ad734c">4,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNy0xLTEtMS05MDE5NA_b6d5bdc5-7bfd-446e-b516-b39d24803f68">10,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNy0zLTEtMS05MDE5NA_c1a384a2-2196-448e-a280-48623a82e800">3,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNy01LTEtMS05MDE5NA_76f09e97-2ec1-496a-8a23-5c0a3f42f0db">34,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNy03LTEtMS05MDE5NA_0616d980-0e44-4995-944c-b565eaf7935b">17,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfOC0xLTEtMS05MDE5NA_230eab93-4e63-4676-964c-da1643a70ab0">113,448,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfOC0zLTEtMS05MDE5NA_c3c7a091-1d67-4a8a-8acc-3e78d079e4a7">110,717,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfOC01LTEtMS05MDE5NA_dcb28284-9455-4884-a3e4-223ff2b26d51">112,650,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfOC03LTEtMS05MDE5NA_eaba367a-ecd4-4dd1-923e-227575ceda33">110,136,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTAtMS0xLTEtOTAxOTQ_8cef5733-c698-40f8-980b-6591d77ebafb">29,269,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTAtMy0xLTEtOTAxOTQ_c6869fb6-0b83-4c72-91b3-823c95ae3046">30,658,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTAtNS0xLTEtOTAxOTQ_d8a49c31-2b99-4a7e-9180-e54fea26036a">28,858,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTAtNy0xLTEtOTAxOTQ_8fd69fb4-ac6a-414c-b5c4-15c18a8b2cfe">30,185,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: antidilutive potential common shares (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTEtMS0xLTEtOTAxOTQ_d911ff00-b7f1-4f8f-92a7-4ec2c9f9f806">29,269,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTEtMy0xLTEtOTAxOTQ_408b6c7b-d136-44f6-a645-c01049e92299">30,658,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTEtNS0xLTEtOTAxOTQ_21ef77db-a1d7-4d1f-b26f-d76c29864d09">28,858,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTEtNy0xLTEtOTAxOTQ_e4a99cec-1152-4bb8-a0f0-4ac828318def">30,185,813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding adjusted for potential common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTMtMS0xLTEtOTAxOTQ_ef5fa861-486f-46c3-852b-7084c4d2ba6c">113,448,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTMtMy0xLTEtOTAxOTQ_ff31b7ea-2251-44db-ae23-46bc121e8be7">110,717,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTMtNS0xLTEtOTAxOTQ_8c610259-3c63-42bc-9a85-66eb5a5f32bf">112,650,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTMtNy0xLTEtOTAxOTQ_3e237a8a-9f6a-45d4-9718-650e0a2d25a8">110,136,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per common share</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTQtMS0xLTEtOTAxOTQ_eca0c2c6-0970-4aba-9a48-c560529df0c1">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTQtMy0xLTEtOTAxOTQ_6be7056d-5f79-40b6-ae74-e9f7648739dc">0.04</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTQtNS0xLTEtOTAxOTQ_a90a7a64-ad5c-4e6b-9c78-b2884aaabb80">0.31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTQtNy0xLTEtOTAxOTQ_909f240b-6253-49a9-b474-1bcbcf561205">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Weighted average common shares outstanding for the calculation of diluted net loss per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RleHRyZWdpb246ZWE2YzIyMGNjY2E4NGExMDlkZmJhNzAzY2E1NGFiZjRfMjQyMg_9324123f-a888-417a-b450-a4197ef02edc" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7039d72af5a465f8d691ffc8453f767_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMi0xLTEtMS05MDE5NA_d2ed170e-e834-411f-9b2c-f8ff7e40ca3f">28,685,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8a6dd65cf2d47b89031b83212416a42_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMi0zLTEtMS05MDE5NA_52b07974-0064-461a-a761-e365b2648bb7">27,027,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10cd3b0255d2440e86f4416f3ed9495c_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMi01LTEtMS05MDE5NA_8cc1125d-69fe-4f91-bb06-a1321398b554">27,850,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f700fb64114418187f075f2e5eed841_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMi03LTEtMS05MDE5NA_9798f361-5587-4215-a19e-0d6e9459d7a9">26,497,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i146f3a7b53384556923cbc98e604b7dd_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMy0xLTEtMS05MDE5NA_ab41ee43-0a0c-4b08-845c-975719ef0624">474,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ec389008cfe43948414a92568159be9_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMy0zLTEtMS05MDE5NA_9d1980a8-567e-4e9e-b7ff-eb00c088ab4e">1,840,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaaf79e5f3ce64e96aa536b235a512ffc_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMy01LTEtMS05MDE5NA_040409a5-05c4-42a0-adb1-34d7da1b87a2">574,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a4925e322ff4faba0e3ed48e1b84008_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMy03LTEtMS05MDE5NA_df3d2283-b55c-47f9-9309-4753c6e8c5e8">1,500,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i355ee9dd6fe8464cb242d9207054f6bf_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNC0xLTEtMS05MDE5NA_98382ff4-51d3-4b03-9dce-5bd93564c0df">22,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70d9b122152d409a9b10de3cb3c9ae48_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNC0zLTEtMS05MDE5NA_85b7f718-3349-47c4-b43f-cbfca75f6f07">974,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0f5ff9fed4948129ee9e875deb95c7b_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNC01LTEtMS05MDE5NA_78d7ff3d-2387-495b-b5df-535530837629">293,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i258db741a42246298eb7aaa18e77a486_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNC03LTEtMS05MDE5NA_f7dcbe3a-c953-4d23-91f5-c2178f4a118f">1,287,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11c7a54774bb43fdba585d030dec991b_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNS0xLTEtMS05MDE5NA_e368ef28-3fde-4bf6-910c-773591781037">22,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0df82c48fe04e96b6b5e4d0a4612c4f_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNS0zLTEtMS05MDE5NA_5e3018ec-f5e1-490c-8534-c813fd71cf23">805,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b8df31d2af641618c113c2cbd9b7b1a_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNS01LTEtMS05MDE5NA_636207b8-af5b-41f2-a02f-1e1700f3dbaa">97,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide1a4fd077334136967497c6a2232e0d_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNS03LTEtMS05MDE5NA_495c455c-7ea4-4b81-ba14-495163572dd4">875,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6b3e0608d9f482b868123001407b5ec_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNi0xLTEtMS05MDE5NA_6e0d3672-cf9b-43f1-a82e-783a5679f89b">59,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17f6805f07fe4bdcb90650b3893165d9_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNi0zLTEtMS05MDE5NA_253eea89-22a5-4038-a16f-cfb79cb18289">10,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39ab2e69b02a42ddb73366a8e9c08937_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNi01LTEtMS05MDE5NA_41a65d81-54cd-4986-b047-f54e736fd91a">40,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i212a4290c2bd47fca04f586a83a7f287_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNi03LTEtMS05MDE5NA_a8eaada2-648d-4884-b34c-16a4ea5519aa">24,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i271d80de58474816b4025b9aebb971f8_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy0xLTEtMS05NTc4NA_0a510b47-d313-4212-ba0b-e9250a067d6b">4,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d9bb93242bb443ba66fd70a01eef477_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy0zLTEtMS05NTc4Ng_425e14ae-f575-46a7-9d33-e484cacbe61f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i692c59774d81444084dea717ebd32069_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy01LTEtMS05NTc4OA_6a6cda41-e3ad-43cc-8216-354681cef9a4">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i784df8506ab9410ea02678d62f33b782_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy03LTEtMS05NTc5MA_6487665b-adf5-4ae6-bcdc-2ee86b059df8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy0xLTEtMS05MDE5NA_6102ac43-cc97-46cc-adc4-6bfec7dd7ddb">29,269,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy0zLTEtMS05MDE5NA_e3683010-f7db-4f1d-b072-4ab8123ca4df">30,658,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy01LTEtMS05MDE5NA_b991d361-b439-4129-a164-3717d051cb77">28,858,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy03LTEtMS05MDE5NA_2e2111ae-62b7-444f-ae9c-8522b692099c">30,185,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:nonNumeric></ix:continuation><div id="ide1fe17276234d55bab608462fe4131b_73"></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg0Nw_81747e0a-1772-47b3-acd8-32690195f6f2" continuedAt="id560544c2fad43188b450345f499e992" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="id560544c2fad43188b450345f499e992" continuedAt="i0fa35e026dd144df859fd7928a7eb93c"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Convertible Preferred Stock </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Convertible Preferred Stock of the Company (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) paid a <ix:nonFraction unitRef="number" contextRef="ie017b823195c4cd28a0e2f85512d9175_D20200702-20200702" decimals="INF" name="mdxg:TemporaryEquityDividendRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTUw_e2bb088a-44e9-4a88-a5b6-d187a07f82d3">4.0</ix:nonFraction>% cumulative dividend per annum prior to the quarterly dividend payment ending on June 30, 2021, and pays a <ix:nonFraction unitRef="number" contextRef="ia2c96a645d0e4a2f9342b55b1148c6a5_D20200702-20200702" decimals="INF" name="mdxg:TemporaryEquityDividendRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjU5_27458cd7-4fe1-47a0-b55b-9cebfcf2e115">6.0</ix:nonFraction>% cumulative dividend per annum thereafter. Dividends, if declared, are paid at the end of each quarter based on dividend amounts that accumulate beginning on the last payment date through the day prior to the end of each quarter. In lieu of paying a dividend, the Company may elect to accrue the dividend owed to shareholders. Accrued dividend balances accumulate dividends at the prevailing dividend rate for each dividend period for which they are outstanding.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Preferred Stock is convertible into the Company&#8217;s common stock at any time at the option of the holder. Shares are converted based on the liquidation preference of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f3a41d5bd2a49d5b12ac3a2ed050c26_I20200702" decimals="INF" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfOTEx_0e8a8be2-5ec3-4360-86c9-4aed36c6ac4a">1,000</ix:nonFraction> per share (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation Preference</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) plus any accrued or accumulated dividends through the date of the conversion at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702" decimals="INF" name="mdxg:TemporaryEquityConversionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTA1Nw_a1d95fc2-3369-46fe-a0db-b584bb05b187">3.85</ix:nonFraction> per common share. The Series B Preferred Stock, including any accumulated and unpaid dividends, automatically converts into common stock at any time after </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i0fa35e026dd144df859fd7928a7eb93c" continuedAt="ic1d0fc8b84cf4c0d8f2ec27f40ac0115"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2, 2023, provided that the common stock has traded at $<ix:nonFraction unitRef="number" contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702" decimals="INF" name="mdxg:TemporaryEquityConversionThresholdPercentageofStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTI3NA_0dbccb3d-1f71-423b-9827-b066b8f65e93">7.70</ix:nonFraction> per share or more for (i) <ix:nonFraction unitRef="day" contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702" decimals="INF" name="mdxg:TemporaryEquityConversionThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTMwMw_0611cc06-747a-445f-a968-54392de0b5d5">20</ix:nonFraction> out of the preceding <ix:nonFraction unitRef="day" contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702" decimals="INF" name="mdxg:TemporaryEquityThresholdConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTMyNw_a6becf34-d0a2-4d69-b019-1d851be44ac2">30</ix:nonFraction> consecutive trading days and (ii) on such date of conversion.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Series B Preferred Stock, voting as a class, are entitled to appoint <ix:nonFraction unitRef="director" contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702" decimals="INF" name="mdxg:NumberOfBoardSeatsElectedByTemporaryEquityHolders" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTQ4MA_09a0a5cf-bd0a-4ffb-bec7-81c3b690d2e0">two</ix:nonFraction> members to the board of directors. The holders of the Series B Preferred Stock are entitled to vote on all matters to be voted on by the Company&#8217;s shareholders on an as-converted basis as a single class with the common stock; provided that the votes represented by the Series B Preferred Stock cannot exceed <ix:nonFraction unitRef="number" contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702" decimals="INF" name="mdxg:TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTc5MQ_34e5de3f-51c6-4b03-8fca-386e107e1954">19.9</ix:nonFraction>% of the total voting stock of the Company and their votes cannot exceed a number of shares equal to the Liquidation Preference divided by $<ix:nonFraction unitRef="usdPerShare" contextRef="iea291f2f9ce54206890c533e3a98eb90_D20200702-20200702" decimals="INF" name="mdxg:TemporaryEquityConversionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTkzMQ_85349157-d97e-48cf-85bb-a198c5e16ea1">5.25</ix:nonFraction> per share. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Series B Preferred Stock are also entitled to the Liquidation Preference plus all accumulated and unpaid dividends in the event of a liquidation, dissolution, or winding-up of the Company.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a change of control (as defined), the Company will have the option to repurchase some or all of the then-outstanding shares of Series B Preferred Stock for cash in an amount equal to the Liquidation Preference plus any accumulated and unpaid dividends, subject to the rights of the holders of the Series B Preferred Stock in connection with such change in control. If the Company does not exercise such repurchase right, holders of the Series B Preferred Stock will have the option to (1) require the Company to repurchase any or all of their then-outstanding shares of Series B Preferred Stock for cash in an amount equal to the Liquidation Preference plus accumulated and unpaid dividends or (2) convert the Series B Preferred Stock into common stock and receive their pro rata consideration thereunder. Since the contingent redemption of the Series B Preferred Stock by the holders in the event of a change in control is outside the Company&#8217;s control, the Series B Preferred Stock is classified as temporary equity.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="i2897a774ae4848988d5570070d7984aa_D20210701-20210930" decimals="-3" name="us-gaap:DividendsPreferredStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjc0ODc3OTA4Mzk1Nw_02d9dca7-7516-4728-8fc4-2e033a40cad8"><ix:nonFraction unitRef="usd" contextRef="iebe0c3fba405441db5355c5f6db48438_D20220101-20220930" decimals="-3" name="us-gaap:DividendsPreferredStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjc0ODc3OTA4Mzk1Nw_6294e189-2c0d-4d9b-ae45-ea077c5ed9d0"><ix:nonFraction unitRef="usd" contextRef="ie539807062614f8bb0131c5c6847be0d_D20220701-20220930" decimals="-3" name="us-gaap:DividendsPreferredStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjc0ODc3OTA4Mzk1Nw_d6392aff-7159-4801-a108-6b1726145996">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> change in the balance of Series B Preferred Stock for the three or nine months ended September&#160;30, 2022 or the three months ended September&#160;30, 2021. <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:TemporaryEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg0OQ_af310202-ed34-4370-8a3a-5a0b9c9f8f21" continuedAt="if7a5a6e3014744b2bb87bed4d00f9bd7" escape="true">The below table illustrates changes in the Company&#8217;s balance of Series B Preferred Stock for the nine months ended September&#160;30, 2021 (in thousands, except share amounts):</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><ix:continuation id="if7a5a6e3014744b2bb87bed4d00f9bd7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.175%"><tr><td style="width:1.0%"></td><td style="width:42.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.610%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred Stock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i753d059860334ec081dc4d69d43cf1c2_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjQ0YjExMjQ3OGE4ZTQwYzQ4YWRkOTcwYzVhNzUwMmExL3RhYmxlcmFuZ2U6NDRiMTEyNDc4YThlNDBjNDhhZGQ5NzBjNWE3NTAyYTFfMi0xLTEtMS05MDE5NA_a53beb41-0e3a-4fa4-8c28-cecf573882cf">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753d059860334ec081dc4d69d43cf1c2_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjQ0YjExMjQ3OGE4ZTQwYzQ4YWRkOTcwYzVhNzUwMmExL3RhYmxlcmFuZ2U6NDRiMTEyNDc4YThlNDBjNDhhZGQ5NzBjNWE3NTAyYTFfMi0zLTEtMS05MDE5NA_03c65ff7-cb50-4303-8cfa-3711c0b17f0f">91,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf3436aa84a4190833ba27b0b9cde6c_D20210101-20210930" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjQ0YjExMjQ3OGE4ZTQwYzQ4YWRkOTcwYzVhNzUwMmExL3RhYmxlcmFuZ2U6NDRiMTEyNDc4YThlNDBjNDhhZGQ5NzBjNWE3NTAyYTFfNC0zLTEtMS05MDE5NA_e0a80362-168d-4434-9308-e9f4daecf88f">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15a5bbe694014b15a1e01cde9e802a57_I20210930" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjQ0YjExMjQ3OGE4ZTQwYzQ4YWRkOTcwYzVhNzUwMmExL3RhYmxlcmFuZ2U6NDRiMTEyNDc4YThlNDBjNDhhZGQ5NzBjNWE3NTAyYTFfNS0xLTEtMS05MDE5NA_bbdc3455-d948-464b-995c-34c51bd044c5">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15a5bbe694014b15a1e01cde9e802a57_I20210930" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjQ0YjExMjQ3OGE4ZTQwYzQ4YWRkOTcwYzVhNzUwMmExL3RhYmxlcmFuZ2U6NDRiMTEyNDc4YThlNDBjNDhhZGQ5NzBjNWE3NTAyYTFfNS0zLTEtMS05MDE5NA_2ebb7df8-9e90-488d-9edf-6c8b84d26e79">92,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not declared or paid any dividends on the Series B Preferred Stock since issuance. Dividends accumulated but not paid as of September&#160;30, 2022 were $<ix:nonFraction unitRef="usd" contextRef="ic02bab3165234f9eb46d4f4c01c5fc77_I20220930" decimals="-5" name="mdxg:DividendAccumulatedByNotPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMzk0Ng_47160640-c267-45ba-9606-114125bedd54">12.1</ix:nonFraction> million. As this amount has not been declared, the Company has not recorded this amount on its unaudited condensed consolidated balance sheet as of September&#160;30, 2022. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on accumulated dividends as of September&#160;30, 2022, the Series B Preferred Stock was convertible into an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic02bab3165234f9eb46d4f4c01c5fc77_I20220930" decimals="INF" name="us-gaap:PreferredStockConvertibleSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDIwMQ_8406ee1a-1fa7-46d1-b561-a474552f496c">29,119,562</ix:nonFraction> shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued restricted stock awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), restricted stock unit awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and performance stock unit awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PSUs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to its employees. The following is summary information for restricted stock awards for the nine months ended September 30, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="if5bc17a4ac384d59a3a5c5e10da5eb81_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDU0OA_0bb5e713-aa73-442c-90c9-22a344fef4d2">26.7</ix:nonFraction>&#160;million of unrecognized share-based compensation expense related to share-based payment arrangements. This expense is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ib50e54e252d5492ca1c749cc11fabfe4_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDcyMQ_7444432f-5347-435b-9521-60890e7bc3cd">1.93</ix:nonNumeric> years, which approximates the remaining vesting period of these grants. <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg0Ng_cbc7cc2d-137e-40e4-aff9-6cdb6fbe2203" continuedAt="i12dcf50c67f44699a95214fc8716ab9e" escape="true">The below table summarizes activity of unvested restricted stock awards by award type from January 1, 2022 through September&#160;30, 2022. Unvested RSAs noted below are included in issued and outstanding common stock as of September&#160;30, 2022, while unvested RSUs and unvested PSUs are not included in issued or outstanding common stock as of September&#160;30, 2022.</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ic1d0fc8b84cf4c0d8f2ec27f40ac0115" continuedAt="iddd298f1461446b797e8ce88a2c004b0"><div style="margin-bottom:10pt;margin-top:11pt;text-align:center"><ix:continuation id="i12dcf50c67f44699a95214fc8716ab9e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:31.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSU</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Grant Date<br/>&#160;Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Grant Date<br/>&#160;Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Grant Date<br/>&#160;Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3049036812934641abae9137fa8bdf2a_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi0xLTEtMS05MDE5NA_c2ceb44d-012d-4086-b887-54e201898327">877,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3049036812934641abae9137fa8bdf2a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi0yLTEtMS05MDE5NA_47fd9da8-de85-43c7-9a40-398994c912ec">4.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2f95c7c08b84d32a4a79f8a8db06aa4_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi00LTEtMS05MDE5NA_f6f08f11-461c-4fe5-8e52-add50b1ee6ad">4,228,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id2f95c7c08b84d32a4a79f8a8db06aa4_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi01LTEtMS05MDE5NA_0662f701-7c1a-4d77-b2fb-1031438412f4">8.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa7c606187fb4813a87a34ec4af106b7_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi03LTEtMS05MDE5NA_8b3f700d-23f4-4156-8b34-d7606c67eaac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa7c606187fb4813a87a34ec4af106b7_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi04LTEtMS05MDE5NA_6e0692c5-c5e2-4b44-98dc-239576d648fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy0xLTEtMS05MDE5NA_0eacc64a-921a-4c56-8dfa-39554e3e7878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy0yLTEtMS05MDE5NA_d2c85ded-884f-4c17-8a2e-defc9dc583b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy00LTEtMS05MDE5NA_0cb4592c-a77a-4006-98b6-e4f3aab31e43">4,181,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy01LTEtMS05MDE5NA_f747a7df-0967-4b58-9551-bb85b39325d0">4.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy03LTEtMS05MDE5NA_59b58af8-619d-4319-9a1e-37ef816b130f">441,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy04LTEtMS05MDE5NA_0c3cb389-32b9-46aa-ab86-c4be3e23c7ab">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC0xLTEtMS05MDE5NA_86f814d8-84a7-41bf-adc0-7e7c27e14e9d">703,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC0yLTEtMS05MDE5NA_702f4570-11bd-47cd-a4ae-9b88bab41d8f">3.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC00LTEtMS05MDE5NA_f3533160-8484-436c-a5b8-1c359f189b1a">1,713,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC01LTEtMS05MDE5NA_bb0d7ab7-f9a9-452c-bd25-08dfaeac0416">8.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC03LTEtMS05MDE5NA_e7ba2510-0b53-48d3-8a28-fff269c6a690">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC04LTEtMS05MDE5NA_fdcb0978-b650-4695-a6c4-1e1be41d4b90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS0xLTEtMS05MDE5NA_bf63f765-020b-4b4f-a485-23c42fc7e31a">5,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS0yLTEtMS05MDE5NA_7eba8000-7aa7-4865-aab2-d350db68c7b7">5.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS00LTEtMS05MDE5NA_838966fc-6bb8-4812-bed7-5fabcc9cf23c">1,274,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS01LTEtMS05MDE5NA_b45c3554-37ee-4b4d-9b4d-2558df209f00">6.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS03LTEtMS05MDE5NA_5ab039bd-e0c8-428f-a8cb-0719ada9e907">200,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS04LTEtMS05MDE5NA_411f9f9b-9244-4ca6-bba8-af19f1e3034b">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04da0588d95741f9bde5e0e130fa9c99_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi0xLTEtMS05MDE5NA_258e02a0-32fb-4a99-84ad-1730b02e3ee7">168,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04da0588d95741f9bde5e0e130fa9c99_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi0yLTEtMS05MDE5NA_08356892-fd27-4646-bad3-8f0e72a2ad86">6.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6572eec66ddc4973bfa1f4addf16e03f_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi00LTEtMS05MDE5NA_ec48660a-483e-4641-abe4-5214ef234f2e">5,422,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6572eec66ddc4973bfa1f4addf16e03f_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi01LTEtMS05MDE5NA_3f2f928c-1614-4df7-b197-1af23b4a4db6">6.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4b6f7cb18684bc78a9c1ac2d353eadf_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi03LTEtMS05MDE5NA_a4e8ec43-f601-4c1e-90f1-f25599f66eb7">241,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4b6f7cb18684bc78a9c1ac2d353eadf_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi04LTEtMS05MDE5NA_8b130947-9af4-4982-9c24-d4e37027a463">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Stock Units</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted PSUs to certain executive officers during the nine months ended September 30, 2022. These PSUs vest only to the extent that stipulated cumulative net sales targets are achieved for the year ending December 31, 2022, the <ix:nonNumeric contextRef="ia2b50c892e824477a3935a03b5a37bc1_D20220101-20220930" name="mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg1Mg_e2dda75e-5f74-41a5-9ec1-1118049663e5">two-year</ix:nonNumeric> period ending December 31, 2023, and the <ix:nonNumeric contextRef="i31fe266b4c6443febd173cafdd41434d_D20220101-20220930" name="mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg1Mw_4ebaa35a-0bf5-46a8-9848-d91e94238c5b">three-year</ix:nonNumeric> period ending December 31, 2024. Performance factors range from <ix:nonFraction unitRef="number" contextRef="ia2b50c892e824477a3935a03b5a37bc1_D20220101-20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNTQ1MQ_d54a82b6-d7e6-41b9-99c4-ba35434f6aee">50</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i31fe266b4c6443febd173cafdd41434d_D20220101-20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNTQ1Nw_039480d6-e2b0-4a0a-9b71-7b2724791a0a">150</ix:nonFraction>% of the net sales targets; if performance is below <ix:nonFraction unitRef="number" contextRef="ia2b50c892e824477a3935a03b5a37bc1_D20220101-20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNTUxMA_d54a82b6-d7e6-41b9-99c4-ba35434f6aee">50</ix:nonFraction>%, the PSUs do not vest. If total shareholder return (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TSR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as defined below, is negative, vesting is limited to <ix:nonFraction unitRef="number" contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNTYyNg_b7a2966a-ebdc-46f4-a861-4d9178f3670f">100</ix:nonFraction>% of the award. All of the PSUs require recipients to continue employment with the Company through the vesting date, which will occur upon approval of the results with respect to the established targets by the Compensation Committee of the Board of Directors after December 31, 2024, but no later than March 15, 2025.</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TSR is calculated as the average trading price of the Company&#8217;s common stock during the final <ix:nonNumeric contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930" name="mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNjA0Mw_cfa7700e-9b30-4ef3-8fca-125fd3499de6">30</ix:nonNumeric> trading days of 2024, adjusted for dividends paid on the Company&#8217;s common stock, less the average trading price during the final <ix:nonNumeric contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930" name="mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNjE3NQ_cfa7700e-9b30-4ef3-8fca-125fd3499de6">30</ix:nonNumeric> trading days of 2021.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since TSR is based on the Company&#8217;s share price, it represents a market condition, which is incorporated in the grant date fair value of shares in excess of <ix:nonFraction unitRef="number" contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNjM1Nw_b7a2966a-ebdc-46f4-a861-4d9178f3670f">100</ix:nonFraction>% vesting. These awards were valued on the date of grant using a Monte Carlo simulation, the inputs for which were informed by a Black-Scholes option pricing model. <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="mdxg:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg1MA_266a3b18-1dd9-4a33-aa21-fd1c1c241e90" continuedAt="i9be4b1e1ac9a47069ed230b2d3499580" escape="true">The assumptions used in determining the fair value of these PSUs were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><ix:continuation id="i9be4b1e1ac9a47069ed230b2d3499580"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"><tr><td style="width:1.0%"></td><td style="width:56.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfMS0xLTEtMS05MDE5NA_a8acba95-622e-49c8-b81b-2c400676215b">2.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfMi0xLTEtMS05MDE5NA_013b21a9-db23-4c83-bb44-f375701d1204">2.74</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (annualized)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfMy0xLTEtMS05MDE5NA_4bf45eae-60ef-4a11-aee6-89cbe5aaab4f">63.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfNC0xLTEtMS05MDE5NA_4de947e8-7c7c-4f70-9073-e365f0bd76b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing stock price on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic48fb527e30240a4917a52a042ced3d9_I20220930" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfNS0xLTEtMS05MDE5NA_8910de22-7018-4287-9a59-32570f6df7e0">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfNi0xLTEtMS05MDE5NA_1bb31430-443e-405d-b374-76056829050d">2.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term was derived from the date of the grant through the latest date of the resolution of the market condition. The risk-free interest rate was derived based on the U.S. Treasury Yield curve in effect at the date of grant for maturities of similar periods to the concluded term. The expected volatility was based on the Company&#8217;s historical daily stock price movements for a term similar in length to the expected term. The dividend yield was based on the Company&#8217;s history of dividends on its common stock.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense related to PSUs is recognized, straight-line, based on the grant date fair value of the relevant shares, over the requisite service period related to each individual tranche, limited to the extent that the achievement of the associated performance condition associated with that tranche is probable. These expectations are derived from the Company&#8217;s latest budget and forecasts for net sales in the associated periods. The fair value of the awards subject to a market condition and expense recognized on such awards are not subsequently reconsidered based on the probability of achievement or ultimate resolution of the market condition. Accordingly, the Company may recognize share-based compensation expense for awards that do not ultimately vest.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="iddd298f1461446b797e8ce88a2c004b0"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg1MQ_b2d40864-c5fe-407b-9fe4-597fb3792645" escape="true"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the nine months ended September 30, 2022 is presented below:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:48.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMS0xLTEtMS05MDE5NA_507c37df-6013-4eed-afbe-6a598f27520c">1,444,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMS0zLTEtMS05MDE5NA_864d9faf-32b2-4caf-997d-fdbf75c73680">5.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMi0xLTEtMS05MDE5NA_ea04475c-8e7f-4e5d-80a4-5e4a9476401b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMi0zLTEtMS05MDE5NA_018e771e-a91f-4eac-8cf9-9ee68c4af546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMy0xLTEtMS05MDE5NA_ad31f9cf-18fc-4321-9152-d5a2944ad17b">285,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMy0zLTEtMS05MDE5NA_b01b08bc-d51f-407d-ad2b-87f250ed9a3d">2.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNC0xLTEtMS05MDE5NA_ddb56f6c-081b-46d4-b770-606ff0a641e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNC0zLTEtMS05MDE5NA_975b761f-8599-4794-b129-f1285b149d36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested options expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNS0xLTEtMS05MDE5NA_70f43215-1b0c-4658-ab29-b49cfb662a84">109,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNS0zLTEtMS05MDE5NA_6b96028d-f80f-4208-9f6d-e71fcb5f5654">4.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNi0xLTEtMS05MDE5NA_87371433-a82d-43a3-84dd-06afe8e5c3b6">1,050,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNi0zLTEtMS05MDE5NA_d0097642-72c9-4683-b2e5-d4c7f516dbe3">6.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNi01LTEtMS05MDE5NA_18cc496e-f782-4dc3-b1f0-1d0f455f8c1b">1.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNi03LTEtMS05MDE5NA_44ba1ce5-1c95-4118-aa50-d9721cd65879">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNy0xLTEtMS05MDE5NA_b6b6a059-91bd-4c3b-b40b-666a02b33125">1,050,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNy0zLTEtMS05MDE5NA_ad892d63-8a10-4dac-93dd-9fe8da629aa2">6.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNy01LTEtMS05MDE5NA_4be38595-700d-4c7c-8e82-0c4f7304fab9">1.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNy03LTEtMS05MDE5NA_c7be51a0-806f-4e99-9ae1-19d08b2e7f4a">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2022, the Company adopted the MiMedx, Inc. Employee Stock Purchase Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Internal Revenue Code. All regular full-time employees of the Company (including officers) and all other employees who meet the eligibility requirements of the plan may participate in the ESPP. The ESPP provides eligible employees an opportunity to acquire the Company&#8217;s common stock on a semi-annual basis at a purchase price of <ix:nonFraction unitRef="number" contextRef="i03bb1d037d4e4920880de2544e838583_D20220607-20220607" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDk0NzgwMjMzNzg5NA_be3f0a9e-9549-422f-a49f-050bf09cafe7">85</ix:nonFraction>% of the lower of the closing price per share of the Company&#8217;s common stock on the first day and the last day of each <ix:nonNumeric contextRef="i03bb1d037d4e4920880de2544e838583_D20220607-20220607" name="mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDk0NzgwMjMzNzk0MQ_9cb9fb12-e802-4f7b-bcab-fb12e7ebeea6">six-month</ix:nonNumeric> purchase period (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The aggregate number of shares which may be issued and sold under the ESPP is <ix:nonFraction unitRef="shares" contextRef="i8a6f0c76a58f4f19bb54eedc889f9037_I20220607" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTI2NDQzODM3MzMyMDA_811537cd-c20d-494a-9f28-f8208350ce09">3</ix:nonFraction> million shares of Common Stock. The first Purchase Period under the ESPP commenced on August 1, 2022 and will result in a purchase of shares on January 31, 2023. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i66ece39c082f4511b28e1e8f2974b42a_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDk0NzgwMjMzNzkwMQ_387a817c-a539-4cf1-89c5-473ab833a082"><ix:nonFraction unitRef="usd" contextRef="ib46a2b85eab64b269ab8d468f2d3b464_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDk0NzgwMjMzNzkwMQ_848ace4e-597d-43a9-a582-0a70e0785f88">0.1</ix:nonFraction></ix:nonFraction>&#160;million in stock-based compensation related to the ESPP. As of the nine months ended September 30, 2022, the Company had cumulative payroll deferrals under the ESPP for future share purchases of $<ix:nonFraction unitRef="usd" contextRef="ib26f2b9f669f4ee6ac92ff0803d5fe9c_I20220930" decimals="-5" name="mdxg:AccruedESPPPayrollDeferrals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjE5OTAyMzI3MTE1Nw_efdb9816-324f-43a9-8ede-542de57823ed">0.2</ix:nonFraction>&#160;million. This amount is included in accrued compensation in the unaudited condensed balance sheet. <ix:nonFraction unitRef="shares" contextRef="i66ece39c082f4511b28e1e8f2974b42a_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjE5OTAyMzI3MTE3MA_c22c068c-62a0-4159-ad8a-3253bd53e206">No</ix:nonFraction> shares have been issued under the plan to date.</span></div></ix:continuation><div id="ide1fe17276234d55bab608462fe4131b_76"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83Ni9mcmFnOmM5ZDZiOTBjMTAxZTQ4ZmE5YjdmODAwZjEyMDM4MGIxL3RleHRyZWdpb246YzlkNmI5MGMxMDFlNDhmYTliN2Y4MDBmMTIwMzgwYjFfMzk3_db125605-73f3-4618-b1c8-f01514a3385f" continuedAt="i70163d01a2474ccea95aa2f40cd2109d" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i70163d01a2474ccea95aa2f40cd2109d"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the Company were (<ix:nonFraction unitRef="number" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83Ni9mcmFnOmM5ZDZiOTBjMTAxZTQ4ZmE5YjdmODAwZjEyMDM4MGIxL3RleHRyZWdpb246YzlkNmI5MGMxMDFlNDhmYTliN2Y4MDBmMTIwMzgwYjFfNjg_2198f65b-2efd-405d-ba49-c9c8425435c3">0.6</ix:nonFraction>)% and (<ix:nonFraction unitRef="number" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83Ni9mcmFnOmM5ZDZiOTBjMTAxZTQ4ZmE5YjdmODAwZjEyMDM4MGIxL3RleHRyZWdpb246YzlkNmI5MGMxMDFlNDhmYTliN2Y4MDBmMTIwMzgwYjFfNzU_588d98c3-20a1-40af-8883-525ab0894395">14.8</ix:nonFraction>)% for the three months ended September&#160;30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the Company were (<ix:nonFraction unitRef="number" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83Ni9mcmFnOmM5ZDZiOTBjMTAxZTQ4ZmE5YjdmODAwZjEyMDM4MGIxL3RleHRyZWdpb246YzlkNmI5MGMxMDFlNDhmYTliN2Y4MDBmMTIwMzgwYjFfMTc2_44a874a6-2dc9-42f5-8ce1-df1adde3f72c">0.6</ix:nonFraction>)% and (<ix:nonFraction unitRef="number" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83Ni9mcmFnOmM5ZDZiOTBjMTAxZTQ4ZmE5YjdmODAwZjEyMDM4MGIxL3RleHRyZWdpb246YzlkNmI5MGMxMDFlNDhmYTliN2Y4MDBmMTIwMzgwYjFfMTg0_bf93c004-4db4-4902-a2b0-7c968b3d05d2">2.9</ix:nonFraction>)% for the nine months ended September&#160;30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material discrete items affecting the effective tax rate in any period. Net operating losses incurred were offset by a valuation allowance.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RleHRyZWdpb246M2MzY2U0ODY5ZjVkNGYyYWFmZjdkM2Y0ZDBhOTIxYmRfMTky_7c7e4a0d-0d50-448f-abb1-48cdd53967fb" continuedAt="i5e22e629451e48548f03d883cf9bea50" escape="true">Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities</ix:nonNumeric></span></div><ix:continuation id="i5e22e629451e48548f03d883cf9bea50"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RleHRyZWdpb246M2MzY2U0ODY5ZjVkNGYyYWFmZjdkM2Y0ZDBhOTIxYmRfMTk0_995c9a47-8100-4f1a-9c34-85e4f7fd60ba" escape="true"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected cash payments, receipts, and non-cash activities are as follows (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:59.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMi0xLTEtMS05MDE5NA_ba19ebcc-e0d0-4e1f-a2e0-9b8e2773ac7c">3,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMi0zLTEtMS05MDE5NA_443b43d8-397b-4b5d-ac71-f05a60c50b53">3,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMy0xLTEtMS05MDE5NA_80e0624f-eea3-422c-975f-0f09db8f7296">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMy0zLTEtMS05MDE5NA_560d2959-41ef-4b93-bf60-a8ae61e2e7c9">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equipment in accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNS0xLTEtMS05MDE5NA_2ec2ca9a-7f12-4958-99f1-0f69f01c32c0">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNS0zLTEtMS05MDE5NA_0c413e2e-9909-4bc6-928f-f24636f98e5a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets arising from operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNi0xLTEtMS05MDE5NA_e44c8e3e-626f-4e80-8d5d-da6ce746d86d">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNi0zLTEtMS05MDE5NA_96f2f01b-8401-4cad-83ed-efc9156a5e0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividends on Series B Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="mdxg:TemporaryEquityDeemedDividends" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNy0xLTEtMS05MDE5NA_e00612c7-2731-424d-9071-42f551192e96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="mdxg:TemporaryEquityDeemedDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNy0zLTEtMS05MDE5NA_399bc5e5-406b-47f9-8d22-5aa2ab2707b5">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of non-cash consideration received for option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="mdxg:FairValueOfNonCashConsiderationReceivedForOptionExercise" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfOC0xLTEtMS05MDE5NA_5c97c3fc-1d56-440b-9507-a7bff95197c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="mdxg:FairValueOfNonCashConsiderationReceivedForOptionExercise" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfOC0zLTEtMS05MDE5NA_d04d4e6c-4977-4095-b9a0-5f7f6974ce6c">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets arising from finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfOS0xLTEtMS05MDE5NA_a5918e52-9940-4f6a-929e-9c500fad0d22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfOS0zLTEtMS05MDE5NA_567e0a34-236e-4f2d-9e6e-8595527d1fc2">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note receivable for sale of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="mdxg:NotesReceivableForSaleOfPropertyAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMTAtMS0xLTEtOTAxOTQ_e4f089af-b44d-457a-8297-8ea206c6214d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="mdxg:NotesReceivableForSaleOfPropertyAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMTAtMy0xLTEtOTAxOTQ_b86e20be-644f-49ae-a7c1-e98b7972d2df">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ide1fe17276234d55bab608462fe4131b_82"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">       13.  <ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfODYwNA_72634540-c553-4184-b175-6693b1889dad" continuedAt="ia939afa8c93b4044a159ddb81591b3c6" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ia939afa8c93b4044a159ddb81591b3c6" continuedAt="i4e2b9a14d93242b6bb55a37810fae4b3"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation Agreement with Timothy R. Wright</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company entered into a Separation Agreement and General Release with Timothy R. Wright, the former Chief Executive Officer of the Company (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Pursuant to the terms of the Separation Agreement and Mr. Wright&#8217;s general release of all claims against the Company, the Company will pay Mr. Wright a total of $<ix:nonFraction unitRef="usd" contextRef="i3172438f25f94d9b8023b961aedcb60f_I20220915" decimals="-5" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTI2NDQzODM3MzczNDU_5cf24a45-12c7-4236-ad3e-f7f8164ec404">3.1</ix:nonFraction> million in cash in a series of installments through September 2024. The terms of the severance benefits provided in the Separation Agreement were the same as those provided for in the original employment Letter Agreement between Mr. Wright and the Company dated April 8, 2019. The $<ix:nonFraction unitRef="usd" contextRef="if25b98ea5f0947a9a6a36132f5efc122_D20220701-20220930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MjEyNw_47aa020f-0883-4f6a-aa3f-9698c4c982d2"><ix:nonFraction unitRef="usd" contextRef="i0fd877d9ecb24d80b443c4b5961d54c0_D20220101-20220930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MjEyNw_a1e31a19-aa21-4ee5-8bc0-6fa567df7e4b">3.1</ix:nonFraction></ix:nonFraction> million was recorded as part of selling, general, and administrative expense on the condensed consolidated statements of operations for the three and nine months ended September 30, 2022. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the $<ix:nonFraction unitRef="usd" contextRef="i3172438f25f94d9b8023b961aedcb60f_I20220915" decimals="-5" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MDQ2MA_3f3e17e9-10b8-407a-8509-7facc1a3d10b">3.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="id4d6590c804a4af396fb91f11d61ca98_I20220930" decimals="-5" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTI2NDQzODM3Mzc0MDE_f21c3b73-1d4d-4f9a-ab1a-1181d441d5f4">1.6</ix:nonFraction> million is reflected in accrued compensation and the remainder is reflected in other liabilities in the unaudited condensed consolidated balance sheet as of September 30, 2022. No payments were required to Mr. Wright under the terms of the Separation Agreement during the nine months ended September 30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nordic Agreement</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a collaboration agreement (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nordic Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) with Nordic Bioscience Clinical Development A/S (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBCD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to provide full operational support for the Company&#8217;s upcoming Knee Osteoarthritis (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KOA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) clinical trial program. As part of the agreement, NBCD will perform site selection and monitoring, manage patient recruitment and enrollment, data management, statistical analysis and reporting activities for the duration of the trial. Under the terms of the Nordic Agreement, the Company is obligated to pay $<ix:nonFraction unitRef="usd" contextRef="i5e04c486503f40a1843903fe17980c71_D20220601-20220630" decimals="-5" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfNTcy_132bd8ea-38d4-4b3a-a61b-48fc52a6d743">13.3</ix:nonFraction> million upon the achievement of specified milestones over the course of the clinical trial. The milestones are based upon various factors including, but not limited to, site selection and enrollment, patient enrollment, patient completion, and certain other activities related to clinical trial operations. The milestone payments are revised semi-annually based on fluctuations in the consumer price index. The Company has the ability to terminate the Nordic Agreement with <ix:nonNumeric contextRef="i5e04c486503f40a1843903fe17980c71_D20220601-20220630" name="mdxg:LongTermPurchaseCommitmentTerminationNoticePeriodRequired" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMjc0ODc3OTA3OTUzMA_47bcb6cf-4d22-439b-8e53-2219e05ee7ca">30</ix:nonNumeric> days written notice to NBCD. At such time, the Company would be required to pay for services performed through the date of termination and any non-cancelable obligations.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company has paid $<ix:nonFraction unitRef="usd" contextRef="i070672d37c8e47f4a3a16fbd57ba5691_I20220930" decimals="-5" name="mdxg:PaymentsMadeOnLongTermPurchaseCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTI2NDQzODM3Mzc2MTE_b2078142-371e-4ba7-ba44-3741b9eef281">2.0</ix:nonFraction> million under the Nordic Agreement, relating to milestones which have been achieved from inception through that date. During each of the three and nine months ended September&#160;30, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i320fdbb729ab4be69c2a59f489c97765_D20220701-20220930" decimals="-5" name="mdxg:ExpensesOnLongTermPurchaseCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MTY5NA_31873372-49d9-4275-826a-a7fb4aa4ff96"><ix:nonFraction unitRef="usd" contextRef="i9f2d728dc47344bca02856d03ee8d0b4_D20220101-20220930" decimals="-5" name="mdxg:ExpensesOnLongTermPurchaseCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MTY5NA_ddc843ca-bb98-45f3-a1b6-41b555520ad4">0.6</ix:nonFraction></ix:nonFraction>&#160;million of expense. This amount is included as part of research and development expense in the unaudited condensed consolidated statements of operations for those periods. The remaining $<ix:nonFraction unitRef="usd" contextRef="i070672d37c8e47f4a3a16fbd57ba5691_I20220930" decimals="-5" name="mdxg:RemainingPrepaidExpensesOnLongTermPurchaseCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MjI1Ng_b2b07d40-479e-4f1a-9171-35078e1a492f">1.4</ix:nonFraction> million is reflected in prepaid expenses on the consolidated balance sheet as of September&#160;30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Matters</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company and its subsidiaries are parties to numerous civil claims and lawsuits and subject to regulatory examinations, investigations, and requests for information. Some of these matters involve claims for substantial amounts. The Company&#8217;s experience has shown that the damages alleged by plaintiffs or claimants are often overstated, based on unsubstantiated legal theories, unsupported by facts, and/or bear no relation to the ultimate award that a court might grant. Additionally, the outcome of litigation and regulatory matters and the timing of ultimate resolution are </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i4e2b9a14d93242b6bb55a37810fae4b3" continuedAt="i5a22daa7afc1472ba088510f82d6fc7f"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inherently difficult to predict. These factors make it difficult for the Company to provide a meaningful estimate of the range of reasonably possible outcomes of claims in the aggregate or by individual claim. However, on a case-by-case basis, reserves are established for those legal claims for which it is probable that a loss will be incurred and the amount of such loss can be reasonably estimated. The Company's unaudited condensed consolidated balance sheet as of September&#160;30, 2022&#160;reflects the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. The actual costs of resolving these claims, as well as the cost to resolve claims that are either not probable or not estimable at this time, may be substantially higher or lower than the amounts reserved. For more information regarding the Company&#8217;s legal proceedings, refer to Note 14, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in the 2021 Form 10-K.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMzA1NQ_b692935d-240e-48b3-b763-5562ed2f3b60">0.7</ix:nonFraction> million toward the resolution of legal matters involving the Company during the nine months ended September&#160;30, 2022. In addition, insurance providers paid $<ix:nonFraction unitRef="usd" contextRef="icbc4ddf32d59495c88aa620c69ed64cb_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMzE4MA_a2040371-6958-4c80-ac97-793fd5d5b4f8">0.6</ix:nonFraction>&#160;million on the Company&#8217;s behalf to settle legal matters.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recovered amounts from certain former officers and directors of the Company relating to legal fees previously advanced on their behalf. These funds were recognized as a reduction to investigation, restatement, and related expense on the condensed consolidated statement of operations for the nine months ended September 30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain litigation and regulatory matters to which the Company is a party:</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 16, 2019, the United States District Court for the Northern District of Georgia entered an order consolidating <ix:nonFraction unitRef="class_action" contextRef="ib6fd656cd99342d2afc041b6ba933413_D20190116-20190116" decimals="INF" name="mdxg:ContingencyLossNumberOfSecuritiesClassActions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMzgyNQ_81bf55f0-47ff-44c1-86a2-334cd9b33341">two</ix:nonFraction> purported securities class actions (MacPhee v. MiMedx Group, Inc., et al. filed February 23, 2018 and Kline v. MiMedx Group, Inc., et al. filed February 26, 2018). The order also appointed Carpenters Pension Fund of Illinois (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CPFI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) as lead plaintiff. On May 1, 2019, CPFI filed a consolidated amended complaint, naming as defendants the Company, Michael J. Senken, Parker H. &#8220;Pete&#8221; Petit, William C. Taylor, Christopher M. Cashman and Cherry Bekaert &amp; Holland LLP. The amended complaint (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action Complaint</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) alleged violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Rule 10b-5 promulgated thereunder, and Section 20(a) of the Exchange Act. It asserted a class period of March 7, 2013 through June 29, 2018. Following the filing of motions to dismiss by the various defendants, CPFI was granted leave to file an amended complaint. CPFI filed its amended complaint against the Company, Michael J. Senken, Parker H. Petit, William C. Taylor, and Cherry Bekaert &amp; Holland (Christopher Cashman was dropped as a defendant) on March 30, 2020. The defendants filed motions to dismiss on May 29, 2020. On March 25, 2021, the Court granted defendants&#8217; respective motions to dismiss, finding that CPFI lacked standing to bring the underlying claims and also could not establish loss causation because it sold all of its shares in MIMEDX prior to any corrective disclosures, and dismissed the case. On April 22, 2021, CPFI filed a motion for reconsideration of the dismissal and for leave to amend to add a new plaintiff to attempt to cure the standing and loss causation issues.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2022, the Court denied CPFI&#8217;s motion to reconsider and motion to substitute class representative. On February 25, 2022, CPFI filed a Notice of Appeal in the 11th Circuit Court of Appeals, Case No. 22-10633-CC. The parties have completed their briefings on the issues on the appeal.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Former Employee Litigation and Related Matters</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2021, the Company filed suit in the Circuit Court of the Eleventh Judicial District in and for Miami-Dade County, Florida (MiMedx Group, Inc. v. Petit, et. al.) against its former CEO, Parker H. &#8220;Pete&#8221; Petit, and its former COO, William C. Taylor, seeking a determination of its rights and obligations under indemnification agreements with Petit and Taylor following a federal jury&#8217;s guilty verdict against Petit for securities fraud and Taylor for conspiracy to commit securities fraud. The Company is seeking a declaratory judgment that it is not obligated to indemnify or advance expenses to Petit and Taylor in connection with certain cases to which Petit and Taylor are parties and also seeking to recoup amounts previously paid on behalf of Petit and Taylor in connection with such cases. On April 22, 2021, Petit and Taylor filed an answer and asserted counterclaims against the Company alleging breach of their indemnification agreements, breach of the covenant of good faith and fair dealing with respect to their indemnification agreements, and seeking a declaration that the Company remains obligated to indemnify and advance fees in connection with certain cases. Petit and Taylor simultaneously also filed a motion seeking to compel the Company to advance and reinstate its payments of Petit and Taylor&#8217;s legal expenses. The Company opposed Petit and Taylor&#8217;s motion and a hearing was set for June 23, 2021. At the joint request of the parties, the hearing was cancelled to allow the parties to attend a mediation to attempt a resolution of this matter; such mediation was held on August 11, 2021.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the mediation, the Company and Mr. Taylor reached an agreement to settle the matter between them. Negotiations with Mr. Petit are ongoing.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i5a22daa7afc1472ba088510f82d6fc7f"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Florida Business Corporation Act and agreements with its current and former officers and directors, the Company is obligated to indemnify its current and former officers and directors who are made party to a proceeding, including a proceeding brought by or in the right of the corporation, with certain exceptions, and to advance expenses to defend such matters. The Company has already borne substantial costs to satisfy these indemnification and expense advance obligations and may continue to do so in the future. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the matters described above, the Company is a party to a variety of other legal matters that arise in the ordinary course of the Company&#8217;s business, none of which are deemed to be individually material at this time. Due to the inherent uncertainty of litigation, there can be no assurance that the resolution of any particular claim or proceeding would not have a material adverse effect on the Company&#8217;s business, results of operations, financial position or liquidity.</span></div></ix:continuation><div id="ide1fe17276234d55bab608462fe4131b_85"></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RleHRyZWdpb246YmZlYjYzMGVhNWJhNDUzMjlhZTJhZDIyNmQ3Yzg3ZmVfMTI3Mw_a9a9f454-6511-40a9-a49c-0531b57437ee" continuedAt="ifbb989277c414de99aaa398387853d3b" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="ifbb989277c414de99aaa398387853d3b"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue by Product</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX has <ix:nonFraction unitRef="product" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="mdxg:NumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RleHRyZWdpb246YmZlYjYzMGVhNWJhNDUzMjlhZTJhZDIyNmQ3Yzg3ZmVfNjY_dabec1af-f9e0-42c7-81bf-2873f0f01698">two</ix:nonFraction> primary classes of products: (1) Advanced Wound Care, or Section 361, products, consisting of its tissue and cord sheet allograft products as well as certain particulate products regulated under Section 361, and (2) Section 351 products, consisting of the Company&#8217;s micronized and certain other particulate products. Advanced Wound Care is further disaggregated between the Company&#8217;s Tissue/Other and Cord products.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the business units responsible for the sale of each of these classes of product can be found in Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RleHRyZWdpb246YmZlYjYzMGVhNWJhNDUzMjlhZTJhZDIyNmQ3Yzg3ZmVfMTI3Ng_7418e598-ecb7-4a91-81ba-87b762550b73" continuedAt="i758c0f55786e4e94836ac2816fdb72d1" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of net sales by class of product (in thousands): </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:37.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Wound Care</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tissue/Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04190c43aa5d47839d90cf05de41f75a_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfMy0xLTEtMS05MDE5NA_ffe4d190-b051-4000-88e5-abc7ee239f64">61,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eec3159aafd457684861f891a8f27b9_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfMy0zLTEtMS05MDE5NA_d164aa5d-7d99-4534-becb-43a44cf2d21d">56,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5fd9ecb73bd40f28e4562a1cd66d365_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfMy01LTEtMS05MDE5NA_86ab7def-1ff4-4cc7-9966-89b9b227821d">174,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9866ce2797684d89afbfd9e13fe710b6_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfMy03LTEtMS05MDE5NA_6a2618f8-6085-4d8d-9f23-9cd660c3d95b">156,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cord</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df0f9cc41a6412e917f9a0100673e83_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNC0xLTEtMS05MDE5NA_e7326ecc-14e6-4092-9230-332ba72e955c">5,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d42aa93cf554f31bdf7957ad6cc2c35_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNC0zLTEtMS05MDE5NA_6189afc3-0971-40be-9669-70547941f99b">6,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbeb9a9186744ee819f52f94ba86e20_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNC01LTEtMS05MDE5NA_844b52b9-892d-461b-b012-a388a5d71994">17,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ef134bfecc49ddb64f099bb97426e5_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNC03LTEtMS05MDE5NA_c275fe38-5bc2-488c-b8fb-2afec56e029e">17,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Advanced Wound Care</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1eade6c04c44338ba36a2a117e94a53_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNS0xLTEtMS05MDE5NA_436ec685-e034-42e8-90f0-0afb63ee9a11">66,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2702a8fab749619f28b833e531c5d1_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNS0zLTEtMS05MDE5NA_8b8722c8-32de-48ce-9cbc-57f3dcc8de7c">62,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea05bcc2c0134bd5964b7bc8be495e5d_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNS01LTEtMS05MDE5NA_13158f48-b12e-4b30-b6d7-a5db16f11e8b">191,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eba5ab3ff8b4cecb6daaf14306ea281_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNS03LTEtMS05MDE5NA_4a28e9b6-dabf-4e5c-aa40-605d13a001ed">173,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 351</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63d182d5355d40909bfcd1ecad0c38f9_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNi0xLTEtMS0xMDA5MDA_cd4d664a-ee88-495a-8a17-18928e526f8e">796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie699609ee0a24b2795a89d47dab42904_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNi0zLTEtMS0xMDA5MTI_1f7bf8f5-5f67-451e-ac72-aaab8e09b238">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce6151aa0c4089a54a9ba0539e2058_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNi01LTEtMS0xMDA5MjI_534b7e8c-7c50-4ed1-b0e3-cf14e7ad90b9">1,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib83b2b7d758f4908890825b2a2b0d822_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNi03LTEtMS0xMDA5Mzk_ce04b236-f3c6-4f74-8475-a515abf708d2">17,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8fcb780f1414fd8b5dfecc6d1682d35_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNy0xLTEtMS05MDE5NA_0daffeee-eaf7-45bc-9531-dc8c1304f165">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6449c9a80962496d82d4f44a69334d4a_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNy0zLTEtMS05MDE5NA_6f0772b4-b03a-42bf-9028-6b0106097c11">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7935978392476a8eb950a2156ec688_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNy01LTEtMS05MDE5NA_878078a7-7b25-4cc2-8904-57a1d06aa66d">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c14d491f3ed491ea1459de970ab3387_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNy03LTEtMS05MDE5NA_0a8797b8-ab6d-4e8c-84ca-6affa3eabbdc">914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfOC0xLTEtMS05MDE5NA_bb1d9de8-14de-40f1-ac06-0e938f51a5ef">67,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfOC0zLTEtMS05MDE5NA_273ced75-3be2-42f1-bc16-868fe49eeee2">63,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfOC01LTEtMS05MDE5NA_184ca223-cb33-479c-8d4f-53e917aa5978">193,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfOC03LTEtMS05MDE5NA_44aa58a9-2de3-4df0-950b-4f298a827e0d">191,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1) &#8220;O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">ther&#8221; represents revenue transactions in the indicated period relating to performance obligations settled prior to October 1, 2019, the date at which the Company changed its pattern of revenue recognition. For all practical purposes, the Company is not able to allocate these revenue transactions to different product groups. This revenue is reflected as part of the Wound &amp; Surgical segment.</span></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue by Customer</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX has <ix:nonFraction unitRef="distribution_channel" contextRef="i4bd517c3847841b09c02473de630860c_I20220930" decimals="INF" name="mdxg:RevenueFromContractWithCustomerNumberOfDistributionChannels" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RleHRyZWdpb246YmZlYjYzMGVhNWJhNDUzMjlhZTJhZDIyNmQ3Yzg3ZmVfODU1_9968e8e4-19ea-41f0-90b6-22e57f605668">two</ix:nonFraction> primary distribution channels: (1) direct to customers (healthcare professionals and/or facilities) (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Direct Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and (2) sales to distributors (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><ix:continuation id="i758c0f55786e4e94836ac2816fdb72d1"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of net sales by each customer type (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.941%"><tr><td style="width:1.0%"></td><td style="width:24.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.975%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct Customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic08501ad9a844ed4bfcec556b74f305f_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMi0xLTEtMS05MDE5NA_41beee6a-fa69-4cab-b151-8b5628a2f657">65,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8e45a1b351403d8b7085dbe2706856_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMi0zLTEtMS05MDE5NA_948eeded-d924-469e-910d-6e937d273d28">61,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af08c412f7f4e7f82c54239d39b7b11_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMi01LTEtMS05MDE5NA_effdaaf2-8968-449d-bc04-10200d404baa">188,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1dffc619904a4d9e56ade452761dd4_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMi03LTEtMS05MDE5NA_aa80e1e0-7bf2-42eb-9b2b-fbd37ede989d">184,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f77e1063b8c4fa59391a91c4b07687c_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMy0xLTEtMS05MDE5NA_03963fe5-0d0e-4c1e-83b4-ff7d7b6d9d8b">1,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1c7de372124c51b75ab2ddc755118f_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMy0zLTEtMS05MDE5NA_78ce52aa-65f0-488c-9663-d320ad9349bc">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de990b776a540a18972151167955eaf_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMy01LTEtMS05MDE5NA_482e2f78-2948-4f7c-98c9-f5dd9800b66f">5,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8be7f2d7a9034919910bd938ce9e1003_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMy03LTEtMS05MDE5NA_985e9db5-6784-4671-8770-12242e179fd5">6,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfNC0xLTEtMS05MDE5NA_873d65d3-b148-4b3a-bf9c-b11402269fd9">67,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfNC0zLTEtMS05MDE5NA_3d753573-46ff-4f3a-bdf8-dc040665afad">63,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfNC01LTEtMS05MDE5NA_1434b30c-f021-4404-8e67-b95f619c742c">193,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfNC03LTEtMS05MDE5NA_4ee7467d-c76d-4b82-871d-74d97df4e1c5">191,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three or nine months ended September&#160;30, 2022 or 2021.</span></div></ix:continuation><div id="ide1fe17276234d55bab608462fe4131b_1354"></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGV4dHJlZ2lvbjo0MDAxZDgwODgzMDA0MmU4OWJiZTNiMTgwNTU4ODcxNl8yNzQ4Nzc5MDc3NjMz_918efb08-2a4d-43b4-b860-eaac85c6efbe" continuedAt="icedc185314d34249b25d0ca8f6418c75" escape="true"><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGV4dHJlZ2lvbjo0MDAxZDgwODgzMDA0MmU4OWJiZTNiMTgwNTU4ODcxNl8yNzQ4Nzc5MDc3NjM2_cccba826-695e-4ff9-bcc0-9c8d43efc093" continuedAt="iefdf70b898d8492fbe6803533b8045db" escape="true">Segment Information</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icedc185314d34249b25d0ca8f6418c75" continuedAt="ia2a76bc4a1544c9db9c9aa26c11a7148"><ix:continuation id="iefdf70b898d8492fbe6803533b8045db" continuedAt="if93bc5306b6f4730a2eebd5654458b49">The Company has <ix:nonFraction unitRef="segment" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGV4dHJlZ2lvbjo0MDAxZDgwODgzMDA0MmU4OWJiZTNiMTgwNTU4ODcxNl8xNjQ5MjY3NDQ1NzQw_49c9a2d1-195e-4085-bace-89e25c311f39">two</ix:nonFraction> reportable segments: Wound &amp; Surgical and Regenerative Medicine.</ix:continuation></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ia2a76bc4a1544c9db9c9aa26c11a7148" continuedAt="i5e6b61df732c469182c1a4d80c882915"><ix:continuation id="if93bc5306b6f4730a2eebd5654458b49" continuedAt="id076001a6ae947a79945f7bd1f21502c"><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wound &amp; Surgical focuses on the Advanced Wound Care and Surgical Recovery markets, the Company&#8217;s existing product portfolio, and near-term product development. Its platform technologies include tissue allografts derived from human placental membrane (EPIFIX&#174;, AMNIOFIX&#174;, and AMNIOEFFECT&#8482;), tissue allografts derived from human umbilical cord (EPICORD&#174; and AMNIOCORD&#174;), and a particulate extracellular matrix derived from human placental disc (AXIOFILL&#8482;). This segment is also responsible for the international sales of the Company&#8217;s Section 351 products.</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Regenerative Medicine business focuses solely on Regenerative Medicine technologies, specifically progressing the Company&#8217;s placental biologics platform towards registration as a FDA-approved biological drug. Micronized dehydrated human amnion chorion membrane is the lead product candidate in its late-stage pipeline targeted at achieving FDA approval for specific clinical indications, including degenerative musculoskeletal conditions, beginning with KOA.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate function includes expenses incurred by executive, finance, human resource, information systems, legal, other functions which are generally shared and whose activities are not specifically identifiable solely to either of the other segments. It also includes amortization of intangible assets. The Company has another operating segment related to an expiring dental sales contract. All net sales and cost of sales presented in the Corporate &amp; Other columns below relate to this operating segment.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wound &amp; Surgical net sales reflects sales of the Company&#8217;s Advanced Wound Care products (as discussed in Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), except for sales of the Company&#8217;s dental product. Sales of the Company&#8217;s dental product are included in the Corporate &amp; Other columns in the tables below. In addition, Wound &amp; Surgical reflects international sales of the Company&#8217;s Section 351 products, which represent all Section 351 sales not reflected in Regenerative Medicine.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as the Company&#8217;s accounting policies. See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, included in the 2021 Form 10-K for significant accounting policies. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the performance of its segments and allocates resources based on segment contribution, defined as net sales less (i) cost of sales, (ii) selling, general and administrative expense, (iii) research and development expense, and (iv) amortization of intangible assets. Prior period results were recast on the basis of new operating segments. The only components which comprise loss before income tax provision that are not included in operating loss are interest expense, net and other expense, net.</span></div><ix:nonNumeric contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGV4dHJlZ2lvbjo0MDAxZDgwODgzMDA0MmU4OWJiZTNiMTgwNTU4ODcxNl8yNzQ4Nzc5MDc3NjM1_c2035de6-0a3d-4017-9e11-31cfc95848f1" continuedAt="ia106129993964e25bd02e331ee1f73ea" escape="true"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales and segment contribution for each reportable segment for the three months ended September 30, 2022 were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xLTEtMS0xLTk4NjA5_404d4d15-4347-4929-8166-eeb21c580ec5">66,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xLTMtMS0xLTk5MDI3_b075cb16-ae3f-4fea-a515-3bf0fa8f0de7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xLTUtMS0xLTEwMDA2NQ_f5f91bfc-8c5c-4dad-bc38-ee3b44ff2324">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xLTctMS0xLTk4NDY3_70458ce1-45cb-4d24-95b9-f3917af3cae5">67,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yLTEtMS0xLTk4NjA5_9b7e5298-3189-4b4a-bf5c-f8f53c362529">11,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yLTMtMS0xLTk5MDI3_01aed598-e4a2-4f28-9ba4-d4af47f955be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yLTUtMS0xLTEwMDA2OA_f49b04b6-f9a7-4caf-aa89-e28b9a0ff8a3">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yLTctMS0xLTk4NDY3_d52e2412-f254-4849-bdf7-be7073dd4a8f">12,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl84LTEtMS0xLTk4NjE1_9888973e-c4e3-4697-bedd-d698528cd980">35,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl84LTMtMS0xLTk5MDMz_dd9493bd-388c-45f5-bdab-1409e87fd790">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl84LTUtMS0xLTEwMDA3NA_635877f9-2f84-4fee-bedf-55e3370aec81">17,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl84LTctMS0xLTk4NDY3_334ef8c4-303c-4e0e-a2f6-23fc3a228175">53,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl85LTEtMS0xLTk4NjE1_932f510d-49f8-40d6-9e79-a860fd654c13">1,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl85LTMtMS0xLTk5MDMz_53cb8fb9-cc54-41b4-9899-db76ffb18c29">4,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl85LTUtMS0xLTEwMDA3NA_48f7e93e-6318-4920-987f-93c7b38c02bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl85LTctMS0xLTk4NDY3_53ca9d48-eb7e-46f5-9300-d9942649efac">5,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0xLTEtMS0xMDUzMjQ_67a93ba1-2fff-4ef9-a6a1-148077344ed4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0zLTEtMS0xMDUzMjQ_d9d1ee60-9753-41cc-bc78-520ec042d628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC01LTEtMS0xMDUzMjQ_c4fb11a6-7f37-48e5-a0d1-fc7f82072db0">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC03LTEtMS0xMDUzMjQ_ecb678e2-85e0-494b-8aac-686515841fc8">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930" decimals="-3" name="mdxg:SegmentContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0xLTEtMS0xMDIzNjI_18a057fc-51ae-48ef-908b-fb8f3f539627">18,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930" decimals="-3" sign="-" name="mdxg:SegmentContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0zLTEtMS0xMDIzNjI_b91d408c-83c3-462d-9c50-4821fbdc89cd">4,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0xLTEtMS0xMDAwNzQ_1e2f5a93-cc60-4922-9884-da8156dd6a32"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0zLTEtMS0xMDAwNzQ_6df3e6e3-3bc9-458f-87b4-ffcb4443db4e"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC01LTEtMS0xMDAwNzQ_6a73a6e8-3f6a-4176-9ac2-5d4d92f1ac65"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="mdxg:InvestigationRestatementAndRelated" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC03LTEtMS05ODQ2Nw_3814843b-45ba-4b9d-b786-f0dd1baba88d">3,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMy0xLTEtMS05ODYyMQ_ddcfc6e9-3a56-4a52-bf7f-73c492656bd5"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMy0zLTEtMS05OTA0Mg_338d6969-9bce-4e20-87d0-9706f0add9f2"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMy01LTEtMS0xMDAwNzQ_fbebf16a-a6da-4483-b6d9-0d1a9525562e"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMy03LTEtMS05ODQ2Nw_5e490f43-f6d1-464d-a00c-0e2b63262d13">7,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMS0xLTEtMS05OTIxMg_a11ef1c7-032f-4569-bc65-af89c51d6834">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMS0zLTEtMS05OTIyNw_f9f71729-0816-4e0a-9486-0f0be6d418f0">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMS01LTEtMS0xMDAwNzk_2ae650e1-0d4d-47db-a350-3963fbd0c3f2">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMS03LTEtMS05OTIwMw_370052d9-a6cb-4df8-ad02-e882bf05e1a2">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMi0xLTEtMS05OTIzNg_72c46868-673f-4675-abe7-7e4e3abd7eb2">1,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMi0zLTEtMS05OTI0Mw_7b63dbbb-8531-4252-8b8c-2928129b3c02">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMi01LTEtMS0xMDAwNzk_1b36662f-3d46-41bc-9e17-fefecdd8c877">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMi03LTEtMS05OTIwOQ_7f2e031b-6ff0-4dcd-9e3f-7dd9b33f1449">2,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Net sales and segment contribution by each reportable segment for the three months ended September 30, 2021 were as follows (in thousands):</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i5e6b61df732c469182c1a4d80c882915"><ix:continuation id="id076001a6ae947a79945f7bd1f21502c"><ix:continuation id="ia106129993964e25bd02e331ee1f73ea"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:37.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xLTEtMS0xLTk4Njcy_d52ca73f-a09a-4147-b474-07c28951b9d3">62,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xLTMtMS0xLTk5MDQ3_06ec6950-c517-4ebb-a11e-39800fa48c78">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xLTUtMS0xLTEwMDEyMg_f6b480fb-8c5e-4ec5-b7d3-9847a0ff545d">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xLTctMS0xLTk4NTU1_dc456ab6-8073-4702-a75f-7aa5418a3380">63,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yLTEtMS0xLTk4Njcy_17c39fdb-4547-4385-a66a-8ebfb4101ded">8,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yLTMtMS0xLTk5MDQ3_73a221fd-e8bd-4ba2-8553-5f8594a7c10e">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yLTUtMS0xLTEwMDEyMg_7ecb10ac-262d-4fc0-8450-3397c7ef9cf4">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yLTctMS0xLTk4NTU1_2dead21f-edc4-42e3-8dcc-d8987871e676">10,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV84LTEtMS0xLTk4Njc3_e68230a8-3763-4c9d-9e29-8d8a7c6c15c6">32,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV84LTMtMS0xLTk5MDUy_7a7bc726-2353-48b8-ba27-531c1a1da71e">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV84LTUtMS0xLTEwMDEyMg_ae3f106c-2e2d-4181-aedf-3799b1c4692f">12,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV84LTctMS0xLTk4NTU1_4e6f90ab-60d4-4e18-9307-c220aec7e6d0">46,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV85LTEtMS0xLTk4Njc3_2f0d86d6-83ca-498a-81cb-05a1e171bf86">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV85LTMtMS0xLTk5MDUy_d90aebbb-dde4-4c27-8865-c3eed6e69e2b">2,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV85LTUtMS0xLTEwMDEyMg_64ea5a1e-f774-4512-a3a8-c4a919d44084">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV85LTctMS0xLTk4NTU1_3babddb1-ac57-4289-983b-e3af652fb633">4,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0xLTEtMS0xMDUzNTM_3f68744d-ec6b-4411-87c0-8149eaf24003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0zLTEtMS0xMDUzNTM_3789ae63-101a-48e2-93b4-aff3ef7cddb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC01LTEtMS0xMDUzNTM_1fb074ad-671a-48e6-8a62-b0c63495bedc">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC03LTEtMS0xMDUzNTM_072ce126-4765-45ee-b170-6680df750884">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930" decimals="-3" name="mdxg:SegmentContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0xLTEtMS0xMDI2MDQ_1c928321-2787-4038-895c-490e978aefd0">19,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930" decimals="-3" sign="-" name="mdxg:SegmentContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0zLTEtMS0xMDI2MDQ_8dcd7622-5dfe-4f1c-9eba-be44d24343d1">4,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0xLTEtMS0xMDAxMTY_c5555006-c6ef-41ac-bc1c-a986b6579e4a"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0zLTEtMS0xMDAxMTk_560ac4f0-93af-4c39-9760-27f00b59bd42"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC01LTEtMS0xMDAxMjI_416dea56-ab45-4482-950e-415b4c763577"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="mdxg:InvestigationRestatementAndRelated" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC03LTEtMS05ODU1NQ_82484051-697b-43e8-83ea-0b47c25378a1">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMy0xLTEtMS05ODY4Mg_21d6020b-f808-4899-9579-0c9660c35dac"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMy0zLTEtMS05OTQ5OQ_de7f7652-55e5-44bb-896e-f6f87a6a3937"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMy01LTEtMS0xMDAxMjI_83ead9f7-bd46-4900-8adb-1ad8f45ccbfc"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMy03LTEtMS05ODU1NQ_4948a8ba-536f-4d39-ae9c-806973f2219a">1,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMS0xLTEtMS0xMDAxMTY_14ce9fbd-cd5a-4dbf-ab65-042f850ba61b">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMS0zLTEtMS0xMDAxMTk_27e923a3-8d5f-4408-93e4-25cc0357ffe2">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMS01LTEtMS0xMDAxMjI_9aeb0f70-7b68-4514-8264-adc07d25033e">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMS03LTEtMS0xMDAxMzU_a99ffa13-12c0-417e-9e7b-3b2692c61ecd">923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMi0xLTEtMS0xMDAxMTY_332e3698-10c0-4e47-be6c-353768d5219d">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMi0zLTEtMS0xMDAxMTk_c81a8622-2fbb-4576-bfce-4d4f9182e36f">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMi01LTEtMS0xMDAxMjI_dbfe3e1f-f802-48c4-8aa2-71bce45ef61d">2,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMi03LTEtMS0xMDAxMzU_169f1c96-687d-40ac-8202-102a31c1a82a">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2022 were as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:37.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xLTEtMS0xLTk5MzI0_0bbe0a61-6a0d-4c5b-a371-99082d63ffa8">191,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xLTMtMS0xLTk5MzMx_75368c29-1877-4cb3-9555-62da11cbd093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xLTUtMS0xLTEwMDE1MQ_a9709967-3932-49e7-b3c2-685e02fcbb80">2,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xLTctMS0xLTk5MTgy_0f0d8aca-03d7-4cc1-aa3d-ff8ea4ab28d5">193,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yLTEtMS0xLTk5MzI0_4c4bfcb3-c524-4f53-b666-23b22b5aa412">31,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yLTMtMS0xLTk5MzMx_4db3cdf4-c260-4ddf-b5d8-6cc31461a6e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yLTUtMS0xLTEwMDE1MQ_2e1a7793-abbb-42e6-841b-8745d312dba6">2,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yLTctMS0xLTk5MTgy_7e067564-8774-4be7-a652-ea223a38a077">33,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV84LTEtMS0xLTk5MzM4_9bda2c10-eec9-4335-8cbb-aa04cd67be47">108,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV84LTMtMS0xLTk5MzY3_9cc7cc63-dddf-4d9b-9531-a3ec0febf38f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV84LTUtMS0xLTEwMDE1NA_4c2f7bcd-5253-4b28-aec9-4b3af0dd03dc">50,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV84LTctMS0xLTk5MTg2_40007806-314d-4f53-8c8b-5d089f70af92">158,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV85LTEtMS0xLTk5MzM4_ca19fe24-40ff-4c43-b20b-1f85f0f95460">6,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV85LTMtMS0xLTk5MzYw_754aaef5-26e1-4b0a-8bfd-5d6a43d46be5">11,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV85LTUtMS0xLTEwMDE1NA_9534747f-3a35-4d13-a97e-6d89ab54aa51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV85LTctMS0xLTk5MTg2_a904f3b2-88ac-492f-b3c9-dddcc8c00189">17,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0xLTEtMS0xMDUyNzQ_fabf4051-f215-4a81-8cd5-4f7a7d55b1c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0zLTEtMS0xMDUyNzQ_a4576fb8-f608-4444-b6cd-2217fe4e84a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC01LTEtMS0xMDUyNzQ_9dbd8f99-57c2-480d-b541-9422dba8bdc4">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC03LTEtMS0xMDUyNzQ_9aa894c3-f52d-418a-990f-aafe1a864caf">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" decimals="-3" name="mdxg:SegmentContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0xLTEtMS0xMDI2MTU_8a8208fa-55d8-4393-b126-80f0b7677272">45,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" decimals="-3" sign="-" name="mdxg:SegmentContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0zLTEtMS0xMDI2MTU_1d766d1c-df88-4149-b162-4ff294242a76">11,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0xLTEtMS0xMDAxMzc_98aeec6c-88ed-4710-8e6b-5b89111ee269"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0zLTEtMS0xMDAxNDY_2c736bb6-3aa3-46c1-88a3-d466176d6c7b"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC01LTEtMS0xMDAxNTQ_3138217e-f52c-47e2-b3d3-c062ba81f5b1"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="mdxg:InvestigationRestatementAndRelated" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC03LTEtMS05OTE4Ng_dad1b718-41fa-46f0-95e8-81d112bd2a39">8,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMy0xLTEtMS05OTQ5NA_72c50bc3-a76f-4aa8-87e9-7d8eb961f7b9"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMy0zLTEtMS05OTcyNQ_94fc714a-f95e-4e6f-a82e-78dc9bb828f7"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMy01LTEtMS0xMDAxNTQ_7da49b85-22fa-4953-9854-3886d27277e1"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMy03LTEtMS05OTE4Ng_83ebf85a-d0ac-483b-8372-7417d12bd933">26,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMS0xLTEtMS05OTI4NA_b862e598-d89e-44f4-896e-e882a58a9dce">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMS0zLTEtMS05OTI4OQ_fcc5bde0-d760-4211-aa26-3b2f1bda609c">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMS01LTEtMS05OTI5NA_7d04c743-fdd3-4775-ab89-f3c8e102af48">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMS03LTEtMS05OTI3OA_f28cbb48-c497-4bdf-b6e0-cd95bf22c0c2">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMi0xLTEtMS05OTMwMQ_0f7bb625-d198-4169-8d85-d255e6008b67">5,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMi0zLTEtMS05OTMwNg_061dc963-5ace-4905-946c-f481ba600cba">910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMi01LTEtMS05OTMxMQ_b57e99d8-e117-493e-9b94-22ed737a5cd7">4,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMi03LTEtMS05OTI4MQ_916ff3c3-eadf-4f61-8134-f34d8a8eb8a1">10,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2021 were as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xLTEtMS0xLTk5NDA2_32836663-071b-4ad2-924a-bc01c3d49183">172,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xLTMtMS0xLTk5NDI3_1a7a6b6e-a0e4-47c9-b72f-93856ea56aea">16,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xLTUtMS0xLTEwMDE1OQ_4d5905e5-aef3-4717-8673-cb187833290d">2,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xLTctMS0xLTk5Mzg1_3fd7e7bb-ee0e-4166-b838-780aac74fdca">191,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yLTEtMS0xLTk5NDA2_55723ba6-cc66-4e6b-827a-bfb6cb5b61b4">25,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yLTMtMS0xLTk5NDI3_5f6e6d04-8fec-4c51-8e9d-0e5f156906b6">3,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yLTUtMS0xLTEwMDE1OQ_4e9ad9a9-189a-4bdb-a40d-41e7bc19a3c4">3,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yLTctMS0xLTk5Mzg1_41d809c7-c1f0-443b-8d07-b4dcf4771967">32,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV84LTEtMS0xLTk5NDM0_b17b0525-5e4e-4f48-8263-fdba6457c00b">87,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV84LTMtMS0xLTk5NDQx_d2bec476-867d-4ead-858b-650ee058dd1a">11,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV84LTUtMS0xLTEwMDE3Mw_4817fc3c-918b-4730-979d-73a7fcb0948c">46,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV84LTctMS0xLTk5Mzg5_c8eaebaf-f662-46a7-bb28-39879fcdca6b">145,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV85LTEtMS0xLTk5NDEz_efe8cda7-f25b-4efc-a2fd-4db37c518d2d">4,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV85LTMtMS0xLTk5NDIw_0fef656d-425d-464a-a1a8-65bb2da8368a">8,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV85LTUtMS0xLTEwMDE3Mw_42811c8d-65ce-4b54-8a33-145c69e0bc28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV85LTctMS0xLTk5Mzg5_a95a6282-f0ee-4bb3-bea8-e7ac4c0173f3">12,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0xLTEtMS0xMDUzMDI_361e525b-dd85-4336-a513-efafd6fbfe51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0zLTEtMS0xMDUzMDI_9a17f009-98c7-4091-9913-1bca8008a8b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC01LTEtMS0xMDUzMDI_fdef3b68-00da-4e23-b23c-bde2bc190771">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC03LTEtMS0xMDUzMDI_815a0aef-17d3-4c74-a64e-ac06e32039cc">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930" decimals="-3" name="mdxg:SegmentContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0xLTEtMS0xMDI2MzI_0bdda405-d8e0-480c-b379-63c784569748">55,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930" decimals="-3" sign="-" name="mdxg:SegmentContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0zLTEtMS0xMDI2MzI_fb4729a7-f4ec-46b1-8806-0b7ac03e6fbe">6,885</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0xLTEtMS0xMDAxNjM_1e35d855-9aa9-4085-9bd0-8650eb332382"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0zLTEtMS0xMDAxNjY_4a8901bc-7037-4272-9e8b-86f79ea66205"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930" xsi:nil="true" name="mdxg:InvestigationRestatementAndRelated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC01LTEtMS0xMDAxNzM_baf3a18d-3832-4cab-9373-f6039b9f4c93"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="mdxg:InvestigationRestatementAndRelated" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC03LTEtMS05OTM4OQ_5243efe8-f261-4b4d-b7fc-69ff4b97f7fb">8,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMy0xLTEtMS05OTUxMQ_00dc8e14-dbf9-439c-a4b8-86260e63f5a2"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMy0zLTEtMS05OTc0Ng_99f9d8fb-7f7b-469b-b293-2fd3c6982c93"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930" xsi:nil="true" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMy01LTEtMS0xMDAxNzM_2356390e-046b-4d1c-aaf9-e76bdedcd31b"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMy03LTEtMS05OTM4OQ_15439f75-4535-4013-813c-ca3cc9788177">8,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMS0xLTEtMS05OTQ0OA_48cac5f2-a318-4e66-961b-523adfad79eb">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMS0zLTEtMS05OTQ1NQ_edf16db9-3fb8-4b10-abad-1767c1bbca7f">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMS01LTEtMS05OTQ2Mg_4c5da6e6-b23e-4bcb-9c0b-70b8b64bbcfc">2,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMS03LTEtMS05OTQwMw_9a130457-280b-47c9-b63d-c1f6cab7028c">3,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMi0xLTEtMS05OTQ2OQ_90a6a163-9ecb-4325-bc23-6d4d04018968">3,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMi0zLTEtMS05OTQ3Ng_41250b11-a6e5-4e1f-b2be-255c4183449d">1,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMi01LTEtMS0xMDAxNzM_622eb5ee-6541-4e8c-b28b-e1ce3fa855a8">6,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMi03LTEtMS05OTQwMA_f7aa874a-d9be-4c72-9f4f-0e7e93f0deb3">11,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company does not allocate any assets to the reportable segments. No asset information is reported or disclosed to the chief operating decision maker in the financial information for each segment.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="ide1fe17276234d55bab608462fe4131b_94"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX is a transformational placental biologics company and a pioneer in placental tissue engineering, focused on addressing the needs of patients with acute and chronic non-healing wounds. The Company is also advancing a promising late-stage biologics pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. To accomplish these goals, the Company operates under two defined internal business units: Wound &amp; Surgical and Regenerative Medicine. All of our products are regulated by the U.S. Food &amp; Drug Administration (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Wound &amp; Surgical business focuses on the Advanced Wound Care and Surgical Recovery markets, the Company&#8217;s existing product portfolio (as described in detail in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section below), and near-term product development.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Regenerative Medicine business focuses on progressing the Company&#8217;s placental biologics platform towards registration as a FDA-approved biological drug. Micronized dehydrated human amnion chorion membrane (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mdHACM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is the lead product candidate in its late-stage pipeline targeted at achieving FDA approval for specific clinical indications, including degenerative musculoskeletal conditions, beginning with Knee Osteoarthritis (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KOA&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Products</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX is a leading supplier of human placental allografts, which are human tissues that are derived from one person (the donor) and used to produce products that treat another person (the recipient). MIMEDX has supplied over two million allografts, through both direct and consignment shipments. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two classes of products: (1) Advanced Wound Care products, or Section 361 products, consisting of our tissue and cord sheet allograft products, as well as certain particulate products regulated under Section 361, and (2) Section 351 products, consisting of our micronized and certain other particulate products, which, prior to May 31, 2021, the date the FDA&#8217;s period of enforcement discretion ended (as described below), were used to treat a variety of clinical conditions, including both advanced wound care and musculoskeletal applications. Our Advanced Wound Care products includes two product categories: Tissue/Other and Cord products. We sell product through two distribution channels: (1) direct to customers (healthcare professionals and/or facilities); and (2) sales through distributors. We apply Current Good Tissue Practice (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CGTP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and Current Good Manufacturing Practice (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CGMP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) standards in addition to terminal sterilization to produce our allografts. MIMEDX provides products primarily in the wound care, burn, and surgical recovery sectors of healthcare. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platform technologies include tissue allografts derived from the amnion and chorion layers of human placental membrane (EPIFIX&#174; and AMNIOFIX&#174;) and tissue allografts derived from human umbilical cord (EPICORD&#174; and AMNIOCORD&#174;).</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most recent product innovations, AMNIOEFFECT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AXIOFILL&#8482;, were introduced in September 2022. AMNIOEFFECT is a tri-layer placental tissue allograft that contains amnion, intermediate layer and chorion membranes. This product is designed to meet the needs of surgeons performing procedures where a more robust allograft with expansive size offerings is desired. AXIOFILL is an extracellular matrix derived from human placental disc, and is designed to provide a cost-effective human collage scaffold that is conducive for use in large, complex wounds and those of irregular geometries.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPIFIX and EPICORD products are marketed for external use, such as in advanced wound care applications, while our AMNIOFIX, AMNIOEFFECT, AXIOFILL and AMNIOCORD products are positioned for use in surgical recovery applications, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMNIOFIX Injectable, or mdHACM, is a micronized configuration of AMNIOFIX and is not currently marketed in the United States. mdHACM is our lead product candidate for our late-stage pipeline targeted at achieving FDA approval for specific clinical indications, including degenerative musculoskeletal conditions, beginning with KOA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the FDA published a series of guidances that established an updated framework for the regulation of cellular and tissue-based products. These guidances clarified the FDA&#8217;s views about the criteria that differentiate those products subject to regulation under Section 361 of the Public Health Service Act from those considered to be drugs, devices, and/or biological products subject to licensure under Section 351 of the Public Health Service Act and related regulations. The FDA exercised enforcement discretion with respect to Investigational New Drug (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) applications and pre-market approval requirements until May 31, 2021 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enforcement Discretion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). As of May 31, 2021, we stopped marketing our Section 351 products in the United States and are precluded from marketing such products until a Biologics License Application (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is granted. If and when the FDA approves a BLA, we expect to be allowed to market our Section 351 products in the United States again, but only for specific indications as permitted by the FDA.</span></div><div id="ide1fe17276234d55bab608462fe4131b_100"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effect of Covid-19 Pandemic</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 Pandemic is still ongoing, though the effects on our operations, such as restricted access to hospitals and difficulties obtaining donor materials, have largely been ameliorated and did not materially affect our operations during the three months ended September&#160;30, 2022. We are continuously monitoring for any developments that may impact our operations, including novel variants of the virus and government and societal responses to mitigate the spread.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to exercise an abundance of caution with respect to the health and well-being of our employees. Our offices are open and staffed, and we are operating under a hybrid work model for some personnel as well as encouraging all employees to get vaccinated if they have not already done so.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Former CEO Separation</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, MIMEDX entered into a separation agreement with Timothy R. Wright, our former CEO, under which he will receive the same severance benefits as those provided for in his original employment Letter Agreement dated April 8, 2019, including compensation of $3.1 million. Additionally, credits related to the forfeiture of the former CEO&#8217;s share-based compensation awards during the three and nine months ended September 30, 2022 were $2.0 million.</span></div><div id="ide1fe17276234d55bab608462fe4131b_103"></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div id="ide1fe17276234d55bab608462fe4131b_1368"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September&#160;30, 2022 Compared to the Three Months Ended September&#160;30, 2021</span></div><div id="ide1fe17276234d55bab608462fe4131b_1442"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Company</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:38.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.397%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,074&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Sales</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded net sales for the three months ended September 30, 2022 of $67.7 million, a $4.6 million, or 7.3%, increase compared to the three months ended September 30, 2021, in which we recognized net sales of $63.1 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales by product were as follows (amounts in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Wound Care</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Tissue/Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cord</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Advanced Wound Care</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 351</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,074&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net sales was driven primarily by growth of our Wound &amp; Surgical products in the Surgical Recovery market, including early results from the recent launches of AMNIOEFFECT and AXIOFILL, both of which were launched in September 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales and Gross Profit Margin</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales for the three months ended September 30, 2022 and 2021 was $12.2 million and $10.1 million, respectively, an increase of $2.1 million, or 20.3%. Gross profit margin for the three months ended September 30, 2022 was 82.0% compared to 83.9% for the three months ended September 30, 2021. Decreases in margins were driven by lower production levels.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These effects were partially offset by $0.5 million of inventory write-downs taken during the three months ended September 30, 2021 related to discontinued products. There were no significant, unusual write-downs during the three months ended September 30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SG&amp;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) expense for the three months ended September 30, 2022 was $53.5 million, compared to $46.3 million for the three months ended September 30, 2021, an increase of $7.2 million, or 15.5%. The increase in SG&amp;A was driven by year-over-year increases in commissions due to greater sales volume as well as proportionally more sales through sales agents. In addition, we incurred more travel expenses during the three months ended September 30, 2022 compared to the prior year when we had more restrictions on travel due to the COVID-19 Pandemic. The remaining variance was primarily due to year-over-year increases in bad debt expense. The increase was further driven by personnel costs. This was primarily due to severance expense associated with our former CEO, whose employment terminated in September 2022, net of credits for forfeitures related to share-based compensation arrangements. The remainder of the increase was primarily the result of year-over-year increases in consulting expenses related to various market assessments conducted as part of the Company&#8217;s strategic planning process and evaluation.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense in Corporate &amp; Other was 26.5% and 20.5% of total net sales for the three months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development expense increased $1.6 million, or 36.3%, to $6.0 million for the three months ended September 30, 2022, compared to $4.4 million for the three months ended September 30, 2021. This increase spans both our Wound &amp; Surgical and Regenerative Medicine business units, with investments in clinical research efforts connected to our Knee Osteoarthritis clinical trial program, along with higher development and testing costs, primarily related to the launches of AMNIOEFFECT and AXIOFILL.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation, Restatement and Related Expense</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investigation, restatement and related expense for the three months ended September 30, 2022 was $3.0 million compared to $3.2 million for the three months ended September 30, 2021. Expenses incurred during the three months ended September 30, 2022 and 2021 included amounts related to legal fees advanced under indemnification agreements with certain former members of management. We remain subject to indemnification agreements with certain former officers and directors of the Company (other than Messrs. Petit and Taylor, our former Chief Executive Officer and Chief Operating Officer) for whom legal proceedings are still ongoing, in particular, our former Chief Financial Officer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was $0.2 million for each of the three months ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense, Net</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net was $1.3 million for the three months ended September 30, 2022 compared to $1.0 million for the three months ended September 30, 2021, an increase of $0.3 million, or 31.9%. The increase was primarily the result of interest income on our income tax receivable recognized in the prior year. The remaining variance was the result of the impact of rising rates on the variable portion of our interest rate index. We expect interest expense to increase in future quarters as a result of rising interest rates.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Provision Expense</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the Company were (0.6)% and (14.8)% for the three months ended September&#160;30, 2022 and September&#160;30, 2021, respectively. There were no material discrete items affecting the effective tax rate in either period. Net operating losses incurred during both periods were offset by a valuation allowance.</span></div><div id="ide1fe17276234d55bab608462fe4131b_1376"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Wound &amp; Surgical</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:38.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,873&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,735&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Wound &amp; Surgical business recorded $66.9 million of net sales for the three months ended September&#160;30, 2022, a $4.7 million, or 7.6%, increase compared to the $62.1 million we recorded for the three months ended September&#160;30, 2021. The increase in net sales was driven primarily by growth of our Wound &amp; Surgical products in the Surgical Recovery market, including early results from the recent launches of AMNIOEFFECT and AXIOFILL, both of which were launched in September 2022.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales for the three months ended September&#160;30, 2022 was $11.2 million, a $2.2 million, or 25.0%, increase compared to the $8.9&#160;million recognized for the three months ended September&#160;30, 2021. Cost of sales increased due to negative impacts from production variances, primarily due to lower production levels, as well as increases in sales volume.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense was $35.5 million for the three months ended September&#160;30, 2022, a $3.4 million, or 10.7%, increase over the three months ended September&#160;30, 2021, during which we incurred $32.1 million of expenses. The increase was driven by year-over-year increases in commissions resulting from increases in sales volume and proportionally more sales through sales agents, as well as increases in bad debt expense.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $1.7 million for the three months ended September&#160;30, 2022, compared to $1.4 million for the three months ended September&#160;30, 2021. The increase was due to greater development and testing costs, primarily related to AMNIOEFFECT and AXIOFILL, both of which launched during the three months ended September&#160;30, 2022. </span></div><div id="ide1fe17276234d55bab608462fe4131b_1385"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regenerative Medicine</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:38.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $4.3 million for the three months ended September&#160;30, 2022, compared to $2.9 million for the three months ended September&#160;30, 2021, an increase of $1.3 million. This increase was due to investments in clinical research efforts connected to our Knee Osteoarthritis clinical trial program, along with higher development and testing costs.</span></div><div id="ide1fe17276234d55bab608462fe4131b_1400"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2022 Compared to the Nine Months Ended September 30, 2021 </span></div><div id="ide1fe17276234d55bab608462fe4131b_1449"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Company</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"></td><td style="width:38.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,466&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,206&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Sales</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded net sales for the nine months ended September 30, 2022 of $193.5 million, a $2.3 million, or 1.2%, increase compared to the nine months ended September 30, 2021, for which we recorded net sales of $191.2 million. Our sales by product were as follows (amounts in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Wound Care</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tissue/Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cord</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Advanced Wound Care</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,316&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 351</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(684)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net sales reflects sales growth in our Advanced Wound Care products of $18.3 million, or 10.6%, year-over-year, offset in part by the decrease in Section 351 product sales described below. Our sales growth in this area was a result of our focus on the application of these products into areas of Surgical Recovery, as well as the results of our prior initiatives to expand, realign and train our sales team.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These results reflect a return to pre-Enforcement Discretion revenue levels, before Section 351 products were removed from the US market,</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">following the end of Enforcement Discretion on May 31, 2021. Sales of our Section 351 products were $1.8 million for the nine months ended September 30, 2022, compared to $17.2 million for the nine months ended September 30, 2021, a decrease of $15.4 million. Sales of Section 351 products during the nine months ended September&#160;30, 2022 were outside the United States.</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales and Gross Profit Margin</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales for the nine months ended September 30, 2022 was $33.9 million, an increase of $1.4 million, or 4.4%, compared to $32.5 million for the nine months ended September 30, 2021.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit margin for the nine months ended September 30, 2022 was 82.5% compared to 83.0% for the nine months ended September 30, 2021. Cost of sales and gross profit margin for the nine months ended September 30, 2021 included inventory write-downs related to our Section 351 products, resulting from the end of Enforcement Discretion and products which were discontinued. Such write-downs were $1.7 million in total. There were no significant unusual write-downs during the nine months ended September 30, 2022. Offsetting this were the negative impacts from production levels.</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses for the nine months ended September 30, 2022 increased $13.5 million, or 9.3%, to $158.8 million, compared to $145.3 million for the nine months ended September 30, 2021. The increase in SG&amp;A reflects increases in travel costs, sales commissions, bad debt expense, and personnel costs, offset, in part, by lower annual meeting-related expenses. The increase in travel expenses reflects the lifting of travel restrictions that were in place during the nine months ended September 30, 2021 due to the COVID-19 Pandemic, as well as inflationary pressures experienced during the nine months ended September 30, 2022. Increases in sales commissions reflected our focus on sales of products into areas of Surgical Recovery, resulting in a proportional increase in sales through sales agents. The increase in bad debt expense was primarily the result of the deterioration of credit for certain specific customers. The increase in personnel costs reflects severance expense associated with our former CEO, whose employment terminated in September 2022, net of credits for forfeitures related to share-based compensation arrangements.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These effects were offset by year-over-year decreases in expenses incurred in connection with our annual meeting of shareholders. During the nine months ended September 30, 2022, we incurred $2.3 million in consulting and advisory expenses related to a withhold the vote campaign launched by a shareholder. This compares to $3.9 million of similar expenses incurred during the nine months ended September 30, 2021 related to a proxy contest initiated by the same shareholder. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense in Corporate &amp; Other was 26.1% and 24.5% of total net sales for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses increased $4.7 million, or 36.5%, to $17.4 million for the nine months ended September 30, 2022, compared to $12.8 million for the nine months ended September 30, 2021. The increase reflects higher personnel costs, driven by increases in headcount to support clinical research efforts, primarily connected to our commercial and late-stage pipelines.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation, Restatement and Related Expense</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investigation, restatement and related expenses for the nine months ended September 30, 2022 increased approximately $0.5 million, or 5.6%, to $8.8 million compared to $8.3 million for the nine months ended September 30, 2021. Year-over-year decreases in litigation fees were offset by the receipt of funds from certain director and officer insurance policies during the nine months ended September 30, 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense decreased $0.1 million or 19.8% from $0.6 million for the nine months ended September 30, 2021 to $0.5 million for the nine months ended September 30, 2022. The decrease was the result of amortization avoided on licenses, supplier relationships, and non-compete agreements, which were fully amortized or impaired during 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense, Net</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net was $3.6 million for the nine months ended September 30, 2022 compared to $3.8 million for the nine months ended September 30, 2021. The decrease was the result of the amortization of deferred financing costs and original issue discount associated with a delayed draw term loan facility under the Hayfin Loan Agreement (described below under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which ceased at the conclusion of the commitment period for the delayed draw facility on June 30, 2021. This effect was offset by interest income recognized on an income tax receivable during the nine months ended September 30, 2021, as well as increases in LIBOR during the nine months ended September 30, 2022.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Provision Expense</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the Company were (0.6)% and (2.9)%&#160;for the nine months ended September 30, 2022 and 2021, respectively. There were no material discrete items affecting the effective tax rate in either period. Net operating losses incurred during both periods were offset by a valuation allowance.</span></div><div id="ide1fe17276234d55bab608462fe4131b_1413"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Wound &amp; Surgical</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:38.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,401&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Wound &amp; Surgical business recorded $191.3 million of net sales for the nine months ended September&#160;30, 2022, a $18.9 million, or 11.0%, increase compared to the $172.4 million we recorded for the nine months ended September&#160;30, 2021. This increase was the result of our focus on the application of these products into areas of Surgical Recovery, as well as the results of our prior initiatives to expand, realign and train our sales team.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales for the nine months ended September&#160;30, 2022 was $31.1 million, a $5.5 million, or 21.4%, increase compared to the $25.6 million recognized for nine months ended September&#160;30, 2021. Cost of sales increased due to negative impacts from production variances, primarily due to lower production levels, as well as increases in sales volume.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense was $108.3&#160;million for the nine months ended September&#160;30, 2022, a $20.9 million, or 23.9%, increase over the nine months ended September&#160;30, 2021, during which we incurred $87.4 million of expenses. The increase was driven by travel expenses, sales commissions, and bad debt expense. Travel expenses increased due to the lifting of restrictions that were in place during the nine months ended September 30, 2021 due to the COVID-19 Pandemic, as well as inflationary pressures experienced during the nine months ended September 30, 2022. Increases in sales commissions reflected our focus on sales of products into areas of Surgical Recovery, resulting in a proportional increase in sales through sales agents. The increase in bad debt expense was primarily the result of the deterioration of credit for certain specific customers.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $6.1 million for the nine months ended September&#160;30, 2022, compared to $4.1 million for the nine months ended September&#160;30, 2021, an increase of $2.0 million, or 48.7%. The increase was primarily the result of expenses related to AMNIOEFFECT and AXIOFILL, both of which launched during the nine months ended September&#160;30, 2022. </span></div><div id="ide1fe17276234d55bab608462fe4131b_1419"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regenerative Medicine</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:38.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,584)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 31, 2021, we ceased marketing certain of our products which are regulated under Section 351 in the United States. After that point in time, we began focusing sales and marketing efforts toward the advancement of our Wound &amp; Surgical products in the United States.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $11.4 million for the nine months ended September&#160;30, 2022, compared to $8.7 million for the nine months ended September&#160;30, 2021, an increase of $2.7 million, or 30.7%. The increase was primarily the result of increases in headcount and the incurrence of clinical trial expenses to support our clinical research efforts.</span></div><div id="ide1fe17276234d55bab608462fe4131b_112"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our GAAP results, we provide certain Non-GAAP measures including Earnings Before Interest, Taxes, Depreciation and Amortization (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EBITDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and Adjusted EBITDA. We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measurements are not a substitute for GAAP measurements, and the manner in which we calculate such metrics may not be identical to the manner in which other companies calculate and present similar metrics. Company management uses these Non-GAAP measurements as aids in monitoring our ongoing financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against comparable companies.</span></div><div id="ide1fe17276234d55bab608462fe4131b_118"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EBITDA and Adjusted EBITDA</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EBITDA is intended to provide a measure of the Company&#8217;s operating performance as it eliminates the effects of financing and capital expenditures. EBITDA consists of GAAP net loss excluding: </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) depreciation, (ii) amortization of intangibles, (iii) interest expense, net, and (iv) income tax provision. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is intended to provide an enduring, normalized view of EBITDA and our broader business operations that we expect to experience on an ongoing basis by removing certain non-cash items and items which may be irregular, one-time, or non-recurring from EBITDA. This also includes share-based compensation, which is predominantly settled in shares. This enables us to identify underlying trends in our business that could otherwise be masked by such items.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA consists of GAAP net loss excluding: </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) depreciation, (ii) amortization of intangibles, (iii) interest expense, (iv) income tax provision, (v) costs incurred in connection with the Audit Committee Investigation and Restatement, and (vi) share-based compensation.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management also assesses EBITDA margin and Adjusted EBITDA margin to provide an additional layer of context to the Company&#8217;s profitability; indicating our ability to convert our sales into sustainable operating results. EBITDA margin is calculated as EBITDA divided by GAAP net sales. Similarly, Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by GAAP net sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of GAAP net loss to EBITDA and Adjusted EBITDA appears in the table below (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:37.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,426)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,339)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,783)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBITDA</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,097)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,971)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,302)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">EBITDA margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional Non-GAAP Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred in connection with Audit Committee Investigation and Restatement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(724)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,402)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Adjusted EBITDA margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="ide1fe17276234d55bab608462fe4131b_121"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Cash Flows</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities during the nine months ended September&#160;30, 2022 was $12.3 million, compared to $1.3 million of cash provided for the nine months ended September&#160;30, 2021. The change was primarily the result of year-over-year increases in selling, general and administrative expenses and research and development expenses. In addition, during the nine months ended September&#160;30, 2021, we received income tax refunds of $9.2 million. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during the nine months ended September&#160;30, 2022, we made our initial milestone payment pursuant to a collaboration agreement with Nordic Bioscience Clinical Development A/S for $2.0 million. Refer to the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section below for further details. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, payments of accrued compensation increased for the nine months ended September&#160;30, 2022 due to a restructuring of our internal commission arrangements during 2021. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These effects were offset by year-over-year decreases in payments related to legal accruals and recoveries from director and officer insurance policies during the nine months ended September&#160;30, 2021.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used for investing activities during the nine months ended September&#160;30, 2022 was $1.0 million, compared to $3.1 million for the nine months ended September&#160;30, 2021. This decrease reflects a $2.0 million year-over-year decrease in capital expenditures.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $0.6 million during the nine months ended September&#160;30, 2022 compared to $3.4 million during the nine months ended September&#160;30, 2021. The decrease was the result of a $3.6 million decrease in cash paid for tax withholdings upon the vesting of restricted stock awards during the nine months ended September&#160;30, 2022 compared to the nine months ended September&#160;30, 2021. This was offset by a $0.8 million decrease in cash proceeds from the exercise of stock options, year-over-year.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business requires capital for our operating activities, including costs associated with the sale of product through direct and indirect sales channels, the conduct of research and development activities, compliance costs, and legal and consulting fees in connection with ongoing litigation and other matters.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had $73.2 million of cash and cash equivalents, total current assets of $136.0 million and total current liabilities of $45.9 million, reflecting a current ratio of 3.0.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently paying our obligations in the ordinary course of business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate cash requirements related to the following items within one year of the date of the filing of this Quarterly Report:</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures required to conduct clinical trials to advance our BLAs and other potential R&amp;D investments;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures required to achieve necessary regulatory approval and establish operations in new markets deemed strategically important toward the enhancement of our global footprint; </span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investments in manufacturing capacity to advance and expand our existing product portfolio;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">indemnification payments to certain former members of our management team; and</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">severance payments related to certain former members of management.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have analyzed our ability to address these commitments and potential liabilities for the 12 months extending from the date of the filing of this Quarterly Report. After completing this analysis, which included a review of expectations of revenue, margins, and expenses, we believe that our existing cash and cash from operations will be sufficient to meet our obligations as they come due.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hayfin Loan Agreement was funded on July 2, 2020 and provided us with a senior secured term loan of $50 million (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Term Loan matures on June 30, 2025 (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maturity Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). On February 28, 2022 (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), we executed an Amendment to the Hayfin Loan Agreement.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No principal payments are due on the Term Loan until the Maturity Date.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest is payable on the Term Loan for principal outstanding quarterly through the Maturity Date. Interest on any borrowings under the Term Loan is equal to LIBOR (subject to a floor of 1.5%) plus a margin of 6.75%. If LIBOR is unavailable, the loan will carry interest at the greatest of the Prime Rate, the Federal Funds Rate plus 0.5% per annum, and 2.5% plus the 6.75% margin.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional 3.0% margin would be applied to the interest rate upon the occurrence of an Event of Default as defined in the Hayfin Loan Agreement, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Hayfin Loan Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). As of September&#160;30, 2022, the Term Loan carried an interest rate of 10.4%.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Hayfin Loan Agreement contains financial covenants requiring the Company, on a consolidated basis, to maintain the following:</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Minimum Consolidated Total Net Sales (as defined in the Amended Hayfin Loan Agreement) of varying amounts, required to be calculated on a quarterly basis, and</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Minimum Liquidity (as defined in the Amended Hayfin Loan Agreement) of $20 million, an at-all-times financial covenant, tested monthly.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we are in compliance with applicable all financial covenants under the Amended Hayfin Loan Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Hayfin Loan Agreement specifies that any prepayment of the Term Loan, voluntary or mandatory, as defined in the agreement, would subject us to a prepayment premium applicable as of the date of the prepayment, as follows:</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">On or before July 2, 2023: 2% of the principal balance repaid.</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">After July 2, 2023 but on or before July 2, 2024: 1% of the principal balance repaid.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">After July 2, 2024: no premium.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Hayfin Loan Agreement also includes certain negative covenants and events of default customary for facilities of this type, and upon the occurrence of such events of default, subject to customary cure rights, all outstanding loans under the Amended Hayfin Loan Agreement may be accelerated or the lenders&#8217; commitments terminated. Mandatory prepayments are also required in the event of a change in control, incurring other indebtedness, certain proceeds from disposal of assets and insured casualty event (as defined in the Amended Hayfin Loan Agreement). Annually, beginning with the fiscal year ending December 31, 2021, we are required to prepay the outstanding loans based on the percentage of our Excess Cash Flow (as defined in the Amended Hayfin Loan Agreement), if such is generated. To date, we have not been required to make any prepayments under this provision.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Preferred Stock</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 100,000 shares of Series B Preferred Stock outstanding as of September&#160;30, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Preferred Stock pays a 6.0% cumulative dividend per annum. Dividends are declared at the sole discretion of our board of directors. Dividends, if declared, are paid in cash at the end of each quarter based on dividend amounts that accumulate beginning on the last payment date through the day prior to the end of each quarter. In lieu of paying a dividend in cash, we may elect to accrue the dividend owed to shareholders. Dividend balances accumulate at the prevailing dividend rate for each dividend period for which they are outstanding.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Preferred Stock, including any accrued and unpaid dividends, is convertible into our common stock at any time at the option of the holder at a conversion price of $3.85 per common share, or 259.74 common shares for each share of Series B Preferred Stock prior to any accrued and unpaid dividends. The Series B Preferred Stock, including any accrued and unpaid dividends, automatically converts into common stock at any time after July 2, 2023, provided that the common stock has traded at $7.70 or higher (i) for 20 out of 30 consecutive trading days and (ii) on such date of conversion.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a change of control, we will have the option to repurchase some or all of the then-outstanding shares of Series B Preferred Stock for cash in an amount equal to the liquidation preference and any accumulated and unpaid dividends, subject to the rights of the holders of the Series B Preferred Stock in connection with such change in control. If we do not exercise such repurchase right, holders of the Series B Preferred Stock will have the option to (1) require us to repurchase any or all of our then-outstanding shares of Series B Preferred Stock for cash in an amount equal to the liquidation preference or (2) convert the Series B Preferred Stock, including accrued and unpaid dividends into common stock and receive its pro rata consideration thereunder.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not declared or paid any cash dividends on our Series B Convertible Preferred Stock since issuance. Dividends accumulated but not paid as of September&#160;30, 2022 were $12.1 million.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not repurchase any shares of our common stock, during the three months ended September 30, 2022. The timing and amount of future repurchases, if any, will depend upon our stock price, economic and market conditions, regulatory requirements, and other corporate considerations. We may initiate, suspend or discontinue purchases at any time.</span></div><div id="ide1fe17276234d55bab608462fe4131b_127"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nordic Agreement</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we entered into a collaboration agreement (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nordic Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) with Nordic Bioscience Clinical Development A/S (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBCD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to provide full operational support for our upcoming KOA clinical trial program, which we expect to begin later this year. As part of the agreement, NBCD will perform site selection and monitoring, manage patient recruitment and enrollment, data management, statistical analysis and reporting activities for the duration of the trial. Under the terms of the Nordic Agreement, we are obligated to pay $13.3 million upon the achievement of specified milestones over the course of the clinical trial. The milestones are based upon various factors including, but not limited to, site selection and enrollment, patient enrollment, patient completion, and certain other activities related to clinical trial activities. The milestone payments are revised semi-annually based on fluctuations in the consumer price index. We have the ability to terminate the Nordic Agreement with 30 days written notice to NBCD. At such time, we would be required to pay for services performed through the date of termination and any non-cancelable obligations.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid $2.0 million under the Nordic Agreement as of September 30, 2022 relating to milestones which have been achieved through that date.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Obligations</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the obligations discussed above, there were no significant changes to our contractual obligations during the nine months ended September&#160;30, 2022 from those disclosed in the section Item 7, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results from Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, in our 2021 Form 10-K.</span></div><div id="ide1fe17276234d55bab608462fe4131b_130"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing financial statements, we follow accounting principles generally accepted in the United States, which require us to make certain estimates and apply judgments that affect our financial position and results of operations. We regularly review our accounting policies and financial information disclosures. A summary of critical accounting estimates in preparing the financial statements was provided in our 2021 Form 10-K.&#160;During the quarter covered by this report, there were no material changes to the accounting policies and assumptions previously disclosed.</span></div><div id="ide1fe17276234d55bab608462fe4131b_136"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the effect of recent accounting pronouncements, see Note 2 to the unaudited condensed consolidated financial statements contained herein.</span></div><div id="ide1fe17276234d55bab608462fe4131b_139"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our lack of market risk sensitive instruments outstanding at September&#160;30, 2022, we have determined that there was no material market risk exposure to our consolidated financial position, results of operations or cash flows as of such date.</span></div><div id="ide1fe17276234d55bab608462fe4131b_142"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective at a reasonable assurance level in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the fiscal quarter ended September&#160;30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="ide1fe17276234d55bab608462fe4131b_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ide1fe17276234d55bab608462fe4131b_148"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are parties to numerous claims and lawsuits arising in the ordinary course of its business activities, some of which involve claims for substantial amounts. The ultimate outcome of these suits cannot be ascertained at this time. The description of our securities class action contained in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ide1fe17276234d55bab608462fe4131b_82">Note&#160;13, &#8220;Commitments and Contingencies,</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; to the unaudited condensed consolidated financial statements included in Part I,&#160;Item 1&#160;of this&#160;Quarterly Report, is incorporated herein by reference.</span></div><div id="ide1fe17276234d55bab608462fe4131b_151"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the Company&#8217;s risk factors included in its 2021 Form 10-K.</span></div><div id="ide1fe17276234d55bab608462fe4131b_154"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) None.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) None.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The following table sets forth information regarding the purchases of the Company&#8217;s equity securities made by or on behalf of the Company or any affiliated purchaser (as defined in Exchange Act Rule 10b-18) during the three month period ended&#160;September&#160;30, 2022:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:32.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of<br/>shares purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid<br/>&#160;per share </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares purchased under publicly announced plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1 - July 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 1 - August 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1 - September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total for the quarter</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div id="ide1fe17276234d55bab608462fe4131b_157"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ide1fe17276234d55bab608462fe4131b_160"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ide1fe17276234d55bab608462fe4131b_163"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ide1fe17276234d55bab608462fe4131b_166"></div><div style="-sec-extract:summary;margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Executive Employment Agreement, by and between MiMedx Group, Inc. and K. Todd Newton, dated September 14, 2022 (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex101.htm">incorporated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex101.htm">by reference to Exhibit 10.1 to the Registrant&#8217;s Form 8-K filed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex101.htm"> on</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex101.htm"> September 16, 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Unit Agreement, by and between MiMedx Group, Inc. and K. Todd Newton, dated September 15, 2022 </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex102.htm">(incorporated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex102.htm">by reference to Exhibit 10.2 to the Registrant&#8217;s Form 8-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex102.htm">on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex102.htm">September 16, 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</span></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Separation Agreement and General Release, by and between MiMedx Group, Inc. and Timothy R. Wright, dated September 15, 2022 </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex103.htm">(incorporated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex103.htm">by reference to Exhibit 10.3 to the Registrant&#8217;s Form 8-K filed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex103.htm"> on</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1376339/000119312522246472/d400313dex103.htm"> September 16, 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1 #</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20220930-10qex311final.htm">Certification of Chief Executive Officer</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2 #</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20220930-10qex312final.htm">Certification of Chief Financial Officer</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 #</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20220930-10qex321final.htm">Certification of Chief Executive Officer</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2 #</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20220930-10qex322final.htm">Certification of Chief Financial Officer</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS #</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH #</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL #</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF #</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB #</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE #</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.157%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:481.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously filed and incorporated herein by reference</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed or furnished herewith</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div id="ide1fe17276234d55bab608462fe4131b_169"></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November&#160;2, 2022</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MIMEDX GROUP, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter M. Carlson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter M. Carlson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Principal Financial Officer</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a20220930-10qex311final.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i58046f5af61f4e2fa64d0e25ece30add_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION OF INTERIM CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">PURSUANT TO RULES 13a-14(A) AND 15d-14(A)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, K. Todd Newton, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font></div><div style="text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, of MiMedx Group, Inc.&#59;&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.706%"><tr><td style="width:1.0%"></td><td style="width:6.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; K. Todd Newton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">K. Todd Newton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a20220930-10qex312final.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icf53bb5113b24a6d9d53c47b676d6a4c_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">PURSUANT TO RULES 13a-14(A) AND 15d-14(A)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Peter M. Carlson, certify that&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, of MiMedx Group, Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Peter M. Carlson</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter M. Carlson</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a20220930-10qex321final.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i94461c6b29eb43f394c29fa51ec3ec38_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.1</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;The undersigned K. Todd Newton, the Interim Chief Executive Officer of MiMedx Group, Inc. (the &#8220;Company&#8221;), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending September 30, 2022 (the &#8220;Report&#8221;). Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned hereby certifies, to his knowledge, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; K. Todd Newton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">K. Todd Newton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a20220930-10qex322final.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic244a579cf9b4bdf86e5dd3ebfe849a8_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.2</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;The undersigned Peter M. Carlson, the Chief Financial Officer of MiMedx Group, Inc. (the &#8220;Company&#8221;), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending September 30, 2022 (the &#8220;Report&#8221;). Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned hereby certifies, to his knowledge, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Peter M. Carlson</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter M. Carlson</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mdxg-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:75aec70c-8992-4432-a811-2ecd9b0ef10b,g:2668ca8b-9129-4930-9d6a-e03d3677c28b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mdxg="http://mimedx.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://mimedx.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdxg-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdxg-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdxg-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdxg-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://mimedx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY" roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://mimedx.com/role/NatureofBusiness">
        <link:definition>0000007 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://mimedx.com/role/SignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNet" roleURI="http://mimedx.com/role/AccountsReceivableNet">
        <link:definition>0000009 - Disclosure - Accounts Receivable, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://mimedx.com/role/Inventory">
        <link:definition>0000010 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://mimedx.com/role/PropertyandEquipmentNet">
        <link:definition>0000011 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNet" roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNet">
        <link:definition>0000012 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://mimedx.com/role/AccruedExpenses">
        <link:definition>0000013 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNet" roleURI="http://mimedx.com/role/LongTermDebtNet">
        <link:definition>0000014 - Disclosure - Long Term Debt, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShare" roleURI="http://mimedx.com/role/NetLossPerCommonShare">
        <link:definition>0000015 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://mimedx.com/role/Equity">
        <link:definition>0000016 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://mimedx.com/role/IncomeTaxes">
        <link:definition>0000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities" roleURI="http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities">
        <link:definition>0000018 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://mimedx.com/role/CommitmentsandContingencies">
        <link:definition>0000019 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://mimedx.com/role/Revenue">
        <link:definition>0000020 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://mimedx.com/role/SegmentInformation">
        <link:definition>0000021 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://mimedx.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>0000022 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetTables" roleURI="http://mimedx.com/role/AccountsReceivableNetTables">
        <link:definition>0000023 - Disclosure - Accounts Receivable, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://mimedx.com/role/InventoryTables">
        <link:definition>0000024 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://mimedx.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000025 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetTables" roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetTables">
        <link:definition>0000026 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://mimedx.com/role/AccruedExpensesTables">
        <link:definition>0000027 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetTables" roleURI="http://mimedx.com/role/LongTermDebtNetTables">
        <link:definition>0000028 - Disclosure - Long Term Debt, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareTables" roleURI="http://mimedx.com/role/NetLossPerCommonShareTables">
        <link:definition>0000029 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://mimedx.com/role/EquityTables">
        <link:definition>0000030 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables" roleURI="http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables">
        <link:definition>0000031 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://mimedx.com/role/RevenueTables">
        <link:definition>0000032 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://mimedx.com/role/SegmentInformationTables">
        <link:definition>0000033 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessDetails" roleURI="http://mimedx.com/role/NatureofBusinessDetails">
        <link:definition>0000034 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://mimedx.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000035 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetAccountsReceivableDetails" roleURI="http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails">
        <link:definition>0000036 - Disclosure - Accounts Receivable, Net - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetNarrativeDetails" roleURI="http://mimedx.com/role/AccountsReceivableNetNarrativeDetails">
        <link:definition>0000037 - Disclosure - Accounts Receivable, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://mimedx.com/role/InventoryDetails">
        <link:definition>0000038 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" roleURI="http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails">
        <link:definition>0000039 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDepreciationExpenseDetails" roleURI="http://mimedx.com/role/PropertyandEquipmentNetDepreciationExpenseDetails">
        <link:definition>0000040 - Disclosure - Property and Equipment, Net - Depreciation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetNarrativeDetails" roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails">
        <link:definition>0000041 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetActivitySummaryDetails" roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails">
        <link:definition>0000042 - Disclosure - Goodwill and Intangible Assets, Net - Activity Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetAmortizationExpenseDetails" roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetAmortizationExpenseDetails">
        <link:definition>0000043 - Disclosure - Goodwill and Intangible Assets, Net - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails">
        <link:definition>0000044 - Disclosure - Goodwill and Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://mimedx.com/role/AccruedExpensesDetails">
        <link:definition>0000045 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetTermLoanDetails" roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanDetails">
        <link:definition>0000046 - Disclosure - Long Term Debt, Net - Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetTermLoanDebtIssuanceCostsDetails" roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails">
        <link:definition>0000047 - Disclosure - Long Term Debt, Net - Term Loan Debt Issuance Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetTermLoanBalancesDetails" roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails">
        <link:definition>0000048 - Disclosure - Long Term Debt, Net - Term Loan Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetTermLoanInterestExpenseDetails" roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails">
        <link:definition>0000049 - Disclosure - Long Term Debt, Net - Term Loan Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetTermLoanMaturityDetails" roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails">
        <link:definition>0000050 - Disclosure - Long Term Debt, Net - Term Loan Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareBasicNetLossPerCommonShareDetails" roleURI="http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails">
        <link:definition>0000051 - Disclosure - Net Loss Per Common Share - Basic Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareDilutedNetLossPerShareDetails" roleURI="http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails">
        <link:definition>0000052 - Disclosure - Net Loss Per Common Share - Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>0000053 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://mimedx.com/role/EquityNarrativeDetails">
        <link:definition>0000054 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityChangesinSeriesBPreferredStockDetails" roleURI="http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails">
        <link:definition>0000055 - Disclosure - Equity - Changes in Series B Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityRestrictedStockAwardsDetails" roleURI="http://mimedx.com/role/EquityRestrictedStockAwardsDetails">
        <link:definition>0000056 - Disclosure - Equity - Restricted Stock Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityFairValueAssumptionsDetails" roleURI="http://mimedx.com/role/EquityFairValueAssumptionsDetails">
        <link:definition>0000057 - Disclosure - Equity - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityStockIncentivePlansDetails" roleURI="http://mimedx.com/role/EquityStockIncentivePlansDetails">
        <link:definition>0000058 - Disclosure - Equity - Stock Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://mimedx.com/role/IncomeTaxesDetails">
        <link:definition>0000059 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" roleURI="http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails">
        <link:definition>0000060 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://mimedx.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000061 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryofRevenuebyProductTypeDetails" roleURI="http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails">
        <link:definition>0000062 - Disclosure - Revenue - Summary of Revenue by Product Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://mimedx.com/role/RevenueNarrativeDetails">
        <link:definition>0000063 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryofRevenuebyCustomerTypeDetails" roleURI="http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails">
        <link:definition>0000064 - Disclosure - Revenue - Summary of Revenue by Customer Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://mimedx.com/role/SegmentInformationNarrativeDetails">
        <link:definition>0000065 - Disclosure - Segment Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails" roleURI="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails">
        <link:definition>0000066 - Disclosure - Segment Information - Net Sales and Operating Income (Loss) by each Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1" roleURI="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1">
        <link:definition>0000066 - Disclosure - Segment Information - Net Sales and Operating Income (Loss) by each Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member" abstract="true" name="PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_SeparationAgreementMember" abstract="true" name="SeparationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember" abstract="true" name="HayfinLoanAgreementDelayedDrawTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_DebtCovenantMinimumLiquidity" abstract="false" name="DebtCovenantMinimumLiquidity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_HayfinLoanAgreementTermLoanMember" abstract="true" name="HayfinLoanAgreementTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_ContingencyLossNumberOfSecuritiesClassActions" abstract="false" name="ContingencyLossNumberOfSecuritiesClassActions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mdxg_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders" abstract="false" name="NumberOfBoardSeatsElectedByTemporaryEquityHolders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mdxg_WoundSurgicalSegmentMember" abstract="true" name="WoundSurgicalSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mdxg_TemporaryEquityDeemedDividends" abstract="false" name="TemporaryEquityDeemedDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_CreditFacilitiesMember" abstract="true" name="CreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_TemporaryEquityConversionThresholdTradingDays" abstract="false" name="TemporaryEquityConversionThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mdxg_SegmentContribution" abstract="false" name="SegmentContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_ScheduleOfInterestExpenseTableTextBlock" abstract="false" name="ScheduleOfInterestExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mdxg_AccruedAdministrativeFeesCurrent" abstract="false" name="AccruedAdministrativeFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_InsuranceProvidersMember" abstract="true" name="InsuranceProvidersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature" abstract="false" name="TemporaryEquityAccretionOfIncreasingRateDividendFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member" abstract="true" name="DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_Section351ProductsMember" abstract="true" name="Section351ProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mdxg_InvestigationRestatementAndRelated" abstract="false" name="InvestigationRestatementAndRelated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember" abstract="true" name="RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_ScheduleOfDepreciationTableTextBlock" abstract="false" name="ScheduleOfDepreciationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mdxg_TreasuryStockSharesAdjustment" abstract="false" name="TreasuryStockSharesAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mdxg_SupplementalInformationAbstract" abstract="true" name="SupplementalInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdxg_PatentsinProcessMember" abstract="true" name="PatentsinProcessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_PaymentsMadeOnLongTermPurchaseCommitment" abstract="false" name="PaymentsMadeOnLongTermPurchaseCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_AccruedESPPPayrollDeferrals" abstract="false" name="AccruedESPPPayrollDeferrals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_TemporaryEquityConversionPricePerShare" abstract="false" name="TemporaryEquityConversionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mdxg_NordicBioscienceClinicalDevelopmentASMember" abstract="true" name="NordicBioscienceClinicalDevelopmentASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_DebtInstrumentCommitmentFees" abstract="false" name="DebtInstrumentCommitmentFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_TemporaryEquityThresholdConsecutiveTradingDays" abstract="false" name="TemporaryEquityThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mdxg_AccruedTravel" abstract="false" name="AccruedTravel" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_NumberOfProducts" abstract="false" name="NumberOfProducts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels" abstract="false" name="RevenueFromContractWithCustomerNumberOfDistributionChannels" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mdxg_NotesReceivableForSaleOfPropertyAndEquipment" abstract="false" name="NotesReceivableForSaleOfPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_DividendAccumulatedByNotPaid" abstract="false" name="DividendAccumulatedByNotPaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_AccruedRebates" abstract="false" name="AccruedRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_PaymentsForApplicationCostsPatent" abstract="false" name="PaymentsForApplicationCostsPatent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired" abstract="false" name="LongTermPurchaseCommitmentTerminationNoticePeriodRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mdxg_AssetRetirementCostMember" abstract="true" name="AssetRetirementCostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_AdvancedWoundCareTissueAndOtherMember" abstract="true" name="AdvancedWoundCareTissueAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_AdvancedWoundCareUmbilicalCordDerivedMember" abstract="true" name="AdvancedWoundCareUmbilicalCordDerivedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock" abstract="false" name="ScheduleOfDebtIssuanceCostsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mdxg_TemporaryEquityDividendRatePercentage" abstract="false" name="TemporaryEquityDividendRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mdxg_WoundSurgicalMember" abstract="true" name="WoundSurgicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_RegenerativeMedicineSegmentMember" abstract="true" name="RegenerativeMedicineSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger" abstract="false" name="TemporaryEquityConversionThresholdPercentageofStockPriceTrigger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mdxg_DebtInstrumentDefaultInterestRate" abstract="false" name="DebtInstrumentDefaultInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis" abstract="false" name="TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mdxg_AdvancedWoundCareMember" abstract="true" name="AdvancedWoundCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise" abstract="false" name="FairValueOfNonCashConsiderationReceivedForOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_InternationalSection351Member" abstract="true" name="InternationalSection351Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_TermLoanAgreementMember" abstract="true" name="TermLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment" abstract="false" name="RemainingPrepaidExpensesOnLongTermPurchaseCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage" abstract="false" name="DebtInstrumentUnusedCapacityCommitmentFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mdxg_AccruedClinicalTrialsCurrent" abstract="false" name="AccruedClinicalTrialsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdxg_RegenerativeMedicineMember" abstract="true" name="RegenerativeMedicineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdxg_DebtInstrumentInterestRateFloorPercentage" abstract="false" name="DebtInstrumentInterestRateFloorPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mdxg_ExpensesOnLongTermPurchaseCommitment" abstract="false" name="ExpensesOnLongTermPurchaseCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mdxg-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:75aec70c-8992-4432-a811-2ecd9b0ef10b,g:2668ca8b-9129-4930-9d6a-e03d3677c28b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3bdef4f8-5715-41ff-ac69-2236b7305acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bfbaee29-0bf9-46c4-ad4f-b745d2b134d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3bdef4f8-5715-41ff-ac69-2236b7305acf" xlink:to="loc_us-gaap_Liabilities_bfbaee29-0bf9-46c4-ad4f-b745d2b134d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4cf29ac-89fc-4a02-a4ae-f38083ea5957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3bdef4f8-5715-41ff-ac69-2236b7305acf" xlink:to="loc_us-gaap_StockholdersEquity_d4cf29ac-89fc-4a02-a4ae-f38083ea5957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4818b53a-f0bf-4fa4-ac91-6969ba68f3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3bdef4f8-5715-41ff-ac69-2236b7305acf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4818b53a-f0bf-4fa4-ac91-6969ba68f3e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e254874d-af8a-4cc7-b1f4-9915d9cb4e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3bdef4f8-5715-41ff-ac69-2236b7305acf" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e254874d-af8a-4cc7-b1f4-9915d9cb4e3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8e7415d3-3c93-44d3-9e1b-da5476e460dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8aedd69f-92d1-4985-9af8-3e0939e2e652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8e7415d3-3c93-44d3-9e1b-da5476e460dd" xlink:to="loc_us-gaap_AccountsPayableCurrent_8aedd69f-92d1-4985-9af8-3e0939e2e652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1f6760f3-7ffd-40cd-9dc5-969e7685a85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8e7415d3-3c93-44d3-9e1b-da5476e460dd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1f6760f3-7ffd-40cd-9dc5-969e7685a85e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_899cd4be-ce4c-42ec-98c6-fa5d461c52bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8e7415d3-3c93-44d3-9e1b-da5476e460dd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_899cd4be-ce4c-42ec-98c6-fa5d461c52bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9a3f924e-29aa-489c-aec7-580d1a2f22fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8e7415d3-3c93-44d3-9e1b-da5476e460dd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9a3f924e-29aa-489c-aec7-580d1a2f22fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_058f790f-30b5-4889-97e5-6ab56a6fa4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05a0b1b8-0fbf-4fa9-ac54-46a49473638d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_058f790f-30b5-4889-97e5-6ab56a6fa4a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05a0b1b8-0fbf-4fa9-ac54-46a49473638d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d6dc9124-9d92-4dc7-8879-a237eda7bfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_058f790f-30b5-4889-97e5-6ab56a6fa4a6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d6dc9124-9d92-4dc7-8879-a237eda7bfa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_efcd631b-b183-485a-9ce9-d0ee511d85d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_058f790f-30b5-4889-97e5-6ab56a6fa4a6" xlink:to="loc_us-gaap_IncomeTaxesReceivable_efcd631b-b183-485a-9ce9-d0ee511d85d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e19f6694-3756-49ef-b3ad-e82785413eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_058f790f-30b5-4889-97e5-6ab56a6fa4a6" xlink:to="loc_us-gaap_InventoryNet_e19f6694-3756-49ef-b3ad-e82785413eb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_6349a48d-d022-495a-bd14-f3699f7eebc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_058f790f-30b5-4889-97e5-6ab56a6fa4a6" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_6349a48d-d022-495a-bd14-f3699f7eebc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e06035f7-5347-4419-927d-5a90e0f3cae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_058f790f-30b5-4889-97e5-6ab56a6fa4a6" xlink:to="loc_us-gaap_OtherAssetsCurrent_e06035f7-5347-4419-927d-5a90e0f3cae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0be8cf89-f9d0-4235-8d62-bf33b81c7b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7160c89c-87c5-4502-be7b-6ac23bf55d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0be8cf89-f9d0-4235-8d62-bf33b81c7b29" xlink:to="loc_us-gaap_Goodwill_7160c89c-87c5-4502-be7b-6ac23bf55d51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3a199e47-0ff6-4b86-9c1d-dd7b22eb76a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0be8cf89-f9d0-4235-8d62-bf33b81c7b29" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3a199e47-0ff6-4b86-9c1d-dd7b22eb76a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8b6495b6-8a2a-4c86-9fe3-4ccad23e223b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0be8cf89-f9d0-4235-8d62-bf33b81c7b29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8b6495b6-8a2a-4c86-9fe3-4ccad23e223b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b6851d02-3c02-41e1-813f-611042c0bdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0be8cf89-f9d0-4235-8d62-bf33b81c7b29" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b6851d02-3c02-41e1-813f-611042c0bdc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_375fa385-6570-4ec3-88ff-e754218bf1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0be8cf89-f9d0-4235-8d62-bf33b81c7b29" xlink:to="loc_us-gaap_AssetsCurrent_375fa385-6570-4ec3-88ff-e754218bf1dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_faab89ae-3332-4090-b548-da939532070b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0be8cf89-f9d0-4235-8d62-bf33b81c7b29" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_faab89ae-3332-4090-b548-da939532070b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f516f598-f9e6-4273-aa64-fc4ade83f14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_57633609-367e-4300-b0fa-5cf3b9e74338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f516f598-f9e6-4273-aa64-fc4ade83f14f" xlink:to="loc_us-gaap_PreferredStockValue_57633609-367e-4300-b0fa-5cf3b9e74338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4fbbc292-8fbf-4358-894a-276228da5b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f516f598-f9e6-4273-aa64-fc4ade83f14f" xlink:to="loc_us-gaap_CommonStockValue_4fbbc292-8fbf-4358-894a-276228da5b87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_81f378f9-acdf-48b7-be10-f71493b7327b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f516f598-f9e6-4273-aa64-fc4ade83f14f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_81f378f9-acdf-48b7-be10-f71493b7327b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_80faf8e5-c038-49d0-aad5-076ebd1e86c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f516f598-f9e6-4273-aa64-fc4ade83f14f" xlink:to="loc_us-gaap_TreasuryStockCommonValue_80faf8e5-c038-49d0-aad5-076ebd1e86c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3050ba6-462f-4936-9522-24ec8bfe5446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f516f598-f9e6-4273-aa64-fc4ade83f14f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3050ba6-462f-4936-9522-24ec8bfe5446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e7b92a9d-27fe-4a73-b1e3-df3876164906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f64c88f4-3f1b-491a-9a7c-f7f0d1d5495f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e7b92a9d-27fe-4a73-b1e3-df3876164906" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f64c88f4-3f1b-491a-9a7c-f7f0d1d5495f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ef1f6d30-5158-4a0c-844e-0e3089648fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e7b92a9d-27fe-4a73-b1e3-df3876164906" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ef1f6d30-5158-4a0c-844e-0e3089648fe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_728ba350-0900-4503-8e1d-0a25a961c5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e7b92a9d-27fe-4a73-b1e3-df3876164906" xlink:to="loc_us-gaap_LiabilitiesCurrent_728ba350-0900-4503-8e1d-0a25a961c5a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_297441c8-b90c-4d85-94dd-4c891fd52c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f6832a8f-be92-474b-8e0d-d60e2ca948ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_297441c8-b90c-4d85-94dd-4c891fd52c1f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f6832a8f-be92-474b-8e0d-d60e2ca948ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_450529f7-08f1-4632-99fd-6d0b381d8bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_297441c8-b90c-4d85-94dd-4c891fd52c1f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_450529f7-08f1-4632-99fd-6d0b381d8bb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e200777c-b20f-4159-9de9-8b6ae9a7ddc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_21841dd4-c194-4604-8cbf-8cd3bad3d06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e200777c-b20f-4159-9de9-8b6ae9a7ddc4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_21841dd4-c194-4604-8cbf-8cd3bad3d06c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_938b52a5-02b0-4e28-814a-b33eec7fd598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e200777c-b20f-4159-9de9-8b6ae9a7ddc4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_938b52a5-02b0-4e28-814a-b33eec7fd598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f7c1c0ca-c38e-4a71-9f0a-c2e9f34e3658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7e290d0a-805b-4e7d-bc7e-c5a84175f252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f7c1c0ca-c38e-4a71-9f0a-c2e9f34e3658" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7e290d0a-805b-4e7d-bc7e-c5a84175f252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ed119cc1-ef93-41af-9b3f-b6e330c3e182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f7c1c0ca-c38e-4a71-9f0a-c2e9f34e3658" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ed119cc1-ef93-41af-9b3f-b6e330c3e182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InvestigationRestatementAndRelated_d7996d1c-5bd7-4955-bb2b-1fb79688d9bf" xlink:href="mdxg-20220930.xsd#mdxg_InvestigationRestatementAndRelated"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f7c1c0ca-c38e-4a71-9f0a-c2e9f34e3658" xlink:to="loc_mdxg_InvestigationRestatementAndRelated_d7996d1c-5bd7-4955-bb2b-1fb79688d9bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_1fc79bec-c603-4e5c-a684-12a3c40be0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f7c1c0ca-c38e-4a71-9f0a-c2e9f34e3658" xlink:to="loc_us-gaap_GrossProfit_1fc79bec-c603-4e5c-a684-12a3c40be0d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cb765f8f-7d47-47b1-af6e-5e76efbf61e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f7c1c0ca-c38e-4a71-9f0a-c2e9f34e3658" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cb765f8f-7d47-47b1-af6e-5e76efbf61e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc33bdd0-89b3-4240-9dac-38cb08cd4e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b31fd63a-376d-4067-8af7-2eb0d5873c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc33bdd0-89b3-4240-9dac-38cb08cd4e03" xlink:to="loc_us-gaap_OperatingIncomeLoss_b31fd63a-376d-4067-8af7-2eb0d5873c79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_4434e980-bf74-4b8f-a514-9bc155d7be44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc33bdd0-89b3-4240-9dac-38cb08cd4e03" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_4434e980-bf74-4b8f-a514-9bc155d7be44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8a75ea5a-3ce0-4244-99cc-6865a9c81228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc33bdd0-89b3-4240-9dac-38cb08cd4e03" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8a75ea5a-3ce0-4244-99cc-6865a9c81228" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bd0f19cd-a242-4447-9da0-63fec1ecbc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_0384a874-b009-4e90-b2bc-65894f0656b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bd0f19cd-a242-4447-9da0-63fec1ecbc8d" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_0384a874-b009-4e90-b2bc-65894f0656b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7aa0826f-f930-40fe-96ab-e9958af9aa06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bd0f19cd-a242-4447-9da0-63fec1ecbc8d" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7aa0826f-f930-40fe-96ab-e9958af9aa06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f7bb3443-0ffb-4f07-a9bd-3a3bdb54f1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bd0f19cd-a242-4447-9da0-63fec1ecbc8d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f7bb3443-0ffb-4f07-a9bd-3a3bdb54f1c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5f8f5ba5-6b73-4b64-9940-14e253d71e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5f8f5ba5-6b73-4b64-9940-14e253d71e31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d03d92be-0ece-4ef6-8f76-2d9ddf4f1cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_ShareBasedCompensation_d03d92be-0ece-4ef6-8f76-2d9ddf4f1cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_79d2290d-abe9-49e7-bf2f-ab3dae67d042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_79d2290d-abe9-49e7-bf2f-ab3dae67d042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_74f67b96-367f-4c4a-b88a-7f5889c98fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_74f67b96-367f-4c4a-b88a-7f5889c98fa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fb001b97-9b0d-4d33-91e0-ddf985652b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fb001b97-9b0d-4d33-91e0-ddf985652b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0a51b443-71c3-43c4-a911-f88a08f15e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0a51b443-71c3-43c4-a911-f88a08f15e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_450f0aa3-861c-457b-83de-bc241a89770a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_450f0aa3-861c-457b-83de-bc241a89770a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f27ce9e2-88be-4d6f-8659-ca65a5be0021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_NetIncomeLoss_f27ce9e2-88be-4d6f-8659-ca65a5be0021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d9074d6a-e50b-4af6-a0cb-4e9932cb8f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d9074d6a-e50b-4af6-a0cb-4e9932cb8f08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ed6bd745-a2de-4394-9fa5-e211a66bdfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_Depreciation_ed6bd745-a2de-4394-9fa5-e211a66bdfc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationAccretionExpense_6f04bfe5-1d5e-4935-bfc9-8ba82498da45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationAccretionExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_AssetRetirementObligationAccretionExpense_6f04bfe5-1d5e-4935-bfc9-8ba82498da45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_13d8ba7e-c3f6-4bf8-9f9f-877406bf73ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_13d8ba7e-c3f6-4bf8-9f9f-877406bf73ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8dc3f1f2-b7e9-463f-a561-b2d6ec91ee50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8dc3f1f2-b7e9-463f-a561-b2d6ec91ee50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b515aa43-03fc-4408-92ad-29df15dd9001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b515aa43-03fc-4408-92ad-29df15dd9001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0e69b406-048b-41f7-b22a-005262c53645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0e69b406-048b-41f7-b22a-005262c53645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_b25cabdc-f176-4832-8438-17688c6ae789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_b25cabdc-f176-4832-8438-17688c6ae789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cb1f4dd1-6417-433e-afee-c358967506ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cb1f4dd1-6417-433e-afee-c358967506ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4319e380-6368-49b9-a14c-72d760fbe337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_697bb566-9b8d-4f63-bf10-3673bc989dd1" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4319e380-6368-49b9-a14c-72d760fbe337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f607628a-f822-48d5-989d-0afb57a9a5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e62d8acb-0ed5-4bad-96d1-2debad59db06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f607628a-f822-48d5-989d-0afb57a9a5d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e62d8acb-0ed5-4bad-96d1-2debad59db06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_be17e51e-258e-4076-a409-79649fed730e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f607628a-f822-48d5-989d-0afb57a9a5d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_be17e51e-258e-4076-a409-79649fed730e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fbb84c37-3eae-4bf0-814e-e97633101b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f607628a-f822-48d5-989d-0afb57a9a5d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fbb84c37-3eae-4bf0-814e-e97633101b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_389958bb-73c5-43f4-aaa8-d9a360fd3844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_d6b88084-cf37-4414-88a8-ff008cfa2b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_389958bb-73c5-43f4-aaa8-d9a360fd3844" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_d6b88084-cf37-4414-88a8-ff008cfa2b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_839b04a0-bb3e-4176-996f-0d3c99ba2002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_389958bb-73c5-43f4-aaa8-d9a360fd3844" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_839b04a0-bb3e-4176-996f-0d3c99ba2002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PaymentsForApplicationCostsPatent_f7e3f0a9-32c7-4dad-a291-189563cfb417" xlink:href="mdxg-20220930.xsd#mdxg_PaymentsForApplicationCostsPatent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_389958bb-73c5-43f4-aaa8-d9a360fd3844" xlink:to="loc_mdxg_PaymentsForApplicationCostsPatent_f7e3f0a9-32c7-4dad-a291-189563cfb417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9b018e05-5436-4d6c-bd73-94bbf6d46df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_389958bb-73c5-43f4-aaa8-d9a360fd3844" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9b018e05-5436-4d6c-bd73-94bbf6d46df7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#AccountsReceivableNetAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a34b5580-6705-4db3-8777-a250c581d2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5b2a1351-1067-4ddb-9c06-3e5a52dff2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_a34b5580-6705-4db3-8777-a250c581d2b1" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5b2a1351-1067-4ddb-9c06-3e5a52dff2aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_c0799445-eb19-4ca5-a6f8-107201660f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_a34b5580-6705-4db3-8777-a250c581d2b1" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_c0799445-eb19-4ca5-a6f8-107201660f03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/InventoryDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_77a80c15-4dce-4552-bf98-78a440a931a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1a2bd66b-d83d-401d-a9c8-8221a03160e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_77a80c15-4dce-4552-bf98-78a440a931a0" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1a2bd66b-d83d-401d-a9c8-8221a03160e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1dd6e429-8199-4ac8-b2c6-a3790c9b19fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_77a80c15-4dce-4552-bf98-78a440a931a0" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1dd6e429-8199-4ac8-b2c6-a3790c9b19fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a233bf0b-8214-4578-bf2b-89e9e3078462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_77a80c15-4dce-4552-bf98-78a440a931a0" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a233bf0b-8214-4578-bf2b-89e9e3078462" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c99038cf-adce-4ce3-87dd-b1f5d1410100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_a4aeaaf6-96f2-4c55-bf72-7ecb5986b064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c99038cf-adce-4ce3-87dd-b1f5d1410100" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_a4aeaaf6-96f2-4c55-bf72-7ecb5986b064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_47e81cfe-1cc0-45c5-9924-88c31f9e12d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c99038cf-adce-4ce3-87dd-b1f5d1410100" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_47e81cfe-1cc0-45c5-9924-88c31f9e12d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_83617619-405c-4b56-984c-d9cc92ac7daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_078931bc-e884-4923-a21e-3f0ed65133c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_83617619-405c-4b56-984c-d9cc92ac7daf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_078931bc-e884-4923-a21e-3f0ed65133c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_c93eb05b-d9ea-4203-99f9-fd25c39c734a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_83617619-405c-4b56-984c-d9cc92ac7daf" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_c93eb05b-d9ea-4203-99f9-fd25c39c734a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#GoodwillandIntangibleAssetsNetActivitySummaryDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a590492e-1f29-430c-a54f-34138c243cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1dbd122b-0d16-4a68-9e41-946d967d41f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a590492e-1f29-430c-a54f-34138c243cb1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1dbd122b-0d16-4a68-9e41-946d967d41f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1aa910bd-6f22-47bf-b8b6-e20e7c9b7129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a590492e-1f29-430c-a54f-34138c243cb1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1aa910bd-6f22-47bf-b8b6-e20e7c9b7129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f190a6c9-470d-4904-b8a4-6460d88ab674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_119136c0-f7ed-40ce-8d94-a3273f40994d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f190a6c9-470d-4904-b8a4-6460d88ab674" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_119136c0-f7ed-40ce-8d94-a3273f40994d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8af39693-0cfe-447f-a700-10aa1fc95ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f190a6c9-470d-4904-b8a4-6460d88ab674" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8af39693-0cfe-447f-a700-10aa1fc95ffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5108a1f-c521-4344-916f-f75c85e82a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a942e7ad-5984-4b35-bd3f-e0d2285d325b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5108a1f-c521-4344-916f-f75c85e82a46" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a942e7ad-5984-4b35-bd3f-e0d2285d325b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_585f25f1-fa80-426c-984c-8cd68d89e783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5108a1f-c521-4344-916f-f75c85e82a46" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_585f25f1-fa80-426c-984c-8cd68d89e783" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aadc9c10-179d-4449-a7e6-276f9ed3e3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_01f19d63-6227-4f7c-a808-7d01d869c71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aadc9c10-179d-4449-a7e6-276f9ed3e3ec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_01f19d63-6227-4f7c-a808-7d01d869c71d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_49067f74-790f-4d5b-af1f-7d6bdc1d3f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aadc9c10-179d-4449-a7e6-276f9ed3e3ec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_49067f74-790f-4d5b-af1f-7d6bdc1d3f60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f9c27d07-197b-4d38-bf63-bcd4790a952d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aadc9c10-179d-4449-a7e6-276f9ed3e3ec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f9c27d07-197b-4d38-bf63-bcd4790a952d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f23e4d6e-67cf-4cd2-b6db-6bf49ea57c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aadc9c10-179d-4449-a7e6-276f9ed3e3ec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f23e4d6e-67cf-4cd2-b6db-6bf49ea57c4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1eab0c02-3978-49a2-8d6b-28a597d36d29" xlink:href="mdxg-20220930.xsd#mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aadc9c10-179d-4449-a7e6-276f9ed3e3ec" xlink:to="loc_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1eab0c02-3978-49a2-8d6b-28a597d36d29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_39aeec3e-8d7e-491f-8e99-9593bab1069e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aadc9c10-179d-4449-a7e6-276f9ed3e3ec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_39aeec3e-8d7e-491f-8e99-9593bab1069e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1016aaaa-bd2f-4c88-b7d0-d94aee4d8ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0717314d-b213-4579-9e74-47d5cab54303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1016aaaa-bd2f-4c88-b7d0-d94aee4d8ae4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0717314d-b213-4579-9e74-47d5cab54303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_856d7f99-ba87-47a8-89f1-c310385bd053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1016aaaa-bd2f-4c88-b7d0-d94aee4d8ae4" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_856d7f99-ba87-47a8-89f1-c310385bd053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedAdministrativeFeesCurrent_00166bb0-894d-45fe-be16-100038fa9cb2" xlink:href="mdxg-20220930.xsd#mdxg_AccruedAdministrativeFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1016aaaa-bd2f-4c88-b7d0-d94aee4d8ae4" xlink:to="loc_mdxg_AccruedAdministrativeFeesCurrent_00166bb0-894d-45fe-be16-100038fa9cb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_cb88cc9d-87cf-49b0-9ffa-f1b4f207486e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1016aaaa-bd2f-4c88-b7d0-d94aee4d8ae4" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_cb88cc9d-87cf-49b0-9ffa-f1b4f207486e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedClinicalTrialsCurrent_e0bb4d24-5db3-43f2-83c6-0b600b179504" xlink:href="mdxg-20220930.xsd#mdxg_AccruedClinicalTrialsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1016aaaa-bd2f-4c88-b7d0-d94aee4d8ae4" xlink:to="loc_mdxg_AccruedClinicalTrialsCurrent_e0bb4d24-5db3-43f2-83c6-0b600b179504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_c0107721-54eb-435f-b5c7-d433505d923a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1016aaaa-bd2f-4c88-b7d0-d94aee4d8ae4" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_c0107721-54eb-435f-b5c7-d433505d923a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedRebates_6e726ecd-86da-4592-893e-61d2630bc231" xlink:href="mdxg-20220930.xsd#mdxg_AccruedRebates"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1016aaaa-bd2f-4c88-b7d0-d94aee4d8ae4" xlink:to="loc_mdxg_AccruedRebates_6e726ecd-86da-4592-893e-61d2630bc231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedTravel_5a98a185-ca43-4615-a8fd-166452017bd7" xlink:href="mdxg-20220930.xsd#mdxg_AccruedTravel"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1016aaaa-bd2f-4c88-b7d0-d94aee4d8ae4" xlink:to="loc_mdxg_AccruedTravel_5a98a185-ca43-4615-a8fd-166452017bd7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanBalancesDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c3a45491-fdb1-4315-b1a0-48b13f2c323f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4adaa6a6-da65-472f-a03e-05eec2df8507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c3a45491-fdb1-4315-b1a0-48b13f2c323f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4adaa6a6-da65-472f-a03e-05eec2df8507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_293f3d51-419e-45d4-b878-47f07d81dcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c3a45491-fdb1-4315-b1a0-48b13f2c323f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_293f3d51-419e-45d4-b878-47f07d81dcf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0d3f1622-e57f-4494-9999-65970fb050f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c3a45491-fdb1-4315-b1a0-48b13f2c323f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0d3f1622-e57f-4494-9999-65970fb050f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c3130a0f-b63c-4962-a7bd-7e0d17743d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8cbd6b1b-fd27-445b-a658-933bf23b36b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_c3130a0f-b63c-4962-a7bd-7e0d17743d45" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8cbd6b1b-fd27-445b-a658-933bf23b36b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_d50cb04b-1426-4b9c-a80c-01fea06b625d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_c3130a0f-b63c-4962-a7bd-7e0d17743d45" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_d50cb04b-1426-4b9c-a80c-01fea06b625d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ac1a5a5d-5531-4a45-9940-d2d5e09fe58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_c3130a0f-b63c-4962-a7bd-7e0d17743d45" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ac1a5a5d-5531-4a45-9940-d2d5e09fe58b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentCommitmentFees_4d80f37a-427a-42d3-a90a-d85257251ae8" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentCommitmentFees"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_c3130a0f-b63c-4962-a7bd-7e0d17743d45" xlink:to="loc_mdxg_DebtInstrumentCommitmentFees_4d80f37a-427a-42d3-a90a-d85257251ae8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanMaturityDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a9b109c1-3f07-46fd-9bcb-f5fd3a3c30af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_7759ba67-9be3-4357-83f3-8d35783dfc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_a9b109c1-3f07-46fd-9bcb-f5fd3a3c30af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_7759ba67-9be3-4357-83f3-8d35783dfc4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5a502641-168b-4429-a3e6-1489ab60a470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_a9b109c1-3f07-46fd-9bcb-f5fd3a3c30af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5a502641-168b-4429-a3e6-1489ab60a470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4e4d4286-fb3e-4d8b-929a-09e08c592421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_a9b109c1-3f07-46fd-9bcb-f5fd3a3c30af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4e4d4286-fb3e-4d8b-929a-09e08c592421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4769d788-c0c6-48c2-a4fc-37d95d3ec3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_a9b109c1-3f07-46fd-9bcb-f5fd3a3c30af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4769d788-c0c6-48c2-a4fc-37d95d3ec3c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_LongTermDebtMaturityAfterYearFour_38473382-6aa0-4647-a7e3-aa5aa11ae3c6" xlink:href="mdxg-20220930.xsd#mdxg_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_a9b109c1-3f07-46fd-9bcb-f5fd3a3c30af" xlink:to="loc_mdxg_LongTermDebtMaturityAfterYearFour_38473382-6aa0-4647-a7e3-aa5aa11ae3c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47d3c2aa-4679-453d-a7e7-d0041c721e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_a9b109c1-3f07-46fd-9bcb-f5fd3a3c30af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47d3c2aa-4679-453d-a7e7-d0041c721e72" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#NetLossPerCommonShareBasicNetLossPerCommonShareDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ad3fcc2d-3f53-4ffc-8d50-490bd05a4856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_50b40e6a-d527-4d66-8045-ffc7c769cd34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ad3fcc2d-3f53-4ffc-8d50-490bd05a4856" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_50b40e6a-d527-4d66-8045-ffc7c769cd34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_12c6a755-9751-4313-97d5-37bdfbfe6164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ad3fcc2d-3f53-4ffc-8d50-490bd05a4856" xlink:to="loc_us-gaap_NetIncomeLoss_12c6a755-9751-4313-97d5-37bdfbfe6164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_f6cb14c7-5a97-41a6-8e02-147e0186b1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature_6a903823-dd06-4f42-b792-ea43f7083857" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_f6cb14c7-5a97-41a6-8e02-147e0186b1a4" xlink:to="loc_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature_6a903823-dd06-4f42-b792-ea43f7083857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_44a19a5d-532b-42d1-b25e-95135311d1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_f6cb14c7-5a97-41a6-8e02-147e0186b1a4" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_44a19a5d-532b-42d1-b25e-95135311d1f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#NetLossPerCommonShareDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2403f733-79e3-409e-a4cd-5d0ba8a07b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57400e10-1b1c-4a3d-82a1-d01dd28120ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2403f733-79e3-409e-a4cd-5d0ba8a07b4a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57400e10-1b1c-4a3d-82a1-d01dd28120ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_29f7835b-0e29-4825-ac59-f76b5eb675db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2403f733-79e3-409e-a4cd-5d0ba8a07b4a" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_29f7835b-0e29-4825-ac59-f76b5eb675db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments_265d22ce-ca9b-4603-80d3-276e1c042ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2403f733-79e3-409e-a4cd-5d0ba8a07b4a" xlink:to="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments_265d22ce-ca9b-4603-80d3-276e1c042ee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc956832-031b-42e8-b113-62f102c9a616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5404e312-ded5-44ee-96b9-866ab8b38e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc956832-031b-42e8-b113-62f102c9a616" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5404e312-ded5-44ee-96b9-866ab8b38e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf5b1aa0-3493-442a-94e9-81e144fc1360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc956832-031b-42e8-b113-62f102c9a616" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf5b1aa0-3493-442a-94e9-81e144fc1360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_849f8409-344c-419d-982e-3d15869091c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc956832-031b-42e8-b113-62f102c9a616" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_849f8409-344c-419d-982e-3d15869091c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_SegmentContribution_06ed8997-17a2-4459-9123-ace48d284262" xlink:href="mdxg-20220930.xsd#mdxg_SegmentContribution"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2376afcb-32c4-4065-ae6a-716266bf551b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdxg_SegmentContribution_06ed8997-17a2-4459-9123-ace48d284262" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2376afcb-32c4-4065-ae6a-716266bf551b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_340078ad-a540-4fb0-9006-12852b523012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdxg_SegmentContribution_06ed8997-17a2-4459-9123-ace48d284262" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_340078ad-a540-4fb0-9006-12852b523012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1239018a-2468-4037-b56d-3291c3a8c1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdxg_SegmentContribution_06ed8997-17a2-4459-9123-ace48d284262" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1239018a-2468-4037-b56d-3291c3a8c1ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e14f5a51-4505-4397-8ce4-cfe906934aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdxg_SegmentContribution_06ed8997-17a2-4459-9123-ace48d284262" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e14f5a51-4505-4397-8ce4-cfe906934aac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_662c97bd-f574-4049-bb86-8dc466fec8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdxg_SegmentContribution_06ed8997-17a2-4459-9123-ace48d284262" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_662c97bd-f574-4049-bb86-8dc466fec8e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_20216bea-19bc-4e19-8d00-8c2e27e79775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InvestigationRestatementAndRelated_88c913cc-40df-422a-8d80-7830aaa57bfb" xlink:href="mdxg-20220930.xsd#mdxg_InvestigationRestatementAndRelated"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_20216bea-19bc-4e19-8d00-8c2e27e79775" xlink:to="loc_mdxg_InvestigationRestatementAndRelated_88c913cc-40df-422a-8d80-7830aaa57bfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_SegmentContribution_663d9a21-2d1e-4aa7-aa55-2bf1ac35e413" xlink:href="mdxg-20220930.xsd#mdxg_SegmentContribution"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_20216bea-19bc-4e19-8d00-8c2e27e79775" xlink:to="loc_mdxg_SegmentContribution_663d9a21-2d1e-4aa7-aa55-2bf1ac35e413" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1"/>
  <link:calculationLink xlink:role="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f3887cfb-2b86-40ee-a0ca-fa4d116ffc91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_53a3f8b7-4d85-4731-ae20-ef527d9f63d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3887cfb-2b86-40ee-a0ca-fa4d116ffc91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_53a3f8b7-4d85-4731-ae20-ef527d9f63d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InvestigationRestatementAndRelated_54c21d16-c781-472d-ba9e-0935e8f72b52" xlink:href="mdxg-20220930.xsd#mdxg_InvestigationRestatementAndRelated"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3887cfb-2b86-40ee-a0ca-fa4d116ffc91" xlink:to="loc_mdxg_InvestigationRestatementAndRelated_54c21d16-c781-472d-ba9e-0935e8f72b52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_42afee64-4675-4a6a-b231-7d4876af1a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3887cfb-2b86-40ee-a0ca-fa4d116ffc91" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_42afee64-4675-4a6a-b231-7d4876af1a45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9e0a6ac6-eb10-433a-8905-f14bfab64f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3887cfb-2b86-40ee-a0ca-fa4d116ffc91" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9e0a6ac6-eb10-433a-8905-f14bfab64f0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0842c216-0adf-42d5-9f8d-4d9b0741faeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3887cfb-2b86-40ee-a0ca-fa4d116ffc91" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0842c216-0adf-42d5-9f8d-4d9b0741faeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94ece027-ca45-484c-8d67-07ce2df3755e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3887cfb-2b86-40ee-a0ca-fa4d116ffc91" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94ece027-ca45-484c-8d67-07ce2df3755e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mdxg-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:75aec70c-8992-4432-a811-2ecd9b0ef10b,g:2668ca8b-9129-4930-9d6a-e03d3677c28b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY" xlink:type="extended" id="i395fce9040824b9ca170f03003d66156_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ec1c31d3-27eb-4bfa-a7c4-a1aafb4ad417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec1c31d3-27eb-4bfa-a7c4-a1aafb4ad417" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b66a7541-1fe5-49a4-b5b2-ca4dd264d008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_CommonStockSharesIssued_b66a7541-1fe5-49a4-b5b2-ca4dd264d008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4b4155d2-d750-4880-8d95-35f3e1aa00e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockholdersEquity_4b4155d2-d750-4880-8d95-35f3e1aa00e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_10fd1bda-c92f-49fe-946d-7738dbafbae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_TreasuryStockCommonShares_10fd1bda-c92f-49fe-946d-7738dbafbae3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_1a3f8ab1-3175-41af-baec-c034f33ec550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_1a3f8ab1-3175-41af-baec-c034f33ec550" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ab25dd6-8004-4b20-b00a-91fed4be030e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ab25dd6-8004-4b20-b00a-91fed4be030e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68d063fd-b186-46eb-b920-6801038d98e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68d063fd-b186-46eb-b920-6801038d98e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dcced1ad-adf3-452d-9460-2e912276347d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dcced1ad-adf3-452d-9460-2e912276347d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1757e608-fa89-476c-9847-855ea3f70a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1757e608-fa89-476c-9847-855ea3f70a1d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_52d8b32c-cc2a-4a8f-979a-0ef275d76ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_52d8b32c-cc2a-4a8f-979a-0ef275d76ab5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_7a59fb1c-f70f-4d4e-8f5c-40f0dc535c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_7a59fb1c-f70f-4d4e-8f5c-40f0dc535c2b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_22baada6-a78a-4dd9-853b-98213c106344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_22baada6-a78a-4dd9-853b-98213c106344" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_41909d6c-3686-4d40-86ef-f03e25fff11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_41909d6c-3686-4d40-86ef-f03e25fff11c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2c643335-ca19-4bb3-a4a2-f6990d22f894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2c643335-ca19-4bb3-a4a2-f6990d22f894" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0c7a2269-231c-45b7-801a-d9d33dc3f121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_NetIncomeLoss_0c7a2269-231c-45b7-801a-d9d33dc3f121" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TreasuryStockSharesAdjustment_d1ceb182-f7b1-4034-8011-c6c46aa89398" xlink:href="mdxg-20220930.xsd#mdxg_TreasuryStockSharesAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_mdxg_TreasuryStockSharesAdjustment_d1ceb182-f7b1-4034-8011-c6c46aa89398" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_35d348ba-b75d-449f-a203-e28390a07bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_35d348ba-b75d-449f-a203-e28390a07bcb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_34b586be-cbe5-4188-a74d-2a5ac7215f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1799d71b-63e8-4982-8b70-45b9f6a773ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9ec2ae09-e10f-4f31-85eb-4d04d2556e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0e939299-0867-4735-bd8d-cab71152bc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ec1c31d3-27eb-4bfa-a7c4-a1aafb4ad417" xlink:to="loc_us-gaap_StatementTable_0e939299-0867-4735-bd8d-cab71152bc67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11d05d41-31a6-42e3-987e-8e140cc0f21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0e939299-0867-4735-bd8d-cab71152bc67" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11d05d41-31a6-42e3-987e-8e140cc0f21f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_11d05d41-31a6-42e3-987e-8e140cc0f21f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11d05d41-31a6-42e3-987e-8e140cc0f21f" xlink:to="loc_us-gaap_EquityComponentDomain_11d05d41-31a6-42e3-987e-8e140cc0f21f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11d05d41-31a6-42e3-987e-8e140cc0f21f" xlink:to="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a72f3e64-638c-4623-aced-ff3273ef16ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:to="loc_us-gaap_CommonStockMember_a72f3e64-638c-4623-aced-ff3273ef16ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3b95b9c5-8bf7-4d1a-86b0-438f4315c2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3b95b9c5-8bf7-4d1a-86b0-438f4315c2de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_81072ae4-d1fa-476d-832a-b384fc562756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:to="loc_us-gaap_TreasuryStockCommonMember_81072ae4-d1fa-476d-832a-b384fc562756" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e2f8a70d-7d07-4e48-a713-b1de0a9d66fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:to="loc_us-gaap_RetainedEarningsMember_e2f8a70d-7d07-4e48-a713-b1de0a9d66fd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#NatureofBusinessDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/NatureofBusinessDetails" xlink:type="extended" id="i919bbbad7aec476b973b39e372c7d495_NatureofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_cb9dd7ae-7f53-4925-9f81-4321851646ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c76b9f74-5732-4e48-90f4-e1db40e5f7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_cb9dd7ae-7f53-4925-9f81-4321851646ec" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c76b9f74-5732-4e48-90f4-e1db40e5f7a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f43b9d74-ec8c-4ae7-a3eb-663d2b081287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_cb9dd7ae-7f53-4925-9f81-4321851646ec" xlink:to="loc_us-gaap_InventoryNet_f43b9d74-ec8c-4ae7-a3eb-663d2b081287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_6e816732-1b73-4bf7-aefd-40d20170e5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_cb9dd7ae-7f53-4925-9f81-4321851646ec" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_6e816732-1b73-4bf7-aefd-40d20170e5b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f0c3261d-74f7-47c1-b16c-9cc659d48e34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_6e816732-1b73-4bf7-aefd-40d20170e5b0" xlink:to="loc_srt_ProductOrServiceAxis_f0c3261d-74f7-47c1-b16c-9cc659d48e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f0c3261d-74f7-47c1-b16c-9cc659d48e34_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f0c3261d-74f7-47c1-b16c-9cc659d48e34" xlink:to="loc_srt_ProductsAndServicesDomain_f0c3261d-74f7-47c1-b16c-9cc659d48e34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_10ff253c-50f2-4ded-81c7-4a7115a13166" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f0c3261d-74f7-47c1-b16c-9cc659d48e34" xlink:to="loc_srt_ProductsAndServicesDomain_10ff253c-50f2-4ded-81c7-4a7115a13166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InternationalSection351Member_3a8bc695-ec9d-466e-84d6-f6804b2ee4d9" xlink:href="mdxg-20220930.xsd#mdxg_InternationalSection351Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_10ff253c-50f2-4ded-81c7-4a7115a13166" xlink:to="loc_mdxg_InternationalSection351Member_3a8bc695-ec9d-466e-84d6-f6804b2ee4d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember_f95e0957-2c61-4215-bf1a-89087e6dece8" xlink:href="mdxg-20220930.xsd#mdxg_AdvancedWoundCareUmbilicalCordDerivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_10ff253c-50f2-4ded-81c7-4a7115a13166" xlink:to="loc_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember_f95e0957-2c61-4215-bf1a-89087e6dece8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/InventoryDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/InventoryDetails" xlink:type="extended" id="ie7f12011d787415f943ef638dad06f46_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_88040fb9-6146-47ff-87ef-cbc752426ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_b5c9c681-b6f9-48d2-984b-5c884bc1f134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_88040fb9-6146-47ff-87ef-cbc752426ff1" xlink:to="loc_us-gaap_InventoryWriteDown_b5c9c681-b6f9-48d2-984b-5c884bc1f134" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_4110872a-f4c1-480e-b001-8d685c2dc170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_88040fb9-6146-47ff-87ef-cbc752426ff1" xlink:to="loc_us-gaap_InventoryCurrentTable_4110872a-f4c1-480e-b001-8d685c2dc170" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_233a3f13-8874-46a1-bcd7-8b0297c291f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_4110872a-f4c1-480e-b001-8d685c2dc170" xlink:to="loc_srt_ProductOrServiceAxis_233a3f13-8874-46a1-bcd7-8b0297c291f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_233a3f13-8874-46a1-bcd7-8b0297c291f6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_233a3f13-8874-46a1-bcd7-8b0297c291f6" xlink:to="loc_srt_ProductsAndServicesDomain_233a3f13-8874-46a1-bcd7-8b0297c291f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b5408f7-e48d-4f31-9bc9-d00dbcf27528" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_233a3f13-8874-46a1-bcd7-8b0297c291f6" xlink:to="loc_srt_ProductsAndServicesDomain_9b5408f7-e48d-4f31-9bc9-d00dbcf27528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InternationalSection351Member_e960d81a-fc38-49c4-8914-b0af9ccb77e0" xlink:href="mdxg-20220930.xsd#mdxg_InternationalSection351Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9b5408f7-e48d-4f31-9bc9-d00dbcf27528" xlink:to="loc_mdxg_InternationalSection351Member_e960d81a-fc38-49c4-8914-b0af9ccb77e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended" id="idb79a924dddd4310a01060b68c156b0e_PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c7c9d973-1706-422c-90a9-f1e1db554e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c7c9d973-1706-422c-90a9-f1e1db554e14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_b1ec3363-3626-4e9a-9a57-d92a64af21d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_b1ec3363-3626-4e9a-9a57-d92a64af21d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_8bcca185-dd6a-4407-b536-5b25cfd82c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_8bcca185-dd6a-4407-b536-5b25cfd82c47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_8c8653d3-9f3a-41aa-8d6e-a596f0daff08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_8c8653d3-9f3a-41aa-8d6e-a596f0daff08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5716efc4-a2b0-4708-a8da-e0306f1294d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5716efc4-a2b0-4708-a8da-e0306f1294d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5feed603-c0d8-4117-b848-0a852a438ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5feed603-c0d8-4117-b848-0a852a438ba8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c60da38a-7a4d-4c5e-ad93-ec165c495cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5feed603-c0d8-4117-b848-0a852a438ba8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c60da38a-7a4d-4c5e-ad93-ec165c495cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c60da38a-7a4d-4c5e-ad93-ec165c495cc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c60da38a-7a4d-4c5e-ad93-ec165c495cc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c60da38a-7a4d-4c5e-ad93-ec165c495cc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c60da38a-7a4d-4c5e-ad93-ec165c495cc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ebf67fcd-c721-48a3-ba97-284f1cab8a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ebf67fcd-c721-48a3-ba97-284f1cab8a56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_053fdd7c-fda2-4bd7-ac1b-4eb8e683fa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:to="loc_us-gaap_EquipmentMember_053fdd7c-fda2-4bd7-ac1b-4eb8e683fa9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_203e490c-93ed-4f07-8c2f-89be7e039d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_203e490c-93ed-4f07-8c2f-89be7e039d3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_78bc67b8-9d2e-444b-80c1-8cbb90e2bce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:to="loc_us-gaap_ConstructionInProgressMember_78bc67b8-9d2e-444b-80c1-8cbb90e2bce4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AssetRetirementCostMember_4f53ecc2-8b42-412d-8e6c-c6a16735ee54" xlink:href="mdxg-20220930.xsd#mdxg_AssetRetirementCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:to="loc_mdxg_AssetRetirementCostMember_4f53ecc2-8b42-412d-8e6c-c6a16735ee54" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#GoodwillandIntangibleAssetsNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" xlink:type="extended" id="id42eb188cd4f4445809647b541cfd6fa_GoodwillandIntangibleAssetsNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_88653d5a-bf06-4435-91e0-1094913d9cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_88653d5a-bf06-4435-91e0-1094913d9cc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_850033e5-0098-44e4-ab80-ba974ba09c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:to="loc_us-gaap_NumberOfReportableSegments_850033e5-0098-44e4-ab80-ba974ba09c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_b108b02d-56b6-4937-99d0-5892f5fc3867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:to="loc_us-gaap_NumberOfReportingUnits_b108b02d-56b6-4937-99d0-5892f5fc3867" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b5e4174c-5274-4f43-aeb5-6be521c5d865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:to="loc_us-gaap_Goodwill_b5e4174c-5274-4f43-aeb5-6be521c5d865" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_10bc74ea-9ab8-4466-948a-e7d62c68d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_10bc74ea-9ab8-4466-948a-e7d62c68d1e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_6b5476ab-f539-45ea-b34c-97fa13000e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_10bc74ea-9ab8-4466-948a-e7d62c68d1e9" xlink:to="loc_us-gaap_ReportingUnitAxis_6b5476ab-f539-45ea-b34c-97fa13000e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_6b5476ab-f539-45ea-b34c-97fa13000e40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_6b5476ab-f539-45ea-b34c-97fa13000e40" xlink:to="loc_us-gaap_ReportingUnitDomain_6b5476ab-f539-45ea-b34c-97fa13000e40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_a64af320-5abb-4cec-bacb-7a04c9301b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_6b5476ab-f539-45ea-b34c-97fa13000e40" xlink:to="loc_us-gaap_ReportingUnitDomain_a64af320-5abb-4cec-bacb-7a04c9301b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_WoundSurgicalMember_974e0607-113a-4252-aaa0-aa8a2bf12313" xlink:href="mdxg-20220930.xsd#mdxg_WoundSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_a64af320-5abb-4cec-bacb-7a04c9301b20" xlink:to="loc_mdxg_WoundSurgicalMember_974e0607-113a-4252-aaa0-aa8a2bf12313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RegenerativeMedicineMember_3cd01cae-3987-4998-9d50-9a941fdd4451" xlink:href="mdxg-20220930.xsd#mdxg_RegenerativeMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_a64af320-5abb-4cec-bacb-7a04c9301b20" xlink:to="loc_mdxg_RegenerativeMedicineMember_3cd01cae-3987-4998-9d50-9a941fdd4451" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#GoodwillandIntangibleAssetsNetActivitySummaryDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails" xlink:type="extended" id="i7b5e57d0694d448d853e068afbbcf94c_GoodwillandIntangibleAssetsNetActivitySummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63511ce3-bd46-4262-91fd-58c9ddbe6172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ef6accd4-0a78-478d-9013-7e5613fb2354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63511ce3-bd46-4262-91fd-58c9ddbe6172" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ef6accd4-0a78-478d-9013-7e5613fb2354" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_82704f08-368e-4c6a-8998-3633fb6f3323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63511ce3-bd46-4262-91fd-58c9ddbe6172" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_82704f08-368e-4c6a-8998-3633fb6f3323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a73483d-ec68-4a83-b01b-9fde9f286abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63511ce3-bd46-4262-91fd-58c9ddbe6172" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a73483d-ec68-4a83-b01b-9fde9f286abb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7cb55b18-888f-4ac9-9367-1230cd155d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63511ce3-bd46-4262-91fd-58c9ddbe6172" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7cb55b18-888f-4ac9-9367-1230cd155d34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_47e869e2-bc2e-4fcd-8e30-40e6b411679e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7cb55b18-888f-4ac9-9367-1230cd155d34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_47e869e2-bc2e-4fcd-8e30-40e6b411679e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_47e869e2-bc2e-4fcd-8e30-40e6b411679e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_47e869e2-bc2e-4fcd-8e30-40e6b411679e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_47e869e2-bc2e-4fcd-8e30-40e6b411679e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_57ec06cc-ea2b-4d62-a64a-42bc03efe5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_47e869e2-bc2e-4fcd-8e30-40e6b411679e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_57ec06cc-ea2b-4d62-a64a-42bc03efe5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_e07f9aad-2e90-424b-945d-7693070d69ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_57ec06cc-ea2b-4d62-a64a-42bc03efe5d7" xlink:to="loc_us-gaap_PatentsMember_e07f9aad-2e90-424b-945d-7693070d69ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_589e5f95-bd79-4359-b34c-7f670bd108d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_58f5004f-4d59-43ae-b82f-facb620287cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_589e5f95-bd79-4359-b34c-7f670bd108d4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_58f5004f-4d59-43ae-b82f-facb620287cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9eef0386-a1dc-4efa-8d6b-950d2e625fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_589e5f95-bd79-4359-b34c-7f670bd108d4" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9eef0386-a1dc-4efa-8d6b-950d2e625fce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_76bb1b72-2b9a-49c0-94ca-73fcbc0bf6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_589e5f95-bd79-4359-b34c-7f670bd108d4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_76bb1b72-2b9a-49c0-94ca-73fcbc0bf6b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_20443f90-d267-4ccd-9d6c-f276e2063318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_589e5f95-bd79-4359-b34c-7f670bd108d4" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_20443f90-d267-4ccd-9d6c-f276e2063318" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_999df169-b950-4772-863b-6a06c5f0e8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_20443f90-d267-4ccd-9d6c-f276e2063318" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_999df169-b950-4772-863b-6a06c5f0e8be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_999df169-b950-4772-863b-6a06c5f0e8be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_999df169-b950-4772-863b-6a06c5f0e8be" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_999df169-b950-4772-863b-6a06c5f0e8be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2559a728-b055-48d0-950f-96f2559ab4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_999df169-b950-4772-863b-6a06c5f0e8be" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2559a728-b055-48d0-950f-96f2559ab4cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_4acfeae7-db71-4a0a-97f7-e8c4f8bb6785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2559a728-b055-48d0-950f-96f2559ab4cb" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_4acfeae7-db71-4a0a-97f7-e8c4f8bb6785" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PatentsinProcessMember_94fe248e-3e97-4f69-8ae1-6dc322277b4c" xlink:href="mdxg-20220930.xsd#mdxg_PatentsinProcessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2559a728-b055-48d0-950f-96f2559ab4cb" xlink:to="loc_mdxg_PatentsinProcessMember_94fe248e-3e97-4f69-8ae1-6dc322277b4c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanDetails" xlink:type="extended" id="if8bc8851219545c684f2f3f1c45c33f5_LongTermDebtNetTermLoanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_84fb4a5b-b7b2-46c2-80a1-efc4c8e2c505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_84fb4a5b-b7b2-46c2-80a1-efc4c8e2c505" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentInterestRateFloorPercentage_4b08e9bc-e903-44f7-a27e-8a98d6bcef9c" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentInterestRateFloorPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_mdxg_DebtInstrumentInterestRateFloorPercentage_4b08e9bc-e903-44f7-a27e-8a98d6bcef9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cbcc410a-a702-4d3f-8178-8df7a175d4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cbcc410a-a702-4d3f-8178-8df7a175d4a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentDefaultInterestRate_0de1b39a-42bf-4b6b-b2cf-5f6431b4ff0c" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentDefaultInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_mdxg_DebtInstrumentDefaultInterestRate_0de1b39a-42bf-4b6b-b2cf-5f6431b4ff0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1ef46109-e9d0-42d3-8d02-ada34c24c107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1ef46109-e9d0-42d3-8d02-ada34c24c107" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtCovenantMinimumLiquidity_2f6d808c-42ff-4ce3-8519-66a825b292da" xlink:href="mdxg-20220930.xsd#mdxg_DebtCovenantMinimumLiquidity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_mdxg_DebtCovenantMinimumLiquidity_2f6d808c-42ff-4ce3-8519-66a825b292da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent_269c929d-c363-4b0c-8db6-eb670f15e262" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent_269c929d-c363-4b0c-8db6-eb670f15e262" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage_782e3996-317e-4c8f-8dd3-122e61aece2c" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage_782e3996-317e-4c8f-8dd3-122e61aece2c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_354ed744-2447-4262-9eaa-62ba709af3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_us-gaap_LongTermDebtFairValue_354ed744-2447-4262-9eaa-62ba709af3c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_57009573-96d2-4b56-a426-b775fce3d04d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:to="loc_srt_RangeAxis_57009573-96d2-4b56-a426-b775fce3d04d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57009573-96d2-4b56-a426-b775fce3d04d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_57009573-96d2-4b56-a426-b775fce3d04d" xlink:to="loc_srt_RangeMember_57009573-96d2-4b56-a426-b775fce3d04d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb87b2d4-a6bb-47a6-9c33-6fc0a4274310" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_57009573-96d2-4b56-a426-b775fce3d04d" xlink:to="loc_srt_RangeMember_eb87b2d4-a6bb-47a6-9c33-6fc0a4274310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7ed26966-e95b-42c2-aa01-7db1b5ed5f3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb87b2d4-a6bb-47a6-9c33-6fc0a4274310" xlink:to="loc_srt_MinimumMember_7ed26966-e95b-42c2-aa01-7db1b5ed5f3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2938003b-d98b-4696-8774-d1046d0940c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb87b2d4-a6bb-47a6-9c33-6fc0a4274310" xlink:to="loc_srt_MaximumMember_2938003b-d98b-4696-8774-d1046d0940c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d501ce43-4ada-40a9-bc6f-7d745455d551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d501ce43-4ada-40a9-bc6f-7d745455d551" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d501ce43-4ada-40a9-bc6f-7d745455d551_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d501ce43-4ada-40a9-bc6f-7d745455d551" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d501ce43-4ada-40a9-bc6f-7d745455d551_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fd9f1e79-00ed-4f21-b2bc-030622353a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d501ce43-4ada-40a9-bc6f-7d745455d551" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fd9f1e79-00ed-4f21-b2bc-030622353a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_19981378-506c-4cbb-bf83-cf984b4d54b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fd9f1e79-00ed-4f21-b2bc-030622353a8c" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_19981378-506c-4cbb-bf83-cf984b4d54b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5080e43f-5c42-4e78-be33-c1c5c46d75cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:to="loc_us-gaap_DebtInstrumentAxis_5080e43f-5c42-4e78-be33-c1c5c46d75cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5080e43f-5c42-4e78-be33-c1c5c46d75cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5080e43f-5c42-4e78-be33-c1c5c46d75cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5080e43f-5c42-4e78-be33-c1c5c46d75cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5080e43f-5c42-4e78-be33-c1c5c46d75cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementTermLoanMember_f5539542-8a09-4d31-8d85-21b1ffe16966" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:to="loc_mdxg_HayfinLoanAgreementTermLoanMember_f5539542-8a09-4d31-8d85-21b1ffe16966" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_CreditFacilitiesMember_08e70334-e364-4d36-bd29-1b12616d8b21" xlink:href="mdxg-20220930.xsd#mdxg_CreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:to="loc_mdxg_CreditFacilitiesMember_08e70334-e364-4d36-bd29-1b12616d8b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_fb5fc64b-6cf4-4aec-a7ff-ae40101ee1b9" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:to="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_fb5fc64b-6cf4-4aec-a7ff-ae40101ee1b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TermLoanAgreementMember_707e359d-3449-4886-9c81-0a3684777079" xlink:href="mdxg-20220930.xsd#mdxg_TermLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:to="loc_mdxg_TermLoanAgreementMember_707e359d-3449-4886-9c81-0a3684777079" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_4cc81245-652e-4c16-89fb-d144e0e8ee44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:to="loc_us-gaap_VariableRateAxis_4cc81245-652e-4c16-89fb-d144e0e8ee44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4cc81245-652e-4c16-89fb-d144e0e8ee44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_4cc81245-652e-4c16-89fb-d144e0e8ee44" xlink:to="loc_us-gaap_VariableRateDomain_4cc81245-652e-4c16-89fb-d144e0e8ee44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_1477c9e9-9b6e-498a-bff3-c53f72e1767a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_4cc81245-652e-4c16-89fb-d144e0e8ee44" xlink:to="loc_us-gaap_VariableRateDomain_1477c9e9-9b6e-498a-bff3-c53f72e1767a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a1158ef8-200c-447d-979d-b4ddfc9235be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1477c9e9-9b6e-498a-bff3-c53f72e1767a" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a1158ef8-200c-447d-979d-b4ddfc9235be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_81275360-2ab1-4a29-b045-83e64affa270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1477c9e9-9b6e-498a-bff3-c53f72e1767a" xlink:to="loc_us-gaap_PrimeRateMember_81275360-2ab1-4a29-b045-83e64affa270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d500b682-0cb6-458b-bdb3-35095cc38893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1477c9e9-9b6e-498a-bff3-c53f72e1767a" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d500b682-0cb6-458b-bdb3-35095cc38893" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_93eb60cc-619a-4d62-a3ae-7205c444e09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_93eb60cc-619a-4d62-a3ae-7205c444e09b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_93eb60cc-619a-4d62-a3ae-7205c444e09b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_93eb60cc-619a-4d62-a3ae-7205c444e09b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_93eb60cc-619a-4d62-a3ae-7205c444e09b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ab515e3-6605-43d7-a354-c8e38415bb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_93eb60cc-619a-4d62-a3ae-7205c444e09b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ab515e3-6605-43d7-a354-c8e38415bb25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_c122c1cc-4528-42a7-a703-8fd4314a7987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ab515e3-6605-43d7-a354-c8e38415bb25" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_c122c1cc-4528-42a7-a703-8fd4314a7987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7642d292-84ad-4f66-8ea3-91670cf5cba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ab515e3-6605-43d7-a354-c8e38415bb25" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7642d292-84ad-4f66-8ea3-91670cf5cba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_4c155b81-9721-41c0-a83d-9ed2342ede63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ab515e3-6605-43d7-a354-c8e38415bb25" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_4c155b81-9721-41c0-a83d-9ed2342ede63" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanDebtIssuanceCostsDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails" xlink:type="extended" id="i21b8da6a2c8c45babcb6c57336768b84_LongTermDebtNetTermLoanDebtIssuanceCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ad354b02-28d5-4e5a-b929-49ee71cee8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_aab77f2d-7616-4939-b163-d3b6618f8113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad354b02-28d5-4e5a-b929-49ee71cee8f6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_aab77f2d-7616-4939-b163-d3b6618f8113" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e451d3fe-6fdd-412f-bddf-981126c87b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad354b02-28d5-4e5a-b929-49ee71cee8f6" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e451d3fe-6fdd-412f-bddf-981126c87b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_245a8e7a-1646-40d5-a2c6-5ef27d1c659d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad354b02-28d5-4e5a-b929-49ee71cee8f6" xlink:to="loc_us-gaap_DebtInstrumentTable_245a8e7a-1646-40d5-a2c6-5ef27d1c659d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ac4c7c1f-b960-4d40-8d26-fb1b6d1d9007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_245a8e7a-1646-40d5-a2c6-5ef27d1c659d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ac4c7c1f-b960-4d40-8d26-fb1b6d1d9007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ac4c7c1f-b960-4d40-8d26-fb1b6d1d9007_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ac4c7c1f-b960-4d40-8d26-fb1b6d1d9007" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ac4c7c1f-b960-4d40-8d26-fb1b6d1d9007_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fb4d8bba-4abf-4525-8b75-8edf90857e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ac4c7c1f-b960-4d40-8d26-fb1b6d1d9007" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fb4d8bba-4abf-4525-8b75-8edf90857e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_69c329ad-c58a-4402-860c-9646e6595fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fb4d8bba-4abf-4525-8b75-8edf90857e45" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_69c329ad-c58a-4402-860c-9646e6595fd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b8b2d6ca-5b48-4e06-90fa-920132c96223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_245a8e7a-1646-40d5-a2c6-5ef27d1c659d" xlink:to="loc_us-gaap_DebtInstrumentAxis_b8b2d6ca-5b48-4e06-90fa-920132c96223" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b8b2d6ca-5b48-4e06-90fa-920132c96223_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b8b2d6ca-5b48-4e06-90fa-920132c96223" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b8b2d6ca-5b48-4e06-90fa-920132c96223_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e8e1f6c-6ed4-4738-8a4b-5f9abc99f2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b8b2d6ca-5b48-4e06-90fa-920132c96223" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e8e1f6c-6ed4-4738-8a4b-5f9abc99f2fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_CreditFacilitiesMember_b7e98bc8-b7bb-42f3-83b2-ef478cdd4013" xlink:href="mdxg-20220930.xsd#mdxg_CreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4e8e1f6c-6ed4-4738-8a4b-5f9abc99f2fa" xlink:to="loc_mdxg_CreditFacilitiesMember_b7e98bc8-b7bb-42f3-83b2-ef478cdd4013" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementTermLoanMember_91bb9972-0366-443c-9d8e-6b53dc2be57e" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdxg_CreditFacilitiesMember_b7e98bc8-b7bb-42f3-83b2-ef478cdd4013" xlink:to="loc_mdxg_HayfinLoanAgreementTermLoanMember_91bb9972-0366-443c-9d8e-6b53dc2be57e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_6b13a12a-e96a-49c7-a85d-71e5ca824067" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdxg_CreditFacilitiesMember_b7e98bc8-b7bb-42f3-83b2-ef478cdd4013" xlink:to="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_6b13a12a-e96a-49c7-a85d-71e5ca824067" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanBalancesDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails" xlink:type="extended" id="id67e0fed19da493e834daf88d569770b_LongTermDebtNetTermLoanBalancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d7b96757-99d1-4e4b-b0ed-e8fe538c8632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d7b96757-99d1-4e4b-b0ed-e8fe538c8632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a682a4dc-6b7d-4720-8b8c-eafca297ebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a682a4dc-6b7d-4720-8b8c-eafca297ebe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_22484874-1395-4a46-a529-08f65943125f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_22484874-1395-4a46-a529-08f65943125f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d85be014-5ab2-491e-9acb-46a96d3dccac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:to="loc_us-gaap_LongTermDebt_d85be014-5ab2-491e-9acb-46a96d3dccac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a737183b-48ad-462f-a95a-72a5e7e006f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:to="loc_us-gaap_DebtInstrumentTable_a737183b-48ad-462f-a95a-72a5e7e006f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c29e31c5-382c-405b-b117-a283610e6d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a737183b-48ad-462f-a95a-72a5e7e006f3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c29e31c5-382c-405b-b117-a283610e6d1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c29e31c5-382c-405b-b117-a283610e6d1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c29e31c5-382c-405b-b117-a283610e6d1d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c29e31c5-382c-405b-b117-a283610e6d1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0fd62672-4178-433d-9310-9107963b8de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c29e31c5-382c-405b-b117-a283610e6d1d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0fd62672-4178-433d-9310-9107963b8de5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_6bd9a8b5-e948-47b2-aed5-41f6bf249709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0fd62672-4178-433d-9310-9107963b8de5" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_6bd9a8b5-e948-47b2-aed5-41f6bf249709" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b3e30e4e-48bb-4db8-8fa1-f4c37dc10314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a737183b-48ad-462f-a95a-72a5e7e006f3" xlink:to="loc_us-gaap_DebtInstrumentAxis_b3e30e4e-48bb-4db8-8fa1-f4c37dc10314" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b3e30e4e-48bb-4db8-8fa1-f4c37dc10314_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b3e30e4e-48bb-4db8-8fa1-f4c37dc10314" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b3e30e4e-48bb-4db8-8fa1-f4c37dc10314_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c70988ad-65b2-44d1-a7ff-67ce8e518870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b3e30e4e-48bb-4db8-8fa1-f4c37dc10314" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c70988ad-65b2-44d1-a7ff-67ce8e518870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementTermLoanMember_42ec08ef-abd2-4c31-b546-0e93840cd4be" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c70988ad-65b2-44d1-a7ff-67ce8e518870" xlink:to="loc_mdxg_HayfinLoanAgreementTermLoanMember_42ec08ef-abd2-4c31-b546-0e93840cd4be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails" xlink:type="extended" id="i4dcb258173554786b91ca9f7bb953237_LongTermDebtNetTermLoanInterestExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c0798906-e4fc-4cd2-9a34-6943706f266a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c0798906-e4fc-4cd2-9a34-6943706f266a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentCommitmentFees_3d8b6ed5-d257-4347-83cd-b555adb55fb9" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentCommitmentFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:to="loc_mdxg_DebtInstrumentCommitmentFees_3d8b6ed5-d257-4347-83cd-b555adb55fb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7af63a41-0cf3-4cfe-9b09-8136bc3cf6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7af63a41-0cf3-4cfe-9b09-8136bc3cf6d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_55dc6ae3-1e7c-462d-825d-2295ceca2772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_55dc6ae3-1e7c-462d-825d-2295ceca2772" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_141cdef0-ef8c-4788-9f6e-25e2375ca783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:to="loc_us-gaap_InterestExpenseDebt_141cdef0-ef8c-4788-9f6e-25e2375ca783" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_449ca469-7289-4b70-8e5c-7caddd5f5659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:to="loc_us-gaap_DebtInstrumentTable_449ca469-7289-4b70-8e5c-7caddd5f5659" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d2219b4a-78f9-4553-9a90-5f8d7cfdd31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_449ca469-7289-4b70-8e5c-7caddd5f5659" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d2219b4a-78f9-4553-9a90-5f8d7cfdd31e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d2219b4a-78f9-4553-9a90-5f8d7cfdd31e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d2219b4a-78f9-4553-9a90-5f8d7cfdd31e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d2219b4a-78f9-4553-9a90-5f8d7cfdd31e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_17a8f092-76a7-49ee-9da7-d080c4a1b9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d2219b4a-78f9-4553-9a90-5f8d7cfdd31e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_17a8f092-76a7-49ee-9da7-d080c4a1b9bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_24065141-e640-42f7-9807-b91820c0c514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_17a8f092-76a7-49ee-9da7-d080c4a1b9bc" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_24065141-e640-42f7-9807-b91820c0c514" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_225434b6-db0c-47cb-9127-dc189c32795a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_449ca469-7289-4b70-8e5c-7caddd5f5659" xlink:to="loc_us-gaap_DebtInstrumentAxis_225434b6-db0c-47cb-9127-dc189c32795a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_225434b6-db0c-47cb-9127-dc189c32795a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_225434b6-db0c-47cb-9127-dc189c32795a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_225434b6-db0c-47cb-9127-dc189c32795a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0ae30ea1-07e0-4229-abaf-42ceed964b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_225434b6-db0c-47cb-9127-dc189c32795a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0ae30ea1-07e0-4229-abaf-42ceed964b81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementTermLoanMember_cd22139f-caa0-41f2-9f74-a40191f44904" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0ae30ea1-07e0-4229-abaf-42ceed964b81" xlink:to="loc_mdxg_HayfinLoanAgreementTermLoanMember_cd22139f-caa0-41f2-9f74-a40191f44904" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_33584f04-f2c4-4956-a2a2-1b4c91440755" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0ae30ea1-07e0-4229-abaf-42ceed964b81" xlink:to="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_33584f04-f2c4-4956-a2a2-1b4c91440755" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#NetLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i84b70ed425504408bd54441265c81c4e_NetLossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_547a5db6-e2f0-45c6-a372-236f0bb7e267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c47d9f5-0c41-4913-a1d8-e9c410731db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_547a5db6-e2f0-45c6-a372-236f0bb7e267" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c47d9f5-0c41-4913-a1d8-e9c410731db8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08c7673f-cfdd-4f53-874c-4f1910f69c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_547a5db6-e2f0-45c6-a372-236f0bb7e267" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08c7673f-cfdd-4f53-874c-4f1910f69c45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c787f5ea-dd9d-4e05-b538-a3ad9aa741a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08c7673f-cfdd-4f53-874c-4f1910f69c45" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c787f5ea-dd9d-4e05-b538-a3ad9aa741a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c787f5ea-dd9d-4e05-b538-a3ad9aa741a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c787f5ea-dd9d-4e05-b538-a3ad9aa741a0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c787f5ea-dd9d-4e05-b538-a3ad9aa741a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c787f5ea-dd9d-4e05-b538-a3ad9aa741a0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_10987b39-14c4-4769-a09d-25b7456c8788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_10987b39-14c4-4769-a09d-25b7456c8788" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fe755abe-a0dc-4da3-9434-9a9e3345e591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fe755abe-a0dc-4da3-9434-9a9e3345e591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_dba424cf-e07d-43b8-90f7-6a65a71e89d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_RestrictedStockMember_dba424cf-e07d-43b8-90f7-6a65a71e89d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ac5b69a8-bc42-4c4a-9150-5f9232dff73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ac5b69a8-bc42-4c4a-9150-5f9232dff73e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f19fae22-e4d3-4ee6-942b-ca8efd246119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_PerformanceSharesMember_f19fae22-e4d3-4ee6-942b-ca8efd246119" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5abcc199-b569-40b9-846d-b00214a5206c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_EmployeeStockMember_5abcc199-b569-40b9-846d-b00214a5206c" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#EquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/EquityNarrativeDetails" xlink:type="extended" id="i3be14fda6784465896f3502681f7399d_EquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityDividendRatePercentage_6d01291f-a602-434e-8c0a-cb9496343aa1" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityDividendRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityDividendRatePercentage_6d01291f-a602-434e-8c0a-cb9496343aa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_d3428a09-8cd2-4a32-a31a-4dd9bdd4495e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_d3428a09-8cd2-4a32-a31a-4dd9bdd4495e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityConversionPricePerShare_68214a14-3251-4f29-b9e3-cfe7acf959b6" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityConversionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityConversionPricePerShare_68214a14-3251-4f29-b9e3-cfe7acf959b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger_67110e93-3d76-4b9c-b3b6-5b13ade291b3" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger_67110e93-3d76-4b9c-b3b6-5b13ade291b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityConversionThresholdTradingDays_79936511-501e-4eeb-a1ea-366ba0f12b1f" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityConversionThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityConversionThresholdTradingDays_79936511-501e-4eeb-a1ea-366ba0f12b1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityThresholdConsecutiveTradingDays_be20a934-27be-4951-9b5d-ad6e33dc02ad" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityThresholdConsecutiveTradingDays_be20a934-27be-4951-9b5d-ad6e33dc02ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders_071d54f1-d981-4045-b41c-30611417217b" xlink:href="mdxg-20220930.xsd#mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders_071d54f1-d981-4045-b41c-30611417217b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis_f29ba733-ee7e-450d-a8c1-48cd0658dc19" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis_f29ba733-ee7e-450d-a8c1-48cd0658dc19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_3fd49363-0906-41d5-87ea-3eebda646104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_DividendsPreferredStock_3fd49363-0906-41d5-87ea-3eebda646104" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DividendAccumulatedByNotPaid_3881e5a3-a5b1-446c-ad36-b2929e57719c" xlink:href="mdxg-20220930.xsd#mdxg_DividendAccumulatedByNotPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_DividendAccumulatedByNotPaid_3881e5a3-a5b1-446c-ad36-b2929e57719c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable_39a89d7f-5228-42f1-b376-ea7d035a1b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_PreferredStockConvertibleSharesIssuable_39a89d7f-5228-42f1-b376-ea7d035a1b1e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_cbd0be4b-16bc-43e7-95f4-f081daef3eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_cbd0be4b-16bc-43e7-95f4-f081daef3eba" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5fba7aeb-7ba2-4aa9-9a2d-ac1be3fe2da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5fba7aeb-7ba2-4aa9-9a2d-ac1be3fe2da5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_9a6614d0-b5f8-4620-b7ae-82168dd1a7f5" xlink:href="mdxg-20220930.xsd#mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_9a6614d0-b5f8-4620-b7ae-82168dd1a7f5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8ef52895-1b3a-459f-b290-a1768e60f618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8ef52895-1b3a-459f-b290-a1768e60f618" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays_b9309421-fe6e-4673-87e4-cd35f76f8b7c" xlink:href="mdxg-20220930.xsd#mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays_b9309421-fe6e-4673-87e4-cd35f76f8b7c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_378a2f67-3312-40dc-82bc-d11c45893efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_378a2f67-3312-40dc-82bc-d11c45893efd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_f7df05e5-c1b0-4173-bada-3c28c63fdd16" xlink:href="mdxg-20220930.xsd#mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_f7df05e5-c1b0-4173-bada-3c28c63fdd16" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f0520b21-2de1-4650-8e65-cc241d3cce45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f0520b21-2de1-4650-8e65-cc241d3cce45" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2db834e4-3627-440b-b467-c66f8574e80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2db834e4-3627-440b-b467-c66f8574e80e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedESPPPayrollDeferrals_d5124197-56d5-48fe-bb26-db775a41f13d" xlink:href="mdxg-20220930.xsd#mdxg_AccruedESPPPayrollDeferrals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_AccruedESPPPayrollDeferrals_d5124197-56d5-48fe-bb26-db775a41f13d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_419443d2-cf3a-40e3-b44d-e2141da82c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_419443d2-cf3a-40e3-b44d-e2141da82c68" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0bbb76d8-ff9c-4b2a-84e7-5b5f6b3cd3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0bbb76d8-ff9c-4b2a-84e7-5b5f6b3cd3cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0bbb76d8-ff9c-4b2a-84e7-5b5f6b3cd3cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0bbb76d8-ff9c-4b2a-84e7-5b5f6b3cd3cd" xlink:to="loc_us-gaap_ClassOfStockDomain_0bbb76d8-ff9c-4b2a-84e7-5b5f6b3cd3cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_41124793-9646-4c71-9fa1-9c1f507bfa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0bbb76d8-ff9c-4b2a-84e7-5b5f6b3cd3cd" xlink:to="loc_us-gaap_ClassOfStockDomain_41124793-9646-4c71-9fa1-9c1f507bfa2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassBMember_f9a2a5c4-9e1b-440d-bb72-4ad6cc87b19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_41124793-9646-4c71-9fa1-9c1f507bfa2c" xlink:to="loc_us-gaap_PreferredClassBMember_f9a2a5c4-9e1b-440d-bb72-4ad6cc87b19c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c01c540e-b519-4921-964c-7f01944ac3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_41124793-9646-4c71-9fa1-9c1f507bfa2c" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c01c540e-b519-4921-964c-7f01944ac3c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAxis_8695418e-0465-44fa-9caf-1d851330d5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:to="loc_us-gaap_DividendsAxis_8695418e-0465-44fa-9caf-1d851330d5a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain_8695418e-0465-44fa-9caf-1d851330d5a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DividendsAxis_8695418e-0465-44fa-9caf-1d851330d5a8" xlink:to="loc_us-gaap_DividendsDomain_8695418e-0465-44fa-9caf-1d851330d5a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain_dfcf1086-0535-48bd-b106-b5f318af2e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DividendsAxis_8695418e-0465-44fa-9caf-1d851330d5a8" xlink:to="loc_us-gaap_DividendsDomain_dfcf1086-0535-48bd-b106-b5f318af2e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member_29b18910-f36c-4221-b473-2fed8d65353c" xlink:href="mdxg-20220930.xsd#mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsDomain_dfcf1086-0535-48bd-b106-b5f318af2e40" xlink:to="loc_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member_29b18910-f36c-4221-b473-2fed8d65353c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member_a847d694-c0ea-42a1-89f8-fbb2b40655b3" xlink:href="mdxg-20220930.xsd#mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsDomain_dfcf1086-0535-48bd-b106-b5f318af2e40" xlink:to="loc_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member_a847d694-c0ea-42a1-89f8-fbb2b40655b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_27ab1647-0769-4272-a892-380b9233b496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:to="loc_us-gaap_AwardTypeAxis_27ab1647-0769-4272-a892-380b9233b496" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27ab1647-0769-4272-a892-380b9233b496_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_27ab1647-0769-4272-a892-380b9233b496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27ab1647-0769-4272-a892-380b9233b496_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db031b14-ee24-435d-a451-717562376ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_27ab1647-0769-4272-a892-380b9233b496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db031b14-ee24-435d-a451-717562376ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember_6d0869f5-fc0d-4bf7-aa4c-5650eb769fab" xlink:href="mdxg-20220930.xsd#mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db031b14-ee24-435d-a451-717562376ac4" xlink:to="loc_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember_6d0869f5-fc0d-4bf7-aa4c-5650eb769fab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_133ed926-e9ab-4e0f-81a4-62182be5bf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db031b14-ee24-435d-a451-717562376ac4" xlink:to="loc_us-gaap_PerformanceSharesMember_133ed926-e9ab-4e0f-81a4-62182be5bf2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bb3cbc0d-597a-4590-b346-2753639f448e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db031b14-ee24-435d-a451-717562376ac4" xlink:to="loc_us-gaap_EmployeeStockMember_bb3cbc0d-597a-4590-b346-2753639f448e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_f6154ec0-3d58-4721-a5dc-cb39145fa1fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:to="loc_srt_TitleOfIndividualAxis_f6154ec0-3d58-4721-a5dc-cb39145fa1fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f6154ec0-3d58-4721-a5dc-cb39145fa1fd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_f6154ec0-3d58-4721-a5dc-cb39145fa1fd" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f6154ec0-3d58-4721-a5dc-cb39145fa1fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96a3ea7a-b77d-4e28-b983-e970c9274403" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_f6154ec0-3d58-4721-a5dc-cb39145fa1fd" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96a3ea7a-b77d-4e28-b983-e970c9274403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_3fe5b8c7-7278-4794-bfe1-d347f9025481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96a3ea7a-b77d-4e28-b983-e970c9274403" xlink:to="loc_srt_ExecutiveOfficerMember_3fe5b8c7-7278-4794-bfe1-d347f9025481" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd11a5d2-db8d-4dba-867b-5c23c21dd0bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:to="loc_srt_RangeAxis_fd11a5d2-db8d-4dba-867b-5c23c21dd0bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd11a5d2-db8d-4dba-867b-5c23c21dd0bc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fd11a5d2-db8d-4dba-867b-5c23c21dd0bc" xlink:to="loc_srt_RangeMember_fd11a5d2-db8d-4dba-867b-5c23c21dd0bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87493f61-ae26-4b8c-9f53-43e0dba41f06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fd11a5d2-db8d-4dba-867b-5c23c21dd0bc" xlink:to="loc_srt_RangeMember_87493f61-ae26-4b8c-9f53-43e0dba41f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7134da3c-dba9-4c43-a2d0-4f14a0ee0e34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_87493f61-ae26-4b8c-9f53-43e0dba41f06" xlink:to="loc_srt_MinimumMember_7134da3c-dba9-4c43-a2d0-4f14a0ee0e34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8ef92269-53d6-4583-bcf1-c19426cbe314" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_87493f61-ae26-4b8c-9f53-43e0dba41f06" xlink:to="loc_srt_MaximumMember_8ef92269-53d6-4583-bcf1-c19426cbe314" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#EquityChangesinSeriesBPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails" xlink:type="extended" id="i271f7d7c09ce4865a208b6b66e7e6127_EquityChangesinSeriesBPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cf536e54-4d70-43ed-a0b2-99a6227e5000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf536e54-4d70-43ed-a0b2-99a6227e5000" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_f82ab011-9f40-45d7-b6ab-09390f17a46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_f82ab011-9f40-45d7-b6ab-09390f17a46f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52553983-2cab-4e86-b01b-1e3c8217f716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52553983-2cab-4e86-b01b-1e3c8217f716" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_888bf40b-df54-4b8c-9565-222c911fd58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:to="loc_us-gaap_DividendsPreferredStock_888bf40b-df54-4b8c-9565-222c911fd58d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0972be33-2b27-4e37-b43d-ce560ece4dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_020114e6-fdc1-4084-a9c0-1a1a2c5fe111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_090c7dc1-10b7-49da-b80b-7cccfddc3b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf536e54-4d70-43ed-a0b2-99a6227e5000" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_090c7dc1-10b7-49da-b80b-7cccfddc3b21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a9a7cdad-1497-4b6d-a072-5edc60815bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_090c7dc1-10b7-49da-b80b-7cccfddc3b21" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a9a7cdad-1497-4b6d-a072-5edc60815bde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a9a7cdad-1497-4b6d-a072-5edc60815bde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a9a7cdad-1497-4b6d-a072-5edc60815bde" xlink:to="loc_us-gaap_ClassOfStockDomain_a9a7cdad-1497-4b6d-a072-5edc60815bde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f89d03c-0ede-45d2-8ba3-d75e972983c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a9a7cdad-1497-4b6d-a072-5edc60815bde" xlink:to="loc_us-gaap_ClassOfStockDomain_4f89d03c-0ede-45d2-8ba3-d75e972983c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_fe4e9032-016c-4bb0-b86d-275a05f45ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4f89d03c-0ede-45d2-8ba3-d75e972983c6" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_fe4e9032-016c-4bb0-b86d-275a05f45ad0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/EquityRestrictedStockAwardsDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#EquityRestrictedStockAwardsDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/EquityRestrictedStockAwardsDetails" xlink:type="extended" id="i49681ea1c7f94537ad05935fe3067955_EquityRestrictedStockAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd4dbc25-062e-49b6-8059-260c3f9194e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd4dbc25-062e-49b6-8059-260c3f9194e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_efaae9f2-099f-4212-a0b4-3cdc99cd6cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_efaae9f2-099f-4212-a0b4-3cdc99cd6cbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_45cb685d-1430-4ee6-a0ab-0fbfba83159e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_45cb685d-1430-4ee6-a0ab-0fbfba83159e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_94ad77e3-eecc-4fea-8f24-c76e5eb66d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_94ad77e3-eecc-4fea-8f24-c76e5eb66d2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_85034b86-3ef9-4aba-a7df-da52f50aff3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_85034b86-3ef9-4aba-a7df-da52f50aff3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6e69518b-9ff2-443b-82a3-993704145b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd4dbc25-062e-49b6-8059-260c3f9194e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa9d718a-b053-4c65-afcd-9ea94280c7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa9d718a-b053-4c65-afcd-9ea94280c7e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_71475c2e-ac45-4602-907d-5af600483849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_71475c2e-ac45-4602-907d-5af600483849" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_28278cef-3351-4217-b4db-2777efb2d86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_28278cef-3351-4217-b4db-2777efb2d86e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4185a996-da01-49f6-8547-8970549799eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4185a996-da01-49f6-8547-8970549799eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bc873a7e-401e-4765-ad27-7ab430fdec8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac37004d-10e8-4274-b52b-f0d78f4fcab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd4dbc25-062e-49b6-8059-260c3f9194e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac37004d-10e8-4274-b52b-f0d78f4fcab3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b3946d62-5edc-41bc-9000-fe18f8e3614a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac37004d-10e8-4274-b52b-f0d78f4fcab3" xlink:to="loc_us-gaap_AwardTypeAxis_b3946d62-5edc-41bc-9000-fe18f8e3614a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3946d62-5edc-41bc-9000-fe18f8e3614a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b3946d62-5edc-41bc-9000-fe18f8e3614a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3946d62-5edc-41bc-9000-fe18f8e3614a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db46a51-0e16-4151-96c1-7c8598eb9a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b3946d62-5edc-41bc-9000-fe18f8e3614a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db46a51-0e16-4151-96c1-7c8598eb9a79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c562ebd7-1284-423b-891e-a3671b7a99d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db46a51-0e16-4151-96c1-7c8598eb9a79" xlink:to="loc_us-gaap_RestrictedStockMember_c562ebd7-1284-423b-891e-a3671b7a99d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ec072bcb-cecb-41e6-8763-4bbf612e4b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db46a51-0e16-4151-96c1-7c8598eb9a79" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ec072bcb-cecb-41e6-8763-4bbf612e4b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b3cb9057-e8b5-4df7-8745-d271a94d29b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db46a51-0e16-4151-96c1-7c8598eb9a79" xlink:to="loc_us-gaap_PerformanceSharesMember_b3cb9057-e8b5-4df7-8745-d271a94d29b6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/EquityFairValueAssumptionsDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#EquityFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/EquityFairValueAssumptionsDetails" xlink:type="extended" id="i3cea6b3048ae4797a55a226664f69d1e_EquityFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f42363fe-8118-45f7-b2ae-15d26c871f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f42363fe-8118-45f7-b2ae-15d26c871f23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d40e0e45-49f7-4f15-b4ea-480553a37e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d40e0e45-49f7-4f15-b4ea-480553a37e25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_225fe296-4a20-4027-b31d-bdfdd4100f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_225fe296-4a20-4027-b31d-bdfdd4100f8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f931bab4-bdcb-459d-9744-a3ab220fdf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f931bab4-bdcb-459d-9744-a3ab220fdf7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ecb50424-4d95-4a39-8941-43cd1e717e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_SharePrice_ecb50424-4d95-4a39-8941-43cd1e717e58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7cc023fd-e339-4a41-8ec1-57c5fdd1a761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7cc023fd-e339-4a41-8ec1-57c5fdd1a761" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f3f90e-40ff-4e8d-8383-4dcb09769f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f3f90e-40ff-4e8d-8383-4dcb09769f0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_25971194-4866-4e0e-9b18-261c7de02902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f3f90e-40ff-4e8d-8383-4dcb09769f0e" xlink:to="loc_us-gaap_AwardTypeAxis_25971194-4866-4e0e-9b18-261c7de02902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25971194-4866-4e0e-9b18-261c7de02902_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_25971194-4866-4e0e-9b18-261c7de02902" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25971194-4866-4e0e-9b18-261c7de02902_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65cf04d8-22f1-47ba-bad6-96d90d4d00ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_25971194-4866-4e0e-9b18-261c7de02902" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65cf04d8-22f1-47ba-bad6-96d90d4d00ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e5822f0f-7654-402f-84b5-a27d6f2d7117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65cf04d8-22f1-47ba-bad6-96d90d4d00ef" xlink:to="loc_us-gaap_PerformanceSharesMember_e5822f0f-7654-402f-84b5-a27d6f2d7117" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_665abab1-350b-4c60-b9c1-eccf44d162aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f3f90e-40ff-4e8d-8383-4dcb09769f0e" xlink:to="loc_srt_TitleOfIndividualAxis_665abab1-350b-4c60-b9c1-eccf44d162aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_665abab1-350b-4c60-b9c1-eccf44d162aa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_665abab1-350b-4c60-b9c1-eccf44d162aa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_665abab1-350b-4c60-b9c1-eccf44d162aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8605d2e8-449d-4a5f-af8e-6d008cc5fb03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_665abab1-350b-4c60-b9c1-eccf44d162aa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8605d2e8-449d-4a5f-af8e-6d008cc5fb03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_28abe0f7-4d0b-4667-9152-44f890b0d878" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8605d2e8-449d-4a5f-af8e-6d008cc5fb03" xlink:to="loc_srt_ExecutiveOfficerMember_28abe0f7-4d0b-4667-9152-44f890b0d878" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ia45b4ce867624d03a27ce8fd652d0998_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_630416c0-00c0-412c-8269-de8461243ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_us-gaap_OtherCommitment_630416c0-00c0-412c-8269-de8461243ba0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db6f66d0-77d8-4481-85c4-772a906641b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db6f66d0-77d8-4481-85c4-772a906641b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_28aa09a2-43dc-4236-a1eb-01248ab2d252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_28aa09a2-43dc-4236-a1eb-01248ab2d252" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired_3c7b6c52-ef78-4384-9484-231f49dc386d" xlink:href="mdxg-20220930.xsd#mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired_3c7b6c52-ef78-4384-9484-231f49dc386d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PaymentsMadeOnLongTermPurchaseCommitment_d4fab190-4ba5-4b23-a884-cff0ec10990e" xlink:href="mdxg-20220930.xsd#mdxg_PaymentsMadeOnLongTermPurchaseCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_mdxg_PaymentsMadeOnLongTermPurchaseCommitment_d4fab190-4ba5-4b23-a884-cff0ec10990e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ExpensesOnLongTermPurchaseCommitment_82f07c58-ba64-4d7d-ba47-7ed82326ab74" xlink:href="mdxg-20220930.xsd#mdxg_ExpensesOnLongTermPurchaseCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_mdxg_ExpensesOnLongTermPurchaseCommitment_82f07c58-ba64-4d7d-ba47-7ed82326ab74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment_c5165b99-7098-477d-8d6a-392606ee765e" xlink:href="mdxg-20220930.xsd#mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment_c5165b99-7098-477d-8d6a-392606ee765e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_472609d5-dd86-4d51-a41e-236c447805b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_472609d5-dd86-4d51-a41e-236c447805b8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ContingencyLossNumberOfSecuritiesClassActions_2dd4fa02-39f9-409b-b569-4ba571faede2" xlink:href="mdxg-20220930.xsd#mdxg_ContingencyLossNumberOfSecuritiesClassActions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_mdxg_ContingencyLossNumberOfSecuritiesClassActions_2dd4fa02-39f9-409b-b569-4ba571faede2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e79c7bc3-1d74-4069-9f62-27c1b533c995" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:to="loc_dei_LegalEntityAxis_e79c7bc3-1d74-4069-9f62-27c1b533c995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e79c7bc3-1d74-4069-9f62-27c1b533c995_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e79c7bc3-1d74-4069-9f62-27c1b533c995" xlink:to="loc_dei_EntityDomain_e79c7bc3-1d74-4069-9f62-27c1b533c995_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ce09ff55-0175-4eea-91bb-dd7a4b4e49b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e79c7bc3-1d74-4069-9f62-27c1b533c995" xlink:to="loc_dei_EntityDomain_ce09ff55-0175-4eea-91bb-dd7a4b4e49b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InsuranceProvidersMember_2baec693-95df-46d8-b6d2-56251e7d613d" xlink:href="mdxg-20220930.xsd#mdxg_InsuranceProvidersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ce09ff55-0175-4eea-91bb-dd7a4b4e49b8" xlink:to="loc_mdxg_InsuranceProvidersMember_2baec693-95df-46d8-b6d2-56251e7d613d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4323d502-d7c1-4c81-9aab-b646353b8d91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:to="loc_srt_TitleOfIndividualAxis_4323d502-d7c1-4c81-9aab-b646353b8d91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4323d502-d7c1-4c81-9aab-b646353b8d91_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_4323d502-d7c1-4c81-9aab-b646353b8d91" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4323d502-d7c1-4c81-9aab-b646353b8d91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_54c954de-9300-45dc-8144-070133b7cc36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_4323d502-d7c1-4c81-9aab-b646353b8d91" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_54c954de-9300-45dc-8144-070133b7cc36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_4bd5c41e-5813-45b0-bec7-4e354d7d5029" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_54c954de-9300-45dc-8144-070133b7cc36" xlink:to="loc_srt_ChiefExecutiveOfficerMember_4bd5c41e-5813-45b0-bec7-4e354d7d5029" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_69cd416f-235d-49c7-ab4c-60f77d07efa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:to="loc_us-gaap_OtherCommitmentsAxis_69cd416f-235d-49c7-ab4c-60f77d07efa1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_69cd416f-235d-49c7-ab4c-60f77d07efa1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_69cd416f-235d-49c7-ab4c-60f77d07efa1" xlink:to="loc_us-gaap_OtherCommitmentsDomain_69cd416f-235d-49c7-ab4c-60f77d07efa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_fc918aac-1aca-4d16-8798-376847197aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_69cd416f-235d-49c7-ab4c-60f77d07efa1" xlink:to="loc_us-gaap_OtherCommitmentsDomain_fc918aac-1aca-4d16-8798-376847197aa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_SeparationAgreementMember_80154b11-b1f6-4e2e-a5fb-634fe4de8cf7" xlink:href="mdxg-20220930.xsd#mdxg_SeparationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_fc918aac-1aca-4d16-8798-376847197aa2" xlink:to="loc_mdxg_SeparationAgreementMember_80154b11-b1f6-4e2e-a5fb-634fe4de8cf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_95718705-5dec-4119-8c4e-315495a3fb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_95718705-5dec-4119-8c4e-315495a3fb4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_95718705-5dec-4119-8c4e-315495a3fb4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_95718705-5dec-4119-8c4e-315495a3fb4a" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_95718705-5dec-4119-8c4e-315495a3fb4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_47a780af-1751-4c3b-9db3-9cd67cbb6859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_95718705-5dec-4119-8c4e-315495a3fb4a" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_47a780af-1751-4c3b-9db3-9cd67cbb6859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_6e30a80f-400f-4462-b70a-dd40e2bc2fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_47a780af-1751-4c3b-9db3-9cd67cbb6859" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_6e30a80f-400f-4462-b70a-dd40e2bc2fa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e387f440-bf6f-45fd-9aa4-f84754b51fd4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:to="loc_srt_CounterpartyNameAxis_e387f440-bf6f-45fd-9aa4-f84754b51fd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e387f440-bf6f-45fd-9aa4-f84754b51fd4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e387f440-bf6f-45fd-9aa4-f84754b51fd4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e387f440-bf6f-45fd-9aa4-f84754b51fd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49327ec1-0af0-4fa0-9137-18f3dd7ba97b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e387f440-bf6f-45fd-9aa4-f84754b51fd4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49327ec1-0af0-4fa0-9137-18f3dd7ba97b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_NordicBioscienceClinicalDevelopmentASMember_7589e3fa-5ed6-4161-b1a5-3e68db0a82f2" xlink:href="mdxg-20220930.xsd#mdxg_NordicBioscienceClinicalDevelopmentASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49327ec1-0af0-4fa0-9137-18f3dd7ba97b" xlink:to="loc_mdxg_NordicBioscienceClinicalDevelopmentASMember_7589e3fa-5ed6-4161-b1a5-3e68db0a82f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#RevenueSummaryofRevenuebyProductTypeDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails" xlink:type="extended" id="i471abe0ad2ce44f8a21ae18959ae6904_RevenueSummaryofRevenuebyProductTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5818ebb6-ba45-4261-95d8-a2e6c9a64364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e45d0ec0-9e9a-474e-82fe-4c29e3b545fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5818ebb6-ba45-4261-95d8-a2e6c9a64364" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e45d0ec0-9e9a-474e-82fe-4c29e3b545fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_12be2ed7-a35a-4fc2-9ae5-7371e5d5f41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5818ebb6-ba45-4261-95d8-a2e6c9a64364" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_12be2ed7-a35a-4fc2-9ae5-7371e5d5f41f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad0c6e6e-ee32-4003-ac81-c6eeee64cfc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_12be2ed7-a35a-4fc2-9ae5-7371e5d5f41f" xlink:to="loc_srt_ProductOrServiceAxis_ad0c6e6e-ee32-4003-ac81-c6eeee64cfc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ad0c6e6e-ee32-4003-ac81-c6eeee64cfc9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ad0c6e6e-ee32-4003-ac81-c6eeee64cfc9" xlink:to="loc_srt_ProductsAndServicesDomain_ad0c6e6e-ee32-4003-ac81-c6eeee64cfc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f29d4354-5e5d-4049-8f05-626115f5769f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ad0c6e6e-ee32-4003-ac81-c6eeee64cfc9" xlink:to="loc_srt_ProductsAndServicesDomain_f29d4354-5e5d-4049-8f05-626115f5769f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AdvancedWoundCareMember_c0cc8966-0356-484a-ad73-45607edffc4e" xlink:href="mdxg-20220930.xsd#mdxg_AdvancedWoundCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f29d4354-5e5d-4049-8f05-626115f5769f" xlink:to="loc_mdxg_AdvancedWoundCareMember_c0cc8966-0356-484a-ad73-45607edffc4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AdvancedWoundCareTissueAndOtherMember_b4868ffd-27a7-4cc4-a3c2-f4ba0b9e7411" xlink:href="mdxg-20220930.xsd#mdxg_AdvancedWoundCareTissueAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdxg_AdvancedWoundCareMember_c0cc8966-0356-484a-ad73-45607edffc4e" xlink:to="loc_mdxg_AdvancedWoundCareTissueAndOtherMember_b4868ffd-27a7-4cc4-a3c2-f4ba0b9e7411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember_ddb69b94-b459-4819-9152-7bb727d91bdf" xlink:href="mdxg-20220930.xsd#mdxg_AdvancedWoundCareUmbilicalCordDerivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdxg_AdvancedWoundCareMember_c0cc8966-0356-484a-ad73-45607edffc4e" xlink:to="loc_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember_ddb69b94-b459-4819-9152-7bb727d91bdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_Section351ProductsMember_402eba51-b5b6-4a00-b1eb-2e05597be5b6" xlink:href="mdxg-20220930.xsd#mdxg_Section351ProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f29d4354-5e5d-4049-8f05-626115f5769f" xlink:to="loc_mdxg_Section351ProductsMember_402eba51-b5b6-4a00-b1eb-2e05597be5b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_d7f96f7f-8a53-456e-b594-01ffe7d2a4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f29d4354-5e5d-4049-8f05-626115f5769f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_d7f96f7f-8a53-456e-b594-01ffe7d2a4c7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#RevenueSummaryofRevenuebyCustomerTypeDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails" xlink:type="extended" id="id7d4d6e65b2242a2919b79b96a408747_RevenueSummaryofRevenuebyCustomerTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_662e3316-13a2-4f14-95c1-06e683c9f9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a91a8cf-a40c-4638-937b-fd8aa437195d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_662e3316-13a2-4f14-95c1-06e683c9f9e8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a91a8cf-a40c-4638-937b-fd8aa437195d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ef7a4897-d4f7-4b56-87fb-4b5a4ed2e7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_662e3316-13a2-4f14-95c1-06e683c9f9e8" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ef7a4897-d4f7-4b56-87fb-4b5a4ed2e7bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_d8cf631c-fa46-44a6-8a14-a97a3efc8f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ef7a4897-d4f7-4b56-87fb-4b5a4ed2e7bb" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_d8cf631c-fa46-44a6-8a14-a97a3efc8f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_d8cf631c-fa46-44a6-8a14-a97a3efc8f3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_d8cf631c-fa46-44a6-8a14-a97a3efc8f3c" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_d8cf631c-fa46-44a6-8a14-a97a3efc8f3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_66ad3b97-b8b9-4af6-bf8d-b327fdcd7545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_d8cf631c-fa46-44a6-8a14-a97a3efc8f3c" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_66ad3b97-b8b9-4af6-bf8d-b327fdcd7545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_b8d78d4c-41af-49d4-b84a-9a1f564fb87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_66ad3b97-b8b9-4af6-bf8d-b327fdcd7545" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_b8d78d4c-41af-49d4-b84a-9a1f564fb87b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_38222070-a4b6-4f48-806e-99c8c5636688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_66ad3b97-b8b9-4af6-bf8d-b327fdcd7545" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_38222070-a4b6-4f48-806e-99c8c5636688" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails" xlink:type="extended" id="ib1f0f6a2547941b289afd56470fd4bc8_SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39086d57-9f23-440c-8c02-efae2b9d4b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39086d57-9f23-440c-8c02-efae2b9d4b0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2f77ca48-f389-4c24-871e-ea3d950a39e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2f77ca48-f389-4c24-871e-ea3d950a39e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8d64bb21-f7e9-403f-b73d-1cdf3c7f430b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8d64bb21-f7e9-403f-b73d-1cdf3c7f430b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0d3a1a63-dc34-42e4-b751-3635fd01d9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0d3a1a63-dc34-42e4-b751-3635fd01d9af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e4f5695c-7d71-458f-af2e-c3c6af811e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e4f5695c-7d71-458f-af2e-c3c6af811e96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_SegmentContribution_dec03386-9232-466e-9852-2cee736c0c71" xlink:href="mdxg-20220930.xsd#mdxg_SegmentContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_mdxg_SegmentContribution_dec03386-9232-466e-9852-2cee736c0c71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InvestigationRestatementAndRelated_cd9b3e03-2532-4205-9646-8300502726ae" xlink:href="mdxg-20220930.xsd#mdxg_InvestigationRestatementAndRelated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_mdxg_InvestigationRestatementAndRelated_cd9b3e03-2532-4205-9646-8300502726ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a419dd17-182a-4fdd-896b-4261ca894f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_OperatingIncomeLoss_a419dd17-182a-4fdd-896b-4261ca894f6f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_SupplementalInformationAbstract_426d142f-05b5-463a-811a-fdfc6d977d23" xlink:href="mdxg-20220930.xsd#mdxg_SupplementalInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_mdxg_SupplementalInformationAbstract_426d142f-05b5-463a-811a-fdfc6d977d23" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_980d192f-3b55-42f8-82fc-e31449b925cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdxg_SupplementalInformationAbstract_426d142f-05b5-463a-811a-fdfc6d977d23" xlink:to="loc_us-gaap_Depreciation_980d192f-3b55-42f8-82fc-e31449b925cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0121cbdf-8e91-458d-b149-942a7a54f888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdxg_SupplementalInformationAbstract_426d142f-05b5-463a-811a-fdfc6d977d23" xlink:to="loc_us-gaap_ShareBasedCompensation_0121cbdf-8e91-458d-b149-942a7a54f888" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bee8ca4a-0397-4711-952e-97073be59ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bee8ca4a-0397-4711-952e-97073be59ed5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f608dfe4-5790-492b-a9c2-8b08dc01678d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bee8ca4a-0397-4711-952e-97073be59ed5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f608dfe4-5790-492b-a9c2-8b08dc01678d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f608dfe4-5790-492b-a9c2-8b08dc01678d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f608dfe4-5790-492b-a9c2-8b08dc01678d" xlink:to="loc_us-gaap_SegmentDomain_f608dfe4-5790-492b-a9c2-8b08dc01678d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3d2ecd09-33f0-409a-ae83-27e8ffcf7d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f608dfe4-5790-492b-a9c2-8b08dc01678d" xlink:to="loc_us-gaap_SegmentDomain_3d2ecd09-33f0-409a-ae83-27e8ffcf7d02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_WoundSurgicalSegmentMember_4399768e-aa7b-4eae-ac66-741ec6f0046e" xlink:href="mdxg-20220930.xsd#mdxg_WoundSurgicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3d2ecd09-33f0-409a-ae83-27e8ffcf7d02" xlink:to="loc_mdxg_WoundSurgicalSegmentMember_4399768e-aa7b-4eae-ac66-741ec6f0046e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RegenerativeMedicineSegmentMember_03a98711-6cc9-4165-89b1-5b0bc289fe97" xlink:href="mdxg-20220930.xsd#mdxg_RegenerativeMedicineSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3d2ecd09-33f0-409a-ae83-27e8ffcf7d02" xlink:to="loc_mdxg_RegenerativeMedicineSegmentMember_03a98711-6cc9-4165-89b1-5b0bc289fe97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_964d6bcc-8fbd-424e-ab34-541e94114ca6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bee8ca4a-0397-4711-952e-97073be59ed5" xlink:to="loc_srt_ConsolidationItemsAxis_964d6bcc-8fbd-424e-ab34-541e94114ca6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_964d6bcc-8fbd-424e-ab34-541e94114ca6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_964d6bcc-8fbd-424e-ab34-541e94114ca6" xlink:to="loc_srt_ConsolidationItemsDomain_964d6bcc-8fbd-424e-ab34-541e94114ca6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ed414c44-1a85-4dc6-9826-8f35abcfba5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_964d6bcc-8fbd-424e-ab34-541e94114ca6" xlink:to="loc_srt_ConsolidationItemsDomain_ed414c44-1a85-4dc6-9826-8f35abcfba5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d5b1195e-3490-44ca-9f75-0dd9f1ac5f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ed414c44-1a85-4dc6-9826-8f35abcfba5d" xlink:to="loc_us-gaap_OperatingSegmentsMember_d5b1195e-3490-44ca-9f75-0dd9f1ac5f55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f1671e04-303e-41ff-b2fc-676d21f494c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ed414c44-1a85-4dc6-9826-8f35abcfba5d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f1671e04-303e-41ff-b2fc-676d21f494c1" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mdxg-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:75aec70c-8992-4432-a811-2ecd9b0ef10b,g:2668ca8b-9129-4930-9d6a-e03d3677c28b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f021601-e658-41ed-b8a4-e49f769f1b64_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member_74247255-5e11-4508-82d5-8d415efcc446_terseLabel_en-US" xlink:label="lab_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perpetual Dividend Rate after Quarterly Dividend Payment ending on June 30, 2021</link:label>
    <link:label id="lab_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member_label_en-US" xlink:label="lab_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perpetual Dividend Rate after Quarterly Dividend Payment ending on June 30, 2021 [Member]</link:label>
    <link:label id="lab_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member_documentation_en-US" xlink:label="lab_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perpetual Dividend Rate after Quarterly Dividend Payment ending on June 30, 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member" xlink:href="mdxg-20220930.xsd#mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member" xlink:to="lab_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_59837b00-8055-45f8-b816-911b1d1deeb8_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_ace690e8-87ff-4183-b406-7d3655fe3634_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_282efaae-f285-4f58-ac7b-7c041f60dc2d_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_NordicBioscienceClinicalDevelopmentASMember_9f89ed2d-9f37-4550-b32d-bb2ea47bef97_terseLabel_en-US" xlink:label="lab_mdxg_NordicBioscienceClinicalDevelopmentASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Bioscience Clinical Development A/S</link:label>
    <link:label id="lab_mdxg_NordicBioscienceClinicalDevelopmentASMember_label_en-US" xlink:label="lab_mdxg_NordicBioscienceClinicalDevelopmentASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Bioscience Clinical Development A/S [Member]</link:label>
    <link:label id="lab_mdxg_NordicBioscienceClinicalDevelopmentASMember_documentation_en-US" xlink:label="lab_mdxg_NordicBioscienceClinicalDevelopmentASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Bioscience Clinical Development A/S</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_NordicBioscienceClinicalDevelopmentASMember" xlink:href="mdxg-20220930.xsd#mdxg_NordicBioscienceClinicalDevelopmentASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_NordicBioscienceClinicalDevelopmentASMember" xlink:to="lab_mdxg_NordicBioscienceClinicalDevelopmentASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3ff888dd-ec55-4781-9ff6-1efddcbfe99f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_TemporaryEquityConversionPricePerShare_85ec08b1-c1d4-4a07-8f01-0a32244dec47_terseLabel_en-US" xlink:label="lab_mdxg_TemporaryEquityConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B preferred stock, conversion price (in dollars per share)</link:label>
    <link:label id="lab_mdxg_TemporaryEquityConversionPricePerShare_label_en-US" xlink:label="lab_mdxg_TemporaryEquityConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Conversion Price Per Share</link:label>
    <link:label id="lab_mdxg_TemporaryEquityConversionPricePerShare_documentation_en-US" xlink:label="lab_mdxg_TemporaryEquityConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Conversion Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityConversionPricePerShare" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityConversionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_TemporaryEquityConversionPricePerShare" xlink:to="lab_mdxg_TemporaryEquityConversionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_c61951ec-9fff-47a2-8b60-6fc57d832ee6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ffd9df7b-c57d-45f3-a740-e7d78282e230_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e740513c-2735-4585-9cef-65bee172cd70_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_c1fd4e74-fad2-4f04-96a7-eaf114ef1c90_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_ea49ea1e-84a7-43dc-ac0f-e97c99cebf45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Activity Summary - Indefinite-lived</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2fe26e06-c9c2-4239-ad42-d2ff197bdd98_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_dfd56d7c-db01-4404-92e8-9839cf3f0a03_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_12d35c57-2824-484e-8d5e-8cbcf083aa99_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_76278269-8a47-4973-a094-360664db6ebe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock shares canceled/forfeited</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_028a26a8-35bc-456c-ba60-b39da348c7f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_638e2f3f-5b79-45f3-81b9-929b248c7a39_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fff7d9ed-3c37-41be-aae1-fd87a6df6c85_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_48b01fa8-fe48-4158-bf37-afb7bdd34a6b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_4cb5265d-1c34-44f8-9022-1e890cd36b1c_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_bb58d652-9b30-48ff-9e6c-8da8b0139545_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4754cc20-d9ab-4bd5-a66e-e71c68a577b4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eecaf08c-37a9-4867-8774-6e385ea11630_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_66ab0d46-729f-407d-8d87-3d2f660d0d1f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_5465bb65-0ffa-49a0-9b02-122cec2b667a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ee988314-0088-455f-8387-dbf218ce772c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b98217ce-1e17-4b46-9431-25a20a108bd4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStock_10778e7b-3b97-46d9-9c7b-9a8cfedf4e66_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, preferred stock</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_666d759f-c5d5-4c1a-a6ed-44eabbfc3181_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividends</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStock" xlink:to="lab_us-gaap_DividendsPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_613a13eb-a717-43a4-83e2-78f4780bdb2f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_73fa51cf-8ba3-40ed-95b4-e8cedd34381a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_ab237338-b7a7-4a0d-8e27-2bb4bd0273d2_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock, outstanding, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_6ada1cd0-c67a-4851-9641-f912cc7e082f_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock, outstanding, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c19f46b7-ecac-47e3-bb1a-22a1877f2c77_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fa5558e9-7989-40e8-bb14-5398fac7d2b0_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_73e431f5-0a5c-4b94-ac4d-01cd5c5c56c6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock_5e0f075e-128d-4c2a-8638-dab6a64a7a7d_terseLabel_en-US" xlink:label="lab_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Issuance Costs</link:label>
    <link:label id="lab_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock_label_en-US" xlink:label="lab_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Debt Issuance Costs [Table Text Block]</link:label>
    <link:label id="lab_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock_documentation_en-US" xlink:label="lab_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Issuance Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock" xlink:href="mdxg-20220930.xsd#mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock" xlink:to="lab_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cbbab3d4-258c-41cb-a0e6-b7504f47bb5d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a082db60-d2f3-491d-bb86-5af34bc8a8fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: antidilutive potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8f3acc2c-3c7e-4b37-b3bf-28b6201a1d64_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential common shares</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0b8903c4-2128-45c7-89d8-504e7371ef5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Principal Payments for the Term Loan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_2e3730d9-4fda-4bc1-a05b-57ff800a3ffc_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_aa3e6223-bf8a-44bc-8a2f-4721171aadbe_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, gross</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a51b03cf-1016-4cda-aeae-119f31774d0b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ade35240-9eb6-4cac-b312-acdebf84a682_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_35f7edeb-d62b-4315-a8be-c71d80686711_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock at cost; 1,838 shares at September&#160;30, 2022 and 778,710 shares at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_TreasuryStockSharesAdjustment_2c6d1676-5161-4e9c-9654-574c4f78a6f8_terseLabel_en-US" xlink:label="lab_mdxg_TreasuryStockSharesAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (in shares)</link:label>
    <link:label id="lab_mdxg_TreasuryStockSharesAdjustment_label_en-US" xlink:label="lab_mdxg_TreasuryStockSharesAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Adjustment</link:label>
    <link:label id="lab_mdxg_TreasuryStockSharesAdjustment_documentation_en-US" xlink:label="lab_mdxg_TreasuryStockSharesAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TreasuryStockSharesAdjustment" xlink:href="mdxg-20220930.xsd#mdxg_TreasuryStockSharesAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_TreasuryStockSharesAdjustment" xlink:to="lab_mdxg_TreasuryStockSharesAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_b079e5c4-eb59-4533-83ab-936d807abc5b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7af0f5dd-d9fd-423a-83ee-98d1e8e75a32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_5eaee9af-0450-41f8-b2a5-5ac589f91de5_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_836fb049-7d35-4fa4-bf15-d7714e0bddfd_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c0b6995b-add6-4696-8799-6432169e8676_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized stock-based compensation related to time-based, nonvested restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_HayfinLoanAgreementTermLoanMember_7457e8cc-f4bd-44f0-b89a-531206373446_terseLabel_en-US" xlink:label="lab_mdxg_HayfinLoanAgreementTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hayfin Loan Agreement Term Loan</link:label>
    <link:label id="lab_mdxg_HayfinLoanAgreementTermLoanMember_label_en-US" xlink:label="lab_mdxg_HayfinLoanAgreementTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hayfin Loan Agreement Term Loan [Member]</link:label>
    <link:label id="lab_mdxg_HayfinLoanAgreementTermLoanMember_documentation_en-US" xlink:label="lab_mdxg_HayfinLoanAgreementTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hayfin Loan Agreement Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementTermLoanMember" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_HayfinLoanAgreementTermLoanMember" xlink:to="lab_mdxg_HayfinLoanAgreementTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_58a599bb-7267-4188-8c17-04fac209015a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c3499687-8641-4da9-af65-330879b546df_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a94d00c7-9bac-4972-871e-9a1f7ca4a1a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_ac4b76ee-b8c8-4a2c-ae59-d02d9ddcb8e8_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_4ed7d6be-66eb-4562-87cd-49ead224a7da_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0b696cec-d671-434e-af8a-b599d81a2662_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_dd8ac6fd-36ad-4602-ab5b-11d67c2f2e7a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_52af5533-3e9e-4f12-8b05-ca7fb3f29e8f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_75778d17-216f-4781-b8d2-2d6ab3e32e32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested options expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_54a9b08a-6d3e-4de8-a6e7-7f6a4d528a70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Awards by Award Type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_NotesReceivableForSaleOfPropertyAndEquipment_64facb6c-d275-47cc-8add-ed4f1a3dd332_terseLabel_en-US" xlink:label="lab_mdxg_NotesReceivableForSaleOfPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable for sale of property and equipment</link:label>
    <link:label id="lab_mdxg_NotesReceivableForSaleOfPropertyAndEquipment_label_en-US" xlink:label="lab_mdxg_NotesReceivableForSaleOfPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable For Sale Of Property And Equipment</link:label>
    <link:label id="lab_mdxg_NotesReceivableForSaleOfPropertyAndEquipment_documentation_en-US" xlink:label="lab_mdxg_NotesReceivableForSaleOfPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable For Sale Of Property And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_NotesReceivableForSaleOfPropertyAndEquipment" xlink:href="mdxg-20220930.xsd#mdxg_NotesReceivableForSaleOfPropertyAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_NotesReceivableForSaleOfPropertyAndEquipment" xlink:to="lab_mdxg_NotesReceivableForSaleOfPropertyAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_303f72af-de62-40d2-9fe7-18efa883257e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Antidilutive Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0409a165-1436-4f2f-ab03-9d77de5880c9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_a8b421cf-66e5-4309-b4e3-e2a291f4af30_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_72f688bb-268d-4251-882b-60ec699e9009_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_TemporaryEquityThresholdConsecutiveTradingDays_a523a78e-07c7-4906-ab6f-175b4cf65591_terseLabel_en-US" xlink:label="lab_mdxg_TemporaryEquityThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B preferred stock, threshold number of consecutive trading days</link:label>
    <link:label id="lab_mdxg_TemporaryEquityThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_mdxg_TemporaryEquityThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_mdxg_TemporaryEquityThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_mdxg_TemporaryEquityThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityThresholdConsecutiveTradingDays" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_TemporaryEquityThresholdConsecutiveTradingDays" xlink:to="lab_mdxg_TemporaryEquityThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_1eb05b47-4506-4c37-9072-1bf9100d4402_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_ff6e70d0-f978-4e25-ba2c-088b9fe771ad_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributors</link:label>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Through Intermediary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:to="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_da2ee550-26f0-4ef3-8f5f-6b8187928703_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fe0f4af-2f92-4b81-bf50-e879ca82fe5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c17ca5a1-9092-4b14-8191-d1bc77eb6ad6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash&#160;flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember_02714e83-3dad-4fe4-a1c0-89c7f2afd8e0_terseLabel_en-US" xlink:label="lab_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cord</link:label>
    <link:label id="lab_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember_label_en-US" xlink:label="lab_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Wound Care, Umbilical Cord-Derived [Member]</link:label>
    <link:label id="lab_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember_documentation_en-US" xlink:label="lab_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Wound Care, Umbilical Cord-Derived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember" xlink:href="mdxg-20220930.xsd#mdxg_AdvancedWoundCareUmbilicalCordDerivedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember" xlink:to="lab_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_TermLoanAgreementMember_98b50b8e-1d05-4367-954a-806979e974ee_terseLabel_en-US" xlink:label="lab_mdxg_TermLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BT Term Loan</link:label>
    <link:label id="lab_mdxg_TermLoanAgreementMember_label_en-US" xlink:label="lab_mdxg_TermLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Agreement [Member]</link:label>
    <link:label id="lab_mdxg_TermLoanAgreementMember_documentation_en-US" xlink:label="lab_mdxg_TermLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TermLoanAgreementMember" xlink:href="mdxg-20220930.xsd#mdxg_TermLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_TermLoanAgreementMember" xlink:to="lab_mdxg_TermLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_ScheduleOfInterestExpenseTableTextBlock_843ecb74-04bb-4973-a6da-3b66a294cbb1_terseLabel_en-US" xlink:label="lab_mdxg_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense</link:label>
    <link:label id="lab_mdxg_ScheduleOfInterestExpenseTableTextBlock_label_en-US" xlink:label="lab_mdxg_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Interest Expense [Table Text Block]</link:label>
    <link:label id="lab_mdxg_ScheduleOfInterestExpenseTableTextBlock_documentation_en-US" xlink:label="lab_mdxg_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ScheduleOfInterestExpenseTableTextBlock" xlink:href="mdxg-20220930.xsd#mdxg_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_ScheduleOfInterestExpenseTableTextBlock" xlink:to="lab_mdxg_ScheduleOfInterestExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9c6f7c38-44d8-4f9c-9eb9-6d1f78889ad8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b6cbd14e-0c7d-48ef-a92a-0f0dc3bcc8eb_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a11cd497-8aad-4f15-a922-8adb55b82caa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_d2450c49-6c6f-4c38-b75b-eda30da6d260_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_30ad1a79-e87e-4426-a638-4fb4aaa7c3de_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8e50825f-6038-4eb4-8d68-efad1dd402bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_91240a0d-340f-450f-bd51-63016489f797_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_724b27af-19b4-47ea-80d6-78a8a0118ace_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated sales returns</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_959a2c68-a71d-444e-9253-448fc0fde67b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_8efc1df1-ff71-419f-8d8f-3df3f55d3cbb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bce5b854-0c7a-419e-b101-61903aace2e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_52bce29d-400f-4272-8811-e37e5fb65583_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d03d3653-d094-4c14-8dc4-435fb569023c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Net</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9ce8185d-ca95-4b56-83bd-b110f02deb23_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f790a53b-ac8b-4c8d-8908-9d29de52669c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_AssetRetirementCostMember_8c13121a-4a45-4cbf-baa0-51b5ba43525b_terseLabel_en-US" xlink:label="lab_mdxg_AssetRetirementCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset retirement cost</link:label>
    <link:label id="lab_mdxg_AssetRetirementCostMember_label_en-US" xlink:label="lab_mdxg_AssetRetirementCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Cost [Member]</link:label>
    <link:label id="lab_mdxg_AssetRetirementCostMember_documentation_en-US" xlink:label="lab_mdxg_AssetRetirementCostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AssetRetirementCostMember" xlink:href="mdxg-20220930.xsd#mdxg_AssetRetirementCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_AssetRetirementCostMember" xlink:to="lab_mdxg_AssetRetirementCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4c819559-e3f0-4962-bca7-7a7cbe528bad_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_20832210-13b1-4256-b8e6-f2d1def503be_terseLabel_en-US" xlink:label="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="mdxg-20220930.xsd#mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3b6f1115-82b7-4bc8-bfad-770b9d601d02_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_705164e6-294e-4869-bbd5-bc4d761ebda1_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4aadb7fa-0364-494a-9e88-ab44f8733c21_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_9d7d95ea-af3d-4f87-baea-52887a504710_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividends, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDividendsAdjustment" xlink:to="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_AccruedAdministrativeFeesCurrent_0136780a-42b0-46dc-928a-85794430997c_terseLabel_en-US" xlink:label="lab_mdxg_AccruedAdministrativeFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued group purchasing organization fees</link:label>
    <link:label id="lab_mdxg_AccruedAdministrativeFeesCurrent_label_en-US" xlink:label="lab_mdxg_AccruedAdministrativeFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Administrative Fees, Current</link:label>
    <link:label id="lab_mdxg_AccruedAdministrativeFeesCurrent_documentation_en-US" xlink:label="lab_mdxg_AccruedAdministrativeFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Administrative Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedAdministrativeFeesCurrent" xlink:href="mdxg-20220930.xsd#mdxg_AccruedAdministrativeFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_AccruedAdministrativeFeesCurrent" xlink:to="lab_mdxg_AccruedAdministrativeFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7b5c32a5-9c16-4bc8-a6ac-2724ce1716ff_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9b2cbd2d-f5ec-47e8-8274-3306c5baecc5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_92e288a1-a721-426e-a518-f606d02e6ed1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired_6d5edab9-f8ba-4a02-a6c4-a3938d50ea36_terseLabel_en-US" xlink:label="lab_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period (in days)</link:label>
    <link:label id="lab_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired_label_en-US" xlink:label="lab_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Termination Notice Period Required</link:label>
    <link:label id="lab_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired_documentation_en-US" xlink:label="lab_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Termination Notice Period Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired" xlink:href="mdxg-20220930.xsd#mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired" xlink:to="lab_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_e00cd7c9-4bf1-45cf-936b-688c1da5d8e2_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock unit awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_45ae6566-c77b-43f8-b09c-7250256022e3_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Performance Stock Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba6f41fe-0e9c-4691-8b7c-37f6e8bfb010_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d28325ee-c2b2-45ef-8c72-09b8f3411f27_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b527db9a-21b7-4d14-9c74-82f234b8d502_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fe9245c6-96b9-4d95-a868-59cef06b237c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8a2f2f7-cfc2-461d-92e1-015438219a57_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_47e13eb0-696d-45b1-a4a6-84b3b98543e0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Term Loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f629a08a-b679-4dc5-8340-ca0c739abb5f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_1a8da72c-7459-4624-98e9-982555b808c0_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_80b4514f-e8ab-4efe-8f60-5830849e479a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_867afacb-bf96-44ca-80de-f1f4f59d15ee_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock Series B; $0.001 par value; 100,000 shares authorized, issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8ab6af50-7185-4a42-bdc3-f7cd755db9c1_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock, outstanding, beginning</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8a0495bf-9c69-4968-bcc7-2149cfaf1007_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock, outstanding, ending</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_7627c318-b777-4395-aae7-52a885843cc8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbd49b2c-e7bc-4fa3-bb9f-deabf17647f4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_128db0c1-656d-4c98-a9db-32d13c7cb279_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' (deficit) equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f9371bb3-84b2-4b0c-8bee-5560a03110b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_bc5ee164-00d8-434c-a8d5-18cdb77e273e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_6cfd0d2b-4c24-4943-800a-d4ef0f068315_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_08b3f9e6-a75a-47a5-a5e5-08381280dde2_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4751606a-440a-405a-b1f9-4db9b9a726a7_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments_5d5f0b7c-4939-4ea5-8ac6-1cd942d92ca5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: antidilutive adjustments</link:label>
    <link:label id="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments_label_en-US" xlink:label="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Preferred Stock Dividends and Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_8daea9c5-a5e0-4f9f-b8a6-3d539424aa7e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions to sales agents</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Commission, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d8590e1-d10a-417d-91f2-e7dd14e7aa3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_683ffd40-28d2-40b8-9e2f-e05d15e5617e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses expected to be recognized over a weighted-average period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_829d46e2-52e1-4686-b58a-bcd8059a96ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Activity Summary - Finite-lived</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1f539386-554d-4538-b2e9-753398bb6f37_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_8b8bde17-05a9-4645-9b57-f7b6b3c57f66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_517f7ad1-2e0c-40d1-827b-2a04eb7d7ca3_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_adf5f5a4-bbd2-490c-a7e7-a7a08bac3528_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_TemporaryEquityConversionThresholdTradingDays_f8ca22e2-3ada-4c9f-9a5d-a1bb87aa673e_terseLabel_en-US" xlink:label="lab_mdxg_TemporaryEquityConversionThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days within consecutive day trading period common stock must exceed trigger conversion price</link:label>
    <link:label id="lab_mdxg_TemporaryEquityConversionThresholdTradingDays_label_en-US" xlink:label="lab_mdxg_TemporaryEquityConversionThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Conversion, Threshold Trading Days</link:label>
    <link:label id="lab_mdxg_TemporaryEquityConversionThresholdTradingDays_documentation_en-US" xlink:label="lab_mdxg_TemporaryEquityConversionThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Conversion, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityConversionThresholdTradingDays" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityConversionThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_TemporaryEquityConversionThresholdTradingDays" xlink:to="lab_mdxg_TemporaryEquityConversionThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_1a5f81d2-95dd-478c-928c-729ce9fc1532_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a7bb6aca-a157-43ca-ae78-e652bf5015e7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_08c7dc08-c7f5-427d-9b4d-08a19c7fdf17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_2c937726-4753-4e01-a3da-253ea417560f_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents and know-how</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0ae1bd35-7548-425c-aa37-c6d77e2a4ab7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise_bcd85c8c-0b6c-4839-8ab4-b65a9ce9c4bc_terseLabel_en-US" xlink:label="lab_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of non-cash consideration received for option exercises</link:label>
    <link:label id="lab_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise_label_en-US" xlink:label="lab_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value Of Non-Cash Consideration Received For Option Exercise</link:label>
    <link:label id="lab_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise_documentation_en-US" xlink:label="lab_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value Of Non-Cash Consideration Received For Option Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise" xlink:href="mdxg-20220930.xsd#mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise" xlink:to="lab_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_AccruedRebates_cb9c62ff-6f81-445d-ad77-ae85e68f80a2_terseLabel_en-US" xlink:label="lab_mdxg_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates</link:label>
    <link:label id="lab_mdxg_AccruedRebates_label_en-US" xlink:label="lab_mdxg_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:label id="lab_mdxg_AccruedRebates_documentation_en-US" xlink:label="lab_mdxg_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedRebates" xlink:href="mdxg-20220930.xsd#mdxg_AccruedRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_AccruedRebates" xlink:to="lab_mdxg_AccruedRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_5642c876-5c2c-471d-86d4-d7c698921902_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4821d8c8-4980-458d-8f30-26fa9e9cb91b_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_578248f4-4792-462a-a9a0-1edbcf76778b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f23ccbe3-54ab-4576-8e3b-d7943f85ee7a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_910e4f4e-fd6b-419d-aceb-fe89b3ed4a86_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_99cbd6cd-5c02-4186-bb59-62d84856d8a1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1306f27f-2544-4fa1-aef4-e99154153f75_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_9110362a-bb4e-462e-ad06-404539a26ac0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_31d95df5-7623-47e5-89b5-5b7829cd3d28_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_a8adda59-356e-4359-bf9c-f206608dda11_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37138573-cbd6-4819-a2f3-e5cb7102c2e4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bf2daf5c-c141-4c0d-ada0-f1366f62005c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_c03d4c5d-333d-42e6-89eb-ec91aba4f85a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_d35b18b9-973f-4c30-a77d-d383390cc54b_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing stock price on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_47356e40-0fea-41cd-9fb1-ab9c1e5e2325_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a0cb26b6-7739-44d1-8a98-a856171790ac_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_8b65150d-11bb-4a80-b0dc-77ff45f01fcb_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_NumberOfProducts_87c13cc9-9e38-4b97-b55d-033fa927edcb_terseLabel_en-US" xlink:label="lab_mdxg_NumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products</link:label>
    <link:label id="lab_mdxg_NumberOfProducts_label_en-US" xlink:label="lab_mdxg_NumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Products</link:label>
    <link:label id="lab_mdxg_NumberOfProducts_documentation_en-US" xlink:label="lab_mdxg_NumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_NumberOfProducts" xlink:href="mdxg-20220930.xsd#mdxg_NumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_NumberOfProducts" xlink:to="lab_mdxg_NumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_b5370745-e959-4853-aea0-a235165a35c6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_07a393b2-ca06-4be1-9755-acf5056e5ba8_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_3522f255-7c75-4724-bfc4-ea5e2eed28d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_be9ea4dd-6e3e-4aaf-8536-07fab5d1b941_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock canceled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b19d115b-b676-4969-9d76-d5acc66d6db4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0e940938-fc60-4571-8ab5-99915a0835fb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a4278572-e573-4bd4-833a-244f43c53f48_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_Section351ProductsMember_ca6a6c5a-cebf-4826-853a-b227fa573c6c_terseLabel_en-US" xlink:label="lab_mdxg_Section351ProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 351</link:label>
    <link:label id="lab_mdxg_Section351ProductsMember_label_en-US" xlink:label="lab_mdxg_Section351ProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 351 Products [Member]</link:label>
    <link:label id="lab_mdxg_Section351ProductsMember_documentation_en-US" xlink:label="lab_mdxg_Section351ProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 351 Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_Section351ProductsMember" xlink:href="mdxg-20220930.xsd#mdxg_Section351ProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_Section351ProductsMember" xlink:to="lab_mdxg_Section351ProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_320cb302-d1bc-4037-87ee-06a99afe17bb_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and clean room equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_8b61f8be-620b-45c0-be34-0bd875eefb57_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fe7c9bb3-d87d-4786-9cdd-10e4100d4b42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_8a2a5337-ca18-49a5-b8ef-627757d444bd_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock unit awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4a85fedb-076a-4f7c-bbce-b4837245ffd0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cea96b7e-f082-4623-b5f5-e4ceda75cffe_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_dc12011a-bdfb-407a-a35e-5e591db91df3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_SeparationAgreementMember_feec966a-32c8-463d-843c-97176bb0a9cb_terseLabel_en-US" xlink:label="lab_mdxg_SeparationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Agreement</link:label>
    <link:label id="lab_mdxg_SeparationAgreementMember_label_en-US" xlink:label="lab_mdxg_SeparationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Agreement [Member]</link:label>
    <link:label id="lab_mdxg_SeparationAgreementMember_documentation_en-US" xlink:label="lab_mdxg_SeparationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_SeparationAgreementMember" xlink:href="mdxg-20220930.xsd#mdxg_SeparationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_SeparationAgreementMember" xlink:to="lab_mdxg_SeparationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a0b85f58-f87b-4136-b098-b781f3c2f8cb_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_CreditFacilitiesMember_4bc89c08-6d86-40f8-9236-779cf67d2b4a_terseLabel_en-US" xlink:label="lab_mdxg_CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facilities</link:label>
    <link:label id="lab_mdxg_CreditFacilitiesMember_label_en-US" xlink:label="lab_mdxg_CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facilities [Member]</link:label>
    <link:label id="lab_mdxg_CreditFacilitiesMember_documentation_en-US" xlink:label="lab_mdxg_CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_CreditFacilitiesMember" xlink:href="mdxg-20220930.xsd#mdxg_CreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_CreditFacilitiesMember" xlink:to="lab_mdxg_CreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_DebtCovenantMinimumLiquidity_0556a5a1-3e8b-4b2e-ac41-c65d214d9e07_terseLabel_en-US" xlink:label="lab_mdxg_DebtCovenantMinimumLiquidity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, minimum liquidity</link:label>
    <link:label id="lab_mdxg_DebtCovenantMinimumLiquidity_label_en-US" xlink:label="lab_mdxg_DebtCovenantMinimumLiquidity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Minimum Liquidity</link:label>
    <link:label id="lab_mdxg_DebtCovenantMinimumLiquidity_documentation_en-US" xlink:label="lab_mdxg_DebtCovenantMinimumLiquidity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Minimum Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtCovenantMinimumLiquidity" xlink:href="mdxg-20220930.xsd#mdxg_DebtCovenantMinimumLiquidity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_DebtCovenantMinimumLiquidity" xlink:to="lab_mdxg_DebtCovenantMinimumLiquidity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3d861b88-69bb-482e-b6ab-7990cd88d0ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_5bcf1f9f-fbfa-4f18-b19b-f653d8e3fe4f_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_d2e5633a-c7b4-4d41-bc16-d5fc1ffa5074_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5b07359e-9e73-4199-893f-492b7e5bda05_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_1ce69a39-73e7-4463-8911-b4046a3bf64c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_93acffd7-c4de-4bb5-964e-35e72cb289b3_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_f27db698-502d-45bd-9426-c6c230bd94f2_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b99454bb-0100-4fc9-ad2c-a0b4d2360e5f_netLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_f2b590e4-21d7-4439-84e9-9e7117e5c7dd_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_798dc231-8b3a-43ff-9198-f6aab8a3817f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_345f1a33-0ff3-4840-8c08-f13385098dba_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7cc15726-076f-467d-a378-97e34e703a36_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_42dc9080-9418-41a1-a3ee-7f606aed107d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate &amp; Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_28996e6e-831c-4e09-a288-e901b7b3e741_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_InternationalSection351Member_b993efbe-e4e1-431c-ae75-35d05d76b2ef_terseLabel_en-US" xlink:label="lab_mdxg_InternationalSection351Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Section 351</link:label>
    <link:label id="lab_mdxg_InternationalSection351Member_label_en-US" xlink:label="lab_mdxg_InternationalSection351Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Section 351 [Member]</link:label>
    <link:label id="lab_mdxg_InternationalSection351Member_documentation_en-US" xlink:label="lab_mdxg_InternationalSection351Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Section 351</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InternationalSection351Member" xlink:href="mdxg-20220930.xsd#mdxg_InternationalSection351Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_InternationalSection351Member" xlink:to="lab_mdxg_InternationalSection351Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c02d2604-0bac-4fb5-8143-d0516475f50f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_455e24ca-a8aa-423e-b475-7ee90d3c3363_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' (deficit) equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_31535a52-ce08-4283-805b-ca153b45b60c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9f885376-9923-439a-847f-afddebfcd918_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_012e41bb-1d1c-45b4-a9aa-a8d67136406a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0b7840d2-346a-430d-9506-927470838c35_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets arising from finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8f299a9d-809b-48fc-af7e-8dd217dd8c45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_cf6a215d-db3d-4e8a-bba3-3a2631cabd6b_terseLabel_en-US" xlink:label="lab_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hayfin Loan Agreement Delayed Draw Term Loan</link:label>
    <link:label id="lab_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_label_en-US" xlink:label="lab_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hayfin Loan Agreement Delayed Draw Term Loan [Member]</link:label>
    <link:label id="lab_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_documentation_en-US" xlink:label="lab_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hayfin Loan Agreement Delayed Draw Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember" xlink:to="lab_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_18d44f5c-0660-4883-a3e1-b95aa94d54c6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9090bb8-1f10-4799-a6d2-fe5c9f60b227_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage_6b7d9caa-0895-4505-b86d-f432b0f96c69_terseLabel_en-US" xlink:label="lab_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional commitment fee (percent)</link:label>
    <link:label id="lab_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:label id="lab_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage_documentation_en-US" xlink:label="lab_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage" xlink:to="lab_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dbd5bf46-c2f8-4ce7-8409-fa84569ce27f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb0e98d0-c079-45d4-90d2-51dec587400c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash resulting from changes in:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ea24662a-31be-4d33-83e4-9a37618cb5c2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ecbae72b-4088-413d-bd3d-36f723406b32_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_c82be560-d0d7-4628-8d86-c92c739e6d0d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment_db23f8d5-43f8-4913-bfff-3736422a9fbf_terseLabel_en-US" xlink:label="lab_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining prepaid expenses on long-term purchase commitment</link:label>
    <link:label id="lab_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment_label_en-US" xlink:label="lab_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Prepaid Expenses On Long-Term Purchase Commitment</link:label>
    <link:label id="lab_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment_documentation_en-US" xlink:label="lab_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Prepaid Expenses On Long-Term Purchase Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment" xlink:href="mdxg-20220930.xsd#mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment" xlink:to="lab_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6dfce46f-1eea-42e0-ab72-b1a84a2735d6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_2f9578d4-b3ba-4643-81af-bc2df48e294b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b6b20370-17e9-4f4f-bdfd-2b49ecd9cbd4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_aac700cd-c750-4359-a592-949570851403_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_455be293-82fe-4185-8bbd-cf52a1161ce8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8e39fcb3-9a30-4918-86f8-bee71dd22a12_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_435c6e52-7bad-4cb6-bc90-e00695c46e6c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_fec69b46-3a31-4277-9c75-ee1f50f68b3c_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_141e155e-87bf-4505-8f58-93dbdc989dc1_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_83089b39-dbd4-4c75-a8d6-9f439695907e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_2ce1ce91-94bf-4155-9140-e73b424d4ed8_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B convertible preferred stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ede25ef7-3b33-4ab0-9289-2e51c1d06883_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f0f504cd-094f-4ecd-9108-64c32ae95a5a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying value, indefinite lived</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_f0e846ab-1faf-4032-815d-ef35929532b5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_00a7a5ff-33f2-4ade-a7cb-1c8fc1162350_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_63e6326f-bdd6-4514-be46-85407e24f742_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f38c030c-27d2-48be-a781-5196393015e1_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_TemporaryEquityDividendRatePercentage_5b9ac815-e7b1-4761-b4ad-09c0fc83331c_terseLabel_en-US" xlink:label="lab_mdxg_TemporaryEquityDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B convertible stock, cumulative dividend (percent)</link:label>
    <link:label id="lab_mdxg_TemporaryEquityDividendRatePercentage_label_en-US" xlink:label="lab_mdxg_TemporaryEquityDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividend Rate, Percentage</link:label>
    <link:label id="lab_mdxg_TemporaryEquityDividendRatePercentage_documentation_en-US" xlink:label="lab_mdxg_TemporaryEquityDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividend Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityDividendRatePercentage" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityDividendRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_TemporaryEquityDividendRatePercentage" xlink:to="lab_mdxg_TemporaryEquityDividendRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ed2aa486-31f4-4d3c-93f8-eeababe53459_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d2d1df58-2279-4794-9972-387bbca66308_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableTable_ed0ba165-e925-4b04-8589-c66bba4291ea_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable [Table]</link:label>
    <link:label id="lab_us-gaap_DividendsPayableTable_label_en-US" xlink:label="lab_us-gaap_DividendsPayableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableTable" xlink:to="lab_us-gaap_DividendsPayableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ac8171a3-85c6-4132-a24b-3fe5f7e3a6e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_eea61e30-93c4-4f28-ac3d-e9419bafc75e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_cb6ba78d-2ff2-4e04-ae70-6e8b4853aa09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested options expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7061c34e-3edb-4b8f-aa28-c53b79e6fa37_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7b7cab72-3c12-4336-a932-04e62dd9accf_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_98f17ae3-c0e3-4e09-acd8-c63d2cee0a78_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a5019caa-fbaf-42e9-84f3-cc54bd2c7e80_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent_9a62f765-9624-49c9-bd86-79e10e14ddc2_terseLabel_en-US" xlink:label="lab_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, prepayment make-whole premium as percent of prepaid principal (percent)</link:label>
    <link:label id="lab_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent_label_en-US" xlink:label="lab_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty As Percent Of Prepaid Principal, Percent</link:label>
    <link:label id="lab_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent_documentation_en-US" xlink:label="lab_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty As Percent Of Prepaid Principal, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent" xlink:to="lab_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_4820b1af-1ab3-41d7-8c29-af671082a445_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels_62399860-1f41-4d07-a4ff-4cdf2eaefa8c_terseLabel_en-US" xlink:label="lab_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of primary distribution channels</link:label>
    <link:label id="lab_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels_label_en-US" xlink:label="lab_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Number Of Distribution Channels</link:label>
    <link:label id="lab_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels_documentation_en-US" xlink:label="lab_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Number Of Distribution Channels</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels" xlink:href="mdxg-20220930.xsd#mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels" xlink:to="lab_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d3d6dfa3-41b4-41cd-8e55-e7f108b0688b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e2e0820-419f-4f30-bf30-1831c98898e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_45314255-2c75-4553-b713-b7e1c1745d2e_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_WoundSurgicalMember_45760160-9a85-4eaa-8ec7-5e58dd367cb1_terseLabel_en-US" xlink:label="lab_mdxg_WoundSurgicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound &amp; Surgical</link:label>
    <link:label id="lab_mdxg_WoundSurgicalMember_label_en-US" xlink:label="lab_mdxg_WoundSurgicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound &amp; Surgical [Member]</link:label>
    <link:label id="lab_mdxg_WoundSurgicalMember_documentation_en-US" xlink:label="lab_mdxg_WoundSurgicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care &amp; Surgical Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_WoundSurgicalMember" xlink:href="mdxg-20220930.xsd#mdxg_WoundSurgicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_WoundSurgicalMember" xlink:to="lab_mdxg_WoundSurgicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f7047c52-e94f-455d-b79a-5230ff2128e9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleSharesIssuable_90cace7e-214c-4ad0-8c5a-b91225d6ca24_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible shares issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleSharesIssuable_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_PatentsinProcessMember_c77061e2-0d8e-4ddb-9894-417e06d4d3aa_terseLabel_en-US" xlink:label="lab_mdxg_PatentsinProcessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents in Process</link:label>
    <link:label id="lab_mdxg_PatentsinProcessMember_label_en-US" xlink:label="lab_mdxg_PatentsinProcessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents in Process [Member]</link:label>
    <link:label id="lab_mdxg_PatentsinProcessMember_documentation_en-US" xlink:label="lab_mdxg_PatentsinProcessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PatentsinProcessMember" xlink:href="mdxg-20220930.xsd#mdxg_PatentsinProcessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_PatentsinProcessMember" xlink:to="lab_mdxg_PatentsinProcessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7b5a2424-072a-4626-b84a-f4232447ac9f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_640c17b5-f857-46d9-b75b-13cca2ccd99f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_78cc4e85-c2d9-4f00-82d6-692bac500e6f_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_784a056e-980f-4727-bd0a-fcaeeb297ada_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_InsuranceProvidersMember_b85e6e8e-f38c-473b-a8ba-8917e28ee03f_terseLabel_en-US" xlink:label="lab_mdxg_InsuranceProvidersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Providers</link:label>
    <link:label id="lab_mdxg_InsuranceProvidersMember_label_en-US" xlink:label="lab_mdxg_InsuranceProvidersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Providers [Member]</link:label>
    <link:label id="lab_mdxg_InsuranceProvidersMember_documentation_en-US" xlink:label="lab_mdxg_InsuranceProvidersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Providers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InsuranceProvidersMember" xlink:href="mdxg-20220930.xsd#mdxg_InsuranceProvidersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_InsuranceProvidersMember" xlink:to="lab_mdxg_InsuranceProvidersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_ac43aebb-5508-4ed6-aef6-75b7dbcd854b_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0861f4d6-172c-4940-bedc-6bc9883ba068_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_ac567af4-4689-48c3-aecd-359189808d1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0d6acc17-d2ef-4dc1-90b5-49ae32d7b3d7_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_debcc06a-f4a7-49bd-b8e3-5ff5d0b692e2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9cb8b863-7128-4b2b-a226-6b16e2f1202f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_14a87758-1a99-4730-a669-ded8934c2402_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_49aa5168-d54b-4b84-967e-34ef88efafd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3d114d0b-af64-4ac4-b1b9-629ddc520c75_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_520e5905-31e4-47eb-b0b5-345f1537fd65_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_7636409a-d978-4c8a-94aa-34450f28101e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ff9e04d6-06d7-407a-a973-def5e68c0fff_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_0dff6c6e-5d95-4af9-8f27-179b6826ea97_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_df78a06f-0bfd-42af-98c8-96c9055c8e85_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_37d23966-79ec-42a1-9893-a968bccc9bf1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_48ecf4a7-a13e-417a-92d0-1333a152b8a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger_ff9ee07d-944b-41b8-8e19-d000dd2fb557_terseLabel_en-US" xlink:label="lab_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B preferred stock, minimum percentage of conversion stock price to trigger conversion (percent)</link:label>
    <link:label id="lab_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger_label_en-US" xlink:label="lab_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Conversion, Threshold Percentage of Stock Price Trigger</link:label>
    <link:label id="lab_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger_documentation_en-US" xlink:label="lab_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Conversion, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger" xlink:to="lab_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_3199cfbe-6896-4889-88a7-2df3005a49fa_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a8fadb79-e7a1-4504-bcc9-914578ae81df_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_19952238-2963-4cf3-87ec-4630e4d352fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_33208c74-f430-4dc9-8631-229d8ab9f768_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fc66aaff-141d-43e3-8c68-bd7eba25952f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_60a8dc0f-299a-4a37-98e8-af2452f08a20_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e13f4eab-a92c-444d-b912-11de929de8da_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1a6e340e-7bb2-4424-b5e1-35e32a2e8b48_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ce880f74-a639-4c90-8ce8-5e9d7ab62e97_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_65d4ebc6-6e70-4c6d-9663-59364722c8c8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d183042-b3f7-414d-9a09-c9112d465698_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding adjusted for potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_941d0911-575d-4159-b8ff-89a9cb99648b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5795c953-fad8-425f-b60f-d76b09ae992e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_a332207a-80a6-4ed3-a3d6-9cad5a0e9159_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_RegenerativeMedicineSegmentMember_95b6072b-2d3d-4528-bc25-568ba9de814b_terseLabel_en-US" xlink:label="lab_mdxg_RegenerativeMedicineSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regenerative Medicine</link:label>
    <link:label id="lab_mdxg_RegenerativeMedicineSegmentMember_label_en-US" xlink:label="lab_mdxg_RegenerativeMedicineSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regenerative Medicine Segment [Member]</link:label>
    <link:label id="lab_mdxg_RegenerativeMedicineSegmentMember_documentation_en-US" xlink:label="lab_mdxg_RegenerativeMedicineSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regenerative Medicine Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RegenerativeMedicineSegmentMember" xlink:href="mdxg-20220930.xsd#mdxg_RegenerativeMedicineSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_RegenerativeMedicineSegmentMember" xlink:to="lab_mdxg_RegenerativeMedicineSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_2efedbef-8b6e-4d5b-b859-afa3c0754f55_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5774a6bd-42b5-45a7-88e3-46343d1430cf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.001 par value; 187,500,000 shares authorized; 113,670,017 issued and 113,668,179 outstanding at September&#160;30, 2022 and 112,703,926 issued and 111,925,216 outstanding at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_LongTermDebtMaturityAfterYearFour_66a33880-f5ec-4971-8bff-c15686c76c40_terseLabel_en-US" xlink:label="lab_mdxg_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_mdxg_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_mdxg_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Four</link:label>
    <link:label id="lab_mdxg_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_mdxg_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_LongTermDebtMaturityAfterYearFour" xlink:href="mdxg-20220930.xsd#mdxg_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_LongTermDebtMaturityAfterYearFour" xlink:to="lab_mdxg_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4c96ccae-5d1f-4896-809a-b71547936dba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_SegmentContribution_eba50033-d13f-454b-85b7-5dbebafa5e90_totalLabel_en-US" xlink:label="lab_mdxg_SegmentContribution" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment contribution</link:label>
    <link:label id="lab_mdxg_SegmentContribution_label_en-US" xlink:label="lab_mdxg_SegmentContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Contribution</link:label>
    <link:label id="lab_mdxg_SegmentContribution_documentation_en-US" xlink:label="lab_mdxg_SegmentContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_SegmentContribution" xlink:href="mdxg-20220930.xsd#mdxg_SegmentContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_SegmentContribution" xlink:to="lab_mdxg_SegmentContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e296f196-52e0-4058-820d-2c4d56f28510_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_ScheduleOfDepreciationTableTextBlock_06500b73-f5cf-42bb-aaa0-8c2f689434c9_terseLabel_en-US" xlink:label="lab_mdxg_ScheduleOfDepreciationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Depreciation Expense</link:label>
    <link:label id="lab_mdxg_ScheduleOfDepreciationTableTextBlock_label_en-US" xlink:label="lab_mdxg_ScheduleOfDepreciationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Depreciation [Table Text Block]</link:label>
    <link:label id="lab_mdxg_ScheduleOfDepreciationTableTextBlock_documentation_en-US" xlink:label="lab_mdxg_ScheduleOfDepreciationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ScheduleOfDepreciationTableTextBlock" xlink:href="mdxg-20220930.xsd#mdxg_ScheduleOfDepreciationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_ScheduleOfDepreciationTableTextBlock" xlink:to="lab_mdxg_ScheduleOfDepreciationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_84a6ecdc-8f24-43dd-806e-47959d10f4c2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_2d757659-64d1-4c40-9fb2-4ebbc44cc0b4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3ac0f275-f5de-485d-a391-028dfdce3c35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_a3bdc587-b4d4-4d27-9cfb-8ada02ad2874_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Customers</link:label>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Directly to Consumer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:to="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_67aa5b1c-6302-448c-b27b-e31525cd6c80_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_36fc26a1-c9bf-488a-be55-b91e3fab02f8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_18d7f2f2-b8b4-425e-800d-c8d2bef07060_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_a7f5c413-51c3-451e-86d8-5cf709e307af_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:to="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ffa588d9-d519-4c9c-bfbf-5ac604c22389_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d9ad809f-d863-4ad8-ae12-aeb932ad2657_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5163eb7f-3ece-4c42-95fa-c186bf39a01b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_267f8f3c-631c-4052-9ea8-6c1d71cab2b2_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5dc49aee-114e-4efb-9408-435723597717_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5df861c0-29c7-4232-98da-5631f34b3442_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss available to common stockholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7002f2a1-116f-4735-a1c8-19b871c239d0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss available to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8324d0cb-9514-4ee1-9ed5-4e873015cad0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss available to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f4668bec-d8fc-4fbd-9364-6c879be023ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4b22ac5e-73dc-40a0-86a3-b8ab8255e854_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_853246b3-25a5-4321-bb14-548d6cf88cf3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4b69e2a5-bfc6-43d9-aeaa-35f47af81d58_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3677ae3d-bab9-4e8c-bbd1-fb35c3df1945_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9585de09-670a-43d4-ad8b-2b21f886145f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a034348b-1285-4076-befc-181fe4aae756_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndNontradeReceivableTextBlock_25877119-f107-4581-833b-e8eb447d7494_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Nontrade Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsAndNontradeReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Nontrade Receivable [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:to="lab_us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_RegenerativeMedicineMember_90a919ae-0ed2-4918-aa6a-b4726112feee_terseLabel_en-US" xlink:label="lab_mdxg_RegenerativeMedicineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regenerative Medicine &amp; Biologics Innovation</link:label>
    <link:label id="lab_mdxg_RegenerativeMedicineMember_label_en-US" xlink:label="lab_mdxg_RegenerativeMedicineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regenerative Medicine [Member]</link:label>
    <link:label id="lab_mdxg_RegenerativeMedicineMember_documentation_en-US" xlink:label="lab_mdxg_RegenerativeMedicineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regenerative Medicine &amp; Biologics Innovation Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RegenerativeMedicineMember" xlink:href="mdxg-20220930.xsd#mdxg_RegenerativeMedicineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_RegenerativeMedicineMember" xlink:to="lab_mdxg_RegenerativeMedicineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_fc79fdb8-82a7-413a-b173-6c7529b12f42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Sales and Segment Contribution for Each Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_a91e9a4a-66cb-4205-9feb-c0c4f31324a5_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f9238bcd-eb3e-4e84-95d8-bf233f7cf659_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_564d4ee4-17f2-4831-a8ad-76dbe7e4e0de_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_328c70bc-81d1-4ecd-9fb4-db585be84086_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a95c830a-4813-4cf3-b911-bdcea18a44ab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_AdvancedWoundCareTissueAndOtherMember_b2051f68-4417-4197-811c-0ab220f3d1e2_terseLabel_en-US" xlink:label="lab_mdxg_AdvancedWoundCareTissueAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tissue/Other</link:label>
    <link:label id="lab_mdxg_AdvancedWoundCareTissueAndOtherMember_label_en-US" xlink:label="lab_mdxg_AdvancedWoundCareTissueAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Wound Care, Tissue And Other [Member]</link:label>
    <link:label id="lab_mdxg_AdvancedWoundCareTissueAndOtherMember_documentation_en-US" xlink:label="lab_mdxg_AdvancedWoundCareTissueAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Wound Care, Tissue And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AdvancedWoundCareTissueAndOtherMember" xlink:href="mdxg-20220930.xsd#mdxg_AdvancedWoundCareTissueAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_AdvancedWoundCareTissueAndOtherMember" xlink:to="lab_mdxg_AdvancedWoundCareTissueAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_AccruedClinicalTrialsCurrent_3c1fe2cc-5a52-4287-8c4b-3ebcf526844d_terseLabel_en-US" xlink:label="lab_mdxg_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trials</link:label>
    <link:label id="lab_mdxg_AccruedClinicalTrialsCurrent_label_en-US" xlink:label="lab_mdxg_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials, Current</link:label>
    <link:label id="lab_mdxg_AccruedClinicalTrialsCurrent_documentation_en-US" xlink:label="lab_mdxg_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedClinicalTrialsCurrent" xlink:href="mdxg-20220930.xsd#mdxg_AccruedClinicalTrialsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_AccruedClinicalTrialsCurrent" xlink:to="lab_mdxg_AccruedClinicalTrialsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_a4a9e776-4444-44f6-8cd5-7c294c08be6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d54c6331-d11f-4915-9300-9c7a966a3ed4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fd9d4802-a3a3-4919-9749-bc6cf3fe0627_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e389ad66-6435-462c-a075-495890985bbf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock (in percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_7a8c7b61-ac3a-4617-a215-4e69d0333ec8_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_7232f3b4-b0b9-40cc-af92-f058f1f157b9_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation preference (USD per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Liquidation Preference Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b0569952-b4a2-432e-8d73-735967501d92_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e085a208-6a13-4559-bd81-edb542b86e17_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67482343-e95e-41c6-8ea8-40c0babea329_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_a94882e5-559a-4d96-9d2c-5a48afe9ec9e_totalLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total adjustments</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_d09bcd36-a402-43d2-88f7-a82d6d9691ca_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4d1fb931-3087-47bd-a4a8-e98c867b554f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5488dbd2-75ee-453f-8284-9b369c03e329_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredClassBMember_5a2d96a7-8883-4b83-9a5d-00e7ecbf16f1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Class B Convertible Stock</link:label>
    <link:label id="lab_us-gaap_PreferredClassBMember_label_en-US" xlink:label="lab_us-gaap_PreferredClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredClassBMember" xlink:to="lab_us-gaap_PreferredClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d552171a-bdeb-4ad4-af42-85c1365757ee_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_addab67d-a6a0-4028-8c7c-031650668a1b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_AdvancedWoundCareMember_6ab0fafc-88e7-4599-9447-372beffcbc92_terseLabel_en-US" xlink:label="lab_mdxg_AdvancedWoundCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Wound Care</link:label>
    <link:label id="lab_mdxg_AdvancedWoundCareMember_label_en-US" xlink:label="lab_mdxg_AdvancedWoundCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Wound Care [Member]</link:label>
    <link:label id="lab_mdxg_AdvancedWoundCareMember_documentation_en-US" xlink:label="lab_mdxg_AdvancedWoundCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Wound Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AdvancedWoundCareMember" xlink:href="mdxg-20220930.xsd#mdxg_AdvancedWoundCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_AdvancedWoundCareMember" xlink:to="lab_mdxg_AdvancedWoundCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_78f8b601-19bf-4710-aa2e-8b268f8dd106_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments:</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_a0438e9d-21f3-47e6-9dcd-fffa1f587252_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Future Amortization Expense for Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_abb42bb9-cf80-430a-b724-bfb4a3c69a47_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_2032d8dc-4585-49fc-80d0-d9277077b5a7_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ed28bf88-74fd-4898-bde0-2456ae00568e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (annualized)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_333b7a81-ef44-4ef2-9b63-ac7fe02ee42c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_59a09509-fb44-49bb-817f-1a42b0e41cea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_71b86860-777c-4a92-8406-cc5e81a145b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d80de4be-96de-4c79-8b55-54e1e8758a77_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_00fb78b6-7161-4b05-b47f-ecd8bc78190f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_3949d110-61d6-4439-bbca-798f95ef46e8_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ee333b10-b010-4f3a-99e1-c77d80f7c411_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_64fc65ab-7709-4196-9a37-a2ca325adeed_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_f25d1e88-dbe4-41cd-a5bc-8f5a6fb24b3d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_759eb612-f442-4934-babd-166d371e2d57_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2fae0b56-8abf-4954-9f17-c0b01e33da17_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_22803727-986d-4c28-a6cb-918f8c5fcfe8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_63903e88-0721-4a32-9f39-d0735af3279c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableLineItems_4c98a34f-521c-4e31-a275-797953ea4fd3_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable [Line Items]</link:label>
    <link:label id="lab_us-gaap_DividendsPayableLineItems_label_en-US" xlink:label="lab_us-gaap_DividendsPayableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableLineItems" xlink:to="lab_us-gaap_DividendsPayableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_84727749-7817-43d1-a664-4672a9d6e23f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_e5c2d5f5-b548-4349-818d-969ec72b2faf_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5f85d04a-2baf-46c6-be28-6d80b016f365_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_426e02ec-a902-495d-875e-aca7af5a09f6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3e28c6e2-aea0-40f6-bf82-5df91b3b29e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued during period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_942dfc99-2c68-4d2d-bbf6-be842044073f_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_d659afd8-3313-4a2d-8994-276e3340b66f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_ef14f995-ef9d-46fb-8ec3-4c05e1cba349_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fabee916-65bc-4e0d-a649-6b3b7b91b858_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e7ae0454-331c-4e4f-8151-d31ef7c7523a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_a37e2bad-cef8-44e6-ba75-1a59308a047d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_9cb99521-312a-40d3-b87a-de7de48d1094_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of original issue discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_563403ef-ecee-4608-bc81-e0e1735dde9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb31da37-1422-4ef7-9a27-a8c52932179c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2ddeb7a8-87bf-4c47-985b-95befb3dc104_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c70c6d7a-b7fd-4619-b04b-839e3649dd95_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ae5b61bd-0623-4307-8328-10fca3cecb2f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_c0cf435c-023f-46e3-b230-88671bf2c750_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividends</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature_3f0c5468-e18b-4878-8fd7-20267c4bf188_terseLabel_en-US" xlink:label="lab_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of increasing-rate dividend feature</link:label>
    <link:label id="lab_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature_label_en-US" xlink:label="lab_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion Of Increasing-Rate Dividend Feature</link:label>
    <link:label id="lab_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature_documentation_en-US" xlink:label="lab_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion Of Increasing-Rate Dividend Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature" xlink:to="lab_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_6ee8b86e-2fd3-4f40-9f51-2d621041998c_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_8e687816-5bd9-4d98-9465-55538eac7c07_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_f0628ad9-e13a-4a7c-816f-ab7235de127b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_93b667c0-1a33-4c5b-a565-3b7a7d8dee03_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e0a1ecec-128a-4995-9085-d71ced6484f9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_115a56f2-b1e3-4e03-9c73-aecf3f4f68b0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c719a456-f9e3-4ccf-9b2b-ff79d7dd22be_terseLabel_en-US" xlink:label="lab_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="mdxg-20220930.xsd#mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_4283f71c-a072-4609-a896-31693dc4cb33_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays_b39e1a5f-727a-4c73-a9b1-efdbb2ac9db0_terseLabel_en-US" xlink:label="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading days (in days)</link:label>
    <link:label id="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays_label_en-US" xlink:label="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Trading Days</link:label>
    <link:label id="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays_documentation_en-US" xlink:label="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays" xlink:href="mdxg-20220930.xsd#mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays" xlink:to="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fd2cbeb6-8e91-4930-9abe-7b312d8bb565_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_7c358789-dece-44ba-b673-66a0cbf6acbd_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:to="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_87e54be4-947b-494d-9b1c-61b657056841_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8a6c6f47-df19-4890-a501-3fd398bf0ef8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_707021ea-aa62-4674-8ed0-1030ee2441e1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the nine months ended September&#160;30, 2022)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_040385b0-bca1-4117-a837-a5def12c0678_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_f3b64f03-6107-4e8e-870b-916ba4a45f74_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_10899bd6-4f5f-47f0-8aaf-4bc903ec2206_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2f00feae-a89e-4157-af1c-76722484c151_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_56725bb8-4fad-4ee4-a2dc-c61d90c2c5f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original issue discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_17d82f50-79df-4aca-9b9f-202876816b11_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original issue discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_AccruedTravel_5b127eba-20b9-4d4c-8d76-60c71914ae3a_terseLabel_en-US" xlink:label="lab_mdxg_AccruedTravel" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued travel</link:label>
    <link:label id="lab_mdxg_AccruedTravel_label_en-US" xlink:label="lab_mdxg_AccruedTravel" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Travel</link:label>
    <link:label id="lab_mdxg_AccruedTravel_documentation_en-US" xlink:label="lab_mdxg_AccruedTravel" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Travel</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedTravel" xlink:href="mdxg-20220930.xsd#mdxg_AccruedTravel"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_AccruedTravel" xlink:to="lab_mdxg_AccruedTravel" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bdad1506-f04f-4740-b708-a0dfa5e4b0e7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_f1449e8c-8945-44c1-a5ed-b033326ca04d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0ce5b500-1ef5-45ae-b71b-db147eccd0b9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d90ef0aa-14bf-4d06-8894-42e21b1fe022_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d35ae4b8-787a-4932-9ebb-39ccca0caf2a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_SupplementalInformationAbstract_6ecc16ba-9868-450d-8059-c48627708eab_terseLabel_en-US" xlink:label="lab_mdxg_SupplementalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental information</link:label>
    <link:label id="lab_mdxg_SupplementalInformationAbstract_label_en-US" xlink:label="lab_mdxg_SupplementalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Information [Abstract]</link:label>
    <link:label id="lab_mdxg_SupplementalInformationAbstract_documentation_en-US" xlink:label="lab_mdxg_SupplementalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_SupplementalInformationAbstract" xlink:href="mdxg-20220930.xsd#mdxg_SupplementalInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_SupplementalInformationAbstract" xlink:to="lab_mdxg_SupplementalInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_DebtInstrumentInterestRateFloorPercentage_fa038da8-863b-4e55-b6c6-214fe016cb10_terseLabel_en-US" xlink:label="lab_mdxg_DebtInstrumentInterestRateFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, floor (percent)</link:label>
    <link:label id="lab_mdxg_DebtInstrumentInterestRateFloorPercentage_label_en-US" xlink:label="lab_mdxg_DebtInstrumentInterestRateFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Floor Percentage</link:label>
    <link:label id="lab_mdxg_DebtInstrumentInterestRateFloorPercentage_documentation_en-US" xlink:label="lab_mdxg_DebtInstrumentInterestRateFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Floor Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentInterestRateFloorPercentage" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentInterestRateFloorPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_DebtInstrumentInterestRateFloorPercentage" xlink:to="lab_mdxg_DebtInstrumentInterestRateFloorPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_81f23318-04bd-4a1b-a5a6-1333da097bcc_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_64b31184-5c81-4df3-8d93-d9dbe7b4fa78_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d90cca59-ba27-4318-ab2a-ae0a591b5829_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_55dcf075-2a1f-4b17-b6fc-44b7657caa3c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bc6e3e8f-691c-4c2b-90ce-dcc66c3582cc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d6f121c1-0810-45b6-9baf-4ea6e997e61f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock Series A; $0.001 par value; 5,000,000 shares authorized, 0 issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_86de5d2a-1857-4e46-80ee-f01bfc2e290a_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_d3537aa4-8e6c-4c13-8259-0aedc31384e3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSA</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f6cee304-dfb2-4087-a7cb-6edbabd37358_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_84e217eb-29dd-4d3c-af17-80b1101b22ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbc4a1ad-8db3-4403-987c-31c1a00d1ef7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b1c6ff95-fbe7-4119-bfe5-7237a64987f2_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsDomain_1904b269-e225-47a6-94d3-04a8a968e3ff_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends [Domain]</link:label>
    <link:label id="lab_us-gaap_DividendsDomain_label_en-US" xlink:label="lab_us-gaap_DividendsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDomain" xlink:to="lab_us-gaap_DividendsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ee41939e-b95d-4f58-9a1d-deb2c5d164fa_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a770b654-1057-4816-8477-8dd4e2b3b199_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_b85699d7-565b-400b-a359-d77beb4b3d85_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_efdce15b-dcdf-4878-afc0-8416e39f386d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_58c6e5fb-0c79-4679-a0a5-5bf8c48df459_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8c2f269b-65b3-4ca4-a6a0-ba6839a4c9f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bd6f1be6-75aa-4275-8934-543bf78dac0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_TemporaryEquityDeemedDividends_31e14386-6b41-4f87-8d60-c188f4496fc8_terseLabel_en-US" xlink:label="lab_mdxg_TemporaryEquityDeemedDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividends on Series B Preferred Stock</link:label>
    <link:label id="lab_mdxg_TemporaryEquityDeemedDividends_label_en-US" xlink:label="lab_mdxg_TemporaryEquityDeemedDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividends</link:label>
    <link:label id="lab_mdxg_TemporaryEquityDeemedDividends_documentation_en-US" xlink:label="lab_mdxg_TemporaryEquityDeemedDividends" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityDeemedDividends" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityDeemedDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_TemporaryEquityDeemedDividends" xlink:to="lab_mdxg_TemporaryEquityDeemedDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_336a6d19-f461-4af0-9b50-675501536e43_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_ContingencyLossNumberOfSecuritiesClassActions_1b0860ba-a35b-469c-882b-50c834c05a1f_terseLabel_en-US" xlink:label="lab_mdxg_ContingencyLossNumberOfSecuritiesClassActions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities class actions</link:label>
    <link:label id="lab_mdxg_ContingencyLossNumberOfSecuritiesClassActions_label_en-US" xlink:label="lab_mdxg_ContingencyLossNumberOfSecuritiesClassActions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingency Loss, Number Of Securities Class Actions</link:label>
    <link:label id="lab_mdxg_ContingencyLossNumberOfSecuritiesClassActions_documentation_en-US" xlink:label="lab_mdxg_ContingencyLossNumberOfSecuritiesClassActions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingency Loss, Number Of Securities Class Actions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ContingencyLossNumberOfSecuritiesClassActions" xlink:href="mdxg-20220930.xsd#mdxg_ContingencyLossNumberOfSecuritiesClassActions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_ContingencyLossNumberOfSecuritiesClassActions" xlink:to="lab_mdxg_ContingencyLossNumberOfSecuritiesClassActions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d39ea4e9-1b09-4432-9ac7-5eb2cc8c3a52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased for tax withholdings on vesting of restricted stock</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_53c9ef47-72c5-4235-833d-3830a5f97f2b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, convertible preferred stock, and stockholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders_68314e37-9712-4f58-8462-e2480fac3a35_terseLabel_en-US" xlink:label="lab_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of board seats elected by Series B preferred stockholders</link:label>
    <link:label id="lab_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders_label_en-US" xlink:label="lab_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Board Seats Elected By Temporary Equity Holders</link:label>
    <link:label id="lab_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders_documentation_en-US" xlink:label="lab_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Board Seats Elected By Temporary Equity Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders" xlink:href="mdxg-20220930.xsd#mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders" xlink:to="lab_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_691624fe-b43c-4ced-96bd-3640ac7b5f38_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember_edb243c6-49fe-4ed9-ab42-d0d2714d7043_terseLabel_en-US" xlink:label="lab_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Restricted Stock Units, And Performance Stock Units</link:label>
    <link:label id="lab_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember_label_en-US" xlink:label="lab_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Restricted Stock Units, And Performance Stock Units [Member]</link:label>
    <link:label id="lab_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember_documentation_en-US" xlink:label="lab_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Restricted Stock Units, And Performance Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:href="mdxg-20220930.xsd#mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:to="lab_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b58e1fe6-45d2-446d-bfd1-fa1b8693b00e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_882be7f9-cbb3-44a3-ace2-af4c1cf23803_terseLabel_en-US" xlink:label="lab_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Shareholder Return Performance Stock Units Assumptions</link:label>
    <link:label id="lab_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="mdxg-20220930.xsd#mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_WoundSurgicalSegmentMember_7b469ca8-3c67-4003-8918-00814e25cb49_terseLabel_en-US" xlink:label="lab_mdxg_WoundSurgicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound &amp; Surgical</link:label>
    <link:label id="lab_mdxg_WoundSurgicalSegmentMember_label_en-US" xlink:label="lab_mdxg_WoundSurgicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound &amp; Surgical Segment [Member]</link:label>
    <link:label id="lab_mdxg_WoundSurgicalSegmentMember_documentation_en-US" xlink:label="lab_mdxg_WoundSurgicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound &amp; Surgical Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_WoundSurgicalSegmentMember" xlink:href="mdxg-20220930.xsd#mdxg_WoundSurgicalSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_WoundSurgicalSegmentMember" xlink:to="lab_mdxg_WoundSurgicalSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e05de38-476b-4688-a118-b51582917f95_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_f43a266f-0ee8-472f-85eb-358a88a5d83e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments from note receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member_313827b1-5779-4bb0-bbe6-fac646cba8fe_terseLabel_en-US" xlink:label="lab_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted Dividend Rate prior to Quarterly Dividend Payment ending on June 30,2021</link:label>
    <link:label id="lab_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member_label_en-US" xlink:label="lab_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted Dividend Rate prior to Quarterly Dividend Payment ending on June 30,2021 [Member]</link:label>
    <link:label id="lab_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member_documentation_en-US" xlink:label="lab_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted Dividend Rate prior to Quarterly Dividend Payment ending on June 30,2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member" xlink:href="mdxg-20220930.xsd#mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member" xlink:to="lab_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1c35ae79-e803-416c-8a7a-53953460fab6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_03ddb5dc-d999-40c7-a957-e5a1e60ab3aa_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0e769e11-7623-4cbf-81fd-293b228acb57_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_PaymentsMadeOnLongTermPurchaseCommitment_4cc4b595-ee08-42d4-b2fd-349a7fedf928_terseLabel_en-US" xlink:label="lab_mdxg_PaymentsMadeOnLongTermPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made on long-term purchase commitment</link:label>
    <link:label id="lab_mdxg_PaymentsMadeOnLongTermPurchaseCommitment_label_en-US" xlink:label="lab_mdxg_PaymentsMadeOnLongTermPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Made On Long-Term Purchase Commitment</link:label>
    <link:label id="lab_mdxg_PaymentsMadeOnLongTermPurchaseCommitment_documentation_en-US" xlink:label="lab_mdxg_PaymentsMadeOnLongTermPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Made On Long-Term Purchase Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PaymentsMadeOnLongTermPurchaseCommitment" xlink:href="mdxg-20220930.xsd#mdxg_PaymentsMadeOnLongTermPurchaseCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_PaymentsMadeOnLongTermPurchaseCommitment" xlink:to="lab_mdxg_PaymentsMadeOnLongTermPurchaseCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_011baf03-75af-40e9-82cc-30eb1dfb2a53_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_14b2243a-cbe6-49fb-a900-9145caa38523_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_01dac638-73ee-497d-8365-07f2514e4981_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss available to common stockholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_800d9f6a-0fc0-4e97-a8b2-76efcc6e87f9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d7358849-583d-4821-9362-2073accda16a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2b8e0d2d-11bb-468f-a1ae-fba06c6d671b_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_4cdd8752-0bb7-40de-8f9a-a09386b4c30a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ca024d7c-18d7-4f50-b648-2a88ae3484ce_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_87f210a9-4c31-42de-8654-15ce5d40b47c_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tradenames and trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_157d50da-1490-408b-8b0e-8cf53936a151_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on fixed asset disposal</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligationAccretionExpense_d9b4284d-fb6d-4a29-a5ac-bfaa149c90ed_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationAccretionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of asset retirement obligation</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligationAccretionExpense_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationAccretionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Obligation, Accretion Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationAccretionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationAccretionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationAccretionExpense" xlink:to="lab_us-gaap_AssetRetirementObligationAccretionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a07ee99c-4a7c-4ba5-9f13-e65b4b4f222f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation&#160;expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_a3d3dac0-dcc1-42e3-a0cc-23979e9408b3_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ddea629d-df6a-4b52-b92c-5456f64343a5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_2a2004a0-721c-466a-a505-f81edead908a_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_70bfaeae-6439-4e6c-8639-ad50461dabcc_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_433e0deb-d166-4de3-a55f-3946232da2b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_d491548a-6272-436c-b8b6-bcb313971f22_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0e8e1429-5e7e-414d-8eb8-e4c60b560195_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_49689ed3-9fa1-4f26-b21c-41e147eca2b6_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e30db517-ba6f-4d4c-95f3-28ea10d161e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d83695ff-20e9-451c-bfa7-a90092a69568_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_726db3c6-c9d5-4133-92bb-723f99410d92_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_PaymentsForApplicationCostsPatent_3404a24b-e199-4a76-aaa0-bc297889ab78_negatedTerseLabel_en-US" xlink:label="lab_mdxg_PaymentsForApplicationCostsPatent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent application costs</link:label>
    <link:label id="lab_mdxg_PaymentsForApplicationCostsPatent_label_en-US" xlink:label="lab_mdxg_PaymentsForApplicationCostsPatent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Application Costs, Patent</link:label>
    <link:label id="lab_mdxg_PaymentsForApplicationCostsPatent_documentation_en-US" xlink:label="lab_mdxg_PaymentsForApplicationCostsPatent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Application Costs, Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PaymentsForApplicationCostsPatent" xlink:href="mdxg-20220930.xsd#mdxg_PaymentsForApplicationCostsPatent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_PaymentsForApplicationCostsPatent" xlink:to="lab_mdxg_PaymentsForApplicationCostsPatent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_35a15d87-fead-4b55-a2c7-02dbd82fb2b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_50ee3bb9-4ea7-4c84-bb86-2b22a823b20e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_ee9cc5ab-441a-446d-a964-e6aa03c5fbc9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7da90d87-7fb2-4146-bec0-dbad95cedb5d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_48183b09-e5b9-43ce-8729-8be634c29347_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_03132f25-b6ef-42ff-a3ac-785a26b035d3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_210adad6-43f5-4223-87cd-f11073386025_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_2fc7d5b0-8b1f-451c-8fab-29f159217d50_terseLabel_en-US" xlink:label="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance period (in years)</link:label>
    <link:label id="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_label_en-US" xlink:label="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period</link:label>
    <link:label id="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_documentation_en-US" xlink:label="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:href="mdxg-20220930.xsd#mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:to="lab_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_bc085051-4fa6-4c29-8a66-ccbcdd95c4f3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ad0af7a6-7627-4fb2-8fd4-73f1f70f701f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the nine months ended September 30, 2022)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fea7acfa-9708-4142-9b12-1991f91aa608_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased for tax withholding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_33abe5eb-7f7b-4345-afc7-5d1b9f8e6f10_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_67e6a9e2-0e9a-4766-a5ff-23a502a069d0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b3c46eab-b29b-41ea-8401-057f241d6151_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_DebtInstrumentCommitmentFees_47bf0b67-7793-474d-9bbe-92fad57fe9b5_terseLabel_en-US" xlink:label="lab_mdxg_DebtInstrumentCommitmentFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee</link:label>
    <link:label id="lab_mdxg_DebtInstrumentCommitmentFees_label_en-US" xlink:label="lab_mdxg_DebtInstrumentCommitmentFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Commitment Fees</link:label>
    <link:label id="lab_mdxg_DebtInstrumentCommitmentFees_documentation_en-US" xlink:label="lab_mdxg_DebtInstrumentCommitmentFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Commitment Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentCommitmentFees" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentCommitmentFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_DebtInstrumentCommitmentFees" xlink:to="lab_mdxg_DebtInstrumentCommitmentFees" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_DebtInstrumentDefaultInterestRate_f119099a-a2d9-4f55-b212-6f1b1f8f63f1_terseLabel_en-US" xlink:label="lab_mdxg_DebtInstrumentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default interest rate (percent)</link:label>
    <link:label id="lab_mdxg_DebtInstrumentDefaultInterestRate_label_en-US" xlink:label="lab_mdxg_DebtInstrumentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Default Interest Rate</link:label>
    <link:label id="lab_mdxg_DebtInstrumentDefaultInterestRate_documentation_en-US" xlink:label="lab_mdxg_DebtInstrumentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Default Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentDefaultInterestRate" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentDefaultInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_DebtInstrumentDefaultInterestRate" xlink:to="lab_mdxg_DebtInstrumentDefaultInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e5d0ac5e-5d7a-4ed2-b65b-169e5ffe0664_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_72f0373d-7c3a-4590-933d-20b90a0811de_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_000cd665-ee2b-4622-9cb6-8853032909d5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future amortization expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c1c34bc5-5367-4924-bf08-c2105001da8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c4864940-2614-421e-8b1a-121aa91a34d3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_51c857a5-5d16-4b73-9cbc-c2dffda04177_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased for tax withholding</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b01b4995-8be8-482c-8bb0-a380d74f45e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2c6daaa0-2487-43fc-8ec4-589eb4a2cbfe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_DividendAccumulatedByNotPaid_4893e38d-7a2c-45b5-a5ee-8601c5e733d8_terseLabel_en-US" xlink:label="lab_mdxg_DividendAccumulatedByNotPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends accumulated but not paid</link:label>
    <link:label id="lab_mdxg_DividendAccumulatedByNotPaid_label_en-US" xlink:label="lab_mdxg_DividendAccumulatedByNotPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend, Accumulated By Not Paid</link:label>
    <link:label id="lab_mdxg_DividendAccumulatedByNotPaid_documentation_en-US" xlink:label="lab_mdxg_DividendAccumulatedByNotPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend, Accumulated By Not Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DividendAccumulatedByNotPaid" xlink:href="mdxg-20220930.xsd#mdxg_DividendAccumulatedByNotPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_DividendAccumulatedByNotPaid" xlink:to="lab_mdxg_DividendAccumulatedByNotPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_183f03f1-be64-42ba-bcfc-c189b1b76bc3_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_InvestigationRestatementAndRelated_383edb47-917a-487b-9ff8-554da786a60c_terseLabel_en-US" xlink:label="lab_mdxg_InvestigationRestatementAndRelated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investigation, restatement and related</link:label>
    <link:label id="lab_mdxg_InvestigationRestatementAndRelated_2001ff83-8278-44d8-8400-7f254a374d52_verboseLabel_en-US" xlink:label="lab_mdxg_InvestigationRestatementAndRelated" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investigation, restatement and related expense</link:label>
    <link:label id="lab_mdxg_InvestigationRestatementAndRelated_label_en-US" xlink:label="lab_mdxg_InvestigationRestatementAndRelated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investigation, Restatement And Related</link:label>
    <link:label id="lab_mdxg_InvestigationRestatementAndRelated_documentation_en-US" xlink:label="lab_mdxg_InvestigationRestatementAndRelated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investigation, Restatement And Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InvestigationRestatementAndRelated" xlink:href="mdxg-20220930.xsd#mdxg_InvestigationRestatementAndRelated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_InvestigationRestatementAndRelated" xlink:to="lab_mdxg_InvestigationRestatementAndRelated" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e121b071-5ec1-4001-8dd9-64185900bf24_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_feb0828e-9d8a-49a8-ab2d-d46590c57d70_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and settlement costs</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b9f97e8f-3136-4f47-80cc-697f047f8b89_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_4e2b90d7-aecf-423d-9336-3b4049af1f82_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_ExpensesOnLongTermPurchaseCommitment_5cdc3325-97a5-476c-91f8-65288e9c9d16_terseLabel_en-US" xlink:label="lab_mdxg_ExpensesOnLongTermPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses on long-term purchase commitment</link:label>
    <link:label id="lab_mdxg_ExpensesOnLongTermPurchaseCommitment_label_en-US" xlink:label="lab_mdxg_ExpensesOnLongTermPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses On Long-Term Purchase Commitment</link:label>
    <link:label id="lab_mdxg_ExpensesOnLongTermPurchaseCommitment_documentation_en-US" xlink:label="lab_mdxg_ExpensesOnLongTermPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses On Long-Term Purchase Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ExpensesOnLongTermPurchaseCommitment" xlink:href="mdxg-20220930.xsd#mdxg_ExpensesOnLongTermPurchaseCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_ExpensesOnLongTermPurchaseCommitment" xlink:to="lab_mdxg_ExpensesOnLongTermPurchaseCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis_dd7f482b-f26d-4962-aec9-ffffc0e65bac_terseLabel_en-US" xlink:label="lab_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B preferred stock, maximum voting stock percentage on an as-converted basis (percent)</link:label>
    <link:label id="lab_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis_label_en-US" xlink:label="lab_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Maximum Voting Stock Percentage On As-Converted Basis</link:label>
    <link:label id="lab_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis_documentation_en-US" xlink:label="lab_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Maximum Voting Stock Percentage On As-Converted Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis" xlink:to="lab_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdxg_AccruedESPPPayrollDeferrals_c6c61f6c-7daf-4b0d-8f97-08708df12a47_terseLabel_en-US" xlink:label="lab_mdxg_AccruedESPPPayrollDeferrals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued ESPP payroll deferrals</link:label>
    <link:label id="lab_mdxg_AccruedESPPPayrollDeferrals_label_en-US" xlink:label="lab_mdxg_AccruedESPPPayrollDeferrals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued ESPP Payroll Deferrals</link:label>
    <link:label id="lab_mdxg_AccruedESPPPayrollDeferrals_documentation_en-US" xlink:label="lab_mdxg_AccruedESPPPayrollDeferrals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued ESPP Payroll Deferrals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedESPPPayrollDeferrals" xlink:href="mdxg-20220930.xsd#mdxg_AccruedESPPPayrollDeferrals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdxg_AccruedESPPPayrollDeferrals" xlink:to="lab_mdxg_AccruedESPPPayrollDeferrals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5c2819cf-cfd3-4906-a960-7c18e5d8c24d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_3cfe14c0-8ebb-43cc-8029-ce0f236898fd_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsAxis_61f25358-4a80-4f8c-a07a-1d97fe886850_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends [Axis]</link:label>
    <link:label id="lab_us-gaap_DividendsAxis_label_en-US" xlink:label="lab_us-gaap_DividendsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsAxis" xlink:to="lab_us-gaap_DividendsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_61d5932a-df92-4c37-b112-a71457bec157_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52f3873a-6128-49e0-95dc-468d5317061b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2126bd6e-dfc1-47d4-83bb-4ab77ba85a6d_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_cc417ceb-9af6-49bb-9de4-1082703eaa4d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4dd4a35d-a1e8-496c-b0e7-c9b03c188d9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_091f0211-1e6f-451e-9e15-7e008c1a9324_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d09aee97-fd4f-4885-bee8-369103a662fe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ec027edb-8ecf-4a3a-a438-0bb40c5d50f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c99463ef-9f5b-42b7-b338-806606422a3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_dafcf189-e581-45a2-8470-edb600c1a8cb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term purchase commitment amount</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4e4ffea1-af73-4392-b38a-f4bede80c08c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bd341894-8309-4ef3-b77f-153d42000c94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets arising from operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_4e651ca0-c61d-4235-b33a-0a5d8501ac6e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementMember_35da70cd-7c8c-4dfc-9bdd-9c7753c85e76_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mdxg-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:75aec70c-8992-4432-a811-2ecd9b0ef10b,g:2668ca8b-9129-4930-9d6a-e03d3677c28b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://mimedx.com/role/Cover" xlink:type="simple" xlink:href="mdxg-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d7755dd1-25ef-499b-baeb-e2fab77ce09a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_DocumentType_d7755dd1-25ef-499b-baeb-e2fab77ce09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_88325db9-7790-423f-ab2f-1ed0bb5d15eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_DocumentQuarterlyReport_88325db9-7790-423f-ab2f-1ed0bb5d15eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ef445107-bf97-4daa-a3ec-4b3632bffffd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_DocumentPeriodEndDate_ef445107-bf97-4daa-a3ec-4b3632bffffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_367af29a-4c1a-4bd1-887c-41a02dbedc6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_DocumentTransitionReport_367af29a-4c1a-4bd1-887c-41a02dbedc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2f0f83ba-9647-4a24-84cc-fc48c13de874" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityFileNumber_2f0f83ba-9647-4a24-84cc-fc48c13de874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ba1c1fd5-ddb4-4518-be41-3fe0a05ad7c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityRegistrantName_ba1c1fd5-ddb4-4518-be41-3fe0a05ad7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_58909894-ce4b-4f52-b93b-0aa8cf42a99d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityIncorporationStateCountryCode_58909894-ce4b-4f52-b93b-0aa8cf42a99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_942f58e2-29ff-489e-9792-5855ed15a771" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityTaxIdentificationNumber_942f58e2-29ff-489e-9792-5855ed15a771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ddfb61aa-9556-4b77-bc58-496ce224d10b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityAddressAddressLine1_ddfb61aa-9556-4b77-bc58-496ce224d10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_54c673b1-b3be-4bdb-bf59-2c4e0557b0a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityAddressCityOrTown_54c673b1-b3be-4bdb-bf59-2c4e0557b0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6ae7417d-ff34-4247-81f1-bc63b08c19b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityAddressStateOrProvince_6ae7417d-ff34-4247-81f1-bc63b08c19b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fdac5d94-89af-445b-834e-2f582db60831" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityAddressPostalZipCode_fdac5d94-89af-445b-834e-2f582db60831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d0a80d9f-d5e0-4d1f-bd3e-36dcd56a73a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_CityAreaCode_d0a80d9f-d5e0-4d1f-bd3e-36dcd56a73a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9f5cec2d-6d5a-47c5-87fe-d81dbafec8a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_LocalPhoneNumber_9f5cec2d-6d5a-47c5-87fe-d81dbafec8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_67dc4a4e-5503-47b8-b27a-14e449d6b9a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_Security12bTitle_67dc4a4e-5503-47b8-b27a-14e449d6b9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0e0a292c-7c9c-4356-a64a-c512f5bc522d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_TradingSymbol_0e0a292c-7c9c-4356-a64a-c512f5bc522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c7c289f9-7cdb-454e-954d-7dbf4ca5529a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_SecurityExchangeName_c7c289f9-7cdb-454e-954d-7dbf4ca5529a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d4381693-4af4-40d1-912c-6468eeec54be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityCurrentReportingStatus_d4381693-4af4-40d1-912c-6468eeec54be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_03a00691-7e10-4136-9e62-eaace2b59776" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityInteractiveDataCurrent_03a00691-7e10-4136-9e62-eaace2b59776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ef5af5fd-2d14-4929-8874-4c42f370f820" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityFilerCategory_ef5af5fd-2d14-4929-8874-4c42f370f820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9171ff48-1ca0-40e5-82f0-e2e812fa0762" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntitySmallBusiness_9171ff48-1ca0-40e5-82f0-e2e812fa0762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_640261d1-10db-4b54-a760-231f710ae745" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityEmergingGrowthCompany_640261d1-10db-4b54-a760-231f710ae745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d7e4a22a-fb86-409b-ac06-15f576e91470" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityShellCompany_d7e4a22a-fb86-409b-ac06-15f576e91470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_53d2b154-76fd-4d87-8210-728cfa57362d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_53d2b154-76fd-4d87-8210-728cfa57362d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1b0fa044-0cea-4ee2-b33f-fda752ed5000" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_EntityCentralIndexKey_1b0fa044-0cea-4ee2-b33f-fda752ed5000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e2eb60cc-732f-4c0d-8146-6474bdc2bbcc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_CurrentFiscalYearEndDate_e2eb60cc-732f-4c0d-8146-6474bdc2bbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_fcf1b2e4-e07b-4278-b2fd-d583623bdb8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_DocumentFiscalYearFocus_fcf1b2e4-e07b-4278-b2fd-d583623bdb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_aad791a8-d594-463e-9842-ff5ccddc429f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_DocumentFiscalPeriodFocus_aad791a8-d594-463e-9842-ff5ccddc429f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_00df4fc4-2b34-45e8-a368-fb77c8a82b01" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2d7f97c9-b46c-4242-9ed4-960ee64149ad" xlink:to="loc_dei_AmendmentFlag_00df4fc4-2b34-45e8-a368-fb77c8a82b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5a06dc55-b7f9-4e61-bcbd-100ca1f1e0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_eb4272ec-2c52-4b11-b659-7f554153c2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5a06dc55-b7f9-4e61-bcbd-100ca1f1e0bf" xlink:to="loc_us-gaap_AssetsAbstract_eb4272ec-2c52-4b11-b659-7f554153c2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1dad1f0e-5f4e-4885-a8ec-3c8c428c59ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_eb4272ec-2c52-4b11-b659-7f554153c2ee" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1dad1f0e-5f4e-4885-a8ec-3c8c428c59ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_310084fd-8815-4111-b914-da89cdd26426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1dad1f0e-5f4e-4885-a8ec-3c8c428c59ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_310084fd-8815-4111-b914-da89cdd26426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_600f452f-2e7d-4ff6-866b-ec0b9e2b82da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1dad1f0e-5f4e-4885-a8ec-3c8c428c59ac" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_600f452f-2e7d-4ff6-866b-ec0b9e2b82da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_136f7027-8efb-4193-8dae-0faef2255caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1dad1f0e-5f4e-4885-a8ec-3c8c428c59ac" xlink:to="loc_us-gaap_InventoryNet_136f7027-8efb-4193-8dae-0faef2255caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_66ebac5d-af12-4a14-a2f6-2e76450fa236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1dad1f0e-5f4e-4885-a8ec-3c8c428c59ac" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_66ebac5d-af12-4a14-a2f6-2e76450fa236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_fb0f6779-8bb3-4b59-8d1a-00b62139f5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1dad1f0e-5f4e-4885-a8ec-3c8c428c59ac" xlink:to="loc_us-gaap_IncomeTaxesReceivable_fb0f6779-8bb3-4b59-8d1a-00b62139f5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a913849d-c52d-4b6d-b0ba-e1191cd44742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1dad1f0e-5f4e-4885-a8ec-3c8c428c59ac" xlink:to="loc_us-gaap_OtherAssetsCurrent_a913849d-c52d-4b6d-b0ba-e1191cd44742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1abd2d2e-cf75-48a1-b879-16d27ec8fd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1dad1f0e-5f4e-4885-a8ec-3c8c428c59ac" xlink:to="loc_us-gaap_AssetsCurrent_1abd2d2e-cf75-48a1-b879-16d27ec8fd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_843f2c2f-9a9e-472c-8d75-fc3cc8cff7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_eb4272ec-2c52-4b11-b659-7f554153c2ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_843f2c2f-9a9e-472c-8d75-fc3cc8cff7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_eb837eee-fac7-4dc6-a4fc-461d2cef1494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_eb4272ec-2c52-4b11-b659-7f554153c2ee" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_eb837eee-fac7-4dc6-a4fc-461d2cef1494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6360b8f9-a08c-4403-a0c5-e911b9a5d067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_eb4272ec-2c52-4b11-b659-7f554153c2ee" xlink:to="loc_us-gaap_Goodwill_6360b8f9-a08c-4403-a0c5-e911b9a5d067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bff534ec-5455-4a64-b3d4-029927537c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_eb4272ec-2c52-4b11-b659-7f554153c2ee" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bff534ec-5455-4a64-b3d4-029927537c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_27ef09c3-a42e-4142-bcf1-ffc7cdd3aa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_eb4272ec-2c52-4b11-b659-7f554153c2ee" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_27ef09c3-a42e-4142-bcf1-ffc7cdd3aa0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eb7f7d24-b301-42cb-8e2a-455aedbba79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_eb4272ec-2c52-4b11-b659-7f554153c2ee" xlink:to="loc_us-gaap_Assets_eb7f7d24-b301-42cb-8e2a-455aedbba79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41711fa1-aeb8-4907-99d0-c5a3aaf1a5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5a06dc55-b7f9-4e61-bcbd-100ca1f1e0bf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41711fa1-aeb8-4907-99d0-c5a3aaf1a5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9d4afda5-4789-47e4-9806-afdda86baf60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41711fa1-aeb8-4907-99d0-c5a3aaf1a5c8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9d4afda5-4789-47e4-9806-afdda86baf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c76e1b14-0cdc-4ed5-a86a-2eb485064867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d4afda5-4789-47e4-9806-afdda86baf60" xlink:to="loc_us-gaap_AccountsPayableCurrent_c76e1b14-0cdc-4ed5-a86a-2eb485064867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_51031072-1a82-4cf4-b574-33f931698569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d4afda5-4789-47e4-9806-afdda86baf60" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_51031072-1a82-4cf4-b574-33f931698569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ab1b436e-6814-4b9c-9e70-6be7a79b1b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d4afda5-4789-47e4-9806-afdda86baf60" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ab1b436e-6814-4b9c-9e70-6be7a79b1b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4bd30d87-84b3-4a0b-b709-bc495151d7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d4afda5-4789-47e4-9806-afdda86baf60" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4bd30d87-84b3-4a0b-b709-bc495151d7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_526711b9-25f2-4ae6-9abd-b75f064eacc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d4afda5-4789-47e4-9806-afdda86baf60" xlink:to="loc_us-gaap_LiabilitiesCurrent_526711b9-25f2-4ae6-9abd-b75f064eacc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e3cd8b76-4864-4135-aabd-0631e4a26523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41711fa1-aeb8-4907-99d0-c5a3aaf1a5c8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e3cd8b76-4864-4135-aabd-0631e4a26523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4c09a52e-1777-4671-9b68-585f3b0e4bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41711fa1-aeb8-4907-99d0-c5a3aaf1a5c8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4c09a52e-1777-4671-9b68-585f3b0e4bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d95b9286-208c-440a-b2fd-23e5f4a5ae79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41711fa1-aeb8-4907-99d0-c5a3aaf1a5c8" xlink:to="loc_us-gaap_Liabilities_d95b9286-208c-440a-b2fd-23e5f4a5ae79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c62f04d6-5bfc-4203-b42c-e1fb29631ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41711fa1-aeb8-4907-99d0-c5a3aaf1a5c8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c62f04d6-5bfc-4203-b42c-e1fb29631ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_58c46750-2d6a-429b-9cbf-00fa51f674a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41711fa1-aeb8-4907-99d0-c5a3aaf1a5c8" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_58c46750-2d6a-429b-9cbf-00fa51f674a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_60e69b61-9bff-4475-9f4d-990efe500076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41711fa1-aeb8-4907-99d0-c5a3aaf1a5c8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_60e69b61-9bff-4475-9f4d-990efe500076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9f014996-b526-4e26-b20e-ced55fc171d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60e69b61-9bff-4475-9f4d-990efe500076" xlink:to="loc_us-gaap_PreferredStockValue_9f014996-b526-4e26-b20e-ced55fc171d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a07e5781-44e2-46e3-b474-b11f42027a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60e69b61-9bff-4475-9f4d-990efe500076" xlink:to="loc_us-gaap_CommonStockSharesIssued_a07e5781-44e2-46e3-b474-b11f42027a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_977b4058-0895-4f27-8263-ef3666063458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60e69b61-9bff-4475-9f4d-990efe500076" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_977b4058-0895-4f27-8263-ef3666063458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_01a2f02a-e335-4bf1-aeb9-056838edb4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60e69b61-9bff-4475-9f4d-990efe500076" xlink:to="loc_us-gaap_CommonStockValue_01a2f02a-e335-4bf1-aeb9-056838edb4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b3105a26-b55f-4612-8a22-965737c7caab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60e69b61-9bff-4475-9f4d-990efe500076" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b3105a26-b55f-4612-8a22-965737c7caab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_45120a58-fcc3-4e6d-9fce-0d5459e1ccce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60e69b61-9bff-4475-9f4d-990efe500076" xlink:to="loc_us-gaap_TreasuryStockCommonValue_45120a58-fcc3-4e6d-9fce-0d5459e1ccce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d1c6991f-eaf8-4fb6-b183-1a68c6fdf8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60e69b61-9bff-4475-9f4d-990efe500076" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d1c6991f-eaf8-4fb6-b183-1a68c6fdf8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_efb59b7a-88fa-491f-8445-72f93c6d0a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60e69b61-9bff-4475-9f4d-990efe500076" xlink:to="loc_us-gaap_StockholdersEquity_efb59b7a-88fa-491f-8445-72f93c6d0a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dcf256a4-2dd0-40c9-82e3-ffc55216a320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41711fa1-aeb8-4907-99d0-c5a3aaf1a5c8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_dcf256a4-2dd0-40c9-82e3-ffc55216a320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a92172d3-0635-4688-9135-11bf7edfe0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b69ccfd-9b87-487a-8cbe-40b56405fb10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a92172d3-0635-4688-9135-11bf7edfe0f5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b69ccfd-9b87-487a-8cbe-40b56405fb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_97588558-caf8-4b03-98ad-aaba8530e560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b69ccfd-9b87-487a-8cbe-40b56405fb10" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_97588558-caf8-4b03-98ad-aaba8530e560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_21b2c525-41a2-4013-8143-6ccbaa50352e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b69ccfd-9b87-487a-8cbe-40b56405fb10" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_21b2c525-41a2-4013-8143-6ccbaa50352e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_1dc35a87-a6b9-466b-a262-01d015247437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b69ccfd-9b87-487a-8cbe-40b56405fb10" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_1dc35a87-a6b9-466b-a262-01d015247437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_eb48815b-d9ee-4fbe-b4ae-53738dcf5c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b69ccfd-9b87-487a-8cbe-40b56405fb10" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_eb48815b-d9ee-4fbe-b4ae-53738dcf5c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3505d3d3-099a-4025-aff9-f2a836c5cc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b69ccfd-9b87-487a-8cbe-40b56405fb10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3505d3d3-099a-4025-aff9-f2a836c5cc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_934944ea-3a9e-4fd3-b847-89341d303868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3505d3d3-099a-4025-aff9-f2a836c5cc9c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_934944ea-3a9e-4fd3-b847-89341d303868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_642a9fa2-84eb-4333-a148-7c3af9bed241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3505d3d3-099a-4025-aff9-f2a836c5cc9c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_642a9fa2-84eb-4333-a148-7c3af9bed241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_032a3f59-a7a5-466f-8f50-2bf5a387d863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3505d3d3-099a-4025-aff9-f2a836c5cc9c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_032a3f59-a7a5-466f-8f50-2bf5a387d863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_03555567-c322-461a-85d1-a07986310a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3505d3d3-099a-4025-aff9-f2a836c5cc9c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_03555567-c322-461a-85d1-a07986310a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ba239819-8bf7-4bc6-b701-ce786c036b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3505d3d3-099a-4025-aff9-f2a836c5cc9c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ba239819-8bf7-4bc6-b701-ce786c036b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4b26ddea-fe01-4674-9f91-6eeae4d9f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3505d3d3-099a-4025-aff9-f2a836c5cc9c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4b26ddea-fe01-4674-9f91-6eeae4d9f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a40999e4-f48f-4ca3-a2e0-65ea3e397ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3505d3d3-099a-4025-aff9-f2a836c5cc9c" xlink:to="loc_us-gaap_CommonStockSharesIssued_a40999e4-f48f-4ca3-a2e0-65ea3e397ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fc32a1ce-bc11-48c2-9659-0e9a7377a90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3505d3d3-099a-4025-aff9-f2a836c5cc9c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fc32a1ce-bc11-48c2-9659-0e9a7377a90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_768d443a-649a-436a-992c-d315bcaa67cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3505d3d3-099a-4025-aff9-f2a836c5cc9c" xlink:to="loc_us-gaap_TreasuryStockCommonShares_768d443a-649a-436a-992c-d315bcaa67cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c79ad0c1-5dde-41af-a095-db4fbf89eb61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c79ad0c1-5dde-41af-a095-db4fbf89eb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ef0db764-3bb9-4aed-9188-06db7d0a646b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ef0db764-3bb9-4aed-9188-06db7d0a646b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_2c953845-0e57-4823-aebf-6b1fe4190d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_GrossProfit_2c953845-0e57-4823-aebf-6b1fe4190d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_55a0a24d-de5a-4a95-92a4-00771b9d09ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_OperatingExpensesAbstract_55a0a24d-de5a-4a95-92a4-00771b9d09ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0b7a3ac9-d032-444f-9554-ff7e5dad0a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_55a0a24d-de5a-4a95-92a4-00771b9d09ee" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0b7a3ac9-d032-444f-9554-ff7e5dad0a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cfb30910-732c-48aa-9e9c-ce54eae49138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_55a0a24d-de5a-4a95-92a4-00771b9d09ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cfb30910-732c-48aa-9e9c-ce54eae49138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InvestigationRestatementAndRelated_794c4d09-a869-4022-b2af-0b688d57691b" xlink:href="mdxg-20220930.xsd#mdxg_InvestigationRestatementAndRelated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_55a0a24d-de5a-4a95-92a4-00771b9d09ee" xlink:to="loc_mdxg_InvestigationRestatementAndRelated_794c4d09-a869-4022-b2af-0b688d57691b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_cbfe067c-869c-47e0-b09b-062d74ff4b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_55a0a24d-de5a-4a95-92a4-00771b9d09ee" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_cbfe067c-869c-47e0-b09b-062d74ff4b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_67b2c114-af62-497e-8149-8ab6bf75c52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_OperatingIncomeLoss_67b2c114-af62-497e-8149-8ab6bf75c52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_df1a61c8-1dda-4f7f-be03-0fa5ac2fbd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_df1a61c8-1dda-4f7f-be03-0fa5ac2fbd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_65ae7805-5cc2-4625-9423-c5a671298f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_df1a61c8-1dda-4f7f-be03-0fa5ac2fbd8e" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_65ae7805-5cc2-4625-9423-c5a671298f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6553b16a-df20-4e54-9022-ef240902c18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_df1a61c8-1dda-4f7f-be03-0fa5ac2fbd8e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6553b16a-df20-4e54-9022-ef240902c18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ce7b59dd-1ef9-4223-b189-36e26ab97ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ce7b59dd-1ef9-4223-b189-36e26ab97ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e4f30f39-89d4-4e3a-98d5-979dd6895db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e4f30f39-89d4-4e3a-98d5-979dd6895db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cffbe2c0-8900-43cc-b9a0-9d25db266dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_NetIncomeLoss_cffbe2c0-8900-43cc-b9a0-9d25db266dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_99823345-6f3a-4f7f-9834-ca9c683cf621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_99823345-6f3a-4f7f-9834-ca9c683cf621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7c3580ea-46d3-486d-890a-a1b25601c258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7c3580ea-46d3-486d-890a-a1b25601c258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_aac214c8-a3cc-4cc1-84de-384bd3a6cdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_EarningsPerShareBasic_aac214c8-a3cc-4cc1-84de-384bd3a6cdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9fad07e2-59cc-4180-8bd9-b29e2af0ef4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9fad07e2-59cc-4180-8bd9-b29e2af0ef4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_151ec6a6-29ae-435c-8aa1-3f6bc2c8ca2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_151ec6a6-29ae-435c-8aa1-3f6bc2c8ca2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_319aae63-913b-4144-a7f8-2e564db132f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95d8eb11-cf32-4740-8545-bf25fd889089" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_319aae63-913b-4144-a7f8-2e564db132f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a7c53ed6-4845-4cd2-b4fb-e1c9ad86e70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0e939299-0867-4735-bd8d-cab71152bc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a7c53ed6-4845-4cd2-b4fb-e1c9ad86e70e" xlink:to="loc_us-gaap_StatementTable_0e939299-0867-4735-bd8d-cab71152bc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11d05d41-31a6-42e3-987e-8e140cc0f21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0e939299-0867-4735-bd8d-cab71152bc67" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11d05d41-31a6-42e3-987e-8e140cc0f21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11d05d41-31a6-42e3-987e-8e140cc0f21f" xlink:to="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a72f3e64-638c-4623-aced-ff3273ef16ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:to="loc_us-gaap_CommonStockMember_a72f3e64-638c-4623-aced-ff3273ef16ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3b95b9c5-8bf7-4d1a-86b0-438f4315c2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3b95b9c5-8bf7-4d1a-86b0-438f4315c2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_81072ae4-d1fa-476d-832a-b384fc562756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:to="loc_us-gaap_TreasuryStockCommonMember_81072ae4-d1fa-476d-832a-b384fc562756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e2f8a70d-7d07-4e48-a713-b1de0a9d66fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4857b96c-8e21-463e-85e2-277274b734a2" xlink:to="loc_us-gaap_RetainedEarningsMember_e2f8a70d-7d07-4e48-a713-b1de0a9d66fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ec1c31d3-27eb-4bfa-a7c4-a1aafb4ad417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0e939299-0867-4735-bd8d-cab71152bc67" xlink:to="loc_us-gaap_StatementLineItems_ec1c31d3-27eb-4bfa-a7c4-a1aafb4ad417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec1c31d3-27eb-4bfa-a7c4-a1aafb4ad417" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b66a7541-1fe5-49a4-b5b2-ca4dd264d008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_CommonStockSharesIssued_b66a7541-1fe5-49a4-b5b2-ca4dd264d008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4b4155d2-d750-4880-8d95-35f3e1aa00e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockholdersEquity_4b4155d2-d750-4880-8d95-35f3e1aa00e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_10fd1bda-c92f-49fe-946d-7738dbafbae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_TreasuryStockCommonShares_10fd1bda-c92f-49fe-946d-7738dbafbae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_1a3f8ab1-3175-41af-baec-c034f33ec550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_1a3f8ab1-3175-41af-baec-c034f33ec550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ab25dd6-8004-4b20-b00a-91fed4be030e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ab25dd6-8004-4b20-b00a-91fed4be030e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68d063fd-b186-46eb-b920-6801038d98e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68d063fd-b186-46eb-b920-6801038d98e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dcced1ad-adf3-452d-9460-2e912276347d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dcced1ad-adf3-452d-9460-2e912276347d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1757e608-fa89-476c-9847-855ea3f70a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1757e608-fa89-476c-9847-855ea3f70a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_52d8b32c-cc2a-4a8f-979a-0ef275d76ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_52d8b32c-cc2a-4a8f-979a-0ef275d76ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_7a59fb1c-f70f-4d4e-8f5c-40f0dc535c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_7a59fb1c-f70f-4d4e-8f5c-40f0dc535c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_22baada6-a78a-4dd9-853b-98213c106344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_22baada6-a78a-4dd9-853b-98213c106344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_41909d6c-3686-4d40-86ef-f03e25fff11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_41909d6c-3686-4d40-86ef-f03e25fff11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2c643335-ca19-4bb3-a4a2-f6990d22f894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2c643335-ca19-4bb3-a4a2-f6990d22f894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0c7a2269-231c-45b7-801a-d9d33dc3f121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_NetIncomeLoss_0c7a2269-231c-45b7-801a-d9d33dc3f121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TreasuryStockSharesAdjustment_d1ceb182-f7b1-4034-8011-c6c46aa89398" xlink:href="mdxg-20220930.xsd#mdxg_TreasuryStockSharesAdjustment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_mdxg_TreasuryStockSharesAdjustment_d1ceb182-f7b1-4034-8011-c6c46aa89398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_35d348ba-b75d-449f-a203-e28390a07bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_35d348ba-b75d-449f-a203-e28390a07bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_34b586be-cbe5-4188-a74d-2a5ac7215f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_CommonStockSharesIssued_34b586be-cbe5-4188-a74d-2a5ac7215f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1799d71b-63e8-4982-8b70-45b9f6a773ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_StockholdersEquity_1799d71b-63e8-4982-8b70-45b9f6a773ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9ec2ae09-e10f-4f31-85eb-4d04d2556e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fcf09-e90f-45a2-8572-6f2bd47db614" xlink:to="loc_us-gaap_TreasuryStockCommonShares_9ec2ae09-e10f-4f31-85eb-4d04d2556e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c6929887-0d2a-43cd-a2ff-4170c555a586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_04d904f1-facf-4a89-a54c-1dc544269200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c6929887-0d2a-43cd-a2ff-4170c555a586" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_04d904f1-facf-4a89-a54c-1dc544269200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_55c636b4-5b17-4d79-b04c-63274f8d81bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_04d904f1-facf-4a89-a54c-1dc544269200" xlink:to="loc_us-gaap_NetIncomeLoss_55c636b4-5b17-4d79-b04c-63274f8d81bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fba384a2-e19c-45c6-9fae-978dc97ba8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_04d904f1-facf-4a89-a54c-1dc544269200" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fba384a2-e19c-45c6-9fae-978dc97ba8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_aef7e04a-c260-44bd-b1f8-631e0d462207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fba384a2-e19c-45c6-9fae-978dc97ba8c7" xlink:to="loc_us-gaap_ShareBasedCompensation_aef7e04a-c260-44bd-b1f8-631e0d462207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c26df5b6-05c5-45b0-a9ee-956bb7cb3b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fba384a2-e19c-45c6-9fae-978dc97ba8c7" xlink:to="loc_us-gaap_Depreciation_c26df5b6-05c5-45b0-a9ee-956bb7cb3b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_9db9d823-ea03-4ffd-886a-138306826b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fba384a2-e19c-45c6-9fae-978dc97ba8c7" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_9db9d823-ea03-4ffd-886a-138306826b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e4bd378b-b191-4d2c-9d1b-c5d3bd107126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fba384a2-e19c-45c6-9fae-978dc97ba8c7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e4bd378b-b191-4d2c-9d1b-c5d3bd107126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_81dddc60-6466-461d-b4da-813372412386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fba384a2-e19c-45c6-9fae-978dc97ba8c7" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_81dddc60-6466-461d-b4da-813372412386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9057b7e0-dce3-4e20-b63e-78ed434992d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fba384a2-e19c-45c6-9fae-978dc97ba8c7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9057b7e0-dce3-4e20-b63e-78ed434992d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationAccretionExpense_d83d933c-d902-41d4-a6e5-1fe3c0a19d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationAccretionExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fba384a2-e19c-45c6-9fae-978dc97ba8c7" xlink:to="loc_us-gaap_AssetRetirementObligationAccretionExpense_d83d933c-d902-41d4-a6e5-1fe3c0a19d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2ef374d8-7cb8-47df-b311-5dfe515bb429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fba384a2-e19c-45c6-9fae-978dc97ba8c7" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2ef374d8-7cb8-47df-b311-5dfe515bb429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_272151b8-0b34-4b39-be59-0efc42663389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fba384a2-e19c-45c6-9fae-978dc97ba8c7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_272151b8-0b34-4b39-be59-0efc42663389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_342b9277-f9b6-4e09-9ca8-4ba11b0f5776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_272151b8-0b34-4b39-be59-0efc42663389" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_342b9277-f9b6-4e09-9ca8-4ba11b0f5776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_548edf9f-bc6b-44a4-b9a6-0d738e91bd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_272151b8-0b34-4b39-be59-0efc42663389" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_548edf9f-bc6b-44a4-b9a6-0d738e91bd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_842846b1-39d1-43da-9eb8-becd97b4dd08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_272151b8-0b34-4b39-be59-0efc42663389" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_842846b1-39d1-43da-9eb8-becd97b4dd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_db439304-8219-4a9e-ad6c-e13451c3498d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_272151b8-0b34-4b39-be59-0efc42663389" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_db439304-8219-4a9e-ad6c-e13451c3498d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dd26fd03-97b1-4493-b3c2-9216d10fbbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_272151b8-0b34-4b39-be59-0efc42663389" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dd26fd03-97b1-4493-b3c2-9216d10fbbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8697d198-5852-4090-bdd5-5bae10493de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_272151b8-0b34-4b39-be59-0efc42663389" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8697d198-5852-4090-bdd5-5bae10493de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_44f36e00-d9c5-4823-a251-2a4ca4f082b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_272151b8-0b34-4b39-be59-0efc42663389" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_44f36e00-d9c5-4823-a251-2a4ca4f082b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_64a22cd2-903a-44bc-aec5-15bfa5e44414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_272151b8-0b34-4b39-be59-0efc42663389" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_64a22cd2-903a-44bc-aec5-15bfa5e44414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_383b0061-4759-43f9-aeaf-e1083e37949e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_272151b8-0b34-4b39-be59-0efc42663389" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_383b0061-4759-43f9-aeaf-e1083e37949e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_34d8bbfb-89a9-4b69-b7a2-565eaa1b230a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_04d904f1-facf-4a89-a54c-1dc544269200" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_34d8bbfb-89a9-4b69-b7a2-565eaa1b230a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0af565a3-fa1d-4942-96ed-816766f52b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c6929887-0d2a-43cd-a2ff-4170c555a586" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0af565a3-fa1d-4942-96ed-816766f52b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fdf42e33-f737-48d5-a983-db5f82843805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0af565a3-fa1d-4942-96ed-816766f52b2c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fdf42e33-f737-48d5-a983-db5f82843805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PaymentsForApplicationCostsPatent_76f824ec-3afb-4ea0-b8c6-523995f4f7ee" xlink:href="mdxg-20220930.xsd#mdxg_PaymentsForApplicationCostsPatent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0af565a3-fa1d-4942-96ed-816766f52b2c" xlink:to="loc_mdxg_PaymentsForApplicationCostsPatent_76f824ec-3afb-4ea0-b8c6-523995f4f7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_0c1fe905-0c7a-4557-91f3-099d888b1431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0af565a3-fa1d-4942-96ed-816766f52b2c" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_0c1fe905-0c7a-4557-91f3-099d888b1431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e5bc15b6-3450-4779-a693-d7fdc74ba053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0af565a3-fa1d-4942-96ed-816766f52b2c" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e5bc15b6-3450-4779-a693-d7fdc74ba053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_669af943-aa78-4241-abde-fed9e7e47e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0af565a3-fa1d-4942-96ed-816766f52b2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_669af943-aa78-4241-abde-fed9e7e47e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce12b557-93fc-4fde-bebc-b072e1fa951e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c6929887-0d2a-43cd-a2ff-4170c555a586" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce12b557-93fc-4fde-bebc-b072e1fa951e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_88b1c9bc-eed5-480c-adee-ed8242dcc5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce12b557-93fc-4fde-bebc-b072e1fa951e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_88b1c9bc-eed5-480c-adee-ed8242dcc5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_210d8fdf-a8aa-46f7-95b6-a153285a102e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce12b557-93fc-4fde-bebc-b072e1fa951e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_210d8fdf-a8aa-46f7-95b6-a153285a102e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_bb89da33-6212-4007-82ff-14b67661f4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce12b557-93fc-4fde-bebc-b072e1fa951e" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_bb89da33-6212-4007-82ff-14b67661f4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48ed2e75-93db-48c3-aee0-f442989ca212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce12b557-93fc-4fde-bebc-b072e1fa951e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48ed2e75-93db-48c3-aee0-f442989ca212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c1b66546-3703-4df0-8167-e95d7f3e820f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c6929887-0d2a-43cd-a2ff-4170c555a586" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c1b66546-3703-4df0-8167-e95d7f3e820f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ac89cc5-ca56-4598-b0c3-93ba2f15a52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c6929887-0d2a-43cd-a2ff-4170c555a586" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ac89cc5-ca56-4598-b0c3-93ba2f15a52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_715d40c7-9950-4a5e-970a-2517499c8187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c6929887-0d2a-43cd-a2ff-4170c555a586" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_715d40c7-9950-4a5e-970a-2517499c8187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/NatureofBusiness" xlink:type="simple" xlink:href="mdxg-20220930.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f5bf496b-1fb1-4633-a647-e23e26314b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a37fc17a-d9d5-4595-95c3-81f8685ef0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f5bf496b-1fb1-4633-a647-e23e26314b5a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a37fc17a-d9d5-4595-95c3-81f8685ef0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9346a5b3-5c8e-48fb-87ff-9a899aceba37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b127cc33-832d-464a-97ec-eb0be1505137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9346a5b3-5c8e-48fb-87ff-9a899aceba37" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b127cc33-832d-464a-97ec-eb0be1505137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/AccountsReceivableNet" xlink:type="simple" xlink:href="mdxg-20220930.xsd#AccountsReceivableNet"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/AccountsReceivableNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_b51ef740-3f5f-4287-87e2-ec6edb3b86bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndNontradeReceivableTextBlock_cff18c0a-8d38-4593-91d6-043976cab6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_b51ef740-3f5f-4287-87e2-ec6edb3b86bf" xlink:to="loc_us-gaap_AccountsAndNontradeReceivableTextBlock_cff18c0a-8d38-4593-91d6-043976cab6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/Inventory" xlink:type="simple" xlink:href="mdxg-20220930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c7586f1e-9453-4064-b787-05460e97548c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_2e956c02-ca71-4839-aa7d-8470527356d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c7586f1e-9453-4064-b787-05460e97548c" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_2e956c02-ca71-4839-aa7d-8470527356d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="mdxg-20220930.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dfaa3721-f27f-4215-b9d8-c9dacd8eb3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_451401ff-522d-48a6-9622-094eaf93718c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dfaa3721-f27f-4215-b9d8-c9dacd8eb3d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_451401ff-522d-48a6-9622-094eaf93718c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="mdxg-20220930.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f19b00d-8665-491e-9182-cbe86db10b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_d172bfc3-59e5-4577-9f4e-f88b32e20c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f19b00d-8665-491e-9182-cbe86db10b26" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_d172bfc3-59e5-4577-9f4e-f88b32e20c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/AccruedExpenses" xlink:type="simple" xlink:href="mdxg-20220930.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_28368818-9e91-4bb5-b704-e43914932f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_84b6dc0d-3777-42cc-8453-f94a399b21c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_28368818-9e91-4bb5-b704-e43914932f18" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_84b6dc0d-3777-42cc-8453-f94a399b21c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNet" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNet"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/LongTermDebtNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7278bd16-a436-4932-a3f4-f9255f499e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_14a39e64-2de2-4465-8f8a-9e6e66352174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7278bd16-a436-4932-a3f4-f9255f499e79" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_14a39e64-2de2-4465-8f8a-9e6e66352174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/NetLossPerCommonShare" xlink:type="simple" xlink:href="mdxg-20220930.xsd#NetLossPerCommonShare"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/NetLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_795b69f6-5a9e-4a74-affa-558cb1a1c4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c815f874-00d3-42a1-be4f-a2c4312be6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_795b69f6-5a9e-4a74-affa-558cb1a1c4c3" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c815f874-00d3-42a1-be4f-a2c4312be6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/Equity" xlink:type="simple" xlink:href="mdxg-20220930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_10502d5b-90c2-4cdd-9f3d-71710e749ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_272130ab-3149-4241-b58c-50de53a99a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_10502d5b-90c2-4cdd-9f3d-71710e749ab4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_272130ab-3149-4241-b58c-50de53a99a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mdxg-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_af0e934d-834f-490b-938f-ba0bba833ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_8c0eab34-bf97-4f2b-ac51-96a92c675a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af0e934d-834f-490b-938f-ba0bba833ca0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_8c0eab34-bf97-4f2b-ac51-96a92c675a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_0e0c19bf-57ee-48db-ba08-9f0ff1fe44fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_92f3486d-1f85-4a8f-9ea3-a73e98fa6213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0e0c19bf-57ee-48db-ba08-9f0ff1fe44fe" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_92f3486d-1f85-4a8f-9ea3-a73e98fa6213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbd6ac70-cefe-4b73-904f-364c3cb51e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dace9670-940e-4ea3-8e29-27f037ff5d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbd6ac70-cefe-4b73-904f-364c3cb51e27" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dace9670-940e-4ea3-8e29-27f037ff5d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/Revenue" xlink:type="simple" xlink:href="mdxg-20220930.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1cf084d0-b5f7-4729-aa51-2fba28413270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5715d258-2c60-4957-8791-ef9e35f08425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1cf084d0-b5f7-4729-aa51-2fba28413270" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5715d258-2c60-4957-8791-ef9e35f08425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SegmentInformation" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_92c96901-6ab7-47f5-80b3-fb50017d70f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_e003b570-a339-4a5c-91d6-39cf8dec65f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_92c96901-6ab7-47f5-80b3-fb50017d70f6" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_e003b570-a339-4a5c-91d6-39cf8dec65f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_68307eec-00ec-4bef-b585-6217719338d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9420a766-a0ee-4c34-aec7-43f341ba6a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68307eec-00ec-4bef-b585-6217719338d5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9420a766-a0ee-4c34-aec7-43f341ba6a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_55c61c5f-a434-4f74-bd72-4ba4f5c9508d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68307eec-00ec-4bef-b585-6217719338d5" xlink:to="loc_us-gaap_UseOfEstimates_55c61c5f-a434-4f74-bd72-4ba4f5c9508d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0b9becaf-dcb8-4e51-a35a-0dafc080fd94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68307eec-00ec-4bef-b585-6217719338d5" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0b9becaf-dcb8-4e51-a35a-0dafc080fd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_268580b8-1e22-47fc-9363-11eae9f6a1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68307eec-00ec-4bef-b585-6217719338d5" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_268580b8-1e22-47fc-9363-11eae9f6a1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6fd81365-31c5-4f87-8a1e-e02542cad9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68307eec-00ec-4bef-b585-6217719338d5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6fd81365-31c5-4f87-8a1e-e02542cad9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fc83b8f6-d8ef-4d61-9c90-f303ba7212bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68307eec-00ec-4bef-b585-6217719338d5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fc83b8f6-d8ef-4d61-9c90-f303ba7212bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/AccountsReceivableNetTables" xlink:type="simple" xlink:href="mdxg-20220930.xsd#AccountsReceivableNetTables"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/AccountsReceivableNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_65c85563-41ff-4d8c-98bc-273b7b2cc37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_62ea7f92-adf0-40cc-b2ec-5ddbf154273d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_65c85563-41ff-4d8c-98bc-273b7b2cc37c" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_62ea7f92-adf0-40cc-b2ec-5ddbf154273d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/InventoryTables" xlink:type="simple" xlink:href="mdxg-20220930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8299a01b-ccce-4d0b-ab29-2afbe22e7c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ab25d8f2-cb71-4488-9d15-0a9cc5a65882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8299a01b-ccce-4d0b-ab29-2afbe22e7c9b" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ab25d8f2-cb71-4488-9d15-0a9cc5a65882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="mdxg-20220930.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_394721af-e717-4153-b680-6c3417be6301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9a07e47e-1b79-4a1f-9570-802d61797590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_394721af-e717-4153-b680-6c3417be6301" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9a07e47e-1b79-4a1f-9570-802d61797590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ScheduleOfDepreciationTableTextBlock_8ae22181-4549-4765-bd21-5a9ba6372c8f" xlink:href="mdxg-20220930.xsd#mdxg_ScheduleOfDepreciationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_394721af-e717-4153-b680-6c3417be6301" xlink:to="loc_mdxg_ScheduleOfDepreciationTableTextBlock_8ae22181-4549-4765-bd21-5a9ba6372c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="mdxg-20220930.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9c0af7b1-7a3c-4bde-a1a8-6faa940c4b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_a975eae2-5692-4070-8e47-3a5c32eeba12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9c0af7b1-7a3c-4bde-a1a8-6faa940c4b8e" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_a975eae2-5692-4070-8e47-3a5c32eeba12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4d0e2ee3-5e87-4c73-a62d-413b6e8735af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9c0af7b1-7a3c-4bde-a1a8-6faa940c4b8e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4d0e2ee3-5e87-4c73-a62d-413b6e8735af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d4cb86a3-76a4-46de-a102-049b710a411d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9c0af7b1-7a3c-4bde-a1a8-6faa940c4b8e" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d4cb86a3-76a4-46de-a102-049b710a411d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="mdxg-20220930.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f9131c28-1490-41dd-b03e-2d2975545067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b12079bf-1e59-4234-be4a-0815434317d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f9131c28-1490-41dd-b03e-2d2975545067" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b12079bf-1e59-4234-be4a-0815434317d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTables" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTables"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/LongTermDebtNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5b811fe4-7e80-45be-83b3-91942c16b9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock_6f8129e7-d329-4a6a-bbd7-213e714ce168" xlink:href="mdxg-20220930.xsd#mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5b811fe4-7e80-45be-83b3-91942c16b9fe" xlink:to="loc_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock_6f8129e7-d329-4a6a-bbd7-213e714ce168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_8e2e125f-5354-4ab9-acac-c5f255c0796c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5b811fe4-7e80-45be-83b3-91942c16b9fe" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_8e2e125f-5354-4ab9-acac-c5f255c0796c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ScheduleOfInterestExpenseTableTextBlock_8dc307bc-9555-4855-b81d-686f7329e163" xlink:href="mdxg-20220930.xsd#mdxg_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5b811fe4-7e80-45be-83b3-91942c16b9fe" xlink:to="loc_mdxg_ScheduleOfInterestExpenseTableTextBlock_8dc307bc-9555-4855-b81d-686f7329e163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_71032f53-af8a-47e4-8098-cd85069023d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5b811fe4-7e80-45be-83b3-91942c16b9fe" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_71032f53-af8a-47e4-8098-cd85069023d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/NetLossPerCommonShareTables" xlink:type="simple" xlink:href="mdxg-20220930.xsd#NetLossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/NetLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2ebc9893-00b6-450e-9d5f-072d99748bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_36584a42-c16e-4b73-aabe-44023a9f6b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ebc9893-00b6-450e-9d5f-072d99748bbe" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_36584a42-c16e-4b73-aabe-44023a9f6b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_4f96d1b3-95a7-48c8-8aad-b32c802de54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ebc9893-00b6-450e-9d5f-072d99748bbe" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_4f96d1b3-95a7-48c8-8aad-b32c802de54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f7613fae-1039-4045-8ac9-9740fe2504a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ebc9893-00b6-450e-9d5f-072d99748bbe" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f7613fae-1039-4045-8ac9-9740fe2504a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/EquityTables" xlink:type="simple" xlink:href="mdxg-20220930.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7adf1ef1-5661-4603-8e27-b379b4803ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_dacd987d-b6de-4df5-8d2a-e193fae6272f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7adf1ef1-5661-4603-8e27-b379b4803ea3" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_dacd987d-b6de-4df5-8d2a-e193fae6272f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_eb119fd9-0885-4b22-9379-5607eb83b48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7adf1ef1-5661-4603-8e27-b379b4803ea3" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_eb119fd9-0885-4b22-9379-5607eb83b48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_a5036e39-e1a1-4910-ae90-52ff57d95972" xlink:href="mdxg-20220930.xsd#mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7adf1ef1-5661-4603-8e27-b379b4803ea3" xlink:to="loc_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_a5036e39-e1a1-4910-ae90-52ff57d95972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_91f16f5d-7abd-4cc4-9182-59906a5429cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7adf1ef1-5661-4603-8e27-b379b4803ea3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_91f16f5d-7abd-4cc4-9182-59906a5429cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_1a33c6c6-0cf9-44b6-8651-6f54702596cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_75613972-ea07-4c23-abe8-4158220c8424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_1a33c6c6-0cf9-44b6-8651-6f54702596cc" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_75613972-ea07-4c23-abe8-4158220c8424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/RevenueTables" xlink:type="simple" xlink:href="mdxg-20220930.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_db826627-622f-4c9f-b294-40df9c174cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_32cc1317-e50b-4f2a-af77-b3bf1969ee22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_db826627-622f-4c9f-b294-40df9c174cb0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_32cc1317-e50b-4f2a-af77-b3bf1969ee22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9306df36-b023-433d-8b74-c52e8dde3ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_8d597fac-6cf0-4a2f-8b94-a8d5618133a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9306df36-b023-433d-8b74-c52e8dde3ccd" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_8d597fac-6cf0-4a2f-8b94-a8d5618133a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#NatureofBusinessDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7181738-1d3b-4f0e-9fc2-824031b72098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c220c033-51ec-4b5b-8ccf-8daa34a1d261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7181738-1d3b-4f0e-9fc2-824031b72098" xlink:to="loc_us-gaap_NumberOfReportableSegments_c220c033-51ec-4b5b-8ccf-8daa34a1d261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_6e816732-1b73-4bf7-aefd-40d20170e5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7181738-1d3b-4f0e-9fc2-824031b72098" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_6e816732-1b73-4bf7-aefd-40d20170e5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f0c3261d-74f7-47c1-b16c-9cc659d48e34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_6e816732-1b73-4bf7-aefd-40d20170e5b0" xlink:to="loc_srt_ProductOrServiceAxis_f0c3261d-74f7-47c1-b16c-9cc659d48e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_10ff253c-50f2-4ded-81c7-4a7115a13166" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f0c3261d-74f7-47c1-b16c-9cc659d48e34" xlink:to="loc_srt_ProductsAndServicesDomain_10ff253c-50f2-4ded-81c7-4a7115a13166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InternationalSection351Member_3a8bc695-ec9d-466e-84d6-f6804b2ee4d9" xlink:href="mdxg-20220930.xsd#mdxg_InternationalSection351Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10ff253c-50f2-4ded-81c7-4a7115a13166" xlink:to="loc_mdxg_InternationalSection351Member_3a8bc695-ec9d-466e-84d6-f6804b2ee4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember_f95e0957-2c61-4215-bf1a-89087e6dece8" xlink:href="mdxg-20220930.xsd#mdxg_AdvancedWoundCareUmbilicalCordDerivedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10ff253c-50f2-4ded-81c7-4a7115a13166" xlink:to="loc_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember_f95e0957-2c61-4215-bf1a-89087e6dece8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_cb9dd7ae-7f53-4925-9f81-4321851646ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_6e816732-1b73-4bf7-aefd-40d20170e5b0" xlink:to="loc_us-gaap_UnusualOrInfrequentItemLineItems_cb9dd7ae-7f53-4925-9f81-4321851646ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c76b9f74-5732-4e48-90f4-e1db40e5f7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_cb9dd7ae-7f53-4925-9f81-4321851646ec" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c76b9f74-5732-4e48-90f4-e1db40e5f7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f43b9d74-ec8c-4ae7-a3eb-663d2b081287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_cb9dd7ae-7f53-4925-9f81-4321851646ec" xlink:to="loc_us-gaap_InventoryNet_f43b9d74-ec8c-4ae7-a3eb-663d2b081287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ec3e3a34-a85e-48d5-87da-e73339fdaedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8e2132f2-71bd-4f27-a3aa-bd3285f49c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec3e3a34-a85e-48d5-87da-e73339fdaedc" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8e2132f2-71bd-4f27-a3aa-bd3285f49c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_f2033169-20ae-48df-9001-b6fa9a12127c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec3e3a34-a85e-48d5-87da-e73339fdaedc" xlink:to="loc_us-gaap_NumberOfReportableSegments_f2033169-20ae-48df-9001-b6fa9a12127c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_3bfcca4e-4da9-4d33-91dd-288b61865845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec3e3a34-a85e-48d5-87da-e73339fdaedc" xlink:to="loc_us-gaap_NumberOfReportingUnits_3bfcca4e-4da9-4d33-91dd-288b61865845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#AccountsReceivableNetAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_e5fed7f4-b435-4893-beff-e8e4cfb8aa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_94cffd30-e854-42d4-8ee7-eec1e70b4fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_e5fed7f4-b435-4893-beff-e8e4cfb8aa9e" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_94cffd30-e854-42d4-8ee7-eec1e70b4fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_68418485-5207-4cdc-b111-bd58f3e411b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_e5fed7f4-b435-4893-beff-e8e4cfb8aa9e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_68418485-5207-4cdc-b111-bd58f3e411b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_45728fef-fabb-4ca6-b6cb-5e84f322ffd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_e5fed7f4-b435-4893-beff-e8e4cfb8aa9e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_45728fef-fabb-4ca6-b6cb-5e84f322ffd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/AccountsReceivableNetNarrativeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#AccountsReceivableNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/AccountsReceivableNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_81b06b43-a748-456e-bc79-7f54d9ec26b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_a3f8c8d1-497a-4259-9a22-0377df9b96f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_81b06b43-a748-456e-bc79-7f54d9ec26b0" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_a3f8c8d1-497a-4259-9a22-0377df9b96f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/InventoryDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_84de8671-378e-47e8-a390-02526b338455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8abc94a-68a6-41e5-9567-362ad7f537f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_84de8671-378e-47e8-a390-02526b338455" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8abc94a-68a6-41e5-9567-362ad7f537f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a2c94c94-eae1-4fba-9cac-85da2770efce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_84de8671-378e-47e8-a390-02526b338455" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a2c94c94-eae1-4fba-9cac-85da2770efce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4ce82d32-dcc1-4b5a-aa79-54d96c2b4fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_84de8671-378e-47e8-a390-02526b338455" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4ce82d32-dcc1-4b5a-aa79-54d96c2b4fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f1bd9b85-897e-4b74-af69-3081f305cda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_84de8671-378e-47e8-a390-02526b338455" xlink:to="loc_us-gaap_InventoryNet_f1bd9b85-897e-4b74-af69-3081f305cda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_4110872a-f4c1-480e-b001-8d685c2dc170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_84de8671-378e-47e8-a390-02526b338455" xlink:to="loc_us-gaap_InventoryCurrentTable_4110872a-f4c1-480e-b001-8d685c2dc170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_233a3f13-8874-46a1-bcd7-8b0297c291f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_4110872a-f4c1-480e-b001-8d685c2dc170" xlink:to="loc_srt_ProductOrServiceAxis_233a3f13-8874-46a1-bcd7-8b0297c291f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b5408f7-e48d-4f31-9bc9-d00dbcf27528" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_233a3f13-8874-46a1-bcd7-8b0297c291f6" xlink:to="loc_srt_ProductsAndServicesDomain_9b5408f7-e48d-4f31-9bc9-d00dbcf27528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InternationalSection351Member_e960d81a-fc38-49c4-8914-b0af9ccb77e0" xlink:href="mdxg-20220930.xsd#mdxg_InternationalSection351Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9b5408f7-e48d-4f31-9bc9-d00dbcf27528" xlink:to="loc_mdxg_InternationalSection351Member_e960d81a-fc38-49c4-8914-b0af9ccb77e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_88040fb9-6146-47ff-87ef-cbc752426ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_4110872a-f4c1-480e-b001-8d685c2dc170" xlink:to="loc_us-gaap_InventoryLineItems_88040fb9-6146-47ff-87ef-cbc752426ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_b5c9c681-b6f9-48d2-984b-5c884bc1f134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_88040fb9-6146-47ff-87ef-cbc752426ff1" xlink:to="loc_us-gaap_InventoryWriteDown_b5c9c681-b6f9-48d2-984b-5c884bc1f134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_476f7d18-9ee2-486c-a7aa-cf39e45c9fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5feed603-c0d8-4117-b848-0a852a438ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_476f7d18-9ee2-486c-a7aa-cf39e45c9fbe" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5feed603-c0d8-4117-b848-0a852a438ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c60da38a-7a4d-4c5e-ad93-ec165c495cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5feed603-c0d8-4117-b848-0a852a438ba8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c60da38a-7a4d-4c5e-ad93-ec165c495cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c60da38a-7a4d-4c5e-ad93-ec165c495cc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ebf67fcd-c721-48a3-ba97-284f1cab8a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ebf67fcd-c721-48a3-ba97-284f1cab8a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_053fdd7c-fda2-4bd7-ac1b-4eb8e683fa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:to="loc_us-gaap_EquipmentMember_053fdd7c-fda2-4bd7-ac1b-4eb8e683fa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_203e490c-93ed-4f07-8c2f-89be7e039d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_203e490c-93ed-4f07-8c2f-89be7e039d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_78bc67b8-9d2e-444b-80c1-8cbb90e2bce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:to="loc_us-gaap_ConstructionInProgressMember_78bc67b8-9d2e-444b-80c1-8cbb90e2bce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AssetRetirementCostMember_4f53ecc2-8b42-412d-8e6c-c6a16735ee54" xlink:href="mdxg-20220930.xsd#mdxg_AssetRetirementCostMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db62a5af-2689-486e-b6fb-191b03d89706" xlink:to="loc_mdxg_AssetRetirementCostMember_4f53ecc2-8b42-412d-8e6c-c6a16735ee54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5feed603-c0d8-4117-b848-0a852a438ba8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c7c9d973-1706-422c-90a9-f1e1db554e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c7c9d973-1706-422c-90a9-f1e1db554e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_b1ec3363-3626-4e9a-9a57-d92a64af21d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_b1ec3363-3626-4e9a-9a57-d92a64af21d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_8bcca185-dd6a-4407-b536-5b25cfd82c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_8bcca185-dd6a-4407-b536-5b25cfd82c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_8c8653d3-9f3a-41aa-8d6e-a596f0daff08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_8c8653d3-9f3a-41aa-8d6e-a596f0daff08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5716efc4-a2b0-4708-a8da-e0306f1294d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d383622-07ef-4637-951c-80809031177a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5716efc4-a2b0-4708-a8da-e0306f1294d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/PropertyandEquipmentNetDepreciationExpenseDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#PropertyandEquipmentNetDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/PropertyandEquipmentNetDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c88b9426-11f2-4483-8b2a-6dcd2121634e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_fedd43e0-de18-451c-bf75-798d58c6301e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c88b9426-11f2-4483-8b2a-6dcd2121634e" xlink:to="loc_us-gaap_Depreciation_fedd43e0-de18-451c-bf75-798d58c6301e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#GoodwillandIntangibleAssetsNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62023912-df1d-4010-8fea-f69a0ae539ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_10bc74ea-9ab8-4466-948a-e7d62c68d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62023912-df1d-4010-8fea-f69a0ae539ca" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_10bc74ea-9ab8-4466-948a-e7d62c68d1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_6b5476ab-f539-45ea-b34c-97fa13000e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_10bc74ea-9ab8-4466-948a-e7d62c68d1e9" xlink:to="loc_us-gaap_ReportingUnitAxis_6b5476ab-f539-45ea-b34c-97fa13000e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_a64af320-5abb-4cec-bacb-7a04c9301b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_6b5476ab-f539-45ea-b34c-97fa13000e40" xlink:to="loc_us-gaap_ReportingUnitDomain_a64af320-5abb-4cec-bacb-7a04c9301b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_WoundSurgicalMember_974e0607-113a-4252-aaa0-aa8a2bf12313" xlink:href="mdxg-20220930.xsd#mdxg_WoundSurgicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_a64af320-5abb-4cec-bacb-7a04c9301b20" xlink:to="loc_mdxg_WoundSurgicalMember_974e0607-113a-4252-aaa0-aa8a2bf12313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RegenerativeMedicineMember_3cd01cae-3987-4998-9d50-9a941fdd4451" xlink:href="mdxg-20220930.xsd#mdxg_RegenerativeMedicineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_a64af320-5abb-4cec-bacb-7a04c9301b20" xlink:to="loc_mdxg_RegenerativeMedicineMember_3cd01cae-3987-4998-9d50-9a941fdd4451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_10bc74ea-9ab8-4466-948a-e7d62c68d1e9" xlink:to="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_88653d5a-bf06-4435-91e0-1094913d9cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_88653d5a-bf06-4435-91e0-1094913d9cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_850033e5-0098-44e4-ab80-ba974ba09c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:to="loc_us-gaap_NumberOfReportableSegments_850033e5-0098-44e4-ab80-ba974ba09c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_b108b02d-56b6-4937-99d0-5892f5fc3867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:to="loc_us-gaap_NumberOfReportingUnits_b108b02d-56b6-4937-99d0-5892f5fc3867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b5e4174c-5274-4f43-aeb5-6be521c5d865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_9539e6ea-819d-424b-9de0-68709fda35e2" xlink:to="loc_us-gaap_Goodwill_b5e4174c-5274-4f43-aeb5-6be521c5d865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#GoodwillandIntangibleAssetsNetActivitySummaryDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e9f31305-f2e1-46be-ba32-4536fe9967a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7cb55b18-888f-4ac9-9367-1230cd155d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e9f31305-f2e1-46be-ba32-4536fe9967a5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7cb55b18-888f-4ac9-9367-1230cd155d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_47e869e2-bc2e-4fcd-8e30-40e6b411679e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7cb55b18-888f-4ac9-9367-1230cd155d34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_47e869e2-bc2e-4fcd-8e30-40e6b411679e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_57ec06cc-ea2b-4d62-a64a-42bc03efe5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_47e869e2-bc2e-4fcd-8e30-40e6b411679e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_57ec06cc-ea2b-4d62-a64a-42bc03efe5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_e07f9aad-2e90-424b-945d-7693070d69ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_57ec06cc-ea2b-4d62-a64a-42bc03efe5d7" xlink:to="loc_us-gaap_PatentsMember_e07f9aad-2e90-424b-945d-7693070d69ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63511ce3-bd46-4262-91fd-58c9ddbe6172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7cb55b18-888f-4ac9-9367-1230cd155d34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63511ce3-bd46-4262-91fd-58c9ddbe6172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ef6accd4-0a78-478d-9013-7e5613fb2354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63511ce3-bd46-4262-91fd-58c9ddbe6172" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ef6accd4-0a78-478d-9013-7e5613fb2354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_82704f08-368e-4c6a-8998-3633fb6f3323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63511ce3-bd46-4262-91fd-58c9ddbe6172" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_82704f08-368e-4c6a-8998-3633fb6f3323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a73483d-ec68-4a83-b01b-9fde9f286abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63511ce3-bd46-4262-91fd-58c9ddbe6172" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a73483d-ec68-4a83-b01b-9fde9f286abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_20443f90-d267-4ccd-9d6c-f276e2063318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e9f31305-f2e1-46be-ba32-4536fe9967a5" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_20443f90-d267-4ccd-9d6c-f276e2063318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_999df169-b950-4772-863b-6a06c5f0e8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_20443f90-d267-4ccd-9d6c-f276e2063318" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_999df169-b950-4772-863b-6a06c5f0e8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2559a728-b055-48d0-950f-96f2559ab4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_999df169-b950-4772-863b-6a06c5f0e8be" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2559a728-b055-48d0-950f-96f2559ab4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_4acfeae7-db71-4a0a-97f7-e8c4f8bb6785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2559a728-b055-48d0-950f-96f2559ab4cb" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_4acfeae7-db71-4a0a-97f7-e8c4f8bb6785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PatentsinProcessMember_94fe248e-3e97-4f69-8ae1-6dc322277b4c" xlink:href="mdxg-20220930.xsd#mdxg_PatentsinProcessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2559a728-b055-48d0-950f-96f2559ab4cb" xlink:to="loc_mdxg_PatentsinProcessMember_94fe248e-3e97-4f69-8ae1-6dc322277b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_589e5f95-bd79-4359-b34c-7f670bd108d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_20443f90-d267-4ccd-9d6c-f276e2063318" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_589e5f95-bd79-4359-b34c-7f670bd108d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_58f5004f-4d59-43ae-b82f-facb620287cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_589e5f95-bd79-4359-b34c-7f670bd108d4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_58f5004f-4d59-43ae-b82f-facb620287cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9eef0386-a1dc-4efa-8d6b-950d2e625fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_589e5f95-bd79-4359-b34c-7f670bd108d4" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9eef0386-a1dc-4efa-8d6b-950d2e625fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_76bb1b72-2b9a-49c0-94ca-73fcbc0bf6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_589e5f95-bd79-4359-b34c-7f670bd108d4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_76bb1b72-2b9a-49c0-94ca-73fcbc0bf6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetAmortizationExpenseDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#GoodwillandIntangibleAssetsNetAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/GoodwillandIntangibleAssetsNetAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d5162117-0baf-4e65-aa99-568f18a7c2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b243a401-15fb-404f-8fe6-74e0ec149935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d5162117-0baf-4e65-aa99-568f18a7c2eb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b243a401-15fb-404f-8fe6-74e0ec149935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e6be2457-25b1-454e-bfe2-5e6d61d159c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_b8d3afaa-10ee-4573-a9d1-65f21c728bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e6be2457-25b1-454e-bfe2-5e6d61d159c7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_b8d3afaa-10ee-4573-a9d1-65f21c728bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_9161fe2e-9895-459f-a34d-36cfacab2b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_b8d3afaa-10ee-4573-a9d1-65f21c728bca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_9161fe2e-9895-459f-a34d-36cfacab2b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1cff6307-5e37-4d24-a505-67aa4e7b8e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_b8d3afaa-10ee-4573-a9d1-65f21c728bca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1cff6307-5e37-4d24-a505-67aa4e7b8e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_86025591-ffd3-4be9-832c-aab48354fc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_b8d3afaa-10ee-4573-a9d1-65f21c728bca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_86025591-ffd3-4be9-832c-aab48354fc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c40cde2a-9fbc-4235-b92c-e87150e5a318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_b8d3afaa-10ee-4573-a9d1-65f21c728bca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c40cde2a-9fbc-4235-b92c-e87150e5a318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_245b6095-9eaf-4db2-97b3-aa66b45b2419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_b8d3afaa-10ee-4573-a9d1-65f21c728bca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_245b6095-9eaf-4db2-97b3-aa66b45b2419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_47b21d9c-c8d9-427a-b61a-f5f7ef229d6b" xlink:href="mdxg-20220930.xsd#mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_b8d3afaa-10ee-4573-a9d1-65f21c728bca" xlink:to="loc_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_47b21d9c-c8d9-427a-b61a-f5f7ef229d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_155f5a5f-49af-411d-b47b-7870f6f37c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_b8d3afaa-10ee-4573-a9d1-65f21c728bca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_155f5a5f-49af-411d-b47b-7870f6f37c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a25eefd9-c3fa-4660-9f3d-4551987df2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_17bb2aac-0f84-4b78-aafd-4ca6ca1e928b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a25eefd9-c3fa-4660-9f3d-4551987df2c9" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_17bb2aac-0f84-4b78-aafd-4ca6ca1e928b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_265af927-4ea1-4bf7-b114-dfd596476b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a25eefd9-c3fa-4660-9f3d-4551987df2c9" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_265af927-4ea1-4bf7-b114-dfd596476b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedRebates_5d813855-7414-43ff-b78a-6f384b780e3a" xlink:href="mdxg-20220930.xsd#mdxg_AccruedRebates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a25eefd9-c3fa-4660-9f3d-4551987df2c9" xlink:to="loc_mdxg_AccruedRebates_5d813855-7414-43ff-b78a-6f384b780e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedAdministrativeFeesCurrent_afd22769-4324-45cb-bcf0-7c179ef91d39" xlink:href="mdxg-20220930.xsd#mdxg_AccruedAdministrativeFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a25eefd9-c3fa-4660-9f3d-4551987df2c9" xlink:to="loc_mdxg_AccruedAdministrativeFeesCurrent_afd22769-4324-45cb-bcf0-7c179ef91d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_fec5d01b-a3ca-4b1b-a385-b43237e01a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a25eefd9-c3fa-4660-9f3d-4551987df2c9" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_fec5d01b-a3ca-4b1b-a385-b43237e01a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedTravel_3e8df5ba-b88c-4cc0-98c4-36806f0de877" xlink:href="mdxg-20220930.xsd#mdxg_AccruedTravel"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a25eefd9-c3fa-4660-9f3d-4551987df2c9" xlink:to="loc_mdxg_AccruedTravel_3e8df5ba-b88c-4cc0-98c4-36806f0de877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedClinicalTrialsCurrent_167d26f5-3f29-4813-9369-8df1fa75e0b8" xlink:href="mdxg-20220930.xsd#mdxg_AccruedClinicalTrialsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a25eefd9-c3fa-4660-9f3d-4551987df2c9" xlink:to="loc_mdxg_AccruedClinicalTrialsCurrent_167d26f5-3f29-4813-9369-8df1fa75e0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ddea4502-7b14-4413-b13c-01a345cd173c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a25eefd9-c3fa-4660-9f3d-4551987df2c9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ddea4502-7b14-4413-b13c-01a345cd173c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_65e8f54b-b662-483c-b929-c79dcfe08b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a25eefd9-c3fa-4660-9f3d-4551987df2c9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_65e8f54b-b662-483c-b929-c79dcfe08b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_64b3feee-2697-4985-8ce6-7f62d5a04183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_64b3feee-2697-4985-8ce6-7f62d5a04183" xlink:to="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_57009573-96d2-4b56-a426-b775fce3d04d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:to="loc_srt_RangeAxis_57009573-96d2-4b56-a426-b775fce3d04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb87b2d4-a6bb-47a6-9c33-6fc0a4274310" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_57009573-96d2-4b56-a426-b775fce3d04d" xlink:to="loc_srt_RangeMember_eb87b2d4-a6bb-47a6-9c33-6fc0a4274310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7ed26966-e95b-42c2-aa01-7db1b5ed5f3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb87b2d4-a6bb-47a6-9c33-6fc0a4274310" xlink:to="loc_srt_MinimumMember_7ed26966-e95b-42c2-aa01-7db1b5ed5f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2938003b-d98b-4696-8774-d1046d0940c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb87b2d4-a6bb-47a6-9c33-6fc0a4274310" xlink:to="loc_srt_MaximumMember_2938003b-d98b-4696-8774-d1046d0940c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d501ce43-4ada-40a9-bc6f-7d745455d551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d501ce43-4ada-40a9-bc6f-7d745455d551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fd9f1e79-00ed-4f21-b2bc-030622353a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d501ce43-4ada-40a9-bc6f-7d745455d551" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fd9f1e79-00ed-4f21-b2bc-030622353a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_19981378-506c-4cbb-bf83-cf984b4d54b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fd9f1e79-00ed-4f21-b2bc-030622353a8c" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_19981378-506c-4cbb-bf83-cf984b4d54b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5080e43f-5c42-4e78-be33-c1c5c46d75cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:to="loc_us-gaap_DebtInstrumentAxis_5080e43f-5c42-4e78-be33-c1c5c46d75cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5080e43f-5c42-4e78-be33-c1c5c46d75cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementTermLoanMember_f5539542-8a09-4d31-8d85-21b1ffe16966" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:to="loc_mdxg_HayfinLoanAgreementTermLoanMember_f5539542-8a09-4d31-8d85-21b1ffe16966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_CreditFacilitiesMember_08e70334-e364-4d36-bd29-1b12616d8b21" xlink:href="mdxg-20220930.xsd#mdxg_CreditFacilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:to="loc_mdxg_CreditFacilitiesMember_08e70334-e364-4d36-bd29-1b12616d8b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_fb5fc64b-6cf4-4aec-a7ff-ae40101ee1b9" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:to="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_fb5fc64b-6cf4-4aec-a7ff-ae40101ee1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TermLoanAgreementMember_707e359d-3449-4886-9c81-0a3684777079" xlink:href="mdxg-20220930.xsd#mdxg_TermLoanAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1664cf64-3cc6-49cd-a8fe-303ea62c87c2" xlink:to="loc_mdxg_TermLoanAgreementMember_707e359d-3449-4886-9c81-0a3684777079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_4cc81245-652e-4c16-89fb-d144e0e8ee44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:to="loc_us-gaap_VariableRateAxis_4cc81245-652e-4c16-89fb-d144e0e8ee44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_1477c9e9-9b6e-498a-bff3-c53f72e1767a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_4cc81245-652e-4c16-89fb-d144e0e8ee44" xlink:to="loc_us-gaap_VariableRateDomain_1477c9e9-9b6e-498a-bff3-c53f72e1767a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a1158ef8-200c-447d-979d-b4ddfc9235be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1477c9e9-9b6e-498a-bff3-c53f72e1767a" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a1158ef8-200c-447d-979d-b4ddfc9235be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_81275360-2ab1-4a29-b045-83e64affa270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1477c9e9-9b6e-498a-bff3-c53f72e1767a" xlink:to="loc_us-gaap_PrimeRateMember_81275360-2ab1-4a29-b045-83e64affa270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d500b682-0cb6-458b-bdb3-35095cc38893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1477c9e9-9b6e-498a-bff3-c53f72e1767a" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d500b682-0cb6-458b-bdb3-35095cc38893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_93eb60cc-619a-4d62-a3ae-7205c444e09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_93eb60cc-619a-4d62-a3ae-7205c444e09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ab515e3-6605-43d7-a354-c8e38415bb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_93eb60cc-619a-4d62-a3ae-7205c444e09b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ab515e3-6605-43d7-a354-c8e38415bb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_c122c1cc-4528-42a7-a703-8fd4314a7987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ab515e3-6605-43d7-a354-c8e38415bb25" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_c122c1cc-4528-42a7-a703-8fd4314a7987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7642d292-84ad-4f66-8ea3-91670cf5cba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ab515e3-6605-43d7-a354-c8e38415bb25" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7642d292-84ad-4f66-8ea3-91670cf5cba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_4c155b81-9721-41c0-a83d-9ed2342ede63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ab515e3-6605-43d7-a354-c8e38415bb25" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_4c155b81-9721-41c0-a83d-9ed2342ede63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98dd858a-63ce-460d-806b-75c0c106130f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_84fb4a5b-b7b2-46c2-80a1-efc4c8e2c505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_84fb4a5b-b7b2-46c2-80a1-efc4c8e2c505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentInterestRateFloorPercentage_4b08e9bc-e903-44f7-a27e-8a98d6bcef9c" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentInterestRateFloorPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_mdxg_DebtInstrumentInterestRateFloorPercentage_4b08e9bc-e903-44f7-a27e-8a98d6bcef9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cbcc410a-a702-4d3f-8178-8df7a175d4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cbcc410a-a702-4d3f-8178-8df7a175d4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentDefaultInterestRate_0de1b39a-42bf-4b6b-b2cf-5f6431b4ff0c" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentDefaultInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_mdxg_DebtInstrumentDefaultInterestRate_0de1b39a-42bf-4b6b-b2cf-5f6431b4ff0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1ef46109-e9d0-42d3-8d02-ada34c24c107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1ef46109-e9d0-42d3-8d02-ada34c24c107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtCovenantMinimumLiquidity_2f6d808c-42ff-4ce3-8519-66a825b292da" xlink:href="mdxg-20220930.xsd#mdxg_DebtCovenantMinimumLiquidity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_mdxg_DebtCovenantMinimumLiquidity_2f6d808c-42ff-4ce3-8519-66a825b292da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent_269c929d-c363-4b0c-8db6-eb670f15e262" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent_269c929d-c363-4b0c-8db6-eb670f15e262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage_782e3996-317e-4c8f-8dd3-122e61aece2c" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage_782e3996-317e-4c8f-8dd3-122e61aece2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_354ed744-2447-4262-9eaa-62ba709af3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7b2fbb9-3736-457b-a5c0-d6e46f103877" xlink:to="loc_us-gaap_LongTermDebtFairValue_354ed744-2447-4262-9eaa-62ba709af3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanDebtIssuanceCostsDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b40a5d2c-1711-4551-9fa6-59e8ba0efeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_245a8e7a-1646-40d5-a2c6-5ef27d1c659d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b40a5d2c-1711-4551-9fa6-59e8ba0efeaf" xlink:to="loc_us-gaap_DebtInstrumentTable_245a8e7a-1646-40d5-a2c6-5ef27d1c659d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ac4c7c1f-b960-4d40-8d26-fb1b6d1d9007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_245a8e7a-1646-40d5-a2c6-5ef27d1c659d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ac4c7c1f-b960-4d40-8d26-fb1b6d1d9007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fb4d8bba-4abf-4525-8b75-8edf90857e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ac4c7c1f-b960-4d40-8d26-fb1b6d1d9007" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fb4d8bba-4abf-4525-8b75-8edf90857e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_69c329ad-c58a-4402-860c-9646e6595fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fb4d8bba-4abf-4525-8b75-8edf90857e45" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_69c329ad-c58a-4402-860c-9646e6595fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b8b2d6ca-5b48-4e06-90fa-920132c96223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_245a8e7a-1646-40d5-a2c6-5ef27d1c659d" xlink:to="loc_us-gaap_DebtInstrumentAxis_b8b2d6ca-5b48-4e06-90fa-920132c96223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e8e1f6c-6ed4-4738-8a4b-5f9abc99f2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b8b2d6ca-5b48-4e06-90fa-920132c96223" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e8e1f6c-6ed4-4738-8a4b-5f9abc99f2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_CreditFacilitiesMember_b7e98bc8-b7bb-42f3-83b2-ef478cdd4013" xlink:href="mdxg-20220930.xsd#mdxg_CreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4e8e1f6c-6ed4-4738-8a4b-5f9abc99f2fa" xlink:to="loc_mdxg_CreditFacilitiesMember_b7e98bc8-b7bb-42f3-83b2-ef478cdd4013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementTermLoanMember_91bb9972-0366-443c-9d8e-6b53dc2be57e" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdxg_CreditFacilitiesMember_b7e98bc8-b7bb-42f3-83b2-ef478cdd4013" xlink:to="loc_mdxg_HayfinLoanAgreementTermLoanMember_91bb9972-0366-443c-9d8e-6b53dc2be57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_6b13a12a-e96a-49c7-a85d-71e5ca824067" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdxg_CreditFacilitiesMember_b7e98bc8-b7bb-42f3-83b2-ef478cdd4013" xlink:to="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_6b13a12a-e96a-49c7-a85d-71e5ca824067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ad354b02-28d5-4e5a-b929-49ee71cee8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_245a8e7a-1646-40d5-a2c6-5ef27d1c659d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ad354b02-28d5-4e5a-b929-49ee71cee8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_aab77f2d-7616-4939-b163-d3b6618f8113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad354b02-28d5-4e5a-b929-49ee71cee8f6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_aab77f2d-7616-4939-b163-d3b6618f8113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e451d3fe-6fdd-412f-bddf-981126c87b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad354b02-28d5-4e5a-b929-49ee71cee8f6" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e451d3fe-6fdd-412f-bddf-981126c87b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanBalancesDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4bdf9bb7-e421-43e4-be6a-43925fd4d0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a737183b-48ad-462f-a95a-72a5e7e006f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4bdf9bb7-e421-43e4-be6a-43925fd4d0fb" xlink:to="loc_us-gaap_DebtInstrumentTable_a737183b-48ad-462f-a95a-72a5e7e006f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c29e31c5-382c-405b-b117-a283610e6d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a737183b-48ad-462f-a95a-72a5e7e006f3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c29e31c5-382c-405b-b117-a283610e6d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0fd62672-4178-433d-9310-9107963b8de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c29e31c5-382c-405b-b117-a283610e6d1d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0fd62672-4178-433d-9310-9107963b8de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_6bd9a8b5-e948-47b2-aed5-41f6bf249709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0fd62672-4178-433d-9310-9107963b8de5" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_6bd9a8b5-e948-47b2-aed5-41f6bf249709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b3e30e4e-48bb-4db8-8fa1-f4c37dc10314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a737183b-48ad-462f-a95a-72a5e7e006f3" xlink:to="loc_us-gaap_DebtInstrumentAxis_b3e30e4e-48bb-4db8-8fa1-f4c37dc10314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c70988ad-65b2-44d1-a7ff-67ce8e518870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b3e30e4e-48bb-4db8-8fa1-f4c37dc10314" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c70988ad-65b2-44d1-a7ff-67ce8e518870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementTermLoanMember_42ec08ef-abd2-4c31-b546-0e93840cd4be" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c70988ad-65b2-44d1-a7ff-67ce8e518870" xlink:to="loc_mdxg_HayfinLoanAgreementTermLoanMember_42ec08ef-abd2-4c31-b546-0e93840cd4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a737183b-48ad-462f-a95a-72a5e7e006f3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d7b96757-99d1-4e4b-b0ed-e8fe538c8632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d7b96757-99d1-4e4b-b0ed-e8fe538c8632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a682a4dc-6b7d-4720-8b8c-eafca297ebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a682a4dc-6b7d-4720-8b8c-eafca297ebe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_22484874-1395-4a46-a529-08f65943125f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_22484874-1395-4a46-a529-08f65943125f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d85be014-5ab2-491e-9acb-46a96d3dccac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6610222e-533f-4250-a45a-93391386fe08" xlink:to="loc_us-gaap_LongTermDebt_d85be014-5ab2-491e-9acb-46a96d3dccac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_42fa6e9e-6fa5-4c60-9c88-80c569b0ecf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_449ca469-7289-4b70-8e5c-7caddd5f5659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42fa6e9e-6fa5-4c60-9c88-80c569b0ecf4" xlink:to="loc_us-gaap_DebtInstrumentTable_449ca469-7289-4b70-8e5c-7caddd5f5659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d2219b4a-78f9-4553-9a90-5f8d7cfdd31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_449ca469-7289-4b70-8e5c-7caddd5f5659" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d2219b4a-78f9-4553-9a90-5f8d7cfdd31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_17a8f092-76a7-49ee-9da7-d080c4a1b9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d2219b4a-78f9-4553-9a90-5f8d7cfdd31e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_17a8f092-76a7-49ee-9da7-d080c4a1b9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_24065141-e640-42f7-9807-b91820c0c514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_17a8f092-76a7-49ee-9da7-d080c4a1b9bc" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_24065141-e640-42f7-9807-b91820c0c514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_225434b6-db0c-47cb-9127-dc189c32795a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_449ca469-7289-4b70-8e5c-7caddd5f5659" xlink:to="loc_us-gaap_DebtInstrumentAxis_225434b6-db0c-47cb-9127-dc189c32795a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0ae30ea1-07e0-4229-abaf-42ceed964b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_225434b6-db0c-47cb-9127-dc189c32795a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0ae30ea1-07e0-4229-abaf-42ceed964b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementTermLoanMember_cd22139f-caa0-41f2-9f74-a40191f44904" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0ae30ea1-07e0-4229-abaf-42ceed964b81" xlink:to="loc_mdxg_HayfinLoanAgreementTermLoanMember_cd22139f-caa0-41f2-9f74-a40191f44904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_33584f04-f2c4-4956-a2a2-1b4c91440755" xlink:href="mdxg-20220930.xsd#mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0ae30ea1-07e0-4229-abaf-42ceed964b81" xlink:to="loc_mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember_33584f04-f2c4-4956-a2a2-1b4c91440755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_449ca469-7289-4b70-8e5c-7caddd5f5659" xlink:to="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c0798906-e4fc-4cd2-9a34-6943706f266a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c0798906-e4fc-4cd2-9a34-6943706f266a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DebtInstrumentCommitmentFees_3d8b6ed5-d257-4347-83cd-b555adb55fb9" xlink:href="mdxg-20220930.xsd#mdxg_DebtInstrumentCommitmentFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:to="loc_mdxg_DebtInstrumentCommitmentFees_3d8b6ed5-d257-4347-83cd-b555adb55fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7af63a41-0cf3-4cfe-9b09-8136bc3cf6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7af63a41-0cf3-4cfe-9b09-8136bc3cf6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_55dc6ae3-1e7c-462d-825d-2295ceca2772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_55dc6ae3-1e7c-462d-825d-2295ceca2772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_141cdef0-ef8c-4788-9f6e-25e2375ca783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91532997-801f-4424-960f-f1276ea504cd" xlink:to="loc_us-gaap_InterestExpenseDebt_141cdef0-ef8c-4788-9f6e-25e2375ca783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#LongTermDebtNetTermLoanMaturityDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8ce27d20-02dd-404f-bd57-c48467b5016f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_168f5d52-d0b6-4222-995a-3d1fcd92ce68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ce27d20-02dd-404f-bd57-c48467b5016f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_168f5d52-d0b6-4222-995a-3d1fcd92ce68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9c995c4f-9090-4aa3-a058-16920b42f9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ce27d20-02dd-404f-bd57-c48467b5016f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9c995c4f-9090-4aa3-a058-16920b42f9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8090101a-42bc-4c18-a267-0c441a37fa39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ce27d20-02dd-404f-bd57-c48467b5016f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8090101a-42bc-4c18-a267-0c441a37fa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_82c8d10a-41fe-4546-be9d-8f1fb485884d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ce27d20-02dd-404f-bd57-c48467b5016f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_82c8d10a-41fe-4546-be9d-8f1fb485884d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f82d8f72-e151-45db-8822-ea449cf38780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ce27d20-02dd-404f-bd57-c48467b5016f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f82d8f72-e151-45db-8822-ea449cf38780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_LongTermDebtMaturityAfterYearFour_7246fcb8-dcb6-4f70-816d-cc0770438a89" xlink:href="mdxg-20220930.xsd#mdxg_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ce27d20-02dd-404f-bd57-c48467b5016f" xlink:to="loc_mdxg_LongTermDebtMaturityAfterYearFour_7246fcb8-dcb6-4f70-816d-cc0770438a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4199d930-ac9b-4adf-be97-22b163fa2d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ce27d20-02dd-404f-bd57-c48467b5016f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4199d930-ac9b-4adf-be97-22b163fa2d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#NetLossPerCommonShareBasicNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0b195b59-d509-46a6-8a17-e2c8ee41eb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6374c104-18b6-4b73-885b-469404c7e6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b195b59-d509-46a6-8a17-e2c8ee41eb28" xlink:to="loc_us-gaap_NetIncomeLoss_6374c104-18b6-4b73-885b-469404c7e6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_a5feeb9f-7451-4801-a1c6-944e2b7f836c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b195b59-d509-46a6-8a17-e2c8ee41eb28" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_a5feeb9f-7451-4801-a1c6-944e2b7f836c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_861317b2-28c7-47bc-b8d6-e9322213c33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_a5feeb9f-7451-4801-a1c6-944e2b7f836c" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_861317b2-28c7-47bc-b8d6-e9322213c33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature_863828f9-a48f-4d41-96f8-160d1bcee5af" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_a5feeb9f-7451-4801-a1c6-944e2b7f836c" xlink:to="loc_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature_863828f9-a48f-4d41-96f8-160d1bcee5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_9f2a7b03-cf85-451e-9dc2-62c6b1288845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_a5feeb9f-7451-4801-a1c6-944e2b7f836c" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_9f2a7b03-cf85-451e-9dc2-62c6b1288845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f5960313-ced9-40d5-b7c7-12701df224a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b195b59-d509-46a6-8a17-e2c8ee41eb28" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f5960313-ced9-40d5-b7c7-12701df224a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14f84fe4-e9a2-4d00-8d8b-4bbc5a48e11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b195b59-d509-46a6-8a17-e2c8ee41eb28" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14f84fe4-e9a2-4d00-8d8b-4bbc5a48e11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7d002f05-51b5-469d-a08d-a8c0d174074f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b195b59-d509-46a6-8a17-e2c8ee41eb28" xlink:to="loc_us-gaap_EarningsPerShareBasic_7d002f05-51b5-469d-a08d-a8c0d174074f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#NetLossPerCommonShareDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f8e6607c-5dbb-4628-86af-07276a9460ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4054153c-2314-440a-99e6-e84eea47e003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f8e6607c-5dbb-4628-86af-07276a9460ef" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4054153c-2314-440a-99e6-e84eea47e003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_009c0f7d-cec8-4242-beec-d2eed196a3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f8e6607c-5dbb-4628-86af-07276a9460ef" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_009c0f7d-cec8-4242-beec-d2eed196a3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments_73bf2cc5-d4f9-4e98-90f5-2b62cadeafb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f8e6607c-5dbb-4628-86af-07276a9460ef" xlink:to="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments_73bf2cc5-d4f9-4e98-90f5-2b62cadeafb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7deb28b0-4637-4353-a3bc-058acad76551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f8e6607c-5dbb-4628-86af-07276a9460ef" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7deb28b0-4637-4353-a3bc-058acad76551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5a66fbf1-4c2d-4cfe-b387-d04fd8f46687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f8e6607c-5dbb-4628-86af-07276a9460ef" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5a66fbf1-4c2d-4cfe-b387-d04fd8f46687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d3e6b9b7-c287-4652-8f6e-c6caab3ff8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f8e6607c-5dbb-4628-86af-07276a9460ef" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d3e6b9b7-c287-4652-8f6e-c6caab3ff8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f64f789c-5786-4484-be63-047694f4a852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f8e6607c-5dbb-4628-86af-07276a9460ef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f64f789c-5786-4484-be63-047694f4a852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3943a438-b920-4e58-b3c1-6babd0ef792e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f8e6607c-5dbb-4628-86af-07276a9460ef" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3943a438-b920-4e58-b3c1-6babd0ef792e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_303c323e-37b0-471e-ad71-ccbb4539e33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f8e6607c-5dbb-4628-86af-07276a9460ef" xlink:to="loc_us-gaap_EarningsPerShareDiluted_303c323e-37b0-471e-ad71-ccbb4539e33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#NetLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_36ee6e6c-4ac9-45f9-b731-c90cb28dee79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08c7673f-cfdd-4f53-874c-4f1910f69c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_36ee6e6c-4ac9-45f9-b731-c90cb28dee79" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08c7673f-cfdd-4f53-874c-4f1910f69c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c787f5ea-dd9d-4e05-b538-a3ad9aa741a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08c7673f-cfdd-4f53-874c-4f1910f69c45" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c787f5ea-dd9d-4e05-b538-a3ad9aa741a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c787f5ea-dd9d-4e05-b538-a3ad9aa741a0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_10987b39-14c4-4769-a09d-25b7456c8788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_10987b39-14c4-4769-a09d-25b7456c8788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fe755abe-a0dc-4da3-9434-9a9e3345e591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fe755abe-a0dc-4da3-9434-9a9e3345e591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_dba424cf-e07d-43b8-90f7-6a65a71e89d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_RestrictedStockMember_dba424cf-e07d-43b8-90f7-6a65a71e89d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ac5b69a8-bc42-4c4a-9150-5f9232dff73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ac5b69a8-bc42-4c4a-9150-5f9232dff73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f19fae22-e4d3-4ee6-942b-ca8efd246119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_PerformanceSharesMember_f19fae22-e4d3-4ee6-942b-ca8efd246119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5abcc199-b569-40b9-846d-b00214a5206c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_734fd40f-4221-4c93-a693-c340f3031f19" xlink:to="loc_us-gaap_EmployeeStockMember_5abcc199-b569-40b9-846d-b00214a5206c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_547a5db6-e2f0-45c6-a372-236f0bb7e267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08c7673f-cfdd-4f53-874c-4f1910f69c45" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_547a5db6-e2f0-45c6-a372-236f0bb7e267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c47d9f5-0c41-4913-a1d8-e9c410731db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_547a5db6-e2f0-45c6-a372-236f0bb7e267" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c47d9f5-0c41-4913-a1d8-e9c410731db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#EquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_59e7f7c2-0f58-4e40-90ab-415a0a070ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_59e7f7c2-0f58-4e40-90ab-415a0a070ab0" xlink:to="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0bbb76d8-ff9c-4b2a-84e7-5b5f6b3cd3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0bbb76d8-ff9c-4b2a-84e7-5b5f6b3cd3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_41124793-9646-4c71-9fa1-9c1f507bfa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0bbb76d8-ff9c-4b2a-84e7-5b5f6b3cd3cd" xlink:to="loc_us-gaap_ClassOfStockDomain_41124793-9646-4c71-9fa1-9c1f507bfa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassBMember_f9a2a5c4-9e1b-440d-bb72-4ad6cc87b19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_41124793-9646-4c71-9fa1-9c1f507bfa2c" xlink:to="loc_us-gaap_PreferredClassBMember_f9a2a5c4-9e1b-440d-bb72-4ad6cc87b19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c01c540e-b519-4921-964c-7f01944ac3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_41124793-9646-4c71-9fa1-9c1f507bfa2c" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c01c540e-b519-4921-964c-7f01944ac3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAxis_8695418e-0465-44fa-9caf-1d851330d5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:to="loc_us-gaap_DividendsAxis_8695418e-0465-44fa-9caf-1d851330d5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain_dfcf1086-0535-48bd-b106-b5f318af2e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAxis_8695418e-0465-44fa-9caf-1d851330d5a8" xlink:to="loc_us-gaap_DividendsDomain_dfcf1086-0535-48bd-b106-b5f318af2e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member_29b18910-f36c-4221-b473-2fed8d65353c" xlink:href="mdxg-20220930.xsd#mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsDomain_dfcf1086-0535-48bd-b106-b5f318af2e40" xlink:to="loc_mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member_29b18910-f36c-4221-b473-2fed8d65353c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member_a847d694-c0ea-42a1-89f8-fbb2b40655b3" xlink:href="mdxg-20220930.xsd#mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsDomain_dfcf1086-0535-48bd-b106-b5f318af2e40" xlink:to="loc_mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member_a847d694-c0ea-42a1-89f8-fbb2b40655b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_27ab1647-0769-4272-a892-380b9233b496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:to="loc_us-gaap_AwardTypeAxis_27ab1647-0769-4272-a892-380b9233b496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db031b14-ee24-435d-a451-717562376ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_27ab1647-0769-4272-a892-380b9233b496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db031b14-ee24-435d-a451-717562376ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember_6d0869f5-fc0d-4bf7-aa4c-5650eb769fab" xlink:href="mdxg-20220930.xsd#mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db031b14-ee24-435d-a451-717562376ac4" xlink:to="loc_mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember_6d0869f5-fc0d-4bf7-aa4c-5650eb769fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_133ed926-e9ab-4e0f-81a4-62182be5bf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db031b14-ee24-435d-a451-717562376ac4" xlink:to="loc_us-gaap_PerformanceSharesMember_133ed926-e9ab-4e0f-81a4-62182be5bf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bb3cbc0d-597a-4590-b346-2753639f448e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db031b14-ee24-435d-a451-717562376ac4" xlink:to="loc_us-gaap_EmployeeStockMember_bb3cbc0d-597a-4590-b346-2753639f448e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_f6154ec0-3d58-4721-a5dc-cb39145fa1fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:to="loc_srt_TitleOfIndividualAxis_f6154ec0-3d58-4721-a5dc-cb39145fa1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96a3ea7a-b77d-4e28-b983-e970c9274403" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_f6154ec0-3d58-4721-a5dc-cb39145fa1fd" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96a3ea7a-b77d-4e28-b983-e970c9274403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_3fe5b8c7-7278-4794-bfe1-d347f9025481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96a3ea7a-b77d-4e28-b983-e970c9274403" xlink:to="loc_srt_ExecutiveOfficerMember_3fe5b8c7-7278-4794-bfe1-d347f9025481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd11a5d2-db8d-4dba-867b-5c23c21dd0bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:to="loc_srt_RangeAxis_fd11a5d2-db8d-4dba-867b-5c23c21dd0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87493f61-ae26-4b8c-9f53-43e0dba41f06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fd11a5d2-db8d-4dba-867b-5c23c21dd0bc" xlink:to="loc_srt_RangeMember_87493f61-ae26-4b8c-9f53-43e0dba41f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7134da3c-dba9-4c43-a2d0-4f14a0ee0e34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_87493f61-ae26-4b8c-9f53-43e0dba41f06" xlink:to="loc_srt_MinimumMember_7134da3c-dba9-4c43-a2d0-4f14a0ee0e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8ef92269-53d6-4583-bcf1-c19426cbe314" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_87493f61-ae26-4b8c-9f53-43e0dba41f06" xlink:to="loc_srt_MaximumMember_8ef92269-53d6-4583-bcf1-c19426cbe314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableTable_bb88581e-b233-40ce-b749-650153945460" xlink:to="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityDividendRatePercentage_6d01291f-a602-434e-8c0a-cb9496343aa1" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityDividendRatePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityDividendRatePercentage_6d01291f-a602-434e-8c0a-cb9496343aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_d3428a09-8cd2-4a32-a31a-4dd9bdd4495e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_d3428a09-8cd2-4a32-a31a-4dd9bdd4495e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityConversionPricePerShare_68214a14-3251-4f29-b9e3-cfe7acf959b6" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityConversionPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityConversionPricePerShare_68214a14-3251-4f29-b9e3-cfe7acf959b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger_67110e93-3d76-4b9c-b3b6-5b13ade291b3" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger_67110e93-3d76-4b9c-b3b6-5b13ade291b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityConversionThresholdTradingDays_79936511-501e-4eeb-a1ea-366ba0f12b1f" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityConversionThresholdTradingDays"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityConversionThresholdTradingDays_79936511-501e-4eeb-a1ea-366ba0f12b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityThresholdConsecutiveTradingDays_be20a934-27be-4951-9b5d-ad6e33dc02ad" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityThresholdConsecutiveTradingDays_be20a934-27be-4951-9b5d-ad6e33dc02ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders_071d54f1-d981-4045-b41c-30611417217b" xlink:href="mdxg-20220930.xsd#mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders_071d54f1-d981-4045-b41c-30611417217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis_f29ba733-ee7e-450d-a8c1-48cd0658dc19" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis_f29ba733-ee7e-450d-a8c1-48cd0658dc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_3fd49363-0906-41d5-87ea-3eebda646104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_DividendsPreferredStock_3fd49363-0906-41d5-87ea-3eebda646104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_DividendAccumulatedByNotPaid_3881e5a3-a5b1-446c-ad36-b2929e57719c" xlink:href="mdxg-20220930.xsd#mdxg_DividendAccumulatedByNotPaid"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_DividendAccumulatedByNotPaid_3881e5a3-a5b1-446c-ad36-b2929e57719c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable_39a89d7f-5228-42f1-b376-ea7d035a1b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_PreferredStockConvertibleSharesIssuable_39a89d7f-5228-42f1-b376-ea7d035a1b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_cbd0be4b-16bc-43e7-95f4-f081daef3eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_cbd0be4b-16bc-43e7-95f4-f081daef3eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5fba7aeb-7ba2-4aa9-9a2d-ac1be3fe2da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5fba7aeb-7ba2-4aa9-9a2d-ac1be3fe2da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_9a6614d0-b5f8-4620-b7ae-82168dd1a7f5" xlink:href="mdxg-20220930.xsd#mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_9a6614d0-b5f8-4620-b7ae-82168dd1a7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8ef52895-1b3a-459f-b290-a1768e60f618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8ef52895-1b3a-459f-b290-a1768e60f618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays_b9309421-fe6e-4673-87e4-cd35f76f8b7c" xlink:href="mdxg-20220930.xsd#mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays_b9309421-fe6e-4673-87e4-cd35f76f8b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_378a2f67-3312-40dc-82bc-d11c45893efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_378a2f67-3312-40dc-82bc-d11c45893efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_f7df05e5-c1b0-4173-bada-3c28c63fdd16" xlink:href="mdxg-20220930.xsd#mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_f7df05e5-c1b0-4173-bada-3c28c63fdd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f0520b21-2de1-4650-8e65-cc241d3cce45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f0520b21-2de1-4650-8e65-cc241d3cce45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2db834e4-3627-440b-b467-c66f8574e80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2db834e4-3627-440b-b467-c66f8574e80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AccruedESPPPayrollDeferrals_d5124197-56d5-48fe-bb26-db775a41f13d" xlink:href="mdxg-20220930.xsd#mdxg_AccruedESPPPayrollDeferrals"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_mdxg_AccruedESPPPayrollDeferrals_d5124197-56d5-48fe-bb26-db775a41f13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_419443d2-cf3a-40e3-b44d-e2141da82c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_5be1cc99-09e0-46ae-bc10-4fbe9ceaf45a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_419443d2-cf3a-40e3-b44d-e2141da82c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#EquityChangesinSeriesBPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4970b231-b239-4dd4-b060-796df98c4d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_090c7dc1-10b7-49da-b80b-7cccfddc3b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4970b231-b239-4dd4-b060-796df98c4d69" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_090c7dc1-10b7-49da-b80b-7cccfddc3b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a9a7cdad-1497-4b6d-a072-5edc60815bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_090c7dc1-10b7-49da-b80b-7cccfddc3b21" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a9a7cdad-1497-4b6d-a072-5edc60815bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f89d03c-0ede-45d2-8ba3-d75e972983c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a9a7cdad-1497-4b6d-a072-5edc60815bde" xlink:to="loc_us-gaap_ClassOfStockDomain_4f89d03c-0ede-45d2-8ba3-d75e972983c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_fe4e9032-016c-4bb0-b86d-275a05f45ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4f89d03c-0ede-45d2-8ba3-d75e972983c6" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_fe4e9032-016c-4bb0-b86d-275a05f45ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cf536e54-4d70-43ed-a0b2-99a6227e5000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_090c7dc1-10b7-49da-b80b-7cccfddc3b21" xlink:to="loc_us-gaap_ClassOfStockLineItems_cf536e54-4d70-43ed-a0b2-99a6227e5000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf536e54-4d70-43ed-a0b2-99a6227e5000" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_f82ab011-9f40-45d7-b6ab-09390f17a46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_f82ab011-9f40-45d7-b6ab-09390f17a46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52553983-2cab-4e86-b01b-1e3c8217f716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52553983-2cab-4e86-b01b-1e3c8217f716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_888bf40b-df54-4b8c-9565-222c911fd58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:to="loc_us-gaap_DividendsPreferredStock_888bf40b-df54-4b8c-9565-222c911fd58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0972be33-2b27-4e37-b43d-ce560ece4dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_0972be33-2b27-4e37-b43d-ce560ece4dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_020114e6-fdc1-4084-a9c0-1a1a2c5fe111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d20d171f-10de-4c7a-99b3-d07d8a01fce3" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_020114e6-fdc1-4084-a9c0-1a1a2c5fe111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/EquityRestrictedStockAwardsDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#EquityRestrictedStockAwardsDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/EquityRestrictedStockAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_71ce70fc-d7b6-416f-9926-39d8ec0e1dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac37004d-10e8-4274-b52b-f0d78f4fcab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_71ce70fc-d7b6-416f-9926-39d8ec0e1dee" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac37004d-10e8-4274-b52b-f0d78f4fcab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b3946d62-5edc-41bc-9000-fe18f8e3614a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac37004d-10e8-4274-b52b-f0d78f4fcab3" xlink:to="loc_us-gaap_AwardTypeAxis_b3946d62-5edc-41bc-9000-fe18f8e3614a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db46a51-0e16-4151-96c1-7c8598eb9a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b3946d62-5edc-41bc-9000-fe18f8e3614a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db46a51-0e16-4151-96c1-7c8598eb9a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c562ebd7-1284-423b-891e-a3671b7a99d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db46a51-0e16-4151-96c1-7c8598eb9a79" xlink:to="loc_us-gaap_RestrictedStockMember_c562ebd7-1284-423b-891e-a3671b7a99d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ec072bcb-cecb-41e6-8763-4bbf612e4b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db46a51-0e16-4151-96c1-7c8598eb9a79" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ec072bcb-cecb-41e6-8763-4bbf612e4b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b3cb9057-e8b5-4df7-8745-d271a94d29b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db46a51-0e16-4151-96c1-7c8598eb9a79" xlink:to="loc_us-gaap_PerformanceSharesMember_b3cb9057-e8b5-4df7-8745-d271a94d29b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd4dbc25-062e-49b6-8059-260c3f9194e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac37004d-10e8-4274-b52b-f0d78f4fcab3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd4dbc25-062e-49b6-8059-260c3f9194e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd4dbc25-062e-49b6-8059-260c3f9194e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_efaae9f2-099f-4212-a0b4-3cdc99cd6cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_efaae9f2-099f-4212-a0b4-3cdc99cd6cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_45cb685d-1430-4ee6-a0ab-0fbfba83159e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_45cb685d-1430-4ee6-a0ab-0fbfba83159e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_94ad77e3-eecc-4fea-8f24-c76e5eb66d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_94ad77e3-eecc-4fea-8f24-c76e5eb66d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_85034b86-3ef9-4aba-a7df-da52f50aff3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_85034b86-3ef9-4aba-a7df-da52f50aff3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6e69518b-9ff2-443b-82a3-993704145b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a17f66c-0c02-431f-a2a5-192ccbac0d12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6e69518b-9ff2-443b-82a3-993704145b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd4dbc25-062e-49b6-8059-260c3f9194e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa9d718a-b053-4c65-afcd-9ea94280c7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa9d718a-b053-4c65-afcd-9ea94280c7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_71475c2e-ac45-4602-907d-5af600483849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_71475c2e-ac45-4602-907d-5af600483849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_28278cef-3351-4217-b4db-2777efb2d86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_28278cef-3351-4217-b4db-2777efb2d86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4185a996-da01-49f6-8547-8970549799eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4185a996-da01-49f6-8547-8970549799eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bc873a7e-401e-4765-ad27-7ab430fdec8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89ad8cf1-3e55-491f-ad2b-d15575ba5801" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bc873a7e-401e-4765-ad27-7ab430fdec8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/EquityFairValueAssumptionsDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#EquityFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/EquityFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_132ee83c-76b4-4239-84a2-d1deeb3ac2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f3f90e-40ff-4e8d-8383-4dcb09769f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_132ee83c-76b4-4239-84a2-d1deeb3ac2d7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f3f90e-40ff-4e8d-8383-4dcb09769f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_25971194-4866-4e0e-9b18-261c7de02902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f3f90e-40ff-4e8d-8383-4dcb09769f0e" xlink:to="loc_us-gaap_AwardTypeAxis_25971194-4866-4e0e-9b18-261c7de02902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65cf04d8-22f1-47ba-bad6-96d90d4d00ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_25971194-4866-4e0e-9b18-261c7de02902" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65cf04d8-22f1-47ba-bad6-96d90d4d00ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e5822f0f-7654-402f-84b5-a27d6f2d7117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65cf04d8-22f1-47ba-bad6-96d90d4d00ef" xlink:to="loc_us-gaap_PerformanceSharesMember_e5822f0f-7654-402f-84b5-a27d6f2d7117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_665abab1-350b-4c60-b9c1-eccf44d162aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f3f90e-40ff-4e8d-8383-4dcb09769f0e" xlink:to="loc_srt_TitleOfIndividualAxis_665abab1-350b-4c60-b9c1-eccf44d162aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8605d2e8-449d-4a5f-af8e-6d008cc5fb03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_665abab1-350b-4c60-b9c1-eccf44d162aa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8605d2e8-449d-4a5f-af8e-6d008cc5fb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_28abe0f7-4d0b-4667-9152-44f890b0d878" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8605d2e8-449d-4a5f-af8e-6d008cc5fb03" xlink:to="loc_srt_ExecutiveOfficerMember_28abe0f7-4d0b-4667-9152-44f890b0d878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f3f90e-40ff-4e8d-8383-4dcb09769f0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f42363fe-8118-45f7-b2ae-15d26c871f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f42363fe-8118-45f7-b2ae-15d26c871f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d40e0e45-49f7-4f15-b4ea-480553a37e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d40e0e45-49f7-4f15-b4ea-480553a37e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_225fe296-4a20-4027-b31d-bdfdd4100f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_225fe296-4a20-4027-b31d-bdfdd4100f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f931bab4-bdcb-459d-9744-a3ab220fdf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f931bab4-bdcb-459d-9744-a3ab220fdf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ecb50424-4d95-4a39-8941-43cd1e717e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_SharePrice_ecb50424-4d95-4a39-8941-43cd1e717e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7cc023fd-e339-4a41-8ec1-57c5fdd1a761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37dcd5f9-3a10-48ab-957e-8feadd0e1c2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7cc023fd-e339-4a41-8ec1-57c5fdd1a761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/EquityStockIncentivePlansDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#EquityStockIncentivePlansDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/EquityStockIncentivePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8c9ff3d9-8f42-4bb7-93b4-c4243f881051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81860880-7d5e-4274-84fb-ea383a4c76b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c9ff3d9-8f42-4bb7-93b4-c4243f881051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81860880-7d5e-4274-84fb-ea383a4c76b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e04a2ffb-8401-46f9-beb7-f4ddab00efaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81860880-7d5e-4274-84fb-ea383a4c76b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e04a2ffb-8401-46f9-beb7-f4ddab00efaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_68d52047-0bc1-4bff-9329-faa893f1c388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81860880-7d5e-4274-84fb-ea383a4c76b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_68d52047-0bc1-4bff-9329-faa893f1c388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ecfa1df1-c543-461d-b191-60ff0947b2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81860880-7d5e-4274-84fb-ea383a4c76b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ecfa1df1-c543-461d-b191-60ff0947b2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a9f1df64-d73d-4bd8-8316-d28026fb3536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81860880-7d5e-4274-84fb-ea383a4c76b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a9f1df64-d73d-4bd8-8316-d28026fb3536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8ea3f84c-ee8d-4fc5-9a11-5c5dd50f8be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81860880-7d5e-4274-84fb-ea383a4c76b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8ea3f84c-ee8d-4fc5-9a11-5c5dd50f8be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2775d32d-4328-45bd-8fb9-94f6e4038ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81860880-7d5e-4274-84fb-ea383a4c76b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2775d32d-4328-45bd-8fb9-94f6e4038ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_495fdd6f-ca11-44b8-87d6-79da4ee968ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c9ff3d9-8f42-4bb7-93b4-c4243f881051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_495fdd6f-ca11-44b8-87d6-79da4ee968ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_049c5701-81ff-429e-a50f-e49a07068b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c9ff3d9-8f42-4bb7-93b4-c4243f881051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_049c5701-81ff-429e-a50f-e49a07068b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c822a57f-c066-45a4-be23-1a9fc33c5b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_049c5701-81ff-429e-a50f-e49a07068b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c822a57f-c066-45a4-be23-1a9fc33c5b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_264fc909-762f-4910-a44d-638380a45d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_049c5701-81ff-429e-a50f-e49a07068b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_264fc909-762f-4910-a44d-638380a45d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d9da3bb0-8227-4163-828b-c0ed312de1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_049c5701-81ff-429e-a50f-e49a07068b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d9da3bb0-8227-4163-828b-c0ed312de1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2e961030-34a4-4f8c-bc9e-feea628f5a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_049c5701-81ff-429e-a50f-e49a07068b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2e961030-34a4-4f8c-bc9e-feea628f5a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6fb1b241-5060-4c8b-9a8a-22923959c22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_049c5701-81ff-429e-a50f-e49a07068b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6fb1b241-5060-4c8b-9a8a-22923959c22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f79d0b5c-9133-452f-9eff-179ffa9f5331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_049c5701-81ff-429e-a50f-e49a07068b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f79d0b5c-9133-452f-9eff-179ffa9f5331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_87cd845c-f306-4e31-a25c-0c298727170b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c9ff3d9-8f42-4bb7-93b4-c4243f881051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_87cd845c-f306-4e31-a25c-0c298727170b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_71fe9af6-1a45-4a02-bde0-d66a4b0a2b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c9ff3d9-8f42-4bb7-93b4-c4243f881051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_71fe9af6-1a45-4a02-bde0-d66a4b0a2b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bd9433ea-1780-4e8f-95cd-ab7f92242b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_71fe9af6-1a45-4a02-bde0-d66a4b0a2b83" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bd9433ea-1780-4e8f-95cd-ab7f92242b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c5772116-2fca-4d1c-8ff9-d8731d35642d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c9ff3d9-8f42-4bb7-93b4-c4243f881051" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c5772116-2fca-4d1c-8ff9-d8731d35642d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d94a908f-9010-454d-b319-4666de6d3172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c5772116-2fca-4d1c-8ff9-d8731d35642d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d94a908f-9010-454d-b319-4666de6d3172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ed1ed2a5-58a1-40fd-860b-25704c315fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c5772116-2fca-4d1c-8ff9-d8731d35642d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ed1ed2a5-58a1-40fd-860b-25704c315fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_91a4d222-3961-4d45-876f-d542e647a9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b176771e-3d28-43ba-8aac-4f4a29b0aa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91a4d222-3961-4d45-876f-d542e647a9df" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b176771e-3d28-43ba-8aac-4f4a29b0aa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_65f5b970-c09a-4540-b3b8-f07831a476aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a08162df-c7c4-40ad-b96c-313dfc0fa2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_65f5b970-c09a-4540-b3b8-f07831a476aa" xlink:to="loc_us-gaap_InterestPaidNet_a08162df-c7c4-40ad-b96c-313dfc0fa2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_32281306-0e4c-44a7-aaca-1e03786c8224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_65f5b970-c09a-4540-b3b8-f07831a476aa" xlink:to="loc_us-gaap_IncomeTaxesPaid_32281306-0e4c-44a7-aaca-1e03786c8224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d268564a-796e-43bd-8ac7-96e8f3c80c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_65f5b970-c09a-4540-b3b8-f07831a476aa" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d268564a-796e-43bd-8ac7-96e8f3c80c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_786488fc-27b7-47a9-af67-f860f481c302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d268564a-796e-43bd-8ac7-96e8f3c80c45" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_786488fc-27b7-47a9-af67-f860f481c302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9c80271a-8046-44dc-b1e7-3f565a199df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d268564a-796e-43bd-8ac7-96e8f3c80c45" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9c80271a-8046-44dc-b1e7-3f565a199df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_TemporaryEquityDeemedDividends_572504d3-5555-41dc-b6ef-de2f45df2848" xlink:href="mdxg-20220930.xsd#mdxg_TemporaryEquityDeemedDividends"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d268564a-796e-43bd-8ac7-96e8f3c80c45" xlink:to="loc_mdxg_TemporaryEquityDeemedDividends_572504d3-5555-41dc-b6ef-de2f45df2848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise_82b8ecc1-c1e5-4bd3-902b-466b2d98cb68" xlink:href="mdxg-20220930.xsd#mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d268564a-796e-43bd-8ac7-96e8f3c80c45" xlink:to="loc_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise_82b8ecc1-c1e5-4bd3-902b-466b2d98cb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_80826be4-1189-4a4a-96bc-032b38d89370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d268564a-796e-43bd-8ac7-96e8f3c80c45" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_80826be4-1189-4a4a-96bc-032b38d89370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_NotesReceivableForSaleOfPropertyAndEquipment_8b56a001-1c6d-4b42-b85f-d4a7061b05d5" xlink:href="mdxg-20220930.xsd#mdxg_NotesReceivableForSaleOfPropertyAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d268564a-796e-43bd-8ac7-96e8f3c80c45" xlink:to="loc_mdxg_NotesReceivableForSaleOfPropertyAndEquipment_8b56a001-1c6d-4b42-b85f-d4a7061b05d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0de0cffd-a293-45db-8b29-3feb93443ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0de0cffd-a293-45db-8b29-3feb93443ad6" xlink:to="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e79c7bc3-1d74-4069-9f62-27c1b533c995" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:to="loc_dei_LegalEntityAxis_e79c7bc3-1d74-4069-9f62-27c1b533c995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ce09ff55-0175-4eea-91bb-dd7a4b4e49b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e79c7bc3-1d74-4069-9f62-27c1b533c995" xlink:to="loc_dei_EntityDomain_ce09ff55-0175-4eea-91bb-dd7a4b4e49b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InsuranceProvidersMember_2baec693-95df-46d8-b6d2-56251e7d613d" xlink:href="mdxg-20220930.xsd#mdxg_InsuranceProvidersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ce09ff55-0175-4eea-91bb-dd7a4b4e49b8" xlink:to="loc_mdxg_InsuranceProvidersMember_2baec693-95df-46d8-b6d2-56251e7d613d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4323d502-d7c1-4c81-9aab-b646353b8d91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:to="loc_srt_TitleOfIndividualAxis_4323d502-d7c1-4c81-9aab-b646353b8d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_54c954de-9300-45dc-8144-070133b7cc36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4323d502-d7c1-4c81-9aab-b646353b8d91" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_54c954de-9300-45dc-8144-070133b7cc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_4bd5c41e-5813-45b0-bec7-4e354d7d5029" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_54c954de-9300-45dc-8144-070133b7cc36" xlink:to="loc_srt_ChiefExecutiveOfficerMember_4bd5c41e-5813-45b0-bec7-4e354d7d5029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_69cd416f-235d-49c7-ab4c-60f77d07efa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:to="loc_us-gaap_OtherCommitmentsAxis_69cd416f-235d-49c7-ab4c-60f77d07efa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_fc918aac-1aca-4d16-8798-376847197aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_69cd416f-235d-49c7-ab4c-60f77d07efa1" xlink:to="loc_us-gaap_OtherCommitmentsDomain_fc918aac-1aca-4d16-8798-376847197aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_SeparationAgreementMember_80154b11-b1f6-4e2e-a5fb-634fe4de8cf7" xlink:href="mdxg-20220930.xsd#mdxg_SeparationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_fc918aac-1aca-4d16-8798-376847197aa2" xlink:to="loc_mdxg_SeparationAgreementMember_80154b11-b1f6-4e2e-a5fb-634fe4de8cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_95718705-5dec-4119-8c4e-315495a3fb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_95718705-5dec-4119-8c4e-315495a3fb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_47a780af-1751-4c3b-9db3-9cd67cbb6859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_95718705-5dec-4119-8c4e-315495a3fb4a" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_47a780af-1751-4c3b-9db3-9cd67cbb6859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_6e30a80f-400f-4462-b70a-dd40e2bc2fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_47a780af-1751-4c3b-9db3-9cd67cbb6859" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_6e30a80f-400f-4462-b70a-dd40e2bc2fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e387f440-bf6f-45fd-9aa4-f84754b51fd4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:to="loc_srt_CounterpartyNameAxis_e387f440-bf6f-45fd-9aa4-f84754b51fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49327ec1-0af0-4fa0-9137-18f3dd7ba97b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e387f440-bf6f-45fd-9aa4-f84754b51fd4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49327ec1-0af0-4fa0-9137-18f3dd7ba97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_NordicBioscienceClinicalDevelopmentASMember_7589e3fa-5ed6-4161-b1a5-3e68db0a82f2" xlink:href="mdxg-20220930.xsd#mdxg_NordicBioscienceClinicalDevelopmentASMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49327ec1-0af0-4fa0-9137-18f3dd7ba97b" xlink:to="loc_mdxg_NordicBioscienceClinicalDevelopmentASMember_7589e3fa-5ed6-4161-b1a5-3e68db0a82f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9395eda7-6956-48c7-bda5-5e3c1f98358d" xlink:to="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_630416c0-00c0-412c-8269-de8461243ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_us-gaap_OtherCommitment_630416c0-00c0-412c-8269-de8461243ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db6f66d0-77d8-4481-85c4-772a906641b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db6f66d0-77d8-4481-85c4-772a906641b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_28aa09a2-43dc-4236-a1eb-01248ab2d252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_28aa09a2-43dc-4236-a1eb-01248ab2d252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired_3c7b6c52-ef78-4384-9484-231f49dc386d" xlink:href="mdxg-20220930.xsd#mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired_3c7b6c52-ef78-4384-9484-231f49dc386d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_PaymentsMadeOnLongTermPurchaseCommitment_d4fab190-4ba5-4b23-a884-cff0ec10990e" xlink:href="mdxg-20220930.xsd#mdxg_PaymentsMadeOnLongTermPurchaseCommitment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_mdxg_PaymentsMadeOnLongTermPurchaseCommitment_d4fab190-4ba5-4b23-a884-cff0ec10990e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ExpensesOnLongTermPurchaseCommitment_82f07c58-ba64-4d7d-ba47-7ed82326ab74" xlink:href="mdxg-20220930.xsd#mdxg_ExpensesOnLongTermPurchaseCommitment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_mdxg_ExpensesOnLongTermPurchaseCommitment_82f07c58-ba64-4d7d-ba47-7ed82326ab74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment_c5165b99-7098-477d-8d6a-392606ee765e" xlink:href="mdxg-20220930.xsd#mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment_c5165b99-7098-477d-8d6a-392606ee765e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_472609d5-dd86-4d51-a41e-236c447805b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_472609d5-dd86-4d51-a41e-236c447805b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_ContingencyLossNumberOfSecuritiesClassActions_2dd4fa02-39f9-409b-b569-4ba571faede2" xlink:href="mdxg-20220930.xsd#mdxg_ContingencyLossNumberOfSecuritiesClassActions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_764758d8-48d0-4973-a4b3-c6e59bada552" xlink:to="loc_mdxg_ContingencyLossNumberOfSecuritiesClassActions_2dd4fa02-39f9-409b-b569-4ba571faede2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#RevenueSummaryofRevenuebyProductTypeDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_25910d43-85b1-4fee-b012-e518ce035e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_12be2ed7-a35a-4fc2-9ae5-7371e5d5f41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_25910d43-85b1-4fee-b012-e518ce035e53" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_12be2ed7-a35a-4fc2-9ae5-7371e5d5f41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad0c6e6e-ee32-4003-ac81-c6eeee64cfc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_12be2ed7-a35a-4fc2-9ae5-7371e5d5f41f" xlink:to="loc_srt_ProductOrServiceAxis_ad0c6e6e-ee32-4003-ac81-c6eeee64cfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f29d4354-5e5d-4049-8f05-626115f5769f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ad0c6e6e-ee32-4003-ac81-c6eeee64cfc9" xlink:to="loc_srt_ProductsAndServicesDomain_f29d4354-5e5d-4049-8f05-626115f5769f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AdvancedWoundCareMember_c0cc8966-0356-484a-ad73-45607edffc4e" xlink:href="mdxg-20220930.xsd#mdxg_AdvancedWoundCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f29d4354-5e5d-4049-8f05-626115f5769f" xlink:to="loc_mdxg_AdvancedWoundCareMember_c0cc8966-0356-484a-ad73-45607edffc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AdvancedWoundCareTissueAndOtherMember_b4868ffd-27a7-4cc4-a3c2-f4ba0b9e7411" xlink:href="mdxg-20220930.xsd#mdxg_AdvancedWoundCareTissueAndOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdxg_AdvancedWoundCareMember_c0cc8966-0356-484a-ad73-45607edffc4e" xlink:to="loc_mdxg_AdvancedWoundCareTissueAndOtherMember_b4868ffd-27a7-4cc4-a3c2-f4ba0b9e7411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember_ddb69b94-b459-4819-9152-7bb727d91bdf" xlink:href="mdxg-20220930.xsd#mdxg_AdvancedWoundCareUmbilicalCordDerivedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdxg_AdvancedWoundCareMember_c0cc8966-0356-484a-ad73-45607edffc4e" xlink:to="loc_mdxg_AdvancedWoundCareUmbilicalCordDerivedMember_ddb69b94-b459-4819-9152-7bb727d91bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_Section351ProductsMember_402eba51-b5b6-4a00-b1eb-2e05597be5b6" xlink:href="mdxg-20220930.xsd#mdxg_Section351ProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f29d4354-5e5d-4049-8f05-626115f5769f" xlink:to="loc_mdxg_Section351ProductsMember_402eba51-b5b6-4a00-b1eb-2e05597be5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_d7f96f7f-8a53-456e-b594-01ffe7d2a4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f29d4354-5e5d-4049-8f05-626115f5769f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_d7f96f7f-8a53-456e-b594-01ffe7d2a4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5818ebb6-ba45-4261-95d8-a2e6c9a64364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_12be2ed7-a35a-4fc2-9ae5-7371e5d5f41f" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5818ebb6-ba45-4261-95d8-a2e6c9a64364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e45d0ec0-9e9a-474e-82fe-4c29e3b545fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_5818ebb6-ba45-4261-95d8-a2e6c9a64364" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e45d0ec0-9e9a-474e-82fe-4c29e3b545fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c2717b59-851f-49d8-9ccc-fc0e8f420adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_NumberOfProducts_8efc6fea-e210-40bb-a8e4-8ef9abd40c10" xlink:href="mdxg-20220930.xsd#mdxg_NumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c2717b59-851f-49d8-9ccc-fc0e8f420adc" xlink:to="loc_mdxg_NumberOfProducts_8efc6fea-e210-40bb-a8e4-8ef9abd40c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels_b77a2269-5b83-4bd7-972b-ee7aaed132d1" xlink:href="mdxg-20220930.xsd#mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c2717b59-851f-49d8-9ccc-fc0e8f420adc" xlink:to="loc_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels_b77a2269-5b83-4bd7-972b-ee7aaed132d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#RevenueSummaryofRevenuebyCustomerTypeDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_30115f75-416d-41b4-9ccb-cfe2dbe0ea9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ef7a4897-d4f7-4b56-87fb-4b5a4ed2e7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_30115f75-416d-41b4-9ccb-cfe2dbe0ea9e" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ef7a4897-d4f7-4b56-87fb-4b5a4ed2e7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_d8cf631c-fa46-44a6-8a14-a97a3efc8f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ef7a4897-d4f7-4b56-87fb-4b5a4ed2e7bb" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_d8cf631c-fa46-44a6-8a14-a97a3efc8f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_66ad3b97-b8b9-4af6-bf8d-b327fdcd7545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_d8cf631c-fa46-44a6-8a14-a97a3efc8f3c" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_66ad3b97-b8b9-4af6-bf8d-b327fdcd7545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_b8d78d4c-41af-49d4-b84a-9a1f564fb87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_66ad3b97-b8b9-4af6-bf8d-b327fdcd7545" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_b8d78d4c-41af-49d4-b84a-9a1f564fb87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_38222070-a4b6-4f48-806e-99c8c5636688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_66ad3b97-b8b9-4af6-bf8d-b327fdcd7545" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_38222070-a4b6-4f48-806e-99c8c5636688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_662e3316-13a2-4f14-95c1-06e683c9f9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ef7a4897-d4f7-4b56-87fb-4b5a4ed2e7bb" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_662e3316-13a2-4f14-95c1-06e683c9f9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a91a8cf-a40c-4638-937b-fd8aa437195d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_662e3316-13a2-4f14-95c1-06e683c9f9e8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a91a8cf-a40c-4638-937b-fd8aa437195d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3f679478-fbcd-4f15-ab6f-3f8a08859b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_4a52dfd6-bcfa-4eb3-ac28-85f8c394fbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3f679478-fbcd-4f15-ab6f-3f8a08859b10" xlink:to="loc_us-gaap_NumberOfReportableSegments_4a52dfd6-bcfa-4eb3-ac28-85f8c394fbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e8aac050-5316-4c37-a9c5-44e7182cbf26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bee8ca4a-0397-4711-952e-97073be59ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8aac050-5316-4c37-a9c5-44e7182cbf26" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bee8ca4a-0397-4711-952e-97073be59ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f608dfe4-5790-492b-a9c2-8b08dc01678d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bee8ca4a-0397-4711-952e-97073be59ed5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f608dfe4-5790-492b-a9c2-8b08dc01678d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3d2ecd09-33f0-409a-ae83-27e8ffcf7d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f608dfe4-5790-492b-a9c2-8b08dc01678d" xlink:to="loc_us-gaap_SegmentDomain_3d2ecd09-33f0-409a-ae83-27e8ffcf7d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_WoundSurgicalSegmentMember_4399768e-aa7b-4eae-ac66-741ec6f0046e" xlink:href="mdxg-20220930.xsd#mdxg_WoundSurgicalSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3d2ecd09-33f0-409a-ae83-27e8ffcf7d02" xlink:to="loc_mdxg_WoundSurgicalSegmentMember_4399768e-aa7b-4eae-ac66-741ec6f0046e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_RegenerativeMedicineSegmentMember_03a98711-6cc9-4165-89b1-5b0bc289fe97" xlink:href="mdxg-20220930.xsd#mdxg_RegenerativeMedicineSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3d2ecd09-33f0-409a-ae83-27e8ffcf7d02" xlink:to="loc_mdxg_RegenerativeMedicineSegmentMember_03a98711-6cc9-4165-89b1-5b0bc289fe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_964d6bcc-8fbd-424e-ab34-541e94114ca6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bee8ca4a-0397-4711-952e-97073be59ed5" xlink:to="loc_srt_ConsolidationItemsAxis_964d6bcc-8fbd-424e-ab34-541e94114ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ed414c44-1a85-4dc6-9826-8f35abcfba5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_964d6bcc-8fbd-424e-ab34-541e94114ca6" xlink:to="loc_srt_ConsolidationItemsDomain_ed414c44-1a85-4dc6-9826-8f35abcfba5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d5b1195e-3490-44ca-9f75-0dd9f1ac5f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ed414c44-1a85-4dc6-9826-8f35abcfba5d" xlink:to="loc_us-gaap_OperatingSegmentsMember_d5b1195e-3490-44ca-9f75-0dd9f1ac5f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f1671e04-303e-41ff-b2fc-676d21f494c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ed414c44-1a85-4dc6-9826-8f35abcfba5d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f1671e04-303e-41ff-b2fc-676d21f494c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bee8ca4a-0397-4711-952e-97073be59ed5" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39086d57-9f23-440c-8c02-efae2b9d4b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39086d57-9f23-440c-8c02-efae2b9d4b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2f77ca48-f389-4c24-871e-ea3d950a39e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2f77ca48-f389-4c24-871e-ea3d950a39e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8d64bb21-f7e9-403f-b73d-1cdf3c7f430b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8d64bb21-f7e9-403f-b73d-1cdf3c7f430b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0d3a1a63-dc34-42e4-b751-3635fd01d9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0d3a1a63-dc34-42e4-b751-3635fd01d9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e4f5695c-7d71-458f-af2e-c3c6af811e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e4f5695c-7d71-458f-af2e-c3c6af811e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_SegmentContribution_dec03386-9232-466e-9852-2cee736c0c71" xlink:href="mdxg-20220930.xsd#mdxg_SegmentContribution"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_mdxg_SegmentContribution_dec03386-9232-466e-9852-2cee736c0c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_InvestigationRestatementAndRelated_cd9b3e03-2532-4205-9646-8300502726ae" xlink:href="mdxg-20220930.xsd#mdxg_InvestigationRestatementAndRelated"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_mdxg_InvestigationRestatementAndRelated_cd9b3e03-2532-4205-9646-8300502726ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a419dd17-182a-4fdd-896b-4261ca894f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_us-gaap_OperatingIncomeLoss_a419dd17-182a-4fdd-896b-4261ca894f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdxg_SupplementalInformationAbstract_426d142f-05b5-463a-811a-fdfc6d977d23" xlink:href="mdxg-20220930.xsd#mdxg_SupplementalInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e5ff416b-1c67-4edb-b7dd-11a280124965" xlink:to="loc_mdxg_SupplementalInformationAbstract_426d142f-05b5-463a-811a-fdfc6d977d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_980d192f-3b55-42f8-82fc-e31449b925cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdxg_SupplementalInformationAbstract_426d142f-05b5-463a-811a-fdfc6d977d23" xlink:to="loc_us-gaap_Depreciation_980d192f-3b55-42f8-82fc-e31449b925cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0121cbdf-8e91-458d-b149-942a7a54f888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdxg_SupplementalInformationAbstract_426d142f-05b5-463a-811a-fdfc6d977d23" xlink:to="loc_us-gaap_ShareBasedCompensation_0121cbdf-8e91-458d-b149-942a7a54f888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1" xlink:type="simple" xlink:href="mdxg-20220930.xsd#SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153898272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MIMEDX GROUP, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2792552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1775 West Oak Commons Ct NE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Marietta<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-9100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDXG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,668,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001376339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890155035264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 73,217<span></span>
</td>
<td class="nump">$ 87,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">40,830<span></span>
</td>
<td class="nump">40,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">13,976<span></span>
</td>
<td class="nump">11,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">4,679<span></span>
</td>
<td class="nump">6,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">756<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,582<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">136,040<span></span>
</td>
<td class="nump">148,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">7,912<span></span>
</td>
<td class="nump">9,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">3,728<span></span>
</td>
<td class="nump">4,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">19,976<span></span>
</td>
<td class="nump">19,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,992<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">172,798<span></span>
</td>
<td class="nump">187,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,820<span></span>
</td>
<td class="nump">7,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">24,090<span></span>
</td>
<td class="nump">23,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">10,986<span></span>
</td>
<td class="nump">9,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">1,565<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">45,858<span></span>
</td>
<td class="nump">42,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt, net</a></td>
<td class="nump">48,475<span></span>
</td>
<td class="nump">48,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">5,491<span></span>
</td>
<td class="nump">4,869<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">99,824<span></span>
</td>
<td class="nump">95,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock Series B; $0.001 par value; 100,000 shares authorized, issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</a></td>
<td class="nump">92,494<span></span>
</td>
<td class="nump">92,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock Series A; $0.001 par value; 5,000,000 shares authorized, 0 issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">113,670,017<span></span>
</td>
<td class="nump">112,703,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">187,500,000<span></span>
</td>
<td class="nump">187,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.001 par value; 187,500,000 shares authorized; 113,670,017 issued and 113,668,179 outstanding at September&#160;30, 2022 and 112,703,926 issued and 111,925,216 outstanding at December&#160;31, 2021</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">171,865<span></span>
</td>
<td class="nump">165,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock at cost; 1,838 shares at September&#160;30, 2022 and 778,710 shares at December&#160;31, 2021</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(4,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(191,492)<span></span>
</td>
<td class="num">(161,709)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="num">(19,520)<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and stockholders&#8217; (deficit) equity</a></td>
<td class="nump">$ 172,798<span></span>
</td>
<td class="nump">$ 187,929<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890248766240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Series B convertible preferred stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Series B convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series B convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series B convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">187,500,000<span></span>
</td>
<td class="nump">187,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">113,670,017<span></span>
</td>
<td class="nump">112,703,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">113,668,179<span></span>
</td>
<td class="nump">111,925,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">1,838<span></span>
</td>
<td class="nump">778,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890154910560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 67,689<span></span>
</td>
<td class="nump">$ 63,074<span></span>
</td>
<td class="nump">$ 193,466<span></span>
</td>
<td class="nump">$ 191,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">12,188<span></span>
</td>
<td class="nump">10,129<span></span>
</td>
<td class="nump">33,947<span></span>
</td>
<td class="nump">32,530<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">55,501<span></span>
</td>
<td class="nump">52,945<span></span>
</td>
<td class="nump">159,519<span></span>
</td>
<td class="nump">158,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">53,475<span></span>
</td>
<td class="nump">46,289<span></span>
</td>
<td class="nump">158,838<span></span>
</td>
<td class="nump">145,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,953<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
<td class="nump">17,429<span></span>
</td>
<td class="nump">12,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_InvestigationRestatementAndRelated', window );">Investigation, restatement and related</a></td>
<td class="nump">3,001<span></span>
</td>
<td class="nump">3,170<span></span>
</td>
<td class="nump">8,771<span></span>
</td>
<td class="nump">8,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(7,103)<span></span>
</td>
<td class="num">(1,075)<span></span>
</td>
<td class="num">(26,038)<span></span>
</td>
<td class="num">(8,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(1,270)<span></span>
</td>
<td class="num">(963)<span></span>
</td>
<td class="num">(3,566)<span></span>
</td>
<td class="num">(3,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax provision</a></td>
<td class="num">(8,373)<span></span>
</td>
<td class="num">(2,038)<span></span>
</td>
<td class="num">(29,605)<span></span>
</td>
<td class="num">(12,145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision expense</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,426)<span></span>
</td>
<td class="num">(2,339)<span></span>
</td>
<td class="num">(29,783)<span></span>
</td>
<td class="num">(12,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders - basic</a></td>
<td class="num">(10,096)<span></span>
</td>
<td class="num">(3,913)<span></span>
</td>
<td class="num">(34,667)<span></span>
</td>
<td class="num">(17,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss available to common stockholders - diluted</a></td>
<td class="num">$ (10,096)<span></span>
</td>
<td class="num">$ (3,913)<span></span>
</td>
<td class="num">$ (34,667)<span></span>
</td>
<td class="num">$ (17,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">113,448,251<span></span>
</td>
<td class="nump">110,717,073<span></span>
</td>
<td class="nump">112,650,713<span></span>
</td>
<td class="nump">110,136,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">113,448,251<span></span>
</td>
<td class="nump">110,717,073<span></span>
</td>
<td class="nump">112,650,713<span></span>
</td>
<td class="nump">110,136,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_InvestigationRestatementAndRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investigation, Restatement And Related</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_InvestigationRestatementAndRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890150847136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock Issued</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,703,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2020</a></td>
<td class="num">$ (150)<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 158,610<span></span>
</td>
<td class="num">$ (7,449)<span></span>
</td>
<td class="num">$ (151,424)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,773,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Deemed dividends</a></td>
<td class="num">(926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation&#160;expense</a></td>
<td class="nump">11,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,184)<span></span>
</td>
<td class="nump">$ 2,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,053)<span></span>
</td>
<td class="nump">$ 4,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted stock canceled/forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Restricted stock shares canceled/forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="num">$ (450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares repurchased for tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares repurchased for tax withholding</a></td>
<td class="num">(4,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_TreasuryStockSharesAdjustment', window );">Other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,009)<span></span>
</td>
<td class="nump">$ 2,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance end of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,703,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2021</a></td>
<td class="num">(5,808)<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">162,003<span></span>
</td>
<td class="num">$ (4,000)<span></span>
</td>
<td class="num">(163,924)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,703,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Jun. 30, 2021</a></td>
<td class="num">(7,137)<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">158,720<span></span>
</td>
<td class="num">$ (4,385)<span></span>
</td>
<td class="num">(161,585)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation&#160;expense</a></td>
<td class="nump">3,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(477)<span></span>
</td>
<td class="nump">$ 477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted stock canceled/forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Restricted stock shares canceled/forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="num">$ (199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares repurchased for tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares repurchased for tax withholding</a></td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,339)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance end of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,703,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2021</a></td>
<td class="num">$ (5,808)<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">162,003<span></span>
</td>
<td class="num">$ (4,000)<span></span>
</td>
<td class="num">(163,924)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">112,703,926<span></span>
</td>
<td class="nump">112,703,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">165,695<span></span>
</td>
<td class="num">$ (4,017)<span></span>
</td>
<td class="num">(161,709)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">778,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation&#160;expense</a></td>
<td class="nump">$ 10,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">285,001<span></span>
</td>
<td class="nump">133,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(697)<span></span>
</td>
<td class="nump">$ 1,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(3,960)<span></span>
</td>
<td class="nump">$ 3,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted stock canceled/forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Restricted stock shares canceled/forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares repurchased for tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares repurchased for tax withholding</a></td>
<td class="num">(1,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,783)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance end of period (in shares) at Sep. 30, 2022</a></td>
<td class="nump">113,670,017<span></span>
</td>
<td class="nump">113,670,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2022</a></td>
<td class="num">$ (19,520)<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">171,865<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">(191,492)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">1,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance beginning of period (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,609,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Jun. 30, 2022</a></td>
<td class="num">$ (13,603)<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">169,352<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">(183,066)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation&#160;expense</a></td>
<td class="nump">2,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted stock canceled/forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Restricted stock shares canceled/forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,426)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance end of period (in shares) at Sep. 30, 2022</a></td>
<td class="nump">113,670,017<span></span>
</td>
<td class="nump">113,670,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2022</a></td>
<td class="num">$ (19,520)<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 171,865<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (191,492)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">1,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_TreasuryStockSharesAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock, Shares, Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_TreasuryStockSharesAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890146345280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,783)<span></span>
</td>
<td class="num">$ (12,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">10,798<span></span>
</td>
<td class="nump">11,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2,549<span></span>
</td>
<td class="nump">3,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">2,817<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expenses</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationAccretionExpense', window );">Accretion of asset retirement obligation</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on fixed asset disposal</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Increase (decrease) in cash resulting from changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(3,295)<span></span>
</td>
<td class="num">(1,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,586)<span></span>
</td>
<td class="num">(835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income taxes</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">9,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(287)<span></span>
</td>
<td class="nump">1,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="num">(828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">495<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,724<span></span>
</td>
<td class="num">(16,768)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">905<span></span>
</td>
<td class="num">(840)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows (used in) provided by operating activities</a></td>
<td class="num">(12,269)<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash&#160;flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(847)<span></span>
</td>
<td class="num">(2,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_PaymentsForApplicationCostsPatent', window );">Patent application costs</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Principal payments from note receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(951)<span></span>
</td>
<td class="num">(3,081)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock repurchased for tax withholdings on vesting of restricted stock</a></td>
<td class="num">(1,191)<span></span>
</td>
<td class="num">(4,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">574<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(646)<span></span>
</td>
<td class="num">(3,374)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash</a></td>
<td class="num">(13,866)<span></span>
</td>
<td class="num">(5,205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">87,083<span></span>
</td>
<td class="nump">95,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 73,217<span></span>
</td>
<td class="nump">$ 90,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_PaymentsForApplicationCostsPatent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Application Costs, Patent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_PaymentsForApplicationCostsPatent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159773280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business</a></td>
<td class="text">Nature of Business<div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MiMedx Group, Inc. (together with its subsidiaries, except where the context otherwise requires, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MIMEDX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; or the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, the Company is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company derives its products from human placental tissues and processes these tissues using its proprietary methods, including the PURION&#174; process. The Company applies Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce its allografts. MIMEDX provides products primarily in the wound care, burn, and surgical recovery sectors of healthcare. All of its products are regulated by the U.S. Food &amp; Drug Administration (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company manages itself as two reportable segments: Wound &amp; Surgical and Regenerative Medicine. Information regarding the principal operations and results of these segments can be found in Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business is currently focused primarily in the United States. The Company is pursuing opportunities for international expansion, with specific focus on the launch of its placental tissue products in Japan.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enforcement Discretion</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the FDA published a series of guidances that established an updated framework for the regulation of cellular and tissue-based products. These guidances clarified the FDA&#8217;s views about the criteria that differentiate those products subject to regulation solely under Section 361 of the Public Health Service Act (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) from those considered to be drugs, devices, and/or biological products subject to licensure under Section 351 of the Public Health Service Act and related regulations. The Company identified its micronized and certain other products (collectively, the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 351 products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) as being subject to regulation under Section 351, requiring pre-market approval from the FDA for a specified indication with demonstrated clinical efficacy.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA exercised enforcement discretion with respect to Investigational New Drug applications and pre-market approval requirements through May 31, 2021. As of May 31, 2021, the Company stopped marketing its Section 351 products in the United States and is precluded from marketing such products until a Biologics License Application (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is granted. If and when the FDA approves a BLA, the Company expects to be allowed to market its Section 351 products in the United States again, but only for specific indications as permitted by the FDA. Sales of the Company&#8217;s Section 351 products were $0.8 million and $0.5&#160;million for the three months ended September&#160;30, 2022 and 2021, respectively, and $1.8&#160;million and $17.2&#160;million for the nine months ended September 30, 2022 and 2021, respectively. Sales of Section 351 products during the three and nine months ended September&#160;30, 2022 were derived from sales outside the United States.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently markets EPICORD&#174; and AMNIOCOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D&#174; tissue products derived from human umbilical cord as providing a protective environment or as a barrier. If the FDA were to determine that EPICORD and AMNIOCORD do not meet the requirements for regulation solely under Section 361, then pre-market clearance or approval would be required for these products. The loss of the Company&#8217;s ability to market and sell its umbilical cord-derived products could have an adverse effect on the Company&#8217;s revenue, business, financial condition, and results of operations. Net sales of the Company&#8217;s umbilical cord-derived products were $5.7 million and $6.2&#160;million for the three months ended September&#160;30, 2022 and 2021 and $17.2 million and $17.1&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively. The Company&#8217;s cord inventory, which would be at risk for write-down in the case of such a determination by the FDA, was $1.8&#160;million and $1.9 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159045104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 2 to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), filed with the Securities and Exchange Commission (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on February 28, 2022 for a description of all significant accounting policies.</span><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GAAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;The operating results for the three and nine months ended September&#160;30, 2022 and 2021 are not necessarily indicative of the results that may be expected for the full fiscal year.&#160;The balance sheet as of December&#160;31, 2021 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2021 Form 10-K.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported unaudited condensed consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates regarding asset retirement obligations, estimates for contingent liabilities, estimates related to the Company&#8217;s assessment of goodwill impairment, the measurement of right of use assets and lease liabilities, management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern, estimates of fair value of share-based payments, estimate for allowance for doubtful accounts, estimates of sales returns and allowances, and valuation of deferred tax assets.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of GAAP requires the use of the &#8220;management approach&#8221; model for segment reporting. The management approach model is based on the way a company&#8217;s chief operating decision maker (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CODM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) organizes segments within the Company for which separate, discrete financial information is available regarding resource allocation and assessing performance. The Company has concluded that its Chief Executive Officer (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CEO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is its CODM. Prior to June 30, 2022, the Company assessed that it operated as one operating and reportable segment. The Company reassesses the existence of operating segments when facts and circumstances suggest that there may have been a change in the way that the Company was managed.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;30, 2022, the Company reassessed its operating segments, concluding that the CODM assesses performance and allocates resources between two, distinct reportable segments: Wound &amp; Surgical and Regenerative Medicine. Information regarding the principal operations and results of these segments can be found in Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment at least annually on October 1 and more frequently whenever events or substantive changes in circumstances indicate that it is more likely than not that goodwill is impaired. In performing the goodwill impairment test, the Company first assesses qualitative factors to determine the existence of impairment. If the qualitative factors indicate that the carrying value of a reporting unit exceeds its fair value, the Company proceeds to a quantitative test to measure the existence and amount, if any, of goodwill impairment. The Company may also choose to bypass the qualitative assessment and proceed directly to the quantitative test.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the quantitative test, impairment loss is recorded to the extent that the carrying value of the reporting unit exceeds its assessed fair value. The Company determines the fair value using the income and market approaches. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the income approach, the fair value of a reporting unit is the present value of its future cash flows as viewed from the lens of a hypothetical market participant in an orderly transaction. These future cash flows are derived from expectations of revenue, expenses, tax deductions and credits, working capital flows, capital expenditures, and other projected sources and uses of cash, as applicable. Value indications are developed by discounting expected cash flows to their present value using a discount rate commensurate with the risks associated with the reporting unit subject to testing.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the market approach, the Company uses market multiples derived from the various comparable companies based on measures salient to investors in those companies. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company concludes that a reporting unit is being managed on the basis of multiple reporting units, the goodwill assigned to the original reporting unit is allocated to the new reporting units based on the relative fair value of the new reporting units.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As indicated above, on September 30, 2022, the Company changed its operating segments, determining that it operates as three operating segments. In concert with this re-evaluation, the Company concluded that it has three reporting units. Management performed a goodwill impairment test as of that date on its previous reporting unit, concluding that goodwill was not impaired as of that date. Management subsequently allocated the goodwill assigned to its previous reporting unit to its new reporting units. Refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding the reallocation of goodwill to the new reporting units.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FASB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) issued Accounting Standards Update (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) 2021-10, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832)&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides disclosure requirements regarding government grants and contributions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ASU requires disclosure of the nature of transactions and related accounting policies used to account for transactions, the effect, including amounts, of government assistance on individual line items on the financial statements, and significant terms and conditions of the transactions, including commitments and contingencies. This ASU is effective for fiscal years beginning after December 15, 2021. The Company adopted the provisions of this ASU effective January 1, 2022. There was no impact upon adoption.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All ASUs issued and not yet effective for the three and nine months ended September&#160;30, 2022, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company&#8217;s financial position and results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159701888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndNontradeReceivableTextBlock', window );">Accounts and Nontrade Receivable</a></td>
<td class="text">Accounts Receivable, Net<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,353&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bad debt expense, included in selling, general and administrative expense on the condensed consolidated statements of operations, for the three and nine months ended September&#160;30, 2022 was $0.4 million and $2.8 million, respectively. Bad debt expense for the three and nine months ended September&#160;30, 2021 was not significant in either period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNontradeReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -URI https://asc.fasb.org/topic&amp;trid=2196771<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -URI https://asc.fasb.org/topic&amp;trid=82887179<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNontradeReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890156896768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the conclusion of the FDA&#8217;s period of Enforcement Discretion on May 31, 2021, the Company wrote-off $1.0 million of its Section 351 product inventory during the nine months ended September 30, 2021. In addition, during the three and nine months ended September 30, 2021, the Company wrote-down $0.5 million and $0.7 million, respectively, for inventory related to product lines which had been discontinued. These amounts are included as part of cost of sales on the unaudited condensed consolidated statements of operations for those periods.</span></div>There were no significant, unusual write-downs of inventory during the three or nine months ended September&#160;30, 2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159720368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and clean room equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three and nine months ended September&#160;30, 2022 and 2021 is summarized in the table below (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense is allocated amongst cost of sales, research and development expense, and selling, general, and administrative expense on the unaudited condensed consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890246115232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">Goodwill and Intangible Assets, Net<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Company had concluded that it operated as a single operating segment and single reporting unit. During the three and nine months ended September 30, 2022, as a result of changes in the management of the Company&#8217;s business, management concluded that the Company operates as three operating segments, including two distinct reportable segments: Wound &amp; Surgical and Regenerative Medicine. See Note 15 for a description of the Company&#8217;s operating segments. Management further concluded that it had three reporting units. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the $20.0&#160;million of consolidated goodwill, which was entirely allocated to its previous reporting unit, to each of Wound &amp; Surgical and Regenerative Medicine based on their relative fair values from a market participant standpoint. The result was $19.5 million and $0.5 million allocated to Wound &amp; Surgical and Regenerative Medicine, respectively. A third reporting unit associated with the Company&#8217;s third operating segment was deemed immaterial and no goodwill was assigned to it. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed goodwill impairment tests using the Company&#8217;s single reporting unit and the new reporting units. In all cases, the Company concluded that the estimated fair values of each reporting unit exceeded their respective carrying values. Therefore, the Company did not record impairment for goodwill during the three or nine months ended September 30, 2022. There was no other activity related to goodwill during the three or nine months ended September&#160;30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, are summarized as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:38.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and know-how</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tradenames and trademarks</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,920&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three and nine months ended September 30, 2022 and 2021 is summarized in the table below (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:28.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization of intangible assets as of September&#160;30, 2022, is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated<br/>Amortization <br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the nine months ended September 30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortized intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890156333104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses&#160;consisted of the following&#160;(in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"/><td style="width:53.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and settlement costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commissions to sales agents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued group purchasing organization fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated sales returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued travel</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890156837376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long Term Debt, Net</a></td>
<td class="text">Long Term Debt, Net<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hayfin Loan Agreement</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2020, the Company entered into a Loan Agreement with, among others, Hayfin Services, LLP (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hayfin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), an affiliate of Hayfin Capital Management LLP (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hayfin Loan Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which Hayfin funded on July 2, 2020 (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Closing Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), providing the Company with a senior secured term loan in an aggregate amount of $50&#160;million (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Term Loan matures on June 30, 2025 (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maturity Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Interest is payable on the Term Loan for the principal balance outstanding quarterly through the Maturity Date. No principal payments on the Term Loan are due and payable until the Maturity Date.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hayfin Loan Agreement also provided the Company an option to draw on an additional delayed draw term loan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DD TL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; collectively with the Term Loan, the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in the form of a committed but undrawn facility until June 30, 2021. The Company did not exercise the option.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022 (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Company executed an Amendment to the Hayfin Loan Agreement (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Amendment was accounted for as a modification. No gain or loss was recognized nor was there a change to the carrying amount of the debt as a result of the Amendment.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on any borrowings under the Hayfin Loan Agreement, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Hayfin Loan Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), is equal to the London Interbank Offered Rate (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LIBOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (subject to a floor of 1.5%), plus a margin of 6.75% per annum. If LIBOR is unavailable, the Term Loan will carry interest at the 6.75% margin plus the greatest of the Prime Rate, the Federal Funds Rate plus 0.5% per annum, and 2.5%.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional 3.0% margin is applied to the interest rate in the event of a default as defined in the Amended Hayfin Loan Agreement. The Term Loan carried an interest rate of 8.3% at issuance and 10.4% as of September&#160;30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Hayfin Loan Agreement, contains financial covenants requiring the Company, on a consolidated basis, to maintain the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum Consolidated Total Net Sales (as defined in the Amended Hayfin Loan Agreement) of varying amounts, required to be calculated on a quarterly basis, and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum Liquidity (as defined in the Amended Hayfin Loan Agreement) of $20 million, an at-all-times financial covenant tested monthly.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company is in compliance with all applicable financial covenants under the Amended Hayfin Loan Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Hayfin Loan Agreement also includes certain negative covenants and events of default customary for facilities of this type, and upon the occurrence of such events of default, subject to customary cure rights, the Term Loan may be accelerated or the lenders&#8217; commitments terminated. Mandatory prepayments are also required in the event of a change in control, incurring other indebtedness, certain proceeds from disposal of assets and insured casualty event (as defined in the Amended Hayfin Loan Agreement). Annually, beginning with the fiscal year ended December 31, 2021, the Company is required to prepay the outstanding loans based on a percentage of Excess Cash Flow (as defined in the Amended Hayfin Loan Agreement), if such is generated. No such prepayments have been required as of September&#160;30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A breach of a financial covenant in the Amended Hayfin Loan Agreement, if uncured or unable to be cured, would likely result in an event of default that could trigger the lender&#8217;s remedies, including acceleration of the entire principal balance of the loan as well as any applicable prepayment premiums.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Hayfin Loan Agreement also specifies that any prepayment of the Term Loan, voluntary or mandatory, will subject the Company to a prepayment premium applicable as of the date of the prepayment as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On or before July 2, 2023: 2% of the principal balance repaid.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">After July 2, 2023 and on or before July 2, 2024: 1% of the principal balance repaid.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">After July 2, 2024: no premium.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hayfin maintains a first-priority security interest in substantially all of the Company&#8217;s assets.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Original issue discount and deferred financing costs were allocated between the sale of the Series B Preferred Stock (which occurred on the same day as the funding of the Hayfin Loan Agreement as described in Note 10) and the Hayfin Loan Agreement on the basis of the relative fair values of the transactions. The costs allocated to the Hayfin Loan Agreement were further allocated between the Term Loan and the DD TL on the basis of the maximum potential principal outstanding between the Credit Facilities. The allocation of the deferred financing costs and original issue discount between the Term Loan and the DD TL on July 2, 2020 was as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.263%"><tr><td style="width:1.0%"/><td style="width:24.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DD TL</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue discount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs and original issue discount associated with the Term Loan are amortized using the effective interest method through the Maturity Date. The amortization of such amounts is presented as part of interest expense, net on the unaudited condensed consolidated statement of operations. Unamortized deferred financing costs and original issue discount associated with the Term Loan are presented as a reduction to the principal balance on the Term Loan as part of long term debt, net on the unaudited condensed consolidated balance sheets as of September&#160;30, 2022 and December&#160;31, 2021.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs and original issue discount associated with the DD TL were amortized using the straight-line method through the expiration of the DD TL commitment term on June 30, 2021. Amortization of these amounts is presented as part of interest expense, net on the unaudited condensed consolidated statement of operations for the nine months ended September 30, 2021. The DD TL was subject to a commitment fee of 1% per annum of the amount undrawn, which was recognized as interest expense.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balances of the Term Loan as of September&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.941%"><tr><td style="width:1.0%"/><td style="width:33.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.339%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.340%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the Term Loan, included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:33.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.770%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.770%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.770%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.774%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stated interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,116</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,573&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the DD TL, included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:34.277%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.467%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitment fee</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of principal payments due on the Term Loan, by year, from September&#160;30, 2022 through maturity are as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the nine months ended September&#160;30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the fair value of the Term Loan was $44.7&#160;million. This valuation was calculated based on a series of Level 2 and Level 3 inputs, including a discount rate based on the credit risk spread of debt instruments of similar risk character in reference to U.S. Treasury instruments with similar maturities, with an incremental risk premium for risk factors specific to the Company. The remaining cash flows associated with the Term Loan were discounted to September&#160;30, 2022 using this discount rate to determine fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153865168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">Net Loss Per Common Share<div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share is calculated using two methods: basic and diluted.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic Net Loss Per Common Share</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated as net loss available to common stockholders divided by weighted average common shares outstanding. Net loss available to common stockholders is calculated as net loss less (i) dividends accumulated on the Company&#8217;s Series B Convertible Preferred Stock during the period, and (ii) periodic accretion of the increasing-rate dividend feature.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of net loss to net loss available to common stockholders and calculation of basic net loss per common share for each of the three and nine months ended September&#160;30, 2022 and 2021 (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:38.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,426)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,339)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,783)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile to net loss available to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated dividend on Series B Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,613</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of increasing-rate dividend feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,096)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,913)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,667)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,039)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,448,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,717,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,650,713</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,136,517</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diluted Net Loss Per Common Share</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per common share is calculated as net loss available to common stockholders, adjusted for dividends on convertible preferred stock (to the extent conversion would be dilutive), divided by weighted average common shares outstanding plus potential common shares. The calculation of potential common shares considers incremental shares resulting from certain transactions, including the exercise of stock options and the issuance of restricted stock, using the treasury stock method, as well as the hypothetical conversion of the Company&#8217;s Series B Convertible Preferred Stock using the if-converted method. The treasury stock method assumes that proceeds from the transaction are used to purchase common stock at the average market price throughout the period. The if-converted method adds back periodic accrued or deemed dividends on the Company&#8217;s Series B Convertible Preferred Stock, and assumes conversion as of the beginning of the period.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each individual transaction is assessed for its dilutive effect on net loss per common share. To the extent that the transaction is antidilutive or does not reduce net loss per common share, the effect is excluded from the calculation.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of diluted net loss per common share (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.507%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,096)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,913)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,667)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,039)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends on Series B Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: antidilutive adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,667)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,448,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,717,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,650,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,136,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,269,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,658,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,858,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,185,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: antidilutive potential common shares (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,269,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,658,193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,858,049)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,185,813)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding adjusted for potential common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,448,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,717,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,650,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,136,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per common share</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Weighted average common shares outstanding for the calculation of diluted net loss per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:39.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,685,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,027,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,850,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,497,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,269,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,658,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,858,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,185,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159701888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Convertible Preferred Stock </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series B Convertible Preferred Stock of the Company (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) paid a 4.0% cumulative dividend per annum prior to the quarterly dividend payment ending on June 30, 2021, and pays a 6.0% cumulative dividend per annum thereafter. Dividends, if declared, are paid at the end of each quarter based on dividend amounts that accumulate beginning on the last payment date through the day prior to the end of each quarter. In lieu of paying a dividend, the Company may elect to accrue the dividend owed to shareholders. Accrued dividend balances accumulate dividends at the prevailing dividend rate for each dividend period for which they are outstanding.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Preferred Stock is convertible into the Company&#8217;s common stock at any time at the option of the holder. Shares are converted based on the liquidation preference of $1,000 per share (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation Preference</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) plus any accrued or accumulated dividends through the date of the conversion at a conversion price of $3.85 per common share. The Series B Preferred Stock, including any accumulated and unpaid dividends, automatically converts into common stock at any time after </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2, 2023, provided that the common stock has traded at $7.70 per share or more for (i) 20 out of the preceding 30 consecutive trading days and (ii) on such date of conversion.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Series B Preferred Stock, voting as a class, are entitled to appoint two members to the board of directors. The holders of the Series B Preferred Stock are entitled to vote on all matters to be voted on by the Company&#8217;s shareholders on an as-converted basis as a single class with the common stock; provided that the votes represented by the Series B Preferred Stock cannot exceed 19.9% of the total voting stock of the Company and their votes cannot exceed a number of shares equal to the Liquidation Preference divided by $5.25 per share. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Series B Preferred Stock are also entitled to the Liquidation Preference plus all accumulated and unpaid dividends in the event of a liquidation, dissolution, or winding-up of the Company.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a change of control (as defined), the Company will have the option to repurchase some or all of the then-outstanding shares of Series B Preferred Stock for cash in an amount equal to the Liquidation Preference plus any accumulated and unpaid dividends, subject to the rights of the holders of the Series B Preferred Stock in connection with such change in control. If the Company does not exercise such repurchase right, holders of the Series B Preferred Stock will have the option to (1) require the Company to repurchase any or all of their then-outstanding shares of Series B Preferred Stock for cash in an amount equal to the Liquidation Preference plus accumulated and unpaid dividends or (2) convert the Series B Preferred Stock into common stock and receive their pro rata consideration thereunder. Since the contingent redemption of the Series B Preferred Stock by the holders in the event of a change in control is outside the Company&#8217;s control, the Series B Preferred Stock is classified as temporary equity.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in the balance of Series B Preferred Stock for the three or nine months ended September&#160;30, 2022 or the three months ended September&#160;30, 2021. The below table illustrates changes in the Company&#8217;s balance of Series B Preferred Stock for the nine months ended September&#160;30, 2021 (in thousands, except share amounts):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.175%"><tr><td style="width:1.0%"/><td style="width:42.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.610%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred Stock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not declared or paid any dividends on the Series B Preferred Stock since issuance. Dividends accumulated but not paid as of September&#160;30, 2022 were $12.1 million. As this amount has not been declared, the Company has not recorded this amount on its unaudited condensed consolidated balance sheet as of September&#160;30, 2022. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on accumulated dividends as of September&#160;30, 2022, the Series B Preferred Stock was convertible into an aggregate of 29,119,562 shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued restricted stock awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), restricted stock unit awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and performance stock unit awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PSUs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to its employees. The following is summary information for restricted stock awards for the nine months ended September 30, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, there was $26.7&#160;million of unrecognized share-based compensation expense related to share-based payment arrangements. This expense is expected to be recognized over a weighted-average period of 1.93 years, which approximates the remaining vesting period of these grants. The below table summarizes activity of unvested restricted stock awards by award type from January 1, 2022 through September&#160;30, 2022. Unvested RSAs noted below are included in issued and outstanding common stock as of September&#160;30, 2022, while unvested RSUs and unvested PSUs are not included in issued or outstanding common stock as of September&#160;30, 2022.</span></div><div style="margin-bottom:10pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:31.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSU</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Grant Date<br/>&#160;Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Grant Date<br/>&#160;Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Grant Date<br/>&#160;Fair Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,181,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,713,078)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,274,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,893)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Stock Units</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted PSUs to certain executive officers during the nine months ended September 30, 2022. These PSUs vest only to the extent that stipulated cumulative net sales targets are achieved for the year ending December 31, 2022, the two-year period ending December 31, 2023, and the three-year period ending December 31, 2024. Performance factors range from 50% to 150% of the net sales targets; if performance is below 50%, the PSUs do not vest. If total shareholder return (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TSR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as defined below, is negative, vesting is limited to 100% of the award. All of the PSUs require recipients to continue employment with the Company through the vesting date, which will occur upon approval of the results with respect to the established targets by the Compensation Committee of the Board of Directors after December 31, 2024, but no later than March 15, 2025.</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TSR is calculated as the average trading price of the Company&#8217;s common stock during the final 30 trading days of 2024, adjusted for dividends paid on the Company&#8217;s common stock, less the average trading price during the final 30 trading days of 2021.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since TSR is based on the Company&#8217;s share price, it represents a market condition, which is incorporated in the grant date fair value of shares in excess of 100% vesting. These awards were valued on the date of grant using a Monte Carlo simulation, the inputs for which were informed by a Black-Scholes option pricing model. The assumptions used in determining the fair value of these PSUs were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"><tr><td style="width:1.0%"/><td style="width:56.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.74</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (annualized)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing stock price on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term was derived from the date of the grant through the latest date of the resolution of the market condition. The risk-free interest rate was derived based on the U.S. Treasury Yield curve in effect at the date of grant for maturities of similar periods to the concluded term. The expected volatility was based on the Company&#8217;s historical daily stock price movements for a term similar in length to the expected term. The dividend yield was based on the Company&#8217;s history of dividends on its common stock.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense related to PSUs is recognized, straight-line, based on the grant date fair value of the relevant shares, over the requisite service period related to each individual tranche, limited to the extent that the achievement of the associated performance condition associated with that tranche is probable. These expectations are derived from the Company&#8217;s latest budget and forecasts for net sales in the associated periods. The fair value of the awards subject to a market condition and expense recognized on such awards are not subsequently reconsidered based on the probability of achievement or ultimate resolution of the market condition. Accordingly, the Company may recognize share-based compensation expense for awards that do not ultimately vest.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the nine months ended September 30, 2022 is presented below:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:48.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested options expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,344&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2022, the Company adopted the MiMedx, Inc. Employee Stock Purchase Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Internal Revenue Code. All regular full-time employees of the Company (including officers) and all other employees who meet the eligibility requirements of the plan may participate in the ESPP. The ESPP provides eligible employees an opportunity to acquire the Company&#8217;s common stock on a semi-annual basis at a purchase price of 85% of the lower of the closing price per share of the Company&#8217;s common stock on the first day and the last day of each six-month purchase period (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The aggregate number of shares which may be issued and sold under the ESPP is 3 million shares of Common Stock. The first Purchase Period under the ESPP commenced on August 1, 2022 and will result in a purchase of shares on January 31, 2023. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recorded $0.1&#160;million in stock-based compensation related to the ESPP. As of the nine months ended September 30, 2022, the Company had cumulative payroll deferrals under the ESPP for future share purchases of $0.2&#160;million. This amount is included in accrued compensation in the unaudited condensed balance sheet. No shares have been issued under the plan to date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890156896768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the Company were (0.6)% and (14.8)% for the three months ended September&#160;30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the Company were (0.6)% and (2.9)% for the nine months ended September&#160;30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material discrete items affecting the effective tax rate in any period. Net operating losses incurred were offset by a valuation allowance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890158556576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities</a></td>
<td class="text">Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected cash payments, receipts, and non-cash activities are as follows (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:59.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.302%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equipment in accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets arising from operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividends on Series B Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of non-cash consideration received for option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets arising from finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note receivable for sale of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159751552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation Agreement with Timothy R. Wright</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company entered into a Separation Agreement and General Release with Timothy R. Wright, the former Chief Executive Officer of the Company (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Pursuant to the terms of the Separation Agreement and Mr. Wright&#8217;s general release of all claims against the Company, the Company will pay Mr. Wright a total of $3.1 million in cash in a series of installments through September 2024. The terms of the severance benefits provided in the Separation Agreement were the same as those provided for in the original employment Letter Agreement between Mr. Wright and the Company dated April 8, 2019. The $3.1 million was recorded as part of selling, general, and administrative expense on the condensed consolidated statements of operations for the three and nine months ended September 30, 2022. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the $3.1&#160;million, $1.6 million is reflected in accrued compensation and the remainder is reflected in other liabilities in the unaudited condensed consolidated balance sheet as of September 30, 2022. No payments were required to Mr. Wright under the terms of the Separation Agreement during the nine months ended September 30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nordic Agreement</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a collaboration agreement (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nordic Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) with Nordic Bioscience Clinical Development A/S (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBCD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to provide full operational support for the Company&#8217;s upcoming Knee Osteoarthritis (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KOA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) clinical trial program. As part of the agreement, NBCD will perform site selection and monitoring, manage patient recruitment and enrollment, data management, statistical analysis and reporting activities for the duration of the trial. Under the terms of the Nordic Agreement, the Company is obligated to pay $13.3 million upon the achievement of specified milestones over the course of the clinical trial. The milestones are based upon various factors including, but not limited to, site selection and enrollment, patient enrollment, patient completion, and certain other activities related to clinical trial operations. The milestone payments are revised semi-annually based on fluctuations in the consumer price index. The Company has the ability to terminate the Nordic Agreement with 30 days written notice to NBCD. At such time, the Company would be required to pay for services performed through the date of termination and any non-cancelable obligations.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company has paid $2.0 million under the Nordic Agreement, relating to milestones which have been achieved from inception through that date. During each of the three and nine months ended September&#160;30, 2022, the Company recognized $0.6&#160;million of expense. This amount is included as part of research and development expense in the unaudited condensed consolidated statements of operations for those periods. The remaining $1.4 million is reflected in prepaid expenses on the consolidated balance sheet as of September&#160;30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Matters</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company and its subsidiaries are parties to numerous civil claims and lawsuits and subject to regulatory examinations, investigations, and requests for information. Some of these matters involve claims for substantial amounts. The Company&#8217;s experience has shown that the damages alleged by plaintiffs or claimants are often overstated, based on unsubstantiated legal theories, unsupported by facts, and/or bear no relation to the ultimate award that a court might grant. Additionally, the outcome of litigation and regulatory matters and the timing of ultimate resolution are </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inherently difficult to predict. These factors make it difficult for the Company to provide a meaningful estimate of the range of reasonably possible outcomes of claims in the aggregate or by individual claim. However, on a case-by-case basis, reserves are established for those legal claims for which it is probable that a loss will be incurred and the amount of such loss can be reasonably estimated. The Company's unaudited condensed consolidated balance sheet as of September&#160;30, 2022&#160;reflects the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. The actual costs of resolving these claims, as well as the cost to resolve claims that are either not probable or not estimable at this time, may be substantially higher or lower than the amounts reserved. For more information regarding the Company&#8217;s legal proceedings, refer to Note 14, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in the 2021 Form 10-K.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $0.7 million toward the resolution of legal matters involving the Company during the nine months ended September&#160;30, 2022. In addition, insurance providers paid $0.6&#160;million on the Company&#8217;s behalf to settle legal matters.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recovered amounts from certain former officers and directors of the Company relating to legal fees previously advanced on their behalf. These funds were recognized as a reduction to investigation, restatement, and related expense on the condensed consolidated statement of operations for the nine months ended September 30, 2022.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain litigation and regulatory matters to which the Company is a party:</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 16, 2019, the United States District Court for the Northern District of Georgia entered an order consolidating two purported securities class actions (MacPhee v. MiMedx Group, Inc., et al. filed February 23, 2018 and Kline v. MiMedx Group, Inc., et al. filed February 26, 2018). The order also appointed Carpenters Pension Fund of Illinois (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CPFI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) as lead plaintiff. On May 1, 2019, CPFI filed a consolidated amended complaint, naming as defendants the Company, Michael J. Senken, Parker H. &#8220;Pete&#8221; Petit, William C. Taylor, Christopher M. Cashman and Cherry Bekaert &amp; Holland LLP. The amended complaint (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action Complaint</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) alleged violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Rule 10b-5 promulgated thereunder, and Section 20(a) of the Exchange Act. It asserted a class period of March 7, 2013 through June 29, 2018. Following the filing of motions to dismiss by the various defendants, CPFI was granted leave to file an amended complaint. CPFI filed its amended complaint against the Company, Michael J. Senken, Parker H. Petit, William C. Taylor, and Cherry Bekaert &amp; Holland (Christopher Cashman was dropped as a defendant) on March 30, 2020. The defendants filed motions to dismiss on May 29, 2020. On March 25, 2021, the Court granted defendants&#8217; respective motions to dismiss, finding that CPFI lacked standing to bring the underlying claims and also could not establish loss causation because it sold all of its shares in MIMEDX prior to any corrective disclosures, and dismissed the case. On April 22, 2021, CPFI filed a motion for reconsideration of the dismissal and for leave to amend to add a new plaintiff to attempt to cure the standing and loss causation issues.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2022, the Court denied CPFI&#8217;s motion to reconsider and motion to substitute class representative. On February 25, 2022, CPFI filed a Notice of Appeal in the 11th Circuit Court of Appeals, Case No. 22-10633-CC. The parties have completed their briefings on the issues on the appeal.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Former Employee Litigation and Related Matters</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2021, the Company filed suit in the Circuit Court of the Eleventh Judicial District in and for Miami-Dade County, Florida (MiMedx Group, Inc. v. Petit, et. al.) against its former CEO, Parker H. &#8220;Pete&#8221; Petit, and its former COO, William C. Taylor, seeking a determination of its rights and obligations under indemnification agreements with Petit and Taylor following a federal jury&#8217;s guilty verdict against Petit for securities fraud and Taylor for conspiracy to commit securities fraud. The Company is seeking a declaratory judgment that it is not obligated to indemnify or advance expenses to Petit and Taylor in connection with certain cases to which Petit and Taylor are parties and also seeking to recoup amounts previously paid on behalf of Petit and Taylor in connection with such cases. On April 22, 2021, Petit and Taylor filed an answer and asserted counterclaims against the Company alleging breach of their indemnification agreements, breach of the covenant of good faith and fair dealing with respect to their indemnification agreements, and seeking a declaration that the Company remains obligated to indemnify and advance fees in connection with certain cases. Petit and Taylor simultaneously also filed a motion seeking to compel the Company to advance and reinstate its payments of Petit and Taylor&#8217;s legal expenses. The Company opposed Petit and Taylor&#8217;s motion and a hearing was set for June 23, 2021. At the joint request of the parties, the hearing was cancelled to allow the parties to attend a mediation to attempt a resolution of this matter; such mediation was held on August 11, 2021.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the mediation, the Company and Mr. Taylor reached an agreement to settle the matter between them. Negotiations with Mr. Petit are ongoing.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Florida Business Corporation Act and agreements with its current and former officers and directors, the Company is obligated to indemnify its current and former officers and directors who are made party to a proceeding, including a proceeding brought by or in the right of the corporation, with certain exceptions, and to advance expenses to defend such matters. The Company has already borne substantial costs to satisfy these indemnification and expense advance obligations and may continue to do so in the future. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the matters described above, the Company is a party to a variety of other legal matters that arise in the ordinary course of the Company&#8217;s business, none of which are deemed to be individually material at this time. Due to the inherent uncertainty of litigation, there can be no assurance that the resolution of any particular claim or proceeding would not have a material adverse effect on the Company&#8217;s business, results of operations, financial position or liquidity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159824416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue by Product</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX has two primary classes of products: (1) Advanced Wound Care, or Section 361, products, consisting of its tissue and cord sheet allograft products as well as certain particulate products regulated under Section 361, and (2) Section 351 products, consisting of the Company&#8217;s micronized and certain other particulate products. Advanced Wound Care is further disaggregated between the Company&#8217;s Tissue/Other and Cord products.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the business units responsible for the sale of each of these classes of product can be found in Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of net sales by class of product (in thousands): </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:37.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Wound Care</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tissue/Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cord</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Advanced Wound Care</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 351</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,074&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1) &#8220;O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">ther&#8221; represents revenue transactions in the indicated period relating to performance obligations settled prior to October 1, 2019, the date at which the Company changed its pattern of revenue recognition. For all practical purposes, the Company is not able to allocate these revenue transactions to different product groups. This revenue is reflected as part of the Wound &amp; Surgical segment.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue by Customer</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX has two primary distribution channels: (1) direct to customers (healthcare professionals and/or facilities) (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Direct Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and (2) sales to distributors (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of net sales by each customer type (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.941%"><tr><td style="width:1.0%"/><td style="width:24.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.975%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct Customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,074&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three or nine months ended September&#160;30, 2022 or 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153402944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment InformationThe Company has two reportable segments: Wound &amp; Surgical and Regenerative Medicine.<div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wound &amp; Surgical focuses on the Advanced Wound Care and Surgical Recovery markets, the Company&#8217;s existing product portfolio, and near-term product development. Its platform technologies include tissue allografts derived from human placental membrane (EPIFIX&#174;, AMNIOFIX&#174;, and AMNIOEFFECT&#8482;), tissue allografts derived from human umbilical cord (EPICORD&#174; and AMNIOCORD&#174;), and a particulate extracellular matrix derived from human placental disc (AXIOFILL&#8482;). This segment is also responsible for the international sales of the Company&#8217;s Section 351 products.</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Regenerative Medicine business focuses solely on Regenerative Medicine technologies, specifically progressing the Company&#8217;s placental biologics platform towards registration as a FDA-approved biological drug. Micronized dehydrated human amnion chorion membrane is the lead product candidate in its late-stage pipeline targeted at achieving FDA approval for specific clinical indications, including degenerative musculoskeletal conditions, beginning with KOA.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate function includes expenses incurred by executive, finance, human resource, information systems, legal, other functions which are generally shared and whose activities are not specifically identifiable solely to either of the other segments. It also includes amortization of intangible assets. The Company has another operating segment related to an expiring dental sales contract. All net sales and cost of sales presented in the Corporate &amp; Other columns below relate to this operating segment.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wound &amp; Surgical net sales reflects sales of the Company&#8217;s Advanced Wound Care products (as discussed in Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), except for sales of the Company&#8217;s dental product. Sales of the Company&#8217;s dental product are included in the Corporate &amp; Other columns in the tables below. In addition, Wound &amp; Surgical reflects international sales of the Company&#8217;s Section 351 products, which represent all Section 351 sales not reflected in Regenerative Medicine.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as the Company&#8217;s accounting policies. See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, included in the 2021 Form 10-K for significant accounting policies. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the performance of its segments and allocates resources based on segment contribution, defined as net sales less (i) cost of sales, (ii) selling, general and administrative expense, (iii) research and development expense, and (iv) amortization of intangible assets. Prior period results were recast on the basis of new operating segments. The only components which comprise loss before income tax provision that are not included in operating loss are interest expense, net and other expense, net.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales and segment contribution for each reportable segment for the three months ended September 30, 2022 were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,503&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,273)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,103)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Net sales and segment contribution by each reportable segment for the three months ended September 30, 2021 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:37.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,170)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,075)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2022 were as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:37.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,847&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,361)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,038)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2021 were as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,885)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,336)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company does not allocate any assets to the reportable segments. No asset information is reported or disclosed to the chief operating decision maker in the financial information for each segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890154940240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GAAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;The operating results for the three and nine months ended September&#160;30, 2022 and 2021 are not necessarily indicative of the results that may be expected for the full fiscal year.&#160;The balance sheet as of December&#160;31, 2021 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2021 Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported unaudited condensed consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates regarding asset retirement obligations, estimates for contingent liabilities, estimates related to the Company&#8217;s assessment of goodwill impairment, the measurement of right of use assets and lease liabilities, management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern, estimates of fair value of share-based payments, estimate for allowance for doubtful accounts, estimates of sales returns and allowances, and valuation of deferred tax assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of GAAP requires the use of the &#8220;management approach&#8221; model for segment reporting. The management approach model is based on the way a company&#8217;s chief operating decision maker (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CODM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) organizes segments within the Company for which separate, discrete financial information is available regarding resource allocation and assessing performance. The Company has concluded that its Chief Executive Officer (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CEO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is its CODM. Prior to June 30, 2022, the Company assessed that it operated as one operating and reportable segment. The Company reassesses the existence of operating segments when facts and circumstances suggest that there may have been a change in the way that the Company was managed.</span></div>On September&#160;30, 2022, the Company reassessed its operating segments, concluding that the CODM assesses performance and allocates resources between two, distinct reportable segments: Wound &amp; Surgical and Regenerative Medicine.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment at least annually on October 1 and more frequently whenever events or substantive changes in circumstances indicate that it is more likely than not that goodwill is impaired. In performing the goodwill impairment test, the Company first assesses qualitative factors to determine the existence of impairment. If the qualitative factors indicate that the carrying value of a reporting unit exceeds its fair value, the Company proceeds to a quantitative test to measure the existence and amount, if any, of goodwill impairment. The Company may also choose to bypass the qualitative assessment and proceed directly to the quantitative test.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the quantitative test, impairment loss is recorded to the extent that the carrying value of the reporting unit exceeds its assessed fair value. The Company determines the fair value using the income and market approaches. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the income approach, the fair value of a reporting unit is the present value of its future cash flows as viewed from the lens of a hypothetical market participant in an orderly transaction. These future cash flows are derived from expectations of revenue, expenses, tax deductions and credits, working capital flows, capital expenditures, and other projected sources and uses of cash, as applicable. Value indications are developed by discounting expected cash flows to their present value using a discount rate commensurate with the risks associated with the reporting unit subject to testing.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the market approach, the Company uses market multiples derived from the various comparable companies based on measures salient to investors in those companies. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company concludes that a reporting unit is being managed on the basis of multiple reporting units, the goodwill assigned to the original reporting unit is allocated to the new reporting units based on the relative fair value of the new reporting units.</span></div>As indicated above, on September 30, 2022, the Company changed its operating segments, determining that it operates as three operating segments. In concert with this re-evaluation, the Company concluded that it has three reporting units. Management performed a goodwill impairment test as of that date on its previous reporting unit, concluding that goodwill was not impaired as of that date. Management subsequently allocated the goodwill assigned to its previous reporting unit to its new reporting units.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FASB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) issued Accounting Standards Update (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) 2021-10, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832)&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides disclosure requirements regarding government grants and contributions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ASU requires disclosure of the nature of transactions and related accounting policies used to account for transactions, the effect, including amounts, of government assistance on individual line items on the financial statements, and significant terms and conditions of the transactions, including commitments and contingencies. This ASU is effective for fiscal years beginning after December 15, 2021. The Company adopted the provisions of this ASU effective January 1, 2022. There was no impact upon adoption.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All ASUs issued and not yet effective for the three and nine months ended September&#160;30, 2022, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company&#8217;s financial position and results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159751552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts, Notes, Loans and Financing Receivable</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,353&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159782272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159768528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and clean room equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_ScheduleOfDepreciationTableTextBlock', window );">Schedule of Depreciation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three and nine months ended September&#160;30, 2022 and 2021 is summarized in the table below (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_ScheduleOfDepreciationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Depreciation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_ScheduleOfDepreciationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153722016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets Activity Summary - Indefinite-lived</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, are summarized as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:38.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and know-how</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tradenames and trademarks</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,920&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets Activity Summary - Finite-lived</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, are summarized as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:38.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and know-how</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tradenames and trademarks</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,920&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three and nine months ended September 30, 2022 and 2021 is summarized in the table below (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:28.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense for Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization of intangible assets as of September&#160;30, 2022, is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated<br/>Amortization <br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the nine months ended September 30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortized intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153785376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses&#160;consisted of the following&#160;(in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"/><td style="width:53.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and settlement costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commissions to sales agents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued group purchasing organization fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated sales returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued travel</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890152840768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock', window );">Schedule of Debt Issuance Costs</a></td>
<td class="text">The allocation of the deferred financing costs and original issue discount between the Term Loan and the DD TL on July 2, 2020 was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.263%"><tr><td style="width:1.0%"/><td style="width:24.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DD TL</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue discount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balances of the Term Loan as of September&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.941%"><tr><td style="width:1.0%"/><td style="width:33.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.339%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.340%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the Term Loan, included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:33.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.770%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.770%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.770%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.774%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stated interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,116</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,573&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the DD TL, included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:34.277%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.467%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitment fee</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Payments for the Term Loan</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of principal payments due on the Term Loan, by year, from September&#160;30, 2022 through maturity are as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the nine months ended September&#160;30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Debt Issuance Costs [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Interest Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890248765152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Basic Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of net loss to net loss available to common stockholders and calculation of basic net loss per common share for each of the three and nine months ended September&#160;30, 2022 and 2021 (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:38.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,426)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,339)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,783)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile to net loss available to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated dividend on Series B Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,613</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of increasing-rate dividend feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,096)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,913)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,667)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,039)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,448,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,717,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,650,713</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,136,517</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of diluted net loss per common share (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.507%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,096)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,913)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,667)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,039)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends on Series B Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: antidilutive adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,667)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,448,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,717,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,650,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,136,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,269,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,658,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,858,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,185,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: antidilutive potential common shares (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,269,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,658,193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,858,049)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,185,813)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding adjusted for potential common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,448,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,717,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,650,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,136,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per common share</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Weighted average common shares outstanding for the calculation of diluted net loss per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:39.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,685,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,027,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,850,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,497,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,269,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,658,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,858,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,185,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:39.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,685,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,027,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,850,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,497,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,269,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,658,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,858,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,185,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890158968896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Series B Preferred Stock</a></td>
<td class="text">The below table illustrates changes in the Company&#8217;s balance of Series B Preferred Stock for the nine months ended September&#160;30, 2021 (in thousands, except share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.175%"><tr><td style="width:1.0%"/><td style="width:42.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.610%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred Stock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Awards by Award Type</a></td>
<td class="text">The below table summarizes activity of unvested restricted stock awards by award type from January 1, 2022 through September&#160;30, 2022. Unvested RSAs noted below are included in issued and outstanding common stock as of September&#160;30, 2022, while unvested RSUs and unvested PSUs are not included in issued or outstanding common stock as of September&#160;30, 2022.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:31.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSU</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Grant Date<br/>&#160;Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Grant Date<br/>&#160;Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Grant Date<br/>&#160;Fair Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,181,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,713,078)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,274,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,893)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Total Shareholder Return Performance Stock Units Assumptions</a></td>
<td class="text">The assumptions used in determining the fair value of these PSUs were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"><tr><td style="width:1.0%"/><td style="width:56.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.74</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (annualized)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing stock price on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the nine months ended September 30, 2022 is presented below:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:48.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested options expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,344&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890155258896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected cash payments, receipts, and non-cash activities are as follows (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:59.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.302%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equipment in accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets arising from operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividends on Series B Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of non-cash consideration received for option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets arising from finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note receivable for sale of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159824416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of net sales by class of product (in thousands): </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:37.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Wound Care</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tissue/Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cord</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Advanced Wound Care</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 351</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,074&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1) &#8220;O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">ther&#8221; represents revenue transactions in the indicated period relating to performance obligations settled prior to October 1, 2019, the date at which the Company changed its pattern of revenue recognition. For all practical purposes, the Company is not able to allocate these revenue transactions to different product groups. This revenue is reflected as part of the Wound &amp; Surgical segment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of net sales by each customer type (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.941%"><tr><td style="width:1.0%"/><td style="width:24.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.975%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct Customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,074&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890159824416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Net Sales and Segment Contribution for Each Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales and segment contribution for each reportable segment for the three months ended September 30, 2022 were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,503&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,273)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,103)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Net sales and segment contribution by each reportable segment for the three months ended September 30, 2021 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:37.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,170)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,075)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2022 were as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:37.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,847&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,361)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,038)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2021 were as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound &amp; Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regenerative Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment contribution</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,885)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,336)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890154806592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,689<span></span>
</td>
<td class="nump">$ 63,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,466<span></span>
</td>
<td class="nump">$ 191,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 13,976<span></span>
</td>
<td class="nump">13,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mdxg_InternationalSection351Member', window );">International Section 351</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareUmbilicalCordDerivedMember', window );">Cord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,678<span></span>
</td>
<td class="nump">$ 6,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,165<span></span>
</td>
<td class="nump">$ 17,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mdxg_InternationalSection351Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mdxg_InternationalSection351Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareUmbilicalCordDerivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareUmbilicalCordDerivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890154940400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890154761520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net - Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable, gross</a></td>
<td class="nump">$ 44,660<span></span>
</td>
<td class="nump">$ 41,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">(3,830)<span></span>
</td>
<td class="num">(1,187)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 40,830<span></span>
</td>
<td class="nump">$ 40,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890155337136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,817<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890149675776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">7,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,913<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">13,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mdxg_InternationalSection351Member', window );">International Section 351</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mdxg_InternationalSection351Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mdxg_InternationalSection351Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890152662256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease right-of-use asset</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">43,043<span></span>
</td>
<td class="nump">42,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(35,131)<span></span>
</td>
<td class="num">(32,878)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">7,912<span></span>
</td>
<td class="nump">9,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9,190<span></span>
</td>
<td class="nump">9,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory and clean room equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">16,302<span></span>
</td>
<td class="nump">16,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">14,997<span></span>
</td>
<td class="nump">14,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,383<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdxg_AssetRetirementCostMember', window );">Asset retirement cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 982<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdxg_AssetRetirementCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdxg_AssetRetirementCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890154896016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Depreciation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 831<span></span>
</td>
<td class="nump">$ 923<span></span>
</td>
<td class="nump">$ 2,549<span></span>
</td>
<td class="nump">$ 3,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153515648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill | $</a></td>
<td class="nump">$ 19,976<span></span>
</td>
<td class="nump">$ 19,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,976<span></span>
</td>
<td class="nump">$ 19,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=mdxg_WoundSurgicalMember', window );">Wound &amp; Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill | $</a></td>
<td class="nump">19,500<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=mdxg_RegenerativeMedicineMember', window );">Regenerative Medicine &amp; Biologics Innovation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill | $</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=mdxg_WoundSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=mdxg_WoundSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=mdxg_RegenerativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=mdxg_RegenerativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153661936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Activity Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 2,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross carrying amount</a></td>
<td class="nump">11,920<span></span>
</td>
<td class="nump">$ 11,791<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net carrying amount</a></td>
<td class="nump">4,992<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Tradenames and trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross carrying value, indefinite lived</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mdxg_PatentsinProcessMember', window );">Patents in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross carrying value, indefinite lived</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents and know-how</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">9,810<span></span>
</td>
<td class="nump">9,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,928)<span></span>
</td>
<td class="num">(6,408)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 2,882<span></span>
</td>
<td class="nump">$ 3,170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mdxg_PatentsinProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mdxg_PatentsinProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890158979536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153623776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated future amortization expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022 (excluding the nine months ended September 30, 2022)</a></td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 2,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153718704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal and settlement costs</a></td>
<td class="nump">$ 4,185<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Commissions to sales agents</a></td>
<td class="nump">2,238<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_AccruedAdministrativeFeesCurrent', window );">Accrued group purchasing organization fees</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Estimated sales returns</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_AccruedTravel', window );">Accrued travel</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_AccruedClinicalTrialsCurrent', window );">Accrued clinical trials</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,454<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 10,986<span></span>
</td>
<td class="nump">$ 9,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_AccruedAdministrativeFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Administrative Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_AccruedAdministrativeFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_AccruedClinicalTrialsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trials, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_AccruedClinicalTrialsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Rebates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_AccruedTravel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Travel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_AccruedTravel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890150908480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt, Net - Term Loan (Details) - Term loan - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jul. 02, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Hayfin Loan Agreement Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Hayfin Loan Agreement Term Loan | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_DebtInstrumentInterestRateFloorPercentage', window );">Debt instrument, interest rate, floor (percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_DebtInstrumentDefaultInterestRate', window );">Default interest rate (percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_DebtCovenantMinimumLiquidity', window );">Debt covenant, minimum liquidity</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Credit Facilities | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent', window );">Debt instrument, prepayment make-whole premium as percent of prepaid principal (percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Credit Facilities | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent', window );">Debt instrument, prepayment make-whole premium as percent of prepaid principal (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Credit Facilities | Debt Instrument, Redemption, Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent', window );">Debt instrument, prepayment make-whole premium as percent of prepaid principal (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Hayfin Loan Agreement Delayed Draw Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage', window );">Additional commitment fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">BT Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of the Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Hayfin Loan Agreement Term Loan | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Hayfin Loan Agreement Term Loan | Fed Funds Effective Rate Overnight Index Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_DebtCovenantMinimumLiquidity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Minimum Liquidity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_DebtCovenantMinimumLiquidity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_DebtInstrumentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_DebtInstrumentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_DebtInstrumentInterestRateFloorPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Floor Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_DebtInstrumentInterestRateFloorPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty As Percent Of Prepaid Principal, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Unused Capacity, Commitment Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdxg_CreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdxg_CreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdxg_TermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdxg_TermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890151166576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Debt, Net - Term Loan Debt Issuance Costs (Details) - Term loan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 02, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Hayfin Loan Agreement Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Hayfin Loan Agreement Delayed Draw Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,084<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdxg_CreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdxg_CreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153469296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Debt, Net - Term Loan Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Term loan | Hayfin Loan Agreement Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">(1,322)<span></span>
</td>
<td class="num">(1,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="num">$ (333)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt, net</a></td>
<td class="nump">$ 48,475<span></span>
</td>
<td class="nump">$ 48,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890150865888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt, Net - Term Loan Interest Expense (Details) - Term loan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Hayfin Loan Agreement Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Stated interest</a></td>
<td class="nump">$ 1,151<span></span>
</td>
<td class="nump">$ 1,054<span></span>
</td>
<td class="nump">$ 3,225<span></span>
</td>
<td class="nump">$ 3,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of original issue discount</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">1,270<span></span>
</td>
<td class="nump">1,164<span></span>
</td>
<td class="nump">3,573<span></span>
</td>
<td class="nump">3,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Hayfin Loan Agreement Delayed Draw Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_DebtInstrumentCommitmentFees', window );">Commitment fee</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of original issue discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_DebtInstrumentCommitmentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Commitment Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_DebtInstrumentCommitmentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890154953648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Debt, Net - Term Loan Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2022 (excluding the nine months ended September&#160;30, 2022)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_LongTermDebtMaturityAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long term debt, net</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890151175696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Basic Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,426)<span></span>
</td>
<td class="num">$ (2,339)<span></span>
</td>
<td class="num">$ (29,783)<span></span>
</td>
<td class="num">$ (12,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract', window );"><strong>Adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Dividends on Series B Convertible Preferred Stock</a></td>
<td class="nump">1,670<span></span>
</td>
<td class="nump">1,574<span></span>
</td>
<td class="nump">4,884<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature', window );">Accretion of increasing-rate dividend feature</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Total adjustments</a></td>
<td class="nump">1,670<span></span>
</td>
<td class="nump">1,574<span></span>
</td>
<td class="nump">4,884<span></span>
</td>
<td class="nump">4,539<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (10,096)<span></span>
</td>
<td class="num">$ (3,913)<span></span>
</td>
<td class="num">$ (34,667)<span></span>
</td>
<td class="num">$ (17,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="nump">113,448,251<span></span>
</td>
<td class="nump">110,717,073<span></span>
</td>
<td class="nump">112,650,713<span></span>
</td>
<td class="nump">110,136,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Accretion Of Increasing-Rate Dividend Feature</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890146355824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (10,096)<span></span>
</td>
<td class="num">$ (3,913)<span></span>
</td>
<td class="num">$ (34,667)<span></span>
</td>
<td class="num">$ (17,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Dividends on Series B Convertible Preferred Stock</a></td>
<td class="nump">1,670<span></span>
</td>
<td class="nump">1,574<span></span>
</td>
<td class="nump">4,884<span></span>
</td>
<td class="nump">4,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPreferredStockDividendsAndAdjustments', window );">Less: antidilutive adjustments</a></td>
<td class="num">(1,670)<span></span>
</td>
<td class="num">(1,574)<span></span>
</td>
<td class="num">(4,884)<span></span>
</td>
<td class="num">(4,539)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Numerator</a></td>
<td class="num">$ (10,096)<span></span>
</td>
<td class="num">$ (3,913)<span></span>
</td>
<td class="num">$ (34,667)<span></span>
</td>
<td class="num">$ (17,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">113,448,251<span></span>
</td>
<td class="nump">110,717,073<span></span>
</td>
<td class="nump">112,650,713<span></span>
</td>
<td class="nump">110,136,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Potential common shares (in shares)</a></td>
<td class="nump">29,269,481<span></span>
</td>
<td class="nump">30,658,193<span></span>
</td>
<td class="nump">28,858,049<span></span>
</td>
<td class="nump">30,185,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Less: antidilutive potential common shares (in shares)</a></td>
<td class="num">(29,269,481)<span></span>
</td>
<td class="num">(30,658,193)<span></span>
</td>
<td class="num">(28,858,049)<span></span>
</td>
<td class="num">(30,185,813)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding adjusted for potential common shares</a></td>
<td class="nump">113,448,251<span></span>
</td>
<td class="nump">110,717,073<span></span>
</td>
<td class="nump">112,650,713<span></span>
</td>
<td class="nump">110,136,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPreferredStockDividendsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of preferred stock dividends and adjustments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SAB Topic 5.Q)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187283-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPreferredStockDividendsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890151066352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="nump">29,269,481<span></span>
</td>
<td class="nump">30,658,193<span></span>
</td>
<td class="nump">28,858,049<span></span>
</td>
<td class="nump">30,185,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="nump">28,685,739<span></span>
</td>
<td class="nump">27,027,252<span></span>
</td>
<td class="nump">27,850,916<span></span>
</td>
<td class="nump">26,497,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock unit awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="nump">474,355<span></span>
</td>
<td class="nump">1,840,483<span></span>
</td>
<td class="nump">574,507<span></span>
</td>
<td class="nump">1,500,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="nump">22,327<span></span>
</td>
<td class="nump">974,687<span></span>
</td>
<td class="nump">293,778<span></span>
</td>
<td class="nump">1,287,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="nump">22,528<span></span>
</td>
<td class="nump">805,437<span></span>
</td>
<td class="nump">97,190<span></span>
</td>
<td class="nump">875,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Performance stock unit awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="nump">59,996<span></span>
</td>
<td class="nump">10,334<span></span>
</td>
<td class="nump">40,141<span></span>
</td>
<td class="nump">24,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="nump">4,536<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890151849360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 07, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 02, 2020 </div>
<div>day </div>
<div>director </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_TemporaryEquityConversionPricePerShare', window );">Series B preferred stock, conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember', window );">Restricted Stock, Restricted Stock Units, And Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized stock-based compensation related to time-based, nonvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expenses expected to be recognized over a weighted-average period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Total Shareholder Return Performance Stock Units | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays', window );">Trading days (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Total Shareholder Return Performance Stock Units | Executive Officer | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod', window );">Performance period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Total Shareholder Return Performance Stock Units | Executive Officer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod', window );">Performance period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock (in percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available for issuance (in shares) | shares</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_AccruedESPPPayrollDeferrals', window );">Accrued ESPP payroll deferrals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued during period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember', window );">Preferred Class B Convertible Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_TemporaryEquityConversionPricePerShare', window );">Series B preferred stock, conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger', window );">Series B preferred stock, minimum percentage of conversion stock price to trigger conversion (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_TemporaryEquityConversionThresholdTradingDays', window );">Number of trading days within consecutive day trading period common stock must exceed trigger conversion price | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_TemporaryEquityThresholdConsecutiveTradingDays', window );">Series B preferred stock, threshold number of consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders', window );">Number of board seats elected by Series B preferred stockholders | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis', window );">Series B preferred stock, maximum voting stock percentage on an as-converted basis (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember', window );">Preferred Class B Convertible Stock | Discounted Dividend Rate prior to Quarterly Dividend Payment ending on June 30,2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_TemporaryEquityDividendRatePercentage', window );">Series B convertible stock, cumulative dividend (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember', window );">Preferred Class B Convertible Stock | Perpetual Dividend Rate after Quarterly Dividend Payment ending on June 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_TemporaryEquityDividendRatePercentage', window );">Series B convertible stock, cumulative dividend (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends, preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_DividendAccumulatedByNotPaid', window );">Dividends accumulated but not paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible shares issuable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,119,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,119,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_AccruedESPPPayrollDeferrals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued ESPP Payroll Deferrals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_AccruedESPPPayrollDeferrals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_DividendAccumulatedByNotPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend, Accumulated By Not Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_DividendAccumulatedByNotPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Board Seats Elected By Temporary Equity Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_TemporaryEquityConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Conversion Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_TemporaryEquityConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Conversion, Threshold Percentage of Stock Price Trigger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_TemporaryEquityConversionThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Conversion, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_TemporaryEquityConversionThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_TemporaryEquityDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Dividend Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_TemporaryEquityDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Maximum Voting Stock Percentage On As-Converted Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_TemporaryEquityThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_TemporaryEquityThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890154987408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Changes in Series B Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series B Preferred Stock, outstanding, beginning (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series B Preferred Stock, outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series B Preferred Stock, outstanding, ending (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series B Preferred Stock, outstanding, ending</a></td>
<td class="nump">$ 92,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series B Preferred Stock, outstanding, beginning (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series B Preferred Stock, outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Deemed dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series B Preferred Stock, outstanding, ending (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series B Preferred Stock, outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890151103600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Restricted Stock Awards (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Beginning Balance (in shares) | shares</a></td>
<td class="nump">877,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(703,405)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(5,338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Ending Balance (in shares) | shares</a></td>
<td class="nump">168,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">3.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">5.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Beginning Balance (in shares) | shares</a></td>
<td class="nump">4,228,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">4,181,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1,713,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(1,274,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Ending Balance (in shares) | shares</a></td>
<td class="nump">5,422,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">4.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">8.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">6.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock unit awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Beginning Balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">441,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(200,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Ending Balance (in shares) | shares</a></td>
<td class="nump">241,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">4.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">4.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153912480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Fair Value Assumptions (Details) - Total Shareholder Return Performance Stock Units<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 4.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">2 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (annualized)</a></td>
<td class="nump">63.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price on grant date (in dollars per share)</a></td>
<td class="nump">$ 4.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 2.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890152668832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Stock Incentive Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">1,444,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(285,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Unvested options forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Vested options expired (in shares)</a></td>
<td class="num">(109,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">1,050,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable options, vested and expected to vest (in shares)</a></td>
<td class="nump">1,050,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 5.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Unvested options forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Vested options expired (in dollars per share)</a></td>
<td class="nump">4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in dollars per share)</a></td>
<td class="nump">6.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 6.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">1 year 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890154918928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(14.80%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890151167616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 3,233<span></span>
</td>
<td class="nump">$ 3,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of equipment in accounts payable</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets arising from operating lease liabilities</a></td>
<td class="num">(37)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_TemporaryEquityDeemedDividends', window );">Deemed dividends on Series B Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise', window );">Fair value of non-cash consideration received for option exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right of use assets arising from finance lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_NotesReceivableForSaleOfPropertyAndEquipment', window );">Note receivable for sale of property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value Of Non-Cash Consideration Received For Option Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_NotesReceivableForSaleOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable For Sale Of Property And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_NotesReceivableForSaleOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_TemporaryEquityDeemedDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividends</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_TemporaryEquityDeemedDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890149881088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 16, 2019 </div>
<div>class_action</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,475<span></span>
</td>
<td class="nump">$ 46,289<span></span>
</td>
<td class="nump">$ 158,838<span></span>
</td>
<td class="nump">$ 145,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_ContingencyLossNumberOfSecuritiesClassActions', window );">Number of securities class actions | class_action</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and Development Arrangement | Nordic Bioscience Clinical Development A/S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term purchase commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired', window );">Termination period (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_PaymentsMadeOnLongTermPurchaseCommitment', window );">Payments made on long-term purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_ExpensesOnLongTermPurchaseCommitment', window );">Expenses on long-term purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment', window );">Remaining prepaid expenses on long-term purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Separation Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mdxg_InsuranceProvidersMember', window );">Insurance Providers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_ContingencyLossNumberOfSecuritiesClassActions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingency Loss, Number Of Securities Class Actions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_ContingencyLossNumberOfSecuritiesClassActions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_ExpensesOnLongTermPurchaseCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses On Long-Term Purchase Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_ExpensesOnLongTermPurchaseCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Purchase Commitment, Termination Notice Period Required</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_PaymentsMadeOnLongTermPurchaseCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Made On Long-Term Purchase Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_PaymentsMadeOnLongTermPurchaseCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining Prepaid Expenses On Long-Term Purchase Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mdxg_NordicBioscienceClinicalDevelopmentASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mdxg_NordicBioscienceClinicalDevelopmentASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=mdxg_SeparationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=mdxg_SeparationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mdxg_InsuranceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mdxg_InsuranceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890151750304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of Revenue by Product Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 67,689<span></span>
</td>
<td class="nump">$ 63,074<span></span>
</td>
<td class="nump">$ 193,466<span></span>
</td>
<td class="nump">$ 191,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareMember', window );">Advanced Wound Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">66,809<span></span>
</td>
<td class="nump">62,282<span></span>
</td>
<td class="nump">191,421<span></span>
</td>
<td class="nump">173,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareTissueAndOtherMember', window );">Tissue/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">61,131<span></span>
</td>
<td class="nump">56,035<span></span>
</td>
<td class="nump">174,256<span></span>
</td>
<td class="nump">156,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareUmbilicalCordDerivedMember', window );">Cord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">5,678<span></span>
</td>
<td class="nump">6,247<span></span>
</td>
<td class="nump">17,165<span></span>
</td>
<td class="nump">17,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mdxg_Section351ProductsMember', window );">Section 351</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">17,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareTissueAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareTissueAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareUmbilicalCordDerivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mdxg_AdvancedWoundCareUmbilicalCordDerivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mdxg_Section351ProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mdxg_Section351ProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890155244928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>product </div>
<div>distribution_channel</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_NumberOfProducts', window );">Number of products | product</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels', window );">Number of primary distribution channels | distribution_channel</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_NumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_NumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Number Of Distribution Channels</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153561760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of Revenue by Customer Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 67,689<span></span>
</td>
<td class="nump">$ 63,074<span></span>
</td>
<td class="nump">$ 193,466<span></span>
</td>
<td class="nump">$ 191,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Direct Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">65,898<span></span>
</td>
<td class="nump">61,087<span></span>
</td>
<td class="nump">188,231<span></span>
</td>
<td class="nump">184,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember', window );">Distributors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 1,791<span></span>
</td>
<td class="nump">$ 1,987<span></span>
</td>
<td class="nump">$ 5,235<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890153706512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139890151459696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Net Sales and Operating Income (Loss) by each Reportable Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 67,689<span></span>
</td>
<td class="nump">$ 63,074<span></span>
</td>
<td class="nump">$ 193,466<span></span>
</td>
<td class="nump">$ 191,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">12,188<span></span>
</td>
<td class="nump">10,129<span></span>
</td>
<td class="nump">33,947<span></span>
</td>
<td class="nump">32,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="nump">53,475<span></span>
</td>
<td class="nump">46,289<span></span>
</td>
<td class="nump">158,838<span></span>
</td>
<td class="nump">145,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">5,953<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
<td class="nump">17,429<span></span>
</td>
<td class="nump">12,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_InvestigationRestatementAndRelated', window );">Investigation, restatement and related expense</a></td>
<td class="nump">3,001<span></span>
</td>
<td class="nump">3,170<span></span>
</td>
<td class="nump">8,771<span></span>
</td>
<td class="nump">8,304<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(7,103)<span></span>
</td>
<td class="num">(1,075)<span></span>
</td>
<td class="num">(26,038)<span></span>
</td>
<td class="num">(8,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_SupplementalInformationAbstract', window );"><strong>Supplemental information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
<td class="nump">3,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">2,372<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
<td class="nump">10,798<span></span>
</td>
<td class="nump">11,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate &amp; Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">2,169<span></span>
</td>
<td class="nump">2,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
<td class="nump">2,821<span></span>
</td>
<td class="nump">3,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="nump">17,944<span></span>
</td>
<td class="nump">12,900<span></span>
</td>
<td class="nump">50,582<span></span>
</td>
<td class="nump">46,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_InvestigationRestatementAndRelated', window );">Investigation, restatement and related expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_SupplementalInformationAbstract', window );"><strong>Supplemental information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
<td class="nump">4,279<span></span>
</td>
<td class="nump">6,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdxg_WoundSurgicalSegmentMember', window );">Wound &amp; Surgical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">66,873<span></span>
</td>
<td class="nump">62,138<span></span>
</td>
<td class="nump">191,297<span></span>
</td>
<td class="nump">172,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">11,159<span></span>
</td>
<td class="nump">8,924<span></span>
</td>
<td class="nump">31,126<span></span>
</td>
<td class="nump">25,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="nump">35,531<span></span>
</td>
<td class="nump">32,104<span></span>
</td>
<td class="nump">108,256<span></span>
</td>
<td class="nump">87,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">1,680<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">6,068<span></span>
</td>
<td class="nump">4,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_SegmentContribution', window );">Segment contribution</a></td>
<td class="nump">18,503<span></span>
</td>
<td class="nump">19,687<span></span>
</td>
<td class="nump">45,847<span></span>
</td>
<td class="nump">55,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_InvestigationRestatementAndRelated', window );">Investigation, restatement and related expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_SupplementalInformationAbstract', window );"><strong>Supplemental information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">1,364<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,945<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">5,609<span></span>
</td>
<td class="nump">3,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdxg_RegenerativeMedicineSegmentMember', window );">Regenerative Medicine | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">4,273<span></span>
</td>
<td class="nump">2,945<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
<td class="nump">8,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_SegmentContribution', window );">Segment contribution</a></td>
<td class="num">(4,273)<span></span>
</td>
<td class="num">(4,170)<span></span>
</td>
<td class="num">(11,361)<span></span>
</td>
<td class="num">(6,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_InvestigationRestatementAndRelated', window );">Investigation, restatement and related expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdxg_SupplementalInformationAbstract', window );"><strong>Supplemental information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="nump">$ 910<span></span>
</td>
<td class="nump">$ 1,147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_InvestigationRestatementAndRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investigation, Restatement And Related</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_InvestigationRestatementAndRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_SegmentContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_SegmentContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdxg_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdxg_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdxg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdxg_WoundSurgicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdxg_WoundSurgicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdxg_RegenerativeMedicineSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdxg_RegenerativeMedicineSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>mdxg-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mdxg="http://mimedx.com/20220930"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mdxg-20220930.xsd" xlink:type="simple"/>
    <context id="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i650ac95e3e044da397aabd67d763d4a6_I20221026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <instant>2022-10-26</instant>
        </period>
    </context>
    <context id="i4bd517c3847841b09c02473de630860c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9c87d212d19e46b4a198d7406d22de6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a352529eb914eca834297bbac755ba4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifba863cfdd014259beb502f94590fb92_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i05b234f7a63247d18255f80516b6b090_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i010a2081c1d248cfb4d5387b5bbf34cb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0f2c1ec8ce8b4a1a914dc56aec2bfe32_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4ed50021a0c24811907cc1f60c6d2cdf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie562cf214f3146d48637101b5f2efb7e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4adfca19515f406a8294d42cfdc70386_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i426adda60bd7408fa92b3d909af64f9d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1a2e885d3bd7477eba0a6949abfbc7e9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie6439b5cd06945f59b73261db40e5502_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie21cf100acb94a0d9ea1bba0d5056893_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0422e54ed7ae463d9a2bd382de7c4376_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i54ac1c07b4df44d9a33e5760e89f8c92_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i960535ac6f674eb3841e739b8d82ee9f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i36cbd2d2be4247e1bf671be0206a929a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i37e08c0b3a7447538e513cbcf68f082c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i40d4e1cc067d40bf8351fad15af71351_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifc5ba08b772c48e2a5927ce471578129_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0cdd5e7db696459ba5ef33f6dca38591_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia13d4f326df848e2877be82415791199_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48d07b19e6c84b74baa49dc3385595a9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i633727b5068940b985f2cd3490575ca0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia6eb0110a1d742c1b1bdca7f8dcb37e1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if938b4beab4546c9b2569f821725e575_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i91fe605c0c2e4cfb8945c919830b2ab5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic5210ebd6b19497b800bc4f988408437_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if74b4382e4f4415ca684233d6d54025e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7c70317011347c28bda53c1ba6ef71c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib877a57ab1704b83960f1ec88ba5f101_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5122095cb1394cab9cd9024590777b14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f8827f716654e7f849b34c082fd49e6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie5b940257a7a48998d89e37643d2bea8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i41b433355fba44f8902c37168d015ce7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i442c898781d04f8abe327191b2190538_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c3b930d9e8c47b89eeb9e3f88386a6a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8859ee77eae6426780f3132bfcc5b59c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia87984b643cc43d69c2042ee0608e0bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib60f056199c240ba8e0dc19accdb2766_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide40f0ea6322436d87854e83f0309547_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i794708492f6546f0a4986be2d9546a2d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i64c6f2694f674696aab0be0e9ea8fdcf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:InternationalSection351Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7d3da0f7b3f74c86bf4b94446691f8cf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:InternationalSection351Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie527d102dd6e4325ad714fa0d48400c5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:InternationalSection351Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i131cd49a86304288b8b62abaeab421af_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:InternationalSection351Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4df0f9cc41a6412e917f9a0100673e83_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5d42aa93cf554f31bdf7957ad6cc2c35_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iacbeb9a9186744ee819f52f94ba86e20_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i81ef134bfecc49ddb64f099bb97426e5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if48f5f99a2a84b0bbb4b58930500f84e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1b90d323d6c9405688c45fcb1f025c0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareUmbilicalCordDerivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9ef31f44ca74b6cb34d09779c82912b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibc5b133a447a448cbfbd88970beedf99_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i74c78ba1965249998d6dc020ae794009_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2e0a68a303f40bba14b646d9df1b2ef_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i907909b20b2e448c9e0b5b78f71df456_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5850839a03ec478ab31c891fe1d1573b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i68aef08154104f7a9e1912924d2a94bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e71c1046d64413295469b7be58e7419_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia4ace787428240a4aca18f56aebd13d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89b2e3aad6cd4af1b759a3681f47bf28_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdxg:AssetRetirementCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ida2ac468ebe44af2a56555cff32b5007_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdxg:AssetRetirementCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0104112777e4d14bd77bb3e2902b0a5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mdxg:WoundSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0ffd915aa45d4727b23956af58280014_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mdxg:RegenerativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia6136baa90f844b998d36da85b2453db_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i659a8e16e9c94e5a93efa999dc1cca89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bb08258960c42db90551aecd2db413d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iec6c48c7387b4e87940f4064398a14df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddd1d1c82ab24631a37cd041c9a9dbe2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mdxg:PatentsinProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4963e235cc9f495d91c3496c848f2cdb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mdxg:PatentsinProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67a12c73e9034b38960c751d13ea184e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-02</instant>
        </period>
    </context>
    <context id="ida0d445363084e00b087a41a67afce57_D20220228-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i78a81d5053e240d4b3ca17890dd5c28f_D20220228-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i19941ad137e24c988a6625220a34fbe7_D20220228-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="ied1ef014d51f4e56b7b022759ec9dc30_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5ca2668ba8fb4aa5a0b452209fcbf752_D20220228-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i2747f527fb9748c58c87520ae15d6b71_D20220228-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i113d9f8cbf62488ba9b7295966501570_D20220228-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="if13a467d34074320a376b1a5273913b3_D20220228-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="iddda1184b02a44928b0c26d038f76bca_I20200702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-02</instant>
        </period>
    </context>
    <context id="ic01dffba8325446a929870e45228e37c_I20200702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-02</instant>
        </period>
    </context>
    <context id="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iea70269e38be47efb68e17ebedd54b55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i06158252259a4bb1be9943fc4f9b8256_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie32894e2f8cb4b40bf661b269dd42436_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5db0a9efc4324b35ab710da5c792ca3e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4ae78b34019f45208b00a4a3385ba0bf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8ed176b1136d4fa38e04ca50f5c1469a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaa56b9335b624293aeb4786b43d54f20_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4c8e4da241644f84bd4f549f2c4d5255_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdxg:TermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie7039d72af5a465f8d691ffc8453f767_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic8a6dd65cf2d47b89031b83212416a42_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10cd3b0255d2440e86f4416f3ed9495c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6f700fb64114418187f075f2e5eed841_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i146f3a7b53384556923cbc98e604b7dd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0ec389008cfe43948414a92568159be9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaaf79e5f3ce64e96aa536b235a512ffc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2a4925e322ff4faba0e3ed48e1b84008_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i355ee9dd6fe8464cb242d9207054f6bf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i70d9b122152d409a9b10de3cb3c9ae48_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia0f5ff9fed4948129ee9e875deb95c7b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i258db741a42246298eb7aaa18e77a486_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i11c7a54774bb43fdba585d030dec991b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if0df82c48fe04e96b6b5e4d0a4612c4f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b8df31d2af641618c113c2cbd9b7b1a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ide1a4fd077334136967497c6a2232e0d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia6b3e0608d9f482b868123001407b5ec_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i17f6805f07fe4bdcb90650b3893165d9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39ab2e69b02a42ddb73366a8e9c08937_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i212a4290c2bd47fca04f586a83a7f287_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i271d80de58474816b4025b9aebb971f8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6d9bb93242bb443ba66fd70a01eef477_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i692c59774d81444084dea717ebd32069_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i784df8506ab9410ea02678d62f33b782_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie017b823195c4cd28a0e2f85512d9175_D20200702-20200702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">mdxg:DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-02</startDate>
            <endDate>2020-07-02</endDate>
        </period>
    </context>
    <context id="ia2c96a645d0e4a2f9342b55b1148c6a5_D20200702-20200702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">mdxg:PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-02</startDate>
            <endDate>2020-07-02</endDate>
        </period>
    </context>
    <context id="i7f3a41d5bd2a49d5b12ac3a2ed050c26_I20200702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-02</instant>
        </period>
    </context>
    <context id="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-02</startDate>
            <endDate>2020-07-02</endDate>
        </period>
    </context>
    <context id="iea291f2f9ce54206890c533e3a98eb90_D20200702-20200702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2020-07-02</startDate>
            <endDate>2020-07-02</endDate>
        </period>
    </context>
    <context id="i2897a774ae4848988d5570070d7984aa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iebe0c3fba405441db5355c5f6db48438_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie539807062614f8bb0131c5c6847be0d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i753d059860334ec081dc4d69d43cf1c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbf3436aa84a4190833ba27b0b9cde6c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i15a5bbe694014b15a1e01cde9e802a57_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic02bab3165234f9eb46d4f4c01c5fc77_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if5bc17a4ac384d59a3a5c5e10da5eb81_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdxg:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib50e54e252d5492ca1c749cc11fabfe4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdxg:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3049036812934641abae9137fa8bdf2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2f95c7c08b84d32a4a79f8a8db06aa4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa7c606187fb4813a87a34ec4af106b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i04da0588d95741f9bde5e0e130fa9c99_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6572eec66ddc4973bfa1f4addf16e03f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia4b6f7cb18684bc78a9c1ac2d353eadf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia2b50c892e824477a3935a03b5a37bc1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i31fe266b4c6443febd173cafdd41434d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic48fb527e30240a4917a52a042ced3d9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i03bb1d037d4e4920880de2544e838583_D20220607-20220607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-07</startDate>
            <endDate>2022-06-07</endDate>
        </period>
    </context>
    <context id="i8a6f0c76a58f4f19bb54eedc889f9037_I20220607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-07</instant>
        </period>
    </context>
    <context id="i66ece39c082f4511b28e1e8f2974b42a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib46a2b85eab64b269ab8d468f2d3b464_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib26f2b9f669f4ee6ac92ff0803d5fe9c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3172438f25f94d9b8023b961aedcb60f_I20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mdxg:SeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="if25b98ea5f0947a9a6a36132f5efc122_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mdxg:SeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0fd877d9ecb24d80b443c4b5961d54c0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mdxg:SeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id4d6590c804a4af396fb91f11d61ca98_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mdxg:SeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5e04c486503f40a1843903fe17980c71_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mdxg:NordicBioscienceClinicalDevelopmentASMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i070672d37c8e47f4a3a16fbd57ba5691_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mdxg:NordicBioscienceClinicalDevelopmentASMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i320fdbb729ab4be69c2a59f489c97765_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mdxg:NordicBioscienceClinicalDevelopmentASMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9f2d728dc47344bca02856d03ee8d0b4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mdxg:NordicBioscienceClinicalDevelopmentASMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icbc4ddf32d59495c88aa620c69ed64cb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdxg:InsuranceProvidersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib6fd656cd99342d2afc041b6ba933413_D20190116-20190116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2019-01-16</startDate>
            <endDate>2019-01-16</endDate>
        </period>
    </context>
    <context id="i04190c43aa5d47839d90cf05de41f75a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareTissueAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9eec3159aafd457684861f891a8f27b9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareTissueAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id5fd9ecb73bd40f28e4562a1cd66d365_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareTissueAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9866ce2797684d89afbfd9e13fe710b6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareTissueAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib1eade6c04c44338ba36a2a117e94a53_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9f2702a8fab749619f28b833e531c5d1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iea05bcc2c0134bd5964b7bc8be495e5d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1eba5ab3ff8b4cecb6daaf14306ea281_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:AdvancedWoundCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i63d182d5355d40909bfcd1ecad0c38f9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:Section351ProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie699609ee0a24b2795a89d47dab42904_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:Section351ProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i46ce6151aa0c4089a54a9ba0539e2058_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:Section351ProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib83b2b7d758f4908890825b2a2b0d822_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mdxg:Section351ProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic8fcb780f1414fd8b5dfecc6d1682d35_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6449c9a80962496d82d4f44a69334d4a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1b7935978392476a8eb950a2156ec688_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1c14d491f3ed491ea1459de970ab3387_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic08501ad9a844ed4bfcec556b74f305f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2c8e45a1b351403d8b7085dbe2706856_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0af08c412f7f4e7f82c54239d39b7b11_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iec1dffc619904a4d9e56ade452761dd4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f77e1063b8c4fa59391a91c4b07687c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iad1c7de372124c51b75ab2ddc755118f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8de990b776a540a18972151167955eaf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8be7f2d7a9034919910bd938ce9e1003_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:WoundSurgicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:RegenerativeMedicineSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:WoundSurgicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icf8676e75a824f97858a0b56380e8050_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:RegenerativeMedicineSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5d33b69702834f838661561304e8f6bd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:WoundSurgicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:RegenerativeMedicineSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:WoundSurgicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdxg:RegenerativeMedicineSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>mdxg:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>mdxg:day</measure>
    </unit>
    <unit id="director">
        <measure>mdxg:director</measure>
    </unit>
    <unit id="class_action">
        <measure>mdxg:class_action</measure>
    </unit>
    <unit id="product">
        <measure>mdxg:product</measure>
    </unit>
    <unit id="distribution_channel">
        <measure>mdxg:distribution_channel</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV8zLTEtMS0xLTkwMTk0_eedafa71-94f3-44f1-aa02-dd490e68b0f1">0001376339</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV80LTEtMS0xLTkwMTk0_ca53414f-12bb-4e48-8a32-2a2540348aec">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV81LTEtMS0xLTkwMTk0_1f332f5f-e7b4-485d-940e-dfa2510811f2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalYearFocus
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV83LTEtMS0xLTkwMTk0_f157020c-d2ec-464d-afc3-9dd7d6b00b6f">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV84LTEtMS0xLTkwMTk0_4779e553-d7cf-4bb0-bd5b-6419afb99c8c">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV8xMC0xLTEtMS05MDE5NA_96810ea4-9e8e-4510-b5da-59f7b9f56697">false</dei:AmendmentFlag>
    <dei:EntityEmergingGrowthCompany
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV8xMS0xLTEtMS05MDE5NA_3a785232-53fb-483f-8656-6940d8d4b10b">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV8xMi0xLTEtMS05MDE5NA_3408746a-dd43-458f-8739-0f11c1f40940">false</dei:EntitySmallBusiness>
    <dei:DocumentPeriodEndDate
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80L2ZyYWc6YWMyMDA3ZGEzMzdkNDhkNzk4NjI4ZDU0M2YxZjZjNzMvdGFibGU6Y2VlYTUzNDA4MjZlNDMxY2E5MDA0ZTg5Zjc0MzBmN2EvdGFibGVyYW5nZTpjZWVhNTM0MDgyNmU0MzFjYTkwMDRlODlmNzQzMGY3YV8xMy0xLTEtMS05MDE5NA_241deca2-03c7-4bf7-84ea-2649490a8d34">2022-09-30</dei:DocumentPeriodEndDate>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i67a12c73e9034b38960c751d13ea184e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzMzL2ZyYWc6NDIxODRiNGEwZWNmNDdlM2I3NGRjM2Q0MGIyMDQxMTgvdGV4dHJlZ2lvbjo0MjE4NGI0YTBlY2Y0N2UzYjc0ZGMzZDQwYjIwNDExOF8yNzQ4Nzc5MDY5NTYw_34ac89ca-1c03-4a00-a7cb-fda59eaa95ca"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportingUnits
      contextRef="i67a12c73e9034b38960c751d13ea184e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzMzL2ZyYWc6NDIxODRiNGEwZWNmNDdlM2I3NGRjM2Q0MGIyMDQxMTgvdGV4dHJlZ2lvbjo0MjE4NGI0YTBlY2Y0N2UzYjc0ZGMzZDQwYjIwNDExOF8yNzQ4Nzc5MDY5NTYz_41af2b11-f377-4f01-a30e-b778387bc281"
      unitRef="segment">1</us-gaap:NumberOfReportingUnits>
    <dei:DocumentType
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzg3_d1cb78ee-a6b7-49d8-b32c-6c353758defa">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6ODczNDA5MzYzOWM3NDNmNDg0NzFiOTM2NWIxNjcxNzEvdGFibGVyYW5nZTo4NzM0MDkzNjM5Yzc0M2Y0ODQ3MWI5MzY1YjE2NzE3MV8wLTAtMS0xLTkwMTk0_267ebed8-f643-40ae-b4ac-a78d496458b0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xMjM_241deca2-03c7-4bf7-84ea-2649490a8d34">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6YTYyYmUxOGE2N2FmNDkzNjkxNDgxNTI5NzRkM2M3MTMvdGFibGVyYW5nZTphNjJiZTE4YTY3YWY0OTM2OTE0ODE1Mjk3NGQzYzcxM18wLTAtMS0xLTkwMTk0_d3945fd4-0266-4e0b-9b53-b572efd7ca56">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzg0_6a90178d-90c5-42ac-9475-4c239e12881f">001-35887</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzg4_23d8bb68-b6e0-4b1b-8d29-48e963b294b4">MIMEDX GROUP, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6ODlhMDIzMmExNWY1NDgyMGExNjcyYmQxYjhlZjA0NTgvdGFibGVyYW5nZTo4OWEwMjMyYTE1ZjU0ODIwYTE2NzJiZDFiOGVmMDQ1OF8wLTAtMS0xLTkwMTk0_102b3d00-a94a-4f22-8702-f07394b69f1a">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6ODlhMDIzMmExNWY1NDgyMGExNjcyYmQxYjhlZjA0NTgvdGFibGVyYW5nZTo4OWEwMjMyYTE1ZjU0ODIwYTE2NzJiZDFiOGVmMDQ1OF8wLTItMS0xLTkwMTk0_05d108e4-e48f-46a8-ab87-5684c5e8e031">26-2792552</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTlkNzVmMTcxNGM3NDE5Zjk5ZmVlNGU4NjZkZThiYzMvdGFibGVyYW5nZTo1OWQ3NWYxNzE0Yzc0MTlmOTlmZWU0ZTg2NmRlOGJjM18wLTAtMS0xLTkwMTk0L3RleHRyZWdpb246ZTEwZjQ2NGEwNzE2NGQ5MDk4MjgzMjIzMzhhYTgzNTVfNA_4dec4393-244a-435c-ba08-1365b56afab9">1775 West Oak Commons Ct NE</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTlkNzVmMTcxNGM3NDE5Zjk5ZmVlNGU4NjZkZThiYzMvdGFibGVyYW5nZTo1OWQ3NWYxNzE0Yzc0MTlmOTlmZWU0ZTg2NmRlOGJjM18wLTAtMS0xLTkwMTk0L3RleHRyZWdpb246ZTEwZjQ2NGEwNzE2NGQ5MDk4MjgzMjIzMzhhYTgzNTVfNw_c682f7d1-c5f0-4ea5-a728-1b374e69fb16">Marietta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTlkNzVmMTcxNGM3NDE5Zjk5ZmVlNGU4NjZkZThiYzMvdGFibGVyYW5nZTo1OWQ3NWYxNzE0Yzc0MTlmOTlmZWU0ZTg2NmRlOGJjM18wLTAtMS0xLTkwMTk0L3RleHRyZWdpb246ZTEwZjQ2NGEwNzE2NGQ5MDk4MjgzMjIzMzhhYTgzNTVfMTE_f3e26488-8f70-4bdd-ab29-3322d97e7298">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTlkNzVmMTcxNGM3NDE5Zjk5ZmVlNGU4NjZkZThiYzMvdGFibGVyYW5nZTo1OWQ3NWYxNzE0Yzc0MTlmOTlmZWU0ZTg2NmRlOGJjM18wLTItMS0xLTkwMTk0_3d03003a-414f-463e-bdb3-1c7af2ea34a9">30062</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzg1_4691e973-1842-4c49-bf14-57b227ec8b60">770</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzgx_b596d1d6-009e-41a6-a28d-12216f6cfd02">651-9100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTZkZmI4YmJjOWY2NDBiNTkwNDliZWRiMmIxYjI5OWMvdGFibGVyYW5nZTo1NmRmYjhiYmM5ZjY0MGI1OTA0OWJlZGIyYjFiMjk5Y18xLTAtMS0xLTkwMTk0_cf678b41-4550-41ae-9875-da4740c02729">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTZkZmI4YmJjOWY2NDBiNTkwNDliZWRiMmIxYjI5OWMvdGFibGVyYW5nZTo1NmRmYjhiYmM5ZjY0MGI1OTA0OWJlZGIyYjFiMjk5Y18xLTEtMS0xLTkwMTk0_e52eb002-e79b-438f-9beb-7c5f8b9b5e7b">MDXG</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6NTZkZmI4YmJjOWY2NDBiNTkwNDliZWRiMmIxYjI5OWMvdGFibGVyYW5nZTo1NmRmYjhiYmM5ZjY0MGI1OTA0OWJlZGIyYjFiMjk5Y18xLTItMS0xLTkwMTk0_26a36f2e-2ff7-41ff-a5aa-62bc70c9529b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzgy_79fad0f8-7227-4776-805c-ec56084dfecc">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNzgz_9bc4d436-7375-4221-842a-62adc6d5121d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6OWU3NjNlNDAyMTE1NGIzYThjYTRlMzMzYTM5NGI2MzkvdGFibGVyYW5nZTo5ZTc2M2U0MDIxMTU0YjNhOGNhNGUzMzNhMzk0YjYzOV8wLTAtMS0xLTkwMTk0L3RleHRyZWdpb246NDJhZGU3MWJmMTNiNDYyNjgyZmM2YzJiMTBlZGEyMDNfNA_1f332f5f-e7b4-485d-940e-dfa2510811f2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6OWU3NjNlNDAyMTE1NGIzYThjYTRlMzMzYTM5NGI2MzkvdGFibGVyYW5nZTo5ZTc2M2U0MDIxMTU0YjNhOGNhNGUzMzNhMzk0YjYzOV8wLTMtMS0xLTkwMTk0L3RleHRyZWdpb246NWNkODM0ZmI5YWZlNDE4ZGI2YWY4NmExOGViMjBjMGZfMzA_3408746a-dd43-458f-8739-0f11c1f40940">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGFibGU6OWU3NjNlNDAyMTE1NGIzYThjYTRlMzMzYTM5NGI2MzkvdGFibGVyYW5nZTo5ZTc2M2U0MDIxMTU0YjNhOGNhNGUzMzNhMzk0YjYzOV8wLTQtMS0xLTkwMTk0L3RleHRyZWdpb246ZjRjZDQzODVjYzlmNGRkNDk5NTUwZjc3MjU2MjljY2JfMjg_3a785232-53fb-483f-8656-6940d8d4b10b">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN180OTQ3ODAyMzI2Nzgy_e35453a0-a7cc-4640-9256-8b9048bd71d2">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i650ac95e3e044da397aabd67d763d4a6_I20221026"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xL2ZyYWc6ZjNkOWYzNjM4N2QyNGM3OWE0NzFhNjYzYTA5YTQxZTcvdGV4dHJlZ2lvbjpmM2Q5ZjM2Mzg3ZDI0Yzc5YTQ3MWE2NjNhMDlhNDFlN18xNjg4_907bd376-15dd-4707-9747-1f5f7acb7581"
      unitRef="shares">113668179</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMy0xLTEtMS05MDE5NA_12f9999c-0372-471b-aa92-cf335cde8eef"
      unitRef="usd">73217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMy0zLTEtMS05MDE5NA_0b2855b2-28a2-4e20-819b-d895e7c5d913"
      unitRef="usd">87083000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNC0xLTEtMS05MDE5NA_375f69d4-4d14-4685-bf3f-070a79cb7dd0"
      unitRef="usd">40830000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNC0zLTEtMS05MDE5NA_e66b5138-a04c-4407-990c-cd34aff26104"
      unitRef="usd">40353000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNS0xLTEtMS05MDE5NA_b0b003b4-2b4d-4c1b-abd5-06106f4dda14"
      unitRef="usd">13976000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNS0zLTEtMS05MDE5NA_d8b2f630-1374-4c33-ad04-c3e7164531d4"
      unitRef="usd">11389000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNi0xLTEtMS05MDE5NA_bb3446c0-52c1-4069-8046-ac1c1ecdbc87"
      unitRef="usd">4679000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNi0zLTEtMS05MDE5NA_7013defa-d1ea-4bcf-90d2-e07aa937c677"
      unitRef="usd">6146000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNy0xLTEtMS05MDE5NA_ee7fb04c-2e41-4759-9c82-5a667f3168fe"
      unitRef="usd">756000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNy0zLTEtMS05MDE5NA_28fb6e39-cda7-465c-882a-7dbf946f58af"
      unitRef="usd">743000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherAssetsCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfOC0xLTEtMS05MDE5NA_cde854f6-be2a-4e62-b2a3-c51e830795ea"
      unitRef="usd">2582000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfOC0zLTEtMS05MDE5NA_959e9cb6-c823-4d48-b95c-633ff6e3ea92"
      unitRef="usd">2809000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfOS0xLTEtMS05MDE5NA_70c619d6-2f9e-413d-94ae-b3a8240e2381"
      unitRef="usd">136040000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfOS0zLTEtMS05MDE5NA_29d0aab6-59e9-48b9-bfc4-eafb228f040b"
      unitRef="usd">148523000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTEtMS0xLTEtOTAxOTQ_2fde3b7a-a964-4e09-acfd-207ac2ad37a6"
      unitRef="usd">7912000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTEtMy0xLTEtOTAxOTQ_1e865462-d57a-4d19-bd0d-6df9a9fd1449"
      unitRef="usd">9165000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTItMS0xLTEtOTAxOTQ_8e1594d8-7cb8-4925-94c0-dfcb8c2f9ab9"
      unitRef="usd">3728000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTItMy0xLTEtOTAxOTQ_6f63dca3-7460-4b21-a613-b46f3bb003da"
      unitRef="usd">4696000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTMtMS0xLTEtOTAxOTQ_9e29d382-fe03-403c-aef4-bac3ad0d42cf"
      unitRef="usd">19976000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTMtMy0xLTEtOTAxOTQ_3d5eaa8a-434b-4bd1-b7b9-df8e261dd3ed"
      unitRef="usd">19976000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTQtMS0xLTEtOTAxOTQ_7962b092-2c32-4a5d-b95c-6473265070d7"
      unitRef="usd">4992000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTQtMy0xLTEtOTAxOTQ_1173dc1d-38d7-48aa-ba4f-7df6ec17b41f"
      unitRef="usd">5383000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTYtMS0xLTEtOTAxOTQ_63c2603b-1fb0-44f5-9892-4dfc875643ef"
      unitRef="usd">150000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTYtMy0xLTEtOTAxOTQ_0e6e0b1b-c0e1-4888-9e41-a1313dbab55c"
      unitRef="usd">186000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTctMS0xLTEtOTAxOTQ_766b602c-405b-4bfc-8ce0-5fc3d2c7d362"
      unitRef="usd">172798000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMTctMy0xLTEtOTAxOTQ_e4f922d1-419a-4f95-8387-c2ba321ad49f"
      unitRef="usd">187929000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjAtMS0xLTEtOTAxOTQ_4fd468d5-16c4-4fa2-b638-44a11f191d68"
      unitRef="usd">8820000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjAtMy0xLTEtOTAxOTQ_3065d841-57aa-46a5-9188-b717bb902f3c"
      unitRef="usd">7385000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjEtMS0xLTEtOTAxOTQ_5d063a28-e00b-4bc0-84e1-51e7ba4118c3"
      unitRef="usd">24090000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjEtMy0xLTEtOTAxOTQ_961ae9bf-e55c-424c-987d-0903fc729b06"
      unitRef="usd">23595000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjItMS0xLTEtOTAxOTQ_092680ae-bd64-4b87-899b-6e4121b21a3a"
      unitRef="usd">10986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjItMy0xLTEtOTAxOTQ_7a256399-697b-426d-8a6d-6b7c67dde8cd"
      unitRef="usd">9812000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjctMS0xLTEtOTAxOTQ_f0fde1d5-26a9-413e-9249-2b173338f258"
      unitRef="usd">1962000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjctMy0xLTEtOTAxOTQ_c2c7f87b-e836-4854-b43c-78d14b4d78d4"
      unitRef="usd">1565000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjgtMS0xLTEtOTAxOTQ_dae3552c-3907-4811-abf6-de832e9e589b"
      unitRef="usd">45858000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjgtMy0xLTEtOTAxOTQ_ef183e15-e752-4ee9-9c17-3592168af6e0"
      unitRef="usd">42357000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjktMS0xLTEtOTAxOTQ_05d0d5b2-4124-469f-bcd3-2c5a8e832ba3"
      unitRef="usd">48475000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMjktMy0xLTEtOTAxOTQ_a2ac952a-6c2e-444a-9968-04f2baa90530"
      unitRef="usd">48127000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzAtMS0xLTEtOTAxOTQ_65dd7283-3ca4-4fe0-9727-e4b2574dd4fb"
      unitRef="usd">5491000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzAtMy0xLTEtOTAxOTQ_321bec83-2254-475c-b540-574f69398036"
      unitRef="usd">4869000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzEtMS0xLTEtOTAxOTQ_774ae092-184b-4427-b8aa-9eb8a9cfa810"
      unitRef="usd">99824000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzEtMy0xLTEtOTAxOTQ_929810fc-ebe6-452a-baf9-d1a72cedb07e"
      unitRef="usd">95353000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzItMS0xLTEtOTAxOTQ_d37d3253-8e4f-49d7-bf41-6dc3c5220476"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzItMy0xLTEtOTAxOTQ_27f23da7-801e-4b8c-962d-0827a0bccb4c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF80Mg_26288bc2-aafc-4dc8-b828-8df1920975ee"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF80Mg_e29828cc-5cf4-4f19-ab78-58a0630b237f"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_1ecd6db1-0f36-4b73-8e15-21dd80a0237a"
      unitRef="shares">100000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_2157cec0-0f01-4c69-835c-67bdf989dcaa"
      unitRef="shares">100000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_464d09af-0840-44e5-8d66-bc742b50a390"
      unitRef="shares">100000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_5d892bdf-e510-41a5-8e3e-0e54b3f063c0"
      unitRef="shares">100000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_664c56a0-e83c-4fe4-82ad-2b62d2b700d0"
      unitRef="shares">100000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo1ZjhiOGI5NTlkNmQ0ZWVjODY5YzM0OTBhMTJlZjE0NF81Ng_8e0146f7-77cd-4988-ad8c-3c5aa1fdc92e"
      unitRef="shares">100000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMS0xLTEtOTAxOTQ_8a3d55e2-797e-40e2-832c-48c31c072453"
      unitRef="usd">92494000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzMtMy0xLTEtOTAxOTQ_a05fbb38-af6d-4c58-abe3-fade4420c958"
      unitRef="usd">92494000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV8zMA_56647d72-e0bb-4e8e-b35f-13048ca07505"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV8zMA_70212ba0-fc19-4334-9f65-feb7bb57ccf7"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV80NA_623cd614-6fc1-42a5-9d83-f90cec3a2259"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV80NA_d1bd0863-d90f-444e-bd5f-99d74d1fdbca"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV82Ng_1504bef4-973f-4345-9aff-8183dbafabaf"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV82Ng_1ac19ad3-5855-44d5-9654-5c5e686ed2c3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV82Ng_1d9143bb-4bc0-40d9-b5f7-f32d75ce8eb1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjo3OWYyYzU3MTcyZDQ0Mjc0YTQxYjU2ZmJkMjYzNzAzMV82Ng_f8b6ecb0-adf3-4252-8485-0adb7a8bb39e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMS0xLTEtOTAxOTQ_38491c2c-d9ef-4d47-be0a-849b2b6fef97"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzUtMy0xLTEtOTAxOTQ_67a1fcf1-e731-46ec-af4d-dcba076f8bfe"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV8xOA_02ca41ba-a564-4e99-a758-6fbb44ef38cf"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV8xOA_8267f66f-5867-4ae9-976e-308a9c4385c4"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV8zMg_66974e12-74e6-4781-b8d4-cc3ae0918209"
      unitRef="shares">187500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV8zMg_b6ea7ae5-c683-4fe3-8978-d969b6857204"
      unitRef="shares">187500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV81NA_e5d1937f-554c-4ea9-83b7-783ac2a34bf9"
      unitRef="shares">113670017</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV82OA_860188d2-c6d5-4bd1-92a4-879c7ab838c1"
      unitRef="shares">113668179</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV85Mw_3a6e94be-5c36-4815-91cf-0b2b0aee40da"
      unitRef="shares">112703926</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjpmYTM5YjVkMTZmYTU0MjFmYjJlMDA0ZTk5ZjhkYWM0YV8xMDc_afc3e15c-d6bb-47ce-bab1-15ad3c32837f"
      unitRef="shares">111925216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMS0xLTEtOTAxOTQ_d3e585fd-04d1-433f-ae9a-5b164723c5b1"
      unitRef="usd">114000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzYtMy0xLTEtOTAxOTQ_8fab6f4a-755b-4555-a91a-ec813f6cf0b3"
      unitRef="usd">113000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzctMS0xLTEtOTAxOTQ_6516c0d0-fa1f-4ac6-b554-32bfcd788558"
      unitRef="usd">171865000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzctMy0xLTEtOTAxOTQ_72fa076c-e4ed-4868-8a28-029a2aaa3da5"
      unitRef="usd">165695000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzgtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjphYzU4NzUzZTBhNTE0YzgzYWFhZDE3MzdkOTBhYTM0NV8yOA_90e39a81-cfa5-4067-b89d-9a91522136d9"
      unitRef="shares">1838</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzgtMC0xLTEtOTAxOTQvdGV4dHJlZ2lvbjphYzU4NzUzZTBhNTE0YzgzYWFhZDE3MzdkOTBhYTM0NV80OA_66a8391b-98e1-4dd1-a231-a14949458552"
      unitRef="shares">778710</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzgtMS0xLTEtOTAxOTQ_1e8194f0-da23-48c3-9fa7-5ea664100269"
      unitRef="usd">7000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzgtMy0xLTEtOTAxOTQ_0d95405c-7d3c-49fc-9a8d-75913ef7eb11"
      unitRef="usd">4017000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzktMS0xLTEtOTAxOTQ_61d1e25d-14f2-41dc-9375-b9a697d2d332"
      unitRef="usd">-191492000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfMzktMy0xLTEtOTAxOTQ_7f74392f-788f-42b4-9e51-fd9a89b46e29"
      unitRef="usd">-161709000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNDAtMS0xLTEtOTAxOTQ_5c2c0747-b7aa-448c-aac7-8671d772415c"
      unitRef="usd">-19520000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNDAtMy0xLTEtOTAxOTQ_9ece2aec-7ca2-4a03-bdd7-03fa3bd96c21"
      unitRef="usd">82000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNDEtMS0xLTEtOTAxOTQ_7ba2bd0a-60ef-470d-997a-ef583c09854d"
      unitRef="usd">172798000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xOS9mcmFnOjVjNGU0NzVhODAzMzQ0ODNiMjQ1OWQ0OWFhMTE4MzE3L3RhYmxlOmMxNjljNjEyMjRmMzQxZjc5ZjU0MTc0ZGIxOWViNjc4L3RhYmxlcmFuZ2U6YzE2OWM2MTIyNGYzNDFmNzlmNTQxNzRkYjE5ZWI2NzhfNDEtMy0xLTEtOTAxOTQ_bf4ad484-292c-49cf-b181-cebe686a9fe3"
      unitRef="usd">187929000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMy0xLTEtMS05MDE5NA_70458ce1-45cb-4d24-95b9-f3917af3cae5"
      unitRef="usd">67689000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMy0zLTEtMS05MDE5NA_dc456ab6-8073-4702-a75f-7aa5418a3380"
      unitRef="usd">63074000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMy01LTEtMS05MDE5NA_0f0d8aca-03d7-4cc1-aa3d-ff8ea4ab28d5"
      unitRef="usd">193466000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMy03LTEtMS05MDE5NA_3fd7e7bb-ee0e-4166-b838-780aac74fdca"
      unitRef="usd">191206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNC0xLTEtMS05MDE5NA_d52e2412-f254-4849-bdf7-be7073dd4a8f"
      unitRef="usd">12188000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNC0zLTEtMS05MDE5NA_2dead21f-edc4-42e3-8dcc-d8987871e676"
      unitRef="usd">10129000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNC01LTEtMS05MDE5NA_7e067564-8774-4be7-a652-ea223a38a077"
      unitRef="usd">33947000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNC03LTEtMS05MDE5NA_41d809c7-c1f0-443b-8d07-b4dcf4771967"
      unitRef="usd">32530000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNS0xLTEtMS05MDE5NA_65caca90-5dab-43b1-b206-1c6c5ede9a23"
      unitRef="usd">55501000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNS0zLTEtMS05MDE5NA_dfae5498-63ae-4b0f-8f64-9c3715f773fc"
      unitRef="usd">52945000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNS01LTEtMS05MDE5NA_d7190298-7963-4989-ac1c-a935b7fb74c7"
      unitRef="usd">159519000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfNS03LTEtMS05MDE5NA_166ce8a9-ae8e-40ff-bdc2-ea583ecdee75"
      unitRef="usd">158676000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOC0xLTEtMS05MDE5NA_334ef8c4-303c-4e0e-a2f6-23fc3a228175"
      unitRef="usd">53475000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOC0zLTEtMS05MDE5NA_4e6f90ab-60d4-4e18-9307-c220aec7e6d0"
      unitRef="usd">46289000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOC01LTEtMS05MDE5NA_40007806-314d-4f53-8c8b-5d089f70af92"
      unitRef="usd">158838000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOC03LTEtMS05MDE5NA_c8eaebaf-f662-46a7-bb28-39879fcdca6b"
      unitRef="usd">145291000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOS0xLTEtMS05MDE5NA_53ca9d48-eb7e-46f5-9300-d9942649efac"
      unitRef="usd">5953000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOS0zLTEtMS05MDE5NA_3babddb1-ac57-4289-983b-e3af652fb633"
      unitRef="usd">4368000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOS01LTEtMS05MDE5NA_a904f3b2-88ac-492f-b3c9-dddcc8c00189"
      unitRef="usd">17429000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfOS03LTEtMS05MDE5NA_a95a6282-f0ee-4bb3-bea8-e7ac4c0173f3"
      unitRef="usd">12770000</us-gaap:ResearchAndDevelopmentExpense>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTAtMS0xLTEtOTAxOTQ_3814843b-45ba-4b9d-b786-f0dd1baba88d"
      unitRef="usd">3001000</mdxg:InvestigationRestatementAndRelated>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTAtMy0xLTEtOTAxOTQ_82484051-697b-43e8-83ea-0b47c25378a1"
      unitRef="usd">3170000</mdxg:InvestigationRestatementAndRelated>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTAtNS0xLTEtOTAxOTQ_dad1b718-41fa-46f0-95e8-81d112bd2a39"
      unitRef="usd">8771000</mdxg:InvestigationRestatementAndRelated>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTAtNy0xLTEtOTAxOTQ_5243efe8-f261-4b4d-b7fc-69ff4b97f7fb"
      unitRef="usd">8304000</mdxg:InvestigationRestatementAndRelated>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTEtMS0xLTEtOTAxOTQ_ecb678e2-85e0-494b-8aac-686515841fc8"
      unitRef="usd">175000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTEtMy0xLTEtOTAxOTQ_072ce126-4765-45ee-b170-6680df750884"
      unitRef="usd">193000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTEtNS0xLTEtOTAxOTQ_9aa894c3-f52d-418a-990f-aafe1a864caf"
      unitRef="usd">519000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTEtNy0xLTEtOTAxOTQ_815a0aef-17d3-4c74-a64e-ac06e32039cc"
      unitRef="usd">647000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTMtMS0xLTEtOTAxOTQ_5e490f43-f6d1-464d-a00c-0e2b63262d13"
      unitRef="usd">-7103000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTMtMy0xLTEtOTAxOTQ_4948a8ba-536f-4d39-ae9c-806973f2219a"
      unitRef="usd">-1075000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTMtNS0xLTEtOTAxOTQ_83ebf85a-d0ac-483b-8372-7417d12bd933"
      unitRef="usd">-26038000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTMtNy0xLTEtOTAxOTQ_15439f75-4535-4013-813c-ca3cc9788177"
      unitRef="usd">-8336000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTctMS0xLTEtOTAxOTQ_996288a3-c5a9-4c35-8ac1-794ba60bd48b"
      unitRef="usd">-1270000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTctMy0xLTEtOTAxOTQ_480dd87c-8e4b-4b8c-b9ff-841a4757cfd7"
      unitRef="usd">-963000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTctNS0xLTEtOTAxOTQ_abfd0890-8676-46dc-a721-1fd03f4f9949"
      unitRef="usd">-3566000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTctNy0xLTEtOTAxOTQ_b54943c6-a05b-4563-950f-95d73427278d"
      unitRef="usd">-3806000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTgtMS0xLTEtOTAxOTQ_c10b2dd5-cd48-4596-adf3-5f5af82f99d2"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTgtMy0xLTEtOTAxOTQ_2729d223-de1f-4369-a792-4b35f71a0326"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTgtNS0xLTEtOTAxOTQ_aaf84531-ae21-4844-9b04-b9b04b4c2f66"
      unitRef="usd">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTgtNy0xLTEtOTAxOTQ_d9d841a5-c9c3-4288-a097-e64aecce83cf"
      unitRef="usd">-3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTktMS0xLTEtOTAxOTQ_00632026-7341-4a37-9cf2-8fc80b400400"
      unitRef="usd">-8373000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTktMy0xLTEtOTAxOTQ_1c83f109-a47e-4082-ac1a-6def11ce696e"
      unitRef="usd">-2038000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTktNS0xLTEtOTAxOTQ_b1f6a275-0087-4e96-a346-8345526a1380"
      unitRef="usd">-29605000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMTktNy0xLTEtOTAxOTQ_50dfeec7-0073-496e-a57b-4dea64a0eb17"
      unitRef="usd">-12145000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjAtMS0xLTEtOTAxOTQ_884dde60-f160-46e1-be9f-6c803449672c"
      unitRef="usd">53000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjAtMy0xLTEtOTAxOTQ_6f75ee6a-2fae-4267-b657-7a550a59aea4"
      unitRef="usd">301000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjAtNS0xLTEtOTAxOTQ_419faf9f-5e0d-417e-93af-86cac5b875b4"
      unitRef="usd">178000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjAtNy0xLTEtOTAxOTQ_0149ece2-0379-4f59-bb6c-284118316dfe"
      unitRef="usd">355000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjEtMS0xLTEtOTAxOTQ_714db2dd-ad2a-4363-b532-5bb15142259b"
      unitRef="usd">-8426000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjEtMy0xLTEtOTAxOTQ_6a59818d-5fd7-4094-8fe8-38e55bab1dab"
      unitRef="usd">-2339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjEtNS0xLTEtOTAxOTQ_a263527b-3007-4898-bb47-24aa9e7106f2"
      unitRef="usd">-29783000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjEtNy0xLTEtOTAxOTQ_e8883b67-b096-4312-95fd-a30f15033258"
      unitRef="usd">-12500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtMS0xLTEtOTAxOTQ_157c151c-762c-456f-943a-ff7552247c10"
      unitRef="usd">-10096000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtMS0xLTEtOTAxOTQ_9893e43e-4f71-4b48-bd68-bf7abcbfda21"
      unitRef="usd">-10096000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtMy0xLTEtOTAxOTQ_3f7070a0-32f3-476d-be79-f5c7866f98fc"
      unitRef="usd">-3913000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtMy0xLTEtOTAxOTQ_8d720cc4-e40c-4cc9-b0f6-a84e3699ed29"
      unitRef="usd">-3913000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtNS0xLTEtOTAxOTQ_24b23f3c-68b9-49fd-95c6-b0c43e3643d0"
      unitRef="usd">-34667000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjMtNy0xLTEtOTAxOTQ_cf34b72c-8241-4215-8776-0db9d3b1bf29"
      unitRef="usd">-17039000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjYtMS0xLTEtOTAxOTQ_d0c1f6de-121f-41d9-8115-673a366455c3"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjYtMy0xLTEtOTAxOTQ_f743c046-e1f3-49bc-b509-c62a98716cae"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjYtNS0xLTEtOTAxOTQ_416d0c97-fbab-4098-b246-b83f5ee421b1"
      unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjYtNy0xLTEtOTAxOTQ_830fef12-96cc-44c6-bdf3-747601bdee50"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjctMS0xLTEtOTAxOTQ_e79751ba-5c68-41ed-b311-87192fe99915"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjctMy0xLTEtOTAxOTQ_c75c9b7c-7137-48de-8a7c-2def7e671478"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjctNS0xLTEtOTAxOTQ_456e8651-5103-4786-b4a5-55a00acc3265"
      unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjctNy0xLTEtOTAxOTQ_6f7c8c87-e4e8-47a1-a43c-21983f637c68"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjktMS0xLTEtOTAxOTQ_83ed1151-2540-42c9-89de-027e9edc17b2"
      unitRef="shares">113448251</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjktMy0xLTEtOTAxOTQ_8b7ecceb-f863-45a8-8f8b-759e224f80e6"
      unitRef="shares">110717073</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjktNS0xLTEtOTAxOTQ_aa5d1507-f3f4-49c4-ba92-e34c5c33bd68"
      unitRef="shares">112650713</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMjktNy0xLTEtOTAxOTQ_820814e9-4777-45de-b846-b4badb1e26c3"
      unitRef="shares">110136517</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMzAtMS0xLTEtOTAxOTQ_0f90b0dd-d17d-4793-b174-11f9d8d77488"
      unitRef="shares">113448251</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMzAtMy0xLTEtOTAxOTQ_76e46b7f-0cd8-44d1-a0f5-1950cea463f5"
      unitRef="shares">110717073</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMzAtNS0xLTEtOTAxOTQ_aeb181e6-4faf-4f50-9f0e-b379c1c16ca8"
      unitRef="shares">112650713</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yMi9mcmFnOjZmZDFlNmI2YWExMDQyNTNhYmVkNmQyNDhmMjU1MDMyL3RhYmxlOjgyMmQ2ZmI3NjZiODQ3OTY4MzBjMDBjOTkxMzhkZTBhL3RhYmxlcmFuZ2U6ODIyZDZmYjc2NmI4NDc5NjgzMGMwMGM5OTEzOGRlMGFfMzAtNy0xLTEtOTAxOTQ_f308a1ea-60c4-4ff3-bcc9-8dfb7007d7ad"
      unitRef="shares">110136517</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ifba863cfdd014259beb502f94590fb92_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi0xLTEtMS05MDE5NA_91585c07-da24-4afc-b06e-2e0070e7bc62"
      unitRef="shares">113609274</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ifba863cfdd014259beb502f94590fb92_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi0yLTEtMS05MDE5NA_bc7342a3-1b64-4d65-aad3-10958911f40c"
      unitRef="usd">114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i05b234f7a63247d18255f80516b6b090_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi0zLTEtMS05MDE5NA_62e7ee6a-37d3-40fe-a6c1-512e7532e430"
      unitRef="usd">169352000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i010a2081c1d248cfb4d5387b5bbf34cb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi00LTEtMS05MDE5NA_edd36b42-8fbd-4ce1-8b1e-7400204ed9a3"
      unitRef="shares">1003</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i010a2081c1d248cfb4d5387b5bbf34cb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi01LTEtMS05MDE5NA_65ffbe5b-366c-459d-8dc0-a66f875d093c"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0f2c1ec8ce8b4a1a914dc56aec2bfe32_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi02LTEtMS05MDE5NA_c4f9e39b-dbf5-4e08-9c3c-27cc885d5bae"
      unitRef="usd">-183066000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ed50021a0c24811907cc1f60c6d2cdf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMi03LTEtMS05MDE5NA_b2a03df1-68d5-4cb2-8bdd-2e7ef39c5900"
      unitRef="usd">-13603000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie562cf214f3146d48637101b5f2efb7e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNS0zLTEtMS05MDE5NA_020e25b4-117d-4b95-a0f5-2ad7f76bf3d2"
      unitRef="usd">2372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNS03LTEtMS05MDE5NA_13c2a776-f189-4a7e-9d17-c9baf7069bc1"
      unitRef="usd">2372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4adfca19515f406a8294d42cfdc70386_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNy0xLTEtMS05MDE5NA_849e1b71-387b-4725-84ab-d91034928eae"
      unitRef="shares">49666</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie562cf214f3146d48637101b5f2efb7e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNy0zLTEtMS05MDE5NA_5a0c0a8b-6f79-4153-aac4-e8d71a486f2e"
      unitRef="usd">132000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i426adda60bd7408fa92b3d909af64f9d_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNy00LTEtMS05MDE5NA_f330378d-3450-4483-bc77-8040377a3b95"
      unitRef="shares">1001</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i426adda60bd7408fa92b3d909af64f9d_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNy01LTEtMS05MDE5NA_5e6ddc5e-fdf6-4a83-8f04-e2cf7aca89af"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfNy03LTEtMS05MDE5NA_0deb9cbe-b3b9-4d4b-86f5-d31f68ffdfa0"
      unitRef="usd">137000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i4adfca19515f406a8294d42cfdc70386_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfOS0xLTEtMS05MDE5NA_dd3b8084-51b9-4f84-aed0-c45630302958"
      unitRef="shares">11077</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfOS03LTEtMS05MDE5NA_3d51aea6-9b09-4762-97fd-69b1a868ea75"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="ie562cf214f3146d48637101b5f2efb7e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTAtMy0xLTEtOTAxOTQ_def7fa7b-73be-43fb-ad98-c2b2c1e758c1"
      unitRef="usd">-9000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i426adda60bd7408fa92b3d909af64f9d_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTAtNC0xLTEtOTAxOTQ_180f5afe-2eb2-4fc3-a6ce-e06734e01fa7"
      unitRef="shares">1836</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i426adda60bd7408fa92b3d909af64f9d_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTAtNS0xLTEtOTAxOTQ_8d9c0b34-287f-412c-a47c-155b1df65361"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTAtNy0xLTEtOTAxOTQ_3e48f1e4-b447-458d-adaa-32426565c2fa"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="i1a2e885d3bd7477eba0a6949abfbc7e9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTQtNi0xLTEtOTAxOTQ_ff8539de-fa23-4d31-922f-68d3fc3461c7"
      unitRef="usd">-8426000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTQtNy0xLTEtOTAxOTQ_1320cc3e-c46f-4504-86f4-01bbac97bedf"
      unitRef="usd">-8426000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie6439b5cd06945f59b73261db40e5502_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtMS0xLTEtOTAxOTQ_68d42d1e-2609-4288-8ab5-57a198f093d2"
      unitRef="shares">113670017</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ie6439b5cd06945f59b73261db40e5502_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtMi0xLTEtOTAxOTQ_d7d6430f-71e9-4bd5-83da-bd0c532b1204"
      unitRef="usd">114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie21cf100acb94a0d9ea1bba0d5056893_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtMy0xLTEtOTAxOTQ_7c431a3c-7804-47e9-a38e-e9cc5399d28f"
      unitRef="usd">171865000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i0422e54ed7ae463d9a2bd382de7c4376_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtNC0xLTEtOTAxOTQ_103c2b1f-a2e5-49b2-8529-5fc32da112c0"
      unitRef="shares">1838</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i0422e54ed7ae463d9a2bd382de7c4376_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtNS0xLTEtOTAxOTQ_6c925565-0413-49a5-8d59-fa2275f340c1"
      unitRef="usd">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54ac1c07b4df44d9a33e5760e89f8c92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtNi0xLTEtOTAxOTQ_f87037db-686f-456a-a8ca-ddbc228d0fe7"
      unitRef="usd">-191492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmNhNGM2M2E3YmY2ZjRkZTFiNGJlOGYzNjZjYTc2YjZjL3RhYmxlcmFuZ2U6Y2E0YzYzYTdiZjZmNGRlMWI0YmU4ZjM2NmNhNzZiNmNfMTUtNy0xLTEtOTAxOTQ_ba978041-0d4e-4fc2-a255-419ad169af78"
      unitRef="usd">-19520000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i960535ac6f674eb3841e739b8d82ee9f_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi0xLTEtMS05MDE5NA_b5805fbc-7e1c-4dce-8fcb-b85e76970714"
      unitRef="shares">112703926</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i960535ac6f674eb3841e739b8d82ee9f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi0yLTEtMS05MDE5NA_f2d548ad-9211-4ae6-8620-d9dbe91a6896"
      unitRef="usd">113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i36cbd2d2be4247e1bf671be0206a929a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi0zLTEtMS05MDE5NA_3901679c-7940-4acc-86fb-cf178921146c"
      unitRef="usd">158720000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i37e08c0b3a7447538e513cbcf68f082c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi00LTEtMS05MDE5NA_0ed81c6f-baf2-4d8d-b31f-e27c9ec09939"
      unitRef="shares">821988</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i37e08c0b3a7447538e513cbcf68f082c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi01LTEtMS05MDE5NA_9c007287-0288-4851-abdb-4f58a22ce48e"
      unitRef="usd">-4385000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40d4e1cc067d40bf8351fad15af71351_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi02LTEtMS05MDE5NA_6b3809a4-ddc4-40f7-a403-f06bbaab5a29"
      unitRef="usd">-161585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifc5ba08b772c48e2a5927ce471578129_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMi03LTEtMS05MDE5NA_e04db16e-a69f-415e-8a07-75f74b06f244"
      unitRef="usd">-7137000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0cdd5e7db696459ba5ef33f6dca38591_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNC0zLTEtMS05MDE5NA_bf1e4073-4206-4bdb-80eb-86199942eaa1"
      unitRef="usd">3811000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNC03LTEtMS05MDE5NA_17726fca-f6f6-4589-9735-d5cc26e7313b"
      unitRef="usd">3811000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0cdd5e7db696459ba5ef33f6dca38591_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNS0zLTEtMS05MDE5NA_bcb93de6-0f68-47df-9d9a-db0dab2b3cb7"
      unitRef="usd">-250000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNS00LTEtMS05MDE5NA_90067c2e-378e-4ecf-a92b-629c0ab52775"
      unitRef="shares">30032</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNS01LTEtMS05MDE5NA_fb8fd851-66cb-4bb7-a684-67b0c063125b"
      unitRef="usd">295000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNS03LTEtMS05MDE5NA_0f855aa9-5a13-4004-bee1-b8a9266d29c5"
      unitRef="usd">45000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i0cdd5e7db696459ba5ef33f6dca38591_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNi0zLTEtMS05MDE5NA_2036ab0b-5326-4942-ae59-85fc63a4fe58"
      unitRef="usd">-477000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNi00LTEtMS05MDE5NA_c6f40547-996b-49db-88ff-027198e2d667"
      unitRef="shares">48630</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNi01LTEtMS05MDE5NA_c8621a51-cf9f-4661-901a-aabb88cc5aa6"
      unitRef="usd">477000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNi03LTEtMS05MDE5NA_090c3c8e-4461-4b2c-aec3-66eb556c0e2c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i0cdd5e7db696459ba5ef33f6dca38591_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNy0zLTEtMS05MDE5NA_23e8354d-7a1b-49c6-8d17-88663e52afe6"
      unitRef="usd">-199000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNy00LTEtMS05MDE5NA_c5220717-163d-40ba-a218-330c67514e9c"
      unitRef="shares">18348</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNy01LTEtMS05MDE5NA_36da734d-ab6a-4e3f-9c0a-a20e213b63e3"
      unitRef="usd">199000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfNy03LTEtMS05MDE5NA_0ee223d8-0727-438d-b5c9-a0e7e0482761"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfOC00LTEtMS05MDE5NA_8caa32f0-8f14-4597-8248-a8388873af4a"
      unitRef="shares">15354</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia13d4f326df848e2877be82415791199_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfOC01LTEtMS05MDE5NA_ddd6d575-c70e-417c-9122-2843c88c4e42"
      unitRef="usd">188000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfOC03LTEtMS05MDE5NA_6fbfdfde-c08f-4939-98ef-bb26e91f30a2"
      unitRef="usd">188000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i48d07b19e6c84b74baa49dc3385595a9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfOS02LTEtMS05MDE5NA_bedf0dd3-1b0c-4a50-b5b1-aa1b1727f981"
      unitRef="usd">-2339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfOS03LTEtMS05MDE5NA_3ff8b4a2-3883-438c-b06a-352d28d56e82"
      unitRef="usd">-2339000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i633727b5068940b985f2cd3490575ca0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtMS0xLTEtOTAxOTQ_f1dedfa5-666b-43de-81c0-7032a18a75e7"
      unitRef="shares">112703926</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i633727b5068940b985f2cd3490575ca0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtMi0xLTEtOTAxOTQ_4a6847e0-283b-4bea-84e0-c487f5da7121"
      unitRef="usd">113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia6eb0110a1d742c1b1bdca7f8dcb37e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtMy0xLTEtOTAxOTQ_dbb9ca14-e860-4660-b4f8-3a2b16c6a10a"
      unitRef="usd">162003000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="if938b4beab4546c9b2569f821725e575_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtNC0xLTEtOTAxOTQ_684b47f5-7123-498f-81e1-92f314ce8f91"
      unitRef="shares">777028</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="if938b4beab4546c9b2569f821725e575_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtNS0xLTEtOTAxOTQ_861acb1e-e566-4c13-abff-e8ba4163d49b"
      unitRef="usd">-4000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91fe605c0c2e4cfb8945c919830b2ab5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtNi0xLTEtOTAxOTQ_e63333b9-9390-4b29-a1fd-a22733a46813"
      unitRef="usd">-163924000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5210ebd6b19497b800bc4f988408437_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8yOC9mcmFnOmQ1OGY2ZWI1ZDRkMzRjYjZhNTE5ZjJmN2VlZGQ3NDg0L3RhYmxlOmVhZjdlOGY5ZTBkYjRjYzNiOWM0ZTIwZTFiZTg0NzA3L3RhYmxlcmFuZ2U6ZWFmN2U4ZjllMGRiNGNjM2I5YzRlMjBlMWJlODQ3MDdfMTEtNy0xLTEtOTAxOTQ_ca8ca762-da54-4b95-a2f2-05d1a8bf6924"
      unitRef="usd">-5808000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="if74b4382e4f4415ca684233d6d54025e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi0xLTEtMS05MDE5NA_ffd409c9-2395-4fc8-bc00-5b04ac9f64ca"
      unitRef="shares">112703926</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="if74b4382e4f4415ca684233d6d54025e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi0yLTEtMS05MDE5NA_999af9d8-0fbf-4cc7-97b1-a5131764c8f5"
      unitRef="usd">113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7c70317011347c28bda53c1ba6ef71c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi0zLTEtMS05MDE5NA_2b12ed6a-fe09-46e6-8d7c-ac604e919ad9"
      unitRef="usd">165695000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ib877a57ab1704b83960f1ec88ba5f101_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi00LTEtMS05MDE5NA_9bd05367-0a07-499e-a84b-0c2af8085d8a"
      unitRef="shares">778710</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="ib877a57ab1704b83960f1ec88ba5f101_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi01LTEtMS05MDE5NA_0e6ad4ed-0e7a-43b1-963d-991fa70dec8f"
      unitRef="usd">-4017000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5122095cb1394cab9cd9024590777b14_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi02LTEtMS05MDE5NA_8677b913-caee-4552-826c-90e02ee9e5de"
      unitRef="usd">-161709000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMi03LTEtMS05MDE5NA_d38c9161-730a-4a15-927b-481bf65581ea"
      unitRef="usd">82000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4f8827f716654e7f849b34c082fd49e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNS0zLTEtMS05MDE5NA_29172c41-b4e5-404f-8886-16a137ed80ac"
      unitRef="usd">10798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNS03LTEtMS05MDE5NA_771271a1-3abf-4c31-bb2f-bbb841033009"
      unitRef="usd">10798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie5b940257a7a48998d89e37643d2bea8_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNi0xLTEtMS05MDE5NA_4b883477-16ef-4a31-94cb-3e24b25849b5"
      unitRef="shares">133762</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4f8827f716654e7f849b34c082fd49e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNi0zLTEtMS05MDE5NA_6a46ccce-e773-4ebb-818c-bcbde20098d3"
      unitRef="usd">-697000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNi00LTEtMS05MDE5NA_8fbc7cbd-15a7-4997-8f59-daad1276085f"
      unitRef="shares">151239</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNi01LTEtMS05MDE5NA_8edee74d-873e-425a-b813-d5adae770504"
      unitRef="usd">1271000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNi03LTEtMS05MDE5NA_c5355cd7-cc9e-4936-b651-7f8235016920"
      unitRef="usd">574000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ie5b940257a7a48998d89e37643d2bea8_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy0xLTEtMS05MDE5NA_d5f7bd73-f844-4aba-a423-ab8254cbec68"
      unitRef="shares">832329</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ie5b940257a7a48998d89e37643d2bea8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy0yLTEtMS05MDE5NA_11d764d4-445f-4a7d-9543-db02e0c23749"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i4f8827f716654e7f849b34c082fd49e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy0zLTEtMS05MDE5NA_bf2e5e4d-3e31-407c-8e85-f7352cb4a8e6"
      unitRef="usd">-3960000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy00LTEtMS05MDE5NA_30f88cfc-aba4-4d15-8631-8daac690cd61"
      unitRef="shares">880749</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy01LTEtMS05MDE5NA_b9481293-9a9a-4f42-9eb7-1adb967e4132"
      unitRef="usd">3959000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfNy03LTEtMS05MDE5NA_3bab4c9b-d346-4b56-87df-2c3b3cc470b7"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i4f8827f716654e7f849b34c082fd49e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOC0zLTEtMS05MDE5NA_b9591c00-1c63-4711-9776-5dfd90bc756b"
      unitRef="usd">-29000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOC00LTEtMS05MDE5NA_7d80429f-7585-497c-8c6c-6d8e5fa2412e"
      unitRef="shares">5338</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOC01LTEtMS05MDE5NA_e45b5cf0-7069-4899-8e8f-5c0377f6cc9d"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOC03LTEtMS05MDE5NA_35f1edaa-881f-47ec-a252-c684f29fad26"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOS00LTEtMS05MDE5NA_4849fcb8-c017-47ce-a4a4-77d1763ca11d"
      unitRef="shares">249778</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4481fbd64be94e6d9f28fd8299acec45_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOS01LTEtMS05MDE5NA_128892ff-9d05-4415-9eea-1091c3edccff"
      unitRef="usd">1191000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfOS03LTEtMS05MDE5NA_5130c707-ace5-430d-8e41-8a997614a822"
      unitRef="usd">1191000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i41b433355fba44f8902c37168d015ce7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTAtNi0xLTEtOTAxOTQ_83fdd220-7a7b-4777-831c-3f89ee78af0a"
      unitRef="usd">-29783000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTAtNy0xLTEtOTAxOTQ_5043ee53-3af4-4f73-91d0-9364db1040df"
      unitRef="usd">-29783000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie6439b5cd06945f59b73261db40e5502_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtMS0xLTEtOTAxOTQ_4259bb80-2344-4272-8818-5dfd5ad5e18f"
      unitRef="shares">113670017</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ie6439b5cd06945f59b73261db40e5502_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtMi0xLTEtOTAxOTQ_a2be4190-ff51-4336-84b1-b9af304c2fcd"
      unitRef="usd">114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie21cf100acb94a0d9ea1bba0d5056893_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtMy0xLTEtOTAxOTQ_7dfef7c6-5efc-4701-9017-e66bdd319d55"
      unitRef="usd">171865000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i0422e54ed7ae463d9a2bd382de7c4376_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtNC0xLTEtOTAxOTQ_1fcbcba3-7134-4830-bb6b-cb3256173cd7"
      unitRef="shares">1838</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i0422e54ed7ae463d9a2bd382de7c4376_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtNS0xLTEtOTAxOTQ_4985a46c-3512-4740-86fa-3c7a5c178e39"
      unitRef="usd">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54ac1c07b4df44d9a33e5760e89f8c92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtNi0xLTEtOTAxOTQ_2ec241be-476a-46b0-a775-e3e44fb421de"
      unitRef="usd">-191492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOmJlOTA5ZjU4ZTZlZTRiNWI4NGRmYzkwMTk2YzAxMTdhL3RhYmxlcmFuZ2U6YmU5MDlmNThlNmVlNGI1Yjg0ZGZjOTAxOTZjMDExN2FfMTEtNy0xLTEtOTAxOTQ_2ad5577e-d7cd-466c-9d54-5b879990c231"
      unitRef="usd">-19520000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i442c898781d04f8abe327191b2190538_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi0xLTEtMS05MDE5NA_482e26e2-87bf-417a-a5dc-40033eddf44c"
      unitRef="shares">112703926</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i442c898781d04f8abe327191b2190538_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi0yLTEtMS05MDE5NA_1ac48086-ea4f-4e44-a63f-bf01b7a9e79a"
      unitRef="usd">113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2c3b930d9e8c47b89eeb9e3f88386a6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi0zLTEtMS05MDE5NA_27e6b783-1d2d-4a6f-ad42-b713ff40f009"
      unitRef="usd">158610000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i8859ee77eae6426780f3132bfcc5b59c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi00LTEtMS05MDE5NA_dab73fa1-77ca-41ba-851c-606b71c23cb7"
      unitRef="shares">1773683</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i8859ee77eae6426780f3132bfcc5b59c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi01LTEtMS05MDE5NA_30678e4b-041d-42eb-b332-9a7b993405ee"
      unitRef="usd">-7449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia87984b643cc43d69c2042ee0608e0bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi02LTEtMS05MDE5NA_1f43a0b3-4e7d-4563-93a7-29171df326aa"
      unitRef="usd">-151424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib60f056199c240ba8e0dc19accdb2766_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMi03LTEtMS05MDE5NA_4b9e4cc6-7328-4483-9881-58dd70cbb832"
      unitRef="usd">-150000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMy0zLTEtMS05MDE5NA_adaf80d5-f9c7-4b89-bc15-9f933295f1c9"
      unitRef="usd">926000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMy03LTEtMS05MDE5NA_de54cfb2-190c-4e6b-bdcb-c2664e82037e"
      unitRef="usd">926000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNC0zLTEtMS05MDE5NA_cb4c30f3-93c7-4d54-886d-e103b77d2232"
      unitRef="usd">11115000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNC03LTEtMS05MDE5NA_670e9c2b-6b2c-45a5-9612-8f6d61b8ae17"
      unitRef="usd">11115000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNS0zLTEtMS05MDE5NA_2ee43318-5552-4899-9375-118f3367aa0e"
      unitRef="usd">-1184000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNS0zLTEtMS05MDE5NA_b84302f3-37cb-4d5c-82ba-eb4566fa133c"
      unitRef="usd">-1184000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNS00LTEtMS05MDE5NA_234fc477-4c23-40e2-9633-3a77aaa26643"
      unitRef="shares">482361</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNS01LTEtMS05MDE5NA_3b683a00-67ab-492a-94f5-aedd2c5a04af"
      unitRef="usd">2588000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNS03LTEtMS05MDE5NA_f366ff74-6bb5-4dd3-a08e-4f468c004e60"
      unitRef="usd">1404000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNi0zLTEtMS05MDE5NA_1400c978-c0c3-45c2-87ea-5eb69dccec53"
      unitRef="usd">-4053000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNi0zLTEtMS05MDE5NA_1826a4a5-9d8a-4aca-851c-3e0784213f1e"
      unitRef="usd">-4053000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNi00LTEtMS05MDE5NA_5bb59f2f-887e-4763-8a0c-af5e2a6dff54"
      unitRef="shares">810405</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNi01LTEtMS05MDE5NA_8b4ab8e9-f87b-43c4-9905-880af332b7a1"
      unitRef="usd">4053000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNi03LTEtMS05MDE5NA_9f2dd0d6-03c3-4adb-9ede-be59754c0177"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNy0zLTEtMS05MDE5NA_6f9c2059-c70f-4068-9f95-a90c9f20c3cb"
      unitRef="usd">-450000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNy0zLTEtMS05MDE5NA_d226deb5-87de-4757-ac09-09d2c9731f7f"
      unitRef="usd">-450000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNy00LTEtMS05MDE5NA_8e986447-02eb-41aa-94d0-b60bd094e8e6"
      unitRef="shares">66374</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNy01LTEtMS05MDE5NA_f19055b2-818a-4d99-8e68-63563bf4abd3"
      unitRef="usd">450000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfNy03LTEtMS05MDE5NA_d0b4554c-a206-4928-9124-d3011f9e0ffa"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfOC00LTEtMS05MDE5NA_02bedd3b-4b76-46cf-85df-648f218de6cb"
      unitRef="shares">469239</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfOC01LTEtMS05MDE5NA_4c2095df-b981-4273-9703-82d5a56211ba"
      unitRef="usd">4751000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfOC03LTEtMS05MDE5NA_43854307-5397-4d53-8e90-3ed8fe2f779e"
      unitRef="usd">4751000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i794708492f6546f0a4986be2d9546a2d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfOS02LTEtMS05MDE5NA_1afe3ca8-b085-47c5-ac86-3ae3c34f1c00"
      unitRef="usd">-12500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfOS03LTEtMS05MDE5NA_8a082ffb-ec1c-42c4-9a97-fa0bc5135f47"
      unitRef="usd">-12500000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i19c54979de6a4cdd9b9207fede9c9627_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTAtMy0xLTEtOTQ1MDM_3ef47413-2252-4ce9-b82d-f4253f729617"
      unitRef="usd">-2009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <mdxg:TreasuryStockSharesAdjustment
      contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTAtNC0xLTEtOTQ1MDM_7ddcb896-561f-4329-bf52-8508b3e3cdab"
      unitRef="shares">239502</mdxg:TreasuryStockSharesAdjustment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="ide40f0ea6322436d87854e83f0309547_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTAtNS0xLTEtOTQ1MDM_3836fe17-29ac-450e-b1c2-d4323b31d4d7"
      unitRef="usd">2009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTAtNy0xLTEtOTQ1MDY_ef0e5e3b-f4e3-4e45-b2b8-e9c929e0a6eb"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i633727b5068940b985f2cd3490575ca0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtMS0xLTEtOTAxOTQ_f2b1ab16-b4b7-48d2-97e1-8fb8055fd96b"
      unitRef="shares">112703926</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i633727b5068940b985f2cd3490575ca0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtMi0xLTEtOTAxOTQ_86746cd2-4ce3-4bf0-94de-106868bcfb26"
      unitRef="usd">113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia6eb0110a1d742c1b1bdca7f8dcb37e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtMy0xLTEtOTAxOTQ_c7e96c76-d386-4a8b-a490-01d72bf6495f"
      unitRef="usd">162003000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="if938b4beab4546c9b2569f821725e575_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtNC0xLTEtOTAxOTQ_751ceb8f-5d38-4b72-aab5-84d38e7ff191"
      unitRef="shares">777028</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="if938b4beab4546c9b2569f821725e575_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtNS0xLTEtOTAxOTQ_eb767fd0-39f6-4fac-adf4-96e437dba413"
      unitRef="usd">-4000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91fe605c0c2e4cfb8945c919830b2ab5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtNi0xLTEtOTAxOTQ_546f2dd0-6ede-4528-a22a-65823d961300"
      unitRef="usd">-163924000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5210ebd6b19497b800bc4f988408437_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zMS9mcmFnOjIwZmQ1ZDVmMzdhMTQ4NzNhNDViMmRmNWZiZWIzMGUyL3RhYmxlOjc1ZWI4NTNhODZjYzQzOGU4ZDc4MDc4YzMxODgwYTcwL3RhYmxlcmFuZ2U6NzVlYjg1M2E4NmNjNDM4ZThkNzgwNzhjMzE4ODBhNzBfMTEtNy0xLTEtOTAxOTQ_0f15a905-690b-41e0-a8a3-6c6a11b1d59e"
      unitRef="usd">-5808000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMy0xLTEtMS05MDE5NA_ab3e893f-5693-4a30-9bf7-7b0cd6a1cfa0"
      unitRef="usd">-29783000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMy0zLTEtMS05MDE5NA_c783e8cc-9fce-4d8d-9d15-0c6b35200137"
      unitRef="usd">-12500000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNS0xLTEtMS05MDE5NA_916ff3c3-eadf-4f61-8134-f34d8a8eb8a1"
      unitRef="usd">10798000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNS0zLTEtMS05MDE5NA_f7aa874a-d9be-4c72-9f4f-0e7e93f0deb3"
      unitRef="usd">11115000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNi0xLTEtMS05MDE5NA_934cccb7-e908-404b-a622-9ebe21370bfd"
      unitRef="usd">2549000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNi0zLTEtMS05MDE5NA_9a130457-280b-47c9-b63d-c1f6cab7028c"
      unitRef="usd">3390000</us-gaap:Depreciation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNy0xLTEtMS05MDE5NA_c77b6d99-a581-471f-8898-81201239a3cb"
      unitRef="usd">2817000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNy0zLTEtMS05MDE5NA_5dc1f46b-29e9-4189-8afb-922b8deb7127"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfOC0xLTEtMS05MDE5NA_81f6b5ac-a1a0-4007-91bf-3e81208b89a4"
      unitRef="usd">519000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfOC0zLTEtMS05MDE5NA_244e42a3-482e-4746-8b09-bab07643a38f"
      unitRef="usd">647000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfOS0xLTEtMS05MDE5NA_604ad515-4942-4c59-93b0-a05e67dddcf2"
      unitRef="usd">348000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfOS0zLTEtMS05MDE5NA_21a63862-4244-49e4-9966-8223c84cefec"
      unitRef="usd">943000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTAtMS0xLTEtOTAxOTQ_13845862-2e7a-46ab-bf33-232559e12a44"
      unitRef="usd">931000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTAtMy0xLTEtOTAxOTQ_b9750a1f-9536-49d5-bd63-03119c9c3dc8"
      unitRef="usd">724000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AssetRetirementObligationAccretionExpense
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTEtMS0xLTEtOTAxOTQ_83ce2b00-f401-4625-b328-0342fa337cb5"
      unitRef="usd">69000</us-gaap:AssetRetirementObligationAccretionExpense>
    <us-gaap:AssetRetirementObligationAccretionExpense
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTEtMy0xLTEtOTAxOTQ_cfead552-a779-417f-8b4c-816529182298"
      unitRef="usd">57000</us-gaap:AssetRetirementObligationAccretionExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTItMS0xLTEtOTAxOTQ_c9a0e0ad-74d8-429c-a9e8-56b5c9a9d978"
      unitRef="usd">17000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTItMy0xLTEtOTAxOTQ_573e65cf-44ec-4b8a-ad39-5e8df9fc7f3c"
      unitRef="usd">-236000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTYtMS0xLTEtOTAxOTQ_b30bfcb3-4182-4823-8983-3132ad9b56a8"
      unitRef="usd">3295000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTYtMy0xLTEtOTAxOTQ_44d3d896-2360-450b-b52e-536217585f2b"
      unitRef="usd">1113000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTctMS0xLTEtOTAxOTQ_7040900e-ff23-4224-ab95-79625a3f4e4b"
      unitRef="usd">2586000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTctMy0xLTEtOTAxOTQ_ba64db23-2170-43b5-9817-0206b8b04be0"
      unitRef="usd">835000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTgtMS0xLTEtOTAxOTQ_0081eb16-f019-480f-9e22-b342fdedb837"
      unitRef="usd">-1467000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTgtMy0xLTEtOTAxOTQ_a7bb1b5c-89f0-4815-8c51-732cce6a9e14"
      unitRef="usd">-3527000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTktMS0xLTEtOTAxOTQ_8ff476f4-80b5-4f83-a1a2-24539c5c3666"
      unitRef="usd">13000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMTktMy0xLTEtOTAxOTQ_48bd1106-ea23-448e-b0f3-8a924dc02e37"
      unitRef="usd">-9420000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjAtMS0xLTEtOTAxOTQ_8997fc21-ca0c-449c-8989-6ae176f578a5"
      unitRef="usd">287000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjAtMy0xLTEtOTAxOTQ_98a1d089-e8c6-4efa-94cd-729b7bf97b36"
      unitRef="usd">-1990000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjEtMS0xLTEtOTAxOTQ_6fafb9cf-cfb0-47c9-b254-e8da7baa22d4"
      unitRef="usd">1090000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjEtMy0xLTEtOTAxOTQ_5f437c59-f09a-404b-9568-140a37ff6d6f"
      unitRef="usd">-828000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjItMS0xLTEtOTAxOTQ_ab68fde2-4c7e-4221-8b8a-f111e087778f"
      unitRef="usd">495000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjItMy0xLTEtOTAxOTQ_4439b0ba-19ca-449a-84da-627ab42f57be"
      unitRef="usd">2085000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjMtMS0xLTEtOTAxOTQ_dc0199a1-410e-41a8-8825-de4fd8bf017e"
      unitRef="usd">1724000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjMtMy0xLTEtOTAxOTQ_c04f4a8b-66a6-4ea4-a144-f43f60786ad6"
      unitRef="usd">-16768000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjQtMS0xLTEtOTAxOTQ_c5417857-fd43-483b-94f0-273c8fb4653f"
      unitRef="usd">905000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjQtMy0xLTEtOTAxOTQ_4b6f5151-cf40-4275-9f6c-54c545bf00aa"
      unitRef="usd">-840000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjUtMS0xLTEtOTAxOTQ_09af2d8d-df88-456e-a5e3-6a64d846fbbf"
      unitRef="usd">-12269000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjUtMy0xLTEtOTAxOTQ_32a2d919-5553-4a13-9941-5b4f6d8f980d"
      unitRef="usd">1250000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjgtMS0xLTEtOTAxOTQ_55985f64-0fd5-4c59-b53d-33ae1669b9ab"
      unitRef="usd">847000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjgtMy0xLTEtOTAxOTQ_60aa0094-d0f1-4dfe-962a-2581b9eb742f"
      unitRef="usd">2893000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <mdxg:PaymentsForApplicationCostsPatent
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjktMS0xLTEtOTAxOTQ_40b2584b-a814-49c7-83b4-c7fa0971056a"
      unitRef="usd">128000</mdxg:PaymentsForApplicationCostsPatent>
    <mdxg:PaymentsForApplicationCostsPatent
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMjktMy0xLTEtOTAxOTQ_81c370cb-9881-40f4-9d30-41bf7b5e4244"
      unitRef="usd">263000</mdxg:PaymentsForApplicationCostsPatent>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzAtMS0xLTEtOTAxOTQ_c49d12a0-2b12-4421-ad23-418fc708fcba"
      unitRef="usd">0</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzAtMy0xLTEtOTAxOTQ_5d5455bb-5f12-4183-9e46-90b82f84b26d"
      unitRef="usd">75000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzEtMS0xLTEtOTAxOTQ_aab01171-576d-464b-b740-71a3ee2da86c"
      unitRef="usd">24000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzEtMy0xLTEtOTAxOTQ_da4ec9da-6599-49e1-a1e6-f137972c1437"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzItMS0xLTEtOTAxOTQ_342d1386-5c6a-43f8-bb71-6afcee1e8522"
      unitRef="usd">-951000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzItMy0xLTEtOTAxOTQ_3b7229b9-30bf-4b2f-bfbb-2e18a3537c3b"
      unitRef="usd">-3081000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzUtMS0xLTEtOTAxOTQ_4f314b25-df12-4560-8edc-251a38a60d3b"
      unitRef="usd">1191000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzUtMy0xLTEtOTAxOTQ_da48c2ba-3a97-408d-bf06-cf5f16ae9af8"
      unitRef="usd">4751000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzYtMS0xLTEtOTAxOTQ_b66e447c-0a6a-4b56-bfa0-f83d2fdde4b0"
      unitRef="usd">574000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzYtMy0xLTEtOTAxOTQ_b662661d-c89f-41fb-853e-2898f3f9bd55"
      unitRef="usd">1404000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzctMS0xLTEtOTAxOTQ_3c087d18-f8a3-4a94-a7d3-d01f2971fd18"
      unitRef="usd">29000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzctMy0xLTEtOTAxOTQ_8f264bf9-3981-4008-8d2f-5bb39b4cca19"
      unitRef="usd">27000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzgtMS0xLTEtOTAxOTQ_c1a45c8d-1d8f-4cbc-9963-078afc8ee997"
      unitRef="usd">-646000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfMzgtMy0xLTEtOTAxOTQ_f01a6b61-3863-407d-9d11-5d06a8c2e53d"
      unitRef="usd">-3374000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDAtMS0xLTEtOTAxOTQ_69f5e0c7-e6aa-4e7f-9704-59d416b6a9c3"
      unitRef="usd">-13866000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDAtMy0xLTEtOTAxOTQ_08b85f93-2f20-4f1a-a661-5051248ca3c2"
      unitRef="usd">-5205000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDItMS0xLTEtOTAxOTQ_67ff3159-9185-4cd4-aa58-25357cf1ba4f"
      unitRef="usd">87083000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib60f056199c240ba8e0dc19accdb2766_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDItMy0xLTEtOTAxOTQ_472ec8f4-3d3e-4e75-9c4e-a5cae78b0696"
      unitRef="usd">95812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDMtMS0xLTEtOTAxOTQ_07461691-ef7d-44d8-a70f-cc14926c2b7c"
      unitRef="usd">73217000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic5210ebd6b19497b800bc4f988408437_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8zNC9mcmFnOmNkNDdmNTU0ZjY2ZTRlMzM5YzMwYjk0N2QwNDlhYjZkL3RhYmxlOjA0YWExZDE3ZDE0NDQ2OGQ4ZGY1YzUwMGY1OWU0OTZmL3RhYmxlcmFuZ2U6MDRhYTFkMTdkMTQ0NDY4ZDhkZjVjNTAwZjU5ZTQ5NmZfNDMtMy0xLTEtOTAxOTQ_277fd20d-0408-4bb4-a7a4-527a3f6043eb"
      unitRef="usd">90607000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjc0ODc3OTA3MzkxNg_9e1a4c0c-6dc1-4861-9bf6-80c438196f51">Nature of Business&lt;div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MiMedx Group, Inc. (together with its subsidiaries, except where the context otherwise requires, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MIMEDX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#x201d; or the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, the Company is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company derives its products from human placental tissues and processes these tissues using its proprietary methods, including the PURION&#xae; process. The Company applies Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce its allografts. MIMEDX provides products primarily in the wound care, burn, and surgical recovery sectors of healthcare. All of its products are regulated by the U.S. Food &amp;amp; Drug Administration (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;FDA&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company manages itself as two reportable segments: Wound &amp;amp; Surgical and Regenerative Medicine. Information regarding the principal operations and results of these segments can be found in Note 15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s business is currently focused primarily in the United States. The Company is pursuing opportunities for international expansion, with specific focus on the launch of its placental tissue products in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Enforcement Discretion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the FDA published a series of guidances that established an updated framework for the regulation of cellular and tissue-based products. These guidances clarified the FDA&#x2019;s views about the criteria that differentiate those products subject to regulation solely under Section 361 of the Public Health Service Act (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Section 361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) from those considered to be drugs, devices, and/or biological products subject to licensure under Section 351 of the Public Health Service Act and related regulations. The Company identified its micronized and certain other products (collectively, the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Section 351 products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) as being subject to regulation under Section 351, requiring pre-market approval from the FDA for a specified indication with demonstrated clinical efficacy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FDA exercised enforcement discretion with respect to Investigational New Drug applications and pre-market approval requirements through May 31, 2021. As of May 31, 2021, the Company stopped marketing its Section 351 products in the United States and is precluded from marketing such products until a Biologics License Application (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BLA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) is granted. If and when the FDA approves a BLA, the Company expects to be allowed to market its Section 351 products in the United States again, but only for specific indications as permitted by the FDA. Sales of the Company&#x2019;s Section 351 products were $0.8 million and $0.5&#160;million for the three months ended September&#160;30, 2022 and 2021, respectively, and $1.8&#160;million and $17.2&#160;million for the nine months ended September 30, 2022 and 2021, respectively. Sales of Section 351 products during the three and nine months ended September&#160;30, 2022 were derived from sales outside the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently markets EPICORD&#xae; and AMNIOCOR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;D&#xae; tissue products derived from human umbilical cord as providing a protective environment or as a barrier. If the FDA were to determine that EPICORD and AMNIOCORD do not meet the requirements for regulation solely under Section 361, then pre-market clearance or approval would be required for these products. The loss of the Company&#x2019;s ability to market and sell its umbilical cord-derived products could have an adverse effect on the Company&#x2019;s revenue, business, financial condition, and results of operations. Net sales of the Company&#x2019;s umbilical cord-derived products were $5.7 million and $6.2&#160;million for the three months ended September&#160;30, 2022 and 2021 and $17.2 million and $17.1&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively. The Company&#x2019;s cord inventory, which would be at risk for write-down in the case of such a determination by the FDA, was $1.8&#160;million and $1.9 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjc0ODc3OTA3MzY0OQ_12172f67-b2ca-47fe-b9a6-7cb7221ffded"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64c6f2694f674696aab0be0e9ea8fdcf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjU1Nw_0874cc39-ff17-4ec1-b5f1-19a53884cd97"
      unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d3da0f7b3f74c86bf4b94446691f8cf_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjU2NA_9b87ba3e-7614-4364-8e40-bf0cd5b4006d"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie527d102dd6e4325ad714fa0d48400c5_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjYyMw_6c0d5517-ccbd-41f7-8737-ac1226897c28"
      unitRef="usd">1800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i131cd49a86304288b8b62abaeab421af_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjYzMA_758ff576-ea79-42d3-8aa9-b63be4610dc0"
      unitRef="usd">17200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4df0f9cc41a6412e917f9a0100673e83_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMzQyNg_5c8b7478-4376-47e8-b287-130be4e95b30"
      unitRef="usd">5700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d42aa93cf554f31bdf7957ad6cc2c35_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMjc0ODc3OTA3MzkwMw_37b9e84d-378f-4437-b8d9-72f80e87530f"
      unitRef="usd">6200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacbeb9a9186744ee819f52f94ba86e20_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMzQ3OA_6155f6bc-22f7-4fd7-a399-1ce2141b4183"
      unitRef="usd">17200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81ef134bfecc49ddb64f099bb97426e5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMzQ4NQ_0bda4f03-7067-4a7a-9320-a62b1736e81e"
      unitRef="usd">17100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryNet
      contextRef="if48f5f99a2a84b0bbb4b58930500f84e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMzY1OA_4b0af92e-2927-4871-be83-299218b92449"
      unitRef="usd">1800000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i1b90d323d6c9405688c45fcb1f025c0f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80MC9mcmFnOjc3ZTllZGZlNGJhMTQ3MWViY2M2OTNmZmQ5MWRmMDU5L3RleHRyZWdpb246NzdlOWVkZmU0YmExNDcxZWJjYzY5M2ZmZDkxZGYwNTlfMzY2NQ_453627ed-bd64-498c-be25-292600afe4d4"
      unitRef="usd">1900000</us-gaap:InventoryNet>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMzk0MA_2afb8e87-843e-466d-90d8-d192352e419d">Significant Accounting Policies&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see Note 2 to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;), filed with the Securities and Exchange Commission (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SEC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) on February 28, 2022 for a description of all significant accounting policies.&lt;/span&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GAAP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;The operating results for the three and nine months ended September&#160;30, 2022 and 2021 are not necessarily indicative of the results that may be expected for the full fiscal year.&#160;The balance sheet as of December&#160;31, 2021 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported unaudited condensed consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates regarding asset retirement obligations, estimates for contingent liabilities, estimates related to the Company&#x2019;s assessment of goodwill impairment, the measurement of right of use assets and lease liabilities, management&#x2019;s assessment of the Company&#x2019;s ability to continue as a going concern, estimates of fair value of share-based payments, estimate for allowance for doubtful accounts, estimates of sales returns and allowances, and valuation of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The application of GAAP requires the use of the &#x201c;management approach&#x201d; model for segment reporting. The management approach model is based on the way a company&#x2019;s chief operating decision maker (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CODM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) organizes segments within the Company for which separate, discrete financial information is available regarding resource allocation and assessing performance. The Company has concluded that its Chief Executive Officer (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CEO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) is its CODM. Prior to June 30, 2022, the Company assessed that it operated as one operating and reportable segment. The Company reassesses the existence of operating segments when facts and circumstances suggest that there may have been a change in the way that the Company was managed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;30, 2022, the Company reassessed its operating segments, concluding that the CODM assesses performance and allocates resources between two, distinct reportable segments: Wound &amp;amp; Surgical and Regenerative Medicine. Information regarding the principal operations and results of these segments can be found in Note 15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses goodwill for impairment at least annually on October 1 and more frequently whenever events or substantive changes in circumstances indicate that it is more likely than not that goodwill is impaired. In performing the goodwill impairment test, the Company first assesses qualitative factors to determine the existence of impairment. If the qualitative factors indicate that the carrying value of a reporting unit exceeds its fair value, the Company proceeds to a quantitative test to measure the existence and amount, if any, of goodwill impairment. The Company may also choose to bypass the qualitative assessment and proceed directly to the quantitative test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing the quantitative test, impairment loss is recorded to the extent that the carrying value of the reporting unit exceeds its assessed fair value. The Company determines the fair value using the income and market approaches. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the income approach, the fair value of a reporting unit is the present value of its future cash flows as viewed from the lens of a hypothetical market participant in an orderly transaction. These future cash flows are derived from expectations of revenue, expenses, tax deductions and credits, working capital flows, capital expenditures, and other projected sources and uses of cash, as applicable. Value indications are developed by discounting expected cash flows to their present value using a discount rate commensurate with the risks associated with the reporting unit subject to testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the market approach, the Company uses market multiples derived from the various comparable companies based on measures salient to investors in those companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company concludes that a reporting unit is being managed on the basis of multiple reporting units, the goodwill assigned to the original reporting unit is allocated to the new reporting units based on the relative fair value of the new reporting units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As indicated above, on September 30, 2022, the Company changed its operating segments, determining that it operates as three operating segments. In concert with this re-evaluation, the Company concluded that it has three reporting units. Management performed a goodwill impairment test as of that date on its previous reporting unit, concluding that goodwill was not impaired as of that date. Management subsequently allocated the goodwill assigned to its previous reporting unit to its new reporting units. Refer to Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Intangible Assets, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for information regarding the reallocation of goodwill to the new reporting units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Financial Accounting Standards Board (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;FASB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) issued Accounting Standards Update (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) 2021-10, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832)&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides disclosure requirements regarding government grants and contributions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ASU requires disclosure of the nature of transactions and related accounting policies used to account for transactions, the effect, including amounts, of government assistance on individual line items on the financial statements, and significant terms and conditions of the transactions, including commitments and contingencies. This ASU is effective for fiscal years beginning after December 15, 2021. The Company adopted the provisions of this ASU effective January 1, 2022. There was no impact upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All ASUs issued and not yet effective for the three and nine months ended September&#160;30, 2022, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company&#x2019;s financial position and results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMzk0MQ_d51497dd-8557-4f20-bcc6-5a14f8080dd0">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GAAP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;The operating results for the three and nine months ended September&#160;30, 2022 and 2021 are not necessarily indicative of the results that may be expected for the full fiscal year.&#160;The balance sheet as of December&#160;31, 2021 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMzkyNw_5bac6acf-3a14-45e9-8387-b1be34d9dd71">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported unaudited condensed consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates regarding asset retirement obligations, estimates for contingent liabilities, estimates related to the Company&#x2019;s assessment of goodwill impairment, the measurement of right of use assets and lease liabilities, management&#x2019;s assessment of the Company&#x2019;s ability to continue as a going concern, estimates of fair value of share-based payments, estimate for allowance for doubtful accounts, estimates of sales returns and allowances, and valuation of deferred tax assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMzkzOQ_0cdff72e-6dbc-425d-8df8-72a3ea05f65a">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk1NA_983b67f4-6a52-4e3f-96bd-88829f8351c8">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The application of GAAP requires the use of the &#x201c;management approach&#x201d; model for segment reporting. The management approach model is based on the way a company&#x2019;s chief operating decision maker (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CODM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) organizes segments within the Company for which separate, discrete financial information is available regarding resource allocation and assessing performance. The Company has concluded that its Chief Executive Officer (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CEO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) is its CODM. Prior to June 30, 2022, the Company assessed that it operated as one operating and reportable segment. The Company reassesses the existence of operating segments when facts and circumstances suggest that there may have been a change in the way that the Company was managed.&lt;/span&gt;&lt;/div&gt;On September&#160;30, 2022, the Company reassessed its operating segments, concluding that the CODM assesses performance and allocates resources between two, distinct reportable segments: Wound &amp;amp; Surgical and Regenerative Medicine.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ia9ef31f44ca74b6cb34d09779c82912b_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk5Mg_ab2da8ce-4a1e-4b95-af72-39dd8582f563"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ia9ef31f44ca74b6cb34d09779c82912b_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk5Mg_bb5672d4-e3e3-4aed-8e8f-4f9ad56b84b8"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk5Mw_a3c17ed2-d691-4332-86b4-bcc933782f9c"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk1NQ_ca3d3800-a192-4168-ae0f-79ff9be20c67">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses goodwill for impairment at least annually on October 1 and more frequently whenever events or substantive changes in circumstances indicate that it is more likely than not that goodwill is impaired. In performing the goodwill impairment test, the Company first assesses qualitative factors to determine the existence of impairment. If the qualitative factors indicate that the carrying value of a reporting unit exceeds its fair value, the Company proceeds to a quantitative test to measure the existence and amount, if any, of goodwill impairment. The Company may also choose to bypass the qualitative assessment and proceed directly to the quantitative test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing the quantitative test, impairment loss is recorded to the extent that the carrying value of the reporting unit exceeds its assessed fair value. The Company determines the fair value using the income and market approaches. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the income approach, the fair value of a reporting unit is the present value of its future cash flows as viewed from the lens of a hypothetical market participant in an orderly transaction. These future cash flows are derived from expectations of revenue, expenses, tax deductions and credits, working capital flows, capital expenditures, and other projected sources and uses of cash, as applicable. Value indications are developed by discounting expected cash flows to their present value using a discount rate commensurate with the risks associated with the reporting unit subject to testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the market approach, the Company uses market multiples derived from the various comparable companies based on measures salient to investors in those companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company concludes that a reporting unit is being managed on the basis of multiple reporting units, the goodwill assigned to the original reporting unit is allocated to the new reporting units based on the relative fair value of the new reporting units.&lt;/span&gt;&lt;/div&gt;As indicated above, on September 30, 2022, the Company changed its operating segments, determining that it operates as three operating segments. In concert with this re-evaluation, the Company concluded that it has three reporting units. Management performed a goodwill impairment test as of that date on its previous reporting unit, concluding that goodwill was not impaired as of that date. Management subsequently allocated the goodwill assigned to its previous reporting unit to its new reporting units.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjE5OTAyMzI2OTc5Mw_6b179c54-c1fe-4af5-b318-260379f876ab"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportingUnits
      contextRef="i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMjc0ODc3OTA4Mjk5MQ_24155079-fdd7-432e-98bd-3141184dbc67"
      unitRef="segment">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80My9mcmFnOjU2ZDcwODg4N2JhODQzN2NhMjk1OWQ3NmU0NDE3MTBiL3RleHRyZWdpb246NTZkNzA4ODg3YmE4NDM3Y2EyOTU5ZDc2ZTQ0MTcxMGJfMzkzMw_d99722b8-6063-4564-b52e-32a54d18d054">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Financial Accounting Standards Board (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;FASB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) issued Accounting Standards Update (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) 2021-10, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832)&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides disclosure requirements regarding government grants and contributions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ASU requires disclosure of the nature of transactions and related accounting policies used to account for transactions, the effect, including amounts, of government assistance on individual line items on the financial statements, and significant terms and conditions of the transactions, including commitments and contingencies. This ASU is effective for fiscal years beginning after December 15, 2021. The Company adopted the provisions of this ASU effective January 1, 2022. There was no impact upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All ASUs issued and not yet effective for the three and nine months ended September&#160;30, 2022, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company&#x2019;s financial position and results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsAndNontradeReceivableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfMzc2_ea9d2feb-d5bb-4c9f-929f-5c7f1afb73d7">Accounts Receivable, Net&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bad debt expense, included in selling, general and administrative expense on the condensed consolidated statements of operations, for the three and nine months ended September&#160;30, 2022 was $0.4 million and $2.8 million, respectively. Bad debt expense for the three and nine months ended September&#160;30, 2021 was not significant in either period.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsAndNontradeReceivableTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfMzc3_56093fbc-24e5-47bb-925d-a543dd4bb037">&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMS0xLTEtMS05MDE5NA_69164580-c09d-4453-8835-9640b50fa7a8"
      unitRef="usd">44660000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMS0zLTEtMS05MDE5NA_2a4f309a-f2d4-4abf-83b8-06bc43b30d7f"
      unitRef="usd">41540000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMi0xLTEtMS05MDE5NA_ad4b419d-8983-4217-8e54-1aee86dfac86"
      unitRef="usd">3830000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMi0zLTEtMS05MDE5NA_1b6a80f5-99d3-4672-b254-05913f564974"
      unitRef="usd">1187000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMy0xLTEtMS05MDE5NA_1adec637-4f58-4786-8eda-e770521f9330"
      unitRef="usd">40830000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RhYmxlOjY5YmE0ZmM3NGQ4YTRhM2ZiMjc2YjNlYzA1ZDU0YzA2L3RhYmxlcmFuZ2U6NjliYTRmYzc0ZDhhNGEzZmIyNzZiM2VjMDVkNTRjMDZfMy0zLTEtMS05MDE5NA_2f25ab12-f2f5-4d92-9e27-f4e1841d07f7"
      unitRef="usd">40353000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfMjY5_199e7144-92d6-4e37-a3cf-e2adee3f73d3"
      unitRef="usd">400000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfMjc2_5df9bb6a-b5c4-4bb9-b6ca-6af169010181"
      unitRef="usd">2800000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfNDk0NzgwMjMyNTM3MA_a22854a0-2bc7-4767-ba42-e0867026cd85"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl80OS9mcmFnOjBiMWYyNjUyMDk2NDQyN2FhNjNkZTdjN2E4YTc3YmYzL3RleHRyZWdpb246MGIxZjI2NTIwOTY0NDI3YWE2M2RlN2M3YThhNzdiZjNfNDk0NzgwMjMyNTM3MA_e6ab3fa5-9f6b-49ea-a2f4-1c2ae36631cd"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfNDE1_c319c315-dd26-47b6-8eec-39bec4b3c24f">Inventory&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the conclusion of the FDA&#x2019;s period of Enforcement Discretion on May 31, 2021, the Company wrote-off $1.0 million of its Section 351 product inventory during the nine months ended September 30, 2021. In addition, during the three and nine months ended September 30, 2021, the Company wrote-down $0.5 million and $0.7 million, respectively, for inventory related to product lines which had been discontinued. These amounts are included as part of cost of sales on the unaudited condensed consolidated statements of operations for those periods.&lt;/span&gt;&lt;/div&gt;There were no significant, unusual write-downs of inventory during the three or nine months ended September&#160;30, 2022</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfNDI1_cbd27220-3cb7-46aa-bc19-0ec222ef5e68">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMS0xLTEtMS05MDE5NA_acc82e90-a436-4751-8498-689d2dbfe074"
      unitRef="usd">670000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMS0zLTEtMS05MDE5NA_3847f9de-37b4-4a5a-928f-782fc4680178"
      unitRef="usd">364000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMi0xLTEtMS05MDE5NA_1ed80eb0-344e-4de9-903d-64ff15d36c1b"
      unitRef="usd">7604000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMi0zLTEtMS05MDE5NA_cc36fac6-a559-41aa-a194-96c61dc0fac7"
      unitRef="usd">6112000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMy0xLTEtMS05MDE5NA_009fdaa8-7146-4349-b108-fc9b89aa0f62"
      unitRef="usd">5702000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfMy0zLTEtMS05MDE5NA_a71c2c9b-a7e1-4822-9e6e-23f0a8e8fddf"
      unitRef="usd">4913000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfNi0xLTEtMS05MDE5NA_b2efe1d8-243c-4e12-9165-a4701cac8be5"
      unitRef="usd">13976000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RhYmxlOmFhZDJmYTY5Mjk2ODQzZjY4YTJmYjQ3ZDg2NmY1MGQzL3RhYmxlcmFuZ2U6YWFkMmZhNjkyOTY4NDNmNjhhMmZiNDdkODY2ZjUwZDNfNi0zLTEtMS05MDE5NA_3c6f3345-4028-473c-b5e8-459bb0345dc9"
      unitRef="usd">11389000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="i131cd49a86304288b8b62abaeab421af_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfMTg5_d19acc49-c5f6-4e8d-a4e9-99d8b2fc7140"
      unitRef="usd">1000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfMTY0OTI2NzQ0MjYxNw_4f014d67-5f66-4c85-99be-a9e58ffa19e4"
      unitRef="usd">500000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfMTY0OTI2NzQ0MjYyOQ_8305bec5-c9d1-44d1-8d85-59b952682a26"
      unitRef="usd">700000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfNDk0NzgwMjMyNjMwNA_75d4d1fb-3218-48d2-961a-b1e0948c0cf1"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81Mi9mcmFnOjI3MDgzYjViMWIyYzQ1MWM4Zjc1OGE5N2ZiNzYxOGUxL3RleHRyZWdpb246MjcwODNiNWIxYjJjNDUxYzhmNzU4YTk3ZmI3NjE4ZTFfNDk0NzgwMjMyNjMwNA_af6ea045-aa53-4460-a9ba-ad918c255030"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RleHRyZWdpb246ZTI2MjI4YjYwOTQzNDJiNzk1N2E5NzUxMzM1ZDEwNTBfNDIy_27fdea60-f37b-434e-a646-e94b69d120c8">Property and Equipment, Net&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and clean room equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset retirement cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the three and nine months ended September&#160;30, 2022 and 2021 is summarized in the table below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense is allocated amongst cost of sales, research and development expense, and selling, general, and administrative expense on the unaudited condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RleHRyZWdpb246ZTI2MjI4YjYwOTQzNDJiNzk1N2E5NzUxMzM1ZDEwNTBfNDMz_9c8b9c67-d349-43ce-a2a4-f3acfae9d4f7">&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and clean room equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset retirement cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibc5b133a447a448cbfbd88970beedf99_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMS0xLTEtMS05MDE5NA_0a55387a-5366-48a2-8a8c-9434379828cd"
      unitRef="usd">9190000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i74c78ba1965249998d6dc020ae794009_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMS0zLTEtMS05MDE5NA_5e672848-adc9-4963-aa88-efa48f078686"
      unitRef="usd">9052000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie2e0a68a303f40bba14b646d9df1b2ef_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMi0xLTEtMS05MDE5NA_54a3f76b-21b3-4e5a-b1df-ee5645384cfa"
      unitRef="usd">16302000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i907909b20b2e448c9e0b5b78f71df456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMi0zLTEtMS05MDE5NA_91785763-bc63-4da3-bab2-bf6e65d8d7e4"
      unitRef="usd">16567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5850839a03ec478ab31c891fe1d1573b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMy0xLTEtMS05MDE5NA_c7661937-f874-45a0-aa55-a03e0dc76d27"
      unitRef="usd">14997000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i68aef08154104f7a9e1912924d2a94bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfMy0zLTEtMS05MDE5NA_789fcff7-9b32-4683-acaa-6366496b3dcc"
      unitRef="usd">14975000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3e71c1046d64413295469b7be58e7419_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNC0xLTEtMS05MDE5NA_658158f8-f918-4c31-975a-71bb0b964031"
      unitRef="usd">1383000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia4ace787428240a4aca18f56aebd13d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNC0zLTEtMS05MDE5NA_23ee7649-279c-4bd5-bf13-d11d480b2736"
      unitRef="usd">397000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i89b2e3aad6cd4af1b759a3681f47bf28_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNS0xLTEtMS05MDE5NA_73d216a2-b82f-4986-a368-b4fc853dbcec"
      unitRef="usd">982000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ida2ac468ebe44af2a56555cff32b5007_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNS0zLTEtMS05MDE5NA_8440dc61-b735-45af-96e5-e8aa4cf25cf8"
      unitRef="usd">863000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNi0xLTEtMS05MDE5NA_9f6d7f05-cc9c-49e3-9f19-0c1bc0050abc"
      unitRef="usd">189000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNi0zLTEtMS05MDE5NA_358e059c-d8f6-4804-b397-1ad66e20d279"
      unitRef="usd">189000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNy0xLTEtMS05MDE5NA_7fe275f0-d0bc-4be0-83b2-1debd2c58755"
      unitRef="usd">43043000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfNy0zLTEtMS05MDE5NA_555535be-3f81-4809-8557-f924f540d12b"
      unitRef="usd">42043000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfOC0xLTEtMS05MDE5NA_2035603d-e7f9-452e-a72f-3cb15d111114"
      unitRef="usd">35131000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfOC0zLTEtMS05MDE5NA_e973e8f7-d1e7-44ea-9894-fd6f0731044f"
      unitRef="usd">32878000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfOS0xLTEtMS05MDE5NA_36864f6e-f2e2-4a74-84c2-9f5d16bdaa44"
      unitRef="usd">7912000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjFiOTUwOTFjZGI2YzRhNWZiNGExNzQ4OTFmNjJkZGI3L3RhYmxlcmFuZ2U6MWI5NTA5MWNkYjZjNGE1ZmI0YTE3NDg5MWY2MmRkYjdfOS0zLTEtMS05MDE5NA_eeefd5ec-90c4-4a25-aa78-732cce53808a"
      unitRef="usd">9165000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <mdxg:ScheduleOfDepreciationTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RleHRyZWdpb246ZTI2MjI4YjYwOTQzNDJiNzk1N2E5NzUxMzM1ZDEwNTBfNDM0_137606e8-535c-45c3-84f2-b8e2ab58634b">&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the three and nine months ended September&#160;30, 2022 and 2021 is summarized in the table below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mdxg:ScheduleOfDepreciationTableTextBlock>
    <us-gaap:Depreciation
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjhiODI3NjlkZWYyNzQzODE4NmE5MDU4MDQ4MzIzNmZjL3RhYmxlcmFuZ2U6OGI4Mjc2OWRlZjI3NDM4MTg2YTkwNTgwNDgzMjM2ZmNfMi0xLTEtMS05MDE5NA_ca60018b-e933-4ede-ad20-cfd9ab9bf1e1"
      unitRef="usd">831000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjhiODI3NjlkZWYyNzQzODE4NmE5MDU4MDQ4MzIzNmZjL3RhYmxlcmFuZ2U6OGI4Mjc2OWRlZjI3NDM4MTg2YTkwNTgwNDgzMjM2ZmNfMi0zLTEtMS05MDE5NA_766548c4-d978-4994-a5dc-56953551c8f2"
      unitRef="usd">923000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjhiODI3NjlkZWYyNzQzODE4NmE5MDU4MDQ4MzIzNmZjL3RhYmxlcmFuZ2U6OGI4Mjc2OWRlZjI3NDM4MTg2YTkwNTgwNDgzMjM2ZmNfMi01LTEtMS05MDE5NA_f28cbb48-c497-4bdf-b6e0-cd95bf22c0c2"
      unitRef="usd">2549000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl81NS9mcmFnOmUyNjIyOGI2MDk0MzQyYjc5NTdhOTc1MTMzNWQxMDUwL3RhYmxlOjhiODI3NjlkZWYyNzQzODE4NmE5MDU4MDQ4MzIzNmZjL3RhYmxlcmFuZ2U6OGI4Mjc2OWRlZjI3NDM4MTg2YTkwNTgwNDgzMjM2ZmNfMi03LTEtMS05MDE5NA_9347929b-21ff-42c7-9d4b-b562e76d15f4"
      unitRef="usd">3390000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjk3_03812d5f-e54e-478e-8ece-a4d1d404b343">Goodwill and Intangible Assets, Net&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, the Company had concluded that it operated as a single operating segment and single reporting unit. During the three and nine months ended September 30, 2022, as a result of changes in the management of the Company&#x2019;s business, management concluded that the Company operates as three operating segments, including two distinct reportable segments: Wound &amp;amp; Surgical and Regenerative Medicine. See Note 15 for a description of the Company&#x2019;s operating segments. Management further concluded that it had three reporting units. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the $20.0&#160;million of consolidated goodwill, which was entirely allocated to its previous reporting unit, to each of Wound &amp;amp; Surgical and Regenerative Medicine based on their relative fair values from a market participant standpoint. The result was $19.5 million and $0.5 million allocated to Wound &amp;amp; Surgical and Regenerative Medicine, respectively. A third reporting unit associated with the Company&#x2019;s third operating segment was deemed immaterial and no goodwill was assigned to it. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed goodwill impairment tests using the Company&#x2019;s single reporting unit and the new reporting units. In all cases, the Company concluded that the estimated fair values of each reporting unit exceeded their respective carrying values. Therefore, the Company did not record impairment for goodwill during the three or nine months ended September 30, 2022. There was no other activity related to goodwill during the three or nine months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net, are summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and know-how&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tradenames and trademarks&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents in Process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for the three and nine months ended September 30, 2022 and 2021 is summarized in the table below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected future amortization of intangible assets as of September&#160;30, 2022, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated&lt;br/&gt;Amortization &lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the nine months ended September 30, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI2MTUwMQ_443d8121-fd3d-4c9f-b0e3-055714c80d02"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI2MTUwMQ_a113c65c-5a93-48b4-861d-c65921131191"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI1OTc2OA_292f9d38-6d9c-40cb-8bd2-41e1ddc34d37"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI1OTc2OA_966903ef-6a75-4214-a183-d05eb1c81b87"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportingUnits
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI2MDU2Mw_4a2b205c-a68f-45ba-a84e-b2d93a9cf758"
      unitRef="segment">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfReportingUnits
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI2MDU2Mw_75be6a99-918e-4753-a89a-0b2208c0e865"
      unitRef="segment">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:Goodwill
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjE5OTAyMzI2MzAyNw_5fd48bd6-c47d-4789-9723-e10b923cb5d9"
      unitRef="usd">20000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia0104112777e4d14bd77bb3e2902b0a5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMTI2NDQzODM3MjY0MjY_f26ae2fb-4d07-440d-922c-77da6a25ce7b"
      unitRef="usd">19500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0ffd915aa45d4727b23956af58280014_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMTI2NDQzODM3MjY0ODY_09dae41c-90c5-414a-8f60-98ba9cc8891c"
      unitRef="usd">500000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjky_734bebad-670d-4d50-85fa-acd9614f3589">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net, are summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and know-how&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tradenames and trademarks&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents in Process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for the three and nine months ended September 30, 2022 and 2021 is summarized in the table below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjc5_b70f7d7b-fd73-4892-875b-e064cfe807f5">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net, are summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and know-how&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tradenames and trademarks&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents in Process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia6136baa90f844b998d36da85b2453db_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy0xLTEtMS05MDE5NA_e717ad6c-8c80-4c37-a3c2-23f496c718b7"
      unitRef="usd">9810000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia6136baa90f844b998d36da85b2453db_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy0yLTEtMS05MDE5NA_d133a86d-249a-43e6-a0d8-6e586e7bbbbf"
      unitRef="usd">6928000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia6136baa90f844b998d36da85b2453db_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy0zLTEtMS05MDE5NA_2a164aa1-dea8-42e5-848c-c2c5a96b397c"
      unitRef="usd">2882000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i659a8e16e9c94e5a93efa999dc1cca89_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy01LTEtMS05MDE5NA_cbebcf21-7832-4478-b9c9-0f6b270dc3e6"
      unitRef="usd">9578000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i659a8e16e9c94e5a93efa999dc1cca89_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy02LTEtMS05MDE5NA_b6667252-9118-4525-9628-6dd5a1b5615d"
      unitRef="usd">6408000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i659a8e16e9c94e5a93efa999dc1cca89_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMy03LTEtMS05MDE5NA_21117fed-d8f1-4608-8898-a7de1bdf960a"
      unitRef="usd">3170000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6bb08258960c42db90551aecd2db413d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTAtMS0xLTEtOTAxOTQ_10562fbf-fdce-41b2-a570-18b8f7008ae4"
      unitRef="usd">1008000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6bb08258960c42db90551aecd2db413d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTAtMy0xLTEtOTAxOTQ_6ed25df1-38f9-4ddd-a0f5-0dd9fa0f56b4"
      unitRef="usd">1008000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iec6c48c7387b4e87940f4064398a14df_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTAtNS0xLTEtOTAxOTQ_128d2803-49e4-44c0-be52-36bcf8f97eb7"
      unitRef="usd">1008000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iec6c48c7387b4e87940f4064398a14df_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTAtNy0xLTEtOTAxOTQ_88e4d483-b43c-485a-b509-1c4679da6602"
      unitRef="usd">1008000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iddd1d1c82ab24631a37cd041c9a9dbe2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTEtMS0xLTEtOTAxOTQ_3b018d2a-96e4-41dd-902b-01d80dab67e3"
      unitRef="usd">1102000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iddd1d1c82ab24631a37cd041c9a9dbe2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTEtMy0xLTEtOTAxOTQ_e4e24344-e4bc-4406-b3b2-de454865a9b3"
      unitRef="usd">1102000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4963e235cc9f495d91c3496c848f2cdb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTEtNS0xLTEtOTAxOTQ_acdea93a-0956-403a-93a4-d911cad0cd3e"
      unitRef="usd">1205000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4963e235cc9f495d91c3496c848f2cdb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTEtNy0xLTEtOTAxOTQ_60759c4a-cccf-4f97-94fc-01e8bacc5531"
      unitRef="usd">1205000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTItMS0xLTEtOTAxOTQ_381599d9-a283-4903-8d1e-a8c153df5c3e"
      unitRef="usd">11920000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTItMy0xLTEtOTAxOTQ_34da7b5b-9af1-45c7-9f7c-c9c5e8a1610c"
      unitRef="usd">4992000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTItNS0xLTEtOTAxOTQ_ea12fcd9-eaf1-454d-abca-02cdbf2185a2"
      unitRef="usd">11791000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjc1ZDFhMmIyMjU1ZTRlN2M5M2IzNjg3MWI1YjAwNmMxL3RhYmxlcmFuZ2U6NzVkMWEyYjIyNTVlNGU3YzkzYjM2ODcxYjViMDA2YzFfMTItNy0xLTEtOTAxOTQ_d4f11fc2-5a51-439d-920e-aa36448636c5"
      unitRef="usd">5383000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjAyYTBlZTZhODBmYTQ0MmI4Y2YxZGU2ZWE1NjZlOTkwL3RhYmxlcmFuZ2U6MDJhMGVlNmE4MGZhNDQyYjhjZjFkZTZlYTU2NmU5OTBfMi0xLTEtMS05MDE5NA_ecb678e2-85e0-494b-8aac-686515841fc8"
      unitRef="usd">175000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjAyYTBlZTZhODBmYTQ0MmI4Y2YxZGU2ZWE1NjZlOTkwL3RhYmxlcmFuZ2U6MDJhMGVlNmE4MGZhNDQyYjhjZjFkZTZlYTU2NmU5OTBfMi0zLTEtMS05MDE5NA_072ce126-4765-45ee-b170-6680df750884"
      unitRef="usd">193000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjAyYTBlZTZhODBmYTQ0MmI4Y2YxZGU2ZWE1NjZlOTkwL3RhYmxlcmFuZ2U6MDJhMGVlNmE4MGZhNDQyYjhjZjFkZTZlYTU2NmU5OTBfMi01LTEtMS05MDE5NA_9aa894c3-f52d-418a-990f-aafe1a864caf"
      unitRef="usd">519000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOjAyYTBlZTZhODBmYTQ0MmI4Y2YxZGU2ZWE1NjZlOTkwL3RhYmxlcmFuZ2U6MDJhMGVlNmE4MGZhNDQyYjhjZjFkZTZlYTU2NmU5OTBfMi03LTEtMS05MDE5NA_815a0aef-17d3-4c74-a64e-ac06e32039cc"
      unitRef="usd">647000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RleHRyZWdpb246YTFmOGNkNjIyMTgyNDQwMjhiYmYzY2RmZjhkNWE2MjJfMjk1_8b1809c7-904b-4807-ad24-138b08a22459">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected future amortization of intangible assets as of September&#160;30, 2022, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated&lt;br/&gt;Amortization &lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the nine months ended September 30, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfMS0xLTEtMS05MDE5NA_93c82161-33b6-4e7f-ad89-0ac744f698c3"
      unitRef="usd">174000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfMi0xLTEtMS05MDE5NA_bda20683-c9c9-4d51-9924-e67f02255ab4"
      unitRef="usd">698000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfMy0xLTEtMS05MDE5NA_9a20f31a-0cbe-43b4-83cf-0a18b481be4d"
      unitRef="usd">698000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfNC0xLTEtMS05MDE5NA_e5898bb4-fe46-43d1-910e-95ebca527704"
      unitRef="usd">303000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfNS0xLTEtMS05MDE5NA_abe434ed-3e3e-48ae-840d-cbcf1a01f8c4"
      unitRef="usd">148000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <mdxg:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfNi0xLTEtMS05MDE5NA_2623a19d-1124-4526-91fc-1cfd20ded703"
      unitRef="usd">861000</mdxg:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82MS9mcmFnOmExZjhjZDYyMjE4MjQ0MDI4YmJmM2NkZmY4ZDVhNjIyL3RhYmxlOmNiZjQ0NzZkZTQ1NzQ1ZDFhMmQzNzcxYjg1ODZlODM0L3RhYmxlcmFuZ2U6Y2JmNDQ3NmRlNDU3NDVkMWEyZDM3NzFiODU4NmU4MzRfNy0xLTEtMS05MDE5NA_5eb02a74-9dec-40d7-9ab3-d2730699a2c0"
      unitRef="usd">2882000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RleHRyZWdpb246NzQ4NDgxZjRjODNjNGIwMjg5NTljYjAwY2I0MTM5MTRfOTA_d8aac797-201d-4206-9f72-8638f328017d">Accrued Expenses&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&#160;consisted of the following&#160;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and settlement costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commissions to sales agents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued group purchasing organization fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued travel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RleHRyZWdpb246NzQ4NDgxZjRjODNjNGIwMjg5NTljYjAwY2I0MTM5MTRfOTE_fbdd7350-d9bc-441c-b0f0-e285b9ce7709">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&#160;consisted of the following&#160;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and settlement costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commissions to sales agents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued group purchasing organization fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued travel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMS0xLTEtMS05MDE5NA_c3499187-b375-45c3-a413-3c391b28468a"
      unitRef="usd">4185000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMS0zLTEtMS05MDE5NA_526161ad-bf47-4bda-94bb-0a3d31c51093"
      unitRef="usd">2806000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMy0xLTEtMS05MDE5NA_0b1d5982-eb0e-4cc0-9414-0c085150b22f"
      unitRef="usd">2238000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMy0zLTEtMS05MDE5NA_706043ed-9305-487c-abc9-b9ddd26c5661"
      unitRef="usd">2630000</us-gaap:AccruedSalesCommissionCurrent>
    <mdxg:AccruedRebates
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNC0xLTEtMS05NDY0Mw_d63fa2b6-c6f3-4179-a152-68cacba01e50"
      unitRef="usd">878000</mdxg:AccruedRebates>
    <mdxg:AccruedRebates
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNC0zLTEtMS05NDY0Mw_58e18f50-71a9-4dde-8c52-9343d2d73e88"
      unitRef="usd">1343000</mdxg:AccruedRebates>
    <mdxg:AccruedAdministrativeFeesCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNC0xLTEtMS05MDE5NA_64c7770c-e1e2-43a9-bfee-5a5b076b6874"
      unitRef="usd">616000</mdxg:AccruedAdministrativeFeesCurrent>
    <mdxg:AccruedAdministrativeFeesCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNC0zLTEtMS05MDE5NA_2e0fe34f-d727-4b59-806e-f72ce6fe778b"
      unitRef="usd">559000</mdxg:AccruedAdministrativeFeesCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNS0xLTEtMS05MDE5NA_7acce63b-5504-46b7-9d5b-9c2b539bf831"
      unitRef="usd">999000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNS0zLTEtMS05MDE5NA_4b09ceac-e8a9-48c2-b370-cba0a0db99ea"
      unitRef="usd">788000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <mdxg:AccruedTravel
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNi0xLTEtMS05MDE5NA_d25efe01-01f2-4a60-bf04-5742aa6d6dd2"
      unitRef="usd">402000</mdxg:AccruedTravel>
    <mdxg:AccruedTravel
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNi0zLTEtMS05MDE5NA_93f62dde-0056-462f-a733-16e87c83128e"
      unitRef="usd">385000</mdxg:AccruedTravel>
    <mdxg:AccruedClinicalTrialsCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNy0xLTEtMS05MDE5NA_dd5249ea-06c4-4f71-99fc-b5a3110e643f"
      unitRef="usd">214000</mdxg:AccruedClinicalTrialsCurrent>
    <mdxg:AccruedClinicalTrialsCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfNy0zLTEtMS05MDE5NA_d068731d-e455-4075-a622-99e5e9eab25e"
      unitRef="usd">694000</mdxg:AccruedClinicalTrialsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfOS0xLTEtMS05MDE5NA_b8ea42d5-9f86-40cc-abe1-5e73bf8a8b0d"
      unitRef="usd">1454000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfOS0zLTEtMS05MDE5NA_c1428516-0e3e-4ca9-b14f-707379027632"
      unitRef="usd">607000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMTAtMS0xLTEtOTAxOTQ_ec51b82c-52bb-408b-b299-9506e535bd71"
      unitRef="usd">10986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82NC9mcmFnOjc0ODQ4MWY0YzgzYzRiMDI4OTU5Y2IwMGNiNDEzOTE0L3RhYmxlOmI2ZWRjZTNiMWE2OTRmOTZiOTMyMzFkNTY5MmFlZjBjL3RhYmxlcmFuZ2U6YjZlZGNlM2IxYTY5NGY5NmI5MzIzMWQ1NjkyYWVmMGNfMTAtMy0xLTEtOTAxOTQ_f9ea00c1-e262-430a-8dcf-6e4403f65bbe"
      unitRef="usd">9812000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjc2MQ_5fa692ea-bc6d-4217-a30c-3837cd490b24">Long Term Debt, Net&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hayfin Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2020, the Company entered into a Loan Agreement with, among others, Hayfin Services, LLP (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hayfin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;), an affiliate of Hayfin Capital Management LLP (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hayfin Loan Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;), which Hayfin funded on July 2, 2020 (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Closing Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;), providing the Company with a senior secured term loan in an aggregate amount of $50&#160;million (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Term Loan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The Term Loan matures on June 30, 2025 (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Maturity Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). Interest is payable on the Term Loan for the principal balance outstanding quarterly through the Maturity Date. No principal payments on the Term Loan are due and payable until the Maturity Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Hayfin Loan Agreement also provided the Company an option to draw on an additional delayed draw term loan (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;DD TL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#x201d; collectively with the Term Loan, the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) in the form of a committed but undrawn facility until June 30, 2021. The Company did not exercise the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2022 (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amendment Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;), the Company executed an Amendment to the Hayfin Loan Agreement (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amendment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The Amendment was accounted for as a modification. No gain or loss was recognized nor was there a change to the carrying amount of the debt as a result of the Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on any borrowings under the Hayfin Loan Agreement, as amended (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended Hayfin Loan Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;), is equal to the London Interbank Offered Rate (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;LIBOR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) (subject to a floor of 1.5%), plus a margin of 6.75% per annum. If LIBOR is unavailable, the Term Loan will carry interest at the 6.75% margin plus the greatest of the Prime Rate, the Federal Funds Rate plus 0.5% per annum, and 2.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An additional 3.0% margin is applied to the interest rate in the event of a default as defined in the Amended Hayfin Loan Agreement. The Term Loan carried an interest rate of 8.3% at issuance and 10.4% as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Hayfin Loan Agreement, contains financial covenants requiring the Company, on a consolidated basis, to maintain the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Minimum Consolidated Total Net Sales (as defined in the Amended Hayfin Loan Agreement) of varying amounts, required to be calculated on a quarterly basis, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Minimum Liquidity (as defined in the Amended Hayfin Loan Agreement) of $20 million, an at-all-times financial covenant tested monthly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company is in compliance with all applicable financial covenants under the Amended Hayfin Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Hayfin Loan Agreement also includes certain negative covenants and events of default customary for facilities of this type, and upon the occurrence of such events of default, subject to customary cure rights, the Term Loan may be accelerated or the lenders&#x2019; commitments terminated. Mandatory prepayments are also required in the event of a change in control, incurring other indebtedness, certain proceeds from disposal of assets and insured casualty event (as defined in the Amended Hayfin Loan Agreement). Annually, beginning with the fiscal year ended December 31, 2021, the Company is required to prepay the outstanding loans based on a percentage of Excess Cash Flow (as defined in the Amended Hayfin Loan Agreement), if such is generated. No such prepayments have been required as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A breach of a financial covenant in the Amended Hayfin Loan Agreement, if uncured or unable to be cured, would likely result in an event of default that could trigger the lender&#x2019;s remedies, including acceleration of the entire principal balance of the loan as well as any applicable prepayment premiums.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Hayfin Loan Agreement also specifies that any prepayment of the Term Loan, voluntary or mandatory, will subject the Company to a prepayment premium applicable as of the date of the prepayment as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On or before July 2, 2023: 2% of the principal balance repaid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;After July 2, 2023 and on or before July 2, 2024: 1% of the principal balance repaid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;After July 2, 2024: no premium.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hayfin maintains a first-priority security interest in substantially all of the Company&#x2019;s assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Original issue discount and deferred financing costs were allocated between the sale of the Series B Preferred Stock (which occurred on the same day as the funding of the Hayfin Loan Agreement as described in Note 10) and the Hayfin Loan Agreement on the basis of the relative fair values of the transactions. The costs allocated to the Hayfin Loan Agreement were further allocated between the Term Loan and the DD TL on the basis of the maximum potential principal outstanding between the Credit Facilities. The allocation of the deferred financing costs and original issue discount between the Term Loan and the DD TL on July 2, 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.263%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DD TL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original issue discount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs and original issue discount associated with the Term Loan are amortized using the effective interest method through the Maturity Date. The amortization of such amounts is presented as part of interest expense, net on the unaudited condensed consolidated statement of operations. Unamortized deferred financing costs and original issue discount associated with the Term Loan are presented as a reduction to the principal balance on the Term Loan as part of long term debt, net on the unaudited condensed consolidated balance sheets as of September&#160;30, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs and original issue discount associated with the DD TL were amortized using the straight-line method through the expiration of the DD TL commitment term on June 30, 2021. Amortization of these amounts is presented as part of interest expense, net on the unaudited condensed consolidated statement of operations for the nine months ended September 30, 2021. The DD TL was subject to a commitment fee of 1% per annum of the amount undrawn, which was recognized as interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balances of the Term Loan as of September&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original issue discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to the Term Loan, included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stated interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of original issue discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to the DD TL, included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commitment fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of original issue discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of principal payments due on the Term Loan, by year, from September&#160;30, 2022 through maturity are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the nine months ended September&#160;30, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the fair value of the Term Loan was $44.7&#160;million. This valuation was calculated based on a series of Level 2 and Level 3 inputs, including a discount rate based on the credit risk spread of debt instruments of similar risk character in reference to U.S. Treasury instruments with similar maturities, with an incremental risk premium for risk factors specific to the Company. The remaining cash flows associated with the Term Loan were discounted to September&#160;30, 2022 using this discount rate to determine fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMzg2_0b259269-84a4-484c-b0d5-5abbf92f4934"
      unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <mdxg:DebtInstrumentInterestRateFloorPercentage
      contextRef="ida0d445363084e00b087a41a67afce57_D20220228-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTQ0MQ_1ab51810-95d5-43fe-9bc2-c833d411913c"
      unitRef="number">0.015</mdxg:DebtInstrumentInterestRateFloorPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ida0d445363084e00b087a41a67afce57_D20220228-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTQ2Mg_f25f1251-d78f-44f9-bea4-a793f155b56e"
      unitRef="number">0.0675</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ida0d445363084e00b087a41a67afce57_D20220228-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTU0Mg_f25f1251-d78f-44f9-bea4-a793f155b56e"
      unitRef="number">0.0675</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i78a81d5053e240d4b3ca17890dd5c28f_D20220228-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTYxNw_29b4dda6-3f6d-42ab-bf10-ef58cdd851fc"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i19941ad137e24c988a6625220a34fbe7_D20220228-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTYzNQ_7d882433-d2b1-4eb1-a7eb-872397943dbd"
      unitRef="number">0.025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <mdxg:DebtInstrumentDefaultInterestRate
      contextRef="ida0d445363084e00b087a41a67afce57_D20220228-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTY1Mw_d692de87-a7ab-4b52-91f4-94e730d7d5b0"
      unitRef="number">0.030</mdxg:DebtInstrumentDefaultInterestRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTgxMg_c2402cb5-8b87-4006-9dd0-2fa93b703cb8"
      unitRef="number">0.083</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ied1ef014d51f4e56b7b022759ec9dc30_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMTgzMg_9262ebc9-daa0-443d-9ab9-aaa9dbcc6210"
      unitRef="number">0.104</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <mdxg:DebtCovenantMinimumLiquidity
      contextRef="i5ca2668ba8fb4aa5a0b452209fcbf752_D20220228-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMjIxNg_5dbeef5b-ad97-49fc-93e1-315af3fd69ab"
      unitRef="usd">20000000</mdxg:DebtCovenantMinimumLiquidity>
    <mdxg:DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent
      contextRef="i2747f527fb9748c58c87520ae15d6b71_D20220228-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMzcxMg_994b69e6-abed-4f1c-a0bd-e8f4f8424d2a"
      unitRef="number">0.02</mdxg:DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent>
    <mdxg:DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent
      contextRef="i113d9f8cbf62488ba9b7295966501570_D20220228-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMzc5OA_b2c8f930-e799-4ddb-b1b3-bfa7430440c9"
      unitRef="number">0.01</mdxg:DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent>
    <mdxg:DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent
      contextRef="if13a467d34074320a376b1a5273913b3_D20220228-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfMzg1NA_3e575920-5f6f-42f7-ac2a-14e4ee385871"
      unitRef="number">0</mdxg:DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent>
    <mdxg:ScheduleOfDebtIssuanceCostsTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjc2Nw_0fa92771-6de8-4b33-85e8-d3ce71829747">The allocation of the deferred financing costs and original issue discount between the Term Loan and the DD TL on July 2, 2020 was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.263%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DD TL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original issue discount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mdxg:ScheduleOfDebtIssuanceCostsTableTextBlock>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfMy0xLTEtMS05MDE5NA_8eb6e66c-927c-4dd9-847a-60300c6fcbef"
      unitRef="usd">333000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iddda1184b02a44928b0c26d038f76bca_I20200702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfMy0zLTEtMS05MDE5NA_cf9df8e7-1162-470a-bb6e-fd63c58acfe7"
      unitRef="usd">167000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ic01dffba8325446a929870e45228e37c_I20200702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfMy01LTEtMS05MDE5NA_4869010c-96d9-45b9-b597-7684e531c6b0"
      unitRef="usd">500000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfNC0xLTEtMS05MDE5NA_576ca5ac-d47c-4543-9796-854b50abb1d6"
      unitRef="usd">2169000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="iddda1184b02a44928b0c26d038f76bca_I20200702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfNC0zLTEtMS05MDE5NA_2dffd4b3-37ec-421a-a23a-12ebcbe450c8"
      unitRef="usd">1084000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ic01dffba8325446a929870e45228e37c_I20200702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmY3YzgwNDE1NWZlODQzYjBiMGJlMjc2MDAxYmZmOGNiL3RhYmxlcmFuZ2U6ZjdjODA0MTU1ZmU4NDNiMGIwYmUyNzYwMDFiZmY4Y2JfNC01LTEtMS05MDE5NA_171dfed9-7a60-4b2f-bfed-9deae918aa50"
      unitRef="usd">3253000</us-gaap:DeferredFinanceCostsGross>
    <mdxg:DebtInstrumentUnusedCapacityCommitmentFeePercentage
      contextRef="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNTYyNQ_cfd0956f-1007-447c-b347-f93f47e38b33"
      unitRef="number">0.01</mdxg:DebtInstrumentUnusedCapacityCommitmentFeePercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjc2NA_9c85174a-615e-47d1-870a-8cdc81f09e32">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balances of the Term Loan as of September&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original issue discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ied1ef014d51f4e56b7b022759ec9dc30_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMS0xLTEtMS05MDE5NA_0c27408a-d05b-488e-9ab6-532f449ab6fe"
      unitRef="usd">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iea70269e38be47efb68e17ebedd54b55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMS0zLTEtMS05MDE5NA_aadce124-63dd-4c78-ba18-b27bd1a107aa"
      unitRef="usd">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ied1ef014d51f4e56b7b022759ec9dc30_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMi0xLTEtMS05MDE5NA_862775b4-525f-463b-9d8e-bc8659fe03f5"
      unitRef="usd">1322000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="iea70269e38be47efb68e17ebedd54b55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMi0zLTEtMS05MDE5NA_f85ddb24-243f-4251-90c8-089a210e10a0"
      unitRef="usd">1624000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ied1ef014d51f4e56b7b022759ec9dc30_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMy0xLTEtMS05MDE5NA_2e645275-3ec0-4fee-bd75-ba610684afaf"
      unitRef="usd">203000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iea70269e38be47efb68e17ebedd54b55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfMy0zLTEtMS05MDE5NA_81387de9-594f-428e-b1c0-75343bbd85a2"
      unitRef="usd">249000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="ied1ef014d51f4e56b7b022759ec9dc30_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfNC0xLTEtMS05MDE5NA_74b5485e-7515-4aa1-8712-6722532ea983"
      unitRef="usd">48475000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iea70269e38be47efb68e17ebedd54b55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmUzODA0NGRkZjIwMTQ4MzlhZWFlNWIxNWYxM2QwYjcwL3RhYmxlcmFuZ2U6ZTM4MDQ0ZGRmMjAxNDgzOWFlYWU1YjE1ZjEzZDBiNzBfNC0zLTEtMS05MDE5NA_7160f34e-c7dd-449e-b7fc-172acd9e7675"
      unitRef="usd">48127000</us-gaap:LongTermDebt>
    <mdxg:ScheduleOfInterestExpenseTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjc2OA_19a66f5b-3f25-405e-bd36-f57b6d439ab3">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to the Term Loan, included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stated interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of original issue discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to the DD TL, included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commitment fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of original issue discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mdxg:ScheduleOfInterestExpenseTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMi0xLTEtMS05MDE5NA_16a2cb8e-0836-4e6e-84fd-f765d59df7ac"
      unitRef="usd">1151000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i06158252259a4bb1be9943fc4f9b8256_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMi0zLTEtMS05MDE5NA_225c5c87-f8fe-4213-ae34-13bac9997267"
      unitRef="usd">1054000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ie32894e2f8cb4b40bf661b269dd42436_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMi01LTEtMS05MDE5NA_a886e3f7-055a-4888-88f4-c508ca44af07"
      unitRef="usd">3225000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i5db0a9efc4324b35ab710da5c792ca3e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMi03LTEtMS05MDE5NA_02f62d58-c00c-4fcd-af82-6be9ee87f4fb"
      unitRef="usd">3116000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMy0xLTEtMS05MDE5NA_f9f052d0-f902-46f8-bc9f-2b38d30287d1"
      unitRef="usd">103000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i06158252259a4bb1be9943fc4f9b8256_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMy0zLTEtMS05MDE5NA_afb7e5d0-a65d-44ce-8ef2-e3d7f49e86fc"
      unitRef="usd">95000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ie32894e2f8cb4b40bf661b269dd42436_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMy01LTEtMS05MDE5NA_9ecb9fe7-721f-45be-83df-315cd08bff5e"
      unitRef="usd">302000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i5db0a9efc4324b35ab710da5c792ca3e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfMy03LTEtMS05MDE5NA_1eb9c85f-d97e-43ff-b88e-093229097bca"
      unitRef="usd">276000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNC0xLTEtMS05MDE5NA_5b9240e1-4278-4228-afac-5b0394c7c8bf"
      unitRef="usd">16000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i06158252259a4bb1be9943fc4f9b8256_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNC0zLTEtMS05MDE5NA_01fb905d-121c-423e-8d59-bb76a51b418c"
      unitRef="usd">15000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ie32894e2f8cb4b40bf661b269dd42436_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNC01LTEtMS05MDE5NA_74dd4d13-90af-4d32-ae0b-6dc753d530fa"
      unitRef="usd">46000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i5db0a9efc4324b35ab710da5c792ca3e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNC03LTEtMS05MDE5NA_55a167b1-c684-4232-a5b3-825bc0445477"
      unitRef="usd">42000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNS0xLTEtMS05MDE5NA_d2a836a8-d089-4925-a3fe-79ccf90bbb27"
      unitRef="usd">1270000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i06158252259a4bb1be9943fc4f9b8256_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNS0zLTEtMS05MDE5NA_60f89a52-b091-492e-8120-20f4ce873a3f"
      unitRef="usd">1164000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ie32894e2f8cb4b40bf661b269dd42436_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNS01LTEtMS05MDE5NA_17ff5415-c9f9-4c04-aac0-926ed4741600"
      unitRef="usd">3573000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i5db0a9efc4324b35ab710da5c792ca3e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjVkYWNkMDU2ZWExODQ0MzE5OGE1ZmJlYjc1Y2MwMDUwL3RhYmxlcmFuZ2U6NWRhY2QwNTZlYTE4NDQzMTk4YTVmYmViNzVjYzAwNTBfNS03LTEtMS05MDE5NA_c144bdc9-64f1-41e4-b01c-f4939865c777"
      unitRef="usd">3434000</us-gaap:InterestExpenseDebt>
    <mdxg:DebtInstrumentCommitmentFees
      contextRef="i4ae78b34019f45208b00a4a3385ba0bf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMi0xLTEtMS05MDE5NA_68185efa-9941-4788-a891-3e6cfb399c1d"
      unitRef="usd">0</mdxg:DebtInstrumentCommitmentFees>
    <mdxg:DebtInstrumentCommitmentFees
      contextRef="i8ed176b1136d4fa38e04ca50f5c1469a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMi0zLTEtMS05MDE5NA_dd7978e8-8f94-4ad3-91ab-b36ce5d5ec28"
      unitRef="usd">0</mdxg:DebtInstrumentCommitmentFees>
    <mdxg:DebtInstrumentCommitmentFees
      contextRef="iaa56b9335b624293aeb4786b43d54f20_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMi01LTEtMS05MDE5NA_06ec32cd-4c9b-4d30-8398-52e8433671b9"
      unitRef="usd">0</mdxg:DebtInstrumentCommitmentFees>
    <mdxg:DebtInstrumentCommitmentFees
      contextRef="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMi03LTEtMS05MDE5NA_fd1fa013-010f-41aa-a458-ddda231e1245"
      unitRef="usd">126000</mdxg:DebtInstrumentCommitmentFees>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4ae78b34019f45208b00a4a3385ba0bf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMy0xLTEtMS05MDE5NA_cf5c70e7-9eff-4f2a-865a-0ed3e8899166"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i8ed176b1136d4fa38e04ca50f5c1469a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMy0zLTEtMS05MDE5NA_6f380b88-710b-4959-9baf-19bc849581a8"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iaa56b9335b624293aeb4786b43d54f20_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMy01LTEtMS05MDE5NA_e434433e-8155-492f-8455-35f3af0d4502"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfMy03LTEtMS05MDE5NA_daa26dce-9ebd-47d3-8702-5e1f19983d03"
      unitRef="usd">542000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i4ae78b34019f45208b00a4a3385ba0bf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNC0xLTEtMS05MDE5NA_24ebf47d-b1ae-4b0f-8ded-63a3101c3294"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i8ed176b1136d4fa38e04ca50f5c1469a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNC0zLTEtMS05MDE5NA_139130a2-f02e-46a5-a095-87125be7bb81"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="iaa56b9335b624293aeb4786b43d54f20_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNC01LTEtMS05MDE5NA_69036717-a79c-4179-9acd-b980bcc519e9"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNC03LTEtMS05MDE5NA_9f0afe7f-a946-4398-bed0-2675e79742ab"
      unitRef="usd">83000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="i4ae78b34019f45208b00a4a3385ba0bf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNS0xLTEtMS05MDE5NA_1c1d2f6a-2dec-400f-8cd3-1db43960e1b3"
      unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i8ed176b1136d4fa38e04ca50f5c1469a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNS0zLTEtMS05MDE5NA_0d8cf607-42ab-43f9-8003-dfa506c79197"
      unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="iaa56b9335b624293aeb4786b43d54f20_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNS01LTEtMS05MDE5NA_283aea11-c5ee-4143-aa8b-09359dbb7660"
      unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9e6b7ae82f1e4bfaa60f649b4c05855e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOmFmMWRlY2NlNWIzOTRmYWY4ZTc0NjJlNDU5Yjg0OWQ2L3RhYmxlcmFuZ2U6YWYxZGVjY2U1YjM5NGZhZjhlNzQ2MmU0NTliODQ5ZDZfNS03LTEtMS05MDE5NA_518f725a-7cee-4749-a363-d7ed436cc14b"
      unitRef="usd">751000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjc2OQ_fa5a10fd-0224-41dc-9cf3-c72cd1617f6f">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of principal payments due on the Term Loan, by year, from September&#160;30, 2022 through maturity are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the nine months ended September&#160;30, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfMS0xLTEtMS05MDE5NA_f7dccd7d-fc0b-4e5d-a4a4-e5df678ba0f0"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfMi0xLTEtMS05MDE5NA_1eece9f3-cfdf-41c2-a63e-24331337793b"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfMy0xLTEtMS05MDE5NA_e12464e0-5a62-4cdc-8fae-971e91297884"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfNC0xLTEtMS05MDE5NA_8e8370ae-e3ca-4be9-9783-75a63fd6e18a"
      unitRef="usd">50000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfNS0xLTEtMS05MDE5NA_8525376a-b5d9-48e8-bb53-e17bc2d20049"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <mdxg:LongTermDebtMaturityAfterYearFour
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfNi0xLTEtMS05MDE5NA_86692126-954c-4961-960a-c538831e4a46"
      unitRef="usd">0</mdxg:LongTermDebtMaturityAfterYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RhYmxlOjI3YTJjZjIzNGQzNTQ1OTJiMTI3MWY4ZDNjZTBmM2RlL3RhYmxlcmFuZ2U6MjdhMmNmMjM0ZDM1NDU5MmIxMjcxZjhkM2NlMGYzZGVfNy0xLTEtMS05MDE5NA_5c86d873-68b0-4ccf-a8f9-b60607b88107"
      unitRef="usd">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="i4c8e4da241644f84bd4f549f2c4d5255_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl82Ny9mcmFnOjM2ZjU2ODJjNGY1ZjRiMTQ5ZWNjNGIxYTkyNjBiMjRmL3RleHRyZWdpb246MzZmNTY4MmM0ZjVmNGIxNDllY2M0YjFhOTI2MGIyNGZfNjMwNg_e963e6ef-f137-4d51-afaa-514ff0769c2a"
      unitRef="usd">44700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RleHRyZWdpb246ZWE2YzIyMGNjY2E4NGExMDlkZmJhNzAzY2E1NGFiZjRfMjQzNw_c039632a-3459-42c3-b5a3-266fbcb0fce0">Net Loss Per Common Share&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per common share is calculated using two methods: basic and diluted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated as net loss available to common stockholders divided by weighted average common shares outstanding. Net loss available to common stockholders is calculated as net loss less (i) dividends accumulated on the Company&#x2019;s Series B Convertible Preferred Stock during the period, and (ii) periodic accretion of the increasing-rate dividend feature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of net loss to net loss available to common stockholders and calculation of basic net loss per common share for each of the three and nine months ended September&#160;30, 2022 and 2021 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile to net loss available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated dividend on Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,613&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of increasing-rate dividend feature&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,448,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,717,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,650,713&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,136,517&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Diluted Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per common share is calculated as net loss available to common stockholders, adjusted for dividends on convertible preferred stock (to the extent conversion would be dilutive), divided by weighted average common shares outstanding plus potential common shares. The calculation of potential common shares considers incremental shares resulting from certain transactions, including the exercise of stock options and the issuance of restricted stock, using the treasury stock method, as well as the hypothetical conversion of the Company&#x2019;s Series B Convertible Preferred Stock using the if-converted method. The treasury stock method assumes that proceeds from the transaction are used to purchase common stock at the average market price throughout the period. The if-converted method adds back periodic accrued or deemed dividends on the Company&#x2019;s Series B Convertible Preferred Stock, and assumes conversion as of the beginning of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each individual transaction is assessed for its dilutive effect on net loss per common share. To the extent that the transaction is antidilutive or does not reduce net loss per common share, the effect is excluded from the calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of diluted net loss per common share (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends on Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: antidilutive adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,448,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,717,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,650,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,136,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,269,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,658,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,858,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,185,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: antidilutive potential common shares (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,269,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,658,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,858,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,185,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding adjusted for potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,448,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,717,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,650,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,136,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Weighted average common shares outstanding for the calculation of diluted net loss per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,685,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,027,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,850,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,497,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,269,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,658,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,858,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,185,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RleHRyZWdpb246ZWE2YzIyMGNjY2E4NGExMDlkZmJhNzAzY2E1NGFiZjRfMjQzNA_ac131eb0-fcae-4d40-95ee-2e3690c89d66">&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of net loss to net loss available to common stockholders and calculation of basic net loss per common share for each of the three and nine months ended September&#160;30, 2022 and 2021 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile to net loss available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated dividend on Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,613&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of increasing-rate dividend feature&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,448,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,717,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,650,713&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,136,517&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfMi0xLTEtMS05MDE5NA_fa3601b2-199a-46be-a446-fe6e6755f314"
      unitRef="usd">-8426000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfMi0zLTEtMS05MDE5NA_f99d2cca-4dd3-4749-b59d-3ae08f559ee4"
      unitRef="usd">-2339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfMi01LTEtMS05MDE5NA_a64fc793-22d0-4382-9433-7fd17aa22c49"
      unitRef="usd">-29783000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfMi03LTEtMS05MDE5NA_b93fb229-62e5-4609-84be-84f077ebd74f"
      unitRef="usd">-12500000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNC0xLTEtMS05MDE5NA_d7cd34d2-c93c-41f6-833c-6ef2cc3032f2"
      unitRef="usd">1670000</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNC0zLTEtMS05MDE5NA_27942509-de31-4b31-98c3-8a012cb73ebc"
      unitRef="usd">1574000</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNC01LTEtMS05MDE5NA_f6b27d25-6000-4a87-abbe-afe9faac6368"
      unitRef="usd">4884000</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNC03LTEtMS05MDE5NA_05bf4efb-3e73-4b41-8932-e84b71e7e3fd"
      unitRef="usd">3613000</us-gaap:TemporaryEquityDividendsAdjustment>
    <mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNS0xLTEtMS05MDE5NA_6dc280c8-a0c0-419e-979b-996e7ab7d83b"
      unitRef="usd">0</mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature>
    <mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNS0zLTEtMS05MDE5NA_f2ba41db-cd47-479a-a6f5-b774f4d2e532"
      unitRef="usd">0</mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature>
    <mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNS01LTEtMS05MDE5NA_e7ea6316-6b37-4c77-b8ba-5cb53fbb84bf"
      unitRef="usd">0</mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature>
    <mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNS03LTEtMS05MDE5NA_cf35fd41-f023-45cd-8649-15bd01e7c54e"
      unitRef="usd">926000</mdxg:TemporaryEquityAccretionOfIncreasingRateDividendFeature>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNi0xLTEtMS05MDE5NA_a93a34d0-9a66-4eca-9384-0c76de1f6ca3"
      unitRef="usd">1670000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNi0zLTEtMS05MDE5NA_06c4b57a-fa3b-420a-9445-9b124e3b6710"
      unitRef="usd">1574000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNi01LTEtMS05MDE5NA_88b15fee-1be8-463c-8bc7-8727ba4133f6"
      unitRef="usd">4884000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNi03LTEtMS05MDE5NA_b4ddc6c5-b941-4a00-92b2-bb2d8962e8fc"
      unitRef="usd">4539000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNy0xLTEtMS05MDE5NA_6a21da31-ce9e-4799-8cc5-6aae1b32bca4"
      unitRef="usd">-10096000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNy0zLTEtMS05MDE5NA_5ff0c814-61aa-4bab-99d6-cd54dcc6e0aa"
      unitRef="usd">-3913000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNy01LTEtMS05MDE5NA_470a15b7-e236-4689-943b-5116b4d42d0a"
      unitRef="usd">-34667000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfNy03LTEtMS05MDE5NA_540b0d44-f147-47a2-9e8f-89090b71190e"
      unitRef="usd">-17039000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOC0xLTEtMS05MDE5NA_8a36f4af-c8b2-4346-8a1d-7558317c4f93"
      unitRef="shares">113448251</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOC0zLTEtMS05MDE5NA_8b7ecceb-f863-45a8-8f8b-759e224f80e6"
      unitRef="shares">110717073</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOC01LTEtMS05MDE5NA_aa5d1507-f3f4-49c4-ba92-e34c5c33bd68"
      unitRef="shares">112650713</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOC03LTEtMS05MDE5NA_be74db14-6190-47bc-ba50-024b22df1bff"
      unitRef="shares">110136517</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOS0xLTEtMS05MDE5NA_2544a5a7-c514-4639-84d0-891bc4bfa5f8"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOS0zLTEtMS05MDE5NA_f0a96186-c7cf-4229-9c32-128baa9d0f11"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOS01LTEtMS05MDE5NA_f184ed3b-226d-4ac7-bc18-b143a653061c"
      unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjZjNWViYzQ3NGNmMjQ5OTA5YTMzYzQ5NGE3NTQxOTQ4L3RhYmxlcmFuZ2U6NmM1ZWJjNDc0Y2YyNDk5MDlhMzNjNDk0YTc1NDE5NDhfOS03LTEtMS05MDE5NA_352f5b8a-a550-4211-a350-322ee2418755"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RleHRyZWdpb246ZWE2YzIyMGNjY2E4NGExMDlkZmJhNzAzY2E1NGFiZjRfMjQzNg_645b8efb-a3a1-4c54-94bc-262d5fe1d8b7">&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of diluted net loss per common share (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends on Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: antidilutive adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,448,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,717,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,650,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,136,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,269,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,658,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,858,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,185,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: antidilutive potential common shares (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,269,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,658,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,858,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,185,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding adjusted for potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,448,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,717,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,650,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,136,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Weighted average common shares outstanding for the calculation of diluted net loss per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,685,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,027,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,850,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,497,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,269,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,658,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,858,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,185,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMi0xLTEtMS05MDE5NA_1d3dce21-d941-4462-8a7c-608706b01075"
      unitRef="usd">-10096000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMi0zLTEtMS05MDE5NA_c5a10547-9fd1-4456-b46c-f48d4887e545"
      unitRef="usd">-3913000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMi01LTEtMS05MDE5NA_b53b724e-584e-4043-911d-eca64dd96311"
      unitRef="usd">-34667000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMi03LTEtMS05MDE5NA_8ed7a881-6bcc-4acd-9e77-c5c081d14b33"
      unitRef="usd">-17039000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNC0xLTEtMS05MDE5NA_283408ca-eec3-4c5b-a37b-d5f7472c56a0"
      unitRef="usd">1670000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNC0zLTEtMS05MDE5NA_06c4b57a-fa3b-420a-9445-9b124e3b6710"
      unitRef="usd">1574000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNC01LTEtMS05MDE5NA_1a9b4824-131d-4a99-9df9-5deeff6f5501"
      unitRef="usd">4884000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNC03LTEtMS05MDE5NA_e2fd4472-9690-4f92-8533-e5da96d2daf8"
      unitRef="usd">4539000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNS0xLTEtMS05MDE5NA_62cbf76a-6d9c-4554-80b5-9251121d704c"
      unitRef="usd">-1670000</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNS0zLTEtMS05MDE5NA_476516f4-eb32-4d7a-aee8-ece88836a691"
      unitRef="usd">-1574000</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNS01LTEtMS05MDE5NA_d3401128-3f75-4ae7-9c90-053611f749bb"
      unitRef="usd">-4884000</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNS03LTEtMS05MDE5NA_b2d3ddcd-36e6-45c6-bf64-69a5e1ad734c"
      unitRef="usd">-4539000</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNy0xLTEtMS05MDE5NA_b6d5bdc5-7bfd-446e-b516-b39d24803f68"
      unitRef="usd">-10096000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNy0zLTEtMS05MDE5NA_c1a384a2-2196-448e-a280-48623a82e800"
      unitRef="usd">-3913000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNy01LTEtMS05MDE5NA_76f09e97-2ec1-496a-8a23-5c0a3f42f0db"
      unitRef="usd">-34667000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfNy03LTEtMS05MDE5NA_0616d980-0e44-4995-944c-b565eaf7935b"
      unitRef="usd">-17039000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfOC0xLTEtMS05MDE5NA_230eab93-4e63-4676-964c-da1643a70ab0"
      unitRef="shares">113448251</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfOC0zLTEtMS05MDE5NA_c3c7a091-1d67-4a8a-8acc-3e78d079e4a7"
      unitRef="shares">110717073</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfOC01LTEtMS05MDE5NA_dcb28284-9455-4884-a3e4-223ff2b26d51"
      unitRef="shares">112650713</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfOC03LTEtMS05MDE5NA_eaba367a-ecd4-4dd1-923e-227575ceda33"
      unitRef="shares">110136517</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTAtMS0xLTEtOTAxOTQ_8cef5733-c698-40f8-980b-6591d77ebafb"
      unitRef="shares">29269481</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTAtMy0xLTEtOTAxOTQ_c6869fb6-0b83-4c72-91b3-823c95ae3046"
      unitRef="shares">30658193</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTAtNS0xLTEtOTAxOTQ_d8a49c31-2b99-4a7e-9180-e54fea26036a"
      unitRef="shares">28858049</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTAtNy0xLTEtOTAxOTQ_8fd69fb4-ac6a-414c-b5c4-15c18a8b2cfe"
      unitRef="shares">30185813</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTEtMS0xLTEtOTAxOTQ_d911ff00-b7f1-4f8f-92a7-4ec2c9f9f806"
      unitRef="shares">29269481</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTEtMy0xLTEtOTAxOTQ_408b6c7b-d136-44f6-a645-c01049e92299"
      unitRef="shares">30658193</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTEtNS0xLTEtOTAxOTQ_21ef77db-a1d7-4d1f-b26f-d76c29864d09"
      unitRef="shares">28858049</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTEtNy0xLTEtOTAxOTQ_e4a99cec-1152-4bb8-a0f0-4ac828318def"
      unitRef="shares">30185813</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTMtMS0xLTEtOTAxOTQ_ef5fa861-486f-46c3-852b-7084c4d2ba6c"
      unitRef="shares">113448251</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTMtMy0xLTEtOTAxOTQ_ff31b7ea-2251-44db-ae23-46bc121e8be7"
      unitRef="shares">110717073</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTMtNS0xLTEtOTAxOTQ_8c610259-3c63-42bc-9a85-66eb5a5f32bf"
      unitRef="shares">112650713</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTMtNy0xLTEtOTAxOTQ_3e237a8a-9f6a-45d4-9718-650e0a2d25a8"
      unitRef="shares">110136517</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTQtMS0xLTEtOTAxOTQ_eca0c2c6-0970-4aba-9a48-c560529df0c1"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTQtMy0xLTEtOTAxOTQ_6be7056d-5f79-40b6-ae74-e9f7648739dc"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTQtNS0xLTEtOTAxOTQ_a90a7a64-ad5c-4e6b-9c78-b2884aaabb80"
      unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjI4MjlkZTFhYWJjMzRiNTQ4ZjZkODIwNmI1NDQ2OGJhL3RhYmxlcmFuZ2U6MjgyOWRlMWFhYmMzNGI1NDhmNmQ4MjA2YjU0NDY4YmFfMTQtNy0xLTEtOTAxOTQ_909f240b-6253-49a9-b474-1bcbcf561205"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RleHRyZWdpb246ZWE2YzIyMGNjY2E4NGExMDlkZmJhNzAzY2E1NGFiZjRfMjQyMg_9324123f-a888-417a-b450-a4197ef02edc">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,685,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,027,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,850,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,497,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,269,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,658,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,858,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,185,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie7039d72af5a465f8d691ffc8453f767_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMi0xLTEtMS05MDE5NA_d2ed170e-e834-411f-9b2c-f8ff7e40ca3f"
      unitRef="shares">28685739</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic8a6dd65cf2d47b89031b83212416a42_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMi0zLTEtMS05MDE5NA_52b07974-0064-461a-a761-e365b2648bb7"
      unitRef="shares">27027252</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i10cd3b0255d2440e86f4416f3ed9495c_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMi01LTEtMS05MDE5NA_8cc1125d-69fe-4f91-bb06-a1321398b554"
      unitRef="shares">27850916</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6f700fb64114418187f075f2e5eed841_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMi03LTEtMS05MDE5NA_9798f361-5587-4215-a19e-0d6e9459d7a9"
      unitRef="shares">26497570</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i146f3a7b53384556923cbc98e604b7dd_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMy0xLTEtMS05MDE5NA_ab41ee43-0a0c-4b08-845c-975719ef0624"
      unitRef="shares">474355</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0ec389008cfe43948414a92568159be9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMy0zLTEtMS05MDE5NA_9d1980a8-567e-4e9e-b7ff-eb00c088ab4e"
      unitRef="shares">1840483</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaaf79e5f3ce64e96aa536b235a512ffc_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMy01LTEtMS05MDE5NA_040409a5-05c4-42a0-adb1-34d7da1b87a2"
      unitRef="shares">574507</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2a4925e322ff4faba0e3ed48e1b84008_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfMy03LTEtMS05MDE5NA_df3d2283-b55c-47f9-9309-4753c6e8c5e8"
      unitRef="shares">1500674</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i355ee9dd6fe8464cb242d9207054f6bf_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNC0xLTEtMS05MDE5NA_98382ff4-51d3-4b03-9dce-5bd93564c0df"
      unitRef="shares">22327</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i70d9b122152d409a9b10de3cb3c9ae48_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNC0zLTEtMS05MDE5NA_85b7f718-3349-47c4-b43f-cbfca75f6f07"
      unitRef="shares">974687</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia0f5ff9fed4948129ee9e875deb95c7b_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNC01LTEtMS05MDE5NA_78d7ff3d-2387-495b-b5df-535530837629"
      unitRef="shares">293778</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i258db741a42246298eb7aaa18e77a486_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNC03LTEtMS05MDE5NA_f7dcbe3a-c953-4d23-91f5-c2178f4a118f"
      unitRef="shares">1287635</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i11c7a54774bb43fdba585d030dec991b_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNS0xLTEtMS05MDE5NA_e368ef28-3fde-4bf6-910c-773591781037"
      unitRef="shares">22528</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if0df82c48fe04e96b6b5e4d0a4612c4f_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNS0zLTEtMS05MDE5NA_5e3018ec-f5e1-490c-8534-c813fd71cf23"
      unitRef="shares">805437</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0b8df31d2af641618c113c2cbd9b7b1a_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNS01LTEtMS05MDE5NA_636207b8-af5b-41f2-a02f-1e1700f3dbaa"
      unitRef="shares">97190</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide1a4fd077334136967497c6a2232e0d_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNS03LTEtMS05MDE5NA_495c455c-7ea4-4b81-ba14-495163572dd4"
      unitRef="shares">875714</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia6b3e0608d9f482b868123001407b5ec_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNi0xLTEtMS05MDE5NA_6e0d3672-cf9b-43f1-a82e-783a5679f89b"
      unitRef="shares">59996</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i17f6805f07fe4bdcb90650b3893165d9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNi0zLTEtMS05MDE5NA_253eea89-22a5-4038-a16f-cfb79cb18289"
      unitRef="shares">10334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i39ab2e69b02a42ddb73366a8e9c08937_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNi01LTEtMS05MDE5NA_41a65d81-54cd-4986-b047-f54e736fd91a"
      unitRef="shares">40141</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i212a4290c2bd47fca04f586a83a7f287_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNi03LTEtMS05MDE5NA_a8eaada2-648d-4884-b34c-16a4ea5519aa"
      unitRef="shares">24220</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i271d80de58474816b4025b9aebb971f8_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy0xLTEtMS05NTc4NA_0a510b47-d313-4212-ba0b-e9250a067d6b"
      unitRef="shares">4536</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6d9bb93242bb443ba66fd70a01eef477_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy0zLTEtMS05NTc4Ng_425e14ae-f575-46a7-9d33-e484cacbe61f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i692c59774d81444084dea717ebd32069_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy01LTEtMS05NTc4OA_6a6cda41-e3ad-43cc-8216-354681cef9a4"
      unitRef="shares">1517</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i784df8506ab9410ea02678d62f33b782_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy03LTEtMS05NTc5MA_6487665b-adf5-4ae6-bcdc-2ee86b059df8"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy0xLTEtMS05MDE5NA_6102ac43-cc97-46cc-adc4-6bfec7dd7ddb"
      unitRef="shares">29269481</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy0zLTEtMS05MDE5NA_e3683010-f7db-4f1d-b072-4ab8123ca4df"
      unitRef="shares">30658193</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy01LTEtMS05MDE5NA_b991d361-b439-4129-a164-3717d051cb77"
      unitRef="shares">28858049</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83MC9mcmFnOmVhNmMyMjBjY2NhODRhMTA5ZGZiYTcwM2NhNTRhYmY0L3RhYmxlOjBhMjhlZDcyODQ0NDQ0NDc5MzUxYzk3YjNjODQxYjViL3RhYmxlcmFuZ2U6MGEyOGVkNzI4NDQ0NDQ0NzkzNTFjOTdiM2M4NDFiNWJfNy03LTEtMS05MDE5NA_2e2111ae-62b7-444f-ae9c-8522b692099c"
      unitRef="shares">30185813</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg0Nw_81747e0a-1772-47b3-acd8-32690195f6f2">Equity&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series B Convertible Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series B Convertible Preferred Stock of the Company (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) paid a 4.0% cumulative dividend per annum prior to the quarterly dividend payment ending on June 30, 2021, and pays a 6.0% cumulative dividend per annum thereafter. Dividends, if declared, are paid at the end of each quarter based on dividend amounts that accumulate beginning on the last payment date through the day prior to the end of each quarter. In lieu of paying a dividend, the Company may elect to accrue the dividend owed to shareholders. Accrued dividend balances accumulate dividends at the prevailing dividend rate for each dividend period for which they are outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of Series B Preferred Stock is convertible into the Company&#x2019;s common stock at any time at the option of the holder. Shares are converted based on the liquidation preference of $1,000 per share (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidation Preference&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) plus any accrued or accumulated dividends through the date of the conversion at a conversion price of $3.85 per common share. The Series B Preferred Stock, including any accumulated and unpaid dividends, automatically converts into common stock at any time after &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;July 2, 2023, provided that the common stock has traded at $7.70 per share or more for (i) 20 out of the preceding 30 consecutive trading days and (ii) on such date of conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of the Series B Preferred Stock, voting as a class, are entitled to appoint two members to the board of directors. The holders of the Series B Preferred Stock are entitled to vote on all matters to be voted on by the Company&#x2019;s shareholders on an as-converted basis as a single class with the common stock; provided that the votes represented by the Series B Preferred Stock cannot exceed 19.9% of the total voting stock of the Company and their votes cannot exceed a number of shares equal to the Liquidation Preference divided by $5.25 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the Series B Preferred Stock are also entitled to the Liquidation Preference plus all accumulated and unpaid dividends in the event of a liquidation, dissolution, or winding-up of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a change of control (as defined), the Company will have the option to repurchase some or all of the then-outstanding shares of Series B Preferred Stock for cash in an amount equal to the Liquidation Preference plus any accumulated and unpaid dividends, subject to the rights of the holders of the Series B Preferred Stock in connection with such change in control. If the Company does not exercise such repurchase right, holders of the Series B Preferred Stock will have the option to (1) require the Company to repurchase any or all of their then-outstanding shares of Series B Preferred Stock for cash in an amount equal to the Liquidation Preference plus accumulated and unpaid dividends or (2) convert the Series B Preferred Stock into common stock and receive their pro rata consideration thereunder. Since the contingent redemption of the Series B Preferred Stock by the holders in the event of a change in control is outside the Company&#x2019;s control, the Series B Preferred Stock is classified as temporary equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no change in the balance of Series B Preferred Stock for the three or nine months ended September&#160;30, 2022 or the three months ended September&#160;30, 2021. The below table illustrates changes in the Company&#x2019;s balance of Series B Preferred Stock for the nine months ended September&#160;30, 2021 (in thousands, except share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not declared or paid any dividends on the Series B Preferred Stock since issuance. Dividends accumulated but not paid as of September&#160;30, 2022 were $12.1 million. As this amount has not been declared, the Company has not recorded this amount on its unaudited condensed consolidated balance sheet as of September&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on accumulated dividends as of September&#160;30, 2022, the Series B Preferred Stock was convertible into an aggregate of 29,119,562 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued restricted stock awards (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RSAs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;), restricted stock unit awards (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;), and performance stock unit awards (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;PSUs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) to its employees. The following is summary information for restricted stock awards for the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, there was $26.7&#160;million of unrecognized share-based compensation expense related to share-based payment arrangements. This expense is expected to be recognized over a weighted-average period of 1.93 years, which approximates the remaining vesting period of these grants. The below table summarizes activity of unvested restricted stock awards by award type from January 1, 2022 through September&#160;30, 2022. Unvested RSAs noted below are included in issued and outstanding common stock as of September&#160;30, 2022, while unvested RSUs and unvested PSUs are not included in issued or outstanding common stock as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average Grant Date&lt;br/&gt;&#160;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average Grant Date&lt;br/&gt;&#160;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average Grant Date&lt;br/&gt;&#160;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at January 1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,228,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,181,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(703,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,713,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,274,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,422,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:11pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted PSUs to certain executive officers during the nine months ended September 30, 2022. These PSUs vest only to the extent that stipulated cumulative net sales targets are achieved for the year ending December 31, 2022, the two-year period ending December 31, 2023, and the three-year period ending December 31, 2024. Performance factors range from 50% to 150% of the net sales targets; if performance is below 50%, the PSUs do not vest. If total shareholder return (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TSR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;), as defined below, is negative, vesting is limited to 100% of the award. All of the PSUs require recipients to continue employment with the Company through the vesting date, which will occur upon approval of the results with respect to the established targets by the Compensation Committee of the Board of Directors after December 31, 2024, but no later than March 15, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The TSR is calculated as the average trading price of the Company&#x2019;s common stock during the final 30 trading days of 2024, adjusted for dividends paid on the Company&#x2019;s common stock, less the average trading price during the final 30 trading days of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since TSR is based on the Company&#x2019;s share price, it represents a market condition, which is incorporated in the grant date fair value of shares in excess of 100% vesting. These awards were valued on the date of grant using a Monte Carlo simulation, the inputs for which were informed by a Black-Scholes option pricing model. The assumptions used in determining the fair value of these PSUs were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (annualized)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing stock price on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant date fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term was derived from the date of the grant through the latest date of the resolution of the market condition. The risk-free interest rate was derived based on the U.S. Treasury Yield curve in effect at the date of grant for maturities of similar periods to the concluded term. The expected volatility was based on the Company&#x2019;s historical daily stock price movements for a term similar in length to the expected term. The dividend yield was based on the Company&#x2019;s history of dividends on its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense related to PSUs is recognized, straight-line, based on the grant date fair value of the relevant shares, over the requisite service period related to each individual tranche, limited to the extent that the achievement of the associated performance condition associated with that tranche is probable. These expectations are derived from the Company&#x2019;s latest budget and forecasts for net sales in the associated periods. The fair value of the awards subject to a market condition and expense recognized on such awards are not subsequently reconsidered based on the probability of achievement or ultimate resolution of the market condition. Accordingly, the Company may recognize share-based compensation expense for awards that do not ultimately vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the nine months ended September 30, 2022 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested options expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 7, 2022, the Company adopted the MiMedx, Inc. Employee Stock Purchase Plan (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The ESPP is intended to qualify as an &#x201c;employee stock purchase plan&#x201d; under Section 423 of the Internal Revenue Code. All regular full-time employees of the Company (including officers) and all other employees who meet the eligibility requirements of the plan may participate in the ESPP. The ESPP provides eligible employees an opportunity to acquire the Company&#x2019;s common stock on a semi-annual basis at a purchase price of 85% of the lower of the closing price per share of the Company&#x2019;s common stock on the first day and the last day of each six-month purchase period (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The aggregate number of shares which may be issued and sold under the ESPP is 3 million shares of Common Stock. The first Purchase Period under the ESPP commenced on August 1, 2022 and will result in a purchase of shares on January 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2022, the Company recorded $0.1&#160;million in stock-based compensation related to the ESPP. As of the nine months ended September 30, 2022, the Company had cumulative payroll deferrals under the ESPP for future share purchases of $0.2&#160;million. This amount is included in accrued compensation in the unaudited condensed balance sheet. No shares have been issued under the plan to date.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <mdxg:TemporaryEquityDividendRatePercentage
      contextRef="ie017b823195c4cd28a0e2f85512d9175_D20200702-20200702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTUw_e2bb088a-44e9-4a88-a5b6-d187a07f82d3"
      unitRef="number">0.040</mdxg:TemporaryEquityDividendRatePercentage>
    <mdxg:TemporaryEquityDividendRatePercentage
      contextRef="ia2c96a645d0e4a2f9342b55b1148c6a5_D20200702-20200702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjU5_27458cd7-4fe1-47a0-b55b-9cebfcf2e115"
      unitRef="number">0.060</mdxg:TemporaryEquityDividendRatePercentage>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="i7f3a41d5bd2a49d5b12ac3a2ed050c26_I20200702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfOTEx_0e8a8be2-5ec3-4360-86c9-4aed36c6ac4a"
      unitRef="usdPerShare">1000</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <mdxg:TemporaryEquityConversionPricePerShare
      contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTA1Nw_a1d95fc2-3369-46fe-a0db-b584bb05b187"
      unitRef="usdPerShare">3.85</mdxg:TemporaryEquityConversionPricePerShare>
    <mdxg:TemporaryEquityConversionThresholdPercentageofStockPriceTrigger
      contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTI3NA_0dbccb3d-1f71-423b-9827-b066b8f65e93"
      unitRef="number">7.70</mdxg:TemporaryEquityConversionThresholdPercentageofStockPriceTrigger>
    <mdxg:TemporaryEquityConversionThresholdTradingDays
      contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTMwMw_0611cc06-747a-445f-a968-54392de0b5d5"
      unitRef="day">20</mdxg:TemporaryEquityConversionThresholdTradingDays>
    <mdxg:TemporaryEquityThresholdConsecutiveTradingDays
      contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTMyNw_a6becf34-d0a2-4d69-b019-1d851be44ac2"
      unitRef="day">30</mdxg:TemporaryEquityThresholdConsecutiveTradingDays>
    <mdxg:NumberOfBoardSeatsElectedByTemporaryEquityHolders
      contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTQ4MA_09a0a5cf-bd0a-4ffb-bec7-81c3b690d2e0"
      unitRef="director">2</mdxg:NumberOfBoardSeatsElectedByTemporaryEquityHolders>
    <mdxg:TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis
      contextRef="iddbc1bda0a424d31944fd6c946826212_D20200702-20200702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTc5MQ_34e5de3f-51c6-4b03-8fca-386e107e1954"
      unitRef="number">0.199</mdxg:TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis>
    <mdxg:TemporaryEquityConversionPricePerShare
      contextRef="iea291f2f9ce54206890c533e3a98eb90_D20200702-20200702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTkzMQ_85349157-d97e-48cf-85bb-a198c5e16ea1"
      unitRef="usdPerShare">5.25</mdxg:TemporaryEquityConversionPricePerShare>
    <us-gaap:DividendsPreferredStock
      contextRef="i2897a774ae4848988d5570070d7984aa_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjc0ODc3OTA4Mzk1Nw_02d9dca7-7516-4728-8fc4-2e033a40cad8"
      unitRef="usd">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="iebe0c3fba405441db5355c5f6db48438_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjc0ODc3OTA4Mzk1Nw_6294e189-2c0d-4d9b-ae45-ea077c5ed9d0"
      unitRef="usd">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="ie539807062614f8bb0131c5c6847be0d_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjc0ODc3OTA4Mzk1Nw_d6392aff-7159-4801-a108-6b1726145996"
      unitRef="usd">0</us-gaap:DividendsPreferredStock>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg0OQ_af310202-ed34-4370-8a3a-5a0b9c9f8f21">The below table illustrates changes in the Company&#x2019;s balance of Series B Preferred Stock for the nine months ended September&#160;30, 2021 (in thousands, except share amounts):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i753d059860334ec081dc4d69d43cf1c2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjQ0YjExMjQ3OGE4ZTQwYzQ4YWRkOTcwYzVhNzUwMmExL3RhYmxlcmFuZ2U6NDRiMTEyNDc4YThlNDBjNDhhZGQ5NzBjNWE3NTAyYTFfMi0xLTEtMS05MDE5NA_a53beb41-0e3a-4fa4-8c28-cecf573882cf"
      unitRef="shares">100000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i753d059860334ec081dc4d69d43cf1c2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjQ0YjExMjQ3OGE4ZTQwYzQ4YWRkOTcwYzVhNzUwMmExL3RhYmxlcmFuZ2U6NDRiMTEyNDc4YThlNDBjNDhhZGQ5NzBjNWE3NTAyYTFfMi0zLTEtMS05MDE5NA_03c65ff7-cb50-4303-8cfa-3711c0b17f0f"
      unitRef="usd">91568000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:DividendsPreferredStock
      contextRef="idbf3436aa84a4190833ba27b0b9cde6c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjQ0YjExMjQ3OGE4ZTQwYzQ4YWRkOTcwYzVhNzUwMmExL3RhYmxlcmFuZ2U6NDRiMTEyNDc4YThlNDBjNDhhZGQ5NzBjNWE3NTAyYTFfNC0zLTEtMS05MDE5NA_e0a80362-168d-4434-9308-e9f4daecf88f"
      unitRef="usd">926000</us-gaap:DividendsPreferredStock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i15a5bbe694014b15a1e01cde9e802a57_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjQ0YjExMjQ3OGE4ZTQwYzQ4YWRkOTcwYzVhNzUwMmExL3RhYmxlcmFuZ2U6NDRiMTEyNDc4YThlNDBjNDhhZGQ5NzBjNWE3NTAyYTFfNS0xLTEtMS05MDE5NA_bbdc3455-d948-464b-995c-34c51bd044c5"
      unitRef="shares">100000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i15a5bbe694014b15a1e01cde9e802a57_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjQ0YjExMjQ3OGE4ZTQwYzQ4YWRkOTcwYzVhNzUwMmExL3RhYmxlcmFuZ2U6NDRiMTEyNDc4YThlNDBjNDhhZGQ5NzBjNWE3NTAyYTFfNS0zLTEtMS05MDE5NA_2ebb7df8-9e90-488d-9edf-6c8b84d26e79"
      unitRef="usd">92494000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <mdxg:DividendAccumulatedByNotPaid
      contextRef="ic02bab3165234f9eb46d4f4c01c5fc77_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMzk0Ng_47160640-c267-45ba-9606-114125bedd54"
      unitRef="usd">12100000</mdxg:DividendAccumulatedByNotPaid>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="ic02bab3165234f9eb46d4f4c01c5fc77_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDIwMQ_8406ee1a-1fa7-46d1-b561-a474552f496c"
      unitRef="shares">29119562</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="if5bc17a4ac384d59a3a5c5e10da5eb81_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDU0OA_0bb5e713-aa73-442c-90c9-22a344fef4d2"
      unitRef="usd">26700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib50e54e252d5492ca1c749cc11fabfe4_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDcyMQ_7444432f-5347-435b-9521-60890e7bc3cd">P1Y11M4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg0Ng_cbc7cc2d-137e-40e4-aff9-6cdb6fbe2203">The below table summarizes activity of unvested restricted stock awards by award type from January 1, 2022 through September&#160;30, 2022. Unvested RSAs noted below are included in issued and outstanding common stock as of September&#160;30, 2022, while unvested RSUs and unvested PSUs are not included in issued or outstanding common stock as of September&#160;30, 2022.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average Grant Date&lt;br/&gt;&#160;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average Grant Date&lt;br/&gt;&#160;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average Grant Date&lt;br/&gt;&#160;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at January 1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,228,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,181,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(703,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,713,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,274,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,422,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3049036812934641abae9137fa8bdf2a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi0xLTEtMS05MDE5NA_c2ceb44d-012d-4086-b887-54e201898327"
      unitRef="shares">877197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3049036812934641abae9137fa8bdf2a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi0yLTEtMS05MDE5NA_47fd9da8-de85-43c7-9a40-398994c912ec"
      unitRef="usdPerShare">4.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id2f95c7c08b84d32a4a79f8a8db06aa4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi00LTEtMS05MDE5NA_f6f08f11-461c-4fe5-8e52-add50b1ee6ad"
      unitRef="shares">4228919</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id2f95c7c08b84d32a4a79f8a8db06aa4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi01LTEtMS05MDE5NA_0662f701-7c1a-4d77-b2fb-1031438412f4"
      unitRef="usdPerShare">8.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iaa7c606187fb4813a87a34ec4af106b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi03LTEtMS05MDE5NA_8b3f700d-23f4-4156-8b34-d7606c67eaac"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iaa7c606187fb4813a87a34ec4af106b7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMi04LTEtMS05MDE5NA_6e0692c5-c5e2-4b44-98dc-239576d648fd"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy0xLTEtMS05MDE5NA_0eacc64a-921a-4c56-8dfa-39554e3e7878"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy0yLTEtMS05MDE5NA_d2c85ded-884f-4c17-8a2e-defc9dc583b4"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy00LTEtMS05MDE5NA_0cb4592c-a77a-4006-98b6-e4f3aab31e43"
      unitRef="shares">4181885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy01LTEtMS05MDE5NA_f747a7df-0967-4b58-9551-bb85b39325d0"
      unitRef="usdPerShare">4.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy03LTEtMS05MDE5NA_59b58af8-619d-4319-9a1e-37ef816b130f"
      unitRef="shares">441964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfMy04LTEtMS05MDE5NA_0c3cb389-32b9-46aa-ab86-c4be3e23c7ab"
      unitRef="usdPerShare">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC0xLTEtMS05MDE5NA_86f814d8-84a7-41bf-adc0-7e7c27e14e9d"
      unitRef="shares">703405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC0yLTEtMS05MDE5NA_702f4570-11bd-47cd-a4ae-9b88bab41d8f"
      unitRef="usdPerShare">3.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC00LTEtMS05MDE5NA_f3533160-8484-436c-a5b8-1c359f189b1a"
      unitRef="shares">1713078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC01LTEtMS05MDE5NA_bb0d7ab7-f9a9-452c-bd25-08dfaeac0416"
      unitRef="usdPerShare">8.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC03LTEtMS05MDE5NA_e7ba2510-0b53-48d3-8a28-fff269c6a690"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNC04LTEtMS05MDE5NA_fdcb0978-b650-4695-a6c4-1e1be41d4b90"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS0xLTEtMS05MDE5NA_bf63f765-020b-4b4f-a485-23c42fc7e31a"
      unitRef="shares">5338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ia83adc44d50b4d2ba16ca9872bbe4e9d_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS0yLTEtMS05MDE5NA_7eba8000-7aa7-4865-aab2-d350db68c7b7"
      unitRef="usdPerShare">5.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS00LTEtMS05MDE5NA_838966fc-6bb8-4812-bed7-5fabcc9cf23c"
      unitRef="shares">1274985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1272d38f41f14f47ad6a95c8e8d9e8d5_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS01LTEtMS05MDE5NA_b45c3554-37ee-4b4d-9b4d-2558df209f00"
      unitRef="usdPerShare">6.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS03LTEtMS05MDE5NA_5ab039bd-e0c8-428f-a8cb-0719ada9e907"
      unitRef="shares">200893</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNS04LTEtMS05MDE5NA_411f9f9b-9244-4ca6-bba8-af19f1e3034b"
      unitRef="usdPerShare">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i04da0588d95741f9bde5e0e130fa9c99_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi0xLTEtMS05MDE5NA_258e02a0-32fb-4a99-84ad-1730b02e3ee7"
      unitRef="shares">168454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i04da0588d95741f9bde5e0e130fa9c99_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi0yLTEtMS05MDE5NA_08356892-fd27-4646-bad3-8f0e72a2ad86"
      unitRef="usdPerShare">6.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6572eec66ddc4973bfa1f4addf16e03f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi00LTEtMS05MDE5NA_ec48660a-483e-4641-abe4-5214ef234f2e"
      unitRef="shares">5422741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6572eec66ddc4973bfa1f4addf16e03f_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi01LTEtMS05MDE5NA_3f2f928c-1614-4df7-b197-1af23b4a4db6"
      unitRef="usdPerShare">6.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia4b6f7cb18684bc78a9c1ac2d353eadf_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi03LTEtMS05MDE5NA_a4e8ec43-f601-4c1e-90f1-f25599f66eb7"
      unitRef="shares">241071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia4b6f7cb18684bc78a9c1ac2d353eadf_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjE1ODhlODFhNjI1NzQ3NmFiMDJkNTRjMWVlZDRjZTJiL3RhYmxlcmFuZ2U6MTU4OGU4MWE2MjU3NDc2YWIwMmQ1NGMxZWVkNGNlMmJfNi04LTEtMS05MDE5NA_8b130947-9af4-4982-9c24-d4e37027a463"
      unitRef="usdPerShare">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod
      contextRef="ia2b50c892e824477a3935a03b5a37bc1_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg1Mg_e2dda75e-5f74-41a5-9ec1-1118049663e5">P2Y</mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod>
    <mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod
      contextRef="i31fe266b4c6443febd173cafdd41434d_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg1Mw_4ebaa35a-0bf5-46a8-9848-d91e94238c5b">P3Y</mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia2b50c892e824477a3935a03b5a37bc1_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNTQ1MQ_d54a82b6-d7e6-41b9-99c4-ba35434f6aee"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i31fe266b4c6443febd173cafdd41434d_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNTQ1Nw_039480d6-e2b0-4a0a-9b71-7b2724791a0a"
      unitRef="number">1.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia2b50c892e824477a3935a03b5a37bc1_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNTUxMA_d54a82b6-d7e6-41b9-99c4-ba35434f6aee"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNTYyNg_b7a2966a-ebdc-46f4-a861-4d9178f3670f"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays
      contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNjA0Mw_cfa7700e-9b30-4ef3-8fca-125fd3499de6">P30D</mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays>
    <mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays
      contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNjE3NQ_cfa7700e-9b30-4ef3-8fca-125fd3499de6">P30D</mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNjM1Nw_b7a2966a-ebdc-46f4-a861-4d9178f3670f"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <mdxg:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg1MA_266a3b18-1dd9-4a33-aa21-fd1c1c241e90">The assumptions used in determining the fair value of these PSUs were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (annualized)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing stock price on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant date fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mdxg:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfMS0xLTEtMS05MDE5NA_a8acba95-622e-49c8-b81b-2c400676215b"
      unitRef="number">0.0268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfMi0xLTEtMS05MDE5NA_013b21a9-db23-4c83-bb44-f375701d1204">P2Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfMy0xLTEtMS05MDE5NA_4bf45eae-60ef-4a11-aee6-89cbe5aaab4f"
      unitRef="number">0.637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfNC0xLTEtMS05MDE5NA_4de947e8-7c7c-4f70-9073-e365f0bd76b9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="ic48fb527e30240a4917a52a042ced3d9_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfNS0xLTEtMS05MDE5NA_8910de22-7018-4287-9a59-32570f6df7e0"
      unitRef="usdPerShare">4.62</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOmI5OTUzZTkxNTM5ZDQ0Mzg4YjdjMDNmYTBmZjFjZWI3L3RhYmxlcmFuZ2U6Yjk5NTNlOTE1MzlkNDQzODhiN2MwM2ZhMGZmMWNlYjdfNi0xLTEtMS05MDE5NA_1bb31430-443e-405d-b374-76056829050d"
      unitRef="usdPerShare">2.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNzg1MQ_b2d40864-c5fe-407b-9fe4-597fb3792645">&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the nine months ended September 30, 2022 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested options expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMS0xLTEtMS05MDE5NA_507c37df-6013-4eed-afbe-6a598f27520c"
      unitRef="shares">1444845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9c87d212d19e46b4a198d7406d22de6b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMS0zLTEtMS05MDE5NA_864d9faf-32b2-4caf-997d-fdbf75c73680"
      unitRef="usdPerShare">5.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMi0xLTEtMS05MDE5NA_ea04475c-8e7f-4e5d-80a4-5e4a9476401b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMi0zLTEtMS05MDE5NA_018e771e-a91f-4eac-8cf9-9ee68c4af546"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMy0xLTEtMS05MDE5NA_ad31f9cf-18fc-4321-9152-d5a2944ad17b"
      unitRef="shares">285001</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfMy0zLTEtMS05MDE5NA_b01b08bc-d51f-407d-ad2b-87f250ed9a3d"
      unitRef="usdPerShare">2.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNC0xLTEtMS05MDE5NA_ddb56f6c-081b-46d4-b770-606ff0a641e3"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNC0zLTEtMS05MDE5NA_975b761f-8599-4794-b129-f1285b149d36"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNS0xLTEtMS05MDE5NA_70f43215-1b0c-4658-ab29-b49cfb662a84"
      unitRef="shares">109500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNS0zLTEtMS05MDE5NA_6b96028d-f80f-4208-9f6d-e71fcb5f5654"
      unitRef="usdPerShare">4.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNi0xLTEtMS05MDE5NA_87371433-a82d-43a3-84dd-06afe8e5c3b6"
      unitRef="shares">1050344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNi0zLTEtMS05MDE5NA_d0097642-72c9-4683-b2e5-d4c7f516dbe3"
      unitRef="usdPerShare">6.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNi01LTEtMS05MDE5NA_18cc496e-f782-4dc3-b1f0-1d0f455f8c1b">P1Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNi03LTEtMS05MDE5NA_44ba1ce5-1c95-4118-aa50-d9721cd65879"
      unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNy0xLTEtMS05MDE5NA_b6b6a059-91bd-4c3b-b40b-666a02b33125"
      unitRef="shares">1050344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNy0zLTEtMS05MDE5NA_ad892d63-8a10-4dac-93dd-9fe8da629aa2"
      unitRef="usdPerShare">6.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNy01LTEtMS05MDE5NA_4be38595-700d-4c7c-8e82-0c4f7304fab9">P1Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RhYmxlOjgwMGM4MjM5ODMwMjQ0MWZhNDc4NGVhYTQ2YTEyOGQyL3RhYmxlcmFuZ2U6ODAwYzgyMzk4MzAyNDQxZmE0Nzg0ZWFhNDZhMTI4ZDJfNy03LTEtMS05MDE5NA_c7be51a0-806f-4e99-9ae1-19d08b2e7f4a"
      unitRef="usd">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i03bb1d037d4e4920880de2544e838583_D20220607-20220607"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDk0NzgwMjMzNzg5NA_be3f0a9e-9549-422f-a49f-050bf09cafe7"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="i03bb1d037d4e4920880de2544e838583_D20220607-20220607"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDk0NzgwMjMzNzk0MQ_9cb9fb12-e802-4f7b-bcab-fb12e7ebeea6">P6M</mdxg:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8a6f0c76a58f4f19bb54eedc889f9037_I20220607"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMTI2NDQzODM3MzMyMDA_811537cd-c20d-494a-9f28-f8208350ce09"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i66ece39c082f4511b28e1e8f2974b42a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDk0NzgwMjMzNzkwMQ_387a817c-a539-4cf1-89c5-473ab833a082"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib46a2b85eab64b269ab8d468f2d3b464_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfNDk0NzgwMjMzNzkwMQ_848ace4e-597d-43a9-a582-0a70e0785f88"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <mdxg:AccruedESPPPayrollDeferrals
      contextRef="ib26f2b9f669f4ee6ac92ff0803d5fe9c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjE5OTAyMzI3MTE1Nw_efdb9816-324f-43a9-8ede-542de57823ed"
      unitRef="usd">200000</mdxg:AccruedESPPPayrollDeferrals>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i66ece39c082f4511b28e1e8f2974b42a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83My9mcmFnOmM0Y2Y0NDMzZTc3ZDQ4NGM5NzUwZjVlYzJiZmIwYmVkL3RleHRyZWdpb246YzRjZjQ0MzNlNzdkNDg0Yzk3NTBmNWVjMmJmYjBiZWRfMjE5OTAyMzI3MTE3MA_c22c068c-62a0-4159-ad8a-3253bd53e206"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83Ni9mcmFnOmM5ZDZiOTBjMTAxZTQ4ZmE5YjdmODAwZjEyMDM4MGIxL3RleHRyZWdpb246YzlkNmI5MGMxMDFlNDhmYTliN2Y4MDBmMTIwMzgwYjFfMzk3_db125605-73f3-4618-b1c8-f01514a3385f">Income Taxes&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rates for the Company were (0.6)% and (14.8)% for the three months ended September&#160;30, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rates for the Company were (0.6)% and (2.9)% for the nine months ended September&#160;30, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no material discrete items affecting the effective tax rate in any period. Net operating losses incurred were offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83Ni9mcmFnOmM5ZDZiOTBjMTAxZTQ4ZmE5YjdmODAwZjEyMDM4MGIxL3RleHRyZWdpb246YzlkNmI5MGMxMDFlNDhmYTliN2Y4MDBmMTIwMzgwYjFfNjg_2198f65b-2efd-405d-ba49-c9c8425435c3"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83Ni9mcmFnOmM5ZDZiOTBjMTAxZTQ4ZmE5YjdmODAwZjEyMDM4MGIxL3RleHRyZWdpb246YzlkNmI5MGMxMDFlNDhmYTliN2Y4MDBmMTIwMzgwYjFfNzU_588d98c3-20a1-40af-8883-525ab0894395"
      unitRef="number">-0.148</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83Ni9mcmFnOmM5ZDZiOTBjMTAxZTQ4ZmE5YjdmODAwZjEyMDM4MGIxL3RleHRyZWdpb246YzlkNmI5MGMxMDFlNDhmYTliN2Y4MDBmMTIwMzgwYjFfMTc2_44a874a6-2dc9-42f5-8ce1-df1adde3f72c"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83Ni9mcmFnOmM5ZDZiOTBjMTAxZTQ4ZmE5YjdmODAwZjEyMDM4MGIxL3RleHRyZWdpb246YzlkNmI5MGMxMDFlNDhmYTliN2Y4MDBmMTIwMzgwYjFfMTg0_bf93c004-4db4-4902-a2b0-7c968b3d05d2"
      unitRef="number">-0.029</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RleHRyZWdpb246M2MzY2U0ODY5ZjVkNGYyYWFmZjdkM2Y0ZDBhOTIxYmRfMTky_7c7e4a0d-0d50-448f-abb1-48cdd53967fb">Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selected cash payments, receipts, and non-cash activities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of equipment in accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets arising from operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividends on Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of non-cash consideration received for option exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets arising from finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note receivable for sale of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RleHRyZWdpb246M2MzY2U0ODY5ZjVkNGYyYWFmZjdkM2Y0ZDBhOTIxYmRfMTk0_995c9a47-8100-4f1a-9c34-85e4f7fd60ba">&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selected cash payments, receipts, and non-cash activities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of equipment in accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets arising from operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividends on Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of non-cash consideration received for option exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets arising from finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note receivable for sale of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMi0xLTEtMS05MDE5NA_ba19ebcc-e0d0-4e1f-a2e0-9b8e2773ac7c"
      unitRef="usd">3233000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMi0zLTEtMS05MDE5NA_443b43d8-397b-4b5d-ac71-f05a60c50b53"
      unitRef="usd">3269000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMy0xLTEtMS05MDE5NA_80e0624f-eea3-422c-975f-0f09db8f7296"
      unitRef="usd">184000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMy0zLTEtMS05MDE5NA_560d2959-41ef-4b93-bf60-a8ae61e2e7c9"
      unitRef="usd">157000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNS0xLTEtMS05MDE5NA_2ec2ca9a-7f12-4958-99f1-0f69f01c32c0"
      unitRef="usd">353000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNS0zLTEtMS05MDE5NA_0c413e2e-9909-4bc6-928f-f24636f98e5a"
      unitRef="usd">6000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNi0xLTEtMS05MDE5NA_e44c8e3e-626f-4e80-8d5d-da6ce746d86d"
      unitRef="usd">37000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNi0zLTEtMS05MDE5NA_96f2f01b-8401-4cad-83ed-efc9156a5e0d"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mdxg:TemporaryEquityDeemedDividends
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNy0xLTEtMS05MDE5NA_e00612c7-2731-424d-9071-42f551192e96"
      unitRef="usd">0</mdxg:TemporaryEquityDeemedDividends>
    <mdxg:TemporaryEquityDeemedDividends
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfNy0zLTEtMS05MDE5NA_399bc5e5-406b-47f9-8d22-5aa2ab2707b5"
      unitRef="usd">926000</mdxg:TemporaryEquityDeemedDividends>
    <mdxg:FairValueOfNonCashConsiderationReceivedForOptionExercise
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfOC0xLTEtMS05MDE5NA_5c97c3fc-1d56-440b-9507-a7bff95197c7"
      unitRef="usd">0</mdxg:FairValueOfNonCashConsiderationReceivedForOptionExercise>
    <mdxg:FairValueOfNonCashConsiderationReceivedForOptionExercise
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfOC0zLTEtMS05MDE5NA_d04d4e6c-4977-4095-b9a0-5f7f6974ce6c"
      unitRef="usd">380000</mdxg:FairValueOfNonCashConsiderationReceivedForOptionExercise>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfOS0xLTEtMS05MDE5NA_a5918e52-9940-4f6a-929e-9c500fad0d22"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfOS0zLTEtMS05MDE5NA_567e0a34-236e-4f2d-9e6e-8595527d1fc2"
      unitRef="usd">189000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <mdxg:NotesReceivableForSaleOfPropertyAndEquipment
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMTAtMS0xLTEtOTAxOTQ_e4f089af-b44d-457a-8297-8ea206c6214d"
      unitRef="usd">0</mdxg:NotesReceivableForSaleOfPropertyAndEquipment>
    <mdxg:NotesReceivableForSaleOfPropertyAndEquipment
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl83OS9mcmFnOjNjM2NlNDg2OWY1ZDRmMmFhZmY3ZDNmNGQwYTkyMWJkL3RhYmxlOjlhZDg4OTdkNDAxZTRhZjc5Y2E1MzRkMDc4MzZlOGNiL3RhYmxlcmFuZ2U6OWFkODg5N2Q0MDFlNGFmNzljYTUzNGQwNzgzNmU4Y2JfMTAtMy0xLTEtOTAxOTQ_b86e20be-644f-49ae-a7c1-e98b7972d2df"
      unitRef="usd">75000</mdxg:NotesReceivableForSaleOfPropertyAndEquipment>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfODYwNA_72634540-c553-4184-b175-6693b1889dad">Commitments and Contingencies&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Separation Agreement with Timothy R. Wright&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2022, the Company entered into a Separation Agreement and General Release with Timothy R. Wright, the former Chief Executive Officer of the Company (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Separation Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). Pursuant to the terms of the Separation Agreement and Mr. Wright&#x2019;s general release of all claims against the Company, the Company will pay Mr. Wright a total of $3.1 million in cash in a series of installments through September 2024. The terms of the severance benefits provided in the Separation Agreement were the same as those provided for in the original employment Letter Agreement between Mr. Wright and the Company dated April 8, 2019. The $3.1 million was recorded as part of selling, general, and administrative expense on the condensed consolidated statements of operations for the three and nine months ended September 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the $3.1&#160;million, $1.6 million is reflected in accrued compensation and the remainder is reflected in other liabilities in the unaudited condensed consolidated balance sheet as of September 30, 2022. No payments were required to Mr. Wright under the terms of the Separation Agreement during the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nordic Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company entered into a collaboration agreement (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nordic Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) with Nordic Bioscience Clinical Development A/S (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NBCD&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) to provide full operational support for the Company&#x2019;s upcoming Knee Osteoarthritis (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;KOA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) clinical trial program. As part of the agreement, NBCD will perform site selection and monitoring, manage patient recruitment and enrollment, data management, statistical analysis and reporting activities for the duration of the trial. Under the terms of the Nordic Agreement, the Company is obligated to pay $13.3 million upon the achievement of specified milestones over the course of the clinical trial. The milestones are based upon various factors including, but not limited to, site selection and enrollment, patient enrollment, patient completion, and certain other activities related to clinical trial operations. The milestone payments are revised semi-annually based on fluctuations in the consumer price index. The Company has the ability to terminate the Nordic Agreement with 30 days written notice to NBCD. At such time, the Company would be required to pay for services performed through the date of termination and any non-cancelable obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company has paid $2.0 million under the Nordic Agreement, relating to milestones which have been achieved from inception through that date. During each of the three and nine months ended September&#160;30, 2022, the Company recognized $0.6&#160;million of expense. This amount is included as part of research and development expense in the unaudited condensed consolidated statements of operations for those periods. The remaining $1.4 million is reflected in prepaid expenses on the consolidated balance sheet as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation and Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company and its subsidiaries are parties to numerous civil claims and lawsuits and subject to regulatory examinations, investigations, and requests for information. Some of these matters involve claims for substantial amounts. The Company&#x2019;s experience has shown that the damages alleged by plaintiffs or claimants are often overstated, based on unsubstantiated legal theories, unsupported by facts, and/or bear no relation to the ultimate award that a court might grant. Additionally, the outcome of litigation and regulatory matters and the timing of ultimate resolution are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inherently difficult to predict. These factors make it difficult for the Company to provide a meaningful estimate of the range of reasonably possible outcomes of claims in the aggregate or by individual claim. However, on a case-by-case basis, reserves are established for those legal claims for which it is probable that a loss will be incurred and the amount of such loss can be reasonably estimated. The Company's unaudited condensed consolidated balance sheet as of September&#160;30, 2022&#160;reflects the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. The actual costs of resolving these claims, as well as the cost to resolve claims that are either not probable or not estimable at this time, may be substantially higher or lower than the amounts reserved. For more information regarding the Company&#x2019;s legal proceedings, refer to Note 14, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; in the 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $0.7 million toward the resolution of legal matters involving the Company during the nine months ended September&#160;30, 2022. In addition, insurance providers paid $0.6&#160;million on the Company&#x2019;s behalf to settle legal matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also recovered amounts from certain former officers and directors of the Company relating to legal fees previously advanced on their behalf. These funds were recognized as a reduction to investigation, restatement, and related expense on the condensed consolidated statement of operations for the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a description of certain litigation and regulatory matters to which the Company is a party:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 16, 2019, the United States District Court for the Northern District of Georgia entered an order consolidating two purported securities class actions (MacPhee v. MiMedx Group, Inc., et al. filed February 23, 2018 and Kline v. MiMedx Group, Inc., et al. filed February 26, 2018). The order also appointed Carpenters Pension Fund of Illinois (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CPFI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) as lead plaintiff. On May 1, 2019, CPFI filed a consolidated amended complaint, naming as defendants the Company, Michael J. Senken, Parker H. &#x201c;Pete&#x201d; Petit, William C. Taylor, Christopher M. Cashman and Cherry Bekaert &amp;amp; Holland LLP. The amended complaint (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Class Action Complaint&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) alleged violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Act&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;), Rule 10b-5 promulgated thereunder, and Section 20(a) of the Exchange Act. It asserted a class period of March 7, 2013 through June 29, 2018. Following the filing of motions to dismiss by the various defendants, CPFI was granted leave to file an amended complaint. CPFI filed its amended complaint against the Company, Michael J. Senken, Parker H. Petit, William C. Taylor, and Cherry Bekaert &amp;amp; Holland (Christopher Cashman was dropped as a defendant) on March 30, 2020. The defendants filed motions to dismiss on May 29, 2020. On March 25, 2021, the Court granted defendants&#x2019; respective motions to dismiss, finding that CPFI lacked standing to bring the underlying claims and also could not establish loss causation because it sold all of its shares in MIMEDX prior to any corrective disclosures, and dismissed the case. On April 22, 2021, CPFI filed a motion for reconsideration of the dismissal and for leave to amend to add a new plaintiff to attempt to cure the standing and loss causation issues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 28, 2022, the Court denied CPFI&#x2019;s motion to reconsider and motion to substitute class representative. On February 25, 2022, CPFI filed a Notice of Appeal in the 11th Circuit Court of Appeals, Case No. 22-10633-CC. The parties have completed their briefings on the issues on the appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Former Employee Litigation and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 12, 2021, the Company filed suit in the Circuit Court of the Eleventh Judicial District in and for Miami-Dade County, Florida (MiMedx Group, Inc. v. Petit, et. al.) against its former CEO, Parker H. &#x201c;Pete&#x201d; Petit, and its former COO, William C. Taylor, seeking a determination of its rights and obligations under indemnification agreements with Petit and Taylor following a federal jury&#x2019;s guilty verdict against Petit for securities fraud and Taylor for conspiracy to commit securities fraud. The Company is seeking a declaratory judgment that it is not obligated to indemnify or advance expenses to Petit and Taylor in connection with certain cases to which Petit and Taylor are parties and also seeking to recoup amounts previously paid on behalf of Petit and Taylor in connection with such cases. On April 22, 2021, Petit and Taylor filed an answer and asserted counterclaims against the Company alleging breach of their indemnification agreements, breach of the covenant of good faith and fair dealing with respect to their indemnification agreements, and seeking a declaration that the Company remains obligated to indemnify and advance fees in connection with certain cases. Petit and Taylor simultaneously also filed a motion seeking to compel the Company to advance and reinstate its payments of Petit and Taylor&#x2019;s legal expenses. The Company opposed Petit and Taylor&#x2019;s motion and a hearing was set for June 23, 2021. At the joint request of the parties, the hearing was cancelled to allow the parties to attend a mediation to attempt a resolution of this matter; such mediation was held on August 11, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the mediation, the Company and Mr. Taylor reached an agreement to settle the matter between them. Negotiations with Mr. Petit are ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Florida Business Corporation Act and agreements with its current and former officers and directors, the Company is obligated to indemnify its current and former officers and directors who are made party to a proceeding, including a proceeding brought by or in the right of the corporation, with certain exceptions, and to advance expenses to defend such matters. The Company has already borne substantial costs to satisfy these indemnification and expense advance obligations and may continue to do so in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the matters described above, the Company is a party to a variety of other legal matters that arise in the ordinary course of the Company&#x2019;s business, none of which are deemed to be individually material at this time. Due to the inherent uncertainty of litigation, there can be no assurance that the resolution of any particular claim or proceeding would not have a material adverse effect on the Company&#x2019;s business, results of operations, financial position or liquidity.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherCommitment
      contextRef="i3172438f25f94d9b8023b961aedcb60f_I20220915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTI2NDQzODM3MzczNDU_5cf24a45-12c7-4236-ad3e-f7f8164ec404"
      unitRef="usd">3100000</us-gaap:OtherCommitment>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if25b98ea5f0947a9a6a36132f5efc122_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MjEyNw_47aa020f-0883-4f6a-aa3f-9698c4c982d2"
      unitRef="usd">3100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0fd877d9ecb24d80b443c4b5961d54c0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MjEyNw_a1e31a19-aa21-4ee5-8bc0-6fa567df7e4b"
      unitRef="usd">3100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherCommitment
      contextRef="i3172438f25f94d9b8023b961aedcb60f_I20220915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MDQ2MA_3f3e17e9-10b8-407a-8509-7facc1a3d10b"
      unitRef="usd">3100000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="id4d6590c804a4af396fb91f11d61ca98_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTI2NDQzODM3Mzc0MDE_f21c3b73-1d4d-4f9a-ab1a-1181d441d5f4"
      unitRef="usd">1600000</us-gaap:OtherCommitment>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="i5e04c486503f40a1843903fe17980c71_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfNTcy_132bd8ea-38d4-4b3a-a61b-48fc52a6d743"
      unitRef="usd">13300000</us-gaap:LongTermPurchaseCommitmentAmount>
    <mdxg:LongTermPurchaseCommitmentTerminationNoticePeriodRequired
      contextRef="i5e04c486503f40a1843903fe17980c71_D20220601-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMjc0ODc3OTA3OTUzMA_47bcb6cf-4d22-439b-8e53-2219e05ee7ca">P30D</mdxg:LongTermPurchaseCommitmentTerminationNoticePeriodRequired>
    <mdxg:PaymentsMadeOnLongTermPurchaseCommitment
      contextRef="i070672d37c8e47f4a3a16fbd57ba5691_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTI2NDQzODM3Mzc2MTE_b2078142-371e-4ba7-ba44-3741b9eef281"
      unitRef="usd">2000000</mdxg:PaymentsMadeOnLongTermPurchaseCommitment>
    <mdxg:ExpensesOnLongTermPurchaseCommitment
      contextRef="i320fdbb729ab4be69c2a59f489c97765_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MTY5NA_31873372-49d9-4275-826a-a7fb4aa4ff96"
      unitRef="usd">600000</mdxg:ExpensesOnLongTermPurchaseCommitment>
    <mdxg:ExpensesOnLongTermPurchaseCommitment
      contextRef="i9f2d728dc47344bca02856d03ee8d0b4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MTY5NA_ddc843ca-bb98-45f3-a1b6-41b555520ad4"
      unitRef="usd">600000</mdxg:ExpensesOnLongTermPurchaseCommitment>
    <mdxg:RemainingPrepaidExpensesOnLongTermPurchaseCommitment
      contextRef="i070672d37c8e47f4a3a16fbd57ba5691_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMTY0OTI2NzQ2MjI1Ng_b2b07d40-479e-4f1a-9171-35078e1a492f"
      unitRef="usd">1400000</mdxg:RemainingPrepaidExpensesOnLongTermPurchaseCommitment>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMzA1NQ_b692935d-240e-48b3-b763-5562ed2f3b60"
      unitRef="usd">700000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="icbc4ddf32d59495c88aa620c69ed64cb_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMzE4MA_a2040371-6958-4c80-ac97-793fd5d5b4f8"
      unitRef="usd">600000</us-gaap:PaymentsForLegalSettlements>
    <mdxg:ContingencyLossNumberOfSecuritiesClassActions
      contextRef="ib6fd656cd99342d2afc041b6ba933413_D20190116-20190116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84Mi9mcmFnOjhkOWRmZTkxOWJhMjQwYjY4NjJjZTYwZWZlMTk3OWIwL3RleHRyZWdpb246OGQ5ZGZlOTE5YmEyNDBiNjg2MmNlNjBlZmUxOTc5YjBfMzgyNQ_81bf55f0-47ff-44c1-86a2-334cd9b33341"
      unitRef="class_action">2</mdxg:ContingencyLossNumberOfSecuritiesClassActions>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RleHRyZWdpb246YmZlYjYzMGVhNWJhNDUzMjlhZTJhZDIyNmQ3Yzg3ZmVfMTI3Mw_a9a9f454-6511-40a9-a49c-0531b57437ee">Revenue&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue by Product&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MIMEDX has two primary classes of products: (1) Advanced Wound Care, or Section 361, products, consisting of its tissue and cord sheet allograft products as well as certain particulate products regulated under Section 361, and (2) Section 351 products, consisting of the Company&#x2019;s micronized and certain other particulate products. Advanced Wound Care is further disaggregated between the Company&#x2019;s Tissue/Other and Cord products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the business units responsible for the sale of each of these classes of product can be found in Note 15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of net sales by class of product (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advanced Wound Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tissue/Other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cord&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Advanced Wound Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(1) &#x201c;O&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;ther&#x201d; represents revenue transactions in the indicated period relating to performance obligations settled prior to October 1, 2019, the date at which the Company changed its pattern of revenue recognition. For all practical purposes, the Company is not able to allocate these revenue transactions to different product groups. This revenue is reflected as part of the Wound &amp;amp; Surgical segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue by Customer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MIMEDX has two primary distribution channels: (1) direct to customers (healthcare professionals and/or facilities) (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Direct Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;), and (2) sales to distributors (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distributors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of net sales by each customer type (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct Customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three or nine months ended September&#160;30, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <mdxg:NumberOfProducts
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RleHRyZWdpb246YmZlYjYzMGVhNWJhNDUzMjlhZTJhZDIyNmQ3Yzg3ZmVfNjY_dabec1af-f9e0-42c7-81bf-2873f0f01698"
      unitRef="product">2</mdxg:NumberOfProducts>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RleHRyZWdpb246YmZlYjYzMGVhNWJhNDUzMjlhZTJhZDIyNmQ3Yzg3ZmVfMTI3Ng_7418e598-ecb7-4a91-81ba-87b762550b73">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of net sales by class of product (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advanced Wound Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tissue/Other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cord&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Advanced Wound Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(1) &#x201c;O&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;ther&#x201d; represents revenue transactions in the indicated period relating to performance obligations settled prior to October 1, 2019, the date at which the Company changed its pattern of revenue recognition. For all practical purposes, the Company is not able to allocate these revenue transactions to different product groups. This revenue is reflected as part of the Wound &amp;amp; Surgical segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of net sales by each customer type (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct Customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04190c43aa5d47839d90cf05de41f75a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfMy0xLTEtMS05MDE5NA_ffe4d190-b051-4000-88e5-abc7ee239f64"
      unitRef="usd">61131000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9eec3159aafd457684861f891a8f27b9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfMy0zLTEtMS05MDE5NA_d164aa5d-7d99-4534-becb-43a44cf2d21d"
      unitRef="usd">56035000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5fd9ecb73bd40f28e4562a1cd66d365_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfMy01LTEtMS05MDE5NA_86ab7def-1ff4-4cc7-9966-89b9b227821d"
      unitRef="usd">174256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9866ce2797684d89afbfd9e13fe710b6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfMy03LTEtMS05MDE5NA_6a2618f8-6085-4d8d-9f23-9cd660c3d95b"
      unitRef="usd">156012000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4df0f9cc41a6412e917f9a0100673e83_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNC0xLTEtMS05MDE5NA_e7326ecc-14e6-4092-9230-332ba72e955c"
      unitRef="usd">5678000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d42aa93cf554f31bdf7957ad6cc2c35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNC0zLTEtMS05MDE5NA_6189afc3-0971-40be-9669-70547941f99b"
      unitRef="usd">6247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacbeb9a9186744ee819f52f94ba86e20_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNC01LTEtMS05MDE5NA_844b52b9-892d-461b-b012-a388a5d71994"
      unitRef="usd">17165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81ef134bfecc49ddb64f099bb97426e5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNC03LTEtMS05MDE5NA_c275fe38-5bc2-488c-b8fb-2afec56e029e"
      unitRef="usd">17093000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1eade6c04c44338ba36a2a117e94a53_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNS0xLTEtMS05MDE5NA_436ec685-e034-42e8-90f0-0afb63ee9a11"
      unitRef="usd">66809000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f2702a8fab749619f28b833e531c5d1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNS0zLTEtMS05MDE5NA_8b8722c8-32de-48ce-9cbc-57f3dcc8de7c"
      unitRef="usd">62282000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea05bcc2c0134bd5964b7bc8be495e5d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNS01LTEtMS05MDE5NA_13158f48-b12e-4b30-b6d7-a5db16f11e8b"
      unitRef="usd">191421000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1eba5ab3ff8b4cecb6daaf14306ea281_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNS03LTEtMS05MDE5NA_4a28e9b6-dabf-4e5c-aa40-605d13a001ed"
      unitRef="usd">173105000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63d182d5355d40909bfcd1ecad0c38f9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNi0xLTEtMS0xMDA5MDA_cd4d664a-ee88-495a-8a17-18928e526f8e"
      unitRef="usd">796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie699609ee0a24b2795a89d47dab42904_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNi0zLTEtMS0xMDA5MTI_1f7bf8f5-5f67-451e-ac72-aaab8e09b238"
      unitRef="usd">489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46ce6151aa0c4089a54a9ba0539e2058_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNi01LTEtMS0xMDA5MjI_534b7e8c-7c50-4ed1-b0e3-cf14e7ad90b9"
      unitRef="usd">1815000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib83b2b7d758f4908890825b2a2b0d822_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNi03LTEtMS0xMDA5Mzk_ce04b236-f3c6-4f74-8475-a515abf708d2"
      unitRef="usd">17187000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8fcb780f1414fd8b5dfecc6d1682d35_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNy0xLTEtMS05MDE5NA_0daffeee-eaf7-45bc-9531-dc8c1304f165"
      unitRef="usd">84000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6449c9a80962496d82d4f44a69334d4a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNy0zLTEtMS05MDE5NA_6f0772b4-b03a-42bf-9028-6b0106097c11"
      unitRef="usd">303000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b7935978392476a8eb950a2156ec688_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNy01LTEtMS05MDE5NA_878078a7-7b25-4cc2-8904-57a1d06aa66d"
      unitRef="usd">230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c14d491f3ed491ea1459de970ab3387_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfNy03LTEtMS05MDE5NA_0a8797b8-ab6d-4e8c-84ca-6affa3eabbdc"
      unitRef="usd">914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfOC0xLTEtMS05MDE5NA_bb1d9de8-14de-40f1-ac06-0e938f51a5ef"
      unitRef="usd">67689000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfOC0zLTEtMS05MDE5NA_273ced75-3be2-42f1-bc16-868fe49eeee2"
      unitRef="usd">63074000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfOC01LTEtMS05MDE5NA_184ca223-cb33-479c-8d4f-53e917aa5978"
      unitRef="usd">193466000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjE0MDIxMzFkNTU1NDQwZWVhYzBhMGQ2ZjY2NDAyYTgwL3RhYmxlcmFuZ2U6MTQwMjEzMWQ1NTU0NDBlZWFjMGEwZDZmNjY0MDJhODBfOC03LTEtMS05MDE5NA_44aa58a9-2de3-4df0-950b-4f298a827e0d"
      unitRef="usd">191206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mdxg:RevenueFromContractWithCustomerNumberOfDistributionChannels
      contextRef="i4bd517c3847841b09c02473de630860c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RleHRyZWdpb246YmZlYjYzMGVhNWJhNDUzMjlhZTJhZDIyNmQ3Yzg3ZmVfODU1_9968e8e4-19ea-41f0-90b6-22e57f605668"
      unitRef="distribution_channel">2</mdxg:RevenueFromContractWithCustomerNumberOfDistributionChannels>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic08501ad9a844ed4bfcec556b74f305f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMi0xLTEtMS05MDE5NA_41beee6a-fa69-4cab-b151-8b5628a2f657"
      unitRef="usd">65898000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c8e45a1b351403d8b7085dbe2706856_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMi0zLTEtMS05MDE5NA_948eeded-d924-469e-910d-6e937d273d28"
      unitRef="usd">61087000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0af08c412f7f4e7f82c54239d39b7b11_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMi01LTEtMS05MDE5NA_effdaaf2-8968-449d-bc04-10200d404baa"
      unitRef="usd">188231000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec1dffc619904a4d9e56ade452761dd4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMi03LTEtMS05MDE5NA_aa80e1e0-7bf2-42eb-9b2b-fbd37ede989d"
      unitRef="usd">184706000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f77e1063b8c4fa59391a91c4b07687c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMy0xLTEtMS05MDE5NA_03963fe5-0d0e-4c1e-83b4-ff7d7b6d9d8b"
      unitRef="usd">1791000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad1c7de372124c51b75ab2ddc755118f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMy0zLTEtMS05MDE5NA_78ce52aa-65f0-488c-9663-d320ad9349bc"
      unitRef="usd">1987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8de990b776a540a18972151167955eaf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMy01LTEtMS05MDE5NA_482e2f78-2948-4f7c-98c9-f5dd9800b66f"
      unitRef="usd">5235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8be7f2d7a9034919910bd938ce9e1003_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfMy03LTEtMS05MDE5NA_985e9db5-6784-4671-8770-12242e179fd5"
      unitRef="usd">6500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfNC0xLTEtMS05MDE5NA_873d65d3-b148-4b3a-bf9c-b11402269fd9"
      unitRef="usd">67689000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfNC0zLTEtMS05MDE5NA_3d753573-46ff-4f3a-bdf8-dc040665afad"
      unitRef="usd">63074000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfNC01LTEtMS05MDE5NA_1434b30c-f021-4404-8e67-b95f619c742c"
      unitRef="usd">193466000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl84NS9mcmFnOmJmZWI2MzBlYTViYTQ1MzI5YWUyYWQyMjZkN2M4N2ZlL3RhYmxlOjYwYjk5Y2ViMjA3NTQ4MWU4ZDhlOTBhNmYxNDAyM2MwL3RhYmxlcmFuZ2U6NjBiOTljZWIyMDc1NDgxZThkOGU5MGE2ZjE0MDIzYzBfNC03LTEtMS05MDE5NA_4ee7467d-c76d-4b82-871d-74d97df4e1c5"
      unitRef="usd">191206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGV4dHJlZ2lvbjo0MDAxZDgwODgzMDA0MmU4OWJiZTNiMTgwNTU4ODcxNl8yNzQ4Nzc5MDc3NjMz_918efb08-2a4d-43b4-b860-eaac85c6efbe">Segment InformationThe Company has two reportable segments: Wound &amp;amp; Surgical and Regenerative Medicine.&lt;div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wound &amp;amp; Surgical focuses on the Advanced Wound Care and Surgical Recovery markets, the Company&#x2019;s existing product portfolio, and near-term product development. Its platform technologies include tissue allografts derived from human placental membrane (EPIFIX&#xae;, AMNIOFIX&#xae;, and AMNIOEFFECT&#x2122;), tissue allografts derived from human umbilical cord (EPICORD&#xae; and AMNIOCORD&#xae;), and a particulate extracellular matrix derived from human placental disc (AXIOFILL&#x2122;). This segment is also responsible for the international sales of the Company&#x2019;s Section 351 products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Regenerative Medicine business focuses solely on Regenerative Medicine technologies, specifically progressing the Company&#x2019;s placental biologics platform towards registration as a FDA-approved biological drug. Micronized dehydrated human amnion chorion membrane is the lead product candidate in its late-stage pipeline targeted at achieving FDA approval for specific clinical indications, including degenerative musculoskeletal conditions, beginning with KOA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s corporate function includes expenses incurred by executive, finance, human resource, information systems, legal, other functions which are generally shared and whose activities are not specifically identifiable solely to either of the other segments. It also includes amortization of intangible assets. The Company has another operating segment related to an expiring dental sales contract. All net sales and cost of sales presented in the Corporate &amp;amp; Other columns below relate to this operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wound &amp;amp; Surgical net sales reflects sales of the Company&#x2019;s Advanced Wound Care products (as discussed in Note 14, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), except for sales of the Company&#x2019;s dental product. Sales of the Company&#x2019;s dental product are included in the Corporate &amp;amp; Other columns in the tables below. In addition, Wound &amp;amp; Surgical reflects international sales of the Company&#x2019;s Section 351 products, which represent all Section 351 sales not reflected in Regenerative Medicine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the segments are the same as the Company&#x2019;s accounting policies. See Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, included in the 2021 Form 10-K for significant accounting policies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the performance of its segments and allocates resources based on segment contribution, defined as net sales less (i) cost of sales, (ii) selling, general and administrative expense, (iii) research and development expense, and (iv) amortization of intangible assets. Prior period results were recast on the basis of new operating segments. The only components which comprise loss before income tax provision that are not included in operating loss are interest expense, net and other expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net sales and segment contribution for each reportable segment for the three months ended September 30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Net sales and segment contribution by each reportable segment for the three months ended September 30, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,885)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company does not allocate any assets to the reportable segments. No asset information is reported or disclosed to the chief operating decision maker in the financial information for each segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGV4dHJlZ2lvbjo0MDAxZDgwODgzMDA0MmU4OWJiZTNiMTgwNTU4ODcxNl8yNzQ4Nzc5MDc3NjM2_cccba826-695e-4ff9-bcc0-9c8d43efc093">Segment InformationThe Company has two reportable segments: Wound &amp;amp; Surgical and Regenerative Medicine.&lt;div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wound &amp;amp; Surgical focuses on the Advanced Wound Care and Surgical Recovery markets, the Company&#x2019;s existing product portfolio, and near-term product development. Its platform technologies include tissue allografts derived from human placental membrane (EPIFIX&#xae;, AMNIOFIX&#xae;, and AMNIOEFFECT&#x2122;), tissue allografts derived from human umbilical cord (EPICORD&#xae; and AMNIOCORD&#xae;), and a particulate extracellular matrix derived from human placental disc (AXIOFILL&#x2122;). This segment is also responsible for the international sales of the Company&#x2019;s Section 351 products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Regenerative Medicine business focuses solely on Regenerative Medicine technologies, specifically progressing the Company&#x2019;s placental biologics platform towards registration as a FDA-approved biological drug. Micronized dehydrated human amnion chorion membrane is the lead product candidate in its late-stage pipeline targeted at achieving FDA approval for specific clinical indications, including degenerative musculoskeletal conditions, beginning with KOA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s corporate function includes expenses incurred by executive, finance, human resource, information systems, legal, other functions which are generally shared and whose activities are not specifically identifiable solely to either of the other segments. It also includes amortization of intangible assets. The Company has another operating segment related to an expiring dental sales contract. All net sales and cost of sales presented in the Corporate &amp;amp; Other columns below relate to this operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wound &amp;amp; Surgical net sales reflects sales of the Company&#x2019;s Advanced Wound Care products (as discussed in Note 14, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), except for sales of the Company&#x2019;s dental product. Sales of the Company&#x2019;s dental product are included in the Corporate &amp;amp; Other columns in the tables below. In addition, Wound &amp;amp; Surgical reflects international sales of the Company&#x2019;s Section 351 products, which represent all Section 351 sales not reflected in Regenerative Medicine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the segments are the same as the Company&#x2019;s accounting policies. See Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, included in the 2021 Form 10-K for significant accounting policies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the performance of its segments and allocates resources based on segment contribution, defined as net sales less (i) cost of sales, (ii) selling, general and administrative expense, (iii) research and development expense, and (iv) amortization of intangible assets. Prior period results were recast on the basis of new operating segments. The only components which comprise loss before income tax provision that are not included in operating loss are interest expense, net and other expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net sales and segment contribution for each reportable segment for the three months ended September 30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Net sales and segment contribution by each reportable segment for the three months ended September 30, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,885)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company does not allocate any assets to the reportable segments. No asset information is reported or disclosed to the chief operating decision maker in the financial information for each segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGV4dHJlZ2lvbjo0MDAxZDgwODgzMDA0MmU4OWJiZTNiMTgwNTU4ODcxNl8xNjQ5MjY3NDQ1NzQw_49c9a2d1-195e-4085-bace-89e25c311f39"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGV4dHJlZ2lvbjo0MDAxZDgwODgzMDA0MmU4OWJiZTNiMTgwNTU4ODcxNl8yNzQ4Nzc5MDc3NjM1_c2035de6-0a3d-4017-9e11-31cfc95848f1">&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net sales and segment contribution for each reportable segment for the three months ended September 30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Net sales and segment contribution by each reportable segment for the three months ended September 30, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Net sales and segment contribution by each reportable segment for the nine months ended September&#160;30, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wound &amp;amp; Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regenerative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,885)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investigation, restatement and related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Supplemental information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xLTEtMS0xLTk4NjA5_404d4d15-4347-4929-8166-eeb21c580ec5"
      unitRef="usd">66873000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xLTMtMS0xLTk5MDI3_b075cb16-ae3f-4fea-a515-3bf0fa8f0de7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xLTUtMS0xLTEwMDA2NQ_f5f91bfc-8c5c-4dad-bc38-ee3b44ff2324"
      unitRef="usd">816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xLTctMS0xLTk4NDY3_70458ce1-45cb-4d24-95b9-f3917af3cae5"
      unitRef="usd">67689000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yLTEtMS0xLTk4NjA5_9b7e5298-3189-4b4a-bf5c-f8f53c362529"
      unitRef="usd">11159000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yLTMtMS0xLTk5MDI3_01aed598-e4a2-4f28-9ba4-d4af47f955be"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yLTUtMS0xLTEwMDA2OA_f49b04b6-f9a7-4caf-aa89-e28b9a0ff8a3"
      unitRef="usd">1029000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yLTctMS0xLTk4NDY3_d52e2412-f254-4849-bdf7-be7073dd4a8f"
      unitRef="usd">12188000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl84LTEtMS0xLTk4NjE1_9888973e-c4e3-4697-bedd-d698528cd980"
      unitRef="usd">35531000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl84LTMtMS0xLTk5MDMz_dd9493bd-388c-45f5-bdab-1409e87fd790"
      unitRef="usd">0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl84LTUtMS0xLTEwMDA3NA_635877f9-2f84-4fee-bedf-55e3370aec81"
      unitRef="usd">17944000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl84LTctMS0xLTk4NDY3_334ef8c4-303c-4e0e-a2f6-23fc3a228175"
      unitRef="usd">53475000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl85LTEtMS0xLTk4NjE1_932f510d-49f8-40d6-9e79-a860fd654c13"
      unitRef="usd">1680000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl85LTMtMS0xLTk5MDMz_53cb8fb9-cc54-41b4-9899-db76ffb18c29"
      unitRef="usd">4273000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl85LTUtMS0xLTEwMDA3NA_48f7e93e-6318-4920-987f-93c7b38c02bc"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl85LTctMS0xLTk4NDY3_53ca9d48-eb7e-46f5-9300-d9942649efac"
      unitRef="usd">5953000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0xLTEtMS0xMDUzMjQ_67a93ba1-2fff-4ef9-a6a1-148077344ed4"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0zLTEtMS0xMDUzMjQ_d9d1ee60-9753-41cc-bc78-520ec042d628"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC01LTEtMS0xMDUzMjQ_c4fb11a6-7f37-48e5-a0d1-fc7f82072db0"
      unitRef="usd">175000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC03LTEtMS0xMDUzMjQ_ecb678e2-85e0-494b-8aac-686515841fc8"
      unitRef="usd">175000</us-gaap:AmortizationOfIntangibleAssets>
    <mdxg:SegmentContribution
      contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0xLTEtMS0xMDIzNjI_18a057fc-51ae-48ef-908b-fb8f3f539627"
      unitRef="usd">18503000</mdxg:SegmentContribution>
    <mdxg:SegmentContribution
      contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0zLTEtMS0xMDIzNjI_b91d408c-83c3-462d-9c50-4821fbdc89cd"
      unitRef="usd">-4273000</mdxg:SegmentContribution>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0xLTEtMS0xMDAwNzQ_1e2f5a93-cc60-4922-9884-da8156dd6a32"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC0zLTEtMS0xMDAwNzQ_6df3e6e3-3bc9-458f-87b4-ffcb4443db4e"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC01LTEtMS0xMDAwNzQ_6a73a6e8-3f6a-4176-9ac2-5d4d92f1ac65"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMC03LTEtMS05ODQ2Nw_3814843b-45ba-4b9d-b786-f0dd1baba88d"
      unitRef="usd">3001000</mdxg:InvestigationRestatementAndRelated>
    <us-gaap:OperatingIncomeLoss
      contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMy0xLTEtMS05ODYyMQ_ddcfc6e9-3a56-4a52-bf7f-73c492656bd5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMy0zLTEtMS05OTA0Mg_338d6969-9bce-4e20-87d0-9706f0add9f2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMy01LTEtMS0xMDAwNzQ_fbebf16a-a6da-4483-b6d9-0d1a9525562e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8xMy03LTEtMS05ODQ2Nw_5e490f43-f6d1-464d-a00c-0e2b63262d13"
      unitRef="usd">-7103000</us-gaap:OperatingIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMS0xLTEtMS05OTIxMg_a11ef1c7-032f-4569-bc65-af89c51d6834"
      unitRef="usd">451000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMS0zLTEtMS05OTIyNw_f9f71729-0816-4e0a-9486-0f0be6d418f0"
      unitRef="usd">36000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMS01LTEtMS0xMDAwNzk_2ae650e1-0d4d-47db-a350-3963fbd0c3f2"
      unitRef="usd">344000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMS03LTEtMS05OTIwMw_370052d9-a6cb-4df8-ad02-e882bf05e1a2"
      unitRef="usd">831000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="i80e21aae85d84fada2600c5e224369b6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMi0xLTEtMS05OTIzNg_72c46868-673f-4675-abe7-7e4e3abd7eb2"
      unitRef="usd">1945000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6190a03b52174343a94df4d3444d1b5e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMi0zLTEtMS05OTI0Mw_7b63dbbb-8531-4252-8b8c-2928129b3c02"
      unitRef="usd">347000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMi01LTEtMS0xMDAwNzk_1b36662f-3d46-41bc-9e17-fefecdd8c877"
      unitRef="usd">80000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2a352529eb914eca834297bbac755ba4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NDhkNDM5MDgzZDgzNDYwMmE2NDg1MWZhNjA4MmYwMDIvdGFibGVyYW5nZTo0OGQ0MzkwODNkODM0NjAyYTY0ODUxZmE2MDgyZjAwMl8yMi03LTEtMS05OTIwOQ_7f2e031b-6ff0-4dcd-9e3f-7dd9b33f1449"
      unitRef="usd">2372000</us-gaap:ShareBasedCompensation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xLTEtMS0xLTk4Njcy_d52ca73f-a09a-4147-b474-07c28951b9d3"
      unitRef="usd">62138000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xLTMtMS0xLTk5MDQ3_06ec6950-c517-4ebb-a11e-39800fa48c78"
      unitRef="usd">76000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xLTUtMS0xLTEwMDEyMg_f6b480fb-8c5e-4ec5-b7d3-9847a0ff545d"
      unitRef="usd">860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xLTctMS0xLTk4NTU1_dc456ab6-8073-4702-a75f-7aa5418a3380"
      unitRef="usd">63074000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yLTEtMS0xLTk4Njcy_17c39fdb-4547-4385-a66a-8ebfb4101ded"
      unitRef="usd">8924000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yLTMtMS0xLTk5MDQ3_73a221fd-e8bd-4ba2-8553-5f8594a7c10e"
      unitRef="usd">16000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yLTUtMS0xLTEwMDEyMg_7ecb10ac-262d-4fc0-8450-3397c7ef9cf4"
      unitRef="usd">1189000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yLTctMS0xLTk4NTU1_2dead21f-edc4-42e3-8dcc-d8987871e676"
      unitRef="usd">10129000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV84LTEtMS0xLTk4Njc3_e68230a8-3763-4c9d-9e29-8d8a7c6c15c6"
      unitRef="usd">32104000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV84LTMtMS0xLTk5MDUy_7a7bc726-2353-48b8-ba27-531c1a1da71e"
      unitRef="usd">1285000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV84LTUtMS0xLTEwMDEyMg_ae3f106c-2e2d-4181-aedf-3799b1c4692f"
      unitRef="usd">12900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV84LTctMS0xLTk4NTU1_4e6f90ab-60d4-4e18-9307-c220aec7e6d0"
      unitRef="usd">46289000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV85LTEtMS0xLTk4Njc3_2f0d86d6-83ca-498a-81cb-05a1e171bf86"
      unitRef="usd">1423000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV85LTMtMS0xLTk5MDUy_d90aebbb-dde4-4c27-8865-c3eed6e69e2b"
      unitRef="usd">2945000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV85LTUtMS0xLTEwMDEyMg_64ea5a1e-f774-4512-a3a8-c4a919d44084"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV85LTctMS0xLTk4NTU1_3babddb1-ac57-4289-983b-e3af652fb633"
      unitRef="usd">4368000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0xLTEtMS0xMDUzNTM_3f68744d-ec6b-4411-87c0-8149eaf24003"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0zLTEtMS0xMDUzNTM_3789ae63-101a-48e2-93b4-aff3ef7cddb0"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC01LTEtMS0xMDUzNTM_1fb074ad-671a-48e6-8a62-b0c63495bedc"
      unitRef="usd">193000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC03LTEtMS0xMDUzNTM_072ce126-4765-45ee-b170-6680df750884"
      unitRef="usd">193000</us-gaap:AmortizationOfIntangibleAssets>
    <mdxg:SegmentContribution
      contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0xLTEtMS0xMDI2MDQ_1c928321-2787-4038-895c-490e978aefd0"
      unitRef="usd">19687000</mdxg:SegmentContribution>
    <mdxg:SegmentContribution
      contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0zLTEtMS0xMDI2MDQ_8dcd7622-5dfe-4f1c-9eba-be44d24343d1"
      unitRef="usd">-4170000</mdxg:SegmentContribution>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0xLTEtMS0xMDAxMTY_c5555006-c6ef-41ac-bc1c-a986b6579e4a"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC0zLTEtMS0xMDAxMTk_560ac4f0-93af-4c39-9760-27f00b59bd42"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC01LTEtMS0xMDAxMjI_416dea56-ab45-4482-950e-415b4c763577"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMC03LTEtMS05ODU1NQ_82484051-697b-43e8-83ea-0b47c25378a1"
      unitRef="usd">3170000</mdxg:InvestigationRestatementAndRelated>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMy0xLTEtMS05ODY4Mg_21d6020b-f808-4899-9579-0c9660c35dac"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMy0zLTEtMS05OTQ5OQ_de7f7652-55e5-44bb-896e-f6f87a6a3937"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMy01LTEtMS0xMDAxMjI_83ead9f7-bd46-4900-8adb-1ad8f45ccbfc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8xMy03LTEtMS05ODU1NQ_4948a8ba-536f-4d39-ae9c-806973f2219a"
      unitRef="usd">-1075000</us-gaap:OperatingIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMS0xLTEtMS0xMDAxMTY_14ce9fbd-cd5a-4dbf-ab65-042f850ba61b"
      unitRef="usd">511000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMS0zLTEtMS0xMDAxMTk_27e923a3-8d5f-4408-93e4-25cc0357ffe2"
      unitRef="usd">34000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMS01LTEtMS0xMDAxMjI_9aeb0f70-7b68-4514-8264-adc07d25033e"
      unitRef="usd">378000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMS03LTEtMS0xMDAxMzU_a99ffa13-12c0-417e-9e7b-3b2692c61ecd"
      unitRef="usd">923000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5d33b69702834f838661561304e8f6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMi0xLTEtMS0xMDAxMTY_332e3698-10c0-4e47-be6c-353768d5219d"
      unitRef="usd">1435000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibcda89e76b884589826eac6a6fb92494_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMi0zLTEtMS0xMDAxMTk_c81a8622-2fbb-4576-bfce-4d4f9182e36f"
      unitRef="usd">322000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie49a9534f8de4f2e98b48e11d0528113_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMi01LTEtMS0xMDAxMjI_dbfe3e1f-f802-48c4-8aa2-71bce45ef61d"
      unitRef="usd">2054000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id398453a4e9b425fae334d967d1fba8a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MjIzN2YwM2JkZGQ1NDEyM2FhMTczMzU2YWIxZDg3MTkvdGFibGVyYW5nZToyMjM3ZjAzYmRkZDU0MTIzYWExNzMzNTZhYjFkODcxOV8yMi03LTEtMS0xMDAxMzU_169f1c96-687d-40ac-8202-102a31c1a82a"
      unitRef="usd">3811000</us-gaap:ShareBasedCompensation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xLTEtMS0xLTk5MzI0_0bbe0a61-6a0d-4c5b-a371-99082d63ffa8"
      unitRef="usd">191297000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xLTMtMS0xLTk5MzMx_75368c29-1877-4cb3-9555-62da11cbd093"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xLTUtMS0xLTEwMDE1MQ_a9709967-3932-49e7-b3c2-685e02fcbb80"
      unitRef="usd">2169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xLTctMS0xLTk5MTgy_0f0d8aca-03d7-4cc1-aa3d-ff8ea4ab28d5"
      unitRef="usd">193466000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yLTEtMS0xLTk5MzI0_4c4bfcb3-c524-4f53-b666-23b22b5aa412"
      unitRef="usd">31126000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yLTMtMS0xLTk5MzMx_4db3cdf4-c260-4ddf-b5d8-6cc31461a6e2"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yLTUtMS0xLTEwMDE1MQ_2e1a7793-abbb-42e6-841b-8745d312dba6"
      unitRef="usd">2821000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yLTctMS0xLTk5MTgy_7e067564-8774-4be7-a652-ea223a38a077"
      unitRef="usd">33947000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV84LTEtMS0xLTk5MzM4_9bda2c10-eec9-4335-8cbb-aa04cd67be47"
      unitRef="usd">108256000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV84LTMtMS0xLTk5MzY3_9cc7cc63-dddf-4d9b-9531-a3ec0febf38f"
      unitRef="usd">0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV84LTUtMS0xLTEwMDE1NA_4c2f7bcd-5253-4b28-aec9-4b3af0dd03dc"
      unitRef="usd">50582000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV84LTctMS0xLTk5MTg2_40007806-314d-4f53-8c8b-5d089f70af92"
      unitRef="usd">158838000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV85LTEtMS0xLTk5MzM4_ca19fe24-40ff-4c43-b20b-1f85f0f95460"
      unitRef="usd">6068000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV85LTMtMS0xLTk5MzYw_754aaef5-26e1-4b0a-8bfd-5d6a43d46be5"
      unitRef="usd">11361000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV85LTUtMS0xLTEwMDE1NA_9534747f-3a35-4d13-a97e-6d89ab54aa51"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV85LTctMS0xLTk5MTg2_a904f3b2-88ac-492f-b3c9-dddcc8c00189"
      unitRef="usd">17429000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0xLTEtMS0xMDUyNzQ_fabf4051-f215-4a81-8cd5-4f7a7d55b1c0"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0zLTEtMS0xMDUyNzQ_a4576fb8-f608-4444-b6cd-2217fe4e84a6"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC01LTEtMS0xMDUyNzQ_9dbd8f99-57c2-480d-b541-9422dba8bdc4"
      unitRef="usd">519000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC03LTEtMS0xMDUyNzQ_9aa894c3-f52d-418a-990f-aafe1a864caf"
      unitRef="usd">519000</us-gaap:AmortizationOfIntangibleAssets>
    <mdxg:SegmentContribution
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0xLTEtMS0xMDI2MTU_8a8208fa-55d8-4393-b126-80f0b7677272"
      unitRef="usd">45847000</mdxg:SegmentContribution>
    <mdxg:SegmentContribution
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0zLTEtMS0xMDI2MTU_1d766d1c-df88-4149-b162-4ff294242a76"
      unitRef="usd">-11361000</mdxg:SegmentContribution>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0xLTEtMS0xMDAxMzc_98aeec6c-88ed-4710-8e6b-5b89111ee269"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC0zLTEtMS0xMDAxNDY_2c736bb6-3aa3-46c1-88a3-d466176d6c7b"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC01LTEtMS0xMDAxNTQ_3138217e-f52c-47e2-b3d3-c062ba81f5b1"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMC03LTEtMS05OTE4Ng_dad1b718-41fa-46f0-95e8-81d112bd2a39"
      unitRef="usd">8771000</mdxg:InvestigationRestatementAndRelated>
    <us-gaap:OperatingIncomeLoss
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMy0xLTEtMS05OTQ5NA_72c50bc3-a76f-4aa8-87e9-7d8eb961f7b9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMy0zLTEtMS05OTcyNQ_94fc714a-f95e-4e6f-a82e-78dc9bb828f7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMy01LTEtMS0xMDAxNTQ_7da49b85-22fa-4953-9854-3886d27277e1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8xMy03LTEtMS05OTE4Ng_83ebf85a-d0ac-483b-8372-7417d12bd933"
      unitRef="usd">-26038000</us-gaap:OperatingIncomeLoss>
    <us-gaap:Depreciation
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMS0xLTEtMS05OTI4NA_b862e598-d89e-44f4-896e-e882a58a9dce"
      unitRef="usd">1364000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMS0zLTEtMS05OTI4OQ_fcc5bde0-d760-4211-aa26-3b2f1bda609c"
      unitRef="usd">120000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMS01LTEtMS05OTI5NA_7d04c743-fdd3-4775-ab89-f3c8e102af48"
      unitRef="usd">1065000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMS03LTEtMS05OTI3OA_f28cbb48-c497-4bdf-b6e0-cd95bf22c0c2"
      unitRef="usd">2549000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="if3fb23f65cb64d2382071ff4df5a520c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMi0xLTEtMS05OTMwMQ_0f7bb625-d198-4169-8d85-d255e6008b67"
      unitRef="usd">5609000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icf8676e75a824f97858a0b56380e8050_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMi0zLTEtMS05OTMwNg_061dc963-5ace-4905-946c-f481ba600cba"
      unitRef="usd">910000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7acdf20bdfa047b9a961fba2b2c7f8d6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMi01LTEtMS05OTMxMQ_b57e99d8-e117-493e-9b94-22ed737a5cd7"
      unitRef="usd">4279000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6NWI3MmI3ZWM5M2VlNGY0Mzk0MWZkNDc3YThjMzUyOGEvdGFibGVyYW5nZTo1YjcyYjdlYzkzZWU0ZjQzOTQxZmQ0NzdhOGMzNTI4YV8yMi03LTEtMS05OTI4MQ_916ff3c3-eadf-4f61-8134-f34d8a8eb8a1"
      unitRef="usd">10798000</us-gaap:ShareBasedCompensation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xLTEtMS0xLTk5NDA2_32836663-071b-4ad2-924a-bc01c3d49183"
      unitRef="usd">172401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xLTMtMS0xLTk5NDI3_1a7a6b6e-a0e4-47c9-b72f-93856ea56aea"
      unitRef="usd">16584000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xLTUtMS0xLTEwMDE1OQ_4d5905e5-aef3-4717-8673-cb187833290d"
      unitRef="usd">2221000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xLTctMS0xLTk5Mzg1_3fd7e7bb-ee0e-4166-b838-780aac74fdca"
      unitRef="usd">191206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yLTEtMS0xLTk5NDA2_55723ba6-cc66-4e6b-827a-bfb6cb5b61b4"
      unitRef="usd">25646000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yLTMtMS0xLTk5NDI3_5f6e6d04-8fec-4c51-8e9d-0e5f156906b6"
      unitRef="usd">3652000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yLTUtMS0xLTEwMDE1OQ_4e9ad9a9-189a-4bdb-a40d-41e7bc19a3c4"
      unitRef="usd">3232000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yLTctMS0xLTk5Mzg1_41d809c7-c1f0-443b-8d07-b4dcf4771967"
      unitRef="usd">32530000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV84LTEtMS0xLTk5NDM0_b17b0525-5e4e-4f48-8263-fdba6457c00b"
      unitRef="usd">87392000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV84LTMtMS0xLTk5NDQx_d2bec476-867d-4ead-858b-650ee058dd1a"
      unitRef="usd">11127000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV84LTUtMS0xLTEwMDE3Mw_4817fc3c-918b-4730-979d-73a7fcb0948c"
      unitRef="usd">46772000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV84LTctMS0xLTk5Mzg5_c8eaebaf-f662-46a7-bb28-39879fcdca6b"
      unitRef="usd">145291000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV85LTEtMS0xLTk5NDEz_efe8cda7-f25b-4efc-a2fd-4db37c518d2d"
      unitRef="usd">4080000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV85LTMtMS0xLTk5NDIw_0fef656d-425d-464a-a1a8-65bb2da8368a"
      unitRef="usd">8690000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV85LTUtMS0xLTEwMDE3Mw_42811c8d-65ce-4b54-8a33-145c69e0bc28"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV85LTctMS0xLTk5Mzg5_a95a6282-f0ee-4bb3-bea8-e7ac4c0173f3"
      unitRef="usd">12770000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0xLTEtMS0xMDUzMDI_361e525b-dd85-4336-a513-efafd6fbfe51"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0zLTEtMS0xMDUzMDI_9a17f009-98c7-4091-9913-1bca8008a8b7"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC01LTEtMS0xMDUzMDI_fdef3b68-00da-4e23-b23c-bde2bc190771"
      unitRef="usd">647000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC03LTEtMS0xMDUzMDI_815a0aef-17d3-4c74-a64e-ac06e32039cc"
      unitRef="usd">647000</us-gaap:AmortizationOfIntangibleAssets>
    <mdxg:SegmentContribution
      contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0xLTEtMS0xMDI2MzI_0bdda405-d8e0-480c-b379-63c784569748"
      unitRef="usd">55283000</mdxg:SegmentContribution>
    <mdxg:SegmentContribution
      contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0zLTEtMS0xMDI2MzI_fb4729a7-f4ec-46b1-8806-0b7ac03e6fbe"
      unitRef="usd">-6885000</mdxg:SegmentContribution>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0xLTEtMS0xMDAxNjM_1e35d855-9aa9-4085-9bd0-8650eb332382"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC0zLTEtMS0xMDAxNjY_4a8901bc-7037-4272-9e8b-86f79ea66205"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC01LTEtMS0xMDAxNzM_baf3a18d-3832-4cab-9373-f6039b9f4c93"
      unitRef="usd"
      xsi:nil="true"/>
    <mdxg:InvestigationRestatementAndRelated
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMC03LTEtMS05OTM4OQ_5243efe8-f261-4b4d-b7fc-69ff4b97f7fb"
      unitRef="usd">8304000</mdxg:InvestigationRestatementAndRelated>
    <us-gaap:OperatingIncomeLoss
      contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMy0xLTEtMS05OTUxMQ_00dc8e14-dbf9-439c-a4b8-86260e63f5a2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMy0zLTEtMS05OTc0Ng_99f9d8fb-7f7b-469b-b293-2fd3c6982c93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMy01LTEtMS0xMDAxNzM_2356390e-046b-4d1c-aaf9-e76bdedcd31b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8xMy03LTEtMS05OTM4OQ_15439f75-4535-4013-813c-ca3cc9788177"
      unitRef="usd">-8336000</us-gaap:OperatingIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMS0xLTEtMS05OTQ0OA_48cac5f2-a318-4e66-961b-523adfad79eb"
      unitRef="usd">1172000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMS0zLTEtMS05OTQ1NQ_edf16db9-3fb8-4b10-abad-1767c1bbca7f"
      unitRef="usd">213000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMS01LTEtMS05OTQ2Mg_4c5da6e6-b23e-4bcb-9c0b-70b8b64bbcfc"
      unitRef="usd">2005000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMS03LTEtMS05OTQwMw_9a130457-280b-47c9-b63d-c1f6cab7028c"
      unitRef="usd">3390000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="i227eac62db7b4218ae63d23d001ea21b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMi0xLTEtMS05OTQ2OQ_90a6a163-9ecb-4325-bc23-6d4d04018968"
      unitRef="usd">3827000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0f0956581a13466abb38115e688ddbcf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMi0zLTEtMS05OTQ3Ng_41250b11-a6e5-4e1f-b2be-255c4183449d"
      unitRef="usd">1147000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i520ef3a5224c446f89666b27c8bcdd4a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMi01LTEtMS0xMDAxNzM_622eb5ee-6541-4e8c-b28b-e1ce3fa855a8"
      unitRef="usd">6141000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9143a8eb80e4462288b122d58c03b937_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlMWZlMTcyNzYyMzRkNTViYWI2MDg0NjJmZTQxMzFiL3NlYzpkZTFmZTE3Mjc2MjM0ZDU1YmFiNjA4NDYyZmU0MTMxYl8xMzU0L2ZyYWc6NDAwMWQ4MDg4MzAwNDJlODliYmUzYjE4MDU1ODg3MTYvdGFibGU6MTMxMGVkNjE3YWUyNDU1YmE1ZjA1NWU5MTYyMjYzYTkvdGFibGVyYW5nZToxMzEwZWQ2MTdhZTI0NTViYTVmMDU1ZTkxNjIyNjNhOV8yMi03LTEtMS05OTQwMA_f7aa874a-d9be-4c72-9f4f-0e7e93f0deb3"
      unitRef="usd">11115000</us-gaap:ShareBasedCompensation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0!]7KW!<5#O"'R6$)>:J-Z1D < B<9I0TS  P$812TVK$^H:X1(Q/K#J*3.
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M-@1&Q+0#IFYZ;X50+8TM&G>>08[%J0ND# WFKG1PI=$94,M F5FK,74S>&N
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MZ?@9K.*P%/*\E"L2G'#%FG<HCGY&)"+$H>?Z^X?C@)SXX-FXG2_V>9:J+=I
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M:1LM2.)120:5).S<HI#LV;/MYB-S+9FIG4BL*W[O3?Y^ZI/M'D>$PR;U1<3
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M!O#]1L#AI+\P/W!XM[S\/U!+ P04    " #T@6)5PYA"/:@(  #M%0  &
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MJ!(MP/?T-BD_T '#[W$N_@U02P,$%     @ ](%B53FY 7,7 P  ! <  !@
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MF?K-OF^9ZT.'KCA<'ZN?OY$IZT.;IUN%\[[I=0[#&VIGFSN)[:4_$(&W#M[
MCOLPFD[L8+ 9#(FL;P<CB 83WXG8DDX-F(RB.H..9')3"8?NT;W6:ZA M7)O
M/DT-G:K0/XR:U>99.?>OJ>_D_DUZP^AH%1IR7!)KV!T/.Z#\.\]/C"S=VVHA
M#;W4W#"CIS$J2T#[2TEWK7IB%32/[=G_4$L#!!0    ( /2!8E6H=Y+VX0(
M #X&   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;(U5;6_3,!#^*Z>
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MN RX$BR:6PQ6+Y[%L^CU ;W9J#<[Q/Y?*3G(\+B^OVEA;\"]H=!<:Y;8I#=
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MBD#FO8HK](Y#6;*%WJZG!J4% W<*2RJ[''?9E?LBJ,=@!UT R?G3 WH*A_;
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M:;R4],8 C^<$=Y$\E$34^'5X"UE R)7\5T=+@VNDFDJ%%AZUA-DM19;8<FR
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MIB<X\;2\]IF05D_[]Z%N/SP_HS(P)R"W_I<^_1T:]'2FNC[0'3"*A>G"B_.
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M8'(N1NETBD(XF6:C9#"=G>.PT7B/Y%^J>JDX'9Q-DM$(RR9IEM&^X72<7,]
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M1^T0M1MX?W22W;FBX6LKUV.>'E$CA=#E(V>+FV:%CJL%,>* &UG7K?*%9J>
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M!$WC=P<1F-ZE^HG337"&A7;D,V%8D[&C\0&T7VGM-A.?8/BKR'\"4$L#!!0
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M5I-%4.\?W5OOT62PXY(X8<!0OKU&_XYT7?6Q]<&L6GC9>;!/3;0L4+T4Y@9
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MBI2YB7)6D LXBM*RU(S0QY5(58F^2GM*)SUK@-!'NMV&Z1ETNI/:;LY]NWI
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MCPWP^TKC+=<_<(+M/Z2K?P!02P,$%     @ ](%B523)KGNK"0  6!P  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULS5EK;]LX%OTKA*<8)(":Z"VY
M>0!IVF*#F;9!TMT98+$?:(FVB4JBEY3B9'[]GDM*LI,Z:=(=[.R'Q!+%>WD?
MYYY+2L=KI;^:I1 MNZVKQIQ,EFV[>G-X:(JEJ+DY4"O1X,E<Z9JWN-6+0[/2
M@I=6J*X.0]]/#VLNF\GIL1V[U*?'JFLKV8A+S4Q7UUS?O1656I],@LDP<"47
MRY8&#D^/5WPAKD7[]]6EQMWAJ*64M6B,5 W38GXR.0O>O(UIOIWP#RG69NN:
MD2<SI;[2S45Y,O')(%&)HB4-'#\WXEQ4%2F"&?_N=4[&)4EP^WK0_L'Z#E]F
MW(AS5?TFRW9Y,LDGK!1SWE7ME5K_3?3^)*2O4)6Q_]G:S0VG$U9TIE5U+PP+
M:MFX7W[;QV%+(/<?$0A[@=#:[1:R5K[C+3\]UFK--,V&-KJPKEII&"<;2LIU
MJ_%40JX]O18+A+AE%XU+,")U?-A",3T^+'HE;YV2\!$E4_91->W2L/=-*<K[
M\H<P:+0J'*QZ&SZI\%JL#ECD>RSTP_ )?='H963U1=_Q\DJLE&YELV#_/)N9
M5@,3_]KEKM,6[]9&=?+&K'@A3B8H!"/TC9B<_OQ3D/I'3]@:C[;&3VE_;D9>
MK.3+4K!S5:]X<\>6W+!VK5!5% \^JP0S3L*\8;^IKBG9S[Q>';'K3B]DP2O&
M,70E%J(1FE,=L8^BE 56/=@]?ZX 7F$8"J_%PF?E#6\*4?:3S[D65N4X_TH4
MZD;H.V!;?Q6M\:Q8;^_//^5AD!T9)FZEL>E;:55V1<O(_+FJI/*LND9P_;H5
MNAXGE.(&Q+,BUP[816O8JN(MQ82UHE@VJE(+"3-E4U1=*5@KC>E@6H5QS>>8
M7PH-=TLVUZIFRZ[F#:DHH ]6UZ*>:=X(MO?^\N+#Q>\ 018?>>SLXZ>+SUOW
M9)L=>__AP_OS+_ GSL.C?>]YZW7U3%8V2H72I5WK_//5.Z=\HWLSMN]6Y&S%
M@?:B@\L"L2.\@_YPJQ'F5LO;I[TKI2G8WMGOY,JOOPY&'[ O2VD&O#!<\LH0
ME,Q*@:L)2XBO39]LD(O&H@_J#*\($/.=F;WN63I*@B%WAE82NU''9IW!CS$C
MT(RJ1'5'>-LML)UNCYF5*.2<8@H9K+> ^8: M<NV341FTFHHMF&DUER7!OXO
M)#&*ZS4("OOP[NPU7T$Y!7B0I+#J;G' /LI"JT;^@6>E6-Z5D,2E2P&O&])2
M+)6FWQ%EB#795Z'YC@ OD&E94H)EPR0 1,E^;5IT5+:2*U%9Y[E>"-+/6_3!
MI10WY"L,9,Y 6[!ZC HK(&5ME5!>6)\0-%<D)%ENA[CN#""FS%>TVM:"%$*]
MR Q1:1H26<MVR7[Y?.:2^C#$ #9*F;R8=XU#0E^25/38@1A7I)W6%,P[#(JB
MH^4]-I<-<8O7!P^95)VF>[DA/V;N3"MJ6%2)!:\\IA!(/2YFV'HIBR4C6G*>
M$2[,DM-J5$KKI3+";2'@&FRAF8UJ[P-)EH )[ARA.D"VB@EI%^N1[U8>Z)9(
MR170Z"^OJ4?]X>R&$*J(-PM;6-P8,=3%-I?SQFG%7HV2@G /Y:E%98$%,Q ;
MA%)JET"+9U>22)AMA0?LK*K H6T_3HX7RK1DA!NQ[:XA?;+I2V7(F^/_S]8,
M;$JZ&D&=T9ZO-X$L:(DXOK'QD0ZRL0/[--K$F:<99%>+&9B$[2%(1&<= FB-
M_Z1@4A![8(L;T8""P9GBMA"KUE7"4ROUP>N5'[#KYT^VN.DS_<P@]I-LE^Y#
M"M" )$I79=[N\(U!^R])V.M+ UL%EWQJ5O=F.I54#/V:SK-'=@L$75X4,-DU
M<C3O0FY,&NK"!LH.\)IPO]/>'7J0#2%<=D./7<M%8ZL39I]M)E\.BWK?Y (;
MSH#1?I\%_NM?'!:VE.Q<<;L:!;BT0RJ=P8"ZI2#@TE9R:[8<I Z-OE_8V0-K
M&7O&**F/#25LRU/..I=LG#@0QY)"LJF0BCKAGMR_7ZX>AC"&(Q#H?.$-S.96
M+G&8Z!O6C1@XUDI A#+--1%B4VYOH3;SZ,&>O-E_#EM=HHMIBH54):G&@0F$
M*Y!@+0I.!KO8PW-I@=#@,/<-3?2!5@U(M4"T56/#Z-!) UJ"HM&'J$@0=5MG
MJJ;*N24TWTA[D&R7O!W9>SO[FP6M#E>H*!UAMMRFD)/KCFZWAP_8IWO$N2M[
M%DZ"NVIZL/$>-TWM4@/!M3M0"3I0 =(K-*\95AS.1"Y\G+8_@-":DD^NJ<Y@
M;;/_R"9^]\YH-_V<HRL"X:7M'AO77K$T]?(LPH4MP_ (5WF0TH/,2_,I!+<[
M1A!X03(=YP:>'TY9$'I!GL.M9P,31.,E4;#1DWG3.&9)Y,59 K^>ABN637.?
MQ5X(PP<5B3=-(G;V/?B.\S=+)_;O>E>"7[$@]Q*?PK-GE]L'5=\ 0G+!7?T2
MGA!3*TKF#@UZ=-3S_8!]O@]&:,N\P(>VZVZUJJRTW9UM-CCOB)\+Z6X&9:]8
M#()^Q2+*3X2 (5>(XC5M;%X[HJ'*P5P^F(^X)G9R1I-]_ N]* N?@V[:EOT)
MX [^2G #F5&.BXPBEJ?D?XJ49/$#7.?>-(P9< ]\ _2![P4 ]HL0C:5\J/#"
M/*&*F/I :(J[Z7/P'(<1$D.Y&G 9>U&:_PB>IY']>PS/4]1.YO <9/X/X!E2
M._ ,)LB2E^,Y"2R>"<E11HF:(A!/XCF.+)[!F01E/[&B7@X]?PZD&X+9_R]=
M!U,@;)K=XVL@+YW:9^#/-'T [0B0#M-Q>NCAET41P):]"."!GWMALE&4^%Z2
MARQ(<B]'C7T7Y*GG ]!H(%%ZC_AC%-K+89X$4_OW",SCQ,LMY>VY!5^,\]S+
MLEV\'<*-*'\YT,D*@FH0^O;.3Q.;N22>/H7WQ$M]2NTT(#%J03;1OI=-\_\=
MX/]*"@^RT(M]8HD@!>!B&[4P#(9:\!_B/43,XA2<D"8A_H=12-R<1/Z+T)YG
M7C0-[7XGS(C(,S3- + *I\'WL1Y[/GIM[J53?P/U$#K\'X!Z"B"GMEAW0CV!
M3;G=H6 GER<_@/0(?>M;I&,\2G\$Z,@8)2F('$/[EJ\13?\IH(/"P\R)V[I-
M\6MSC($@N7<F*U5_/AV.6XQ&^^#9UQ)BUYMP[.B5FW7/#6GZR71*T_:M B+@
M7K&0)GJ]-M\Z393PV9X\:OX5N.W/F>ZEE7P0HO%\,+P:V?4]X7#K:T\M],)^
MTZ*W.#B8N@\_X^CXV>S,?2W:3'??W#YR5%Y#Y\<Y1/V#+)DP[;YCN9M6K>RW
MHYEJ6U7;RZ7@I= T <_G"B?M_H86&#\FGOX'4$L#!!0    ( /2!8E6M$G++
M@ L  !,A   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;+U::9,;MQ']
M*RBZRB5747M0UBUM%5=7[)2LC59RDDKE S@#<B#- &, LUSFU^=U YACQ:5E
MY?BRG /=Z&[T\;IGGVVM^^PKI8*X;FKCG\^J$-HGQ\>^J%0C_9%ME<&;M76-
M#+AUFV/?.B5+)FKJX\7)R8/C1FHS.WO&SR[<V3/;A5H;=>&$[YI&NMVYJNWV
M^>QTEA^\UYLJT(/CLV>MW*A+%3ZV%PYWQSV74C?*>&V-<&K]?+8\?7+^F-;S
M@E^UVOK1M2!-5M9^IIN?RN>S$Q)(U:H(Q$'BYTJ]4'5-C"#&;XGGK-^2",?7
MF?MKUAVZK*17+VS]5UV&ZOGLT4R4:BV[.KRWVS^II,]]XE?8VO-?L4UK3V:B
MZ'RP32*&!(TV\5=>)SM\#<$B$2Q8[K@12_E2!GGVS-FM<+0:W.B"565J"*<-
M'<IE<'BK01?.+O7&Z+4NI EB612V,T&;C;BPM2ZT\N).OOKAV7' ?D1U7"3>
MYY'WXA;>C\5;:T+EQ2M3JG)*?PPY>V$76=CSQ4&&EZH]$O=.YF)QLE@<X'>O
M5_X>\[MW"[]]"O]CN?+!P5G^N4_AR._'_?PH@)[X5A;J^0P1XI6[4K.S[[\[
M?7#R]("T/_;2_GB(^]FY]-H+NQ87Q-L$26Z]3\AO8",^5$IT1G:E#JH4A<6)
M&1^O/$Q32GJ\UD::0LM:>) IQ&;PHI)72JR4,@(ZM])AG:9H*ZPKL5K!H4/%
M]\G4K=-@TM8P]D89Y61=[^B]:D.D#9#EHV%!+FD?EG;9* <W%7>^_^[18G'R
M5+Q9+B\$WYP^_4$@/8$T8$TS$E.;F+8X_DT912'VVN"0.TX,7@0K*,+%Z<G=
MO_"RI0NZJ!4>T,[OU::K(X_+NW\[XC!Q)32I=W-BMA.E%<8&,"WJKE0""A%=
MW&<JP-K:@*50R:G?.DW&6NVB*J1!81O8):B]ECX2/T7;V%8;8H@]&FF0.NGU
MG+>5Y2?DC'@P='2Z5+2'487R'DF7=Y%B+;43[?C\D[QXA'3&!D?>=S(:B(CH
M+9YH6_I,"<;#X2?ERR-VI42,T\X<,X]0.:78%@:.*9J8(11E"'%)+M"LE.N#
MG!?BXE3 L=C(614-I]&FA$M06K\I?ZAD@'%VD$VHZQ8E@-PWB;#N8*FU]@7,
MNU/219%7LF9WC;50L@U>8K,HS^D\BK'%"]@46X*?LPTS'(7-[P0+I&+1:,E<
MK#I<63C#_\5[H*3_UB#WE>WJDJQ)E9^"%#2?.A-+:Q]6E4;!HC"MOX)G4O(%
MI)9FUSM0S@!L[AR7?SXZD$#O]PGT_L',]]&SG[SR03>45O;ESC_&X7^>-NEL
MCV B=@0==L/3[ )^E ,HDS7R,UR^%Y#<1GI KC;E.O(^N5XC(E+ M-:1D+*A
M_,RG@O4J1-):RY6N==")58FHJ:WO'-L!6E*,T\ZWT<1=R [YO+_-7,1X(N_O
MLIEZVBB;E9VCQ#1PXZ+$J8V2>^BP<\XC!;M]J6$PE^/=^I&!C\0800UVS]&<
MGT!@KY!X8)VK9,L6D0S[49E"!&C')PA16T?"XJQI$1URRV_H#A5.FHU>H39%
M@\]'6SJUD5R7XCO<!_A'Y+JJ]2:J/Z:(2:,_P]'!3?G6K "<:Q2O5'E/'S[U
MO)GW6?B-M>56UV.=N$B*1DERF[S.$5JF"YAEXCQ8IJ:2#/Y]RYY[I6+Z'0D=
M->QH&Y2^C24+X5FAG!FK"49<%J]DW;&S^@I1>9<@/\Y*[MB5!H)826LT-1RM
M=%?:;A7HC!/8\3?8>UFS.4/G3(K,3(^E=$][]_48O85RE!>"O$XF.I0%'_19
M\,'!''8QP"]L\J(/F5O Y#<S^P]R8PX>KJW)EL3_K7ZKRFOQQMFNG0,-%4<Q
M*O!V6UG R+MV:RCTNQ60CP9(H !=DC<2-"Q2I4F5/B45)XV7"0D.25G5&MU6
M#-S6FI'06'CH&![VQ_#PH.4NU8;]]WU.0?N,_P=9L,EEV]:,BJ(736L%)V#?
MY^*$I4<5!-3.RJ)*P!KXK%0U>[=/N_4Y,\*F/;2)"%U&#!X;"_H6<$R*XD:@
M%I56ZQ%>+%6AN>.G0N8&N/_BW<NW ]RW;B.-_A<T2F)YKHP).F1(06)O*PV)
M/)58QEQ4P=P4)(UA%H265U+7DG+LD%%A.]NY@M&9+09$%A-1*B#,!8X5#9.%
MJ"1#\01NN/Z2P[Y@O5]=JZ)C /MNC1HR4?C5NT%?B,5$,,(1&C=-2-:*GSL@
MZ R5YQ/5HV##ALG"5.@12F:,T$F/>*BL=#+H5 F@OL@PNI"Z!M!3E/?L^.R&
MLZ@00FM$58RQ0KNB:Q#@''6^VVR0%Z-DX.84(_4A]N D%<J<RDB0'"<O[B4B
M(!Y]KSP4CH_Z<'QT,);>I+JU+PJ_CG)BK]Y:?3WD!G6H\]"&2AV5==-Q!PR/
M>E<$2]W&*5NML;#,FD(7!%A 1E57>(T_G! =)SI8E1THVLPS-I_8.W5)JG<%
M.!/SKO5G5;-I#7<@_'XHX#[)2ST=.L_DX!DZ[2GT G4N3-UPK9T/@S5^@ZHZ
MQ(Z-W,,Z[KY+Q"-Q5E\ZU\ =0L2DM8_)5$=:54CG=B1L7\_E".YU!G90UX52
M98RLH?1/%4!&BXL@IJ2M8>RT=V GMAG9W)"=LP-CZKG0V-SLYK?@HVFD42C(
MV@.V5):0)C98[5I8\ O=1R"(X624% G. =S7NXS7OI!YWVE^L6@^/E<@?D_^
M ,;H3@8HJ*X#'_OM-I^"["^LWF>IP?Q3:_2>$=4? ;3.9]F!%FP3#=Y(]UD-
MA8BJ_T? #C=9EU[.;W+<YR(Z[IL&'L-"=IDNT+$7TE=B#1Q'ZH@KK;;CT4 -
MS!,Y5SL _@J8G+KC)"B*$NYU2[T#=7^HV+"OH\,;8$GNW/?LA]O),"*..E*?
M0RB;4@6Y-+T ^ +,)#")(\RS+T[/"'%-:)4&Z(R.90M?J.,N\_Z6F6 EI$AX
ME12B09+]%"<LL4A&KIV/H)#DG3/VCL $->9(_,J&S/,;%H1UN5(UR@F/-:A0
MYY%A/\(9*1]]<)AC3?Q"]N2"JAZA#OJ2T/%-/ZYPVG]F)[3  <1^>#-U ^39
M3]PQ6PX.!C^#8]WPNFD"83.D%0UZR@B6OQ@A70&LVLY'>.2X$$>D1%UT#Z-2
MJO'42NC4\&N#AC(EP=2=]I1]SLS29""2!P%[_'VEZ"Z5UHS=5GEHG%6X0>CG
MTZ( FZ(M'C*%1;\'O%7OV2\AJF&M4=N;W*= DAO2F/W'P7L+[2%T\+A'!X\/
MUOCWJH@U>%E:GE*/OAQ<HLR6@(G1Z_N5/WG?W;;P%Q3;O\,?$K=]F.._(0_2
M_"_V*@XP:9H6S^AUCWOW$IU;_ PH]/7R\GP,0V]7ZF/+4YZ><GGY<2"D[>^>
M JGVTWL(Y@Q7ER5\)6(5<>>#;74A'MU;_) ;D'E"\(BM*TV..QI!I;8F8LX!
MK&\&WANDT0Q"K0E.K[J8;F*9(1G[WF@ZVV)ODB'?C;O$")CC4&3\72-_0NI\
M=.;T+LZ=1PSB.2@>PLU3L\M)JTE3 \8)O0YRL \U*,B9, 0-J<@K4(E4XW-D
M[.NF8Z;VHRD5E=3>)LCGN5KP>'XBYR ;)5 =AEE</S8J.,U\J!#)9$W\1,4X
M/J'X:,Y.N059P+"N:T@QS-=/[\?Y^K3ZR^3=L03C_/T@:MIOV.QG"2#M=B).
MZA?,R2GN$XQE-(,$SKT\L^7"^BW1RO,$;.US-/"W#*S98<U4]S_^O6.>!IW.
M=IOJQNB4 1BE-H0$:=:#)Q[,9J#$GD=?/3379A)L*+S4,U"A[>LIUG+?!4K=
MI$DDS&0G?73?JP_NU5JO^R9X[T>CO6GW>/2ANE%NPY_C><IJ0OQFW3_MO_@O
MXX?N87G\=X&WTL&7/ #6&J0G1P_OS^)0,=\$V_)G[Y4-P39\62F)PDL+\)X^
MIN0;VJ#_/XBS?P-02P,$%     @ ](%B5<[74+.9 @  S04  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL?51M;]HP$/XKIVR:0$+-&U#&(!*TJSJI
MG:JREP_3/ICD0JPZ=F8[I?OW.R<A91+E"SY?[IY['LYWB[W23Z9 M/!2"FF6
M7F%M-?=]DQ98,G.A*I3T)5>Z9):N>N>;2B/+FJ12^%$03/V2<>DEB\;WH).%
MJJW@$A\TF+HLF?Z[1J'V2R_T#HY'OBNL<_C)HF([W*#]7CUHNOD]2L9+E(8K
M"1KSI;<*Y^NQBV\"?G#<FR,;G)*M4D_N\B5;>H$CA )3ZQ 8'<]XA4(X(*+Q
MI\/T^I(N\=@^H-\TVDG+EAF\4N(GSVRQ]&8>9)BS6MA'M;_%3L_$X:5*F.87
M]FWL-/ @K8U599=,#$HNVY.]=/_#4<+LK82H2X@:WFVAAN4ULRQ9:+4'[:()
MS1F-U":;R''IFK*QFKYRRK/)*DU5+:V!1TR1/[.MP!%\I<<P^.9L,USXELJX
M8#_M(-<M9/0&Y$>X5](6!C[+#+/_\WVBUW.,#AS7T5G #587$ <CB((H.H,7
M]YKC!B]^ ^]5JH%?JZVQFM[&[U-"6YSQ:1PW+W-3L127'@V$0?V,7O+A73@-
M/IUA.>Y9CL^A)QN:OZP6""J'0Y>H-<HB'7>*20-,9G##)9,IE[NC#IZ2<K;8
M:2G]V]!';T.B'4&J:"J-Q<R1LP5"K@2-MV,QX)(\JC9$S@SG0,VS6&Y1]QV$
M:X)K/6'C">%DI9U6QL![&(]'TVG@C' T&0=PA\;,@;F"I-S5UI"I>FOS6M"4
M=TB#>#2+@R$,PE$XNQR>+D%B'&[@0ELCGL1PJGG^T8B5J'?-(C'08+;3UGO[
M7;5J1_0UO%UT]TSO.'5/8$ZIP<7EQ /=+H_V8E75#.Q661K_QBQHWZ)V ?0]
M5_0(NHLKT&_PY!]02P,$%     @ ](%B56QCUOV" @  < 4  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&ULA51=3]LP%/TK5]DT@121KY+2KHU$80@>
MD!#=QL.T!S>Y;2P<.[,= O]^UTD;.JET+XGO]3W'Y]H^GK5*/YL2T<)K):29
M>Z6U]30(3%YBQ<R9JE'2S%KIBED*]28PM496=*!*!'$8ID'%N/2R69=[T-E,
M-59PB0\:3%-53+\M4*AV[D7>+O'(-Z5UB2";U6R#2[0_Z@=-43"P%+Q":;B2
MH'$]]RZCZ6+DZKN"GQQ;LS<&U\E*J6<7W!5S+W2"4&!N'0.CWPM>H1".B&3\
MV7)ZPY(.N#_>L=]TO5,O*V;P2HDG7MAR[EUX4.":-<(^JO86M_V<.[Y<"=-]
MH>UKD]B#O#%655LP*:BX[/_L=;L/>X"+\ - O 7$G>Y^H4[E-;,LFVG5@G;5
MQ.8&7:L=FL1QZ0YE:37-<L+9[$Z^H+1*O\')=[82:$YG@25>-QOD6XY%SQ%_
MP#&!>R5M:>";++#X%Q^0GD%4O!.UB(\2+K$^@R3T(0[C^ A?,C29='S)?YN\
MYB87RC0:X=?EREA-M^+WH8Y[PM%A0N>4J:E9CG./K&!0OZ"7??D4I>'7(W)'
M@]S1,?9L2<XK&H&@UC!(/R3R*,UAD>];D2MREK%8N&5LB;!6@BS*Y09.N*2,
M:@R3A3F= IV'Q6J%>C@4N,9\FXFZ3 2/K*6+:5%S)@Q\AG0<TC=)1_!$O@2B
MK+7*T1@8^VDX@M2/HAANN.1T>PO8*%48./?'80PC?Q(E[ZT3393XDW'J!I&?
M7$S@T"X'>RZH4&\ZKQOJLY&V-\20'9Z3R]Y%[^7]6W3/](9+ P+7! W/QN<>
MZ-[??6!5W7EJI2PYM!N6]"2B=@4TOU;*[@*WP/#(9G\!4$L#!!0    ( /2!
M8E7NL3&"DP,  '8(   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;(56
MVX[;. S]%<(M%C. .[[EODF N6(7F!9!I]U]*/J@V$PLU)9<29Y,^_5+21E/
MLO6D#[%NY.&A2)&9[Z3ZIDM$ T]U)?0B*(UI9E&D\Q)KIB]D@X).-E+5S-!2
M;2/=*&2%4ZJK*(WC450S+H+EW.VMU'(N6U-Q@2L%NJUKIGY<825WBR )GC<^
M\FUI[$:TG#=LBP]H/C<K1:NH0REXC4)S*4#A9A%<)K.KH95W O]PW.F#.5A/
MUE)^LXN_BT406T)886XL J/A$:^QJBP0T?B^QPPZDU;Q</Z,?N=\)U_63..U
MK/[EA2D7P22  C>LK<Q'N?L+]_XX@KFLM/O"SLL.R&+>:B/KO3*M:R[\R)[V
M]W"@,(E?44CW"JGC[0TYEC?,L.5<R1TH*TUH=N)<==I$C@L;E >CZ)23GEFN
M%,57F1_ 1 &WWUO>T(V;$#Y0/IQ]8NL*]?D\,F3)RD?Y'O7*HZ:OH$[AO12F
MU' K"BR.]2-BV-%,GVE>I2<!'["Y@"P.(8W3] 1>UKF=.;SL-VZ'L*J8,,?>
MPY?+M3:*$N9KG^L>>="/;!_13#<LQT5 KT2C>L1@^<>;9!3_>8+WH.,].(6^
M?/!O!^0&^B/71_@D9#_A(W!\20N!],DEO4EML+ T3(FPD14];BZV<,8%[<A6
MDYX^GP'%S6"]1M4%#VXPW^\D;B>!>Z1G5<JJ %XW2CZBM:7A+4S#9!J[,1ZF
M<,_64C$CE6>55\BH+DA9OQ"$9!1F<6J'X6@,=ZT2W+0*C]V 9!!.IV,WC(=P
M3>X8U?HJ0?R)PI8N0D,29I,,,I*\U)K>@T+#E2-'5Z -3"<I3$89W''!1(Y0
M63] V3KP3F[>M;1@3C&93-WOM5O=*DGF!ED8#S(8I&ZX)P8S*EIY6[<5LY==
M(,4GY\Q7,T)@M52&__0;9]DP3++DG"9I.!E/SE^U1C&D.QV'TR3U=SP:PHG4
M'':I.3R=FM0OBK9"FQ0WAU1OGZB#:.S+S).(_9EY!(T>FA)0N40TI4(?;$%8
M4/LBA+8(]:6B%709R/6^*_&?).ERF,!L]8.U[5N_Y/4G9^BPR/T/_X.U?^+<
MV7>V7V:]KKV%29;8.*49?=-P.)C2F(49O8R^J$4'O:!&M74=3U/"ML+XMM#M
M=DWUTO>2%W'?D=\SM>5"4UYO2#6^&%.XE.]R?F%DXSK+6AKJ4VY:TA\#5%:
MSC=2FN>%-=#]U5C^!U!+ P04    " #T@6)5-=XS, ($  #N#   &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-BYX;6SM5TMOVS@0_BN$=K%( "5ZV)9EKVW
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M]S@=:<#2*RPYX$\!.+<%8HL4U=</[->O#0:6T56?Z6,L.?R@,OO9)2L[.+W
MU*TS=/QU?:;_@[7?<>[L.]N/5&MHF(#AP#Y'/9N#:(3/I#_L:N^D:>_DA]O[
M6AM6.)#>E,9^<)\X<WV4YQ<705NC=QIN;W1K([,.K"L'Z+$#Z.%+L&#/X_[+
MO/JVGAT7PE] E06%;;PG-\%C$EQ13N ^XZ5CLWCX$4B=NGKU+=TCR2BU1/]
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MZ&8E%59JT.]<K I"6NV_LN!EDAJ06% EIFG;4B)+$XM-E!&U6&B;,73$2UL
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M35]R*,T">K\4=/PV#\9!^VTX_1=02P,$%     @ ](%B50(B,#=< P  JP<
M !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULM57;;MLX$/V5@;HH-D V
MLB7;<5S;0)PTV#ZT,.J]/"SV@99&%A&*5$G*3OY^9RA93@&OMR_[(EXTEW,.
MA\/YP=AG5R)Z>*F4=HNH]+Z>Q;'+2JR$NS$U:OI3&%L)3TN[BUUM4>3!J5)Q
M,AA,XDI('2WG86]MEW/3>"4UKBVXIJJ$?5VA,H=%-(R.&U_EKO2\$2_GM=CA
M!OWO]=K2*NZCY+)"[:318+%81/?#V6K$]L'@#XD']V8.S&1KS#,O/N6+:,"
M4&'F.8*@88\/J!0'(AC?NIA1GY(=W\Z/T9\"=^*R%0X?C/I3YKY<1-,(<BQ$
MH_Q7<_@5.SYCCI<9Y<(7#IWM((*L<=Y4G3,AJ*1N1_'2Z? C#DGGD 3<;:*
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M'(%MGX9VX4T=VO'6>&KN85K2:XJ6#>A_88A>M^ $_?N\_ =02P,$%     @
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M3LW+JT*NZDA6F,)CP:0J8TQSK6I?X#I O5\Q)G<=/4%338=_ 5!+ P04
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M?W)NQJ5LED4C:%&[:3@7VLQ6=RS-?@5I#<S]0@B]%:R#;F.G?P%02P,$%
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M)8TV"WS-#B=EO2#U1#@G1;VY1S!%5#80Y[>$\.<=:= MLP;_ 5!+ P04
M" #T@6)5;A1-CA\$  #*%   &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6RU6%V/FS@4_2L66ZU::6; D!"832*UF:U:J:VB9KO[L-H'#[E)K *FMDG:
M_?5K \-'XC";BKPDF-Q[<N[UP1Q[>F#\J]@!2/0]B5,QLW929O>V+:(=)$3<
ML0Q2]<N&\81(->1;6V0<R+I(2F+;=1S?3@A-K?FTN+?D\RG+94Q36'(D\B0A
M_,<;B-EA9F'KZ<9GNMU)?<.>3S.RA17(+]F2JY%=HZQI JF@+$4<-C/K-;Y?
MN$5"$?$GA8-H72-=RB-C7_7@_7IF.9H1Q!!)#4'4UQX6$,<:2?'X5H%:]7_J
MQ/;U$_K;HGA5S",1L&#Q7W0M=S,KL- :-B2/Y6=V> =506.-%[%8%)_H4,4Z
M%HIR(5E2)2L&"4W+;_*]:D0K 8_.)+A5@OM_$[PJP2L*+9D593T02>93S@Z(
MZVB%IB^*WA39JAJ:ZFE<2:Y^I2I/SI=<*8++'XBD:_3[MYQF:H[D#?JD%'2+
M5N7D(K9!YD#T\@$DH;%XI:*_K![0RQ>OT M$4_3'CN5"Q8JI+15/_6]V5'%Z
M4W)RSW!:07:'/.<&N8[K&M(7_>D/$*ET7*3C;KJMNE.WR*U;Y!9XWC,MND'+
MF*B2NPWX^X,*1^\E).(?4ZDE]LB,K1_2>Y&1"&:6>@H%\#U8\U]_P;[SFZGP
M@< Z;?#J-GA]Z/.W-"5I!"@&]=0@KA^/6[:YS=6 " '25'R)Z!>(>D'9SW$0
M3NU]NZ;^F [544UUU$NUHU5H1+WE3!CU6,*-6QQ&GC/RCI@:HMQV5(?KN.8Z
M[N7Z 82X5ZM9E"=Y3"2LU2*D9B^BI%SF5 4D85S2?XL;)O;C$UZWWAA[^(B^
M*<P-)H&9OU_S]W^JUZE9$?X)B4F(W2.FIT$A]L=FGI.:Y^29/BO9[EB\1C3)
M.-N#IFD40R_.I4_L0&"=DH.ZY."*"U<P9!L& NNT(:S;$ Z[&H0&^87.D48-
M0<[8-6L4.\W;V.E7*7EDG$C&2[:16FR56V(L:8@;WZ>]J)=.UE!HW1ZT' F^
MHFPK\*%:,1!:MQ6-\\"];_3+I5OAM66)?<\Y7F"-86-_<D:^C47 SWB$G*=4
MYARZA(U,>Y$NGJ>!T+IU-WX#CZXIV5XW<W$K!D+KMJ*Q,[C?SUPNV5-?@D=A
M.#F6K#%L<L85X,:^X'[_LF"ID#PO-Y5JWZ*\P5;UQ4RU%^KBB1H(K5MXXX?P
MY)J:'=0E#876;47CDW"O__@)S0:G8O2"X_V"(<H+SZVQC9O!_7;FM=YL(0Z2
M\L+#HH@)\PK;BW/Q% V$UMV"-\;(=:ZY"1_4'PV%UFU%XX_<7M-QN5HKO/86
M.PR.+8$A*/"/][9VZZ!)G_)])'Q+4X%BV*@LYVZBM,[+@[-R(%E6G#T],BE9
M4ESN@*R!ZP#U^X8Q^330QUGU\>7\/U!+ P04    " #T@6)5-6:EC:,"  #F
M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6RM5=]OFS 0_E<L5DV=
MU!4"M&NR!*D)F;:'3E&S;@_3'ARX!*M@4]LD[7^_LR$L:6E6;7T!^WS?=S]\
MOAMNA+Q5&8 F]T7.U<C)M"X'KJN2# JJ3D4)'$^60A94XU:N7%5*H*D%%;GK
M>]ZY6U#&G6AH93,9#46E<\9A)HFJBH+*AS'D8C-R>LY6<,U6F38"-QJ6= 5S
MT#?E3.+.;5E25@!73' B83ER+GN#:6CTK<)W!ANULR8FDH40MV;S)1TYGG$(
M<DBT8:#X6\,$\MP0H1MW#:?3FC3 W?66_9.-'6-94 43D?]@J<Y&SH5#4EC2
M*M?78O,9FGC.#%\B<F6_9-/H>@Y)*J5%T8#1@X+Q^D_OFSSL )"G&^ W /\Q
M('P&$#2 X*46P@80OM3"60.PH;MU[#9Q,=4T&DJQ(=)H(YM9V.Q;-.:+<5,G
M<RWQE"%.1S.))2?U Z$\)=.[BI58!/J$?,42?4]BP.)+&+5W.KW'XE1 CF/0
ME.7J'2K<S&-R?/2.'!'&R;=,5 IYU-#5Z)HQX":-&^/:#?\9-P)R);C.%)GR
M%-(.?'P8WS^ =S$E;5[\;5[&_D'".92G)/!.B._Y?H<_DY?#>UWA_)_UZ3];
MWTM&T!9)8/F"OQ3)"9GEE.O]6B$_+Q=*2WSQO[KNO68.NYE-%QRHDB8P<K#2
M%,@U.-';-[US[V-7TE^3+'Y-LNDKD>U=3]A>3WB(/=I[I5"_TJZKJ%G.+8N9
M'^OH(L#R6.]F^*E.WP_V=>*G.OY9V-]7FCY5"H*^URK5@;H[C:L N;(30Y%$
M5%S7Y=E*VZ%T:7OQ(_FX-YCT.N0Q#K%ZYORAKR?@%94KQA7)88FFO-,/V%=E
M/57JC1:E;9L+H;$)VV6&@QBD4<#SI1!ZNS$&VM$>_0902P,$%     @ ](%B
M572R!8 ,!   /A<  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULK9AK
M;^)&%(;_RLB-5KO2-KZ!"5E "C%N4S51%+K=#U4_#/8!K+4][,P8MM+^^,[8
MQL% QJ:=+^#+>9\S?L]<[!GM"/W*U@ <?4^3C(V-->>;6]-DX1I2S*[)!C)Q
M9TEHBKDXI2N3;2C@J!"EB>E8EF>F.,Z,R:BX]DPG(Y+S),[@F2*6IRFF_TPA
M(;NQ81O["R_Q:LWE!7,RVN 5S(%_WCQ3<6;6E"A.(6,QR1"%Y=BXLV\#VY6"
M(N+/&';LX!C)1UD0\E6>/$1CPY(M@@1"+A%8_&WA'I)$DD0[OE50H\XIA8?'
M>WI0/+QXF 5F<$^2+W'$UV/CQD 1+'&>\!>R^Q6J!^I+7D@25ORB71D[< T4
MYHR3M!*+%J1Q5O[C[Y41!P+7>D/@5 *GJ\"M!.Z1P''>$/0J0:]KAGXEZ'<5
M>)7 *[POS2J<]C''DQ$E.T1EM*#)@Z)<A5H8'&>R9\TY%7=CH>.37PB)=G&2
M()Q%Z"'C.%O%BP30'6/ V4?T)#KWS^@)4XIE%T#O?> X3M@'=(7B#/VQ)CD3
M4C8RN6B-9)IAE?F^S.R\D=E%CR3C:X9F6031&;VOUGMM^IE:/VS3!VJ][2@
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M""B-0M%<Y9JZ L:@ 1"#EAA :0241J%HKC!-B0'[U^7_UP 8M03 S>@'6G0
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ME\:@#XY5ARW1!DA;]#'$;['$!HAKECQL) \[)3=' :B. B9YP^.YNP.G)=
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MJHLVYIBP+V6*RLPR$X?IO11+,@-5D@G,\9S\,.?@2S-P+ZD@#Q1KQ?"-G$X
M*>/ZC)P0)LBLD+6F(M>)C\:&%?.S#?*F089[D%.H+D@O."=A$(;D>3HAIR=G
M_\OX)HLVE;!-)72ZO3VZ-@$R83KC4M<*R._KN49E7ON?+H^-5K];RWX*5[JB
M&8P]<]8UJ!5XZ>=/EW'P]8#37NNT=T@]=8F?PFO&ZYR9_<<"B#!K2"D%%IJ
MR"$G9I\0RCFHAKO=L;.N;!I>['CV.URE0>*O.BSV6XO]8Q9[7: F*CH.BEI0
M= S4[P)%'P7%+2@^!HJZ0/$[4!287S=LT,(&QV!Q%VSPT:R&+6AX$#0KP-3B
M!8+JP@T_BANUN-%!G"L7:*M#[LJ% .SBCMX=QZX]]7?*EKT!'JA:,J$)AX6)
M"RX&QKAJJFK305FY2C:7:.JB:Q;F(@)E%YCYA92X[=CBV%YMZ3]02P,$%
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MA.JD15IIL2[:,*%]NPLG6["K),8^OXQ -O+'"G-N%OJ.%_AC@5'@0MOW@['
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MD8>0GRJ>E?\=.,^KEN</\]2D\+%<LCF_&,E1O^3BD8\N__XW9S;YQY!<D+
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M(91&.UI?DEOJ> MWT]7NION*N[F^9.PZ9:6ZB.RZN6:L2E1RL-N^@'J<4%H
MI850&H72(A3-O$A5^YX>NM;5@YJ>4%H I850&H72(A3-E(TV1SV[.?I+\KU.
MXC:?7#;##V_6'NKZZ0.N2;5'.5A+SE"&N#%8!]"8(91&H;0(13,UHIU1SUY^
M>?OFES3;3^!@^;2T_D7-WI:E%D!CAE :A=(B%,V43^_^"7:'=+=\LK;LM?]_
M=8U_NA95ZZ&VTE(7&HKDX4&JJG?$.YNY:C^Q@V4U8-6>')]LR@I[CP7L31:P
M=UEX"V_5T]ZJ9W=&M8U6]>OSGY)J(0<A*9%R596D[J*R.J9;:QD>?5:7%>'/
M<ZXN:-R66"N_/Q1F4&1(;_*ZHYGKYDV)09U:*(U":1&*9DI,.[6>W:G=/7)5
M"QE/U<>1?"W#ON0,2>Z6#K3<UAOR@3>E S5MH30*I44HFBD=;=IZ=M-6CTYW
M!1-2-YQ5)6ENG295=/="=FFK+;IL1-/=^&E0.5!_U]MV9-U-X4#K:J$T"J5%
M*)HI'&T#>W8;V)(MM26UY+%H"IRZW*B7.N6$R;_EAW;N:G3&RJ1\)4>"FL@=
M[<SXWVSG[&Q33= R6RB-0FD1BF:J2?O-GMUOWL-1E"--D)3SHLZ58E8V$OG"
MJJ:FH1 J\_Y7S:2@1/JB#[AA+YD4%9';2HY2?3_7.5=W8%,W8!N4&M2XAM("
M*"V$TBB4%J%HIB*UQ^V=H7U*J+T-I0506@BE42@M0M',F^II>]NWE_6NI\5Y
M;_Q:N5!U5J?M34?CU>ADG?/LL0Y5E#]0!#LYGOB;-]&#6MI0&H72(A3-E(JV
MM'V[I;W?G'?#Q9)7-4LWICQV+^>YP^8[LFO"LY_HP3J#UA5#:2&41J&T"$4S
MY:C=<Q]=5^Q#W7 H+8#20BB-0FD1BF;*1KOF_IZN.63"@QKA_F#-\F2V.>%!
MG7 HC4)I$8IF2J5WQV&[$[Z62G^>T[/@SKH1._9@52!I 9060FD42HM0-%,\
MVN/VI^CI">I:0VD!E!9":11*BU T4S;:W_;M_O9:-D>;1N6@9*!V-906^-OF
M]V:=JK]=/KQQ"'W]D&C@D#-73YIF1VB_V+?[Q?KWE\V[O$ 9OW5%\J(B2Y8,
M7G5BAQ[<(=#287^[CM=QMRO$H4'I?D$C5%"SL[6=Z]OMW/X$7^I2XF;8WK=\
MV![BX*Z'NK#^=HFN>^8X9].9N]G[4(=U[[@1*FXK@''OB3L9%P_-PY1*TICQ
M[1-*UGO7#VSZU#RF:&-_X'P,G8']U/D8M8]CTOCVZ5"?F7A(\I*D_%Z&FAR?
MR \OV@<NM2^J8MD\[^>NJ*HB:S87G,5<J /D^_=%4:U>J #KQUY=_A]02P,$
M%     @ ](%B51BGWA3B P  UQ8  !D   !X;"]W;W)K<VAE971S+W-H965T
M-34N>&ULO5A=CZ,V%/TK%EU5,]+L\!&2F4P3I$V@ZCZL-)ITVX>J#TZX"=:
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M R*VI-M$/?#]7ZSJT#"/M^")+/Z#?7FM3QRPV$K%TZJQ5I#&6?E)?U2%.&B
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MH.^;*'=LRA/%-\4NR3-7BJ?%X9K1B(G\ OW[DG/U<I(GJ/?-IO\!4$L#!!0
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M[@#]SY6RSPNGH.WY%G\#4$L#!!0    ( /2!8E42D8\'#P0  -T/   9
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M1F2*\DA-?&W8; 0_W'/<%1SD!,<8?15<;Q1ZY!%$'^U]LZ=R8^2PL3OB=+B
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MJ:I^LQH86;B6;2,--H#N,\,>'90UP/6MQ(C5 [M!T_7/_@=02P,$%     @
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M%,^JPPTE>C4O*^C?5YRKAY/20?M>QN(_4$L#!!0    ( /2!8E723!2_=@0
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M<UQ-J@"G?+3=50"$J<?4<1G:H!A:2*=2B].1384)7IY"8IJIZ\D0BE'U. >
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M<?SX+#O;]&_Y;/PCVN(%4$L! A0#%     @ ](%B50=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #T
M@6)5$O4A,.X    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #T@6)5F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /2!8E5.9@_Z
MTP4  ,\>   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #T@6)5-N$*&.L&  #D'0  &
M@($6#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ](%B
M58?%4 _F P  DP\  !@              ("!-Q4  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( /2!8E7I+0H?508  !(=   8
M      " @5,9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #T@6)5/H[L!KT,  !H=0  &               @('>'P  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ ](%B59L#3Q$1!P  9QX  !@
M             ("!T2P  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( /2!8E7#F$(]J @  .T5   8              " @1@T  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #T@6)5C@JF8[D,  ";
M(P  &               @('V/   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ ](%B53FY 7,7 P  ! <  !@              ("!Y4D
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( /2!8E6Y_=DV
M>0,  (,'   9              " @3)-  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ ](%B53YH!H;" P  D0@  !D
M ("!XE   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #T
M@6)5@-QF1KH%  !X#P  &0              @(';5   >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( /2!8E6H=Y+VX0(  #X&   9
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M970Q-RYX;6Q02P$"% ,4    " #T@6)5CVA]#4X#  #K!P  &0
M    @('>A   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M /2!8E4PF*O4W1   -DM   9              " @6.(  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ ](%B55X,E>RE!0  +0T  !D
M             ("!=YD  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #T@6)5),FN>ZL)  !8'   &0              @(%3GP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( /2!8E6M$G++@ L
M !,A   9              " @36I  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ ](%B5<[74+.9 @  S04  !D              ("!
M[+0  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #T@6)5
M;&/6_8("  !P!0  &0              @(&\MP  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( /2!8E7NL3&"DP,  '8(   9
M      " @76Z  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ ](%B537>,S "!   [@P  !D              ("!/[X  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #T@6)5*AFG%?<"  !%!@
M&0              @(%XP@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( /2!8E6M/^;BO00   T.   9              " @:;%  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ](%B5:2?.$S)
M!0  %A,  !D              ("!FLH  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #T@6)5IJ],V8H%   G#@  &0
M@(&:T   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( /2!
M8E4"(C W7 ,  *L'   9              " @5O6  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ ](%B5:TIA9TD!   *@D  !D
M         ("![MD  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " #T@6)50W.&F50%  !R$   &0              @(%)W@  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( /2!8E57H]^RX 0  #DA
M   9              " @=3C  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ ](%B54V)?I'I @  60L  !D              ("!Z^@
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #T@6)5']MZ
M;70"  !U!@  &0              @($+[   >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( /2!8E49S]E%D@(  +T'   9
M  " @;;N  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M](%B54)Q?X?3 P  <A4  !D              ("!?_$  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " #T@6)5;A1-CA\$  #*%   &0
M            @(&)]0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( /2!8E4U9J6-HP(  .8'   9              " @=_Y  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ ](%B572R!8 ,!
M/A<  !D              ("!N?P  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " #T@6)5NS[;H-$#   R$0  &0              @('\
M  $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( /2!8E6
M'D,JIP(  /@'   9              " @00% 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ ](%B568.B!R] @  -P<  !D
M     ("!X@<! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /2!8E7"<X<!&00  #T3   9              "
M@58< 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ ](%B
M54F?-Y^. @  Y@8  !D              ("!IB ! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " #T@6)5#R$9-30$  "H#P  &0
M        @(%K(P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( /2!8E4. 5XW800  *D0   9              " @=8G 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ ](%B50CM58HG!0  5B(
M !D              ("!;BP! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " #T@6)5HGIZF^@*   ":P  &0              @(',,0$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( /2!8E48I]X4
MX@,  -<6   9              " @>L\ 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ ](%B5;W!?X?_!   0QL  !D
M ("!!$$! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #T
M@6)5V3@ZC6(#  #_"0  &0              @($Z1@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( /2!8E42D8\'#P0  -T/   9
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M970V,BYX;6Q02P$"% ,4    " #T@6)5:_\^>R4"  #9!   &0
M    @('#7P$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M /2!8E68.^.57@,  .</   9              " @1]B 0!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ ](%B5;>#]!EY @  QP<  !D
M             ("!M&4! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    " #T@6)5)C3F>C )  !0/P  &0              @(%D: $ >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( /2!8E49T=P+*P,
M .X2   -              "  <MQ 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !* $H /10  ,I_ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>203</ContextCount>
  <ElementCount>306</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Accounts Receivable, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/AccountsReceivableNet</Role>
      <ShortName>Accounts Receivable, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/GoodwillandIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Long Term Debt, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/LongTermDebtNet</Role>
      <ShortName>Long Term Debt, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities</Role>
      <ShortName>Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://mimedx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Accounts Receivable, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/AccountsReceivableNetTables</Role>
      <ShortName>Accounts Receivable, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mimedx.com/role/AccountsReceivableNet</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mimedx.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mimedx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/GoodwillandIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mimedx.com/role/GoodwillandIntangibleAssetsNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mimedx.com/role/AccruedExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Long Term Debt, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/LongTermDebtNetTables</Role>
      <ShortName>Long Term Debt, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mimedx.com/role/LongTermDebtNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mimedx.com/role/NetLossPerCommonShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mimedx.com/role/Equity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables</Role>
      <ShortName>Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mimedx.com/role/Revenue</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mimedx.com/role/SegmentInformation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/NatureofBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mimedx.com/role/NatureofBusiness</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Accounts Receivable, Net - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails</Role>
      <ShortName>Accounts Receivable, Net - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Accounts Receivable, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/AccountsReceivableNetNarrativeDetails</Role>
      <ShortName>Accounts Receivable, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mimedx.com/role/InventoryTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Property and Equipment, Net - Depreciation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/PropertyandEquipmentNetDepreciationExpenseDetails</Role>
      <ShortName>Property and Equipment, Net - Depreciation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Goodwill and Intangible Assets, Net - Activity Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Activity Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Goodwill and Intangible Assets, Net - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/GoodwillandIntangibleAssetsNetAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Goodwill and Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mimedx.com/role/AccruedExpensesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Long Term Debt, Net - Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/LongTermDebtNetTermLoanDetails</Role>
      <ShortName>Long Term Debt, Net - Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Long Term Debt, Net - Term Loan Debt Issuance Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails</Role>
      <ShortName>Long Term Debt, Net - Term Loan Debt Issuance Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Long Term Debt, Net - Term Loan Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails</Role>
      <ShortName>Long Term Debt, Net - Term Loan Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Long Term Debt, Net - Term Loan Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails</Role>
      <ShortName>Long Term Debt, Net - Term Loan Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Long Term Debt, Net - Term Loan Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails</Role>
      <ShortName>Long Term Debt, Net - Term Loan Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Net Loss Per Common Share - Basic Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share - Basic Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Net Loss Per Common Share - Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Common Share - Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Equity - Changes in Series B Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails</Role>
      <ShortName>Equity - Changes in Series B Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Equity - Restricted Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/EquityRestrictedStockAwardsDetails</Role>
      <ShortName>Equity - Restricted Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Equity - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/EquityFairValueAssumptionsDetails</Role>
      <ShortName>Equity - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Equity - Stock Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/EquityStockIncentivePlansDetails</Role>
      <ShortName>Equity - Stock Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mimedx.com/role/IncomeTaxes</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails</Role>
      <ShortName>Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mimedx.com/role/CommitmentsandContingencies</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Revenue - Summary of Revenue by Product Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails</Role>
      <ShortName>Revenue - Summary of Revenue by Product Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Revenue - Summary of Revenue by Customer Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails</Role>
      <ShortName>Revenue - Summary of Revenue by Customer Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Segment Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mdxg-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Segment Information - Net Sales and Operating Income (Loss) by each Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails</Role>
      <ShortName>Segment Information - Net Sales and Operating Income (Loss) by each Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentPeriodEndDate, dei:EntityEmergingGrowthCompany, dei:EntityFilerCategory, dei:EntitySmallBusiness, us-gaap:NumberOfOperatingSegments, us-gaap:NumberOfReportingUnits -  mdxg-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="mdxg-20220930.htm">mdxg-20220930.htm</File>
    <File>a20220930-10qex311final.htm</File>
    <File>a20220930-10qex312final.htm</File>
    <File>a20220930-10qex321final.htm</File>
    <File>a20220930-10qex322final.htm</File>
    <File>mdxg-20220930.xsd</File>
    <File>mdxg-20220930_cal.xml</File>
    <File>mdxg-20220930_def.xml</File>
    <File>mdxg-20220930_lab.xml</File>
    <File>mdxg-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="912">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mdxg-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 203,
   "dts": {
    "calculationLink": {
     "local": [
      "mdxg-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mdxg-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mdxg-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mdxg-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mdxg-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mdxg-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 481,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 9,
    "total": 11
   },
   "keyCustom": 43,
   "keyStandard": 263,
   "memberCustom": 21,
   "memberStandard": 34,
   "nsprefix": "mdxg",
   "nsuri": "http://mimedx.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://mimedx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Inventory",
     "role": "http://mimedx.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Property and Equipment, Net",
     "role": "http://mimedx.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Goodwill and Intangible Assets, Net",
     "role": "http://mimedx.com/role/GoodwillandIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Accrued Expenses",
     "role": "http://mimedx.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Long Term Debt, Net",
     "role": "http://mimedx.com/role/LongTermDebtNet",
     "shortName": "Long Term Debt, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Net Loss Per Common Share",
     "role": "http://mimedx.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Equity",
     "role": "http://mimedx.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Income Taxes",
     "role": "http://mimedx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities",
     "role": "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities",
     "shortName": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Commitments and Contingencies",
     "role": "http://mimedx.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Revenue",
     "role": "http://mimedx.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Segment Information",
     "role": "http://mimedx.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://mimedx.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Accounts Receivable, Net (Tables)",
     "role": "http://mimedx.com/role/AccountsReceivableNetTables",
     "shortName": "Accounts Receivable, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Inventory (Tables)",
     "role": "http://mimedx.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://mimedx.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "role": "http://mimedx.com/role/GoodwillandIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://mimedx.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mdxg:ScheduleOfDebtIssuanceCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Long Term Debt, Net (Tables)",
     "role": "http://mimedx.com/role/LongTermDebtNetTables",
     "shortName": "Long Term Debt, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mdxg:ScheduleOfDebtIssuanceCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Net Loss Per Common Share (Tables)",
     "role": "http://mimedx.com/role/NetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Equity (Tables)",
     "role": "http://mimedx.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)",
     "role": "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables",
     "shortName": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Revenue (Tables)",
     "role": "http://mimedx.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Segment Information (Tables)",
     "role": "http://mimedx.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Nature of Business (Details)",
     "role": "http://mimedx.com/role/NatureofBusinessDetails",
     "shortName": "Nature of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i64c6f2694f674696aab0be0e9ea8fdcf_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Significant Accounting Policies - Narrative (Details)",
     "role": "http://mimedx.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Accounts Receivable, Net - Accounts Receivable (Details)",
     "role": "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails",
     "shortName": "Accounts Receivable, Net - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Accounts Receivable, Net - Narrative (Details)",
     "role": "http://mimedx.com/role/AccountsReceivableNetNarrativeDetails",
     "shortName": "Accounts Receivable, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Inventory (Details)",
     "role": "http://mimedx.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i9c87d212d19e46b4a198d7406d22de6b_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "role": "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdxg:ScheduleOfDepreciationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Property and Equipment, Net - Depreciation Expense (Details)",
     "role": "http://mimedx.com/role/PropertyandEquipmentNetDepreciationExpenseDetails",
     "shortName": "Property and Equipment, Net - Depreciation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details)",
     "role": "http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Goodwill and Intangible Assets, Net - Activity Summary (Details)",
     "role": "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Activity Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Goodwill and Intangible Assets, Net - Amortization Expense (Details)",
     "role": "http://mimedx.com/role/GoodwillandIntangibleAssetsNetAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Goodwill and Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details)",
     "role": "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Accrued Expenses (Details)",
     "role": "http://mimedx.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Long Term Debt, Net - Term Loan (Details)",
     "role": "http://mimedx.com/role/LongTermDebtNetTermLoanDetails",
     "shortName": "Long Term Debt, Net - Term Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i3996d9d84f0b4ebd9d6cf3d12bf3f6a8_I20200702",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "ic01dffba8325446a929870e45228e37c_I20200702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Long Term Debt, Net - Term Loan Debt Issuance Costs (Details)",
     "role": "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails",
     "shortName": "Long Term Debt, Net - Term Loan Debt Issuance Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "ic01dffba8325446a929870e45228e37c_I20200702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Long Term Debt, Net - Term Loan Balances (Details)",
     "role": "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails",
     "shortName": "Long Term Debt, Net - Term Loan Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "ied1ef014d51f4e56b7b022759ec9dc30_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdxg:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Long Term Debt, Net - Term Loan Interest Expense (Details)",
     "role": "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails",
     "shortName": "Long Term Debt, Net - Term Loan Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdxg:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "if7fec7fc01744dbcbaa3628b33a5b958_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i442c898781d04f8abe327191b2190538_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY",
     "role": "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i442c898781d04f8abe327191b2190538_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Long Term Debt, Net - Term Loan Maturity (Details)",
     "role": "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails",
     "shortName": "Long Term Debt, Net - Term Loan Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Net Loss Per Common Share - Basic Net Loss Per Common Share (Details)",
     "role": "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Common Share - Basic Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityDividendsAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Net Loss Per Common Share - Diluted Net Loss Per Share (Details)",
     "role": "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Common Share - Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherPreferredStockDividendsAndAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)",
     "role": "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "ie7039d72af5a465f8d691ffc8453f767_D20220701-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "iea291f2f9ce54206890c533e3a98eb90_D20200702-20200702",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mdxg:TemporaryEquityConversionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Equity - Narrative (Details)",
     "role": "http://mimedx.com/role/EquityNarrativeDetails",
     "shortName": "Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "iea291f2f9ce54206890c533e3a98eb90_D20200702-20200702",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mdxg:TemporaryEquityConversionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquitySharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i9c87d212d19e46b4a198d7406d22de6b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Equity - Changes in Series B Preferred Stock (Details)",
     "role": "http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails",
     "shortName": "Equity - Changes in Series B Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i753d059860334ec081dc4d69d43cf1c2_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i3049036812934641abae9137fa8bdf2a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Equity - Restricted Stock Awards (Details)",
     "role": "http://mimedx.com/role/EquityRestrictedStockAwardsDetails",
     "shortName": "Equity - Restricted Stock Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i3049036812934641abae9137fa8bdf2a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "ia38002926e044d8cb4fe2d95277bce68_D20220101-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Equity - Fair Value Assumptions (Details)",
     "role": "http://mimedx.com/role/EquityFairValueAssumptionsDetails",
     "shortName": "Equity - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i69b65bc7bda741e7bc0fd73dd267bbfe_D20220101-20220930",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i9c87d212d19e46b4a198d7406d22de6b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Equity - Stock Incentive Plans (Details)",
     "role": "http://mimedx.com/role/EquityStockIncentivePlansDetails",
     "shortName": "Equity - Stock Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i9c87d212d19e46b4a198d7406d22de6b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Income Taxes (Details)",
     "role": "http://mimedx.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details)",
     "role": "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails",
     "shortName": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://mimedx.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForLegalSettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Revenue - Summary of Revenue by Product Type (Details)",
     "role": "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails",
     "shortName": "Revenue - Summary of Revenue by Product Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "ib1eade6c04c44338ba36a2a117e94a53_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mdxg:NumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Revenue - Narrative (Details)",
     "role": "http://mimedx.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i4bd517c3847841b09c02473de630860c_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mdxg:NumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Revenue - Summary of Revenue by Customer Type (Details)",
     "role": "http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails",
     "shortName": "Revenue - Summary of Revenue by Customer Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "ic08501ad9a844ed4bfcec556b74f305f_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i130e7b81b0bf4cea890f4ffbfa8680c0_D20220930-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Segment Information - Narrative (Details)",
     "role": "http://mimedx.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i2a352529eb914eca834297bbac755ba4_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Segment Information - Net Sales and Operating Income (Loss) by each Reportable Segment (Details)",
     "role": "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails",
     "shortName": "Segment Information - Net Sales and Operating Income (Loss) by each Reportable Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i16bb96a8ab744d53aea8efbdfee2b370_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Nature of Business",
     "role": "http://mimedx.com/role/NatureofBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Significant Accounting Policies",
     "role": "http://mimedx.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsAndNontradeReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Accounts Receivable, Net",
     "role": "http://mimedx.com/role/AccountsReceivableNet",
     "shortName": "Accounts Receivable, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220930.htm",
      "contextRef": "i61eee753f5304fbdb209e49ca0f77bde_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsAndNontradeReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 60,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mimedx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mdxg_AccruedAdministrativeFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Administrative Fees, Current",
        "label": "Accrued Administrative Fees, Current",
        "terseLabel": "Accrued group purchasing organization fees"
       }
      }
     },
     "localname": "AccruedAdministrativeFeesCurrent",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_AccruedClinicalTrialsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trials, Current",
        "label": "Accrued Clinical Trials, Current",
        "terseLabel": "Accrued clinical trials"
       }
      }
     },
     "localname": "AccruedClinicalTrialsCurrent",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_AccruedESPPPayrollDeferrals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued ESPP Payroll Deferrals",
        "label": "Accrued ESPP Payroll Deferrals",
        "terseLabel": "Accrued ESPP payroll deferrals"
       }
      }
     },
     "localname": "AccruedESPPPayrollDeferrals",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_AccruedRebates": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/AccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Rebates",
        "label": "Accrued Rebates",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_AccruedTravel": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/AccruedExpensesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Travel",
        "label": "Accrued Travel",
        "terseLabel": "Accrued travel"
       }
      }
     },
     "localname": "AccruedTravel",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_AdvancedWoundCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced Wound Care",
        "label": "Advanced Wound Care [Member]",
        "terseLabel": "Advanced Wound Care"
       }
      }
     },
     "localname": "AdvancedWoundCareMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_AdvancedWoundCareTissueAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced Wound Care, Tissue And Other",
        "label": "Advanced Wound Care, Tissue And Other [Member]",
        "terseLabel": "Tissue/Other"
       }
      }
     },
     "localname": "AdvancedWoundCareTissueAndOtherMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_AdvancedWoundCareUmbilicalCordDerivedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced Wound Care, Umbilical Cord-Derived",
        "label": "Advanced Wound Care, Umbilical Cord-Derived [Member]",
        "terseLabel": "Cord"
       }
      }
     },
     "localname": "AdvancedWoundCareUmbilicalCordDerivedMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/NatureofBusinessDetails",
      "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_AssetRetirementCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Retirement Cost [Member]",
        "label": "Asset Retirement Cost [Member]",
        "terseLabel": "Asset retirement cost"
       }
      }
     },
     "localname": "AssetRetirementCostMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_ContingencyLossNumberOfSecuritiesClassActions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingency Loss, Number Of Securities Class Actions",
        "label": "Contingency Loss, Number Of Securities Class Actions",
        "terseLabel": "Number of securities class actions"
       }
      }
     },
     "localname": "ContingencyLossNumberOfSecuritiesClassActions",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mdxg_CreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facilities [Member]",
        "label": "Credit Facilities [Member]",
        "terseLabel": "Credit Facilities"
       }
      }
     },
     "localname": "CreditFacilitiesMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_DebtCovenantMinimumLiquidity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Minimum Liquidity",
        "label": "Debt Covenant, Minimum Liquidity",
        "terseLabel": "Debt covenant, minimum liquidity"
       }
      }
     },
     "localname": "DebtCovenantMinimumLiquidity",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_DebtInstrumentCommitmentFees": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Commitment Fees",
        "label": "Debt Instrument, Commitment Fees",
        "terseLabel": "Commitment fee"
       }
      }
     },
     "localname": "DebtInstrumentCommitmentFees",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_DebtInstrumentDefaultInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Default Interest Rate",
        "label": "Debt Instrument, Default Interest Rate",
        "terseLabel": "Default interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentDefaultInterestRate",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mdxg_DebtInstrumentInterestRateFloorPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Floor Percentage",
        "label": "Debt Instrument, Interest Rate, Floor Percentage",
        "terseLabel": "Debt instrument, interest rate, floor (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateFloorPercentage",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mdxg_DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty As Percent Of Prepaid Principal, Percent",
        "label": "Debt Instrument, Prepayment Penalty As Percent Of Prepaid Principal, Percent",
        "terseLabel": "Debt instrument, prepayment make-whole premium as percent of prepaid principal (percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyAsPercentOfPrepaidPrincipalPercent",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mdxg_DebtInstrumentUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Unused Capacity, Commitment Fee Percentage",
        "label": "Debt Instrument, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Additional commitment fee (percent)"
       }
      }
     },
     "localname": "DebtInstrumentUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mdxg_DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounted Dividend Rate prior to Quarterly Dividend Payment ending on June 30,2021 [Member]",
        "label": "Discounted Dividend Rate prior to Quarterly Dividend Payment ending on June 30,2021 [Member]",
        "terseLabel": "Discounted Dividend Rate prior to Quarterly Dividend Payment ending on June 30,2021"
       }
      }
     },
     "localname": "DiscountedDividendRatepriortoQuarterlyDividendPaymentendingonJune302021Member",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_DividendAccumulatedByNotPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend, Accumulated By Not Paid",
        "label": "Dividend, Accumulated By Not Paid",
        "terseLabel": "Dividends accumulated but not paid"
       }
      }
     },
     "localname": "DividendAccumulatedByNotPaid",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_ExpensesOnLongTermPurchaseCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses On Long-Term Purchase Commitment",
        "label": "Expenses On Long-Term Purchase Commitment",
        "terseLabel": "Expenses on long-term purchase commitment"
       }
      }
     },
     "localname": "ExpensesOnLongTermPurchaseCommitment",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_FairValueOfNonCashConsiderationReceivedForOptionExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value Of Non-Cash Consideration Received For Option Exercise",
        "label": "Fair value Of Non-Cash Consideration Received For Option Exercise",
        "terseLabel": "Fair value of non-cash consideration received for option exercises"
       }
      }
     },
     "localname": "FairValueOfNonCashConsiderationReceivedForOptionExercise",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hayfin Loan Agreement Delayed Draw Term Loan [Member]",
        "label": "Hayfin Loan Agreement Delayed Draw Term Loan [Member]",
        "terseLabel": "Hayfin Loan Agreement Delayed Draw Term Loan"
       }
      }
     },
     "localname": "HayfinLoanAgreementDelayedDrawTermLoanMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_HayfinLoanAgreementTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hayfin Loan Agreement Term Loan [Member]",
        "label": "Hayfin Loan Agreement Term Loan [Member]",
        "terseLabel": "Hayfin Loan Agreement Term Loan"
       }
      }
     },
     "localname": "HayfinLoanAgreementTermLoanMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_InsuranceProvidersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Providers",
        "label": "Insurance Providers [Member]",
        "terseLabel": "Insurance Providers"
       }
      }
     },
     "localname": "InsuranceProvidersMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_InternationalSection351Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Section 351",
        "label": "International Section 351 [Member]",
        "terseLabel": "International Section 351"
       }
      }
     },
     "localname": "InternationalSection351Member",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/InventoryDetails",
      "http://mimedx.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_InvestigationRestatementAndRelated": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investigation, Restatement And Related",
        "label": "Investigation, Restatement And Related",
        "terseLabel": "Investigation, restatement and related",
        "verboseLabel": "Investigation, restatement and related expense"
       }
      }
     },
     "localname": "InvestigationRestatementAndRelated",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_LongTermDebtMaturityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, after Year Four",
        "label": "Long-Term Debt, Maturity, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturityAfterYearFour",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_LongTermPurchaseCommitmentTerminationNoticePeriodRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Purchase Commitment, Termination Notice Period Required",
        "label": "Long-Term Purchase Commitment, Termination Notice Period Required",
        "terseLabel": "Termination period (in days)"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTerminationNoticePeriodRequired",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mdxg_NordicBioscienceClinicalDevelopmentASMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nordic Bioscience Clinical Development A/S",
        "label": "Nordic Bioscience Clinical Development A/S [Member]",
        "terseLabel": "Nordic Bioscience Clinical Development A/S"
       }
      }
     },
     "localname": "NordicBioscienceClinicalDevelopmentASMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_NotesReceivableForSaleOfPropertyAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Receivable For Sale Of Property And Equipment",
        "label": "Notes Receivable For Sale Of Property And Equipment",
        "terseLabel": "Note receivable for sale of property and equipment"
       }
      }
     },
     "localname": "NotesReceivableForSaleOfPropertyAndEquipment",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_NumberOfBoardSeatsElectedByTemporaryEquityHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Board Seats Elected By Temporary Equity Holders",
        "label": "Number Of Board Seats Elected By Temporary Equity Holders",
        "terseLabel": "Number of board seats elected by Series B preferred stockholders"
       }
      }
     },
     "localname": "NumberOfBoardSeatsElectedByTemporaryEquityHolders",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mdxg_NumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Products",
        "label": "Number Of Products",
        "terseLabel": "Number of products"
       }
      }
     },
     "localname": "NumberOfProducts",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mdxg_PatentsinProcessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents in Process",
        "label": "Patents in Process [Member]",
        "terseLabel": "Patents in Process"
       }
      }
     },
     "localname": "PatentsinProcessMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_PaymentsForApplicationCostsPatent": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Application Costs, Patent",
        "label": "Payments For Application Costs, Patent",
        "negatedTerseLabel": "Patent application costs"
       }
      }
     },
     "localname": "PaymentsForApplicationCostsPatent",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_PaymentsMadeOnLongTermPurchaseCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Made On Long-Term Purchase Commitment",
        "label": "Payments Made On Long-Term Purchase Commitment",
        "terseLabel": "Payments made on long-term purchase commitment"
       }
      }
     },
     "localname": "PaymentsMadeOnLongTermPurchaseCommitment",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Perpetual Dividend Rate after Quarterly Dividend Payment ending on June 30, 2021 [Member]",
        "label": "Perpetual Dividend Rate after Quarterly Dividend Payment ending on June 30, 2021 [Member]",
        "terseLabel": "Perpetual Dividend Rate after Quarterly Dividend Payment ending on June 30, 2021"
       }
      }
     },
     "localname": "PerpetualDividendRateafterQuarterlyDividendPaymentendingonJune302021Member",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_RegenerativeMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regenerative Medicine &amp; Biologics Innovation Reporting Unit",
        "label": "Regenerative Medicine [Member]",
        "terseLabel": "Regenerative Medicine &amp; Biologics Innovation"
       }
      }
     },
     "localname": "RegenerativeMedicineMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_RegenerativeMedicineSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regenerative Medicine Segment",
        "label": "Regenerative Medicine Segment [Member]",
        "terseLabel": "Regenerative Medicine"
       }
      }
     },
     "localname": "RegenerativeMedicineSegmentMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_RemainingPrepaidExpensesOnLongTermPurchaseCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Prepaid Expenses On Long-Term Purchase Commitment",
        "label": "Remaining Prepaid Expenses On Long-Term Purchase Commitment",
        "terseLabel": "Remaining prepaid expenses on long-term purchase commitment"
       }
      }
     },
     "localname": "RemainingPrepaidExpensesOnLongTermPurchaseCommitment",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock, Restricted Stock Units, And Performance Stock Units",
        "label": "Restricted Stock, Restricted Stock Units, And Performance Stock Units [Member]",
        "terseLabel": "Restricted Stock, Restricted Stock Units, And Performance Stock Units"
       }
      }
     },
     "localname": "RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_RevenueFromContractWithCustomerNumberOfDistributionChannels": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Number Of Distribution Channels",
        "label": "Revenue From Contract With Customer, Number Of Distribution Channels",
        "terseLabel": "Number of primary distribution channels"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerNumberOfDistributionChannels",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mdxg_ScheduleOfDebtIssuanceCostsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Debt Issuance Costs [Table Text Block]",
        "label": "Schedule Of Debt Issuance Costs [Table Text Block]",
        "terseLabel": "Schedule of Debt Issuance Costs"
       }
      }
     },
     "localname": "ScheduleOfDebtIssuanceCostsTableTextBlock",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mdxg_ScheduleOfDepreciationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Depreciation",
        "label": "Schedule Of Depreciation [Table Text Block]",
        "terseLabel": "Schedule of Depreciation Expense"
       }
      }
     },
     "localname": "ScheduleOfDepreciationTableTextBlock",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mdxg_ScheduleOfInterestExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Interest Expense [Table Text Block]",
        "label": "Schedule Of Interest Expense [Table Text Block]",
        "terseLabel": "Schedule of Interest Expense"
       }
      }
     },
     "localname": "ScheduleOfInterestExpenseTableTextBlock",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mdxg_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Total Shareholder Return Performance Stock Units Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mdxg_Section351ProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Section 351 Products",
        "label": "Section 351 Products [Member]",
        "terseLabel": "Section 351"
       }
      }
     },
     "localname": "Section351ProductsMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_SegmentContribution": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Contribution",
        "label": "Segment Contribution",
        "totalLabel": "Segment contribution"
       }
      }
     },
     "localname": "SegmentContribution",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_SeparationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation Agreement",
        "label": "Separation Agreement [Member]",
        "terseLabel": "Separation Agreement"
       }
      }
     },
     "localname": "SeparationAgreementMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period",
        "terseLabel": "Performance period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Trading Days",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Trading Days",
        "terseLabel": "Trading days (in days)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTradingDays",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mdxg_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mdxg_SupplementalInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Information",
        "label": "Supplemental Information [Abstract]",
        "terseLabel": "Supplemental information"
       }
      }
     },
     "localname": "SupplementalInformationAbstract",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mdxg_TemporaryEquityAccretionOfIncreasingRateDividendFeature": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PreferredStockDividendsAndOtherAdjustments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Accretion Of Increasing-Rate Dividend Feature",
        "label": "Temporary Equity, Accretion Of Increasing-Rate Dividend Feature",
        "terseLabel": "Accretion of increasing-rate dividend feature"
       }
      }
     },
     "localname": "TemporaryEquityAccretionOfIncreasingRateDividendFeature",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_TemporaryEquityConversionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Conversion Price Per Share",
        "label": "Temporary Equity, Conversion Price Per Share",
        "terseLabel": "Series B preferred stock, conversion price (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityConversionPricePerShare",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mdxg_TemporaryEquityConversionThresholdPercentageofStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Conversion, Threshold Percentage of Stock Price Trigger",
        "label": "Temporary Equity, Conversion, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Series B preferred stock, minimum percentage of conversion stock price to trigger conversion (percent)"
       }
      }
     },
     "localname": "TemporaryEquityConversionThresholdPercentageofStockPriceTrigger",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mdxg_TemporaryEquityConversionThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Conversion, Threshold Trading Days",
        "label": "Temporary Equity, Conversion, Threshold Trading Days",
        "terseLabel": "Number of trading days within consecutive day trading period common stock must exceed trigger conversion price"
       }
      }
     },
     "localname": "TemporaryEquityConversionThresholdTradingDays",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mdxg_TemporaryEquityDeemedDividends": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Deemed Dividends",
        "label": "Temporary Equity, Deemed Dividends",
        "terseLabel": "Deemed dividends on Series B Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityDeemedDividends",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mdxg_TemporaryEquityDividendRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Dividend Rate, Percentage",
        "label": "Temporary Equity, Dividend Rate, Percentage",
        "terseLabel": "Series B convertible stock, cumulative dividend (percent)"
       }
      }
     },
     "localname": "TemporaryEquityDividendRatePercentage",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mdxg_TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Maximum Voting Stock Percentage On As-Converted Basis",
        "label": "Temporary Equity, Maximum Voting Stock Percentage On As-Converted Basis",
        "terseLabel": "Series B preferred stock, maximum voting stock percentage on an as-converted basis (percent)"
       }
      }
     },
     "localname": "TemporaryEquityMaximumVotingStockPercentageOnAsConvertedBasis",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mdxg_TemporaryEquityThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Threshold Consecutive Trading Days",
        "label": "Temporary Equity, Threshold Consecutive Trading Days",
        "terseLabel": "Series B preferred stock, threshold number of consecutive trading days"
       }
      }
     },
     "localname": "TemporaryEquityThresholdConsecutiveTradingDays",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mdxg_TermLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Agreement [Member]",
        "label": "Term Loan Agreement [Member]",
        "terseLabel": "BT Term Loan"
       }
      }
     },
     "localname": "TermLoanAgreementMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_TreasuryStockSharesAdjustment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock, Shares, Adjustment",
        "label": "Treasury Stock, Shares, Adjustment",
        "terseLabel": "Other (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAdjustment",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "mdxg_WoundSurgicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound Care &amp; Surgical Unit",
        "label": "Wound &amp; Surgical [Member]",
        "terseLabel": "Wound &amp; Surgical"
       }
      }
     },
     "localname": "WoundSurgicalMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mdxg_WoundSurgicalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound &amp; Surgical Segment",
        "label": "Wound &amp; Surgical Segment [Member]",
        "terseLabel": "Wound &amp; Surgical"
       }
      }
     },
     "localname": "WoundSurgicalSegmentMember",
     "nsuri": "http://mimedx.com/20220930",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r107",
      "r160",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r186",
      "r190",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r278",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r107",
      "r160",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r186",
      "r190",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r278",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r55",
      "r57",
      "r105",
      "r106",
      "r287",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails",
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r258",
      "r260",
      "r261",
      "r262",
      "r286",
      "r327",
      "r369",
      "r370",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r504",
      "r506",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r258",
      "r260",
      "r261",
      "r262",
      "r286",
      "r327",
      "r369",
      "r370",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r504",
      "r506",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r193",
      "r260",
      "r261",
      "r362",
      "r365",
      "r473",
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/InventoryDetails",
      "http://mimedx.com/role/NatureofBusinessDetails",
      "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r193",
      "r260",
      "r261",
      "r362",
      "r365",
      "r473",
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/InventoryDetails",
      "http://mimedx.com/role/NatureofBusinessDetails",
      "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r250",
      "r258",
      "r260",
      "r261",
      "r262",
      "r286",
      "r327",
      "r368",
      "r369",
      "r370",
      "r399",
      "r400",
      "r401",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r504",
      "r506",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r250",
      "r258",
      "r260",
      "r261",
      "r262",
      "r286",
      "r327",
      "r368",
      "r369",
      "r370",
      "r399",
      "r400",
      "r401",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r504",
      "r506",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r105",
      "r106",
      "r287",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r198",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails",
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails",
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails",
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails",
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndNontradeReceivableTextBlock": {
     "auth_ref": [
      "r203",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable.",
        "label": "Accounts and Nontrade Receivable [Text Block]",
        "terseLabel": "Accounts and Nontrade Receivable"
       }
      }
     },
     "localname": "AccountsAndNontradeReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccountsReceivableNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43",
      "r464"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r6",
      "r25",
      "r199",
      "r200"
     ],
     "calculation": {
      "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, gross"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "calculation": {
      "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://mimedx.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccruedExpensesDetails",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://mimedx.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Legal and settlement costs"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "auth_ref": [
      "r10",
      "r46"
     ],
     "calculation": {
      "http://mimedx.com/role/AccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Sales Commission, Current",
        "terseLabel": "Commissions to sales agents"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r27",
      "r464"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r407",
      "r408",
      "r409",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares repurchased for tax withholding"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": {
     "auth_ref": [
      "r341",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.",
        "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings",
        "negatedTerseLabel": "Deemed dividends"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r372",
      "r410",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation\u00a0expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash flows (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r32",
      "r201",
      "r206"
     ],
     "calculation": {
      "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedTerseLabel": "Less: allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r71",
      "r87",
      "r306",
      "r448"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of original issue discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r67",
      "r87",
      "r306",
      "r450"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r87",
      "r306",
      "r317",
      "r318",
      "r450"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r87",
      "r229",
      "r236"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails": {
       "order": 5.0,
       "parentTag": "mdxg_SegmentContribution",
       "weight": -1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "netLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetAmortizationExpenseDetails",
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "negatedTerseLabel": "Less: antidilutive potential common shares (in shares)",
        "terseLabel": "Potential common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetRetirementObligationAccretionExpense": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.",
        "label": "Asset Retirement Obligation, Accretion Expense",
        "terseLabel": "Accretion of asset retirement obligation"
       }
      }
     },
     "localname": "AssetRetirementObligationAccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r18",
      "r102",
      "r168",
      "r181",
      "r188",
      "r204",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r279",
      "r281",
      "r282",
      "r429",
      "r432",
      "r440",
      "r462",
      "r464",
      "r478",
      "r493"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r42",
      "r102",
      "r204",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r279",
      "r281",
      "r282",
      "r429",
      "r432",
      "r440",
      "r462",
      "r464"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails",
      "http://mimedx.com/role/EquityNarrativeDetails",
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of equipment in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r13",
      "r89"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r81",
      "r89",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r81",
      "r441"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r99",
      "r102",
      "r125",
      "r126",
      "r131",
      "r134",
      "r136",
      "r145",
      "r146",
      "r147",
      "r204",
      "r268",
      "r273",
      "r274",
      "r275",
      "r281",
      "r282",
      "r324",
      "r325",
      "r330",
      "r334",
      "r341",
      "r440",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails",
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r51",
      "r483",
      "r497"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r263",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock Issued"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance end of period (in shares)",
        "periodStartLabel": "Balance beginning of period (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24",
      "r464"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.001 par value; 187,500,000 shares authorized; 113,670,017 issued and 113,668,179 outstanding at September\u00a030, 2022 and 112,703,926 issued and 111,925,216 outstanding at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://mimedx.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "terseLabel": "Estimated sales returns"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelAxis": {
     "auth_ref": [
      "r362",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by sales channel for delivery of good or service in contract with customer.",
        "label": "Contract with Customer, Sales Channel [Axis]",
        "terseLabel": "Contract with Customer, Sales Channel [Axis]"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelDomain": {
     "auth_ref": [
      "r362",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.",
        "label": "Contract with Customer, Sales Channel [Domain]",
        "terseLabel": "Contract with Customer, Sales Channel [Domain]"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r190",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate &amp; Other"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r69",
      "r473"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails": {
       "order": 3.0,
       "parentTag": "mdxg_SegmentContribution",
       "weight": -1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r300",
      "r307",
      "r308",
      "r310",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long Term Debt, Net"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r101",
      "r107",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r315",
      "r316",
      "r317",
      "r318",
      "r451",
      "r479",
      "r480",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r21",
      "r311",
      "r480",
      "r492"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Outstanding principal",
        "totalLabel": "Long term debt, net"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r283",
      "r315",
      "r316",
      "r449",
      "r451",
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r48",
      "r313",
      "r449",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49",
      "r101",
      "r107",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r315",
      "r316",
      "r317",
      "r318",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Three"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r49",
      "r101",
      "r107",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r309",
      "r315",
      "r316",
      "r317",
      "r318",
      "r342",
      "r345",
      "r346",
      "r347",
      "r448",
      "r449",
      "r451",
      "r452",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r296",
      "r448",
      "r452"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Original issue discount",
        "terseLabel": "Original issue discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "verboseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r296",
      "r450"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r87",
      "r242"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://mimedx.com/role/PropertyandEquipmentNetDepreciationExpenseDetails",
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.",
        "label": "Dividends [Axis]",
        "terseLabel": "Dividends [Axis]"
       }
      }
     },
     "localname": "DividendsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.",
        "label": "Dividends [Domain]",
        "terseLabel": "Dividends [Domain]"
       }
      }
     },
     "localname": "DividendsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsPayableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Dividends Payable [Line Items]",
        "terseLabel": "Dividends Payable [Line Items]"
       }
      }
     },
     "localname": "DividendsPayableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPayableTable": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.",
        "label": "Dividends Payable [Table]",
        "terseLabel": "Dividends Payable [Table]"
       }
      }
     },
     "localname": "DividendsPayableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r348",
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "terseLabel": "Dividends, preferred stock",
        "verboseLabel": "Deemed dividends"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails",
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r65",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r122",
      "r125",
      "r134",
      "r135",
      "r136",
      "r141",
      "r142",
      "r438",
      "r439",
      "r486",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share (in dollars per share)",
        "verboseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r65",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r125",
      "r134",
      "r135",
      "r136",
      "r141",
      "r142",
      "r438",
      "r439",
      "r486",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expenses expected to be recognized over a weighted-average period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized stock-based compensation related to time-based, nonvested restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock",
        "verboseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails",
      "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails",
      "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory and clean room equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r62",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r144",
      "r205",
      "r341",
      "r348",
      "r407",
      "r408",
      "r409",
      "r418",
      "r419",
      "r437",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r460",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r455",
      "r457"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Principal payments on finance lease"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "verboseLabel": "Finance lease right-of-use asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r16",
      "r235"
     ],
     "calculation": {
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the nine months ended September 30, 2022)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r230",
      "r232",
      "r235",
      "r239",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated future amortization expense [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r235",
      "r475"
     ],
     "calculation": {
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r230",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r235",
      "r474"
     ],
     "calculation": {
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      },
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails",
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "(Gain) loss on fixed asset disposal"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r15",
      "r214",
      "r215",
      "r222",
      "r226",
      "r464",
      "r477"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r225",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r68",
      "r102",
      "r168",
      "r180",
      "r184",
      "r187",
      "r190",
      "r204",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r277",
      "r279",
      "r281",
      "r282",
      "r440"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r168",
      "r180",
      "r184",
      "r187",
      "r190",
      "r476",
      "r484",
      "r488",
      "r501"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax provision"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r415",
      "r416",
      "r417",
      "r420",
      "r422",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r120",
      "r121",
      "r166",
      "r413",
      "r421",
      "r423",
      "r502"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax provision expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r83",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r26",
      "r482",
      "r498"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedTerseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Increase (decrease) in cash resulting from changes in:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r231",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Gross carrying value, indefinite lived"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r231",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r228",
      "r233"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r71",
      "r304",
      "r314",
      "r317",
      "r318"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r73",
      "r305",
      "r317",
      "r318"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Stated interest"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r80",
      "r82",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r210"
     ],
     "calculation": {
      "http://mimedx.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r39",
      "r464"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://mimedx.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mimedx.com/role/InventoryDetails",
      "http://mimedx.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r35",
      "r210"
     ],
     "calculation": {
      "http://mimedx.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r34",
      "r210"
     ],
     "calculation": {
      "http://mimedx.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r102",
      "r182",
      "r204",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r277",
      "r279",
      "r281",
      "r282",
      "r430",
      "r432",
      "r433",
      "r440",
      "r462",
      "r463"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r102",
      "r204",
      "r440",
      "r464",
      "r481",
      "r496"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock, and stockholders\u2019 (deficit) equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r47",
      "r102",
      "r204",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r277",
      "r279",
      "r281",
      "r282",
      "r430",
      "r432",
      "r433",
      "r440",
      "r462",
      "r463",
      "r464"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r21",
      "r297",
      "r312",
      "r315",
      "r316",
      "r480",
      "r494"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Long term debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Fair value of the Term Loan"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r107",
      "r266",
      "r302"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r107",
      "r266",
      "r302"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r107",
      "r266",
      "r302"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r107",
      "r266",
      "r302"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the nine months ended September\u00a030, 2022)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Long-term purchase commitment amount"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "terseLabel": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r49",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash\u00a0flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r85",
      "r88"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r58",
      "r59",
      "r62",
      "r64",
      "r88",
      "r102",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r132",
      "r168",
      "r180",
      "r184",
      "r187",
      "r190",
      "r204",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r277",
      "r279",
      "r281",
      "r282",
      "r439",
      "r440",
      "r485",
      "r499"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY",
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r122",
      "r123",
      "r133",
      "r136",
      "r168",
      "r180",
      "r184",
      "r187",
      "r190"
     ],
     "calculation": {
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "netLabel": "Net loss available to common stockholders - basic",
        "terseLabel": "Net loss available to common stockholders",
        "totalLabel": "Net loss available to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails",
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r124",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r136"
     ],
     "calculation": {
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss available to common stockholders - diluted",
        "totalLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanBalancesDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDebtIssuanceCostsDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails",
      "http://mimedx.com/role/LongTermDebtNetTermLoanInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails",
      "http://mimedx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails",
      "http://mimedx.com/role/NatureofBusinessDetails",
      "http://mimedx.com/role/SegmentInformationNarrativeDetails",
      "http://mimedx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails",
      "http://mimedx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r168",
      "r180",
      "r184",
      "r187",
      "r190"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "verboseLabel": "Non-cash lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://mimedx.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r41",
      "r464"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Other commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r464"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPreferredStockDividendsAndAdjustments": {
     "auth_ref": [
      "r123",
      "r349"
     ],
     "calculation": {
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of preferred stock dividends and adjustments classified as other.",
        "label": "Other Preferred Stock Dividends and Adjustments",
        "terseLabel": "Less: antidilutive adjustments"
       }
      }
     },
     "localname": "OtherPreferredStockDividendsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents and know-how"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Stock repurchased for tax withholdings on vesting of restricted stock"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Total Shareholder Return Performance Stock Units",
        "verboseLabel": "Performance stock unit awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails",
      "http://mimedx.com/role/EquityNarrativeDetails",
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails",
      "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Preferred Class B [Member]",
        "terseLabel": "Preferred Class B Convertible Stock"
       }
      }
     },
     "localname": "PreferredClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of preferred stock.",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "terseLabel": "Convertible shares issuable (in shares)"
       }
      }
     },
     "localname": "PreferredStockConvertibleSharesIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r123",
      "r137"
     ],
     "calculation": {
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      },
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "terseLabel": "Dividends on Series B Convertible Preferred Stock",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails",
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Dividends and Other Adjustments [Abstract]",
        "terseLabel": "Adjustments:"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r23",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r23",
      "r464"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock Series A; $0.001 par value; 5,000,000 shares authorized, 0 issued and outstanding at September\u00a030, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r7",
      "r40",
      "r212",
      "r213"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Collection of Notes Receivable",
        "terseLabel": "Principal payments from note receivable"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r78",
      "r406"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r244",
      "r454",
      "r456"
     ],
     "calculation": {
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r245",
      "r456"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r18",
      "r243",
      "r453"
     ],
     "calculation": {
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r247",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r14",
      "r243"
     ],
     "calculation": {
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r66",
      "r207"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Bad debt expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccountsReceivableNetNarrativeDetails",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.",
        "label": "Research and Development Arrangement [Member]",
        "terseLabel": "Research and Development Arrangement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r412",
      "r472",
      "r518"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails": {
       "order": 4.0,
       "parentTag": "mdxg_SegmentContribution",
       "weight": -1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "RSA",
        "verboseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails",
      "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSU",
        "verboseLabel": "Restricted stock unit awards"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails",
      "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r348",
      "r464",
      "r495",
      "r510",
      "r511"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r205",
      "r407",
      "r408",
      "r409",
      "r418",
      "r419",
      "r437",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r159",
      "r160",
      "r179",
      "r185",
      "r186",
      "r193",
      "r194",
      "r196",
      "r361",
      "r362",
      "r473"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails": {
       "order": 1.0,
       "parentTag": "mdxg_SegmentContribution",
       "weight": 1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net sales",
        "verboseLabel": "Net sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/NatureofBusinessDetails",
      "http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails",
      "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails",
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r458",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right of use assets arising from finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r458",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "negatedTerseLabel": "Right of use assets arising from operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesChannelDirectlyToConsumerMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred directly to consumer.",
        "label": "Sales Channel, Directly to Consumer [Member]",
        "terseLabel": "Direct Customers"
       }
      }
     },
     "localname": "SalesChannelDirectlyToConsumerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesChannelThroughIntermediaryMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred through intermediary.",
        "label": "Sales Channel, Through Intermediary [Member]",
        "terseLabel": "Distributors"
       }
      }
     },
     "localname": "SalesChannelThroughIntermediaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccountsReceivableNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Summary of Antidilutive Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "auth_ref": [
      "r126",
      "r136",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]",
        "terseLabel": "Basic Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "auth_ref": [
      "r126",
      "r136",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]",
        "terseLabel": "Diluted Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/RevenueSummaryofRevenuebyCustomerTypeDetails",
      "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r230",
      "r234",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r230",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets Activity Summary - Finite-lived"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r238",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r238",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets Activity Summary - Indefinite-lived"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Principal Payments for the Term Loan"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r168",
      "r171",
      "r183",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r168",
      "r171",
      "r183",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Net Sales and Segment Contribution for Each Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails",
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r377",
      "r392",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Awards by Award Type"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r99",
      "r145",
      "r146",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r330",
      "r334",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Future Amortization Expense for Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r155",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r196",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r226",
      "r251",
      "r252",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r155",
      "r157",
      "r158",
      "r168",
      "r172",
      "r184",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails": {
       "order": 2.0,
       "parentTag": "mdxg_SegmentContribution",
       "weight": -1.0
      },
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/CommitmentsandContingenciesDetails",
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r22",
      "r23",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails",
      "http://mimedx.com/role/EquityNarrativeDetails",
      "http://mimedx.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails",
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested, Ending Balance (in shares)",
        "periodStartLabel": "Unvested, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested, Ending Balance (in dollars per share)",
        "periodStartLabel": "Unvested, Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (annualized)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails",
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contractual Term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Vested options expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Unvested options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued during period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails",
      "http://mimedx.com/role/EquityNarrativeDetails",
      "http://mimedx.com/role/EquityRestrictedStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Vested options expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Unvested options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Closing stock price on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock (in percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "terseLabel": "Shares repurchased for tax withholding (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r155",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r196",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r226",
      "r246",
      "r251",
      "r252",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SegmentInformationNetSalesandOperatingIncomeLossbyeachReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r99",
      "r102",
      "r125",
      "r126",
      "r131",
      "r134",
      "r136",
      "r145",
      "r146",
      "r147",
      "r204",
      "r268",
      "r273",
      "r274",
      "r275",
      "r281",
      "r282",
      "r324",
      "r325",
      "r330",
      "r334",
      "r341",
      "r440",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails",
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r52",
      "r60",
      "r61",
      "r62",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r144",
      "r205",
      "r341",
      "r348",
      "r407",
      "r408",
      "r409",
      "r418",
      "r419",
      "r437",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r460",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r144",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r23",
      "r24",
      "r341",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Restricted stock canceled/forfeited (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r341",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r24",
      "r341",
      "r348",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY",
      "http://mimedx.com/role/EquityStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r23",
      "r24",
      "r341",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedTerseLabel": "Restricted stock shares canceled/forfeited"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r23",
      "r24",
      "r341",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r341",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r29",
      "r30",
      "r102",
      "r202",
      "r204",
      "r440",
      "r464"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "totalLabel": "Total stockholders' (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:",
        "verboseLabel": "Stockholders' (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r325",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r348",
      "r352",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r268",
      "r273",
      "r274",
      "r275",
      "r281",
      "r282"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Series B Preferred Stock, outstanding, ending",
        "periodStartLabel": "Series B Preferred Stock, outstanding, beginning",
        "terseLabel": "Convertible preferred stock Series B; $0.001 par value; 100,000 shares authorized, issued and outstanding at September\u00a030, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDividendsAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PreferredStockDividendsAndOtherAdjustments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).",
        "label": "Temporary Equity, Dividends, Adjustment",
        "terseLabel": "Dividends on Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityDividendsAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreferencePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference Per Share",
        "terseLabel": "Liquidation preference (USD per share)"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreferencePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Series B convertible preferred stock par value (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Series B convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Series B convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Series B Preferred Stock, outstanding, ending (in shares)",
        "periodStartLabel": "Series B Preferred Stock, outstanding, beginning (in shares)",
        "terseLabel": "Series B convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://mimedx.com/role/EquityChangesinSeriesBPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r12",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Series B Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Tradenames and trademarks"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/GoodwillandIntangibleAssetsNetActivitySummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "periodEndLabel": "Treasury stock, ending balance (in shares)",
        "periodStartLabel": "Treasury stock, beginning balance (in shares)",
        "terseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r54",
      "r350",
      "r351"
     ],
     "calculation": {
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedTerseLabel": "Treasury stock at cost; 1,838 shares at September\u00a030, 2022 and 778,710 shares at December\u00a031, 2021"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual or Infrequent Item, or Both [Line Items]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Line Items]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemTable": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Table]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Table]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/LongTermDebtNetTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Potential common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r124",
      "r136"
     ],
     "calculation": {
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding - diluted (in shares)",
        "totalLabel": "Weighted average shares outstanding adjusted for potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r122",
      "r136"
     ],
     "calculation": {
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding - basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mimedx.com/role/NetLossPerCommonShareBasicNetLossPerCommonShareDetails",
      "http://mimedx.com/role/NetLossPerCommonShareDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "310",
   "URI": "https://asc.fasb.org/topic&trid=2196771"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "326",
   "URI": "https://asc.fasb.org/topic&trid=82887179"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.Q)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187283-122770"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130611-203046-203046"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r519": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r521": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r522": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r523": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r524": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r525": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0001376339-22-000127-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001376339-22-000127-xbrl.zip
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M.,.6%QF&N;(!6.'R#:LF4AO<MX]]L)8.L=#BS+F_94H$)"&;'TD7BJ./Y>Y
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M^B)@Y8*6[*  A4 7+1/!W E4YZ$63% EK '"5Q]'AJE=*=>V(KC<T*Y\.*K
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M8^OOBHI/_RLG]WNKR_\!4$L#!!0    ( /6!8E6WC+&!$@4  %,5   ;
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M-] !]D"7M[]UE[M?I<M9AFDI+?,C)D=%F YUS)2[>"!,Y[1<4*E=W]33)$D
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M9]1[2>Z[8;GW@J]ZEM>-Q<7GZ$]02P,$%     @ ]8%B5069/](1!0  "A8
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M!4UF1%I!\6P6"KQ/*3DG8BVQE9IRG=9)")/I[%BK.2 @S$5P0LVVM9RT=$[
MIW08A%#C2$/Z+QC,N/9!2P2.)IV)PU^GE)PO93NO'6R2BMW808((7]RAZ71"
MZZ%#3N[>.6[]T<NF#BF.L/&@VAD#Y@$O-CC.A94L4L3C#)CI,7^LP;@*X_J?
M\_[AVJ#7[[9#L6M:H;=6S<VM<LG7KJR7Q\6TALTNM-$;M.?3A).4&<H-MH \
M&:( R200W]M )!**BQDPX3-(ZHF8=V0B4HYA$F5D049%'&>$:D^UE1;/4HFC
M&2+U9,YR<=C'Z 36.NU$\3IP83P(.I$">\]FP/3/(*DGXE+S*&7 2% +LAT-
MUU1CH[%C%DFAI/LE;'7SL.@.#@ZW4D9M._C<%,-Y--;&8R=]H))@PAP'?XT;
M2[QWDG.,5?PEC/7+TWHBUEJ!IZ:1E:GR2KE_3 /5@<I":LZ#B;^$M9Z(7+^\
MN586X!CQTFA$P5/7&B/K-54N:%#MB/X2YGHB<OWR]EJA0+ Q 9PL!?;:&R(0
M<CP0PF@JLC=#]OKR_*&_!KV\$WJ]W:J)ZYN&R^7^W4%QD#:PC*X_Q:[A!.FZ
MK=R7^Y'3[I3>3<[:!I+ M<[!N$_SB < WZ.R1BW!DE%&C68^,D\98QY;'F:
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M,A8OJ^ YQLL<59KV?@5_I3]O7R1\6?*'+W_UV:]>9 H_ON7[C0=A7[$>8^M
M3LZ3?;A.AU:(=V>M>_)X&5\M<M.J?>SDKNM#K;[[D)"C6T+.;@MY93N?7[X_
M# ">A:(UW F $_M+M?+0O#Z\X+R_$O/SX+-^,9A-%;"9V[<?Q?:ZNVBLK_+Z
MQ=[%]N<Z;:PWVHW4)^C+=K-.&I^WSAM'#L1^8_3,)W@7[^PWNZQQ44?U]>/T
M/@XJ ]7)'MI>3VIC*[6']XY ?5S &#ZILW?-U7Y]%YV_:QZ?U9O'Z L1,M@
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MWD,:^I'\\1EF.4E)[^<XHW9>^\X7/REC-KK?^_HG&G<*0*@_[DCN/"OTI.A
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MIG'];K$(8<Z?3'/\E#(]Z[;ZUXAA?NQ<*WZ^:UK5/I5J:?]Z->[DP'SLE3L
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MG?M1!-"$:2 62TJIBH2KI!]WM2@G]Y<8PXT>:"L8GC&&:\JQ(TY&E?3BH*@
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ML0J']^*SV%L-@K=F;R&O.4/<@?2Y"+F.+BE:RH/D&M,09; 8KVVP.Q.#G@7
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MD QA1HCQQK/@]=J&NB0K:66Z>##3A??=.+);%,<=M?QWM\B?5^LX:&$5)/+
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M9ICH-MN^>69;.>R_D(32PM?N]./+K0#UJ(:*;@=6<^B]@6EXW6FU8M&$O=2
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M^$+W&W#LVB8\9S69YU075D(#+A2L<B;R>1MH%MT\K9V\"P;@\[U"XQWK+7_
M&AJIEUE3OF3R8!QB.YLDYR=-7&/2RMVYU#(FJV >2[.5NEQ_&?I.F[[;:4/G
M0^G*%X%2 .@5=J-)"W_SPU*\H+Y?U%?7/#(]7*/&K\1* ;;N8MZ^+A?4A<FN
M#^UUA6&D&Q$@[]?8SYHT:+"P=H8KKT2XC$UVM-$5"6S"T(I0;H$AGL(RR$IE
M/A@>62IB@EW1^HL;;6TK@_?[P[Z/T@F'6IS:R\)X+RM' #CKV7#4AP62CD9\
M(;>GT+VGC2]#Z\CBN ^MJ"7?[1]W.X.CX]JNO:@Q4NALI# M@:1.?S:KQ_6
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MX%+$V<%*JJ?A^5U%N%18MJJ'YQ66+1O+YD_)\W:33(B(*9<#681%ANJ$<I%
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ML("X-Z!PX\@0%D(1[C4.F/Y$.[E\GN]H?ZGF>?GS; EA7@J/A#4,<>TXTI*
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M8L$U]"] Z9P=ED]>OG6Z)^BP>_*8ZBRKEDU\71=7)F?82L*DL];@I#EWQNC
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M:,<U<9&'N4#.XG&:+SKDB&+N+"#DY$R8 CKW )W&V]F@3*&-=@ U*7+8?;$
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M_>>J:$ N4T/Q("E>9:/=K.K,7]>UA:.WO9Z/NS;^G]X8:>;LSR<F5MZ.;K"
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MW&<PW(9*&G/)IF M!DN9!62L,\A::X+S7E*"<][-QFR.\__)2 %*?5XL?A1
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M?V>U9N=X..BOP[^3,"M[3HA:Z\&S+AZ5YYSOQ="$+YK];[7^,6R5PJC,BQO
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M64+8"S"\3$!# 887 89ISP66GCNA+$PPYA"G&("!<X$,V+4\,B<5P?,-;"C
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M&XE7G#B9&+9>3!F>,SH%<$PO>\<K/%#3WRG19?@[ZE6P)ISA'CL"]6DK=R>
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MNF)*N<[ #A?DG>5D,C";1P.X>ZQ2&LL.;*@=-&6XY;@\ 5;HNZ/0[$>]S+C
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M;GI?QLU\2+MN:&&!X57OQ7< A[W]^+(_V!T?U7_R2?VG.:B35HA=1XC-Q^5
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MI=A.(,W&IB[2J-L]0YJPE>7HZ*@/R'9F]NFIVVET!,(YRZW_ZP$4W2V'L0]
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MD$1-]&"0UJ,J*_-7^:K,Z80F]5KSG/+7!+:7RHLW6:#E79;9H2_#"C0;?Y^
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M8CX!<*$=U ^J3]I,%=8TL"?A\M-K_\IQ!RSKLW&P^RAO5G,W73XOUAE>(@)
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MC/"U5.1<,WR]4I&3,U!:L4<)MD?$.>9(1ZF0,R))8KSBU#]J1<X"L 5@GQ'
MEOJ;:P:P5^IOPO[)P1Y!7N7.34Y3I!4)2(&9HD+BD7CQJ/4WGP1@5\Z_O7P#
M+E<^  -<+A'[QUS-LE4I-?E^IE)I &'.I4H/[;?8&,+8.@EDM3?*& _W]!K]
MXS@85UK-Q4_AFMX!0 /,)0YZMGM1Q"S!%C(NKTKP_Y<O/H)'S)12'39.(WP
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MSGN,C->!LY@\T'9^I6,*26&GC0Z:&PJ\(#5F@C$P K@(;GZEQTO1V.W5:CK
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M5A;ZIQ;T&UC$@WP*ML8YFRN\_[6SC>PQ/#QSR>3.S!N#DX/-1JOC!_T>T"(
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M0T8+CIC6,E!%E8KWM])*3++$)!_34IV+2?X00XJ9NE" F3=3-8LN:6%1P/D
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MI4=@;A)G 8&\LQM;AMS;$U;@I\#/JGK"BG+T*-@TXQ-K?0?ER D5C0D:14+
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M+I5H;##6(**-S2>\';(<![ JP,+PQ%CF>19IRHI(K[%(+]QK4$3ZL41ZSCG
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M;,I/QS%G?YRR">SP+0NNV3)Y\685- "7-53L!<7_9$DJ)LL7V[FMW-3&YQ'
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MPCP_B!"GQ (W#Q5*<Y!L>SQ1!BLL44QDRL#XG/L"#2OYC"ICY>Q#1P<B*6F
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M!1,+RL4DDB$42P,C!Q%\D/,J0B+@L.&D%E\TE59 K &V0+5P%$.T<0!H*E@
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M'CQYYP--;T=+;W:GU=+MP*.MCO4\ ?&&.#AM;(6R6P%WUW(?KH#;J314J5_
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M7Z+P]->SLZ_&1Q$"=R&\/@.@L?%(&SGE(C10Y9!P G0CFFEWJO$421^0#U>
MRT+L%2"8JXTC.049*B[C XN!ZJ>)\0L'TN#&!98_\20UC1_L)W:A><\7,?>$
M;#A"+2?FV/;DO_*#$SSZ=TJ]^4@@H2?NWL#APR\7/]Z?/?*:;D43@<5^]UJV
M[#GSD6A G,B%6<;OJ"(" 8).:A!D<>R' R)OK1-9@3*%U 1[30$"& @'Y/6
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M=^K%/M=B1^Y#]BMLP\'ZYG/-8E.C73;5P*98/V8QW[ESXI[]_]H*FT=H*GD
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MR"8L#S^#M<H\--(K,H&HY.>") +@D_\4T@?/[5 D U B(M+"X)D1Z_-Y*";
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M9<)_ I.C48$BHUBB"@QME">'8%9\B3#O,,0 65#:5QA!Q*0<==)8,FP&1D1
MGZWPP2% HIAN#@8+  +SGF_N'RVF$EY1EB;@]9.]]&=A"^5G$3>A9!3OH.CU
MTAA'<4SQQL1 M12OO0U6PO_$9#>@PD\7OUQ^,TZ2;/P?/-2@=*E)$$44E+2M
MWJO7QB+(,!]" A@_[EN#WBMXZT3=+? U[(J) '<G3T)(FY%!Y+$8!(C(E\A2
M^AZ('9:>I+D)^#4&H!O?X#-Y_T?N4^+I1\KLQ,_E.CJP) -,+MAGF,VE\>;0
M9_@MWDFK4ZMMY\%'F0$* '"M3KX;XSK* A\M3+98@(E:Q)<+X&+PJ#S)CSP9
MKO?(T(:-?+A20:/W?,(P8X!AX DDD,R"V"J13+R0S>4I?<,U *QPXQZ:H!#
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MZ^ETAH)IM[9B;&[BW3:L/&>N7>W.E2?-!.TOY^\; 4Z*(I,K"(H#;=N\[@E
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M/#Y UWRCKJ4JL>*R**-O@+5KT@"(+*:$"N,CVI5VY_1?^P<6W$X# PNWAQ'
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M1(K]=,'WDOUA(LRN K\,MZ*L<AE[0*A,64RO*\!?4@IY0RO=_5A./$:R3$"
MFTI=HF<Q@S=<<\J#P,B0VJM4?0AKCX64F:-.Q?)@:X5(BI3)B)+A8,,%1:Z^
MEDX?YCR5!QRP!+XB> L"AU?>^3Y,/,N?CME%O"A1267N,J9^Q&"\5K,]B#J8
MG-$2+BL1;+0K< !,8U.);H]B*&\/-G>1CWM3JDN>@I74]BT_Q&NC#OM1M?;*
M[,BU,7>5?9?V77EX>8M^F:SHETFA7U9UA93-LM+,KX9&5=U2[K+?'AVEIV!:
M<6ZU8H"%)+)24B3[E$A>&H'X V5 &MV\WJP' 'TD<\>1S.A!YOYT>^V?^W-[
M9/.)L+19Y'T]^_;#N+B@@P/;?F=<_OCGAV_&Q9>/E]\^G_VXN/SR",';31"L
M0Q'#5OIZMF5\HDD]7V6)*/;;:[B6W%Z2IAII25,!3%(P01/A"T:)S+(4+"8_
M @1MB D/F/OA!4PHNS!@UTDF*(]")#3I9.L@&+RJ&.)4G88DRQLF13?GJRC
M<FCYDHFTB]&(H8;3JL!,YG/@C*0YY3)DJ:>>DE+':KDH9:IA[7&B@NYYK1S6
M2V/2J)JLEWBQ6%0=OJ1TH6 E:L516(GDP4[O.+.:3!ZOK)ZHR$=?@,S%M^0T
MX%5 3*PQ:S%F,9_\_<5?[I8&0P?S"5,NK0+;+8Y S]=ZCY]3$O"4AQBT-__V
MAOVC 2>']XL.%PW,@:2^8L;;A2G!(.6-_%E5^<M?UENE4[D<CD97F=5YG!E]
MSJ)$9/^H7,]NIZ0^LRA^;'Q4R6H/:>./F??'%,1AZ)^J34WHOW=/:_R7+MLM
MQUU*RI<>/@)E-8-/4A\*S8<Z_.YU6TDT#B9IQGPJ$IF=+1L4 O=]^#/#?+Y*
M; W%T6]2N2E;8+LAL.LF7?KO$<GFA+TVOD3A+9EHM>V]FEM\=,XX&3_6%AL<
M"SCQ7I,M4PZ=2REV2<U*P(I*9VM1RCQ@1M'1HJ!&>?CK$H-+XJ]817/F<U0O
MF/L->H;/6#!9NYOJ(4-RRT4@1V[F+XK7PPXKH4X9@^B,3^WAZRVE3WE EX(*
M4BENB2SL.3.OM\FY6^GKY'3)%P5\*TCGSG\,YL\IE7,L$OXV_^$=-I$)V/*M
M" E[=-.[U37@2ZERT&.!>C&]47ZMO-Z18SD]&QW?-(8_?OYBY1-;Y!._2?V;
MW[F.!0#9^G7'LK=^=]MC;0!$=[#78^]X97^_IS[#8CO6J#/2B^WM1EUOB'(E
M]0)_('_^_87[H@P+4<^PMQW#)O[*GW?+I<[B)UZ\@677^$FRTM,+:0I5R;['
MX$AC5GDT(66CRCYSR5BV)+Y[TP<'GS.<S37EJJH"<_8)1%*@8Y<.V7;CF$&T
M1D+&.OFHX\-%-@Z$AS'Q4&8T@>X-*@.9CA!R9WB8^%,&C-ZC4HZ-_V%!)KNX
M2"C2(<1GMC3^'T^-7[CQM8"J+-SZ&C"9^_)5EK,E*_"\0ZKE^C^,*$IS"USU
ME:M7W@'8FZZX!\X8N.*WT">VH[QA:D6+9R)-ZKUC&Z>R"8_JZ>=L95;G[JTK
M*Q0M66>1&A2!,O*-5.'2,39 AQJF-(IYR1-QWDE-L Z8!P,&@(' T=D=&+>0
M\IUTN2YB'Q>IFTC^67'Z\M'P6 -_FI@?B9BUM#IP!&MII:75\Q-S;=M0'=.T
MQC8\RZ99DI)UJ'Z\EWVX8?L'+50WH_M1Y>;:*_=2C!I-&DT:33N@Z=ZH:;&A
ML6F+FNH>UEQH6RBI[%J#%L/-'C;W"2H=C9C;C/2V>-,:31I-&DWW"5T<LM&P
M:8N:ZHX[QB!!>_-O>=B<][14A5SW"3NH<)!*=W(!'WZ48?)4OL=*O,@^WDCP
M@T.KX4[:(Y-%BZ7UPP-(\TOS^46+5$TBNY+(#L]XF$VOK(!,HC>4P[Q/;4@3
M)R[LU,7JO1R:FAB_83?L[SS$(5]E3<@!M$C\$J65(?3[U__T6]?\,F_E]!E;
MNGYG$YXNJXW)-&Y+W+JMQ&W/,F2;X(NR$N8NK#8)A[:S"P[5>G3W"EQEMW-(
M#<7W;LF@'O-8K1SZ&[N; LZ\4W@C=M!^JWK'OFM$"=TM,J)O&1]^SL18[-OA
MM+=M2T]<)3:RACUWGRHQN'&X_=M]:XX<R^X^?.G9L&?U!L.'K#EJ6BW##5+M
MW-[]01$O\?,7JA)YLIH/1>HM =3[LNE'G2J.FT[6&,3@[<'>S03T?.%>&_CB
M_^Q %G?N=2^G]&YX;0^.-ZS<O"-[RF/7A7FEO>&'^2*(Y&CSRDBGL6RS,^;I
M-?9K^"P^<_^G\2O 9F&"1>I9]/6_+.-'Y/NXN!1[9\J^(953_:YJF';R3-UG
M[F"KLOO,BOKG4BR]>_8%JI8TLS1=)&_?O+F^OK9@G=8TNGIS%GLS;-;XAOM3
M%K_!26!O;'?0=]W1&UBO;8]<V^DYCM/M=P?.&Q_>[-JNSW_:'=N:I2#B5EJP
M4&^:8X9&M?D,MB)1JLE \9.W)OE&G39B5IDI0KU'AJ?_HKZH_M%#T4#]=.PP
MJ,B_?I[']&R=GTCJOU[SO!_KH+B!MH.SG^WP@ 'M@[$=OG$0?L)+B_'@.$/F
M$8R&GC(:M,W0'-GF2-EVHHV&*CAN,1J<G8T&#<8HU# X5*.AE0$'5P<<'C#%
MGZGITI69M6 &_"I'TX%\##A+^*[6 RPN2F=+XYME_$X)#-J :(68<[4!L0$<
MMQ@0KHXZ[ K%HXXZN#KJT# #PK4MV_C+,84=M":]C>$9,F-GY'9.[<Z?_*=K
MV]A9/9!\>XYHP('>>4/_+>.GGIN9L6E?@E,Q42U]5Q/ W8Y3C'%C\9B%/#F]
M_!GP93[!S>F ?W.<;@1( 6=/*=!2/T)+@5I2P+E;"MP8-'?D4J"%MH"C;0$M
M!;9+ >=@;(%1IZ]M@>U20-L"6@ILEP('8PL\G11HGRV &2(77[XWVAS8DA;[
M?$#[]R_?/AD7:C"P\3[R,CQ!.+XD6-OZ?O[/1NN09I+.#_8S"J/Y$JRHE(<X
M@-OX[LWXG#T0+;53#)V??=)BZ"%HZ9P%'DZ9QY\_B?"/,4N.6TJ]__!12ZF'
MH*SW.&],/ 9AM5-D?3K[18NLAR"L3VS, RVLD*:^?ON@A=5#T-37F"> WYWU
MX,UF'-NJ59^\%M4=6G9OL%<MZM :=78K1E7\E5^@8.S*[6XFGY6V*-O;T^_2
M^*1%E<$]V[9Z'0F7S>C8U+M+5?'V\IF7VTIU]_RR.[1W?_)F5-O=6W#=FE9\
MNZ1)MDF\@1B[$E&6!$N5FHT9AW>-*M^D. \2V[MHRC9A^R.A.(J-21:'(IDI
M]%Z+='8?C;5WPXL'>-*N+3!&=[?$N;TUT!/U2=G<^^+[Q:]?SG[\]NW#][W;
M'#U3AY=MO4N_5D+I&#N/<89U3,G2Q9CKRC#WE0'4\+4]<KNFNC%/%C5F.+0:
M1_1Y+,.ID.E,)/ ]2#)ZS1B4.& 2.2 T!+Q&C<4&T88/HC,+=0&V(>)9"#?1
M\UB6SJ(8=NUO;^BSH;U2\XR+_=N.= ?6J+M;*X\ZCW6MWK#WX$_M]BQ[Q^'4
M^_<=N?4$\7GD^Y?HJC)BW5D;*5 >/57WVF^?6OY\\?G#^W\;OWZ[_.VK:5Q\
M.;?JN/*MV>;F%IIZ1PW?D2:_IN[HE^7;0]K.F^2-\96#46I\MHQS%@=)O5Y)
MK=GHX5'BSCNJM/[M6+V[.AXW=\.:3O6.&K&C+:EE%/?Z&@OX< &?;D@]NT=X
MY(':@^J6L=0RUM[>,O;-./*7\,\LG0?_^/\!4$L#!!0    ( /6!8E4*UGL1
MY!   !&Z   1    ;61X9RTR,#(R,#DS,"YX<V3M75MWV[@1?M]?@>JEV7-6
ML2WG9I\X/;)D;=PZEFHI3?NT!R(A"0U%: '0MOKKBP%)4>(-H"QOV-+[L+%(
MS#? ?(/;8$A^_,OCTD/WA O*_(O6R>OC%B*^PUSJSR]:7R>#]H?67S[]]-/'
M/[7;_[R\NT%]Y@1+XDO4XP1+XJ('*A?HFTO$=S3C;(F^,?Z=WN-V^Y,6ZK'5
MFM/Y0J+.<:>3OLO/W[_%Q'E_[+0_G)UUVF_>G';:^,/)2;M#'/=L>DQF)\?3
M7^;GG7?O/CCXP[1]=M(Y:[\Y.SUNG[GO<)L<G[JG[]Z_=SKJ'H ^BG/A+,@2
M(]4P7YP_BHO60LK5^='1P\/#ZX?3UXS/CSK'QR='__QR,]9%6U%9C_K?=TH_
M3KD7ES\]@MM3+$A<?.D^SC?%EW1)W,?7#EL>04./50WC<H!"2W"I+R3VG0VN
M*WE;KE=$Y,NHVT=P&_0<MX^5J4Y:"$O)Z3209,#XLD]F./#D12OP?P^P1V>4
MN(I6CP!Q.P6V;DO,YT3>XB41*^R0TH9]^@DAL#1=KAB7R,\(S;"8ZLH*+K58
M"X6LW# '2^UJ4%*HHKI=F?)'Q),"?K7AU^M'X;:.[+4&HCW'>%5)\[9,J#VZ
M4J4&6RYV<G9V=O0(/I-?@UQ7T.7;\&?[I-,^/:F@MLBG['6K7^U8[A!U2/I+
MM3K$<D^L0VX_*?(%DZ3^+2RKH8$$<5[/V?V12ZB-'Z:+PQ\YGH=]GTDM#U>B
M:ZL5]6<LO* N@?W.8R/>D5D\#&6&MQQ/U?^<8^YPYAG<^FC%V8IP28G8'AHU
MP(*3V44+!LAV/&C\YN'I:U63N$A&P:XGP.TC)4*\FZ0EL2R0<=$2B@"/A+:I
M<\-7G%1MN!(1:JS61/_/M]_!7M7V*Q$G\/X_FN^26=7F*Q'JTSU:#](3=1]1
M]Z+58VI=UT)P[>O===Z$KI6%Q6*<&"FIPJ=C_=\):B>+OS;24A^/TF53*($@
M[M#_I/].^W0D'!4I$4PY@[7<KA5SQ:*+L=G*C#F\[5_=CJ_ZZH_Q\.:ZWYU<
M]2^[-]W;WM7X\]759&QA:3.&D8:.LOU8&9'$/,28:!L41:@HA'WA:<O&(\Q5
M\Q9$4E7A0Y"V"VAD\'0?!M&K'2T_-YW1\43]_\O5[60\' Q'5W?=R;6ZNR>;
M!6!&)M_8,9G H^$ )0I>.$S,/IX,>W_[/+SI7]V-^U>#Z][UY.KO7Z\G_SH
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M_IRJCMX5@DAAQ8=!WDA+)TU+#*AI22!1B-DT>M0HS /B7CVNB"]LYN.T@)&
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M>T5R[,",C&6B-QO&(@6(JJZE5:!+M%&"M)8&<WFGEO.<.C*R=_<!<]=^D+3
M,#)7\&X1G<T:XT8TA<@-9FN *?\']@((60?+%6!7):L,PLA5)HRSX0I@D<9%
M6\ -IDI[[+7OJ':HV6+DX<I,E2 8B<J$:39$A3UI XLT;B-YVGI+3X44KHR,
MD8M,F&7[!3^-M/S!GF^Q3UP^M$83Z^\R89GG>:2F@=Y3\A8?:W^PP# RG G-
ME+X0J)%41<\C;7(HH]_3]8@S-W D%+3FK J8D;S"1Z=VDB_CB],UBI0@W;8&
M<UE]$UXD:.0H$RY).&KV-KRP)_0"(=72@A^F7^6A&4G+A$Y,'2O6TMR>E7T
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M"UUH$43P!D2M@P+.RT9>LV!=5Q=JOE"658I&G,%(R0W#3W'Y&@Y 0 L!'>"
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M5!4:AV22,H$<8NEOY%[<3BV[_S6/4]F-Q;M!\[VC\UU.'UXO/N)L)'66RL4
MD5Q04,H7"())0.&D9X'9F%J[=IW!/4[Z#*NC#6SJ'8/?ED D5=3.1(04:P(1
M=X[,>I5!!!V2%5P7USH8U2F!JTDN$K?>9\LC&(D.%#DHX*)E=1GWQ01K)0X2
MW+TC%ZEE;HW') )6YO+*W"(Y,;=F(F:FLM#:H&RMNXZY-3U2;]^'>(8CAK2\
M"N^!.6-!63*]8G:9[*]H.=<B)C-8VNT20<-UZ\I=B\'32GN(<5-ZX ^KS/F_
MIK,IF<1_^W$QN\!OOYQ.%OAY\>)L^<*__3C'#[<-AAY,6$V?:H=/)W6%??)Y
M/!]QGIDF"8#D@;Q!@1*\LP@.N6(IL2)X&8H8FP UY,D=]U_NX,T>BM[&F=X"
M'R##] :FYTL;H!.HT8T;.8W8L!%02RMGVXVB.SC07W'3H:1^,$HH,MJB-XG0
M"#+7:<>OFZ&@1=0*JZ*5Y*\_7"I<NZQU?";L(NP!&'#%@OQEZ0V,@A5%HE%D
MZ3ERTXV0$!)F*$4*LO(*-]@ZO'L+Q.%=G0;*V7[/8 _)#G#Q9(M3M08GHR=3
M/FDRZPMM>YD'(&>&#'SIBI)<)Y';IU3> >@Q4*"=Q >8^1O\CS4PQYDE;TA!
MYF0P*VLR."G(WY9.E:2-L-H,[PP]'AJTD?0 =TUNYHVO4:$H+EB6P69&Q$15
M QE<0N096?#9F-+:U]^,Y#$HOX&,MUXD^?>?;@B&/-]_[GX%^]=03Z.GY>G%
MG)#.Y\\KY+/Y]==WNU^][5&]+D]WPG?C9K3G/L88L@V8:%Y%;V64'J45R6;E
M]6C;0_O-J-\F%_.+</9Z]G)29OBO"^)0C41\BTBDZ',%!;9H"<H+#;XX(I44
MW&EN5'OKZCY,_5>1WW%R@3_39'HVG2QF(2WJ2>"SB_EB>HZS%Y_3V44]$WPR
MGY.<,;\/GT>IJJ18!=I*L:*_9T4!\AP50UUL:!V4V@/FX=>?IORYO10-JZ@!
M;-:7$X),'_GR*RY&9!71Z D+IFH_![00)$8P1F81F>/"M2;-U?<_,C;L+=H!
M;-$M UT%Y PZ;BK[..VT-8A+V+!D4"P+QBV1,+:^K'@7GD.%LP=5?C.!'SO4
M/9\M1F]FTWR1%J]GZRMBRTA-84D*P\G 4M6[LHF3;563VE,RVF?E4';*%Z(7
M7&$,_?2-+=O>?:Q =CNE3AL*M^%R<07/_,DDKQ'-UU9Z%U"[1+*[:?XVD,-&
ML-OHZ+;"&PGX8-KGK!2A90+-"ADJY F XXE@AGIJ$[CDIE/0XK2TOB58?4"E
M[R+7ALI>9A6]I*UB-@FK$-H[3/4;J?EE_"RXF(S79+-X6L>,(:]<90/%.*:B
M0%39=TK:NO,UA[/Z&NIA.H@0&]KW2V1/\N^U-&3^Q_1BDI^%&?YV'L=GXQ3.
MGM'SG^-L_#OF-<[B-3*O+8ADR,017$,L-6+JF;-H,B;LEJ&WPTL?O.J'$O#6
M>=XH(/75->D1B;KUC%XAJ+L1W8@]H2V<;"J>K;.*Z^*5Q&*DRR$S4Y09W7I:
M(R?YFV_@:/:R$CT8K@SM Z4 :;% BLEJH80II75>\VT4S9S_?\S&"WP^_6,R
MBCKY9,C)B:9X4"Z+>DLU@DZ._I-XX=VL^GW&]17%,1(Q>VEXJ^N_GV"'C/,\
MNYC-OJ;B*,YI\1$!BB)#1CF&M:@'!Y>-J\=CB?R6H;1]%<BA7/ZAU+RW4$_6
MNQ=2!DF<!$=++)DM@8B;L@47F? V"<]+0VO_)+S[!MJ\SZW?1:H'<^RZ@/J.
MW/J==-3)P]M'P ?3OH]:,4>^+-*>M$K,]C%YR(SEF&JE -&I*NII:7U7M[Z]
MTG>1ZV'=>O2&94>>1TFRWC1(BGP0KFA9"\6G%*V]6?7T(;OU.^FANUN_BQ"W
MFG.-O#D:/&USBR]ADFMZQ:=J$/R*BW<7Y^=A]F5:-OV]A^/7YW6]?,1FX[SA
M3N9H??!"9?J?DIP%QIEAT;C$M8D,1WU>W,]LOWSRF[,P63RY\O@K!FR63AHA
M@%6S51EIP6N>P#''/).<6QL:V_#WH^KKKFQ]PZJT3;+)9V\ED/%5LX1% L^"
MA\+KL;G6"IL7?;\;T>$]UL;,N.G:-%3  -[LS^-)C;N]JG<FW]8&0*_+;W.L
M:16+IUBF,WR2TL7YQ?+F_)/SZ6PQ_C^KR_&18Y+22""Y$&[T 7S0%K(7P:A0
M!,^M:\#OB_714>H@2AL@=V*K6.C[7<;T'#_-,(V78Z)_>FV(+J84N-.0:^,I
MI9B%J*4!'85.)3N15.O,FP,,Z]%1^-2H,$#*\IY#[#JXY(R668(O,M2ZV:$&
M4A""]J:P'$IIWH-CT ']R?#!U#] =?]]!U?($^PX0FVYP5)O0(MZT\0R!\'E
M92]!9@H77C4W,(8?U9\L'Y8( W0(J-TA\\49OBY;Q[J*;^N"F V3D%AV-"4Y
M;3=..6#!:1&4=#&T)FQ7;(<Z%1J8;(.HXM@'1_?*[NF7]_2(97 U&5K:I0M@
M@\J@DJ8%/WL)F+C127F=4NM"_!U@':T:PB!TZ+K [:F60[I5%> Z>-L%XD"U
M$SK .TXEA>:J[4J=GGHY$H5R-+4^5 %A:MEU1]9F-"4"]SPRF9VWK/5=VZ-1
MYY[*"Z? G%W4,0!CEE9=+7GU\OS3;/K[<B_\>F,T%F-+RE!KB1&T("$&;T$X
M57@*T87FM[+O@'-"-O>^ZIL.(_L!XLE?A[J&P[0L.=L$)0<!*F8+(?$("J-#
MXV0)OO4%[1L0'I_Z^\AX@)7@YXO99%DD?.GR?5Z6"U\C$TRB\BR!EUB/C)D%
MET0!YR-:\M]\EJU/U+:C>7Q$:"3Y 6*?SZ:3.3E-RZ/^EQ.2PP>"=HG-UCQ^
M&QWX+!"44I&\O\0)8(R>H8@)6Y\YWH7G\?&BF?0;1@Y76?XU]O,6%^/9<L]Z
M-IU?KF&J:(DIU5*=BM8P+C+0VI4@F5#O FI$?8,3VRY-;'O%XU%S0U%NC9<U
M2JCYS^DT_S$^(P'DEY-%F'P8DS^^A#[_%1>_AMDL+,:_8X\<FAW?T"MMIL]H
M;F;**%'K3+N45:$YJ!WS1MFH%4\EFQ)&.[ZKWW)]^;)O83JOI4># 1ROEZT$
MK1(^8VT>:)DG.X-HU+JPWBT0O>OG7]3Y\+J\IEE(PII\>+>*U-54]7IXH@/$
M4I,NE-3@.8V.,Z\\E]FGU#I4NQ7,X=>E?MJ^53F_B90'<$4N@;W%3]/9H@8"
MOR'3C$F)&ACSCI"A O*,V-)34C$PGYK?S=F.YK$0H*><!_!,KB,C:OY&DIV/
M(F<U&SF#-I%XZ>L1A,\,M/.BZ)J&VKS,]&8DCTOS>\EW -_C<HRCJ%%QJQ)H
M45/1BY(0,&HP$;7@26=:GP;:PQZZ9O>2X0!Y!M^.>"X1K4YT.(O)*JSI:[$N
M+,: 5RX VFQ$,BYS](U5NP7*H8Y6V^JWA5Q/Y>#TVNJS#+T;LJ-K4TX@3XB<
M*HVU3"5QV-L2N&2,H6I]&?,6B.,?BO;0[*UJ;'TD/,#&?@W0VI/N FF@$\X-
M<(YSHME347>IO8>4#T2 90:S%&1GA!A!)4QD9Z8(-C"5O&0\BD%G_1'/(X?7
M^R[";7T);UD3Y-W%[$,M![(.<I'_@,PP"YS7_$>A!800&'UQ0<3"A>0W,F&V
MQ LW//SPQEMOB4\;BJMU[9RW^ $GN I7_8)YG,B"N2SIDS+C*2!([RQY"KY&
MI36C/<HK7G)62O-.6MS^C@>NS$;"&[H,SMW1RB>)X(\77];7_ :+]FYYSX Q
MWRXCNQ'YM>12:9N9\8I4Y++3DJ:F"R7&5+Q*]T1^M[RQ]RVP\0)?U1I+-U_Y
MS=\P4G.>4$+,M;Z', (\\8S<^N1SCFBX;1T2[H*KP0VX;>]8W=##8D)*60$+
MEBQGZS)XQB58U(;+$H6\>30UY+B/=$FR.4,VW&EKIX9A+DINP[?MMIT3EJG"
M7.UAC;3HFUJBS-<?)>$U14K1.EMW=Y3?%Y5:J&J(%)KMB&O):Q>L5$YF0'+4
M005'8B&3 7S)Z(MP9.>W;O5Z-Z+OBS2[JF" F/:WJ,X=.%>!'INBUI$[<,X5
M0IH\>&G(\A>2I<QU;4D[6&CT/G2'BI8.3I>!%'(J,=4[!O7TRR_AOZ>S9V=A
MOFHTIRPZXU% 3#6AJ.:>.I0,%$,3%>?&^M;MN': =_PX;%N"=%^V>BGJL)O<
M-Z"_AO/+U*@N< <*Z.X(]3C!WL%4WYUBS?1V G33%A,S*0$&4;MITVY0HS:T
M+\3$)!;4N756P$G0[)[0\JFR;!=U#7%ABER(*Y<NF"T^A P"/5L?Q2J=P1HO
MF679^-"Z5=8U "=EC_=7U\W;4'O+>I#ROVOQWC\GOEF:VGG4Q=?VW-:#DMJO
M3F-L,9;%S)G+[6M![XYS8-E\[=KU-;M$NZ(9.=Y$"%WE$A"B$P5*2-'0D)Q-
MK?NZ[XKQ&!6T!V;8[>++ ZIMD"FX(3YX&Z5'+$PZ X'G!(H,CEHBA58+S;)
M(W1)K?V2;LB^"THU5]$ F_B&0,]MC-;$R*,5(*(/M3XIH_TF!;"R)-J[8C&Q
M=12W"Z[OD$2]U3-H8.X>\:Q<?<&4DH7LEBS(P5>)+&2?38(BK$'!C)1\N!HQ
M71 >KG_ @<DTH*(VT>H80;L=9+ITU[SWN7!#0J3U%I2E2>2,C& "6>JZ,'2Q
M_0:Y$\3C!^_:DV4WXZN7T@;9,N^$N]'WZP)YH$#>'G"/$\P;E :[4:Z9#D^$
M?D)K'ZQP$)G6M5\0J_9E 6_*\D]1I=:GIR=#NWN">Z?.NEU4-P#;WL]"QO,P
M^V?MAK#\H6*[#$2ID K6]M,Y6@XJL%"S:RV@2ZJX&(UUK:\7W0GHY#R"_BJ=
M#J6/UCFNZQ#EN!9;2-]J+7A54"B'(-&385!HYKB '$Q.4@AA+8VV4W[KYN<_
M7HVW$NK0>:^OII,/[W%V_AQC[6-1OWTU#9,>&:[W/+%7+NLN:&]DK=($2LYI
M+KC72B?C5!%%%I[H!RF+'MWS['X+<7WHRV5-D^O%1(.-HL3H05II0&D;(>A$
M=KA!90IGTMG69W9;H/3=:JX_]N>0\,GY]&*R&)&@HPHZ0J2Q@C*UK@<+'&I%
MW.10),U:[S+;L!Q^N6FA]YN;2!-)M]X_KH-:-DS"^>(M+8 _GTVGLS?DNM+O
MPP<<J<@<^I@ /9.@:N_L("S2$NAKZ#1A\=VVE,ZO?-AJ'U"\ UB<UX$^#?/Q
M_-VG&8;\>O+W,!O7:$-%S4<IIJ0XF3C!LMIH619PW#IPN=C K<YD_PRZ+&S'
M]K#Y,J@F&@:@-_#Z^<K]ODKO$<O(H_3+@_8"*AI:WD0JH(M1DD=5"MMGN=CP
MJH>M]@'$.4 YA.WKV(M2:F.]W_'*6L:Q*,.9I[4LUTR)+(F4Q-&0@U1)J,39
ML-;1/0 ?-F.&UTG#9@9?Z?UL^CM.PF3Q"\GZ_.+\U?A?%^,\7GP9B6*R8RX1
MIE+J#44"IKD'8X(3.@HO<NB\4&Q[R\/6>%LAWM:N;K@7O)GAI_!E^1U!/5M\
M>3)?L[!6RZ>_C?.;V7B2QI_"V?H/(V%\\L)G2+5%&%E"B;@9#6 TEA6N41BQ
MQUZQ!Y1'PI/#J>,VF4Q#,OTVN9AC?A8^A40L?S8]/Q\OELX37EW:K!,HO3<@
MN:UWJ!P90IG6-RX$&AXPD0NU!WTZO?S1$::]R&]3Q/:N 7\EYO-S&,_^'LXN
M<"2UPFR5 J&475^KP1# B$@FL@]%IM:NR48@#YL3[61\6_&NK1VZ.@0G_S@[
M[0B#3,1%PS(X1O:QI9&256.X9*US.3? .%3^RO"6Y.Y2/?;EL=H^_&V8?%CU
MO]"6,:^M!&]RK4JO#00B*D1K:UJ?S$QUJOQ/3[W"!?KI&P^NO?!8N2*]M3;M
M*[V&<:BO(-9G+5U@[)*ZT469[<^V[D_#Z"'\F^KK(;D!%8G1T<J4%013"]#8
M8, G*<&4Q B7K=W:'X("MR0TM-??+@)KK+>U6WE9KQ\S>0*&['ZO"8A(M703
MXV!SY%%CUD6V6$>OO?1PIE,OL4];R*SA4<X22/A\!8CPTC$F(V3O" AA C(
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MC@*.!P5&<"<BZEA$:;SVG4PUZI.A6$LE#;#I;BJL'*-,L3)9>[N\FL0@2F5
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M,&&BP2CXH'S?[N(8E>"SY2Y 9/6>1#(:0DD9/ :OA&/)X@-<,N\=]P.:>Z=
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M>O.RT. E#3YE<HIL49(U]PE.M"W=X&090"4-TQKNOEU]"8YE&7@P$G*2"I1
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M_>6R.,I"GJA !SA1,(R(A$A$#)+4'"(DXRE+$3-G">E<UM6YVZE-]-V;,77
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MT=0#)AQ%H=#V:E8"41Q0R)&*H8I81$.-F(Z]'&NGNYG:Z;,NIK0C9L>*P&=
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MH:\)?Z:7<:=^NZI')'#A\8ZQS@_+O%R7&/F@-_<H7BZ+LKA=2)LFV?H*BEE
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MQMHQM]YA5ZKT?#6A*Y)]WEKPEF'\"PU=83IYUZ%S8]?<B*[NQ9F=JLJ^5B'
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MR%BZ98YS[W)JT]X("AX:23O.]_/X>L[_7E ;BP]N@,5N(^\-L"6ZEQHT,@]
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M5TS^MNFIS?J79A]J5]:Z($%5<0"8K_J^*MDA6=F/@WL'6L=-3"? AMZ;6*'
M76M5AFXI_O8T[3,77]WP^$GS]A0ZF=UN_PG_^+5UBOI/3P]\.9\A;"V[*("!
M5@RB4$A(-0\AXU2$*E%1'#D%J!RU/+7YVI1.J*5SCTG;AZM]$EX%PN"KL)/^
M7G%F)W7M%%FVW])HL60G%=B-'CO]0->@T3?97-5%<&8L$#Q*>0HQCBE$R!;@
M8Y1 1I(TQ"&F 7,R(IQJ?&I3;QWR: 4$M82^(:$[P%V>@=? ,? D]$"B0\#G
ML<I71'GN-#9R:.>Q&L?QG">>Z1I=L9^3?&MAW-ZH)CQ-PB20, PYAXB1 /)
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ML8 4ASCE/&#4XR+\V6ZF1HY;0<%&4J]PD'-PMM-=?R -S68G\.D6-W,.**_
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M?S9-U#MO\Y?MAOMBPZ,0AJMZ#3\X/]_-9/3F?&3*K3 +U&K.["9UYY+[3-"
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M&#">)X!#1C!+<I1*KZ(0)RV,;0BI#(Q*"Z/[HM@H3S&B4PS=HMB;D.F9V@]
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M7KJTX]F]B\4EW[&U>EJN?GW1MMQQ\WOY?FGK5$YSGHNR-"02T(2\"&6 492
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MV\?<X793QW7Z;:'Q#VQE#[!:2:#FY,],O+5E@Y^7BS)M?3]"2;.<:0QP1BC
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MSCUVN%BEQ:F#(*7MNM?9:?FR61=KMI"SQ5.]^*YBDK(D)B!C]E1/FE+ )8%
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M]-9F3OY0JW6I7++UK=IIZJU/W$;-?I#N>3@\@C#:@<ZV1S#O'%Y[[^'-'ZU
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M_XGCQ]G:IIC=FT_#Q*T;-O_G;/V]5$BV7\?WV<OCLLH8>;^TNKG3)$:))%(
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M6!_+N^!&F>/NX9Z9.&3IX2T0DZB!(JJQB$HP(HO&_CGH/I0>7Z\[0Z;/#.O
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MMQMQIL9&QRFEE;?Y49+I2OH9D'J!CF+=7QKLKX:/I\8FU^LHC4QW3@;H>JS
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MCD240))R 5$D!,0QIC#+$QRE)(@3II6$ZVI/4R.,QHU/2@L.Q06UO*8.CY<
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M"+".3$^#$#6F)4-\'!&3;J]>J<D0BF-R,GW=CIYVH915!C5YPHR2.,DAPGD
MD<@IQ$&&8<B*3/ \3_/$R#?NH/6I4<T^BM0F,=TA<'KD80W'R!2AC80Q'9S5
MV-&D/VS;Z]0^J];Q!#[_D.4T/:B/=,\9?ZR29=8EDYNYRY(BCC!DHH@@HG$&
M21A&$&<A2C+":9AH&8CTNYS<A#ZNW+47>E<\W6JJ7P=?<_X[A71L4AB.ICE=
M: /DBD.N=^B76+0!.&$;_3?M*.@KWZIZ[7?E6M$:>_?Z]XW*6_EIL<(KJDH+
MTZTD/)7W8F]TB42<9S&&:1C)/47! U@DC$*4YBR)PRQ(0Z-$^>8B3(VBE/A
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M6)VM"<VKJXXB=/2RY;'1VE"._8)U]Y$DSA:<;HH:@_8E\@1T HFW66$=<)A
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MBM;7]LWUQ]5XW0'L:-%T *L-CU9$./G^SQ<7<5TN9F<I+2Z(NQ.?H\].2,#
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M+%OIT/.85>N)-(\2U%L?R2<"VK$BZ?DZ?KO$SV&:KTQAIX13IC9W\YF#DCF
M1^)?Q)3I3E Y-V]]^R.:>FLN^41@.T$P/>-M:[%\"%_QIK[.44DOF0(G:C5>
M\ BA%I<BETKS))5WK5]Y]B2MM_Z03Z;J3A53SR#<U,%\MXVW+P2UG73)3)(!
M7 NTE)?D8"4!7G"3.2LQ-A^-NA]EO;5A?"((GBRDGA%X9;.^#=\V)\L9;S/W
M#K33 A3S#&+.&G0,R!EM,^/P]^X=HGIKEOC$[L0QHNG2@7UQ_GFV^(9X62/_
M>AKB=+:)!4R4*M(@8Y#K+"M5'^N#T!Q$4"FHPARY48/#;C=]O35#?"($-A)8
MEV"LP?>+VWLR*@A1I\]Z)D/-@DL0D';'=2Q!HU+J"8:ZW*>KM_:&3Z?^3A%0
MEZ"[;4K<W)IT,C)FR)2PQ#$EBZ>MA5+KPYQ$:;WRK;MV'T!>;ST+1['\CA57
M!TC</S%^(E5V9+Q&<#[4?C2&.&B# &TTAL"CD"R,5G$U;@CFZ4MDAA#:\7!<
MT$D;$HXUK+G:Q<A0:#-!$B-Y!N4570(&,SANK#%%BRA:=VL[G,I.!OH]42%@
M*W%UH!_)Q;IJ6)+^ZV*ZQ%MOWV?S_/WYN^12)X73SJRT9/B2 Q:\DY"C+DXX
M)1UKG7BS/W5=EA VP\G=G.]AA#9^M&;3Q.EJ=R\7R[//GV?3M!'C)DWS+2U#
MF[*&:%>80 ;2_ H#@^B2 2VD][JH8O&'=?;[+=5E55]K6 W ]?&A=*,^(B'F
MU4OB[K/%;(9IF__[^V)]*[#.$B_HF8;:60Z4UK9.AI' O,_.N<B5;-W);T_2
MNC3]!E-M XBKAVOVQK8>R#&[I;)1Q\1K[9A4=4JBM60Y&T\JVY:<K(J!Z=9C
M? X@;]S7N!'1V%)L'2!R?TY.C/&A>"4A!.M "<4AQ(Q0,'NTJ"R*)W*,'Z!N
MW*>Y)\;C0$+KUS&^KM)Y@)$)N8@;Q2]+ E5H<Q%C@LBL0%Z"U[QUX/!P*L>]
MO)_:,6XEK@[TXY4]?'!;ZVI\)$\;HXNCO@^Q!"$C F:RGD5.2<?6F8+'TMJE
MT]P,0SN<YD$%VJ??\_ L-\%9=B47""[0^3>%V%KME\"U%$X'SD1K_?E#HKKT
MMP=#9%,1=: SMXS"39'BV^64>/:YMC_>GKM)C,[G("48P6L6![/@ZGW#5:R6
M#R\JM_:P'R6H2[]Z**RU$TT_*FY_%DYJJKA JXEU.9(.3V07(S(H2I$-Y%,0
MWP?)/+FMV*5+/100!Q):!RY,W5;]_QH2^!)F6UOC:NA4_8VS>;[]@QM_<CNI
MZOY#?)I=5.ODQ=?T*<P_XCLZ02]*P2H$'HW1RH"TM;=++FSC0@)ZG6V1Z 1K
M;6<^[0['/1:#N4X=P^1G/T03'1+IA51'"FD#2GM'.HG4AI>1Y,-)+J*K,S%N
M\*I/B!\DQ!,[A!,'EFWZ!9VV9<MU5BS1A>IK[#CH6@/, @C-K?(^.>Y:-XT<
M'K>#Y:5WBMM#A-AG9_O?0YV%N2B_7:RF<URM;E.[7__Z>]\XL4O]XS0UZD7_
M9ODQS"];Z#PC#WPQF^8MG.?Y[0VBK]M&A=DU"&^4\^M8E#<1>*F5,8;\J6 4
M7;5"HC"2G"G=^IVD">$G-Z ZA8C:=FNV6)&,/Y P?Z/O_GT2I"V)V\TTM]H]
MTY,+H.D&<+PXXS06AJV+^UOO8=S0ZM/C^5['JC$QT2P4UDRSOI]^G$_+--5'
MXVUQ4YU.3$Q)U?\_0LT^_L$3=>X!U#92P/>7N4:AE\H$'27HY!"4J[F^EBYT
M'YSW(6$D9#16!KNI.;EI^&.<_0[VR(5-B<Z;DR+3R5.!3 E,@)%%Y)IIWGS/
M^U$V<E/Q-BBYUQJ\O5#ZTT#W6[3\CNMC-,_#'SI1X^Q!72--\WV%[^")FF.Q
MBH$LFCP%0=Z#LR@ D\$<972F^9/M V2<W$+QDH=TP_Z^F-,G,WY?Y3N,4RG<
M)?)+7):N7J3D6?-L@"GIK4DAMM_L?I2-JUM.Q<6]WH?MI=&?4KEJQ_/M&$7R
M_2^?J#QV4-%(85Q__;M5^CW88+4SA9.CK[0$Q8R":&OL02O#T%NM7.O:G$?(
M.;UJ\]ZGOP-5H-<F,0$I6'(&G/0ULRR#4Y9I8:4VN7W#M=WTC-UHK0TF[A=B
M-I) PYZ^S93%5>ILN)$U>Z0-LNM3)RJ2O2ALI%9V)A)? RF70$:KX%"$K;</
MUU"G.4#R.:3L,,K<O-[J1T0UR$IZ>(&' *\T5XR3$:]%-;A=,."-$,"\PE"\
MM+RY=CV$OG%54%O\/)":-(R<^K-A_FVQR'],9[31?'=DQ9':Z0=?/%%)'4)O
M(UUUM>39_24?N #I\O.1,;J8C-&@?+T*N1-U+KDS.7(6FX]I.8C T\VD72M\
M/Q*96Q%+DJ!]'<:NK05?%$)Q+DJ!@B49FUM+/R1K7(TU'(KNFU%M)=2C-779
M).:R.>51,>2[GS@]AK.;HE96T[8C6/6J-\N%V7=O73AIG.,./-;Y0C'2?6>9
M B17FBLO!7G:[1/O=Y'3*IISN<35"K?: CV$:Z>BR8G.C;0$:252(@>!')'B
M59#>1\%3Z[G11Y(ZLOW4"$F[XCY#RJT_(^KU8O[Q R[/GV,\UJ>[^XD3M=&C
M%#721O7;#UQ=5E@7,S<0E#10\0)!%D6B%%H7Y3W:UBW]'J;D]&FC\4&#GU=(
MHE$@,@I0BBYH5UQMAVS0&*D%MZW;Q>T@95P=TD#^]Z>(GL[R_M0#'< Z(>,M
M+I\MSL\7\TVEU5'910]^Z-04HQ]3UTAAO C+^73^L2ZU6>0[9&I9CR\&=.WH
MK()5$$H)H+5+D0>>5&I=\[^+EE.5QMWOWGCK<%P71ULCLU[2%1<X1%0%@DA*
M<A&Q_<O33F+&51Q-<'!7=;1A?(^^3HT^K8]Z8[K\FR<JB(?6;Z41-I^^EC]G
MFHFL(WB62,VGG,DKE1DLMYRA53[$UC?K;0I.3G"I=8RUI):NDNV7:^>6!Y\S
MK."2A0B23.IM@X)(* ?-,FH9O ^\=8AD;^)&U@['8^)>:LL@XNC/P+@Q+.&X
MI^CO?_WDQ^@=E#1[CK[\_@.&9R@,O509G"3MKCPCS$A7( 868W!2IM#:]W^$
MG 9-A.]^^H:[G!B&VNDV%D_N<A$10M(<O E>)&-U, .,*]E)S]C/T6TP\4!?
MX#82Z-&H>'_QF31#?=,*L^_[6UR7E(1-XDZB_[INKT,_>JA\]PB%TV[Q4U-]
MA^%"(V5WD[HKBE[,[J2I,V2)^UA 6ZRIGSE6<#NZ)%DIO*!2I74?BWWH:E%1
M5K_[L(1NY*5Z4:1R)@,O3M=.RP4\!@G!2O2N!$,7>^/][TO;N&JQ.7H>JA=K
M+J+^C*L:%9EN9Y_2V7^VV.1'X_S8TH7'/G>B-MN;TD;ZZ<9Z9W?6>^ JCC&;
MD"R#1&(%%:V$VB(=I"&O/M5D4]&\RO,0 D_66/LL=N,%-B3TAMCA%</:3U:"
M0^%!V,*D+45GUUIO'T;AN-IK.&S=4V/#R:T_9?8.O^#\XJC@\]5?/5%)/4A!
ML^J&S;>WW7/G&VC4'F?/+E9KLN27WV,*J3"G,B,?OY#Q;D7-):U#C$H,PBDN
MA6WM*>Y)VJE*Z ?+?(>QKO7:0CL@9X618Z1K<K_G@,6CU)4]HG5ZY;ZTC5T)
MT1Y#=U7.(%+J3]F\QX]5K;Z:E\7R?-MR\1AG\?Y73O7Z?D!7*_=MN\P[_+Q8
M;MK37E?KB>2-9QQ,B!4Z18-C44*)FC%NLV6E=8K@+EI.#GC?^>Y#-R82TJ*F
M&S-(68>VZK0M\I$^%9<Q&5U:=Q_;@ZR1G;,6V+@7[FXLC XURF.UJH,5E#])
M8?E8!>;&24:^?P+&Z!\J8JDO'[KV0K26>RE=\SJ+X0K,?PNKZ>I-N;/ M^T_
M;P0DE&#!&@.!U:A'DJK.$[1UGIM4/ 83=.NG^/THZ[; _!"4W%5+ PBE@VZO
M?UWAF_)BM9Z2!8&KB=;)\*1+S7I2H(I5$+,5Q*J@BDY>L^8#Y&]3,&[OX(&@
M<P*3.X#(K<XO=^'.HH^80H&<H@.%Y#H$J0.P'$IBCI7L6^<Z/$;/N.V !X)/
M,P%T *:[QMW#2E08I\E>=,!1B&H^DGDGC03.,: O)O#4_#5H'\+&[68Z$+S:
MBZ0#G#U2IW3U6]L=3DS)CDNC0?(Z"KS4_A"!(R 36HD4LL^M-=C>Q(W;6G0@
MO TCF@XP]SO^<8-ER\6<?IFV+Y4/GZF2G(RN&,B.&*BRX>"39U D>;?!"BZ:
MY](>2N.X34('0N"@@NHOW/!@7Z8/F\*I8X(,CWUNB Y2#U$Z8!\IHY/3FFXV
M5:OA579TT;F80%@9;10I2=NZ8<$ ?:3>IT^8+^JPNRN>;H8OOEZ$>7T?O,[]
M>:B=D1$8;/$"0FTTKEA*$ 4=,IUS+)PTKY6MG< 3R!W[G>4T!-TSQIY(;OUI
MJ>NV.<=KIKN?:-62:D -]%@3(B>\#XQ'2"DAX8A%"+&^T8<2R0A'FWS[_@.#
M-:;ZCNSK19Y=+.L9^W ;QK1'G5VI70)JBR3E'/C,-;!0&\H'HYUK_M"R)VUC
M9PBWP<ING=-0,OTIF!V-H8Y7-X]_<)@V5@.JHA\W(Y)>D:T;"J#EEFXW+2$:
MQ\ DJ;B-:"0;8+SV2,VL;H3T ]O,6@4>;7ULY 5\?7MT3) G8+W5OG6>S8^I
MZKUQU2%8V;MQU7$R&3$T4)7&#?WZ'(F --V(Z8YN=8'4-'>D5G4MW;)&0\R"
MUQK2&(RT(KGR(X6T]VKCOK(, YYA6-W?-?9XZ[#C;[.]OCMHV[,![[;#VE;Y
MQ$*QD8,-LL:6,D+@P8$I(7CRJU1LGM3\I,W/;AI\&<MT/EWCZ^D7O+?T7?N/
MU"K2X0%M?)TP6?4M*6&002<I$&-H/H#Q2%)_IB9IAZ#M,=-]*$EV$%G_OLV7
M>V^1?""DG4C0Z.@.2;8./JFM+;F,AGXD=6@=7#^"S'%OXC& .HP$.P+IXK$M
MOKRHD[#.SNM3ZW:PSF6KO3M[SRI%9X($:X("93:\9@*8\N1[LZ X'RH&VX+^
M<?,PGA[63R[S_NS2.YTC3WI?>N!#;?M:#AE&>:0G8?%<\B0<<.49Z;&<(3*)
M(+*@"UDKS4SKXL$!NUO>>JNXTQWQ#K0C%\S6 EV.NC8FJ1T'4 5@CFLEE>2V
M>9+%_M3UV\/R$+P\^I+43CK]*9X[32*/5SP/?ZAM"\L!%<^.1H8Z.EY+X,&B
M(PSIB.!DK!-JO!*)F^B;=U9HV\CR7F GKE^M5A=AGO#98G7/:C3%<>'10I:B
M1@9-@!BS!<$E6JX2<N-^A(3#ENRR?^4A8M\90FO'Z8[L\^W&[L8$R=/@0A?0
M4I/M%:*'D$*"I(O0.I%Z-*VS/AZC9URWL"&DFC._GV ^F?E(@ED_;,R[G"2S
M,8'76H-R] ]B7P;C3+%T7NAPR /5T*,+CNMQ#:>$VG&Y*Q7TESH1>V.+O2DW
M380[^R.W3XJB)83:)UA98J5CWD'*CFP_SX0<T&[>C\9Q<^('554#"*D_\_G!
MQLG'&]&/?6Z(%L\#&M0[&_P*C,D[+X&Q: A=#,%GNKZ8%=E[JUR,K4WJH1H]
M?P?[W15JO6/Z[=N6U<]F876C%98TVJF@!-!1NFQ4$^C;H!2!/?AB(F^=$7$4
MH9TVB#X$/[NUTU "Z^J>O+O)Y]/9Q1KSCFVJXDWF5<_K8,D<2 Y<"!FB%*EF
MAJ!6P[WY'$3JN ;^$R.SG="ZPN;9?#W-=6O3+_@>TZ6I\.)KFEW0Y;-MBW/^
M^6(KUOM<N5%>8@V7)2"0(4&.-%.:.) \$,-90:&9"JUGC;3?Q;@.R,"('D74
M_=F*V^[CQQN'M_Y^DW[^0YI_MSNXVY +Q\)!&\-!&;;IF&=)35D?E6,20_/I
M'DV[^G_ \\^+95A^N\&Y6PT!LW>6U&Y]=U2Y=NS)(@!R7_%JA!6MK\Y'">JJ
M>_\ALK^K1-JQO:O+;Z/78EAAKIH/YZN-;-XA<6R:Z++?#"TXF^<[/_GK?+I>
M73:<OLL+C)S[DCTP5QOL1B' $X.)Z<QB)/]=-4^[&W(_(YMX[1#<C=#[B?U>
M.5R8WX9OF]3E/\(R;WG^:DZ;O]A4$[]9?\+EAT]A_N9S9=3J/\+L8HN U>KB
M?/NSNYEYFDF#9!L@#[R.3&40T#/0HA1ML]?>BA]=LT]%[,@FW^D([U*J_:GY
MW^Z>^,VIOMS]CG/M>>&FZ PVQ PJ);4=_:N]9R9H)7QJ/AGH9*K'C64/I[*'
M%F!_GDJSD1C'.SNM2>AE2,B +M=>PQYXD#*99("E0BZT(K?>&<V!P*HL$]J;
MU/RI_@E&A7P_LC^:2''G]4D;+NGZ  RL9DD+"?1Q5ZNF'*$Q.26&>R(\B-2?
M8)#((=C:K7.'$V!_BO:R"?CQ:O+V!]JTY1^T9<Q^C=5S=,*0^PY&B$)2]06B
M\ H4R\4G;E6*/VES?D)R^/AQB1\O@YTW>7[CQ4FDQ"6W@)K%.EDL0"BV6B^Q
M<&\\HFA=*[8786.WBVF/GGO3IYO+IS^M<[_W_0EVVJYO->_//Z3EM+,3NV0F
M%VD@,KI8E)097+0*DA;H<D:94O-"HJ&Z]']W:NZL<(/'OWV[_,V;26+D7I>0
MP*3:%RG0B7*1#E.@WS#<<2E#ZZJ+(TGMM9O_ 1AZQ!,=3&C]Z:??:^88.5>_
M7:RF<URMGN,Z3&?')53M^-2IR53[4-A(.;U9DBMY6?IVJYGQV3R_O4'[ICBT
MNIMA]IY^<L<V#Y;$;J4#GF6]L>I+;DD"G%!,\FB)9:[Q,6Y"^,EM12_.(R[K
M/5X/3KU"+@_+:I*J?\"D!,TW33!U!)<2G90<@E2!9V%:-^393<VXRNOI,7:O
MJV@;.740_OWK_&)U$69OEJ2BE_A?%]6*(4YMS)>)0<>-E:)VWJ'+(!8+ 4NN
MIJE@W#+4S1V;Q^@9]Y5M?-0UD]6(N%LMU[4I4+Y(ZS?+][C\,DUX]G6ZFA26
M)!V-#%9MII,E#I&;!#XEHWU6#N5>L2U:X ;.Z+^^8VS7VN-JLW92731D<1\0
MJ96RESM8/5^<A^E\PEDI0LL$FA4!BBP6<+P.7:&3Q74@/]?L-8IL/YS<)V <
ML+21Z7V G,C@L5_I-Q5#\PWW2=MBJK^0FO\%Z_4\D<'%9+P&3)Z.C#$(3F4#
MQ3BFHD!4V?_()/_Q,J,#XE09+@9AZ-C0.,M?:C%K_MOB8IZ?$2__>EY+XE.8
M/2.9/,=E;=]QN:_B-;(ZJE*D^OPJN(98> #GF;-H,B;<KX[X@$7',68&@LU0
MS.[70";?&^N_R>"//F<;$&RM"U->:++H:L=!*;C3W"B#K=\H?T33N(9R<X-F
M$%%T *T?O!!L4\YK<&ZU0OI?_A"^3I*M!8U6@:Y,5*@<>%84(,]1$?>*;1[@
M/(+,+BWJ(W%RV"3DDX76 2ZO6X/_CNM)49*X1;1C<HEN J0#*S&",3*+R!P7
MKC7@;J[?I2IK@Z2CV=Q?#/S1.;&_A^4RU&J:$R+CARTPY-3;QW<S_/1;3!)E
MJ*-&G490+FMP-@= *Z7T)0?,K<V-X:;?7L51WWS&RM3YQ^LPJD/!I2 KU/*:
MDEA$/0\A0,Q2.%V43[SUQ/&=Q'0[X_80+.P*89_&^@YNJT=B\44P23Z+)UF'
M#7\*W;N,0S0E^, %%\WG.YWX9C+&N-L6*#J1^=W!B/BTJ629R%A2"JK6:P5/
M_Y"UL4C.()R+AKM::]]ZV/C#E'0[[K8=?(YB>G_&T(.3[>[_\ 1KZ, 5AIC4
MM^=^!AS>1VX39DM>5%2R]H/R$B*6 NA0I1)="+YU">$ P_ON\_'?EHO5ZG(H
MT\335DJ6C'95VZ6)K, A^0:(B:-E414,PUA[.R@:.Z?R-!S<U3\-N=_!%78V
MV]1V)'RY6#Y?7,1UN9C=W^'5YHQ3W"FG08M-+GI.$#FG^SEK5R0JSF-KQ_X@
M L>UEYHC;3#9' X\OP7>O*8-8_[0#G\/71176U+:"E>P0 DQTI:"(4LPQ=KP
M7Q4I!!VTUHU/'J-G7'-J>#UV).>/UV*+=9@]F375(J2TWX>'L)V>)(3T$,0<
MC\P0O"!8Y4!I@Q"3]35XJ;+'),P A2K-3::WR\67Z8J$\( JG0197'*Y%E[;
M0%>V]N"#$,"DM;GXZ$T98(#?3GKZ,Y<.P< #P_K:<+X_I^W[P-7C-<J];[0:
M2CRDGGATTJS*Z(SE(*W#VNW409"> 1.:8"(EN>&M@Q\#3B6^_O2[\,=?R/)9
M3L.LSJ*KX8<5+K_@:I)=B,FK ,;1+:DX:O#:6)!&A%R?>&P9[+%K)U4=3R(^
M !\[7[_:2*,#]^MZ1W];+/_^:D[*,N'JSI:"H W1_P #DJ8L,8"O[<^=SD%8
MR["DUD&+/<@:U]4:'&&-Y-$3Q.H(JM4GS'7\U9TMJ81.9"D@I\1K 4* $&J7
M);K>31)1M7>T]B!K7']K<(@UDD=/$-MD)?"8?70:G+>;7L(*0C$>)'.\2*93
M#JV+C@Y._ABL1\_@H#F4P\V<\P;HN PN;)/Z%.?,61&@J IQQ\BGJ$]]+ANG
MD\B)V]9.UX.$[(47_=/BY6B>]U',<;MP04A)'B.7X)RM$Q #)S\T6W"1"6^3
M\+PTK./HJ-ZG@3A_5.AS"&_[P,8#R>@^:L5<L8#*U304R<&3.P"9L1Q3$5:+
MO6J _T$*?0Z2Z5Z%/H<P>.QJCL?K4M ;EAVGPY.D ^63HNN4*SI!H?B4HK5X
MY_[Y1RGT.4B&^Q?Z',+0GFS6U]>)N<XQQ4KT8+@R=.&6 LYB@103\40)4\I@
MENOK/NHPVETTC?C<$U+^MIRN\?GBC_DDZN23<9O$-%_SEP1XIR+HY.A?B9/.
M;=U4[SX5G9@D1\IU9^#E*";W]SA ^O<S+M??PGS3(?AS37 DY^W]Q?EY6'Y;
ME(=^_X1WA%.6._')H=E.6TW8OESO[:PFX]]8]-JS4M84F[F#VL:,D&42!!L"
MI"(]*H)=:3Z@ZX=$M>M^M7.IK3+7!3'7;L&)KFL@U6XA.N6 !:=%4-+%T+I/
MSKZTC3QINREN=C>Z:BB?#F['G;OY[=L'^L3&#TED&0;I MB@:J]HC1"REX")
M&YV4URFUGHVR!UDC=U,;! _W']^;"J=GO-4-77HX.1H1="@@C*N60\U7,"4"
M]SPRF9VWK'4AT!YD=:K=CH7"OE [4BX=0.TUAA5^6LSRJ_//R\67;5>F*V\W
M%F-+RI"LJ"Y1D!"#MR"<*CR%Z()N#;%'R.D46L>*?C&,'#J U#5K+LEG6I:<
M;8*2 UD4,5L(B4=0&!T:)TOPK=NOWB%AW'C#T- YA=\=P.7EQ7(^K8TXS^JH
MA:_U5U? %TRB\BR!EUBC>,R"2[4+JH]HD4F?9>LJC]W4C/M2/S2(&DFA SS5
M'H3KY<4F<KO);OE(6[G:BZV-FFPD[R:+.OI717 L<=I0C)ZAB E;![4>HV?<
MA_RA,=5,$F._LM2>)>MWN)XN-_?RL\7J2M>JHB6FVJ<R*M*U7&0@'9L@F5#;
M^6A$?0=/NSID[5IBW+?[H2#2D*T=J)R=7+H1-\[225/3OFNT6!EIP6N>"/..
M>2;)X[6MK[(?4S6N731N=. XT?0,MDV)YB39Y+.W$C@=.U!"T+W-@H?":U<E
MK17RUC?<XQ1UZK<=*?]]X76X,#J UK9!,VY\T7?3CY_6;\I?5[A1T[]A69!Q
MF-+%^<6LED>>G=?.!-NVSY/(,4EI9$U!IWVB#^"#MI"]"$:%(GAN'6\_EM9.
M?<$V<'P2 1X-U"^XC(NAM>#9U<"^_;CP'&D/:7K5L/P64\A"38$[#3F;0"8J
M.3Y12P,Z"IU*=B*IUE4O3["M3OW8@?7Q2+#H(#7Y2);LRXSDC)99@B^2F,%#
MJ!DS"$'7NL8<2F&M-?^@&^K4(Q_U= P A7Z:,QS+DT)FUYZ,T98;+$E!$)&!
MLLS5$4X!D$EF"A=>-;>.AM]5IW&)<0_*0*#HK_O$CGRHFQM^\;6.VCZE$\7A
MBPR3Y;7OKIXLMRNY.@>.#'7.:S]ZY22X* *8G++@@ANI?KK<KIM,GA3,64ED
MD)'79@QT;&.Q&JQW6;MD)..M-WAS_4Y#%D?)_]YHU&/YW-#M:Z:&:EGI'],9
M,2J_H@_-/T[C;*N*5XVZX1RXPHD*Z)3]--(^5R2<W2?A@?H]0\R2G@O(A==A
M!9R!*QB@&!]80"U]:AW6/HC =AFG5\MN0]*<Q605UBA)I(.CC &O7&WNF8U(
MQF6.K8O)=Y RKJX:#BV[<TN/ET0'(=9;'5TW"6DF:F5-B%!H_Z2#:2M1J@1U
M]"N7C#%4[9M/W2&BES31$T1[;QS%*7SN#2B7+ZV;4*P4#/2V8QW2=1U2!!N8
M2G1C\2@&A4H/.9XG"O8QF!S!Y;$S$S:#I=Y?+#_6F5*7C^>>S@PSS))U*#<-
MQP2$$!C]PY&O2:ZEY/)'9L^NCW<D^V.DM6C(NK%%_PX_XARW!N%?,$_3=(Y7
M\^A29CP%!.F=!>5]S;+1C/2H5[R0R4^6_EX(V+W&V%UH&P*A$2,[N#.NKL_O
M03!/*A$-:43'ZV1"H2)M@/P]XRRK/>BE1C&0??ZZMRR3=L;%:7SN "B/##G9
MQ/ U7:&E9BS4EKN>TT8X\\ISF7U*K6/5G<Z7.5'(^X^5.8#C'4'G@<DF3M-Z
M$C4PYNN10@5TMMBF6$'%P'QJ7C'>ZUB98<!S(L^[0\_U8)/(6>W7DD&;2&?
MU[<:G^DJ=UX479MMF-:9%CU.DQD2-4?QN@/$7/%D$C4J;LFOTZ(V^BFU53-&
M#2:B%CSI3'IT(%-FW*2 MJ@XBI_]M9YX/%)^ELB8GZZ_7?9G&"S^OV.=05\!
M]MG;*&\!Z NYQTQ#$;5G+.&(;J$ZUU5+4]![8\-0!_2)WP)J5],UOJ[#N^\N
MNW4N;(I:1^[ .5= A>3!2V.!"\E2YEKGYI;0_M3U85:WQ]3N%X.F\NK@3GQD
M/[]]^TOXWXOELUE8K3;1T=I3TW@4$%.MLZIEQ XE \701,6YL<W'@1U 7B\/
M#VT1<C\K>Q!Q]8W$[QO[/9Q?U8IIBXF9E "#B*"R$5#C=F3#Q,0D[4'GUH;^
M@22.B\C!H+(_)$^66P>P?!O6-_LG,%M\"!D$>G9I+BN=P1JR\BS+QH?6XVYO
M$= MI$X7]=V\R:/YW@%H'F'4=]?+2,UY0@DQU_Y_@KCC>2%GVB6?<T3#;>N
M^CYT]1)C'^L>/4Y ?8-N6T*(Q824L@(6K -E70;/N 2+VG!9HI!W*\R'!%P'
M%9WM4; _S X72=\0VU4.Z(1EJC 'TM2V_,D$</7Q4QI)^S-%2M&ZF=WA5(ZK
M\\:$80NQ]5.!\\A&ZR00%ZQ43F; 9.BT!4?<9)Q,B9+1%^%,B/'IL+CO])7!
MW@C&Q-VAXNB@^O&[:?)JGK'\R#P13"E9R%K-PM0!P^13^6P2%&$-"D;GB _7
M.'8?"OMXUGS*X%USN75P)?]@3_=<?>]]+MQXB%[78C$KP!D9P03RU'1AZ)HW
M<SZ0Q%X">>W1<J^)^W"BZQ^9#T8,A-8^6.'H(M!U0G=F0'LMX$W9_%94J?4-
M?0298X\2&! VAT'T9!EV -,/RY#Q/"S_7F>_;/ZC[N4J\*1"*AC00HZ6+I[
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M(X_DEXGH0YT%24:/2@&L+"DF%HN)K=](]J%K[('R(P/P9%'UUVOI!^G -QZ
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MZ0N(_UA<KC&_#%]"JBTO:TOFS=:IQ9LJV#J!TGL#DMM:IN;(4,RDA[D0:'C
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M'?P91?8N13,,8L?N8-K:R>G ]R02.Y-K>\=JO*7/'7/"1%3 N=O.)PC$U9B
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M<>T?#M^YDPF[;(\)F09L?^YO3F:WC/TI7IW0'KIZ=W*;)]<O3VB7>S'6+Y&
M]3__V_\#4$L! A0#%     @ ]8%B5?;<RY]$"   428  !L
M ( !     &$R,#(R,#DS,"TQ,'%E>#,Q,69I;F%L+FAT;5!+ 0(4 Q0    (
M /6!8E51)!CJ.0@  ,HE   ;              "  7T(  !A,C R,C Y,S M
M,3!Q97@S,3)F:6YA;"YH=&U02P$"% ,4    " #U@6)5MXRQ@1(%  !3%0
M&P              @ 'O$   83(P,C(P.3,P+3$P<65X,S(Q9FEN86PN:'1M
M4$L! A0#%     @ ]8%B5069/](1!0  "A8  !L              ( !.A8
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G+3(P,C(P.3,P7W!R92YX;6Q02P4&      H "@"N @  D#4$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
